<SEC-DOCUMENT>0001485003-22-000033.txt : 20220228
<SEC-HEADER>0001485003-22-000033.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228085150
ACCESSION NUMBER:		0001485003-22-000033
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		22684186

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sesn-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa,d:f1c5a63ddb584a0db5ee835d7440b255--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:sesn="http://www.sesenbio.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sesn-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF80LTEtMS0xLTI3NzQz_b1cafb70-0236-46f1-927a-370b6de93ff0">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF82LTEtMS0xLTI3NzQz_c84400d1-661a-4620-9218-07b869194b37">2021</ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF83LTEtMS0xLTI3NzQz_32bcc5a1-6f95-4f5e-80b7-25f21a6959fc">FY</ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF84LTEtMS0xLTI3NzQz_dfe63572-2a68-4e09-81e4-5e258c5a6c54">false</ix:nonNumeric><ix:nonNumeric contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sesn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i92f97507a36b49449af460f15366dc07_I20220221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8984440967a74e3abe0feaafbe79712a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2c88f9a9af124db29eb627c2bb0fd0e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b5ef8f93c04e62a666090e00118055_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30a5968b1a146dbb7ffcec09da88262_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf44be67ed84033b15e86e3de2e9088_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c1773348a6144f8927754151f83c6b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic78f2f0a6b1d4a20ad7e12e40d1cacd4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707ab57c26dd479d83f5e95b7b236b54_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d87267df014bc9b3e806eba7f1b0f5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d90314fd70472fa324352884486d5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3412d8401e304f0aae1eecacbcdbab85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8c7f863b2f43bb922132621a9e5cda_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc289b8985ac49eb80e78ca2748e4a96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06678b0cf6c04477b759eb44801366df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id593ab74c6634403b9f73b261b779b5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1cd661b638041f898d4ddc61a940fa7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iededb75b8b3d41909c578b96949d296b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b663c4ccd24528baa91746670f2709_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92612297cd0642f585229a45cac68bd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548b9f86fcd54ebe9243040061933762_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449b028e12ab447dbe3d1ff217dca3f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6cc5cde3c2444458bf73121a4a8d8f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c9ad583a050492ebb28f616a7b10aaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bdadfe711654c368dce057e84bccbf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d93ef4c012e45c7b10ee227a4cdf96d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbcc2cd80c644c9bba710067ba49b410_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>sesn:patient</xbrli:measure></xbrli:unit><xbrli:context id="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb4126fec9d47d299096c36c0f06713_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i36e9d8387a934ec497a4731a279af3dc_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533b84da1d2441468aadec080d52600b_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2334efa0613474c99d0b53f5f47619c_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7059bd4c3d114e288eb8029d693c5dd6_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d7d3d671d44f1fb8dc94865706738c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f42726b9d2d45519a3279adbdeaf414_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16d8fcfc6064d57a72284ee2689a0c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649bc58c14754d8497732ebb7fb60f40_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2a6758069a4a888d0e5d69c12d58ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>sesn:unit</xbrli:measure></xbrli:unit><xbrli:context id="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibecee94376694fc393e30898f2ff86a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028ccf70c10c4129a5d10bd536d297b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de469ec0aa540adac05ef95232f5a15_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a34442b9744cb6ae08c574b84b89b9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4609a0afbc594078808154f146946ab1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2453680b1ee48d49d18b917c46773a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b5f8ea9c52413084c453c81936288b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6d609604934e33aa33ca5fc59ce894_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537b107b17f34737a20ec184a594ae82_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i695006bd273747aeb95e43b893e8b867_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib942d47e8aca410e959ff68b5d97942f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3d4b0f71404387b7089a237b8a5500_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9280baa377514c5b8f3b86112af15bc1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8e07a02a314fe58d21f5e73b65454b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2904e8fab3f54e409e119eb43ab1f654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5309a9a57784300b6ab55b4dbfaa087_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f21fbe1815427897b0c6ef0565f88f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33449a16f50d42fda82fa03444b362a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03bde29f9a84402bee0c3bc6cf735f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58772c205c8a4b93bd99d62ff3f8e8af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294acb7d2420400b8155b9d8ca59ecac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a8c65717624d59b77914baa103c3bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9873482dcdab4f8e99687d14de08bf30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ab9cefc27e4b67b11ffb55b439770b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90b2409cd1e47e9a97d51b1bda3f754_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461f7c863e8845a1bf3aecbdde6819d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccafbadd781745f8a66ce65217af032c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208c2cdd76674e1490701e0cd5f02c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15fd8a9c40534aeaaf4598e6db3abbf6_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a83c24db234a7e8561b517d543d5e4_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21f2148bbe744ea9737cdc30b3b639e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34539641171840f78745ef893c090fa7_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea343b4020f4cf29f1266e2dc6a6b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib230fbf43aab492384091cb48ddd7af2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea35f777e5264bc1a11c1a5275407d2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9439e6445a46079edce40b074a4cb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1ae7c86aed4911bffc0db6ed1d7ca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4126ae783347adb9e0ab895ddfa18d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e085c71b3d4eb89b00ee3fce28ada1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1639a88a7f44d28ddedc2f01af5b1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if671dcdd4df94af4a5b9fb93620a325b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e5f96e4bd74651b225f0392286c025_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52b03759bf044b3b5e17cf2a7c4a0b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12322603449433985e3779be27b8eab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d622315903d4829a4f582cfffed067f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425fb86623034e39aa2df73efd925f25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe412d00cd048258c144cd9ed556654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1e110f756945ed9233483c148b8a4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d83f49999a40659f8cb5c98716447b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43faec616e1467283e341842cd9d4ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sesn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i81e534a3b6984e9ca7a46fb4761feeec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>sesn:term</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="ie35eeadb1df94fb4940973f807cc6e7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sesn:MassachusettsAndPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d207bdc8bb44456958770de74b1eabe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sesn:MassachusettsAndPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68866b76b55f41f7a5558f5272486883_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8cf18e833d4913a7dc5dbc354f10c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b4c01413da485fa2ac23775d55bed5_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65be1969c492411ba4743fe748508e67_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ed6ecc802f45c586c3b6cfff6e28d2_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb861283e22418081b9e629463e783d_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072f60a137e94674991638220c6ed9ec_D20210601-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd395e5e95f84b618c6884bc4356ae1a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0d8f6abc7e49829c395d208a3436f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id916d4f7441d4a088be2fca47e276005_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1156bb975047729b334bf2e3fa2fc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3950633399b7426dbfabb5690ebcde85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75020eb264af4e39a21665962a79801e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f92707265b84c70ae5a42f1daae1378_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e1aa3b61664f47b00658c43dfd99fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7858b2eb979a432a96faff9ead49ee39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d44dfab69545dabde220a346b37456_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>sesn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i877528c6538245119864f9c0c2e52211_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466f369ef0774c33bd619700d8de5551_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cacad06c024286911346564a7662f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8512f475d73400cabc282795a6d7b65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae2e392a7c740b1988ab6b7b8b786d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie688301f8b994be195f31b42f85842e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d5371af6c3e495888104af773d10b15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174b4bb16b14432aaeeb74b47fc49556_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e67736b7d564e33bad48ed099f8786c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic128bae021684a57b2549146b666bae9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id470afa5cc9848b2a4b4f535d4b6c1f0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec6e4d46e284f0594c5222b5698833c_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9a990e22cc41d8af941ad8a743ae8d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc016955920f4e64b8ed1852c953e88a_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae3ad21e639847039d2f1b31b55bc122_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db3ec5f4dbd471f8ba45bdc77ad6b70_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dda2c9095f1418e975214cb9c010492_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150fe7eff7ea4fdb9a21acd3372500e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5156f45bd4749bab08cc813bedda252_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90f693a8f7e416ba3582374b0255711_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica1ef2678e204ea598c3a695c7bf3daa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b84bfa887d467f8571564e41e8618e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3279ce60c04cfdb6610631e4f95328_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6966455303f44235a15aa41b9bdb897d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8dfe926ee5f4392a3f17922b1910370_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33db38ac6691417da69866ecf8c6be7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3155b0a68be6497d8886c0858eccfe59_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b59ed3d58ff421abae5edfb38249ce6_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05ac20284034cf78dcee6454eac36b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9542ee3724344137b968a7e2f78a7249_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6565370c486e4b11b00a6d3e11fa682f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3fee83c1a8e4b838f1b1364ca7244be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5019c429efc54a3d939b95facb6113a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f275e89a3774f7cbca3fb8965e7a354_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30373a67e51d44d48f81e5dc9200383a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99964945ffc46049f3cdcd6ac3fa481_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if520d25ca9304b37b3cf574ce10e6659_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ad27b86d2646489f5ab053b12babde_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a7749193cc45fc901d310757b0a9ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d8a19fb4244ecfaa96a4eff824e050_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8645ab0e887d4a8bbf9664668f155fb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558d72c250fc4f3bb70e9309cb978078_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3408800d9ca34cbc9107500cccfb1efe_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19aa28ed63b64ecf8600a587af11639c_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2265e9372ef14f33a95d480831dcfd36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i256cad603adc478fbe2bb635d926f6d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0714416d3dbb41bf905d3f30d60053a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b01c3a7a584c8c83ef29c8a5d2f83b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc2b6152b3a498aa18f90d825cf3988_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff556de6a08542a29c8cf9c6757a93ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95faf853daed44049bbacea1c98c9719_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fac383649084445a8d938fea7593c9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b0f304a6e34b6abcd67c26db8d37c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="sesn:NetOperatingLossCarryforwardAxis">sesn:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6573654cd29340309dbe2c811248a720_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda208642281438089144b87cd645d8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6b0fe41f5b4f79ac97691814a89591_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia696bc1cbc724e098ee3bd580cfb8b6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id24bd2e4f3be4ae1b8b83df732484432_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sesn:NonCapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb901b4a5ff4839828a1c82f4bea528_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878819bdb7ce45d78433cd5efbbd8d27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996be0ab5ebb4bf2948b029b33aae0b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810bedfc811b413cbc1b773410810321_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e35e96c504045f9b37880d11d241235_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c28bbf66e0b4945bbdff22096e98ec1_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53830883489044f7a20fd0f2afe3ada7_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536ac10f94b7496ebcf21cf333f739f3_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36fc4d06bbde4724b5f3f5d605df0dda_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1e9a4c5180446d85e2e5552350fe42_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672850f3381947678ce8bad19d353cfe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34be4d2750144c28965180b21ad35c2c_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f3a5e587554717a5b2e59570cb1b71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592275577a9d4f158b7f51ca29978045_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced271cdb5d7466d9c7c148965459481_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013a145bc60a457a851dd9b22eab7d0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f7872b3f9441f786d65989d956951c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>sesn:period</xbrli:measure></xbrli:unit><xbrli:context id="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3854b11b1f004bb585ab8a3ed3e68622_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028e8f65759541db8dc7760918e71d52_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d8a2af6cca4ab8b80ffdc3f2434161_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818c0861bdb74095a88cb8cfcda94efa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb1bcb7e3874976b1397e8d0fc3b469_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a168b0aa4c647e1997b38ac0934768d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b79f0dfcd8c4696998a76eff4413ecf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ebdbf98df0844558086fd4461793449_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d384e7e18448558f3f9903191a5912_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149c70a89b234c42b784e047bac76480_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i544162f98c2149b991bf17fc6d17e544_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289b399c61c441cdbd3ee11d6f7a9ff8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0bc936be4b4983b3016c269a7787db_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic637e93aa17d4ad6a3c0e4e24f9685b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41763d631ab94cc3954f93769f016e8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit><xbrli:context id="id7ea168da84a45ce835565576cb8541c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a50664b1a24d31b0f259776c76eef4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77fcf675f74847e4ab66d5e451e81521_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="document"><xbrli:measure>sesn:document</xbrli:measure></xbrli:unit><xbrli:unit id="interview"><xbrli:measure>sesn:interview</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="if1c5a63ddb584a0db5ee835d7440b255_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU1_a6c761d5-68cf-42a9-b4fd-faed8f67b32d">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YTM1Y2EzN2RjNmJhNDZkZmIzY2JjZTExMTkyOTBkM2UvdGFibGVyYW5nZTphMzVjYTM3ZGM2YmE0NmRmYjNjYmNlMTExOTI5MGQzZV8wLTAtMS0xLTI3NzQz_c84a5ab5-a563-43b9-8324-260d98be02d2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMzI_fcaaccff-09d5-41c6-944d-38736053795e"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMzI_e7873fde-901b-4d61-8e24-6c478ac53fdb">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZDQ5NTY0NjEzNWU0NGE2ZDg5MDc2ODBlNTUxY2NhZmUvdGFibGVyYW5nZTpkNDk1NjQ2MTM1ZTQ0YTZkODkwNzY4MGU1NTFjY2FmZV8wLTAtMS0xLTI3NzQz_665c98bd-9886-49ee-bbfc-28ce5b9adce3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjQ4_27f8cf8f-da43-42a7-9f73-ddb7fcfeb15b">001-36296</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU2_62f92caa-d49c-488c-a00c-5ce0e4229385">Sesen Bio, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZTcyYjU2ZGFlNDhkNDI3ZDg2YWVkYzU1ODM0ZDk0NTkvdGFibGVyYW5nZTplNzJiNTZkYWU0OGQ0MjdkODZhZWRjNTU4MzRkOTQ1OV8wLTAtMS0xLTI3NzQz_e874d3c3-2832-4288-a249-c96e0c820d36">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZTcyYjU2ZGFlNDhkNDI3ZDg2YWVkYzU1ODM0ZDk0NTkvdGFibGVyYW5nZTplNzJiNTZkYWU0OGQ0MjdkODZhZWRjNTU4MzRkOTQ1OV8wLTEtMS0xLTI3NzQz_eb3b8bb8-4600-4e44-8dbb-3eb3d880e98e">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfNA_a773c3f5-b938-438a-b199-ecb2343a65cc">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfOA_b8cf61d2-8655-4c8c-9bd3-340f47b125be">Suite 1800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfMTE_9b57684f-64a7-40ed-9cbd-543c31abb206">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfMTU_2f4ca687-9b17-4a55-a3ca-0fd87f5f1dbe">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTEtMS0xLTI3NzQz_1a2b7128-bfc9-4f63-9770-6d0777d9b378">02142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zNTQ_f2535667-b01b-48f7-af7f-3e630019618d">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU3_c979bd1b-4156-429a-a7fd-76005eac7013">444-8550</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.472%"><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTAtMS0xLTI3NzQz_c81bb2cc-7b3a-48af-b584-404fe7af72a8">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTEtMS0xLTI3NzQz_7adb4571-21ef-4baa-8ebe-ccefc9e1c0d6">SESN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTItMS0xLTI3NzQz_bf36588e-c49d-4b3d-84fe-c9e0889784c2">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU4_88753fa5-8075-444f-91cb-b7ddd1d8f103">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU5_fa9b099f-96bb-4f9f-8c2f-42f60a5bd0b7">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjQ5_74b4a2c7-ecbc-4270-8547-99876a796b8e">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjUy_dabd669a-3947-4afd-ba9f-1a68902cf177">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer," &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8wLTAtMS0xLTQ1ODk4_06a99ac2-7f5c-482c-b2be-56f0e4225d06">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8wLTMtMS0xLTI3NzQz_67a6cd17-d59f-49aa-9e45-6ef3dee348ea">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8xLTMtMS0xLTI3NzQz_5b1fec30-ad64-4d0e-b6e3-9d54a9cf535c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjUw_39384eab-cfbc-4aac-a40f-7f1c8c860f3b">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMjA5NDYyNzkwOTI4NQ_678a1f04-ef23-46e7-9caf-a58cdcc6cf82">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant, computed by reference to the closing price of the common stock on the Nasdaq Global Market on June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18yNzYy_0836b742-a1f0-4baf-9b93-e5b311f7dc80">870.7</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i92f97507a36b49449af460f15366dc07_I20220221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18yNzc4_3bb00bd5-780a-416b-b9b8-7b5a417a8531">199,463,645</ix:nonFraction> shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2022</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMjA5NDYyNzkwOTI4Ng_9a693323-2ff3-443a-8e84-4bbf582acbdc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders ("2022 Proxy Statement"), which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:17pt;margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form 10-K for the Fiscal Year ended December&#160;31, 2021</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_10">ii</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Factors Summary </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_10">v</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_19">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Properties.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22">6</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_28">69</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Reserved.]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_28">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_31">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_34">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_34">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_34">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_37">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_40">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_40">88</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Compensation.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43">8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accountant Fees and Services.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43">8</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;IV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits and Financial Statement Schedules.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_49">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K Summary.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_52">92</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_55">SIGNATURES</a></span></div></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to "Sesen," the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future product research or development, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;goals,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; "contemplate," &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resolve the issues identified in the complete response letter (&#8220;CRL&#8221;) we received from the US Food and Drug Administration (&#8220;FDA&#8221;) regarding our Biologics License Application (&#8220;BLA&#8221;) for Vicineum&#8482; for the treatment of bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;)-unresponsive non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resolve the concerns identified in the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Withdrawal Assessment Report related to our marketing authorization application (&#8220;MAA&#8221;) for Vysyneum&#8482; (the &#8220;EMA Withdrawal Report&#8221;);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we have a clear understanding of what additional information regarding chemistry, manufacturing and controls ("CMC") is required for potential resubmission of a BLA for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, including an additional Phase 3 clinical trial, and that any such future clinical trials can proceed while addressing CMC issues raised in the CRL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation to discuss the study protocol for an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive carcinoma in situ (&#8220;CIS&#8221;) of the bladder in patients previously treated with adequate or less than adequate BCG in a Type C Meeting with the FDA scheduled for March 28, 2022 (&#8220;Type C Meeting&#8221;);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to address questions related to clinical matters raised in the CRL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to use the information from the Type A Meetings following the CRL we received regarding our BLA for Vicineum to determine the appropriate path forward with regulators;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to the FDA following the issuance of the CRL by the FDA, and if approved by the FDA, our ability to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resume pursuing regulatory approval of Vysyneum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union) of BCG-unresponsive NMIBC in the European Union when there is more clarity from the FDA on next steps for Vicineum in the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to work closely with the FDA to understand next steps for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to work closely with the EMA to understand next steps for Vysyneum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the European Union;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future loss and accumulated deficit levels;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulties and expenses associated with obtaining and maintaining regulatory approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States, the European Union and other non-US jurisdictions, and the labeling under any approval we may obtain;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position and estimated cash burn rate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we will have sufficient future cash flows from additional geographic regions outside the US to support the value of our goodwill and EU indefinite-lived, acquired in-process research and development ("IPR&amp;D");</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations regarding any remeasurement of contingent consideration liability in the future;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations regarding any potential impairment to our goodwill and indefinite-lived intangible asset in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to raise substantial additional capital to fund our operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our pre-clinical studies and clinical trials in the United States and other non-US</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third parties, including contract research organizations (&#8220;CROs&#8221;) in the conduct of our pre-clinical studies and clinical trials, including an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs associated with our manufacturing process and technology transfer to Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) for the production of Vicineum drug substance and drug product, and our reliance on Qilu to perform under our agreement with Qilu;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the potential markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic operating plan to sublicense Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to business development partners in all regions outside the US, including the European Union, to earn a potential combination of upfront, milestone, and royalty payments, and the business development partner to bear the majority of regulatory and commercialization costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding key advantages of our targeted fusion protein therapeutics (&#8220;TFPT&#8221;) platform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that Vicineum may work via a dual mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that there may be potential for a synergistic effect when Vicineum is given in combination with checkpoint inhibitors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount and timing of milestone and royalty payments pursuant to our out-license agreements and OUS business development partnership agreements, including our license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;), (the &#8220;Roche License Agreement&#8221;) and our exclusive license agreement with Qilu for the development, manufacture and commercialization of Vicineum in China, Hong Kong, Macau and Taiwan ("Greater China");</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to regain compliance with Nasdaq&#8217;s minimum bid price requirement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to seek additional OUS business development partnerships; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies and products that are or become available.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the issues raised in the CRL we received from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the concerns identified in the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not determine a viable path forward for continued clinical development of Vicineum, which would prevent us from resubmitting a BLA for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not achieve profitable operations or access needed capital;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays or difficulties related to the continued clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including delays in clinical trial sites receiving the supplies and materials needed to conduct clinical trials, difficulties </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients or treating patients in active trials due to COVID-19 or otherwise;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including an additional Phase 3 clinical trial for Vicineum, or any of our other product candidates, may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other non-US regulatory authorities or otherwise produce favorable results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not obtain marketing approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States, the European Union or other non-US jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum may not gain market acceptance for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States, the European Union or other non-US jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market opportunity for Vicineum may be limited to those patients who are ineligible for established therapies or for</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whom prior therapies have failed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience issues or delays with third-party disposition, labelling and packaging of clinical supply of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors may discover, develop or commercialize products before, or more successfully than, we do;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain, maintain, defend and enforce patent claims and other intellectual property rights; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to comply with all regulatory requirements or experience unanticipated problems with our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may recognize impairment of our goodwill and indefinite-lived intangible asset; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not meet the Nasdaq minimum bid price requirement during any compliance period or in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be granted relief from delisting from Nasdaq if necessary; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described in &#8220;Item 1A. Risk Factors&#8221; and &#8220;Item 5. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are investigational biologics undergoing clinical development and have not been approved by the FDA, EMA or other comparable non-US regulatory authorities. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. A Type C Meeting has been scheduled with the FDA for March 28, 2022 in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to the &#8220;Company,&#8221; &#8220;Sesen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following summarizes the principal factors that make an investment in us speculative or risky, all of which are more fully described in &#8220;Item 1A. Risk Factors&#8221; below. This summary should be read in conjunction with &#8220;Item 1A. Risk Factors&#8221; and should not be relied upon as an exhaustive summary of the material risks facing our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the exception of specified regulatory, development and commercial milestones under our out-licensing and OUS business development partnership agreements, we currently have no source of revenue and may never become profitable.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval of Vicineum </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on our lead product candidate, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. If we are unable to obtain marketing approval for or successfully commercialize our lead product candidate, either alone or through an out-license or an OUS business development partnership, or experience significant delays in doing so, our business could be materially harmed. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If additional clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other non-US regulatory authorities or do not otherwise produce favorable results, we will be unable to complete the development and potential commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We  may not be able to develop a more sensitive bioanalytical assay which is needed for the additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may cause undesirable side effects, serious adverse events or have other properties that could delay or halt clinical trials, delay or prevent its regulatory approval, limit the commercial profile of its labeling, if approved, or result in significant negative consequences following any marketing approval. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to obtain regulatory authority approval of any proposed names for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and any failure or delay associated with such naming approval may adversely impact our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The marketing approval process is expensive, time-consuming and uncertain. As a result, we cannot predict when or if we, or any licensees or partners, will obtain marketing approval to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG or any other product candidate.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to obtain marketing approval in non-US jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in non-US jurisdictions.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will depend on Qilu for the development and commercialization of Vicineum in Greater China.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on third parties to formulate and manufacture Vicineum, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of our products or result in higher product costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products, or if our licensors are unable to obtain and maintain patent protection for the technology or products that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and affect the prices we may obtain.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 coronavirus could adversely impact our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could materially adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and certain of our officers have been named as defendants in three pending securities class action lawsuits and three related shareholder derivative lawsuits have been filed. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to regain compliance with the listing requirements of the Nasdaq Global Market, our common stock may be delisted from the Nasdaq Global Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_16"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. &#160;&#160;&#160;&#160;Business.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union. In October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a Type A Meeting with the FDA to discuss questions related to CMC raised in the CRL (the &#8220;CMC Type A Meeting&#8221;). During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum (the &#8220;Clinical Type A Meeting&#8221;), which the FDA confirmed will be required for a potential resubmission of a BLA. The trial design may include these elements:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators&#8217; choice of intravesical chemotherapy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trial may include both patients who have received adequate BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patients who have received less than adequate BCG;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA encouraged us to submit the final results from the Phase 3 VISTA trial for Vicineum with a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the 2018 FDA guidance on NMIBC, adequate BCG is defined as at least one of the following: (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the items we expect to be discussed in the Type C Meeting is the patient population for the additional Phase 3 clinical trial, which may be different than the patient population studied in previous clinical trials for Vicineum for the treatment of NMIBC in two primary ways. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, the additional Phase 3 clinical trial may include patients with only non-muscle invasive carcinoma in situ (CIS) of the bladder, and may not include patients with only papillary disease of the bladder. This change would lead to a smaller overall patient population than previously studied, as some of our past clinical trials of Vicineum in NMIBC have included patients with CIS or high-grade papillary disease of the bladder. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, the additional Phase 3 clinical trial may include patients who have received less than adequate BCG in addition to those who have received adequate BCG, per the FDA&#8217;s guidance. Receipt of less than adequate BCG could be due to (i) failure of, or intolerance to, a BCG therapy prior to reaching the FDA&#8217;s definition of adequate BCG or (ii) supply shortages of BCG, among other reasons. This change would lead to a larger patient population than previously studied, as past clinical trials of Vicineum in NMIBC only included patients who had previously been treated with adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential changes related to the additional Phase 3 clinical trial for Vicineum will be discussed at the upcoming Type C Meeting with the FDA scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our TFPT Platform</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current product candidates are based on our proprietary TFPT platform and are focused on addressing areas of unmet medical need in cancer. Our novel TFPTs have been designed to overcome the efficacy and safety challenges of existing ADCs and are being developed for both local and systemic-administration. Our TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through our proprietary recombinant one-step, microbial manufacturing process. Our TFPT platform uses protein binding antibody fragments, which include Fabs, single chain variable domains ("ScFvs"), and non-covalent scFv dimers ("diabodies"), derived from the domains of antibodies that confer antigen recognition. We select antibody fragments for our product candidates depending upon the target therapeutic indication. We target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and that also have limited expression in normal cells. For local administrations, we utilize an immunogenic cytotoxic protein payload designed to both target cancer cells and promote a heightened local immune response against the tumor. For systemic-administrations, we use deBouganin, a plant-derived, protein payload of reduced immunogenic potential that we believe can be repeatedly administered via infusion without the generation of an efficacy-limiting immune response against the payload.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Locally-administered TFPTs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our TFPTs with immunogenic cytotoxic protein payloads for tumors that can be targeted locally rather than systemically. Local administration allows for the TFPT to reach the tumor without being cleared by the immune system, which enables us to maximize the concentration of TFPTs directly to tumors. Our locally-administered TFPT Vicineum, which is our lead product candidate in development for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, contains a targeting antibody binding domain that is designed to bind to EpCAM, a protein over-expressed in many cancers. This binding domain is genetically fused to a truncated form of exotoxin A ("ETA"), which is an immunogenic cytotoxic protein payload that is produced by the bacterial species Pseudomonas. This product candidate is designed to bind to EpCAM on the surface of cancer cells. The TFPT-EpCAM complex is subsequently internalized into the cell and, once inside the cell, the TFPT is cleaved by a cellular enzyme to release the cytotoxic protein payload, thus enabling cancer cell killing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe that our TFPTs designed for local administration may not only directly kill cancer cells through targeted delivery of a cytotoxic protein payload, but also potentiate an anti-cancer therapeutic immune response. This immune response is believed to be triggered by the immunogenic cell death of the cancer cells due to our payload's mechanism of action and the subsequent release of tumor antigens and the immunologically active setting created by the nature of the cytotoxic protein payloads. We believe that this immune response may also enhance the action of checkpoint inhibitors, that require a pre-existing immune response for maximum efficacy.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced locally-administered TFPT product candidate is Vicineum, in development for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and recurrent, locally advanced or metastatic EpCAM-expressing squamous cell carcinoma of the head and neck ("SCCHN"). This TFPT is not, however, suitable for systemic-administration over multiple doses because the body&#8217;s immune system would recognize and eliminate foreign proteins, such as ETA, prior to their reaching targeted cancer cells.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemically-administered TFPTs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also utilize our TFPTs with a de-immunized payload where systemic-administration is required. Our systemically-administered TFPTs are built around deBouganin. Since the body&#8217;s immune system naturally recognizes and attempts to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eliminate foreign proteins, we designed our systemically-administered TFPTs with a deBouganin payload to avoid inducing an immunogenic response. DeBouganin is constructed by mutating the immunogenic T-cell epitopes from bouganin so that they are not recognized as foreign by the immune system. However, we also believe that deBouganin may enhance the action of checkpoint inhibitors as a result of the promotion of a local tumor immune response following the death of cancer cells. Our systemically-administered product candidate is VB6-845d for the treatment of multiple types of EpCAM-positive solid tumors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Differentiated Approach to Targeted Therapies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our TFPT platform will address many challenges experienced with existing ADCs. The basic construct for our TFPTs and existing ADCs is similar as each is comprised of a targeting domain that specifically binds to cancer cells and delivers a cytotoxic payload. However, existing ADCs have been associated with limitations that we believe are addressed by our TFPTs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Existing ADC Approaches to Treating Tumors </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe existing ADCs have the following fundamental efficacy and safety challenges:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Deliver insufficient drug to tumors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Existing ADCs utilize full-length antibodies, which, due to their large size, have a reduced ability to penetrate tumors, thereby potentially reducing their efficacy.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Inability to kill a broad array of cancer cells within a tumor. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsets of cancer cells within tumors may have mechanisms to resist and not be responsive to the cytotoxic payloads, or small molecule chemotherapies, used in existing ADCs.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Off-target toxicities due to unstable chemical linkage between targeting antibody and cytotoxic payload. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing ADCs utilize chemical linkage strategies to join antibodies to small molecule cytotoxic payloads. While in the circulatory system, these chemical linkages can break and release free cytotoxic payloads in the circulation. These free small molecule cytotoxic payloads are not targeted and cannot discriminate between dividing cancer cells and non-cancerous cells, thus resulting in increased off-target toxicities.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Limited combination therapy potential. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events may limit the potential utility of existing ADCs in combination therapies with immune checkpoint inhibitors which have their own adverse events, including immune-related adverse events.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Complex and challenging manufacturing process. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The multi-step manufacturing process of existing ADCs creates a non-homogeneous product that limits efficacy and drives greater costs than those estimated for our manufacturing process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantages of our TFPT Platform</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe our TFPTs offer the following key advantages:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Deliver a greater amount of drug to tumors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TFPTs are designed using smaller targeting proteins that have an increased ability to exit the circulatory system and have binding properties designed to enable deeper penetration into targeted tumors, and we believe this will increase efficacy.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Ability to kill a broader array of cancer cells within a tumor. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel cytotoxic payloads consist of proteins rather than small molecule cytotoxic payloads. We believe the larger size of our cytotoxic protein payloads helps circumvent multi-drug resistance mechanisms that can make certain cancer cells resistant to small molecule cytotoxic payloads. By contrast to existing ADCs, which employ cytotoxic payloads that inhibit cellular replication and are effective at killing rapidly proliferating cancer cells, our cytotoxic protein payloads inhibit protein synthesis and are designed to kill not only rapidly proliferating, but also slowly growing cancer cells including tumor progenitor cells/cancer stem-like cells.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Increase safety due to a more stable linkage between targeting protein and cytotoxic payload. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our single protein molecules are designed to remain intact until they reach the inside of the cancer cell and to not release free cytotoxins into the circulatory system, thereby minimizing off-target toxicity.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Promote a therapeutic immune response. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the potent TFPT toxin-mediated killing of cancer cells in this immunologically active setting leads to the efficient presentation of cancer antigens to the immune system, thereby promoting an anti-tumor cellular immune response. Our locally-administered TFPTs utilize an immunogenic cytotoxic payload that we believe promotes a heightened immune response in the local tumor environment.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Potential combination with checkpoint inhibitors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the potential effect of checkpoint inhibitors, which are antibodies that promote the action of anti-tumor T-cells by blocking inhibitory ligand/receptor interactions that include PD-1 and PD-L1, may be enhanced when used in combination with other agents. We believe that, by mediating specific killing of tumor cells and promoting anti-tumor immune responses, our TFPTs, while potentially effective on their own, may complement checkpoint inhibitors. In particular, we believe that the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use of our cytotoxin payload ETA, which induces immunogenic cell death, may facilitate the presentation of tumor cell surface antigens following the death of cancer cells, thereby providing a tumor immune response to enhance the action of checkpoint inhibitor therapies.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Utilize a simpler and more efficient manufacturing process. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary recombinant one-step manufacturing process creates a homogeneous product that we believe will improve efficacy and result in lower manufacturing costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to designing, engineering, developing and commercializing TFPTs to identify and address oncology indications that suffer from a high unmet medical need. The key elements of our strategy are as follows:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Obtain regulatory approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum to the FDA for the treatment of BCG-unresponsive NMIBC, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022 in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Maximize the commercial potential Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We own exclusive, worldwide rights to Vicineum and we have out-licensed the rights to Vicineum in Greater China, the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey. If Vicineum receives marketing approval from the FDA for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we plan to pursue commercialization strategies that maximize the value of Vicineum in the United States by partnering with a contract sales organization. Based on our market research, we believe Vicineum has an innovative profile with a high possibility that patients, healthcare professionals and payors will be advocates for its use for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which we believe represents a significant commercial opportunity. We believe that we will be able to effectively communicate differentiating characteristics and key attributes of Vicineum to patients, physicians and payors, with the goal of establishing favorable reimbursement as well as a favorable formulary status in targeted urology practices. Additionally, we believe that our plans to partner with a contract sales organization should allow us to address the urologists-initiated treatment market for non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States in an efficient and effective way. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expand on the value of Vicineum through strategic partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we intend to build a North American specialty urology sales force to market the product in the United States. Outside the United States, we will continue to seek additional business development partners with urology expertise by selectively partnering with pharmaceutical and biopharmaceutical companies when we believe that a partner could bring additional resources and expertise to maximize the value of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. In 2020 and 2021, we entered into license agreements to support such commercialization efforts outside the United States for Greater China, MENA and Turkey.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Explore opportunities in combination therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We plan to continue discussions with potential partners that utilize technologies whose mechanism of action could be complementary to our TFPT platform. These technologies include, but are not limited to, checkpoint inhibitors, immune modulators and other immuno-oncology agents. In June 2017, we entered into a Cooperative Research and Development Agreement (&#8220;CRADA") with the National Cancer Institute ("NCI") for the development of Vicineum in combination with AstraZeneca&#8217;s immune checkpoint inhibitor durvalumab for the treatment of NMIBC. Vicineum is believed to work via a dual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells. Because of this second mechanism, there may be potential for a synergistic effect when given in combination with checkpoint inhibitors. Under the terms of the CRADA, this hypothesis is being tested by the NCI in Phase 1 clinical trial in patients with BCG-unresponsive NMIBC to evaluate the safety, efficacy and biological correlates of Vicineum in combination with durvalumab (&#8220;NCI Trial&#8221;). On September 10, 2021, preliminary results from an interim analysis of 12 patients in the NCI Trial (&#8220;Interim Analysis&#8221;) were presented at a conference hosted by the American Urological Association. Enrollment in the Phase 1 clinical trial is ongoing. Based on the Interim Analysis, the combination of Vicineum and durvalumab has been generally well-tolerated with no new safety signals emerging (no Grade 4 or 5 treatment-related adverse events) and has a similar safety profile compared to both agents used individually. The Interim Analysis also indicated a 3-month complete response rate of 42% (5/12) and a 12-month complete response rate of 17% (2/12). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deferred further development of Vicineum for the treatment of SCCHN and of VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, the commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We are also exploring collaborations for Vicineum for the treatment of SCCHN and for VB6-845d.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we are focused exclusively on the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and have deferred further development of our other product candidates. The following table sets forth our current development stage programs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><img src="sesn-20211231_g1.jpg" alt="sesn-20211231_g1.jpg" style="height:586px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vicineum for the Treatment of Non-Muscle Invasive CIS of the Bladder in Patients Previously Treated with Adequate or Less Than Adequate BCG</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing Vicineum, oportuzumab monatox, for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Vicineum is given via intravesical administration directly into the bladder. Vicineum utilizes an immunogenic cytotoxic protein payload that is a truncated form of ETA produced by the bacterial species </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Vicineum also includes an anti-EpCAM ScFv targeting domain that is required to deliver the ETA into EpCAM-expressing cancer cells. The toxicity to non-cancerous bladder cells is minimized due to their not having EpCAM over-expressed on their surface. In August 2018, we received Fast Track designation from the FDA for Vicineum for the treatment of BCG-unresponsive NMIBC. The FDA has conditionally accepted the proprietary brand name VICINEUM&#8482; for our product candidate, oportuzumab monatox.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most cancers that form in the bladder are transitional cell carcinomas that derive from the transitional cell lining of the bladder. Transitional cell carcinoma of the bladder can be characterized as either high-grade or low-grade. Low-grade bladder cancer often occurs</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the lining of the bladder, but rarely invades the muscular wall of the bladder or spreads to other parts of the body and is unlikely to be fatal. High-grade bladder cancer commonly occurs in the bladder, has a strong tendency to invade the muscular wall of the bladder, spread to other parts of the body and is more likely to result in death. Bladder cancer is also divided into muscle-invasive and non-muscle invasive, based on invasion of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">muscularis propria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is the thick muscle deep in the bladder wall. Muscle-invasive disease is more likely to spread to other parts of the body.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three forms of high-grade NMIBC: Ta, a papillary tumor in the innermost layer of the bladder lining; T1, a papillary tumor that has started to grow into the connective tissue beneath the bladder lining; and CIS, flat lesions of the transitional cell lining of the bladder. Papillary tumors are generally low-grade with low risk of progression, although about two to nine percent are high-grade, with a moderately high risk of progression to muscle-invasive bladder cancer. Evaluable CIS tumors are always high-grade, with a worse prognosis than papillary tumors, as such CIS tumors are more aggressive, with a higher probability of progression to muscle-invasive disease. Furthermore, the incidence of CIS in conjunction with Ta or T1 tumors results in a higher risk of recurrence and progression. About 75% to 85% of bladder cancers are non-muscle invasive. Of these, Ta tumors account for about 70%, T1 tumors account for about 20% and CIS lesions account for about 10%.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to World Cancer Research Fund International figures, bladder cancer is the tenth most common cancer diagnosed worldwide and the second most common malignancy of the genitourinary system, which refers to cancers of the urinary system of men and women and the reproductive organs of men.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, there were an estimated 573,000 new cases of bladder cancer diagnosed and 213,000 deaths worldwide, according to data from the Global Cancer Observatory. The 5-year global prevalence of bladder cancer, or the number of individuals with bladder cancer in a 5-year period, is estimated at 1.7 million individuals. The most recent data from the NCI's Surveillance, Epidemiology and End-Result Program ("SEER") estimated that approximately 84,000 new cases of bladder cancer would be diagnosed in 2021 and there would be approximately 17,000 deaths due to bladder cancer in the United States during 2021. Based on a 2014 publication in Current Opinion in Urology, among cancers in the United States, bladder cancer has the highest per-patient treatment costs, with an estimated overall cost of approximately $4.0 billion annually and has the highest overall cost among the elderly. Based on our assessment of the market, the treatment paradigm has remained the same since those figures were generated, and we believe the cost of care has increased.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMIBC makes up 75% to 85% of all bladder cancers. The high recurrence rate and ongoing invasive monitoring requirement of bladder cancers are the key contributors to the economic and human toll of this disease. Bladder cancer occurs predominantly in older patients (about nine of the ten people with bladder cancer are over the age of 55 years). The median age at diagnosis is approximately 73 years of age. Overall, the five-year survival rate for bladder cancer in the United States is 77%. While the five-year survival rates are 98% for stage zero and 88% for stage one NMIBC, once the cancer becomes invasive, the rates drop dramatically with five-year survival rates of 63%, 46% and 15% for stage two, three and four muscle invasive bladder cancers, respectively. We are targeting patients with non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Our initial target market includes the approximately 6,000 patients in the US diagnosed annually, including those patients with non-muscle invasive CIS of the bladder previously treated with adequate or less than adequate BCG. We would expect that, if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is approved by the FDA, patients would receive treatment until the earlier of 2 years and disease recurrence.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Approaches to Treatment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the initial treatment of Ta or T1 is transurethral resection of the bladder tumor ("TURBT") followed by BCG treatment. For CIS, whether or not TURBT is an option, BCG is the standard of care. BCG is a live attenuated strain of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium bovis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a diminished virulence in humans. Since BCG works by utilizing an immune/inflammatory mechanism, BCG is generally initiated two to four weeks after TURBT, allowing the urothelium to heal and lowering the risk of systemic infection. When high-grade bladder tumors have been completely resected, BCG is used as adjuvant therapy to prevent recurrence. In patients with residual disease after resection, BCG helps to eradicate residual disease and delay progression. The BCG regimen consists of an induction phase followed by a maintenance phase. The induction phase involves six consecutive once-weekly instillations of the drug into the bladder. The maintenance phase involves three consecutive once-weekly instillations repeated every three to six months for at least one year. The response rate to a single induction phase of BCG is 60% to 70% with an additional 30% to 50% of the non-responders becoming responders following a second induction phase. However, BCG&#8217;s failure rate for all responders is estimated to be as high as 50% within the first 12 months of treatment and 90% within five years. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patients who received BCG and whose disease is now BCG-unresponsive, surgical removal of the bladder, or a radical cystectomy has been recommended due to the risk of progression to muscle invasive disease, which greatly reduces a patient&#8217;s prognosis. Radical cystectomy is a complex surgery associated with a mortality rate of 8% within six months of surgery. The surgery also entails a number of short-term risks including bleeding and/or clots, infections, bowel obstruction, bowel perforation, peritonitis and injury to the urethra. More than 25% of radical cystectomy patients require hospital readmission for surgery-related complications within 90 days following surgery. The impact of radical cystectomy is life-altering, with major lifestyle changes, including incontinence and sexual dysfunction, and daily issues related to management of the external bag for urine collection.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Keytruda was approved by the FDA in January 2020 for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy and is the only approval of Keytruda in the NMIBC space. Keytruda has been on the market for the treatment of BCG-unresponsive CIS (+/- Ta/T1) patients since January 2020. In 2009, Endo Pharmaceuticals Inc.'s Valstar (valrubicin) was re-launched in the United States for the treatment of BCG-refractory CIS bladder cancer in patients for whom radical cystectomy is not an option. Valstar is administered directly into the bladder once a week for six weeks. Due to drug resistance and toxicities, Valstar has had limited clinical utility. Other than Keytruda and Valstar, there are no other approved therapies for BCG-unresponsive CIS bladder cancer. However, there are various other intravesical product candidates in development for the treatment of NMIBC, including product candidates developed by FerGene Inc. (Adstiladrin/nadofaragene firadenovec (rAd-IFN/Syn3)), AADi, LLC (ABI-009), ImmunityBio (Anktiva/N-803 in combination with BCG), Theralase Technologies Inc. (TLD-1433), Janssen (Erdafitinib and TAR-200) and CG Oncology (CG0070). In addition, systemically-administered checkpoint inhibitors are being evaluated for the treatment of NMIBC including products developed by Bristol-Myers Squibb (Opdivo alone or in combination with BCG +/- BMS986205), F. Hoffmann-La Roche AG (Tecentriq) and AstraZeneca (Imfinzi). Another route of administration for checkpoint inhibitor is currently being evaluated by Pfizer with the subcutaneous administration of Sasanlimab (PF-06801591) for the treatment of BCG-unresponsive NMIBC patients. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Update</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a CMC Type A Meeting with the FDA. During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that any of these future trials can proceed while addressing CMC issues raised in the CRL. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Clinical Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA.</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA encouraged us to include the Vista Trial data in a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the FDA previously conditionally accepted the name Vicineum for our product candidate, oportuzumab monatox, in the United States, this approval is subject to further and final review by FDA upon potential resubmission of a BLA. If the FDA objects to our proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">European Union</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we submitted a MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC under the EMA&#8217;s centralized procedure. On March 31, 2021, we were informed that the Committee for Medicinal Products for Human Use of the EMA had conditionally accepted the proprietary brand name Vysyneum for our product candidate, oportuzumab monatox, in the European Union. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the EMA previously conditionally accepted the name Vysyneum for our product candidate, oportuzumab monatox, in the European Union, this approval is subject to further and final review by the EMA upon potential resubmission of the MAA. If the EMA objects to our proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the EMA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, to develop, manufacture and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in Greater China. The Investigational New Drug application (&#8220;IND&#8221;) for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the partnership agreement between Sesen Bio and Qilu Pharmaceutical, the trial is being run at the sole cost of Qilu Pharmaceutical.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in the MENA region (20 countries in the Middle East and North Africa). No submission for registration has taken place in any of the countries as approvals are contingent on FDA or EMA approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. No submission for registration has taken place in either region as approvals are contingent on FDA or EMA approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Review</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 we disclosed that our Board of Directors (the &#8220;Board&#8221;) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#8220;Review&#8221;). The Review took place over the course of five months, involved full cooperation from our management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. It is now complete. As a result of the Review, the Board continues to fully support our current management team and believes no changes or amendments relating to our prior disclosures to the Securities and Exchange Commission (&#8220;SEC&#8221;) or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted. We intend to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Proposed Phase 3 Clinical Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior Phase 3 Clinical Trial &#8211; VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, through our subsidiary Viventia, commenced our single-arm, multi-center, open-label Phase 3 clinical trial ("VISTA Trial') in patients with BCG-unresponsive NMIBC who have received adequate BCG and whose disease is now BCG-unresponsive, and for whom the then-current standard of care was a radical cystectomy in the third quarter of 2015 in the United States and Canada. Based on safety and efficacy data observed with the longer 12-week induction in our Phase 2 clinical trial, the FDA agreed to our plan to employ more frequent dosing in the VISTA Trial, in which the primary endpoints were complete response ("CR") and duration of response ("DoR") in patients with CIS whose disease is BCG-unresponsive. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA&#8217;s guidance. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary and secondary endpoints for the VISTA Trial were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"></td><td style="width:26.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dose</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 mg of Vicineum (in 50 mL of saline)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total enrollment</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 patients, including 93 CIS patients whose disease is BCG-unresponsive</span></div></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary endpoints</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive; and</span></td></tr><tr style="height:23pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kaplan-Meier estimate of DoR for BCG-unresponsive CIS patients who experience a CR at 3 months (post-induction).</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with CIS were considered to have a CR if at the time of any disease status evaluation (per protocol every 13 weeks or any unscheduled evaluation) there was no evidence of high-grade disease (CIS, high-grade Ta or any grade T1 disease) or disease progression (e.g., to muscle invasive disease). Low-grade disease was not considered a treatment failure in these patients, and they could remain on study treatment following TURBT.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"><tr><td style="width:1.0%"></td><td style="width:27.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.485%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="7" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secondary endpoints</span></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-free survival in all patients;</span></td></tr><tr style="height:30pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRR at 6, 9, 12, 15, 18, 21 and 24 months in patients with CIS whose disease is BCG-unresponsive;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to cystectomy in all patients;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to disease recurrence in papillary patients;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFS in all patients;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS in all patients; and</span></td></tr><tr style="height:27pt"><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety and tolerability of Vicineum therapy in all patients.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exploratory endpoint</span></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate biomarkers that may be associated with response or disease progression or treatment failure, which may include, for example, EpCAM status, tumor subtype morphology, furin levels in tumor cell endosomes, presence of a glycosaminoglycan coat and presence of receptors that could impede a host anti-tumor immune response, such as PD-L1.</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment (under 2018 FDA guidance on treatment of NMIBC, adequate BCG is defined as at least one of the following (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course):</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and DoR for BCG-unresponsive CIS patients who experience a CR.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%), all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Phase 1 and 2 Clinical Trials</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Clinical Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We initiated an open-label, dose-escalating Phase 1 clinical trial of Vicineum for the treatment of BCG-unresponsive NMIBC in September 2004 at 22 sites in Canada. We enrolled 64 patients with high-grade Ta or T1 tumors with or without CIS (17 of which had CIS) and who had previously received at least one treatment of BCG. The Phase 1 clinical trial was designed to assess safety and determine the maximum tolerated dose, and the recommended Phase 2 dose. The secondary objective was to explore the anti-tumor activity of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eight dose levels were initially evaluated, ranging from 0.1 to 10.56 mg, and given once weekly for six consecutive weeks. Each dose was administered by instillation and held for two hours prior to voiding. Safety data from each dose cohort was evaluated after three weeks of treatment before proceeding to the next dose cohort. A maximum tolerated dose was not reached; therefore, additional escalations through 13.73 mg, 17.85 mg, 23.20 mg and 30.16 mg were undertaken. No dose-limiting toxicities were reported and no maximum tolerated dose was reached in these additional dose-escalations. Vicineum was generally well-tolerated at each of these escalated doses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CR was defined in this Phase 1 clinical trial as non-positive urine cytology and either normal cystoscopy or abnormal cystoscopy with negative biopsy. Of the 64 patients enrolled, only 61 were considered to be evaluable for efficacy as two patients were excluded from the analysis due to an absence of BCG treatment prior to this Phase 1 clinical trial, and there was one unrelated death for whom no final tumor assessment was obtained. Evidence of clinical efficacy, as defined by a CR, was achieved by 24 of the 61 randomized patients (39%). Only three of the 17 patients (18%) treated in the 0.1-&lt;1 mg/dose range were CRs. In contrast, seven of the 14 patients (50%) treated in 1.0-&lt;10 mg/dose range and 14 of the 30 patients (46.7%) treated in the &#8805;10 mg/dose range experienced CRs at the three-month assessment. Of the patients with CIS, five of the 17 patients (29%) achieved a CR, while non-recurrence was observed in seven of the 16 patients with T1 (43.8%) and 12 of the 28 patients with Ta (42.8%). This Phase 1 clinical trial was completed in April 2006.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 Clinical Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on our Phase 1 clinical trial conducted in Canada, we submitted the IND for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA in August 2005, and we initiated an open-label Phase 2 clinical trial of Vicineum in March 2007 at 20 sites in Canada and the United States. We enrolled 46 patients with CIS (with or without Ta or T1) who had previously received at least one treatment of BCG. Of the 46 patients enrolled, 27 patients (58.7%) had received at least two treatments of BCG. The Phase 2 clinical trial was designed to determine the tolerability and explore the potential for clinical benefit from Vicineum. Clinical benefit was defined in this Phase 2 clinical trial as a CR or no evidence of disease at the three-month evaluation. A CR was defined in this Phase 2 clinical trial as no histological evidence of disease and negative urine cytology. Any cases with no histological evidence of disease on initial biopsy but atypical or suspicious urine cytology were also considered CRs only if they remained negative after being evaluated with repeat biopsy, directed and random. A patient was considered to have a durable CR if that patient obtained a CR and remained disease-free for a period of at least 12 months from initiation of treatment. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dosing regimen for our Phase 2 clinical trial included an induction phase followed by a maintenance phase, consisting of three weekly treatments and then nine weeks of no treatment repeated every three months for at least one year. There were two treatment groups in this Phase 2 clinical trial. Treatment Arm A consisted of 23 patients, of which 22 were ultimately evaluable as one patient violated eligibility requirements early in this Phase 2 clinical trial. Twenty-two patients in the induction phase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received six consecutive once-weekly instillations of 30 mg of Vicineum. At the three-month assessment, patients with residual disease but no disease progression-where disease progression was defined as being muscle invasive-were eligible for either a second induction phase or a maintenance phase, which consisted of three consecutive once-weekly instillations repeated every three months for at least one year. Of the 13 patients who did not achieve a CR at the three-month assessment, nine patients elected additional treatment. From these nine, two became CRs after receiving maintenance dosing. Treatment Arm B was added to evaluate a longer induction cycle using the same dose. In Treatment Arm B, 23 patients in the induction phase received 12 consecutive once-weekly instillations of 30 mg Vicineum. At the three-month assessment, the combined CR rate for both treatment arms was 40%. At the 12-month assessment, the CR rate in Treatment Arm A was 13%, but 17% in Treatment Arm B. Of those patients who did not achieve a CR at the three-month assessment, 73% had either a reduction in tumor size or did not experience further tumor growth.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data below shows the percentage change in surface area of cancer within the bladder, based on bladder mapping data utilizing cystoscopy in 40 patients. The following charts demonstrate the responses in this Phase 2 clinical trial in Treatment Arm A and Treatment Arm B:</span></div><div style="margin-bottom:6pt;text-align:center"><img src="sesn-20211231_g2.jpg" alt="sesn-20211231_g2.jpg" style="height:342px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><img src="sesn-20211231_g3.jpg" alt="sesn-20211231_g3.jpg" style="height:425px;margin-bottom:5pt;vertical-align:text-bottom;width:638px"/></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Phase 2 clinical trial was completed in September 2009.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Near the completion of this Phase 2 clinical trial in 2009, Valstar was re-launched in the United States for the treatment of BCG-refractory CIS bladder cancer in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. However, because physicians were not widely prescribing Valstar to their patients and it was not an approved therapy in Europe, this disrupted our originally designed clinical path of a head-to-head pivotal Phase 3 clinical trial of Vicineum against Valstar. Due to the uncertainty of the standard of care in this space, our efforts were put on hold until a clear clinical path was established. In May 2013, the FDA co-sponsored a public workshop where it evaluated potential trial designs for the development of therapies for NMIBC and specifically provided regulatory guidance supporting the idea that a single-arm clinical trial could provide sufficient evidence of benefit if the results were robust. The panel suggested it is acceptable to include high-risk papillary patients without CIS in a clinical trial with CIS patients because the clinical management and outcome if left untreated is considered to be the same. In September 2014, we conducted an end of Phase 2 meeting with the FDA and, consistent with our interactions with the FDA during this meeting, refocused our resources to commence an open-label, non-randomized Phase 3 clinical trial of Vicineum in BCG-unresponsive NMIBC, which ended up being our Phase 3 VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety data</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our safety data from 110 patients in our Phase 1 and Phase 2 clinical trials support further development of Vicineum for the treatment of NMIBC BCG failures. There were no Grade 4 or Grade 5 serious adverse events that were considered by the clinical investigators to be related to Vicineum during the Phase 1 and Phase 2 clinical trials of Vicineum for the treatment of NMIBC BCG failures. There was one Grade 5 serious adverse event, or death, which was determined by the clinical investigator to be unrelated to Vicineum. The most common reported treatment-related adverse events were an abnormally frequent passage of small amounts of urine, blood in the urine and painful urination, the majority of which were considered to be mild or moderate in severity. No patients discontinued treatment due to a Vicineum-related adverse event during the Phase 1 and Phase 2 clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outside of United States ("OUS") Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan. We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing Vicineum for the prevention and treatment of cancers including, but not limited to, NMIBC and various sub-types of NMIBC (the &#8220;Field&#8221;) in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize Vicineum in the Field in Greater China. A joint development committee was established between us and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to Vicineum in Greater China. We and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which we will manufacture or have manufactured and supply Qilu with all quantities of Vicineum necessary for Qilu to develop and commercialize Vicineum in the Field in Greater China until we have completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for Vicineum has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a licensed product-by-licensed product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to us in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in the MENA region (20 countries in the Middle East and North Africa). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties on net sales in the MENA region for the term of the Hikma License Agreement. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with EIP pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the license agreement, we are entitled to receive an upfront payment of $1.5 million. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive additional regulatory and commercial milestone payments of $2.0 million and are entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vicineum for the Treatment of SCCHN</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vicineum (formerly referred to as Proxinium in publications, focused on this clinical setting), is also being developed as a treatment for patients with recurrent, locally advanced or metastatic EpCAM-expressing SCCHN who have received at least one prior platinum-based chemotherapy regimen. To treat SCCHN, Vicineum is administered via injection directly into the targeted tumor, or intratumoral injection. Vicineum for the treatment of SCCHN has received Orphan Drug Designation from the FDA and the EMA and Fast Track designation from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our two Phase 1 clinical trials encompassing 44 patients treated with Vicineum, a complete resolution or reduction in size of injected tumors was observed in 16 of the 30 evaluable patients (53%) with EpCAM-expressing tumors as assessed by the investigators&#8217; clinical measurements, the investigators' overall assessment including qualitative changes and assessment of available radiologic data. An additional 27% of evaluable patients had stable disease and, therefore, the results indicate an overall tumor control rate of approximately 80%. In addition, three out of the four patients with CRs of injected tumors had regression or complete resolution of adjacent non-injected lesions. Vicineum was generally well-tolerated during the clinical trials. Dose-limiting toxicity in the Phase 1 clinical trials was transaminase elevation in liver enzymes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our clinical trials involving Vicineum for the treatment of SCCHN, we also observed some stabilization, partial reduction and complete resolution of non-injected tumors. We believe that TFPT mediated killing of cancer cells occurs via a mechanism known as ICD, which is known to enhance the presentation of neoantigens to the immune system. We believe that this, combined with the immunogenic nature of our cytotoxic protein payload creates a heightened immune response, wherein naive cytotoxic T-cells are stimulated by antigen presenting cells, such as dendritic cells, presenting tumor cell surface antigens following the death of cancer cells. We believe that this anti-tumor response may complement checkpoint inhibitor therapies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our clinical trials involving Vicineum for the treatment of SCCHN, there were no Grade 5 serious adverse events that were considered by the clinical investigator to be related to Vicineum. The serious adverse events (Grade 3 and Grade 4) that were reported in the clinical trials of Vicineum for the treatment of SCCHN and were considered to be possibly, probably or definitely related to treatment consisted of abnormal tumor growth, anorexia, cancer pain, decrease in red blood cells, difficulty swallowing, elevated calcium levels, facial pain, fatigue, high blood sugar, influenza like illness, injection site pain, liver function abnormalities, low albumin level, low sodium concentration, nausea, rash, swelling, tumor hemorrhage and tumor necrosis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the combined Phase 1 (VB4-101 and VB4-101A) and Phase 2 (VB4-845-01-IIA) studies, seven subjects died during the clinical trials of Vicineum for the treatment of SCCHN, but none of the deaths were deemed to be Vicineum-related. Out of the four patients who discontinued treatment due to liver function test abnormalities, 2 subjects were in study VB4-101 and 2 were subjects were in VB4-101A). Four subjects withdrew from the clinical trials. Three of the four subjects withdrew at their request and one of the four subjects withdrew at the request of the investigator.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 (VB4-845-01-lllA) VB4-845-01-lllA was a randomized, multicentre therapeutic confirmatory study evaluating the safety and efficacy of Vicineum plus BSC versus BSC alone in the treatment of patients with advanced SCCHN who had received at least 1 anti-cancer treatment regimen for advanced disease. One hundred and sixty-six of the approximately 292 patients were enrolled at 75 sites. The primary endpoint for the study was overall survival. A total of 166 patients had been randomized into the study. Of the 166 patients, 82 were randomized to the Vicineum treatment plus BSC arm and 84 patients were randomized to the BSC arm.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VB4-845-01-IIIA was terminated early due to a corporate decision unrelated to safety or efficacy. At the time of study termination, survival data was available for 133 of 142 patients that had been randomized. A total of 66 were enrolled on the BSC arm and 67 enrolled in the Vicineum plus BSC treatment arm. Of the 66 BSC patients enrolled in the BSC arm, there were 43 documented deaths in this treatment arm; the date of death was known for 36 patients and unknown for 7. Of the patients treated with Vicineum, 41 deaths were documented with the date of death known for 37 patients and unknown for 4. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim safety data was available for 132 of 139 patients that had been randomized. One hundred and eleven patients reported at least 1 AE. Thirty-six patients reported 205 adverse events (AEs) that were treatment related. Most of the treatment-related AEs were mild to moderate in severity. Of the 205 treatment-related AEs reported, there were 23 Grade 3 events and 2 Grade 4 events. There were no Grade 5 related AEs reported. The 2 related Grade 4 events were 2 occurrences of tumour necrosis in 1 patient; both were considered probably related to the treatment. Most related AEs resolved on their own and did not require additional treatment. Others were treated with concomitant medications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four patients in the Vicineum plus BSC group reported Grade 3 increases in both ALT and AST. One patient reported a Grade 3 increase in ALT and another patient reported a Grade 3 increase in AST. All of the Grade 3 increases in ALT/AST occurred in the Vicineum plus BSC group. No Grade 4 increases in ALT/AST were reported. In 1 patient, Vicineum was discontinued due to liver function test abnormalities, in 1 patient Vicineum was interrupted due to liver function test abnormalities and in the last patient Vicineum was discontinued due to disease progression.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deferred further development of Vicineum for the treatment of SCCHN in order to focus our efforts and our resources on our ongoing development and, if approved, the commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We are also exploring collaborations for the development of Vicineum for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or exclusively license worldwide rights to our Vicineum for the treatment of SCCHN intellectual property portfolio that provides for an unextended patent term until 2036. See &#8216;&#8216;Our Intellectual Property&#8217;&#8217; below for additional details.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VB6-845d</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead systemically-administered product candidate, VB6-845d, is being developed as a treatment for multiple types of EpCAM-positive solid tumors. VB6-845d is a TFPT consisting of an EpCAM targeting Fab genetically linked to deBouganin, which is administered by intravenous infusion. DeBouganin acts by inhibiting protein synthesis and helps circumvent multi-drug resistance mechanisms. EpCAM is over-expressed on the cell surface of many solid tumors, including breast, colorectal, gastric, lung, ovarian and prostate. EpCAM overexpression has been shown to be involved in promoting malignant progression. In addition, EpCAM overexpression is associated with increased tumor grade, disease progression, increased proliferative phenotypes and diminished survival. EpCAM is also a cancer stem cell marker. A Phase 1 clinical trial conducted with VB6-845, the prior version of VB6-845d, revealed no clinically relevant immune response to the deBouganin payload. Five of seven patients (71.4%) maintained stable disease (meaning no change in tumor size from baseline) after one completed cycle of treatment (four weeks). Two patients had decreases in target tumor size, and one subject who continued treatment through a third cycle (12 weeks) maintained stable disease. Interim safety data from our Phase 1 clinical trial was consistent with expectations for the study population of patients with advanced solid tumors and the anticipated effects of targeted biological therapies containing immunogenic sequences.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the antibody responses directed against the Fab seen in our Phase 1 clinical trial conducted in Russia and in the country of Georgia, we de-immunized the Fab portion of VB6-845 to create VB6-845d. In April 2016, we submitted an IND to the FDA in preparation of initiating a Phase 1/2 clinical trial of VB6-845d in patients with EpCAM-positive cancers in the United States.&#160;The IND was withdrawn in July 2016 after we received initial feedback from the FDA indicating that they had identified hold and non-hold deficiencies that needed to be addressed.&#160;In December 2016, we submitted a request for a pre-IND meeting to&#160;seek input on the manufacturing,&#160;nonclinical and clinical plans for VB6-845d prior to resubmitting an IND. In February 2017, the FDA provided guidance on our manufacturing and nonclinical plans for VB6-845d. Overall, we believe that our pre-clinical data and the interim Phase 1 clinical data support further clinical investigation of VB6-845d to explore whether it may fulfill the significant unmet medical need in the treatment of patients with EpCAM-positive solid tumors. Specifically, we believe that VB6-845d has potential to be a first-in-class TFPT capable of providing clinical benefit in these difficult to treat patient populations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our TFPTs utilizing our de-immunized deBouganin payload may be enhanced if combined with checkpoint inhibitors. We believe that deBouganin&#8217;s potential effect on cancer cells could promote an immunogenic response that may enhance the action of checkpoint inhibitors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deferred further development of VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We are also exploring collaborations for VB6-845d.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or exclusively license worldwide rights to our VB6-845d intellectual property portfolio that provides for an unextended patent term until at least June 2025 and, method of treatment patents and applications for VB6-845d are granted, until at least 2036. See &#8216;&#8216;Our Intellectual Property&#8217;&#8217; below for additional details.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMC</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2020, we and Leiden University Medical Center (&#8220;LUMC&#8221;) agreed to the co-development of an imaging agent (the &#8220;Imaging Agent&#8221;) that is comprised of an antibody fragment of Vicineum&#8482;, and an imaging molecule supplied by LUMC. The Imaging Agent is designed to delineate tumor from normal tissue during surgery so that the tumor margin is clearly visible, thereby helping to ensure clear margins after surgical excision of cancerous tissue. A Phase 1/2 clinical trial of the Imaging Agent was successfully completed by LUMC with favorable tolerability and demonstrated tumor detection, which we believe further supports the targeting specificity of Vicineum. We signed an agreement with LUMC whereby we have an option to obtain an exclusive, worldwide license to any intellectual property related to the Imaging Agent. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBI-031 - Out-License Agreement with Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into the Roche License Agreement, pursuant to which we granted Roche an exclusive, worldwide license, including the right to sublicense, to our patent rights and know-how related to our monoclonal antibody EBI-031 and all other IL-6 anti-IL antagonist monoclonal antibody technology owned by us (collectively, the &#8220;Licensed Intellectual Property&#8221;). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (the &#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost. At the time of the Roche License Agreement, EBI-031, which was derived using our previous AMP-Rx platform, was in pre-clinical development as an intravitreal injection for diabetic macular edema and uveitis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received from Roche an upfront license fee of $7.5 million in August 2016 upon the effectiveness of the Roche License Agreement following approval by our stockholders, and Roche agreed to pay up to an additional $262.5 million upon the achievement of specified regulatory, development and commercial milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5 million is payable to us for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5 million in development milestones, the next of which is $30.0 million for initiation of the first Phase III study, (ii) $50.0 million in regulatory milestones and (iii) $75.0 million in commercialization milestones. In September 2016, Roche paid us the first development milestone of $22.5 million as a result of the IND application for EBI-031 becoming effective on or before September 15, 2016.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, a $20 million milestone was achieved due to Roche initiating a Phase II clinical trial. We invoiced Roche $20 million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $20 million was received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional amounts of up to $65.0 million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to us and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing ("Initiation") in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay us $135.0 million within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from us, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay us, within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from us, $265.0 million, which amount would be reduced to $220.0 million if none of our patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either we or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to us or by providing written notice if we are debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. We may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of 12 months where Roche is not conducting sufficient development activities with respect to the products made from the Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Roche reported that it started a multi-center, non-randomized, open-label, multiple ascending dose Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravitreal EBI-031 monotherapy in patients with diabetic macular edema. Further, Roche reported that once determined, an extended cohort will be dosed with the optimal dose of EBI-031 while another arm of the trial will test EBI-031 in combination with Lucentis (ranibizumab) following intravitreal administration in patients with diabetic macular edema.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Roche reported that it started enrollment of two Phase 2 clinical trials in patients with diabetic macular edema (&#8220;DME&#8221;). The first clinical trial, BP43445 (NCT05151731), is a multicenter, randomized, double-masked, active comparator-controlled trial to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of EBI-031 administered intravitreally in patients with DME. The second clinical trial, BP43464 (NCT05151744), is a combination trial to assess the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of EBI-031 with ranibizumab (an anti-vascular endothelial growth factor inhibitor) compared with ranibizumab alone in DME patients. For both trials, only one eye will be chosen as the trial eye and the duration of the trial will be 52 weeks.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own or exclusively license approximately 13 families of patents and applications, which generally relate to our TFPT-based product candidates and evolving our platform of targeting agents, cytotoxins (such as deBouganin) and linker technologies. As our product candidates evolve through clinical development, we continue to monitor advancements and bolster patent coverage where possible.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidate - Vicineum </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclusively license two families under a license agreement with the University of Zurich ("Zurich") (the "Zurich License Agreement") which, among other things, include composition of matter claims directed to EpCAM antibody chimeras, EpCAM antibody chimera-cytotoxin conjugates, and their potential use in treating bladder and head and neck cancer. These families claim all or portions of Vicineum, as well as methods of treating bladder and head and neck cancer consist of issued patents in the United States, Europe, Canada, China, Israel and Japan and also include pending applications in the United States. The expiry dates of the patents in this family are April 2024 and June 2025, subject to any applicable patent term adjustment or extension that may be available on a jurisdictional basis. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Zurich portfolio, we own two issued US patents related to Vicineum. The expiry date of these patents is February 2029, subject to any applicable patent term extension that may be available on a jurisdictional basis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have patent families relating to treatment regimens using Vicineum that include issued patents in the United States, Australia and Japan and patent applications in Canada, Europe and Hong Kong. These patents will expire in 2036. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a license agreement with Micromet AG ("Micromet") (the "Micromet License Agreement"), now part of Amgen, Inc., which grants us non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with XOMA Ireland Limited ("XOMA") (the "XOMA License Agreement") which grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBI-031 and our Legacy Product Candidates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wn the following families of patents and patent applications related to EBI-031 and our legacy product candidates. As of February&#160;28, 2022, our patent portfolio includes the following patents and applications related to our legacy product candidates:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provisional application directed to compositions and methods for increasing the retention of therapeutic agents in the eye which, if converted and granted, is expected to expire in 2038.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provisional application directed to compositions and methods for increasing the retention of anti-VEGF therapeutic agents in the eye which, if converted and granted, is expected to expire in 2038; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provisional application directed to compositions and methods for increasing the retention of RGD therapeutic agents in the eye which, if converted and granted, is expected to expire in 2038.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of our knowledge based on correspondence received on February 25, 2022, the followi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng families are owned by us, and licensed to Roche pursuant to the Roche License Agreement dated June 10, 2016:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents covering the IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including IL-6 antibody EBI-029, filed in the United States, Australia, China, Japan, Korea, New Zealand, Russia and South Africa, that expire in November 2033; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications covering the IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including IL-6 antibody EBI-029, filed in Brazil, Canada, Europe, India, Mexico, United States and Singapore, and, if granted, are expected to expire in 2033; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents covering IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including the IL-6 antibody EBI-031, in Australia, Austria, Belgium, Bulgaria, Chile, China, Columbia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Indonesia, Ireland, Italy, Japan, Lithuania, Macau, Malaysia, Mexico, Morocco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United States and United Kingdom, that expire in November 2035; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications covering IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including the IL-6 antibody EBI-031, having applications pending or to be filed in Algeria, Bahrain, Brazil, Canada, Costa Rica, Europe, Egypt, India, Israel, Korea, New Zealand, Oman, Peru, Philippines, Qatar, Saudi Arabia, Singapore, Thailand, United Arab Emirates, United States and Vietnam, and, if granted, are expected to expire in 2035; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications in China, Europe, Japan and the United States, each corresponding to a United States provisional application covering the IL-6 antibody EBI-031 formulation, which, if granted, are expected to expire in 2037.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Vicineum License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview and Exclusivity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with the University of Zurich ("Zurich") which grants us exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to our targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same. These patents cover some key aspects of Vicineum. Upon receipt of the CRL regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, we became obligated to pay $0.5&#160;million in a milestone payment to Zurich. We are also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by us to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. For the year ended December 31, 2020, we recorded an expense of $0.3&#160;million for the achievement of the development milestone related to the submission of our BLA for Vicineum with the FDA. For the year ended December 31, 2021, we recorded an expense of $0.5&#160;million for the regulatory milestone related to receipt of the CRL from the FDA in August 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights, at our sole expense, while Zurich is afforded reasonable opportunities to review and comment on such activities. If appropriate, we shall apply for an extension of the term of any licensed patent where available, for example, in at least the United States, Europe and Japan. In the event of any substantial infringement of the patent rights, we may request Zurich to take action to enforce the licensed patents against third parties. If the infringing activity is not abated within 90 days and Zurich has elected not to take legal action, we may bring suit in our own name (and in Zurich&#8217;s name, if necessary). Such action will be at our own expense and Zurich will have the opportunity to join at its own expense. Recoveries from any action shall generally belong to the party bringing the suit, but (a) in the event that we bring the action and an acceptable settlement or monetary damages are awarded, then Zurich will be reimbursed for any amount that would have been due to Zurich if the products sold by the infringer actually had been sold by us, or (b) in the event a joint legal action is brought, then the parties shall share the expense and recoveries shall be shared in proportion to the share of expense paid by the respective party. Each party is required to cooperate with the other in litigation proceedings at the expense of the party bringing the action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Zurich License Agreement expires as of the expiration date of the last patent to expire within the Zurich patent rights. We are currently projecting an expiration date for the United States licensed patents in June 2025, subject to any applicable patent term extension that may be available on a jurisdictional basis. Zurich has the right to terminate the Zurich License Agreement if we breach any obligation of the agreement and fail to cure such breach within the applicable cure periods. We have the right to terminate the Zurich License Agreement at any time and for any reason by giving 90 days written notice to Zurich.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants us nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of December 31, 2021, we may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&#160;million at exchange rates in effect on December 31, 2021). We are also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, we are required to pay to Micromet an annual license maintenance fee of &#8364;50,000 (approximately $56,625 at exchange rates in effect as of December 31, 2021), which can be credited towards any royalty payment we owe to Micromet. We recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of our BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. We recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Micromet, at its sole expense, is responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights. In any patent enforcement action initiated by Micromet, we may be required, upon the request of Micromet and at Micromet&#8217;s expense, to provide reasonable assistance to Micromet with respect to such enforcement action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Micromet License Agreement expires as of the expiration of any royalty obligations under the License Agreement. Either party has the right to terminate the Micromet License Agreement if the other party fails to comply with any of its material obligations under the Micromet License Agreement and fails to cure such non-compliance within the applicable cure periods.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with XOMA Ireland Limited ("XOMA") which grants us non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, we are required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, we anticipate that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. We are also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. We have the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XOMA, at its sole expense, is responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights. In any patent enforcement action initiated by XOMA, we may be required, upon the request of XOMA and at XOMA&#8217;s expense, to provide reasonable assistance to XOMA with respect to such enforcement action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the XOMA License Agreement expires as of the expiration of any royalty obligations under the XOMA License Agreement. Either party has the right to terminate the XOMA License Agreement if the other party fails to comply with any of its material obligations under the XOMA License Agreement and fails to cure such non-compliance within the applicable cure periods.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a 31,100 square foot manufacturing, laboratory, warehouse and office facility in Winnipeg, Manitoba. We have three 15-liter fermenters, one 30-liter fermenter, one 150-liter fermenter, one 500-liter fermenter and one 1,500-liter fermenter. Our classified fermentation suite and post-production processing capabilities were dedicated to producing our pre-clinical study and clinical trial batches of Vicineum. In September 2017, we completed the manufacturing of all Vicineum necessary for our Phase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 VISTA Trial and for our CRADA with the NCI. In conjunction with this achievement, we ended our manufacturing activities at our facility in Winnipeg and completed the technology transfer process</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to outsource future Vicineum clinical and commercial to third-party manufacturers.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fujifilm and Baxter </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm (the &#8220;Fujifilm MSA&#8221;) for the manufacturing process and technology transfer of Vicineum drug substance production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter (the &#8220;Baxter CSA&#8221;) for the manufacturing process and technology transfer of Vicineum drug product production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed manufacturing of the drug substance process performance qualification (&#8220;PPQ&#8221;) batches at Fujifilm and in September 2020, we successfully completed the drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach is in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for Vicineum produced by Fujifilm and Baxter were found to be highly comparable to our supply of Vicineum produced at our Winnipeg facility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, and that any of these future trials can proceed while addressing CMC issues raised in the CRL.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we signed a Scope of Work ("SOW #11") with Fujifilm under the Fujifilm MSA for the manufacturing of commercial batches of Vicineum in 2022 and 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use Vicineum produced by Fujifilm and Baxter for any future clinical trials of Vicineum, including the additional Phase 3 clinical trial, and, if approved, for commercial supply.</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qilu</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Competition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is highly competitive, subject to rapid and significant technological change and has a strong emphasis on developing proprietary products. While we believe that our next generation TFPT platform, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from both large and small pharmaceutical and biotechnology companies, academic institutions and other research organizations; specifically with companies, institutions and organizations that are actively researching and developing products that attach proprietary cell-killing payloads to antibodies for targeted delivery to cancer cells. Our competitors include, but are not limited to:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">NMIBC: Merck &amp; Co., Inc. (Keytruda/pembrolizumab and BCG) (approved drugs), Endo Pharmaceuticals Inc. (Valstar/valrubicin) (approved drug), FerGene Inc. (Adstiladrin/nadofaragene firadenovec (rAd-IFN/Syn3)), Medical Enterprises Ltd. (Synergo RITE plus mitomycin C), Aadi, LLC (ABI-009), ImmunityBio (Anktiva/N-803 in combination with BCG), CG Oncology. (CG0070), Theralase Technologies Inc. (TLD-1433 photodynamic compound), Bristol-Myers Squibb (Opdivo/nivolumab with or without BCG or BMS-986205), F. Hoffmann-La Roche AG (Tecentriq/Atezolizumab), AstraZeneca (Imfinzi/durvalumab with or without BCG or External Beam Radiotherapy), Eli Lilly and Company (Gemcitabine) and Telormedix SA (Vesimune); Pfizer, Inc. (Sasanlimab);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SCCHN: Bristol-Myers Squibb Company (Opdivo/nivolumab) (approved drug), Eli Lilly and Company, and Merck (Erbitux, pembrolizumab) (approved drugs);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple types of solid tumors: Amgen Inc. (Panitumumab) (approved drug), Bayer AG and Onyx Pharmaceuticals (Sorafenib) (approved drug), Bristol-Myers Squibb Company, Eli Lilly and Company, and Merck (Erbitux) (approved drug), F. Hoffmann-La Roche AG (Bevacizumab) (approved drug), Genentech, Inc. (Bevacizumab, Erlotinib and Trastuzumab) (approved drugs), Pfizer, Inc. (Sunitinib) and Trion Research GmbH (Removab); and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition to competition from alternative treatments, we may also face competition from products that are biosimilar to, and possibly interchangeable with, our product candidates. Biosimilar products are expected to become available over the coming years. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then and insurers or other third-party payors may encourage or even require the use of lower priced biosimilar products. Even if our treatments receive market authorization, they may not be listed on the formularies of payors (public or private insurers) or reimbursed. This may impact the uptake of the drug as a treatment option for patients and/or the price at which the drug can be sold at. Further, if the drug is reimbursed it may be at a narrower indication than the full scope of market authorization.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical studies, conducting clinical trials, obtaining regulatory approval and marketing than we do. These competitors are also active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Moreover, specialized biologics, biopharmaceutical and biotechnology companies may prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or cheaper than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our product&#8217;s entry. We believe the factors determining the success of our programs will be the drug design, effectiveness against multi-drug resistance mechanisms, efficacy, safety, price and convenience of our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biologics company, we are subject to extensive regulation by the FDA, and other national, supranational, state, provincial and local regulatory agencies. We are also subject to extensive regulation by similar governmental authorities in other countries in which we operate. In the United States, the Federal Food, Drug, and Cosmetic Act ("FDCA") and the Public Health Service Act ("PHSA") and their implementing regulations set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval, post-approval monitoring and reporting, labeling, storage, record keeping, distribution, import, export, advertising and promotion of our product candidates. Although the discussion below focuses on regulation in the United States, we anticipate seeking approval to market our products in other countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope to that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the EU are addressed in a centralized way through the European Commission following the opinion of the EMA, but country-specific regulation in the individual European Union Member States ("EU Member States") remains essential in many respects. The process of obtaining regulatory marketing approvals and the subsequent compliance with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate supranational, federal, state, provincial, local and non-US statutes and regulations require the expenditure of substantial time and financial resources, and we may not be successful in any given jurisdiction.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">US Government Regulation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, drug products are regulated by the FDA under the FDCA and other laws, including, in the case of biologics, the PHSA. Drug products are also subject to other federal, state and local statutes and regulations. A failure to comply with any applicable requirements during the product development, approval, or post-approval periods may lead to administrative or judicial sanctions, including, among other things, the imposition by the FDA or an institutional review board ("IRB") of a hold on clinical trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, or administrative, civil and/or criminal investigation, penalties or prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, all of our product candidates are regulated by the FDA as biologics. Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the United States. Manufacturers of biologics may also be subject to state and local regulation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps required before a biologic may be marketed in the United States generally include:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of pre-clinical studies, animal studies and formulation studies, some in compliance with the FDA&#8217;s current Good Laboratory Practices ("GLP") regulations, and the Animal Welfare Act administered and enforced by the United States Department of Agriculture;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND to support human clinical testing, which must become effective before human clinical trials may commence;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an IRB before each trial may be initiated at each clinical site;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled clinical trials under protocols submitted to the FDA and reviewed and approved by each IRB, conducted in accordance with federal regulations and current Good Clinical Practices ("GCP") to establish the safety, purity and potency of the biologic for each targeted indication;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of a BLA to the FDA;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facilities at which the biologic is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of a BLA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-clinical Studies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical studies include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the pre-clinical studies must comply with federal regulations and requirements, including, as applicable, GLP and the Animal Welfare Act. The results of the pre-clinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA evaluates the IND to determine whether there is an adequate basis for starting the product candidate in initial clinical trials, and the IND must become effective before human clinical trials may be commenced. Additional pre-clinical studies may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If during this 30-day period the FDA does not raise any concerns or issues that must be addressed prior to the commencement of clinical trials or does not impose a clinical hold, the IND becomes effective 30 days following the FDA&#8217;s receipt of the IND and the clinical trial proposed in the IND may begin.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators. Clinical trials are subject to extensive regulation and must be conducted in compliance with (i) federal regulations, (ii) GCP standards, which set safeguards to protect the rights and health of patients and establish standards for conducting, recording data from, and reporting results of clinical trials, and (iii) protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if any. Non-US studies conducted under an IND generally must meet the same requirements that apply to studies being conducted in the United States. The informed written consent of each study patient must be obtained before the patient may begin participation in the clinical trial. The study protocol, study plan, and informed consent forms for each clinical trial must be reviewed and approved by an IRB for each clinical site, and the study must be conducted under the auspices of an IRB for each trial site. Investigators and IRBs must also comply with FDA regulations and guidelines, including those regarding oversight of study patient informed consent, complying with the study protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial program for a product candidate is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases are as follows:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 involves the initial introduction of a product candidate into humans. Phase 1 clinical trials are typically conducted in healthy human subjects, but in some situations are conducted in patients with the target disease or condition. These clinical trials are generally designed to evaluate the safety, metabolism, pharmacokinetic ("PK") properties and pharmacologic actions of the product candidate in humans, the side effects associated with increasing doses and, if possible, to gain early evidence of effectiveness. During Phase 1 clinical trials, sufficient information about the product candidate&#8217;s PK properties and pharmacological effects may be obtained to inform and support the design of Phase 2 clinical trials. The total number of participants included in Phase 1 clinical trials varies, but is generally in the range of 20 to 80;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 includes the controlled clinical trials conducted to obtain initial evidence of effectiveness of the product candidate for a particular indication(s) in patients with the target disease or condition, to determine dosage tolerance and optimal dosage, and to gather additional information on possible adverse side effects and safety risks associated with the product candidate. Phase 2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 clinical trials are clinical trials conducted in an expanded patient population at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the product candidate has been obtained and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the product candidate and to provide an adequate basis for regulatory approval. Phase 3 clinical trials usually involve several hundred to several thousand participants. In most cases, the FDA requires two adequate and well controlled Phase 3 clinical trials to demonstrate the efficacy of the product candidate, although a single Phase 3 clinical trial with other confirmatory evidence may be sufficient in certain instances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decision to suspend or terminate development of a product candidate may be made by either a health authority body, such as the FDA, by an IRB, or by a company for various reasons and during any phase of clinical trials. The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. In some cases, clinical trials are overseen by a data safety monitoring board ("DSMB"), which is an independent group of qualified experts organized by the trial sponsor to evaluate at designated points in time whether or not a trial may move forward and/or should be modified. These decisions are based on unblinded access to data from the ongoing trial and generally involve determinations regarding the benefit-risk ratio for study patients and the scientific integrity and validity of the clinical trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are requirements for the registration of certain clinical trials of product candidates on public registries, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.clinicaltrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the submission of certain information pertaining to these trials, including clinical trial results, after trial completion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, a sponsor submits extensive information about the product candidate to the FDA in the form of a BLA to request marketing approval for the product candidate in specified indications.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologics License Applications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain approval to market a biologic in the United States, a marketing application must be submitted to the FDA that provides data establishing the safety and effectiveness of the product candidate for the proposed indication. The application includes all relevant data available from pertinent pre-clinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a product candidate, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the product candidate to the satisfaction of the FDA. For example, in November 2016, the FDA issued a draft guidance document on developing new drugs and biologics for treating BCG-unresponsive NMIBC and finalized this guidance in February 2018. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, the fees payable to the FDA for reviewing an original BLA, as well as annual program fees for approved products, can be substantial, subject to certain limited deferrals, waivers and reductions that may be available. The FDA has 60 days from receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission, in which case the BLA will have to be updated and resubmitted. The FDA&#8217;s PDUFA review goal is to review 90% of priority BLA applications within </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months of filing and 90% of standard applications within 10 months of filing, but the FDA can and frequently does extend this review timeline to consider certain later-submitted information or information intended to clarify or supplement information provided in the initial submission. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not complete its review or approve a BLA within these established goal review times. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure, and potent for its intended use, and whether the product is being manufactured in compliance with cGMP. The FDA may also refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured or the facilities that are significantly involved in the product development and distribution process and will not approve the product candidate unless cGMP compliance is satisfactory. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the Pediatric Research Equity Act, certain BLAs must include an assessment, generally based on clinical trial data, of the safety and effectiveness of the biological product in relevant pediatric populations. The FDA may waive or defer the requirement for a pediatric assessment, either at a company&#8217;s request or by its own initiative, including waivers for certain products not likely to be used in a substantial number of pediatric patients. Products with orphan drug designation are exempt from these requirements for orphan-designated indications with no formal waiver process required.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a CRL. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of a BLA, the FDA may issue an approval letter. The FDA&#8217;s PDUFA review goal is to review such resubmissions within two or six months of receipt, depending on the type of information included. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval and deny approval of a resubmitted BLA. FDA approval of any application may include many delays or never be granted. An approval letter authorizes commercial marketing of the product candidate with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy ("REMS") to help ensure that the benefits of the product outweigh the potential risks. REMS can include Medication Guides, communication plans for healthcare professionals, and also may include elements to assure safe use ("ETASU"). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the biologic. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the biologic&#8217;s safety, purity, or potency, which can be costly.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or a supplemental BLA before the change can be implemented. A supplemental BLA for a new indication typically requires clinical data similar to that in the original application, and the FDA generally uses the same procedures and actions in reviewing a supplemental BLA as it does in reviewing a new BLA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur following initial marketing. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to spend time, money and effort to maintain cGMP compliance. In addition, new or modified government requirements, including from new legislation, may be established that could delay or prevent regulatory approval of our product candidates under development or affect our ability to maintain product approvals we have obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Market Exclusivity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), the FDA can approve products that are biosimilar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. To be biosimilar, a biological product must be highly similar to an already-licensed FDA biological product, or reference product and can have no clinically meaningful differences in safety, purity and potency from the reference product. An interchangeable biosimilar product must meet additional standards for interchangeability and, if approved, may be substituted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the reference product. At this juncture, it is unclear whether any product biosimilar deemed &#8216;&#8216;interchangeable&#8217;&#8217; by the FDA, in fact, will be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After an innovator has marketed its product for four years, a manufacturer may file an application for approval of a &#8216;&#8216;biosimilar&#8217;&#8217; version of the innovator product. However, although an application for approval of a biosimilar may be filed four years after approval of the innovator product, qualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA under the PHSA. The BPCIA also provides a mechanism for innovators to enforce the patents that protect innovative biological products and for biosimilar applicants to challenge the patents. Such patent litigation may begin as early as four years after the innovative biological product is first approved by the FDA. Although the patents for the reference biologic may be challenged by the biosimilar applicant during that time period pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be licensed by the FDA until the end of the exclusivity period. The first biologic product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against any other determinations of interchangeability to the reference product for the lesser of (i) one year after first commercial marketing of the interchangeable biosimilar product, (ii) 18 months after approval of the interchangeable biosimilar product if there is no legal challenge, (iii) 18 months after the resolution in the interchangeable biosimilar product applicant&#8217;s favor of a lawsuit challenging the reference product&#8217;s patents, and (iv) 42 months after approval of the interchangeable biosimilar product if a lawsuit is ongoing within the 42-month period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of the BPCIA are conceptually similar to those of the Hatch-Waxman Act, which established abbreviated pathways for the approval of generic drugs. The FDA has published several guidance documents providing direction on developing and obtaining approval of biosimilar product candidates. The guidance documents to date explain, among other things, that the FDA will approve a biosimilar product if there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency. A determination of biosimilarity may be based upon: (1) analytical studies showing that the biological product is highly similar to, with no clinically meaningful differences from, the reference product, (2) animal studies, including toxicity assessments, and/or (3) a clinical trial or trials (including assessment of immunogenicity and PKs) that are sufficient to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is licensed and for which licensure is sought for the biological product. The FDA recommends that sponsors use a stepwise approach to developing the data and information needed to support biosimilarity. At each step, the sponsor should evaluate the extent of residual uncertainty of biosimilarity that remains and incorporate the FDA&#8217;s advice for additional studies to address remaining uncertainty. To meet the higher standard for interchangeability the sponsor must demonstrate, in addition to biosimilarity, that the proposed biological product can be expected to produce the same clinical result and, if administered more than once to any given patient, the safety risk and potential for diminished efficacy associated with switching between the proposed biological product and the reference product is not greater than continuing to use the reference product. A biological product that is determined to be interchangeable may be substituted for the reference product without the intervention of the prescribing healthcare provider. In March 2015, the FDA approved the first biosimilar product under the BPCIA, and it has approved other biosimilar products since then. If any of our product candidates is approved by the FDA, the approval of a biosimilar to one of our products could have a material impact on our business. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than our products, if approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Purple Book," first published by the FDA in September 2014, lists biological products, including any biosimilar and interchangeable biological products licensed by the FDA under the PHSA. The lists include the date a biological product was licensed under Section 351(a) of the PHSA and whether the FDA evaluated the biological product for reference product exclusivity under Section 351(k)(7) of the PHSA. The Purple Book will also enable a user to see whether a biological product licensed under Section 351(k) of the PHSA has been determined by the FDA to be biosimilar to or interchangeable with a reference biological product. Biosimilar and interchangeable biological products licensed under Section 351(k) of the PHSA will be listed under the reference product to which biosimilarity or interchangeability was demonstrated.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of biologics through standards and regulations for, among other things, direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the internet. A biologic cannot be promoted before it is approved. After approval, promotion of a biologic can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers are permitted, however, to prescribe products for unapproved uses (also known as &#8216;&#8216;off-label&#8217;&#8217; uses) &#8211; that is, uses not approved by the FDA and therefore not described in the product&#8217;s labeling &#8211; because the FDA does not regulate the practice of medicine. However, FDA restricts manufacturers&#8217; communications regarding unapproved uses. Broadly speaking, a manufacturer may not promote a product for an unapproved use, but may engage in non-promotional, balanced communication regarding unapproved uses under specified conditions. Failure to comply with applicable FDA requirements and restrictions in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this area may subject a company to adverse publicity and enforcement action by the FDA, the United States Department of Justice ("DOJ"), or the Office of Inspector General of the United States Department of Health and Human Services ("HHS"), as well as state authorities. Such enforcement action could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-approval Regulation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After regulatory approval of a product is obtained, a company is required to comply with a number of post-approval requirements. For example, as a condition of BLA approval, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the product. In addition, as a holder of an approved BLA, a company would be required to report adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of its products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of our product candidates is required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP regulations. Biologic manufacturers and other entities involved in the manufacture and distribution of approved biologics are also required to register their establishments and list any products they make with the FDA and to comply with related requirements in certain states. The FDA and certain state agencies periodically inspect manufacturing facilities to assess compliance with cGMP and other laws. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery of problems with a product after approval may result in serious and extensive restrictions on a product or the manufacturer or holder of an approved BLA, as well as lead to potential market disruptions. These restrictions may include suspension of product manufacturing until the FDA is assured that quality standards can be met, continuing oversight of manufacturing by the FDA under a &#8216;&#8216;consent decree,&#8217;&#8217; which frequently includes the imposition of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product from the market. Other potential consequences include interruption of production, issuance of warning letters or other enforcement letters, refusal to approve pending BLAs or supplements to approved BLAs, product seizure or detention, and injunctions or imposition of civil and/or criminal penalties.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation, correction, and reporting of any deviations from cGMP and impose reporting and documentation requirements upon a company and any third-party manufacturers that a company may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, such as additional post-market clinical trials to assess new safety risks or distribution-related or other restrictions under a REMS.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Extension</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of the FDA approval of our product candidates, some of our US patents may be eligible for limited patent term extension. The provisions of the Hatch-Waxman Act permit a patent term extension of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office ("USPTO"), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for patent term extension for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other countries also provide for patent term extensions or similar extensions of patent protection for biologic products. For example, in Japan, it may be possible to extend the patent term for up to five years and in Europe, it may be possible to obtain a supplementary patent certificate that would effectively extend patent protection for up to five years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act ("FCPA") prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any non-US official, political party or candidate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the purpose of influencing any act or decision of the non-US entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring such companies to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Union and other International Government Regulation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in countries outside of the United States prior to the commencement of clinical trials or marketing of a product in those countries. Some countries outside of the United States have a similar process that requires the submission of a CTA much like the IND prior to the commencement of human clinical trials. In the EU, for example, a CTA must be submitted to the competent authorities of the EU Member States where the clinical trial is conducted and to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization Application for Biologic Medicinal Products</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval to commercialize a new product under EU regulatory systems, we must submit a marketing authorization application.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, a marketing authorization for a medicinal product can be obtained through a centralized, mutual recognition, decentralized procedure, or national procedure (single country). The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products and certain biologic products and optional for certain other products, including medicinal products that are a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public or animal health.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the centralized procedure, the applicant can submit a single application for marketing authorization to the EMA which will provide a positive opinion regarding the application if it meets certain quality, safety, and efficacy requirements. Based on the opinion of the EMA, the European Commission takes a final decision to grant a centralized marketing authorization which permits the marketing of a product in all 27 EU Member States and three of the four European Free Trade Association States - Iceland, Liechtenstein and Norway. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the EMA CHMP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the EU, such as the United Kingdom and countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCPs, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable non-US regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising, Promotion and Compliance</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of our products will also be subject to EU laws and EU Member States&#8217; national laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. Other EU Member State national legislation may also apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics ("SmPC"), as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. The SmPC forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion and is prohibited in the EU. The applicable laws at the EU level and in the individual EU Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of development (pre- and post-marketing), failure to comply with applicable regulatory requirements may result in administrative or judicial sanctions. These penalties could include the imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant Orphan Drug Designation to biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States or a disease or condition that affects more than 200,000 individuals in the United States but there is no reasonable expectation that the cost of developing and making the biologic would be recovered from sales in the United States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax credits for certain research and user fee waivers under certain circumstances. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to seven years of market exclusivity, which means the FDA may not approve any other application for a biologic for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same biologic for a different disease or condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, medicinal products: (a) that are used to diagnose, treat or prevent life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the EU; or (b) that are used to treat or prevent life-threatening, seriously debilitating or serious and chronic conditions and that, for economic reasons, would be unlikely to be developed without incentives; and (c) where no satisfactory method of diagnosis, prevention or treatment of the condition concerned exists, or, if such a method exists, the medicinal product would be of significant benefit to those affected by the condition, may be granted an orphan designation in the EU. The application for orphan designation must be submitted to the EMA and approved by the European Commission before an application is made for marketing authorization for the product. Once designated, Orphan medicinal product designation also entitles a party to financial incentives such as reduction of fees or fee waivers. Moreover, ten years of market exclusivity is granted following marketing authorization, if the product continues to be designated as an orphan medicinal product upon grant of the marketing authorization. During this ten-year period, with a limited number of exceptions, neither the competent authorities of the EU Member States, the EMA, or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal products with the same therapeutic indication. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this latter product is demonstrated to be safer, more effective or otherwise clinically superior to the original orphan medicinal product. This period of market exclusivity may be reduced to six years, at the end of the fifth year, if the orphan designation criteria are no longer met, including where it can be demonstrated on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation must be requested before submission of an application for marketing approval or marketing authorization. Orphan drug designation does not convey any advantage in, nor shorten the duration of the regulatory review and approval process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vicineum for the treatment of SCCHN has received Orphan Drug Designation from the FDA and the EMA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Programs in the United States and Other Jurisdictions</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a product may be granted Fast Track designation if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address unmet medical needs for such condition. With Fast Track designation, the sponsor may be eligible for more frequent opportunities to obtain the FDA&#8217;s feedback, and the FDA may initiate review of sections of a BLA before the application is complete. This Rolling Review is available if the applicant provides, and the FDA approves, a schedule for the remaining information. Even if a product receives Fast Track designation, the designation can be rescinded and provides no assurance that a product will be reviewed or approved more expeditiously than would otherwise have been the case, or that the product will be approved at all.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA may designate a product candidate as a breakthrough therapy if it finds that the product candidate is intended, alone or in combination with one or more other product candidates or approved products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates designated as breakthrough therapies, more frequent interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development. Product candidates designated as breakthrough therapies by the FDA may also be eligible for Priority Review. We may apply for breakthrough therapy designation for some of our product candidates. However, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for designation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated approval under FDA regulations allows a product designed to treat a serious or life-threatening disease or condition that provides a meaningful therapeutic advantage over available therapies to be approved on the basis of either an intermediate clinical endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit. Approvals of this kind typically include requirements for confirmatory clinical trials to be conducted with due diligence to validate the surrogate endpoint or otherwise confirm clinical benefit and for all promotional materials to be submitted to the FDA for review prior to dissemination.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant Priority Review designation to a product candidate, which sets the target date for FDA action on the application at six months from FDA filing, or eight months from the sponsor&#8217;s submission. Priority Review may be granted where a product is intended to treat a serious or life-threatening disease or condition and, if approved, has the potential to provide a safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in safety or efficacy compared to available therapy. If criteria are not met for Priority Review, the standard FDA review period is ten months from FDA filing or 12 months from sponsor submission. Priority Review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Centralized Procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding &#8216;&#8216;clock stops,&#8217;&#8217; when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Accelerated evaluation might be granted by CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, which should be justified and assessed on a case-by-case basis. In this circumstance, EMA ensures that the opinion of CHMP is given within 150 days.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vicineum has received Fast Track and Priority Review designations from the FDA for the treatment of BCG-unresponsive NMIBC and Fast Track designation from the FDA for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some non-US jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any partners, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any partners, may receive for any approved products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services ("CMS"), the agency that administers the Medicare and Medicaid programs, may revise reimbursement and implement coverage restrictions. Any reduction in reimbursement from Medicare, Medicaid or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in March 2010, President Obama signed one of the most significant healthcare reform measures in decades. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the "ACA") substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. The ACA has impacted existing government healthcare programs and has resulted in the development of new programs. For example, the ACA provides for Medicare payment for performance initiatives.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Among the ACA's provisions of importance to the pharmaceutical industry are the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biological products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program ("MDRP") to 23.1% for innovator drugs and 13% for non-innovator drugs of the average manufacturer price ("AMP");</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which AMP is calculated and reported by manufacturers for products that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new partial prescription drug benefit for Medicare recipients ("Medicare Part D") coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient products to be covered under Medicare Part D (subsequent legislation increased this amount to 70% effective as of January 1, 2019);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service Act's 340B drug pricing program;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new requirements to report to CMS annually specifying financial arrangements with physicians and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any &#8216;&#8216;payments or other transfers of value&#8217;&#8217; made or distributed to prescribers, teaching hospitals, and other healthcare providers and reporting any ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations during the preceding calendar year;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a mandatory non-deductible payment for employers with 50 or more full-time employees (or equivalents) who fail to provide certain minimum health insurance coverage for such employees and their dependents;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payments and service delivery models; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the ACA have been subject to judicial challenges, as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017, eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, commonly referred to as the &#8220;individual mandate,&#8221; effective January 1, 2019. Further, the Bipartisan Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage gap in most Medicare prescription drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the manufacturer discount under the Medicare Part D coverage gap discount program to 70%. Additional legislative changes, regulatory changes and judicial challenges related to the ACA remain possible. It is unclear how the ACA and its implementation, as well as efforts to repeal, replace, or otherwise modify, or invalidate, the ACA, or portions thereof, will affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, among other things, led to aggregate reductions in Medicare payments for all items and services, including prescription drugs and biologics, to service providers of, on average, 2% per fiscal year beginning April 1, 2013, and due to subsequent legislation, will continue until 2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022). On December 10, 2021, President Biden signed a law that provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012 also, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For example, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient programs, and reform government healthcare program reimbursement methodologies for drug products. For example, Congress is currently considering changes that could affect our overall rebate liability. Changes under consideration include a drug price negotiation program, Medicare Part B and Part D inflation rebates, under which manufacturers would owe rebates if the average sales price or average manufacturer price of a drug were to increase faster than the pace of inflation, and Part D benefit redesign, including a proposed new manufacturer discount program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing and Reimbursement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we obtain regulatory approval. In the United States and in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a biologic may be separate from the process for setting the price or reimbursement rate that the payor will pay for the biologic. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the products approved by the FDA, or comparable non-US regulatory authorities for a particular indication or if a product is included it may not be listed on the formulary for all the indications or it may be listed on a narrower basis than what is approved by the FDA, or comparable non-US regulatory authorities. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA, or other comparable non-US regulatory authorities&#8217; approvals. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2003, the United States Congress enacted legislation creating Medicare Part D, which became effective at the beginning of 2006. Government payment for some of the costs of prescription drugs may increase demand for any products for which we receive marketing approval. However, to obtain payments under this program, we would be required to sell products to Medicare recipients through prescription drug plans operating pursuant to this legislation. These plans will likely negotiate discounted prices for our products. Federal, state and local governments in the United States continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Future legislation could limit payments for pharmaceuticals such as the product candidates that we are developing or modify manufacturer discounts. For example, Congress is currently considering legislation that would sunset the current Part D discount program and replace it with a new manufacturer discount program, effective 2024. Congress further could enact a Medicare Part D inflation rebate, under which manufacturers would owe rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different pricing and reimbursement schemes exist in other countries. Further, there are national, provincial and territorial formularies funded by government healthcare systems, in addition to formularies for private payors (private insurers) and hospitals or hospital groups. Listing on the formularies and price depend on evidence and submissions regarding the cost-benefit of the drug and comparison of the cost-effectiveness of a particular product candidate to currently available therapies and is often subject to negotiations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, once a marketing authorization is granted for a medicinal product the applicant is required to engage in pricing and reimbursement discussions and negotiate with a separate pricing authority in each of the EU Member States. The EU Member States governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of the EU Member States may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU Member States allow companies to fix their own prices for medicinal products but monitor and control company profits. The downward pressure on healthcare costs in general, particularly pharmaceuticals, has become more intense. As a result, increasingly high barriers are being erected to the entry of new products. Furthermore, many EU Member States and other non-US countries use prices for medicinal products established in other countries as &#8220;reference prices&#8221; to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere. The EU Member States have discretion to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. We may face competition for our products, if approved, from lower priced products in non-US countries that have placed price controls on pharmaceutical products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Technology Assessment ("HTA") of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States. These EU Member States include France, Germany, Ireland, Italy and Sweden. The HTA process in European Economic Area ("EEA") countries is governed by the national laws of these countries. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those elements of medicinal products are compared with other treatment options available on the market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between EU Member States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">American Society of Clinical Oncology ("ASCO") Value Assessment for Cancer Treatments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2016, ASCO published a framework to assess the value of cancer treatment options. The framework was developed in response to concern that new, expensive cancer treatments may not be supported by adequate medical evidence. The purpose of the framework is to provide a standardized quantification of cancer treatments and assist oncologists and patients in deciding between new cancer treatments and the standard of care. The framework takes into account a medication&#8217;s (i) efficacy, (ii) safety and (iii) cost, to derive an overall treatment value. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the safety and efficacy profiles of our product candidates are potentially better than that of the standard of care and, if approved, we intend to price our products competitively, we do not know how the data will be assessed by ASCO. It is also unknown whether use of this application could adversely affect the assessment of any of our product candidates. If this framework were adopted and utilized by payors and physicians, and if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG were to receive low ratings, this could adversely affect the price and reimbursement of Vicineum, if approved, reduce prescriptions and harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our arrangements with third-party payors and customers will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by United States federal and state governments and by governments in non-US jurisdictions in which we conduct our business. We have described below some of the key federal, state and non-US healthcare laws and regulations that may affect our ability to operate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds; knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government; or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. The False </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the statute and to share in any monetary recovery. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fraud provisions of the federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively, "HIPAA"), among other things, impose criminal and civil liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in our by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have adopted analogous laws and regulations, including state anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states, regardless of the payor. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs; file periodic reports with the state, including reports on gifts and payments to individual healthcare providers; make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities; and/or register their sales representatives. Some states prohibit pharmacies and other healthcare entities from providing specified physician prescribing data to pharmaceutical companies for use in sales and marketing. Some states prohibit other specified sales and marketing practices, including the provision of gifts, meals, or other items to certain healthcare providers, and/or offering co-pay support to patients for certain prescription drugs. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. In addition, in order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in some states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to data privacy and security laws and regulations by both the federal government and the states in which we conduct our business. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, including the California Consumer Privacy Act ("CCPA"), govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that could negatively affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes requirements relating to the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions have corresponding laws and regulations governing the handling of personal information and third-party communications that may be more or less stringent than those of the United States. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our activities are potentially subject to additional regulation by various federal, state and local authorities in addition to the FDA, including CMS, other divisions of HHS (for example, the Office of Inspector General), the DOJ and individual United States Attorney offices within the DOJ, and state and local governments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we participate in the MDRP, we will have certain price reporting obligations to the MDRP, and we may have obligations to report average sales price ("ASP") figures to the Medicare program. Under the MDRP, we would be required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds available for our drugs under Medicaid and Medicare Part B. Those rebates would be based on pricing data reported by us on a monthly and quarterly basis to CMS. These data would include AMP and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. On December 21, 2020, CMS issued a final rule that modified MDRP regulations to permit reporting multiple best price figures with regard to value based purchasing arrangements (beginning in 2022); provide definitions of &#8220;line extension,&#8221; &#8220;new formulation,&#8221; and related terms with the practical effect of expanding the scope of drugs considered to be line extensions (beginning in 2022); and revise best price and AMP exclusions of manufacturer-sponsored patient benefit programs, including with respect to the potential inapplicability of such exclusions in the context of pharmacy benefit manager &#8220;accumulator&#8221; programs (beginning in 2023). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law also requires that a company that participates in the MDRP report ASP information each quarter to CMS for certain categories of drugs that are paid under Part B of the Medicare program. Manufacturers calculate ASP based on a statutorily defined formula and interpretations of the statute. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. For calendar quarters beginning January 1, 2022, manufacturers will be required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate Program. In addition, starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologicals, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. The Health Resources and Services Administration ("HRSA"), which administers the 340B program, issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. HRSA also has implemented a ceiling price reporting requirement, pursuant to which manufacturers must report the 340B ceiling prices for their covered outpatient drugs to HRSA on a quarterly basis. HRSA then publishes those prices to 340B covered entities. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. HRSA further could terminate a manufacturer&#8217;s agreement to participate in the 340B program for a failure to comply with 340B program requirements. In the event that HRSA were to terminate such an agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs that we are able to successfully commercialize.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order to be eligible to have its products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, a manufacturer also must participate in the Department of Veterans Affairs Federal Supply Schedule ("FSS") pricing program, established by Section 603 of the Veterans Health Care Act of 1992. Under this program, the manufacturer is obligated to make its &#8220;covered drugs&#8221; (biologics or innovator drugs) available for procurement on an FSS contract and charge a price to four federal agencies - Department of Veterans Affairs, Department of Defense, Public Health Service and Coast Guard - that is no higher than the statutory federal ceiling price. We also expect to participate in the Tricare Retail Pharmacy Program, under which we would pay quarterly rebates to DoD for prescriptions of innovator drugs dispensed to Tricare beneficiaries through Tricare Retail network pharmacies. The requirements under the 340B and FSS programs could reduce the revenue we may generate from any products that are commercialized in the future and could adversely affect our business and operating results. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. The Medicaid rebate amount for each covered outpatient drug is computed each quarter based on the manufacturer&#8217;s submission to CMS of its current AMP and, in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the case of innovator products, best price figures, for the quarter. If we participate in the MDRP and become aware that our reporting for a prior quarter was incorrect, or has changed, we will be obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Such restatements and recalculations would increase our costs for complying with the laws and regulations governing the MDRP. Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the ceiling price at which we would be required to offer our products to certain covered entities, such as safety-net providers, under the 340B program, and we may be obligated to issue refunds to covered entities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we participate in the MDRP or our products are covered under Medicare Part B, we will be liable for errors associated with our submission of pricing data. We cannot assure you that our submissions, if we participate in these programs, will not be found by CMS to be incomplete or incorrect. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted false AMP, ASP or best price information to the government, we may be liable for civil monetary penalties per item of false information. If we are found to have made a misrepresentation in the reporting of our ASP, the Medicare statute provides for civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. Civil monetary penalties also can be applied if we are found to have intentionally charged 340B covered entities more than the statutorily mandated ceiling price. Our failure to submit monthly/quarterly AMP, ASP and best price data on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we would participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs that we are able to successfully commercialize. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including (depending on the applicable law) criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#8216;&#8216;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;&#8217; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a non-US country, we may be subject to similar non-US laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and more extensive reporting of payments or transfers of value to healthcare professionals.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States and by the United Kingdom's Bribery Act 2010. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The national laws of certain EU Member States require payments made to physicians to be publicly disclosed. Moreover, the European Federation of Pharmaceutical Industries and Associations ("EFPIA") Code on disclosure of transfers of value from pharmaceutical companies to healthcare professionals and healthcare organizations imposes a general obligation on members of EFPIA or related national industry bodies to disclose transfers of value to healthcare professionals. In addition, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her competent professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable non-US regulatory requirements, we may be subject to, among other things, warning letters or untitled letters, injunctions, civil, administrative, or criminal penalties, monetary fines or imprisonment, suspension or withdrawal of regulatory approvals, suspension of ongoing clinical studies, refusal to approve pending applications or supplements to applications filed by us, suspension or the imposition of restrictions on operations, product recalls, the refusal to permit the import or export of our products or the seizure or detention of products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental and Safety Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of federal, provincial and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. Our operations involve such hazardous materials and produce such hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by federal, provincial and local regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. Radioactive materials in Canada come under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal jurisdiction. Canada&#8217;s Nuclear Safety and Control Act 1997 c.9 contains a general prohibition against any activity, including possession of radioactive material, except in accordance with the terms and conditions set out in a federal license issued by the Canadian Nuclear Safety Commission. The Nuclear Substances and Radiation Devices Regulation does however, exempt licensing requirements for small quantities of radioactive substances that either meet concentrations set out in a schedule to the Regulation or, for radioactive substances not set out in the schedule, that meet certain regulatory criteria. Our operations do not currently require a federal license issued by the Canadian Nuclear Safety Commission. Our operations in Canada may be subject to license approvals, notification requirements and investigation and enforcement for air and water and waste matters.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History and Acquisition of Viventia</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in 2008. We were formerly known as Denovo Therapeutics, Inc. and Newco LS14, Inc. before changing our name to Eleven Biotherapeutics, Inc. in February 2010 and again to Sesen Bio, Inc. in May 2018. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada, the shareholders of Viventia named therein (collectively, the "Selling Shareholders") and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;), pursuant to which we agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the "Viventia Acquisition"). In connection with the closing of the Viventia Acquisition, we issued 4.0 million shares of our common stock to the Selling Shareholders according to their pro rata share of Viventia&#8217;s then-outstanding shares of common stock, which represented approximately 19.9% of our voting power as of immediately prior to the issuance of such shares of common stock. Clairmark is an affiliate of Leslie L. Dan, who served on our board of directors until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition, we are obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the acquisition agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the "Purchased Product"), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) and quarterly earn-out payments equal to two percent (2%) of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Share Purchase Agreement, we, our affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key human capital management objectives are to recruit, retain, manage and motivate our employees. There are a limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense given the numerous pharmaceutical and biotechnology companies looking for similar personnel as well as universities and research institutions. We rely on our executive officers and other key employees to achieve our research, development and commercialization objectives and to successfully implement our business strategy. We also rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to maintaining a diverse and inclusive workplace in which our employees from all backgrounds can fully contribute to the growth and success of our business. We communicate shared values and leadership behaviors, which are expected of all employees. Additionally, every employee has an annual performance review and has opportunities to contribute to corporate goals. We rely on a variety of sources to fill open positions, including job boards and postings on our corporate website.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a demonstrated history of investing in our workforce through comprehensive and competitive compensation and benefits, and a focus on health and employee wellbeing. We have adopted our 2014 Stock Incentive Plan ("2014 Plan") and Employee Stock Purchase Plan (&#8220;ESPP&#8221;) to enable us and our subsidiaries to recruit and retain highly qualified employees, directors and consultants, provide those individuals with an incentive for productivity, and provide those individuals with an opportunity to share in our growth and value.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had thirty-five full-time employees and no part-time employees, nine hold Ph.D. degrees and one is a veterinary doctor. This number consists of fifteen employees engaged in administration and twenty employees engaged in research and development (eight in clinical and regulatory, three in supply chain, five in manufacturing/engineering, and four in quality and support). Two of our employees are located in our corporate headquarters in Cambridge, fifteen of our employees are located in our Winnipeg facility, and five of our employees are located in our Philadelphia office. We have no collective bargaining agreements with our employees, and none are represented by labor unions. We have not experienced any work stoppages. We believe our relationship with our employees is satisfactory.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the COVID-19 pandemic, approximately 30% of our employees have continued to work at our Winnipeg facility, where we have adopted health screening, implemented socially distancing and personal protective equipment requirements, enhanced cleaning and sanitation protocols, and modified workspaces to reduce the potential for transmission of the virus. All other employees who do not require access to our facility to perform their work have been working from home during the pandemic. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information and Access to SEC Reports</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 245 First Street, Suite 1800, Cambridge, Massachusetts 02142, our telephone number is (617)-444-8550 and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sesenbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports, available free of charge in the &#8220;Investors&#8221; section of our website as soon as reasonably practicable after we file these reports with the SEC. We routinely post these reports, recent news and announcements, financial results and other important information about our business on our website at www.sesenbio.com. Information contained on our website is not a part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the SEC maintains an Internet website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties. The occurrence of any of the following risks and uncertainties, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects. In these circumstances, the market price of our common shares could decline, and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Risks and uncertainties of general applicability and additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a specialty pharmaceutical company with a limited operating history. Over the past few years, we have focused primarily on developing our lead product candidate, Vicineum. Since our inception, we have received no revenues from sales of our products, have incurred significant operating losses and expect to continue to incur operating losses for the foreseeable future as we continue the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and seek marketing approval from the FDA. We had net losses of $0.3 million, $22.4 million and $107.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. We incurred negative cash flows from operating activities of $68.9 million, $30.8 million and $37.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. As of December&#160;31, 2021, we had cash and cash equivalents of $162.6 million, net working capital (current assets less current liabilities) of $194.0 million and an accumulated deficit of $316.3 million. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our initial public offering ("IPO"), our follow-on public offerings, sales effected in at-the-market ("ATM") offerings and, our out-licensing and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The majority of our revenue to date has been from milestone payments received under our out-licensing and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur losses for the foreseeable future, and we expect these losses to increase as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States and the European Union;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed drugs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek and conduct combination trials of one or more of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to develop additional product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates or technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development and commercialization, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform trials in addition to those expected or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">With the exception of specified regulatory, development and commercial milestones under our out-licensing and OUS business development partnership agreements, we currently have no source of revenue and may never become profitable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become and remain profitable depends on our ability to generate revenue. Although we may be entitled to certain payments under our out-licensing and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, neither we nor any of our business development partners have commercialized any of our product candidates. We do not expect to generate significant revenue from the development of our product candidates unless and until we or one of our business development partners obtain marketing approval for, and commercialize, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Our ability to generate revenue from Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG will depend on a number of factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain regulatory approval for, and successfully commercialize, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete and submit applications to, and obtaining regulatory approval from, non-US regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the markets in the territories for which we or our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partners gain regulatory approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to find a suitable contract sales organization ("CSO") to help us market and promote Vicineum, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and maintain effective medical affairs, sales, marketing and distribution to market and sell Vicineum, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into and maintain commercially reasonable agreements with wholesalers, distributors and other third parties in our supply chain;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in establishing a commercially viable price for Vicineum, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in defending against potential competition and other developments in our market generally;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture commercial quantities of Vicineum at acceptable cost levels;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain coverage and adequate reimbursement from third-party payors, including government payors; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partners' ability to successfully complete development activities, including necessary clinical trials, for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is approved for commercial sale, Vicineum may not gain market acceptance or achieve commercial success. If our addressable market is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or clinical practice guidelines, we may not generate significant revenue from sales of Vicineum. In addition, we would anticipate incurring significant costs associated with commercializing Vicineum, if approved. We may not achieve profitability soon after generating product sales from Vicineum, if ever. If we are unable to generate product revenues from Vicineum, we will not become profitable and may be unable to continue operations without continued funding.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain drug approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are devoting substantial financial resources to our ongoing and planned activities, including a new Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and functions associated with operating as a public company. We expect to continue to spend substantial amounts to continue the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and, if approved, commercialize Vicineum. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of continuing the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of the regulatory approval process for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG by the FDA and comparable non-US regulatory authorities, including the potential for the FDA to require that we perform more studies and clinical trials than those we currently expect;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain commercial arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third party licensors under our in-licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available when needed on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we also could be required to:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek out-licensing or commercialization partners to assist in the clinical development or commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States and other markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, limit, reduce or terminate the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly curtail our operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our cash and cash equivalents of $162.6 million as of December&#160;31, 2021, will be sufficient to fund our operations into 2024; however, we have based this estimate on assumptions that may prove to be wrong, and our capital resources may be utilized faster than we currently expect.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of shares of our common stock or rights to purchase shares of our common stock, including common stock purchase warrants and stock options, could result in additional dilution of the percentage ownership of our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, licensing and OUS business development partnership agreements, strategic alliances and marketing and distribution arrangements and other commercial arrangements. We do not have any committed external source of funds other than the amounts payable under our out-licensing and OUS</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business development partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as holders of our common stock.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also adopted the 2014 Plan to enable us and our subsidiaries to recruit and retain highly qualified employees, directors and consultants, provide those individuals with an incentive for productivity, and provide those individuals with an opportunity to share in our growth and value. As of December&#160;31, 2021, we had an aggregate of 15.8 million stock options and RSUs outstanding under the 2014 Plan, our prior equity plan and inducement awards granted outside of our equity plans. In addition, as of December&#160;31, 2021, we had 8.9 million shares of common stock available for grant under our 2014 Plan. Future equity incentive grants and issuances of shares of common stock under the 2014 Plan, or other grants outside of the 2014 Plan pursuant to inducement equity awards, may have an adverse effect on the market price of shares of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through government or other third-party funding, licensing or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, strategic alliances or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval of Vicineum</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our lead product candidate, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. If we are unable to obtain marketing approval for or successfully commercialize our lead product candidate, either alone or through an out-license or OUS business development partnership, or experience significant delays in doing so, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for sale and have invested a significant portion of our efforts and financial resources in the development of Vicineum. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to address the issues identified in the CRL from the FDA or resubmit a BLA for Vicineum, or address the concerns identified in the EMA Withdrawal Assessment Report or resubmit our MAA for Vysyneum, including because of a lack of capital or otherwise. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the issues identified in the CRL or the concerns identified in the EMA Withdrawal Assessment Report are resolved to the satisfaction of the FDA or the EMA, respectively, the FDA and the European Commission retain the right not to approve a BLA or MAA, respectively, or to require additional information, or to raise additional issues with regard to regulatory approval, which could further delay or prevent its approval or limit product labelling claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prospects are substantially dependent on our ability and the ability of our out-licensing and OUS business development partners to obtain marketing approval for and commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. In addition, either the substance of the issues identified by the FDA in the CRL, or the CRL itself, or the concerns identified in the EMA Withdrawal Assessment Report could have an adverse impact on future efforts to obtain marketing authorization for Vicineum from other non-US regulatory authorities, or on our future efforts to commercialize Vicineum and gain acceptance of Vicineum from third party payors. The success of Vicineum will depend on several factors, including the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing the issues identified in the CRL we received from the FDA and the concerns identified in the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving marketing approvals from the FDA, the European Commission or comparable non-US regulatory authorities, including our ability to address the issues identified by the FDA in the CRL or the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining the commercial manufacturing supply and distribution chain for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of our current and future out-licensing or OUS business development partners;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales, if and when marketing approval is received;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrating an acceptable safety profile prior to and following any marketing approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining marketplace acceptance, if approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining pricing sufficient to realize a meaningful return on our investment; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other therapies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our OUS business development partners are unable to develop, receive marketing approval for, or successfully commercialize Vicineum or experience delays as a result of any of these factors or otherwise, our business could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other non-US regulatory authorities or do not otherwise produce favorable results, we will be unable to complete the development and potential commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we must complete pre-clinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of Vicineum in humans. In order to address the issues identified in the CRL we received from the FDA for the BLA for Vicineum and the concerns </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identified in the EMA Withdrawal Assessment Report, we will need to complete one or more additional clinical trials. Such trials will require us to incur substantial additional costs and will delay the potential commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Further, the outcome of pre-clinical studies and early clinical trials may not be predictive of the success of later clinical trials, and preliminary results of a clinical trial do not necessarily predict final results. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if such clinical trials are successfully completed as planned, the results may not support approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG under the laws and regulations of the FDA, the European Commission or comparable non-US regulatory authorities. We cannot be certain that additional clinical data will demonstrate Vicineum is both safe and effective for its intended uses to the satisfaction of the FDA, the EMA or comparable non-US regulatory authorities. Pre-clinical and clinical data and analyses are often able to be interpreted in different ways. Even if we view our results favorably, we may be unable to demonstrate safety and efficacy of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to the satisfaction of the FDA, the EMA or other non-US regulatory authorities. If a regulatory authority has a different view, we may still fail to obtain regulatory approval of Vicineum. This, in turn, would prevent us from commercializing Vicineum and our ability to generate revenues in the future would be materially impaired.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to develop a more sensitive bioanalytical assay which is needed for the additional Phase 3 clinical trial for Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to develop a more sensitive bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay for the additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG than was used in our prior VISTA Trial for Vicineum. This bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay will be used to measure levels of Vicineum in the blood. The development of a new bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay for a novel biologic like Vicineum can be complex. There is risk that an adequately sensitive bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay may not be scientifically or economically feasible or that any new bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay developed by us or a third party will not be accepted by the FDA or other comparable regulatory bodies. As a result, further development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may be negatively impacted or delayed, which would have an adverse impact on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could be delayed or prevented. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG that we may develop, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of Vicineum may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon the development of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in these clinical trials may be slower or more challenging than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements, including GCP or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations, trial sites or manufacturing facilities by the FDA or other comparable non-US regulatory authorities could result in findings of non-compliance and the imposition of a clinical suspension or termination;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs/Ethics Committees may delay or not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays or fail to reach agreement with the FDA or a comparable non-US regulatory authority on a trial design that we are able to execute;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including for the same indications as our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trial sites and investigators may deviate from clinical trial protocols or otherwise fail to conduct the trial in accordance with regulatory requirements, and investigators may drop out of the clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trial sites may withdraw from our clinical trials, including as a result of changing standards of care or ineligibility of a site to participate in our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide, or regulators or IRBs/Ethics Committees or other reviewing entities, including comparable non-US regulatory authorities, may require us to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements including GCP or a finding that the patients are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may be greater than we anticipate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may receive feedback from DSMBs or the FDA, or a comparable non-US regulatory authority, that might require modification to the protocol for the clinical trial or performance of additional studies before clinical trials may continue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as a clinical trial proceeds, or as the results of earlier stage studies or concurrent studies become available, we may determine that we need to modify the protocol and/or other aspects of the clinical trial before it may continue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, a comparable non-US regulatory authority, or we may decide to, or a DSMB may recommend to, suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of Vicineum or other materials necessary to conduct clinical trials of Vicineum may be insufficient or inadequate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs/Ethics Committees to suspend or terminate the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue a clinical trial, including the occurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials or increased expenses associated with the services of our CROs and other third parties; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in applicable laws, governmental regulations or administrative actions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their activities, we have limited control over their actual performance. Any delays in completing our clinical trials will increase our costs, slow down our development and regulatory submission process for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and jeopardize our ability to obtain regulatory approval, commence commercial sales and generate revenues, if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is ultimately approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials outside of the United States, as we have done historically for Vicineum (both for the treatment of BCG-unresponsive NMIBC and for the treatment of SCCHN) and as we may decide to do in the future, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in countries outside of the United States to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with non-US regulatory frameworks, as well as political and economic risks relevant to such countries.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of Vicineum or other testing, if the results of these trials or tests are not favorable or are only modestly favorable or if there are safety concerns, we may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, or is subject to a REMS;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have Vicineum removed from the market after obtaining marketing approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our pre-clinical studies or clinical trials will begin as planned, will need to be restructured or will be completed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on schedule, or at all. Significant pre-clinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of patients to participate in these trials as required by the FDA or similar non-US regulatory authorities. We have previously experienced difficulties with clinical trial enrollment and retention, which led to the early termination of our Phase 3 trial of Vicineum for the treatment of SCCHN in 2008, and we may experience difficulties in patient enrollment in our clinical trials in the future for a variety of reasons. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject enrollment is affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the clinical trial in question;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population for the disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for statistically significant analysis of the clinical trial&#8217;s primary endpoints;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinicians' and patients' perceived risks and benefits of the product candidate under study, including relative to alternative treatments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any ongoing clinical trials conducted by competitors for the same indication;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our ability to successfully initiate, enroll and complete a clinical trial in any country outside of the United States, should we decide to do so, is subject to numerous risks unique to conducting business in such countries, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in establishing or managing relationships with CROs and physicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different or additional standards for the conduct of clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">absence in some countries of established groups with sufficient regulatory expertise for review of the protocols associated with our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring that clinical trial quality is sufficient to meet the standards of the FDA or other regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to locate qualified local consultants, physicians and partners; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential burden of complying with a variety of non-US laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for other product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any of our clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may cause undesirable side effects, serious adverse events or have other properties that could delay or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">halt clinical trials, delay or prevent its regulatory approval, limit the commercial profile of its labeling, if approved, or result in significant negative consequences following any marketing approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects or serious adverse events caused by Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could cause us or regulatory authorities to interrupt, delay or halt respective clinical trials and could result in a restrictive label or the delay or denial of regulatory approval by the FDA or other comparable non-US regulatory authorities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Grade 4 or Grade 5 serious adverse events that were considered by the clinical investigators to be related to Vicineum during the Phase 1 and Phase 2 clinical trials of Vicineum for the treatment of NMIBC. There was one Grade 5 serious adverse event, or death, which was determined by the clinical investigator to be unrelated to Vicineum. The most common reported treatment-related adverse events were an abnormally frequent passage of small amounts of urine, blood in the urine and painful urination, the majority of which were considered to be mild or moderate in severity. No patients discontinued treatment due to a Vicineum-related adverse event during the Phase 1 and Phase 2 clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, side effects and serious adverse events or further safety or toxicity issues that we may experience in our clinical trials or in post-marketing experience, if approved, could lead to the FDA's or other comparable non-US regulatory authority's imposition of a REMS or other post-marketing obligations, which could hinder us from generating revenues or achieving profitability. Results of our clinical trials could reveal an unacceptably high severity and prevalence of side effects or serious adverse events. As a result, our clinical trials could be suspended or terminated, and the FDA or comparable non-US regulatory authorities could order us to cease further development or deny approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The related drug-side effects or serious adverse events in our clinical trials could affect clinical trial patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG receives marketing approval, and we or others later identify undesirable side effects or serious adverse events caused by Vicineum, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may suspend or be forced to suspend marketing of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be obliged to conduct a product recall or product withdrawal;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend, vary, or withdraw their approvals of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may order the seizure or recall of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label or a REMS or other post-marketing obligations that could diminish the usage or otherwise limit the commercial success of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to conduct post-marketing studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be required to pay fines and face other administrative, civil and criminal penalties; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to obtain regulatory authority approval of any proposed names for oportuzumab monatox for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and any failure or delay associated with such naming approval may adversely impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the FDA previously conditionally accepted the name Vicineum, and EMA previously conditionally accepted the name Vysyneum, for our product candidate, oportuzumab monatox, these approvals are subject to further and final review by FDA and EMA upon potential resubmission of our respective applications and at the time of regulatory authority review of such applications. If the FDA or EMA object to any proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the FDA and EMA, as applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The marketing approval process is expensive, time-consuming and uncertain. As a result, we cannot predict when or if we, or any licensees or partners, will obtain marketing approval to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG or any other product candidate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s quality, safety, and efficacy. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, especially if additional clinical trials are required, if approval is obtained at all. In October and December 2021, we participated in a CMC Type A Meeting and Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other comparable non-US regulatory authorities may determine that any product candidate that we may develop is not safe, effective or of appropriate quality, is only moderately effective or has undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The different requirements and expectations of the non-US regulatory authorities compared with the FDA may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post approval limitations or restrictions. If we experience delays in obtaining regulatory approvals, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in non-US jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in non-US jurisdictions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell any product candidate that we may develop outside of the United States, we or our third-party licensees or commercialization partners must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States it is required that the product be approved for reimbursement before the product can be sold in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. For example, on March 5, 2021, we submitted our MAA to the EMA for Vicineum for the treatment of BCG-unresponsive NMIBC under the EMA&#8217;s centralized procedure. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC. We have decided to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on the next steps for Vicineum in the United States. Additionally, on October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory authorities in other jurisdictions, the commercial prospects of our product candidates may be significantly diminished, and our business prospects could decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new biologics products is highly competitive. We face competition with respect to Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG from both large and small pharmaceutical, biopharmaceutical and biotechnology companies, academic institutions and other research organizations. There are a number of large pharmaceutical, biopharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of NMIBC. For instance, in January 2020, the FDA approved Merck &amp; Co., Inc.'s Keytruda (pembrolizumab) as a systemic monotherapy to treat patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. In addition, FerGene Inc. is developing Adstiladrin (nadofaragene firadenovec (rAd-IFN/Syn3) for BCG-unresponsive NMIBC for the United States market. On May 17, 2020, the FDA issued a CRL that indicated outstanding questions regarding CMC = issues of Adstiladrin. In September 2020, CG Oncology (CG0070, a recombinant adenovirus type 5, same type as Adstiladrin) initiated a Phase 3 study for the treatment of BCG-unresponsive patients with expected primary and study completion dates of December 2022 and December 2024, respectively. In December 2020, ImmunityBio (Anktiva/N-803 in combination with BCG) released preliminary Phase 2 data for the CIS cohort and is expected to file its BLA following a meeting with the FDA in the first quarter of 2022. However, the Phase 2 trial did not include a BCG only control arm. In May 2020, the preliminary results of the Phase 2 study of Tecentriq for the treatment of BCG-unresponsive CIS patients were presented at ASCO by the NCI (National Cancer Institute) which sponsored the trial. The data showed that the trial did not meet its primary endpoint and further development of Tecentriq remains uncertain. Finally, another route of administration for checkpoint inhibitors is currently being evaluated by Pfizer with the subcutaneous administration of Sasanlimab (PF-06801591) for the treatment of BCG-unresponsive NMIBC patients. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody fragment and immuno-oncology therapeutics fields. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than product candidates that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to compete may be affected in many cases by insurers or other third-party payors, particularly Medicare, seeking to encourage the use of generic drug products. Generic products are currently being used as part of the standard of care for the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If any product candidate that we may develop achieves marketing approval, we expect that it will be priced at a significant premium over competitive generic products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More established companies may have a competitive advantage over us due to their greater size, cash resources and institutional experience. Compared to us, many of our competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors may obtain regulatory approval of their product candidates before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or non-competitive before we can recover the expenses of development and commercialization.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may face competition from biosimilar products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the BPCIA, abbreviated pathways for approval of biosimilar and interchangeable biological products were created. The BPCIA establishes legal authority for the FDA to review and approve biosimilars for marketing, as well as biosimilars that have been designated as &#8220;interchangeable&#8221; with a previously approved biologic, or reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a full BLA. This period of regulatory exclusivity runs concurrently with, but is independent of, periods of patent protection for the reference product.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, approved as a biological product under a full BLA should qualify for a 12-year period of exclusivity. However:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the United States Congress could amend the BPCIA to significantly shorten this exclusivity period as has been previously proposed; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a potential competitor could seek and obtain approval of its own BLA during our exclusivity period instead of seeking approval of a biosimilar version.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and its provisions continue to be interpreted and implemented by the FDA and United States courts. As a result, the ultimate impact, implementation and implications of the BPCIA are subject to uncertainty and could compromise the future commercial prospects for our biological products. Moreover, it is not yet clear the extent to which a biosimilar, once approved, may be substituted for any one of our reference products in a way that is similar to traditional generic substitution for pharmaceutical products; this will depend on a number of marketplace and regulatory factors that are still developing at both the federal and state levels of government.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the use of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. If we cannot successfully defend ourselves against claims that Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial patients;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial patients;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced time and attention of our management to pursue our business strategy; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10.0 million CAD in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million CAD, which may not be adequate to cover all liabilities that we may incur. We would need to increase our insurance coverage if we expand our clinical development activities beyond historical levels. We would need to further increase our insurance coverage if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is approved, and we commence commercialization. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will depend on Qilu for the development and commercialization of Vicineum in Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we entered into the Qilu License Agreement. Under the terms of the Qilu License Agreement, Qilu has an exclusive license to manufacture, develop and commercialize Vicineum in Greater China, including mainland China, Hong Kong, Macau and Taiwan. The timing and amount of any milestone and royalty payments we may receive under the Qilu License Agreement will depend in part on Qilu&#8217;s efforts. We will also depend on Qilu to comply with all applicable laws relative to the manufacturing, development and commercialization of Vicineum in Greater China. We do not control the individual efforts of Qilu, and any failure by Qilu to devote sufficient time and effort to the manufacture, development and commercialization of Vicineum could have a material adverse impact on our financial results and operations, such as by a failure of Qilu to meet its obligations to us, including future milestone and royalty payments. In addition, if Qilu were to violate, or was alleged to have violated, any laws or regulations during the performance of its obligations for us, it is possible that we could suffer financial and reputational harm or other negative outcomes, including possible legal consequences. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any termination, breach or expiration of the Qilu License Agreement could have a material adverse effect on our financial position by reducing or eliminating the potential for us to receive milestones and royalties. In such an event, we may be required to devote additional efforts and to incur additional costs associated with pursuing the manufacture, development and commercialization of Vicineum in Greater China. If we breach our obligations under the Qilu License Agreement and are unable to cure such breach, Qilu may terminate the Qilu License Agreement and retain all rights to manufacture, develop and commercialize Vicineum in Greater China with no obligation to make any additional milestone or royalty payments. Qilu has the right to receive a refund of all amounts paid us in the event the Qilu License Agreement is terminated under certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances. In addition, the royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent for Vicineum in a particular region or no data or regulatory exclusivity for Vicineum in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into and may enter into additional OUS business development partnerships or out-license agreements with third parties for the commercialization or development of our product candidates. If our OUS business development partnerships or out-licenses are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought and may seek additional third-party partners or licensees for development and commercialization of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Our current and likely commercialization partners or licensees include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. Our ability to generate revenues from these arrangements depend and will depend on our partners' or licensees' abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships and licenses involving our product candidates pose a number of risks, including the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees have significant discretion in determining the amount and timing of efforts and resources that they will apply to these partnerships or licenses;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may not perform their obligations as expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may not pursue commercialization and development of our product candidates that receive marketing approval or may elect not to continue or renew commercialization or development programs based on clinical trial results, changes in any such partner&#8217;s or licensee&#8217;s strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the partners or licensees believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered under the partnership or license with us may be viewed by our partners or licensees as competitive with their own product candidates or products, which may cause partners or licensees to cease to devote resources to the commercialization of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees could become involved in a business combination, which might deemphasize or terminate the commercialization or development of any product candidate licensed to it by us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with partners or licensees, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be time-consuming and expensive;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialization partners or licenses may be terminated for the convenience of the partner or licensee and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnership agreements and licenses may not lead to commercialization or development of product candidates in the most efficient manner, or at all. If any partnerships or licenses that we enter into, do not result in the successful commercialization and development of products or if one of our partners or licensees terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the partnership or license. All of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of any current or future OUS business development partners and licensees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one of our partners or licensees terminates its agreement with us, we may find it more difficult to attract new partners or licensees and our perception in the business and financial communities could be harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to reach agreements with suitable new partners or licensees on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into partnerships and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on domestic and international third-party CROs to monitor and manage data for our pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and we control only some aspects of their activities. Nevertheless, we are responsible for ensuring that each of our pre-clinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to assist in conducting our pre-clinical studies in accordance with GLP and the Animal Welfare Act requirements. We and our CROs are required to comply with US federal regulations and GCP, which are international standards meant to protect the rights and health of patients and assure the credibility of clinical trial data that are enforced by the FDA and comparable non-US regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable non-US regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2021, the FDA published a Warning Letter (the &#8220;FDA Warning Letter&#8221;) issued to a former clinical investigator in our VISTA trial for Vicineum arising from a 2021 FDA inspection related to the review of our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. We discontinued use of the clinical site and the clinical investigator over four years ago when we learned of professional misconduct by the clinical investigator that was unrelated to the VISTA trial. The FDA Warning Letter indicated that the clinical investigator did not comply with applicable statutory requirements and applicable regulations regarding conduct of clinical investigations. The clinical investigator's medical license was temporarily suspended on May 29, 2017, due to inaccurate recordkeeping, which was unassociated with Sesen Bio and the patients in the VISTA trial. We notified the FDA of the misconduct at that time. There was no evidence found that patients were harmed by the clinical investigator&#8217;s actions. We included the corresponding patient data from the clinical site in the BLA submission to the FDA, which were thoroughly analyzed and discussed during the BLA review.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Failure to comply with these regulations may require us to repeat pre-clinical studies and clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical and pre-clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our pre-clinical studies and clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have relied and will continue to rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose our relationships with CROs, our product development efforts could be delayed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on domestic and international third-party vendors and CROs for pre-clinical studies and clinical trials related to our product development efforts. Switching or adding additional CROs would involve additional cost and requires management time and focus. Our CROs generally have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements or research projects with us pursuant to such agreements if it can be reasonably demonstrated that the safety of the patients participating in our clinical trials warrants such termination in accordance with the reasonable opinion of the relevant CRO. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider. If any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on third parties to formulate and manufacture Vicineum, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of our products or result in higher product costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we completed the manufacturing of all Vicineum necessary for our VISTA Trial and for our CRADA with the NCI. In conjunction with this achievement, we ended our manufacturing activities at our facility in Winnipeg and completed the technology transfer process to outsource future Vicineum clinical and commercial to third-party manufacturers. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and, among other things, raised CMC issues pertaining to a recent pre-approval inspection and product quality. At the CMC Type A Meeting held in October 2021, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that such trials can proceed while addressing CMC issues. Therefore, we have no current plans to re-build internal manufacturing capacity for Vicineum and we expect to continue to rely on third-party expertise in this area. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers exposes us to certain risks that we would not be subject to if we manufactured Vicineum ourselves, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development of manufacturing capabilities to produce clinical supply of Vicineum may require our third-party manufacturers to invest substantial additional funds and hire and retain technical personnel who have the necessary manufacturing experience. Our third-party manufacturers may fail to devote sufficient time and resources to develop the capabilities to manufacture Vicineum.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because of the complex nature of Vicineum, our third party manufacturers, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy our clinical supply demands, may not be able to achieve such volume at an acceptable cost, may experience technical issues that impact comparability, quality, or compliance with applicable regulations governing the manufacture of biological products, and may experience shortages of qualified personnel to adequately staff production operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers could default on their agreements with us to meet our requirements for supply of Vicineum, or they may terminate or decide not to renew their agreements with us, based on their own business priorities, at a time that is costly or damaging to us. If our third-party manufacturers were to terminate our arrangements or fail to meet our manufacturing demands, we may be delayed in our ability to obtain and maintain regulatory approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It may be difficult or impossible for us to find replacement manufacturers on acceptable terms quickly, or at all. Identifying alternate manufacturers may be difficult because the number of potential manufacturers that have the necessary expertise to produce biologics is limited. Additionally, the FDA must approve any alternative manufacturer before we may use the alternative manufacturer to produce clinical supply of Vicineum.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any third-party manufacturer makes improvements in the manufacturing process for Vicineum, we may not own, or may have to share, the intellectual property rights to such improvements.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A third-party manufacturer may gain knowledge from working with us that could be used to supply one of our competitors with a product that competes with ours.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers reduces our control over production and supply of Vicineum but does not relieve us of our responsibility to ensure compliance with applicable legal and regulatory standards. The FDA and other non-US </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar non-US standards. Methods of manufacture as well as validation of manufacturing procedures and quality control systems are reviewed by regulatory authorities, such as the FDA and other comparable non-US regulatory authorities, to determine their effect on the quality, purity and potency of product candidates. All such manufacturing procedures, validation programs and quality assessment activities must be properly documented in accordance with regulatory requirements. Any failure by our third-party manufacturers to comply with cGMP or similar non-US standards, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. For example, we may be unable to resolve the issues raised in the CRL pertaining to a recent pre-approval inspection and product quality. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a failure by our third-party manufactures to comply with cGMP or similar non-US standards could be the basis for the FDA or any other non-US regulatory authorities to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, imposing administrative or civil penalties, or pursuing criminal prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur significant costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products, or if our licensors are unable to obtain and maintain patent protection for the technology or products that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent protection in the United States and other countries with respect to Vicineum and our other proprietary technology and product candidates. We and our licensors have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications in jurisdictions of interest at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. In addition, the laws of non-US countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned or licensed patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon our ability to generate additional pre-clinical or clinical data that support the patentability of our proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Moreover, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party preissuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. In addition, invalidation of our patent rights by third parties could jeopardize the anticipated revenue streams from current licensees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on Vicineum and our other product candidates and technologies throughout the world would be prohibitively expensive, and our or our licensors&#8217; intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of countries outside the United States do not protect intellectual property rights to the same extent as federal and state laws in the United States. Moreover, the intellectual property laws of the United States change over time. For example, several United States Supreme Court cases have redefined what is considered to be patentable subject matter. Consequently, we and our licensors may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in all countries inside or outside the United States, or from selling or importing products made using our and our licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export infringing products to territories where we or our licensors have patent protection, but where enforcement is not as strong as in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in non-US jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our or our licensor&#8217;s patents or marketing of competing products in violation of our proprietary rights generally in those countries. Proceedings to enforce our patent rights in non-US jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our and our licensors&#8217; patents at risk of being invalidated or being interpreted narrowly and put our and our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of certain countries outside of the US may not protect our rights to the same extent as the laws of the United States, and such laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic and/or biosimilar product manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic or biosimilar product manufacturers may develop, seek approval for, and generic versions or biosimilar versions, respectively, of our products. The FDA has published several guidance documents on biosimilar product development. If a biosimilar product is also found to be interchangeable with a reference product, it may be substituted for the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. If any of our product candidates are approved by the FDA, the approval of a biologic product biosimilar to or interchangeable with one of our products could have a material impact on our business. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than our products, if approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including EU countries, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections from the USPTO or other applicable non-US intellectual property offices. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections, or have to expend additional resources to secure registrations, such as commencing cancellation proceedings against third-party trademark registrations to remove them as obstacles to our trademark applications. In addition, in the USPTO and in comparable agencies in many non-US jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our license agreements with Zurich, Micromet and XOMA, and if we cannot meet the requirements under the agreements, we could lose important rights to Vicineum, which could have material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive license agreement with Zurich. Pursuant to the Zurich License Agreement, we were granted an exclusive license, with the right to sublicense, under certain patents primarily relating, in part, to our targeting agents, EpCAM chimera and immunoconjugates (including aspects of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN) and methods of use, to make, use, sell and import products that would otherwise infringe such patents in the field of the treatment, stasis and palliation of disease in humans. If we fail to meet our obligations under the Zurich License Agreement, Zurich may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed Zurich patent rights would end. To the extent such licensed technology or patent rights relate to our product candidates, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the Zurich License Agreement could result in our loss of rights to practice the patent rights licensed to us under the Zurich License Agreement, and to the extent such patent rights and other technology relate to our product candidates or other of our compounds, it could have a material adverse effect on our commercialization efforts for our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with Micromet, which grants us non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. If we fail to meet our obligations under the Micromet License Agreement, Micromet may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed Micromet patent rights would end. To the extent such licensed technology or patent rights relate to our product candidates, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the Micromet License Agreement could result in our loss of rights to practice the patent rights licensed to us under the Micromet License Agreement, and to the extent such patent rights and other technology relate to our product candidates or other of our compounds, it could have a material adverse effect on our commercialization efforts for our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with XOMA, which grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. If we fail to meet our obligations under the XOMA License Agreement, XOMA may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed XOMA patent rights and related know-how would end. To the extent such licensed technology or patent rights relate to our product candidates, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the XOMA License Agreement could result in our loss of rights to practice the patent rights licensed to us under the XOMA License Agreement, and to the extent such patent rights and other technology relate to our product candidates or other of our compounds, it could have a material adverse effect on our commercialization efforts for our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks or other intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. In a trademark infringement proceeding, we could be enjoined from continued use of a trademark deemed to be infringing and forced to rebrand product packaging, product inserts, market and advertising materials, resulting in a loss of sales and established goodwill in that name or mark. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a trademark. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our partners, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the USPTO. The risks of being involved in such litigation and proceedings may increase as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. We may not be aware of all such intellectual property rights potentially relating to our product candidates and their uses. Thus, we do not know with certainty that any product candidate, or our commercialization thereof, does not and will not infringe or otherwise violate any third party&#8217;s intellectual property.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants, independent contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and our licensors&#8217; employees, including our senior management, were previously employed at universities, medical institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make product candidates that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have licensed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biosimilar product manufacturers may develop, seek approval for, and launch biosimilar versions of our products, which could be significantly less costly to bring to market and priced significantly lower than our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first inventor to file patent applications covering certain of our inventions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may design around our intellectual property rights or independently develop similar or alternative technologies or duplicate any of our technologies without infringing or misappropriating our intellectual property rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents with claims that cover our products or even issued patents;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies or product candidates that are patentable; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the intellectual property rights of others may have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If and when we commercialize, our relationships with customers and third-party payors may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by United States federal and state governments and by governments in non-US jurisdictions in which we conduct our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a full discussion of these laws, see the subsection titled &#8220;Other Healthcare Laws and Compliance Requirements&#8221; in Item 1. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government funded healthcare programs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and affect the prices we may obtain.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some non-US jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any commercialization partners, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any commercialization partners, may receive for any approved products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS, the agency that administers the Medicare and Medicaid programs, may revise reimbursement and implement coverage restrictions. Any reduction in reimbursement from Medicare, Medicaid or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in March 2010, President Obama signed into law the ACA. Among the provisions of the ACA of potential importance to our business and our product candidates are the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biological products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the MDRP to 23.1% for innovator drugs and 13% for non-innovator drugs of the AMP;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which AMP is calculated and reported by manufacturers for products that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient products to be covered under Medicare Part D;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service Act's 340B drug pricing program;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new requirements to report to CMS annually specifying financial arrangements with physicians and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any &#8216;&#8216;payments or other transfers of value&#8217;&#8217; made or distributed to prescribers, teaching hospitals, and other healthcare providers and reporting any ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations during the preceding calendar year;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a mandatory non-deductible payment for employers with 50 or more full-time employees (or equivalents) who fail to provide certain minimum health insurance coverage for such employees and their dependents;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the ACA have been subject to judicial challenges, as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017, eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Code, commonly referred to as the &#8220;individual mandate,&#8221; effective January 1, 2019. Further, the Bipartisan Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage gap in most Medicare prescription drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the manufacturer discount under the Medicare Part D coverage gap discount program to 70%. Additional legislative changes, regulatory changes and judicial challenges related to the ACA remain possible. It is unclear how the ACA and its implementation, as well as efforts to repeal, replace, or otherwise modify, or invalidate, the ACA, or portions thereof, will affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, among other things, led to aggregate reductions in Medicare payments for all items and services, including prescription drugs and biologics, to service providers of, on average, 2% per fiscal year beginning April 1, 2013, and due to subsequent legislation, will continue until 2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022). On December 10, 2021, President Biden signed a law that provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012 also, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which regulatory approval is obtained, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which could have a material adverse effect on our financial operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For example, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient programs, and reform government healthcare program reimbursement methodologies for drug products. For example, Congress is currently considering changes that could affect our overall rebate liability. Changes under consideration include a drug price negotiation program, Medicare Part B and Part D inflation rebates, under which manufacturers would owe rebates if the average sales price </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or average manufacturer price of a drug were to increase faster than the pace of inflation, and Part D benefit redesign, including a proposed new manufacturer discount program. If healthcare policies or reforms intended to curb healthcare costs are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. We cannot be sure whether additional legislative changes will be enacted in the United States or outside of the United States, or whether regulatory changes, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory environment surrounding information security, data collection, and privacy is increasingly demanding. In the United States, we are subject to a number of data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, such as Section 5 of the Federal Trade Commission Act, govern the collection, use, and disclosure of health-related and other personal information. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy and security requirements in the United States under HIPAA. Although we are not directly subject to HIPAA-other than potentially with respect to providing certain employee benefits-we could be subject to criminal penalties if we knowingly obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Finally, a data breach affecting sensitive personal information, including health information, could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to US data protection laws and regulations, we also may be subject to European and other international data protection requirements, such as the EU General Data Protection Regulation. Our failure to comply with data privacy and security laws and regulations, or changes in the way in which these laws are implemented, could lead to unfavorable outcomes, including increased compliance costs, delays or impediments in the development of new products, increased operating costs, diversion of management time and attention, regulatory liability as a result of government enforcement actions and significant penalties against us, civil liability as a result of claims initiated by data subjects (including claims initiated as class actions) contracting parties or other third parties as a result of non-compliance with data protection laws and/or contractual obligations, and adverse publicity that could negatively affect our operating results, financial condition and our overall and business. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space. Such liabilities could adversely impact our results of operations, financial condition and our overall business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our current and future operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we operate. The FCPA prohibits any United States individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any non-US official, political party or candidate for the purpose of influencing any act or decision of the non-US entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered non-US officials. Certain payments to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-United States nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on United States exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct, including intentional failure to comply with FDA regulations or similar regulations of comparable non-United States regulatory authorities, failure to provide accurate information to the FDA or comparable non-United States regulatory authorities, including the competent authorities of the EU Member States, failure to comply with manufacturing standards we have established, failure to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-United States regulatory authorities, and failure to report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 coronavirus could adversely impact our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effect of the novel strain of coronavirus, COVID-19. The COVID-19 coronavirus has spread and has caused significant disruptions around the world. We may experience disruptions as a result of the COVID-19 pandemic that could severely impact our business, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties related to the continued clinical development of Vicineum for non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including delays in clinical trial sites receiving the supplies and materials needed to conduct clinical trials, difficulties in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients or treating patients in active trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in raising additional capital needed for the continued development of Vicineum for non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and if approved, commercialization for Vicineum due to the long-term negative effects of the pandemic on the financial, banking and capital markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators and other important agencies and contractors due to limitations in employee resources, travel restrictions or forced furlough of government employees;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key business activities due to illness and/or quarantine of key individuals and delays associated with recruiting, hiring and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evolving changes in local regulations as part of a response to the COVID-19 outbreak that may require us to change the ways in which operate, which may result in unexpected costs; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key commercialization, manufacturing, and related activities due to limitations on work and travel imposed or recommended by federal or state governments, employers and others.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global pandemic of COVID-19 continues to evolve. The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the virus. The full impact of the COVID-19 pandemic on our operational and financial performance, including our ability to execute our business strategies and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiatives in the expected time frame, will depend on future developments, including the duration of the pandemic and continuing restrictions on travel and transports, and shelter-in-place, social distancing, and similar measures, all of which are uncertain and difficult to predict. The broad-based business and economic disruptions caused by the pandemic could materially affect our business condition, results of operations and cash flows, including our ability to raise additional capital.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees. The loss of any member of our senior management team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm our operating results. Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could materially adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we rely on information technology networks and systems, some of which are provided, hosted or managed by third parties, to collect, store, process and transmit electronic data. In addition, we handle certain data, including proprietary business information and personal information that is subject to data protection laws and regulations. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have implemented processes, procedures, and controls to help mitigate the risks associated with a cyber security incident, there can be no assurance that these measures will be sufficient for all possible situations. Even security measures that are appropriate, reasonable, and/or in accordance with applicable legal requirements may not be able to protect the networks, systems and information we maintain and those of third parties with which we contract. Unauthorized parties, whether within or outside our company, may disrupt or gain access to our systems, or those of third parties with whom we do business, through human error, misfeasance, fraud, trickery, or other forms of deceit, including break-ins, use of stolen credentials, social engineering, phishing, ransomware, computer viruses or other malicious codes, and similar means of unauthorized and destructive tampering. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted cyber security incidents evolve and generally are not recognized until launched against a target. Accordingly, we may be unable to anticipate these techniques or to implement adequate security barriers or other preventative measures, making it impossible for us to entirely mitigate this risk. While we have experienced, and expect to continue to experience, threats and disruptions to our information technology infrastructure, none of them to date has had a material impact on our business or operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, our product research, development and, if approved, commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could be delayed, or we could be subject to regulatory and other government investigations, enforcement actions, or incur liability, substantial fines or costs, any of which could materially adversely affect our business, our reputation, results of operations and financial condition. Although we maintain insurance coverage for various cyber security risks, there can be no guarantee that all costs or losses incurred will be fully insured.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring plan and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unresponsive NMIBC. The restructuring plan included a reduction in our workforce by 18 positions (approximately 35%) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring expenses for the year ended December 31, 2021 were approximately $5.5&#160;million, consisting primarily of severance and other employee-related costs of $2.8&#160;million and contract termination costs of $2.7&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, our restructuring plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing our business strategy, including retention of our remaining employees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and certain of our officers have been named as defendants in three pending securities class action lawsuits and three related shareholder derivative lawsuits have been filed. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021 and October 7,2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by us concerning our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants&#8217; response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with Sesen Bio, Inc. named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by us concerning our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these lawsuits are without merit and intend to vigorously defend against these actions. However, whether or not the claims are successful, litigation is often expensive and can divert management&#8217;s attention and resources from other business concerns, which could adversely affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are not able to estimate the possible cost to us from these actions, as the pending lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that we may be required to pay. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. We maintain liability insurance; however, if any costs or expenses associated with the pending lawsuits or any other litigation exceed our insurance coverage, we may be forced to bear some or all costs and expenses directly, which could adversely affect our business, financial condition, results of operations or stock price.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to regain compliance with the listing requirements of the Nasdaq Global Market, our common stock may be delisted from the Nasdaq Global Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders' equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Global Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, we received notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") that we are not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement by having the closing bid price of our common stock meet or exceed $1.00 per share for at least ten consecutive business days. The notification had no immediate effect on the listing of our common stock, and our common stock will continue to trade on the Nasdaq Global Market under the symbol &#8220;SESN&#8221; at this time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not regain compliance by July 25, 2022, we may be eligible for an additional 180 calendar day grace period. If we fail to regain compliance during the applicable period, we will receive notification from Nasdaq that our common stock is subject to delisting. At that time, we may then appeal the delisting determination to a Nasdaq hearings panel. Such notification will have no immediate effect on our listing on the Nasdaq Global Market, nor will it have an immediate effect on the trading of our common stock pending such hearing. There can be no assurance, however, that we will be able to regain compliance with Nasdaq&#8217;s minimum bid price requirement. If we regain compliance with the Nasdaq&#8217;s minimum bid price requirement, there can be no assurance that we will be able to maintain compliance with the continued listing requirements for the Nasdaq Global Market or that our common stock will not be delisted from the Nasdaq Global Market in the future. In addition, we may be unable to meet other applicable listing requirements of the Nasdaq Global Market, including maintaining minimum levels of stockholders&#8217; equity or market values of our common stock in which case, our common stock could be delisted notwithstanding our ability to demonstrate compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delisting from the Nasdaq Global Market may adversely affect our ability to raise additional financing through the public or private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are delisted from Nasdaq and we are not able to list our common stock on another exchange, our common stock could be quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and little or no analyst coverage for us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we would no longer qualify for exemptions from state securities registration requirements, which may require us to comply with applicable state securities laws; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities (including pursuant to short-form Registration Statements on Form S-3) or obtain additional financing in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our common stock becomes subject to the penny stock rules, it would become more difficult to trade our shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain our listing on Nasdaq and if the price of our common stock is less than $5.00, our common stock may be deemed a penny stock. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be affected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our Certificate of Incorporation or bylaws.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a 31,100 square foot manufacturing, laboratory, warehouse and office facility in Winnipeg, Manitoba. We have three 15-liter fermenters, one 30-liter fermenter, one 150-liter fermenter, one 500-liter fermenter and one 1,500-liter fermenter. Our classified fermentation suite and post-production processing capabilities were dedicated to producing our pre-clinical study and clinical trial batches of Vicineum.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we completed the manufacturing of all Vicineum necessary for our Phase 3 VISTA Trial and for our CRADA with the NCI.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with this achievement, we ended our manufacturing activities at our facility in Winnipeg and completed the technology transfer process to outsource future Vicineum clinical and commercial to third-party manufacturers. We operate our Winnipeg facility under a two-year renewable lease expiring in September 2022, and we have a right to renew the lease for one subsequent three-year term.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Cambridge, MA, where we occupy office space under a lease that was executed in October 2016. The initial term of the lease expired in July 2017, with the lease now continuing on a renewable four-month term unless terminated by either party with the requisite notice. The lease is currently extended through</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have office space in Philadelphia, PA, where we occupy office space under a lease executed in December 2017. The initial term of the lease expired in May 2018, which now continues on renewable six-month terms unless terminated by either party with the requisite notice. The lease has been extended through</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities are adequate to meet our current needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants&#8217; response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets and violations of federal securities laws, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D&#8217;Arcy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages, and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_28"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Price</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol "SESN" on the Nasdaq Global Market. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2022, there were 17 holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid, and for the foreseeable future do not expect to declare or pay, cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Securities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.          &#160;&#160;&#160;&#160;[Reserved.]</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_31"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes thereto and other financial information included elsewhere in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. You should review "Item 1A. Risk Factors" of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a Type A Meeting with the FDA to discuss questions related to CMC raised in the CRL (the &#8220;CMC Type A Meeting&#8221;). During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum (the &#8220;Clinical Type A Meeting&#8221;), which the FDA confirmed will be required for a potential resubmission of a BLA. The trial design may include these elements:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators&#8217; choice of intravesical chemotherapy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trial may include both patients who have received adequate BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patients who have received less than adequate BCG;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA encouraged us to submit the final results from the Phase 3 Vista Trial for Vicineum with a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the 2018 FDA guidance on NMIBC, adequate BCG is defined as at least one of the following: (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the items we expect to be discussed in the Type C Meeting is the patient population for the additional Phase 3 clinical trial, which may be different than the patient population studied in previous clinical trials for Vicineum for the treatment of NMIBC in two primary ways. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, the additional Phase 3 clinical trial may include patients with only non-muscle invasive carcinoma in situ (CIS) of the bladder, and may not include patients with only papillary disease of the bladder. This change would lead to a smaller overall patient population than previously studied, as some of our past clinical trials of Vicineum in NMIBC have included patients with CIS or high-grade papillary disease of the bladder. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, the additional Phase 3 clinical trial may include patients who have received less than adequate BCG in addition to those who have received adequate BCG, per the FDA&#8217;s guidance. Receipt of less than adequate BCG could be due to (i) failure of, or intolerance to, a BCG therapy prior to reaching the FDA&#8217;s definition of adequate BCG or (ii) supply shortages of BCG, among other reasons. This change would lead to a larger patient population than previously studied, as past clinical trials of Vicineum in NMIBC only included patients who had previously been treated with adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential changes related to the additional Phase 3 clinical trial for Vicineum will be discussed at the upcoming Type C Meeting with the FDA scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The single-arm, multi-center, open-label Phase 3 clinical trial (&#8220;VISTA Trial&#8221;) completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and duration of response ("DoR") for BCG-unresponsive CIS patients who experience a complete response ("CR").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm (the "Fujifilm MSA") for the manufacturing process and technology transfer of Vicineum drug substance production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter for the manufacturing process and technology transfer of Vicineum drug product production.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed manufacturing of the drug substance process performance qualification (&#8220;PPQ&#8221;) batches at Fujifilm and in September 2020, we successfully completed the drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach is in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for Vicineum produced by Fujifilm and Baxter were found to be highly comparable to supply of Vicineum at our Winnipeg facility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, and that any of these future trials can proceed while addressing CMC issues raised in the CRL.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we signed a Scope of Work ("SOW #11") with Fujifilm under the Fujifilm MSA for the manufacturing of commercial batches of Vicineum in 2022 and 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use Vicineum produced by Fujifilm and Baxter for any future clinical trials of Vicineum and, if approved, for commercial supply.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Outside of United States ("OUS") Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan ("Greater China"). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8 million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9 million of revenue during the three months ended June 30, 2021, for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments to Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in MENA region (20 countries in Middle East and North Africa) (the &#8220;MENA License Agreement&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties on net sales in the MENA region for the term of the Hikma License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $1.5 million. We are in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. We are also eligible to receive additional regulatory and commercial milestone payments of $2.0 million and are entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal Review</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 we disclosed that our Board of Directors (the &#8220;Board&#8221;) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#8220;Review&#8221;). The Review took place over the course of five months, involved full cooperation from our management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. It is now complete. As a result of the Review, the Board continues to fully support our current management team and believes no changes or amendments relating to our prior disclosures to the Securities and Exchange Commission (&#8220;SEC&#8221;) or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted. We intend to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement, which is assessed under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). In the future, we may generate revenue from a combination of up-front payments, milestone payments and royalties in connection with our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations ("CROs") and investigative sites that conduct our clinical trials, including the additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, outcome and costs of our clinical trials, including the additional Phase 3 clinical trial, and other research and development activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG compared to alternative treatments, including any standard of care;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market acceptance of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of the implementation of commercial-scale manufacturing of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and terms of any marketing approvals.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could mean a significant change in the costs and timing associated with the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing beyond those that we currently contemplate will be required for the completion of clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we could be required to expend significant additional financial resources and time on the completion of clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of BCG-unresponsive NMIBC and other expenses by category. We have deferred further development of Vicineum for the treatment of SCCHN and VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of BCG-unresponsive NMIBC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, insurance, investment banking fees, patent, consulting and accounting services, pre-commercial United States market research and pre-launch market readiness for the potential commercial launch of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). The Restructuring Plan included a reduction in our workforce by 18 positions (or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring costs related to the Restructuring Plan were recorded in operating expenses in our Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed. The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region as well as discount rates applied to the projected cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to Viventia's shareholders pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-US jurisdictions pursuant to our OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years ended December&#160;31, 2021 and 2020 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,093&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,549)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss and Comprehensive Loss Before Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,952)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,343</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,397)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(98)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December 31, 2021 was $26.5 million, primarily due to the $20 million milestone achieved pursuant to the Roche License Agreement upon initiating a Phase II clinical trial, $5.0 million related to the Qilu License Agreement (achievement of the IND milestone, clinical supply revenue, and license revenue for additional purchase price due to the recovery of VAT), and $1.5 million upfront milestone revenue achieved pursuant to the MENA License Agreement. Revenue for the year ended December 31, 2020 was $11.2 million, which was due to the recognition of revenue pursuant to the Qilu License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $25.3 million for the year ended December&#160;31, 2021, compared to $29.2 million for the year ended December&#160;31, 2020. The decrease of $3.9 million was primarily due to lower costs associated with technology transfer and manufacturing ($7.4 million). This was partially offset by increases in employee-related compensation driven by increased headcount as part of the commercial build and the retention program implemented after receipt of the CRL in August 2021 ($2.1 million), regulatory and clinical consulting fees ($1.0 million)</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other R&amp;D expense, none of which were individually material ($0.5 million). We anticipate that R&amp;D expenses will increase beginning in 2022 due to additional clinical trial activity costs related to our plans to conduct an additional Phase 3 clinical trial for Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $29.4 million for the year ended December&#160;31, 2021, compared to $14.3 million for the year ended December&#160;31, 2020. The increase of $15.1 million was primarily due to increases in employee-related compensation ($5.0 million), legal costs ($4.8 million), and marketing and commercial expenses ($4.1 million) driven by preparation for the commercial launch of Vicineum prior to the issuance of the CRL in August 2021. Additionally, increases in accounting services ($0.4 million), insurance expenses ($0.4 million), IT expenses ($0.3 million) and others ($0.1 million) contributed to the increase. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). The Restructuring Plan included a reduction in our workforce by 18 positions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructurin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g expenses were $5.5 million for the year ended December&#160;31, 2021, compared to no restructuring expenses for the year ended December&#160;31, 2020. The increase was due to one-time costs associated with the Restructuring Plan implemented in response to the CRL for severance and other employee-related costs ($2.8 million) and termination of certain contracts ($2.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an intangibles impairment charge of $31.7 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any impairment charges during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the year ended December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2021, we received a CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The impairment charge of $31.7 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relates to the full impairment of our US in-process research and development asset due to expected delays in the start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market at this time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $56.8 million for the year ended December&#160;31, 2021, compared to income of $11.2 million for the year ended December&#160;31, 2020. The decrease in the fair value of contingent consideration of $45.7 million from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021, was driven by the receipt of a CRL from the FDA, regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. Due to the inherent uncertainty in the path forward for Vicineum at this time, we reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of the contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success POS; we expect delays in the start of commercialization and estimate lower POS as a direct result of the CRL and our withdrawal of the MAA. We will need to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, we now assume a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. We participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped us determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was income of $11.2 million for the year ended December&#160;31, 2020. This was primarily attributable to significantly higher discount rates as a result of financial market conditions as of the year ended December&#160;31, 2020, offset by changes to the competitive landscape.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (expense) income, net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was $0.1 million for the year ended December&#160;31, 2021, compared to other income of $0.1 million for the year ended December&#160;31, 2020. The change of $0.2 million was due primarily to lower interest income.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December 31, 2021, we recorded a benefit from income taxes of $8.3 million. In the third quarter of 2021, we determined that the fair value of the Vicineum United States in-process research and development asset was zero, which resulted in an impairment charge of $31.7 million. In connection with this impairment charge, in the third quarter of 2021, we wrote-down the associated deferred tax liability by $8.6 million as a benefit. Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the twelve months ended December 31, 2020, we recorded a provision for income taxes of $1.4 million</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision consisted of income taxes paid to non-US jurisdictions pursuant to our commercialization partnership agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years ended December&#160;31, 2020 and 2019 </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comparison of our results of operations for the years ended December&#160;31, 2020 and 2019, see "Part II - Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, filed with the United States Securities and Exchange Commission ("SEC") on March 15, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and cash equivalents of $162.6 million, net working capital of $194.0 million and an accumulated deficit of $316.3 million. We incurred negative cash flows from operating activities of $68.9 million, $30.8 million and $37.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. We believe that our cash and cash equivalents of $162.6 million as of December&#160;31, 2021, are sufficient to fund our operating plan into 2024. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future as we seek to address the issues raised in the CRL we received for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our OUS business development partnerships and license agreements and, to a lesser extent, from a collaboration.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time for an aggregate sales price of up to $35 million through Jefferies (the "ATM Offering"). In October 2020 and February 2021, we entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No.2 modified the Sale Agreement to reflect that we may issue and sell shares of our common stock from time to time for an aggregate sales price of up to an additional $50.0&#160;million and $34.5&#160;million, respectively. In June 2021, we entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of our common stock pursuant to the Sale Agreement. Sale of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. As of December&#160;31, 2021, we have $97.8&#160;million in available ATM capacity.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell shares of our common stock efficiently from time to time but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We raised $175.0 million of net proceeds from the sale of 56.9 million shares of common stock at a weighted-average price of $3.17 per share during the year ended December&#160;31, 2021. We raised $38.0 million of net proceeds from the sale of 33.4 million shares of common stock at a weighted-average price of $1.17 per share during the year ended December&#160;31, 2020. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million and $1.2 million for the year ended December&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effect of the outbreak of COVID-19. We are proactively executing risk mitigation strategies to attenuate the impact of COVID-19 on us, and at this time, we have not yet experienced any business disruptions as a result of the pandemic. We are continually assessing the effect of the COVID-19 pandemic on our operations, and we are monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to develop and, if approved, commercialize our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon our ability to attain profitable operations. In order to commercialize our product candidates, including Vicineum, we need to complete clinical development and comply with comprehensive regulatory requirements. We are subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of our product candidates, raising additional capital, development and commercialization by our competitors of new technological innovations, protection of proprietary technology and market acceptance of our products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and we expect to seek additional funds through equity or debt financings or through additional OUS business development partnerships, collaborations, licensing transactions or other sources. We may be unable to obtain equity or debt financings or enter into additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships, collaborations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or licensing transactions at favorable terms, or at all, and, if necessary, we may be required to implement cost reduction strategies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">address the issues identified in the CRL we received from the FDA for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, including the completion of an additional Phase 3 clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities (including completing the manufacturing process and technology transfer to any third-party manufacturers) to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and our other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to discover and develop additional product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates or technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, initiation, progress, timing, costs and results of pre-clinical development and laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and our other product candidates, including an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on our business</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional OUS business development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships, collaborations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third-party licensors under our licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA, and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA or comparable non-US regulatory authorities to require that we perform more studies than those that we currently expect to perform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain future regulatory, development and commercialization milestones under our out-license and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization OUS business development partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues from commercial sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic OUS business development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alliances, and licensing arrangements. We do not have any committed external source of funds other than the amounts payable under our out-license and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, strategic </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alliances or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on our operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect our ability to raise additional capital in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to our cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5 &#8220;Fair Value Measure and Financial Instruments,&#8221; as well as the description of our leases in Note 7 &#8220;Property and Equipment&#8221;, and the description of our license agreement and collaborations in Note 17, &#8220;License Agreements&#8221; of Part IV - Item 15. Exhibits and Financial Statements - Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Operating Activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,878)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,837)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $68.9 million for the year ended December&#160;31, 2021 and consisted primarily of a net loss of $0.3 million, which includes $26.5 million of revenue recognized pursuant to the Roche License Agreement upon Roche initiating a Phase II clinical trial, achievement of the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to Qilu, our OUS partner for Greater China, and license revenue for additional purchase price due to the recovery of VAT by our OUS business development partner for Greater China, adjusted for non-cash items, including share-based compensation of $5.1 million, a decrease in the fair value of contingent consideration of $56.8 million, impairment charge of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a net decrease in operating assets and liabilities of $48.6&#160;million. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $30.8 million for the year ended December&#160;31, 2020 and consisted primarily of a net loss of $22.4 million, adjusted for non-cash items, including depreciation of $0.1 million, share-based compensation of $1.8 million, a change in the fair value of the contingent consideration of $11.2 million and a net increase in operating assets and liabilities of $0.9 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $37.5 million for the year ended December&#160;31, 2019 and consisted primarily of a net loss of $107.5 million, adjusted for non-cash items, including depreciation of $0.2 million, share-based compensation of $1.2 million, a change in the fair value of contingent consideration of $71.6 million and a net decrease in operating assets and liabilities of $3.1 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of de minimis purchases and sales or property and equipment during each of the years ended December&#160;31, 2021, and 2020 and $0.1 million for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $176.1 million for the year ended December&#160;31, 2021 and consisted of $175.0 million in net proceeds from the sale of common stock under the ATM Offering and $1.1 million in proceeds from the exercise of common stock warrants.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $38.1 million for the year ended December&#160;31, 2020 and consisted of $38.0 million net proceeds from the sale of common stock under the ATM Offering and $0.1 million in proceeds from the exercise of common stock warrants.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $35.4 million for the year ended December&#160;31, 2019 and consisted primarily of $27.8 million in net proceeds from our June 2019 Financing, $5.5 million from the exercise of outstanding warrants to purchase our common stock and $1.9 million in net proceeds from our ATM Offering.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in accordance with GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Management has determined that our most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is not obtained, we will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we received a CRL from the FDA regarding our BLA for Vicineum for the treatment of NMIBC, our lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and our withdrawal of the MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of our intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, we have assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that we expect the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on our reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein we determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bladder in patients previously treated with adequate or less than adequate BCG. We performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of our intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on our consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and our withdrawal of the MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of our intangible assets, Vicineum US Rights, we concluded that the carrying value of our goodwill of $13.1&#160;million was not impaired as of September 30, 2021. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We performed the annual goodwill impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. While our stock price has declined since December&#160;31, 2021, this is consistent with the general biotech sector overall, as world economic conditions continue to be impacted by the highly contagious Omicron variant. We believe that we have sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. We project future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. We will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future commercial launch milestones and net sales royalties due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. For additional information on how contingent consideration has changed over the relevant period, see "Part IV - Item 15. Financial Statements - Notes to Consolidated Financial Statements - Note 1. Description of Business" of this Annual Report on Form 10-K. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); we expect delays in the start of commercialization and estimate lower POS as a direct result of the CRL. We plan to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally and any significant changes or delays could have a significant impact on the fair value of contingent consideration. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, we now assume a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, we will note recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in "Part IV - Item 15. Exhibits and Financial Statements - Notes to Consolidated Financial Statements - Note 4. Recent Accounting Pronouncements" in our consolidated financial statements, which begin on page F-1 of this Annual Report on Form 10-K.</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_34"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements, together with the report of our independent registered public accounting firm, appear in the Index to Financial Statements beginning on page F-1 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices or financial disclosure required to be reported under this Item.</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_37"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Act Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principle financial officer, to allow timely decisions regarding required disclosure. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Annual Report on Form 10-K. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting ("ICFR"), as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. ICFR includes our policies and procedures, such as our Code of Conduct, which (i) require our employees, officers and directors to adhere to certain ethical standards; (ii) require the maintenance of records, in reasonable detail, to help to ensure that our transactions, assets and liabilities are accurately and fairly recorded; (iii) provide reasonable assurance that transactions are authorized by our management and directors and are recorded as necessary to allow for the accurate preparation of financial statements in accordance with GAAP; and (iv) provide reasonable assurance regarding the safeguarding of our assets and the prevention or timely detection of the unauthorized acquisition, use or disposition of our assets, which could have a material effect on the financial statements. ICFR includes the controls themselves, management's monitoring of those controls, actions taken to correct any deficiencies identified and oversight of our internal control environment by the audit committee of our board of directors. Any system of internal control has inherent limitations and therefore may not prevent or detect misstatements. Projections of any evaluation of the effectiveness of ICFR to future periods are subject to the risk that controls may become inadequate over time because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our ICFR as of the end of our fiscal year 2021 and has reviewed the results of this assessment with the audit committee of our board of directors. Management based its assessment on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that our ICFR was effective as of December&#160;31, 2021 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our ICFR as of December 31, 2021 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included immediately below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sesen Bio, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Sesen Bio Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Sesen Bio, Inc. (the &#8220;Company&#8221;) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; (deficit) equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8zNy9mcmFnOjI2MTg4NGZjNTE3ZDRiMmQ5NDEwOWVkMThkOWFhNTk2L3RleHRyZWdpb246MjYxODg0ZmM1MTdkNGIyZDk0MTA5ZWQxOGQ5YWE1OTZfNDM5ODA0NjU0OTcxMA_2f495277-264d-4d37-988f-cb6f8f3951e8">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston, Massachusetts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 28, 2022</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been changes in our internal control over financial reporting during the quarter ended December 31, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_40"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_43"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has adopted a written Code of Business Conduct and Ethics applicable to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Business Conduct and Ethics covers fundamental ethical and compliance-related principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection and use of our property and information and compliance with legal and regulatory requirements. A current copy of the code is posted on the Corporate Governance section of our website, which is located at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sesenbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any substantive amendment to, or waiver from, a provision of this Code and by posting such information on the website address and location specified above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. &#160;&#160;&#160;&#160;Executive Compensation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. &#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. &#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. &#160;&#160;&#160;&#160;Principal Accountant Fees and Services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_49"></div><div style="-sec-extract:summary;margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1)&#160;Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements listed in the Index to Financial Statements beginning on page F-1 are filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(2) Financial Statement Schedules</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statement schedule listed in the Index to Financial Statements on page F-1 is filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) Exhibits</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form&#160;10-K are set forth on the Exhibit&#160;Index immediately preceding such exhibits and are incorporated herein by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex21.htm">Share Purchase Agreement, effective as of September 20, 2016, by and between Eleven Biotherapeutics, Inc., Viventia Bio Inc. and Clairmark Investments Ltd., as representative of the selling shareholders (we hereby agree to furnish supplementally a copy of any omitted schedules to the SEC upon request). Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on September 21, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-Laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit41-fy2021form10xk.htm">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on Form S-1 filed on December 19, 2014 (Reg. No. 333-201176).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 3, 2017 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex101.htm">Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1 filed on December&#160;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex102.htm">Form of Incentive Stock Option Agreement under the Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 filed on December&#160;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex103.htm">Form of Non-statutory Stock Option Agreement under the Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.3 to our Registration Statement on Form S-1 filed on December&#160;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000045/sesenbio-2014stockincentiv.htm">2014 Stock Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on June 25, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex106.htm">Form of Incentive Stock Option Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit 10.6 to our Registration Statement on Form S-1/A filed on January&#160;23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex107.htm">Form of Non-statutory Stock Option Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit&#160;10.7 to our Registration Statement on Form S-1/A filed on January&#160;23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312515239156/d34817dex101.htm">Form of Restricted Stock Unit Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit&#160;10.1 to our Current Report on Form 8-K filed on June 29, 2015 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108_formindemnifica.htm">Form of Indemnification Agreement by and between Sesen Bio, Inc. and Each of its Directors and Executive Officers. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex1013.htm">2014 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.13 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500316000144/ebio-063016x101.htm">License Agreement, dated as of June 10, 2016, by and among Eleven Biotherapeutics, Inc., F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on August 12, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex101.htm">License Agreement, effective January 13, 2003, as amended and restated on October 14, 2015, by and between The University of Zurich and Viventia Bio Inc. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on September 21, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit101micrometli.htm">Non-Exclusive Product License Agreement, effective as of October 18, 2005, by and between Micromet AG and Viventia Biotech Inc. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit102xomanonexc.htm">Non-Exclusive License Agreement, effective as of November 30, 2001, by and between XOMA Ireland Limited and Viventia Biotech Inc. Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on November 9, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000105/exhibit101-tcannellemploym.htm">Employment Agreement, dated August 7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 13, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit101.htm">Form of Securities Purchase Agreement. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-spaamendment.htm">Amendment to Securities Purchase Agreement, dated October 28, 2019, by and among Sesen Bio, Inc. and the undersigned parties thereto. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000015/ex1032sesn-tomcannellstock.htm">Stock Option Award Agreement, dated August 7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell, D.V.M. Incorporated by reference to Exhibit 10.32 to our Annual Report on Form 10-K filed on March 1, 2019 (File. No. 001-36296). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000015/ex1034sesn-fujimbsafullred.htm">Master Bioprocessing Services Agreement, dated October 4, 2018, between Sesen Bio, Inc. and FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Incorporated by reference to Exhibit 10.34 to our Annual Report on Form 10-K filed on March 1, 2019 (File. No. 001-36296). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">E</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000029/glenmacdonaldebioemploym.htm">mployment Agreement, dated September 20, 2016, by and between Eleven Biotherapeutics, Inc. and Glen Macdonald, as amended on February 21, 2017. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 10, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000070/sesenbio-monicaforbesemplo.htm">Employment Agreement, dated August 26, 2019, by and between Monica Forbes and Sesen Bio, Inc. Incorporated herein by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2019 (File No. 001-36296).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex101.htm">Employment Agreement, dated July 26, 2019, by and between Mark R. Sullivan and Sesen Bio, Inc. Incorporated herein by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 12, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex103.htm">Stock Option Award Agreement, dated August 1, 2019, by and between Sesen Bio, Inc. and Monica Forbes. Incorporated herein by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed on November 12, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">, dated November 2019, by and between Sesen Bio, Inc. and Jeff</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">ries LLC. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">Amendment No. 1 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">, dated October 30, 2020, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on October 30, 2020 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000118/sesn-ex101qilulicensea.htm">Exclusive License Agreement, dated July 30, 2020, by and among Sesen Bio, Inc., Viventia Bio, Inc. and Qilu Pharmaceutical Co., Ltd. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2020 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">Amendment No. 2 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">, dated February 17, 2021, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on February 17, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit101-amendmentno2t.htm">Amendment No. 2 to the Sesen Bio, Inc. 2014 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 3, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit102-amendmentno1t.htm">Amendment No. 1 to the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on May 3, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001485003/000148500321000114/sesn-amendmentno3toatmsa.htm">Amendment No. 3 to the Open Market Sale AgreementSM, dated June 1, 2021, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on June 1, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1030-rsuandcashrete.htm">Form of RSU Award Agreement for Retention Awards</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1031-performancexba.htm">Form of PSU Award Agreement for Retention Awards </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312021x10kex211.htm">Subsidiaries of Sesen Bio, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231eyconsentforfy20.htm">Consent of Ernst &amp; Young LLP.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312021x10kex311.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312021x10kex312.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312021x10kex321.htm">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312021x10kex322.htm">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit is a compensatory plan or arrangement in which our executive officers or directors participate.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.</span></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;Form 10-K Summary.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:142.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:285.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.&#160;</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Capacity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Monica Forbes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elly Ryu</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Controller<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elly Ryu</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay S. Duker, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay S. Duker, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carrie L. Bourdow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrie L. Bourdow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Jason A. Keyes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason A. Keyes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter K Honig, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter K Honig, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael A.S. Jewett, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A.S. Jewett, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:88.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV81OC9mcmFnOjcxYjA3ZmRlZDJlNDRiOTBhZjQwYzg0MWQxNjk1OTI1L3RhYmxlOmY5OGE5ZGRhMGI0NjQ2OTlhZmVmNWQ3MWFiODlkMDNiL3RhYmxlcmFuZ2U6Zjk4YTlkZGEwYjQ2NDY5OWFmZWY1ZDcxYWI4OWQwM2JfMS0wLTEtMS01MDgyMy90ZXh0cmVnaW9uOmNmNjA0ODY1ODcyZDQ2NTdhMWVlMTliYTQyNmQ1ODIzXzE3MDQyNDMwMjMwNjA0_2bcd8e6a-5ae6-410f-9889-4b49b81396dd">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_61">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_64">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_67">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_70">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_76">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_79">8</a></span></div></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sesen Bio, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Sesen Bio, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; (deficit) equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value of Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 3 and 5 to the consolidated financial statements under the caption &#8220;Contingent Consideration,&#8221; the Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. Fluctuations in the fair value of the liability result in a charge to earnings (or loss) during the period. As of December 31, 2021, the Company estimated the fair value of the contingent consideration liability as $52.0 million and recorded the change in fair value of $56.8 million as operating income for the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the fair value of the contingent consideration liability required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate the fair value. In particular, the fair value measurement was sensitive to the significant assumptions underlying the projected commercial sales of Vicineum and probabilities of success and timing of certain milestone events and achievements.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the development of the significant assumptions over the Company&#8217;s process to estimate the fair value of the contingent consideration liability. This included testing controls over management&#8217;s review of the significant estimation assumptions and methods used to develop the fair value estimate, the accuracy of the calculations included within the fair value model, and the underlying data used in the model.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the contingent consideration liability, our audit procedures included, among others, assessing the terms of the arrangement, evaluating the methodology used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry and economic trends and standards, external data sources, probability of success benchmarks, and regulatory factors. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management&#8217;s conclusions. In addition, we involved our valuation professionals to assess the methodology used to determine the fair value of the contingent consideration liability, which included performing corroborative fair value calculations.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impairment Evaluation of Goodwill and Indefinite-Lived Intangible Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 3 and 8 to the consolidated financial statements under the captions &#8220;Indefinite-Lived Intangible Assets&#8221; and &#8220;Goodwill,&#8221; the Company&#8217;s intangible assets consist of indefinite-lived, acquired in-process research and development (IPR&amp;D) worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of IPR&amp;D requires management to estimate the future discounted cash flows of the underlying asset. Impairment testing of goodwill requires management to estimate the future discounted cash flows of the Company&#8217;s one reporting unit.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s impairment assessments required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate the fair value of the reporting unit for and the IPR&amp;D. In particular, the fair value estimates of goodwill and of IPR&amp;D were sensitive to the significant assumptions underlying the projected commercial sales of Vicineum.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the development of the significant assumptions over the Company&#8217;s goodwill and indefinite-lived intangible asset impairment review processes. This included testing controls over management&#8217;s review of the quantitative impairment analyses of goodwill and IPR&amp;D, including the significant estimation assumptions and methods used, the accuracy of the calculations included within the valuation models, and the underlying data used in those models.</span></div><div style="margin-bottom:3pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the impairment evaluations over goodwill and IPR&amp;D assets, our audit procedures included, among others, evaluating the methodology and valuation models used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry and economic trends and standards, external data sources, probability of success benchmarks, and regulatory factors. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management&#8217;s conclusions. In addition, we inspected the Company&#8217;s reconciliation of the fair value of the reporting unit to the market capitalization of the Company and assessed the results. We involved our valuation professionals to assess the methodology and valuation of the discounted cash flow models, including evaluating the reasonableness of certain significant assumptions.</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82MS9mcmFnOjMzOWI5ZWEwZjRlYzRjMmRhYTIxMjE2ZTBkMWQwMzllL3RleHRyZWdpb246MzM5YjllYTBmNGVjNGMyZGFhMjEyMTZlMGQxZDAzOWVfNTQ5NzU1ODE4MjI0MQ_2f495277-264d-4d37-988f-cb6f8f3951e8">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2010.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82MS9mcmFnOjMzOWI5ZWEwZjRlYzRjMmRhYTIxMjE2ZTBkMWQwMzllL3RleHRyZWdpb246MzM5YjllYTBmNGVjNGMyZGFhMjEyMTZlMGQxZDAzOWVfNTQ5NzU1ODE4MjIxOA_5c2af772-bd81-4ce8-94a0-10f6f6e071d7">Boston, Massachusetts</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 28, 2022</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNC0xLTEtMS0yNzc0Mw_c427a9bc-4398-4ef3-8f58-10f5d3af827b">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNC0zLTEtMS0yNzc0Mw_4a4c21e5-2107-47b1-9fcb-f7d1467d39d7">52,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0xLTEtMS0zNjQwNw_a7b9d6ad-5951-462d-9a61-1eba04d83d01">21,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0zLTEtMS0zNjQxNA_bcd87d43-6a0c-4c3c-b40b-68f67e95768d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0xLTEtMS0zNjM5Mg_d8f40cd3-57ca-4850-826f-21827656413d">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0zLTEtMS0zNjQwMA_b97cb8c1-15bc-4c35-8f59-2b19673cb9e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0xLTEtMS0yNzc0Mw_bab830d3-76c0-4fab-b042-3a16fb3b3769">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0zLTEtMS0yNzc0Mw_81b98b70-5430-41d5-813d-c8a6106f7910">7,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0xLTEtMS0yNzc0Mw_d6b304cc-5443-4437-a395-b5b1ccabccdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0zLTEtMS0yNzc0Mw_77fa4435-9db0-4b39-85f3-97190de5fd80">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNy0xLTEtMS0yNzc0Mw_8936dd71-817f-41c7-8b54-6960fd135b98">205,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNy0zLTEtMS0yNzc0Mw_e4202f41-88e5-4a17-837d-97f9b1f779f3">62,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOC0xLTEtMS0yNzc0Mw_59a08bda-a49e-4583-9695-d226cdda8fae">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOC0zLTEtMS0yNzc0Mw_554f5813-c2a0-40dd-8a33-6fa4431cf774">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOS0xLTEtMS0yNzc0Mw_844b6939-b618-4972-9566-acf19ce6db2b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOS0zLTEtMS0yNzc0Mw_310f0dc9-8e74-46b1-a209-be8249e68b67">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTAtMS0xLTEtMjc3NDM_10f2a147-b8ec-4bf0-8d1e-b19149602e70">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTAtMy0xLTEtMjc3NDM_9901ff4e-a4d6-415b-82d9-633b567f4e8f">46,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTEtMS0xLTEtMjc3NDM_0cceaafe-4039-457e-9ab7-3e69fecdd7e9">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTEtMy0xLTEtMjc3NDM_6b1a01cd-c124-4a32-847c-e2b7e51e7d1c">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMS0xLTEtMzY0MzI_95d8eb86-b49a-49ac-939b-97622e614abe">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMy0xLTEtMzY0MzI_b70b091a-ab51-45ce-ae83-dda1a33c1bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTItMS0xLTEtMjc3NDM_3edd6372-023a-4b7b-8904-4f043278c195">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTItMy0xLTEtMjc3NDM_df61253c-b48b-4dca-a8d8-9f3596f4f44d">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMS0xLTEtNDU5MTY_ea3f63b6-27bc-49e9-ae14-b212795582fc">35,142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMy0xLTEtNDU5MTY_1aa3503e-2e1b-436d-8d6b-ac08e9ea4f60">59,956</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTMtMS0xLTEtMjc3NDM_d1a59f29-614b-418d-ae12-32936860f87f">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTMtMy0xLTEtMjc3NDM_0ca21761-d016-46af-a4ff-a668808490ea">122,823</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMS0xLTEtMjc3NDM_cb4e35d5-87fc-4f06-9eda-8e5f6a45bcd6">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMy0xLTEtMjc3NDM_7b180eb3-4419-4779-833c-c84915adbe0e">3,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTctMS0xLTEtMjc3NDM_e5b34edc-f33c-4648-8497-ac38515bf7b6">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTctMy0xLTEtMjc3NDM_5509dae4-daf4-4ca3-9776-2e5ee525fd8e">3,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMS0xLTEtMjc3NDM_8509c057-18e1-4ea8-9461-9677407a1bb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMy0xLTEtMjc3NDM_6a4eb248-2c79-4a54-ac4f-b434bb8a5157">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTktMS0xLTEtMjc3NDM_82599e7d-c96e-40fd-8542-d66a83aff52f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTktMy0xLTEtMjc3NDM_7ed8e5f0-c603-4675-bad9-785c3c747cad">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjAtMS0xLTEtMjc3NDM_b25e04c8-fd46-4cd3-9968-3a0969126359">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjAtMy0xLTEtMjc3NDM_e9c24e21-395f-4a3e-8027-2ac0d98db33e">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjEtMS0xLTEtMjc3NDM_b2981b03-40e0-4590-aaed-b37def878f1c">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjEtMy0xLTEtMjc3NDM_aa67bdb0-c6e5-4e8a-8c72-271da2cb6fe2">18,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjItMS0xLTEtMjc3NDM_65e6ac33-1175-4c42-aa1c-1a431df66de7">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjItMy0xLTEtMjc3NDM_e7dc99ea-b63d-429f-9d74-b8e81420deec">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjMtMS0xLTEtMjc3NDM_442efe3d-b5fb-40a3-b753-6400745aaf46">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjMtMy0xLTEtMjc3NDM_e38547cd-b141-4cce-9ece-89ac51114611">12,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMS0xLTEtMjg1OTk_b8be25c0-6618-4ba5-bab5-4a4d780c64da">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMy0xLTEtMjg1OTk_e8d5edad-5f91-4ea9-a618-30238607de6f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjUtMS0xLTEtMjc3NDM_0302ef1f-e7ee-4433-9b30-3fa35dc78464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjUtMy0xLTEtMjc3NDM_2793571b-61de-4cb6-9a21-31ea20e3bd36">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzUtMS0xLTEtNDU5MjU_ed727ce2-d46d-464a-a206-d8dd46de763d">57,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzUtMy0xLTEtNDU5MjU_d4469eee-cdb0-4ba0-aba1-d43e0238252f">114,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjYtMS0xLTEtMjc3NDM_748cc669-cff2-44fd-b6a7-4b8d116bd301">69,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjYtMy0xLTEtMjc3NDM_12c6c89c-c044-4564-90db-537661134ba0">132,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity (Deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDU3_1d9b135f-a2f7-402a-9a19-c06b3ac7d9d5"><ix:nonFraction unitRef="usdPerShare" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDU3_6c5638a7-e0d4-49d8-9187-9342a31d7ce2">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDY5_269149d2-8053-4019-a81e-dceb9665154e"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDY5_33659c5f-5b3a-4b9a-b171-d8446bebbf32">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at  December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_08295af6-3c58-4b06-9087-309fbe303a0e"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_4c71215a-6af9-49de-9a7f-5d4af64adcd8"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_a5dd636f-cdd3-4297-b4d7-47a6259e9b6c"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_ce04d179-b392-43ad-bf37-88ceebac556b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMS0xLTEtMjc3NDM_e65004aa-68fc-4735-9cee-e65cbe12a4e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMy0xLTEtMjc3NDM_0fa3adb4-da87-4cf1-91b7-2dba042dc67a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTEw_b7333fe5-ebb1-4092-94c3-1732fa3bf01c"><ix:nonFraction unitRef="usdPerShare" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTEw_c87da43c-0c21-481f-aa37-34fc4e5bab2c">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTI0_e162648c-5e3b-416c-982f-4a7289978736">400,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTM4_53157d89-23c4-4111-aa61-8e18478057d8">200,000,000</ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTUy_3b9be6e7-fe7a-486f-8e8e-db3038c67d8e"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTUy_5b7fec1c-08e6-44f5-8777-245e46e8b4fb">199,463,645</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTY2_6220807b-42e8-4ba2-b416-e8db52fdd5ea"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTY2_94a15690-7b20-40d7-9593-a3652f00f6c9">140,449,647</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMS0xLTEtMjc3NDM_8f1def5d-5d0e-4622-aeac-71e32d7e30aa">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMy0xLTEtMjc3NDM_1944510f-9c70-4093-b7a1-f0e3c019ccc3">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzEtMS0xLTEtMjc3NDM_dce7ddbd-ddba-430e-97df-4992a957f8b9">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzEtMy0xLTEtMjc3NDM_c8520221-5a8e-40e3-a0de-c062cc686a21">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMS0xLTEtMjc3NDM_4bad118f-4fde-4308-abf8-393008d50f1d">316,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMy0xLTEtMjc3NDM_e193fe34-734c-412d-9837-a2776339e3ad">315,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzMtMS0xLTEtMjc3NDM_0aebd621-5b03-483e-85d1-571240e4420c">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzMtMy0xLTEtMjc3NDM_cdebca43-7523-4204-aa7c-18c34d8db849">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzQtMS0xLTEtMjc3NDM_215ce228-ddec-4b04-86eb-13e10be191d1">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzQtMy0xLTEtMjc3NDM_8d46905d-802b-45d0-b9e7-1a77b7f59f0f">122,823</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c88f9a9af124db29eb627c2bb0fd0e3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy0xLTEtMS0yNzc0Mw_955fb855-c58e-4bfa-9ace-a99aa19e0bf2">26,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b5ef8f93c04e62a666090e00118055_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy0zLTEtMS0yNzc0Mw_16df42d7-7146-46e4-97ba-9a05a36458cd">11,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30a5968b1a146dbb7ffcec09da88262_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy01LTEtMS0yNzc0Mw_5002f366-8174-44ce-b294-71e4e562802f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS0xLTEtMS00OTU2Ng_23098667-9591-4937-83f1-dacafd809cbd">26,544</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS0zLTEtMS00OTU2Ng_6055c3ad-dfc3-46cb-a6c4-9e4acc90370f">11,236</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS01LTEtMS00OTU2Ng_4cb1108d-f125-4155-95f3-e2d304705bc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi0xLTEtMS0yNzc0Mw_42ce0de9-3533-4ea1-9139-6b74e6c1d8c3">25,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi0zLTEtMS0yNzc0Mw_7dc08a3f-7377-40d5-8a19-a05f120f9650">29,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi01LTEtMS0yNzc0Mw_963e0199-8cfc-495a-bf9e-ce6a187478b8">24,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0xLTEtMS0yNzc0Mw_51a694aa-6d20-4749-a926-f1e319b15cb9">29,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0zLTEtMS0yNzc0Mw_00cf2429-5bd3-4839-96cb-cd579a2ef70c">14,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy01LTEtMS0yNzc0Mw_7ff00aa0-16f6-4158-aed8-e035cc5152dc">12,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0xLTEtMS0yODc1NQ_2b61f082-346c-4222-8618-f70f5e35bf5b">5,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0zLTEtMS0yODc2NA_8b21c6cf-0a07-4a7c-ae38-b24204c51d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy01LTEtMS0yODc3NQ_6fa850d5-494f-4988-9660-730f38dc1ce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0xLTEtMS0yODc1NQ_32f72440-6dd6-409a-82ba-ac13c02fdaa8">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0zLTEtMS0yODc2NA_416cdf83-25f6-42c0-89c7-1557dc00280c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC01LTEtMS0yODc3NQ_02d2f742-73a5-41a6-b029-e1adcf936907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0xLTEtMS0yNzc0Mw_4d7b5ef8-8022-4e30-9680-ae521d60b66a">56,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0zLTEtMS0yNzc0Mw_6a424469-d5f6-418c-ad15-9ff42c6f356c">11,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC01LTEtMS0yNzc0Mw_1abdfbb5-4d5c-4c5c-b6d0-7b68769e255f">71,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS0xLTEtMS0yNzc0Mw_ee232fc0-ca17-43e6-bd27-214e3d65dcb4">35,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS0zLTEtMS0yNzc0Mw_a08fbb26-310d-4620-8aed-c3a9f300ea64">32,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS01LTEtMS0yNzc0Mw_e1a1a786-4bd4-4e36-bf82-caa16699eae5">108,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMS0xLTEtMjg4Mzg_2a57fedd-7b70-48d4-95c8-18156f874987">8,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMy0xLTEtMjg4Mzg_dc25e598-9f3c-4e37-965d-58d5080796fb">21,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItNS0xLTEtMjg4Mzg_62d0caf4-f1a6-443f-8b5f-e023e1102da2">108,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMS0xLTEtMjc3NDM_d5b0b77a-67d7-4795-a490-81757f154f4c">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMy0xLTEtMjc3NDM_5843c52a-969f-44df-b9a1-c3aa3bef953f">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItNS0xLTEtMjc3NDM_78d61d9e-3813-4f34-ad93-66e143c60428">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtMS0xLTEtMjc3NDM_317e8a05-f1db-409f-b803-08067796d34f">8,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtMy0xLTEtMjc3NDM_97bd15c2-b4d2-4803-bcd7-1459d5cd6d43">20,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtNS0xLTEtMjc3NDM_bd40abd1-a5a9-4f7c-83f9-2a0a1c5b4325">107,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtMS0xLTEtMjc3NDM_31d95823-0302-4b16-a6d6-6067ff7e0b42">8,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtMy0xLTEtMjc3NDM_0c026e21-1b23-40ef-bc8c-8c77f4b10966">1,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtNS0xLTEtMjc3NDM_ffb1cdd7-8f42-434e-9d29-f0c5673f8b07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMS0xLTEtMjc3NDM_2bccea8f-4ed7-49ee-8933-ecc3d24d2c4f"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMS0xLTEtMjc3NDM_56134193-a39d-41e8-8ff0-ae0549d50a63">336</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMy0xLTEtMjc3NDM_04753fc1-0ac6-42f6-92f5-fad075f64c9d"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMy0xLTEtMjc3NDM_8912388c-6614-49a0-b6dd-a1ca15a101b1">22,397</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtNS0xLTEtMjc3NDM_87ae26ff-1706-4b89-b019-5642bf12a078"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtNS0xLTEtMjc3NDM_deeb1d50-7a0b-4d9f-b50d-a61f59e0471f">107,500</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend on adjustment of exercise price of certain warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjkwMTY_e723fb68-6ad4-4f06-add1-7481211c3a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjkwMTY_41e471dd-fe89-401b-8aef-f8424acb3f1d">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjkwMTY_6a1d3f93-5f57-424a-9d07-72a84f7d6bb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjg5NTk_c31311e3-afb6-46ab-8f98-ff2e5f631ce3"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjg5NTk_d68d798a-ac66-41c1-b88c-01af6aa6e050">336</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjg5NTk_1273d8ad-2140-4818-9fc3-9d93b11e7538"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjg5NTk_1f1094e7-68f8-4613-829d-201f8de3ba76">22,544</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjg5NTk_2b71b8f9-23f3-40c5-b330-bd8d69923958"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjg5NTk_ff4267d8-8cda-4854-b2b6-ab069eab48c7">107,500</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMS0xLTEtNDU5MzI_3dcf45b4-e36a-449a-932f-9b63593d2eca"><ix:nonFraction unitRef="usdPerShare" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMS0xLTEtNDU5MzI_53ac7a66-f9e5-4afb-9bf1-38ccab2df4ab">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMy0xLTEtNDU5MzI_3c4f7391-f1d5-4da7-b520-56ef98bef3a4"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMy0xLTEtNDU5MzI_d983829a-90ea-4972-944c-431a1a41098e">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtNS0xLTEtNDU5MzI_658eef7f-2a55-44a0-97a0-09863d992453"><ix:nonFraction unitRef="usdPerShare" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtNS0xLTEtNDU5MzI_f1f23e88-9297-4dc3-bd9b-6ae0912d5102">1.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMS0xLTEtMjc3NDM_00f6e191-d783-4e19-a795-d0600cac7ce6"><ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMS0xLTEtMjc3NDM_e23418f5-5b57-418a-ace3-372e3dcf1383">182,323</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMy0xLTEtMjc3NDM_407116ad-e5f4-447d-b5e1-be5a416f8acc"><ix:nonFraction unitRef="shares" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMy0xLTEtMjc3NDM_980ba4b3-48c5-45e5-b7f4-89b8496cd6f9">118,221</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtNS0xLTEtMjc3NDM_0d5ab724-813f-4c2f-a2b4-b7bf4a214c01"><ix:nonFraction unitRef="shares" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtNS0xLTEtMjc3NDM_e59ad112-ea24-4477-a261-d79c6a223c2c">90,929</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:26.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.962%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf44be67ed84033b15e86e3de2e9088_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi0xLTEtMS0yNzc0Mw_d8de166f-d74f-40d7-beaa-231d93ce2dfd">77,456,180</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf44be67ed84033b15e86e3de2e9088_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi0zLTEtMS0yNzc0Mw_d6df409d-5a6a-4920-b7f6-69374d78c30d">77</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1773348a6144f8927754151f83c6b2_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi01LTEtMS0yNzc0Mw_ce36fcae-ec5c-4a27-aac1-f7bf3478a8ca">230,154</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic78f2f0a6b1d4a20ad7e12e40d1cacd4_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi03LTEtMS0yNzc0Mw_bf9a07ab-5f3f-4a38-8bb6-1bf5e8cc92ac">186,024</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi05LTEtMS0yNzc0Mw_72b5258f-8f1b-4293-937c-3a492010c054">44,207</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d87267df014bc9b3e806eba7f1b0f5_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMy03LTEtMS0yNzc0Mw_1f9ed555-7dd4-4e70-ab39-7c68abb6fe62">107,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMy05LTEtMS0yNzc0Mw_a603efe2-732f-4aad-bea5-f8087731ffd3">107,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNC01LTEtMS0yNzc0Mw_12660377-b858-4bd2-be4e-bd92916fd95e">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNC05LTEtMS0yNzc0Mw_1eb2604e-106e-4043-84e3-59de920ae204">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options and vesting of RSAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS0xLTEtMS0yNzc0Mw_1a93878f-a49b-4015-8fde-b9e66f953768">89,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS01LTEtMS0yNzc0Mw_1c894e25-0507-4318-82d6-c588aeea5774">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS05LTEtMS0yNzc0Mw_427ec341-3f9f-49d6-b111-5a0429b86e46">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi0xLTEtMS0yNzc0Mw_90564f58-e4b2-483f-aff9-1c6f44a97385">10,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi01LTEtMS0yNzc0Mw_369444d3-db77-4313-8f21-3cf80028417f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi05LTEtMS0yNzc0Mw_b17e1780-368b-4447-96f8-6d6907ef24be">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0wLTEtMS0yNzc0My90ZXh0cmVnaW9uOjk3MjRkYTM0MWE2NzQ3ZjU4ZmE2ZmEzMTI3ZWIyZDRlXzU0OTc1NTgxMzg5Nzc_bca1c4c5-3009-4445-a3ba-cdb96b0e4b6f">2.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0xLTEtMS0yNzc0Mw_ba4eb62f-c69f-40d9-a98a-a0e3856629dd">20,410,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0zLTEtMS0yNzc0Mw_17b2ac41-f411-49c1-ad97-68938a4ae7f8">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy01LTEtMS0yNzc0Mw_be098684-13ae-416e-8ade-7e8e116107e8">27,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy05LTEtMS0yNzc0Mw_52773094-3822-469b-a122-e95ebca7d79c">27,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC0xLTEtMS0yOTA5MQ_a7843989-92a6-4ffe-b266-8b4535e5e841">6,772,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC0zLTEtMS0yOTA5MQ_253644d0-9e5a-4bee-b711-54bf4e431c72">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC01LTEtMS0yOTA5MQ_d622f749-1bf2-4ee9-be5c-c43acd825d37">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC05LTEtMS00NjI5Ng_0460dbf6-f1d7-4a3f-9299-b82c37e0b3c4">5,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0wLTEtMS00MDA5MC90ZXh0cmVnaW9uOjE3NzdjOWZiZTc4ZDRiNWY5YTkzYzdiNWRiOTBlMjZkXzU0OTc1NTgxMzg5NzA_f4ccd4c5-09a3-4375-b3d6-850eed18226c">0.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0xLTEtMS00MDEwMw_cd42b65f-9887-4fcc-9158-f209317d54f8">2,062,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0zLTEtMS00MDEwMw_eed521c3-1624-4950-853e-0dafd4c016ba">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3412d8401e304f0aae1eecacbcdbab85_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS01LTEtMS00MDEwMw_7aecef4a-82b7-4a13-b6b6-69b5afc951d8">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS05LTEtMS00MDEwMw_a4f9db66-3149-4558-af30-4e602c28a880">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0xLTEtMS0yNzc0Mw_f66eb284-a3c0-49e8-8a1c-17097970459d">106,801,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0zLTEtMS0yNzc0Mw_1d029cd5-6867-4940-b6cc-b2683b6a94bb">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8c7f863b2f43bb922132621a9e5cda_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS01LTEtMS0yNzc0Mw_9f6a90f8-6d08-4bd5-a267-bdc7a2cd4606">266,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc289b8985ac49eb80e78ca2748e4a96_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS03LTEtMS0yNzc0Mw_7e791209-b185-411d-aa27-f422a4a4d640">293,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS05LTEtMS0yNzc0Mw_51ea597f-6777-4161-a3f8-1fcdea91a821">26,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06678b0cf6c04477b759eb44801366df_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTAtNy0xLTEtMjc3NDM_9be35b65-90dc-4ab6-8b27-24f5d4c3031a">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTAtOS0xLTEtMjc3NDM_9b936e69-5c10-416d-aa8a-8a0c1fa3655c">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTEtNS0xLTEtMjc3NDM_f54e199f-81f4-476b-97a9-adf5523061c0">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTEtOS0xLTEtMjc3NDM_e4394c68-598b-4aa8-a2b9-628040a7433a">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItMS0xLTEtMjc3NDM_8316c5ad-c741-4ac4-b579-a2c193aa60c4">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItNS0xLTEtMjc3NDM_8d4022d9-2425-45d5-a0f9-704643f9e8c6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItOS0xLTEtMjc3NDM_71a89f3d-8225-4bf7-8eee-928483c99d56">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtMS0xLTEtMjc3NDM_a2dc0553-3da5-471b-8094-60ad8c892ea5">28,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtNS0xLTEtMjc3NDM_0f49d931-1667-4f3c-a423-d7510c4e690d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtOS0xLTEtMjc3NDM_472263cf-8a80-46ee-b6d3-df70c6ce5294">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtMS0xLTEtMjc3NDM_c7c23d14-0649-4b66-a65a-e69ae40d100c">238,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtNS0xLTEtMjc3NDM_982d13f9-c08b-42d3-9cfe-18a6ff18aa34">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtOS0xLTEtMjc3NDM_58497511-c2d4-4a37-af8e-7b449681343a">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjo5MGI5OTljN2E5YmI0MGFkYmJmNDE0OWQxM2FiZTg3N181NDk3NTU4MTM4OTcw_2fe6374a-3877-44fe-8e57-b85b10de254b">1.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMS0xLTEtMjc3NDM_3053161d-fcce-47c7-a668-fe03c3bd7c88">33,369,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMy0xLTEtMjc3NDM_a34928b1-b773-4ca5-aab0-b527b7ee4357">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id593ab74c6634403b9f73b261b779b5a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtNS0xLTEtMjc3NDM_e9adfaaf-5135-4176-a5d9-7fe9c5200622">37,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1cd661b638041f898d4ddc61a940fa7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtOS0xLTEtMjc3NDM_a692a336-248b-4794-bf07-58bfcdd16666">37,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iededb75b8b3d41909c578b96949d296b_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctMS0xLTEtMjc3NDM_e61031a6-0c23-464b-98a7-c3d680d4f222">140,449,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iededb75b8b3d41909c578b96949d296b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctMy0xLTEtMjc3NDM_416b73ae-2865-472e-9c0c-1b066ce07d4f">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b663c4ccd24528baa91746670f2709_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctNS0xLTEtMjc3NDM_7246dd05-ac7a-4709-8ef4-5baf31e6d2af">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92612297cd0642f585229a45cac68bd8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctNy0xLTEtMjc3NDM_8cd11026-c01d-42d7-9d7c-982bf3c328c5">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctOS0xLTEtMjc3NDM_e32d68c3-9324-4966-a8fd-08ae0d465efc">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i548b9f86fcd54ebe9243040061933762_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTgtNy0xLTEtMjc3NDM_413445d8-ae7c-4195-8ee3-fdbc722d2979">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTgtOS0xLTEtMjc3NDM_9e48b881-7af3-4170-94a7-80d91309bbd5">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTktNS0xLTEtMjc3NDM_5f3e7a6f-9101-4b75-9cf6-92895e40db8e">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTktOS0xLTEtMjc3NDM_67d1491e-1f16-4b31-8592-30bf402af3d6">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtMS0xLTEtMjc3NDM_30e7adb0-5730-443e-a3fb-107974f6713a">33,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtNS0xLTEtMjc3NDM_5760d775-5236-4dc5-94ee-ff5284307bb9">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtOS0xLTEtMjc3NDM_978870f2-0b0e-4c6a-b9c7-74a30271ec30">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItMS0xLTEtMjc3NDM_70634e9b-dc1a-4252-8c46-09104de4b620">2,048,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItMy0xLTEtMjc3NDM_6eb55470-c445-46bc-b0c6-e7e7ba3831fd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItNS0xLTEtMjc3NDM_821c27fe-e77b-4b57-b61d-ab4758801d0c">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItOS0xLTEtMjc3NDM_98bdaf4c-8725-471f-82c0-e298da2a55ac">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjpmOGE0ODQyNGRlMTc0OWRhYTRjZmQ0ZTlmMzI0MmRiYl81NDk3NTU4MTM4OTcw_0f8c243f-4365-409b-9730-4495e08a44a9">5.4</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMS0xLTEtMjc3NDM_2bfa1b11-a74a-4a37-9f8a-8235625ba313">56,932,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMy0xLTEtMjc3NDM_56f1d63b-26fe-4e42-87cd-d91a2a35c81b">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449b028e12ab447dbe3d1ff217dca3f7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtNS0xLTEtMjc3NDM_248893e3-3ac4-417c-a76e-dbcc2b9e7cf7">174,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cc5cde3c2444458bf73121a4a8d8f5_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtOS0xLTEtMjc3NDM_3ca3ae41-9308-4d3e-b627-d28a001e83da">174,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c9ad583a050492ebb28f616a7b10aaf_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtMS0xLTEtMjc3NDM_3f2cc55c-f99b-47a8-b60f-55e6f92e1a1e">199,463,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9ad583a050492ebb28f616a7b10aaf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtMy0xLTEtMjc3NDM_9e743bab-60bd-4b9e-9097-d67fafda6000">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdadfe711654c368dce057e84bccbf9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtNS0xLTEtMjc3NDM_1a2bb20f-a76e-4e4d-a414-cf0247dd97e3">487,768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d93ef4c012e45c7b10ee227a4cdf96d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtNy0xLTEtMjc3NDM_8c4c463c-3ac7-4e13-8b03-ad8290be25c4">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtOS0xLTEtMjc3NDM_e53fad47-f051-4162-8219-cc92542fc001">171,710</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:65.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy0xLTEtMS0yNzc0Mw_f2026e3a-01f0-4c12-8d50-6b5d724f02f8">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy0zLTEtMS0yNzc0Mw_b1a1b020-a960-42c8-9466-fe83d0f3c939">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy01LTEtMS0yNzc0Mw_3a75e822-882d-43c1-9954-cf92a0f73969">107,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS0xLTEtMS0yNzc0Mw_12a2d367-6a47-435b-9453-8f32fc679950">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS0zLTEtMS0yNzc0Mw_1c60d6fa-02ed-493c-bbe6-67e51acbe170">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS01LTEtMS0yNzc0Mw_5c3b0749-d686-4766-a077-5b167faead5b">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi0xLTEtMS0yNzc0Mw_5860771b-d0f6-47b3-b3cf-0aa68cd86686">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi0zLTEtMS0yNzc0Mw_426d5422-5114-4ff7-876c-051d288731cb">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi01LTEtMS0yNzc0Mw_dffced38-f9ca-4e4f-9683-864022efa08e">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy0xLTEtMS0yNzc0Mw_4d7b5ef8-8022-4e30-9680-ae521d60b66a">56,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy0zLTEtMS0yNzc0Mw_6a424469-d5f6-418c-ad15-9ff42c6f356c">11,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy01LTEtMS0yNzc0Mw_1abdfbb5-4d5c-4c5c-b6d0-7b68769e255f">71,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS0xLTEtMS0yOTUyMg_b29b8dd9-602b-4add-907a-c4d61f9bb04f">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS0zLTEtMS0yOTUyMg_1e993444-5cd6-4412-95ad-db2a346ef5c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS01LTEtMS0yOTUyMg_bb57271f-fa75-413b-a99c-06f2cba56eeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMS0xLTEtMjk1NDY_e1e4b669-0055-4b1d-9530-644253d17ea2">24,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMy0xLTEtMjk1NDY_0ed09fc7-a32d-4d19-815c-d1a80e6a1dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtNS0xLTEtMjk1NDY_a5f849b5-5e1f-4aeb-87f2-0428320a4920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtMS0xLTEtMjc3NDM_e02ebc7a-4030-4011-93ef-b6e68a960c95">17,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtMy0xLTEtMjc3NDM_dba15542-e519-4f19-be1a-48ce4bc867da">1,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtNS0xLTEtMjc3NDM_b1a6ecc7-78b5-4455-b406-1c00f301116a">5,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMS0xLTEtMjc3NDM_d61428c7-520f-49f2-a3d4-565e37959c0f">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMy0xLTEtMjc3NDM_7fda028b-4e8f-4ebf-9777-ba02918f59a8">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtNS0xLTEtMjc3NDM_997c8d4c-746a-4520-b946-3b99346ef320">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItMS0xLTEtMjc3NDM_eb281b58-4173-4f3e-9dfe-691580192494">4,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItMy0xLTEtMjc3NDM_4d42d619-addb-4549-93e5-d67ce3d8ba1b">2,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItNS0xLTEtMjc3NDM_e97ce54e-6a23-4e82-a0d9-2fcee3b7a2a8">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtMS0xLTEtMjc3NDM_52d8c648-ddf2-45d1-94d2-720da1dc4633">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtMy0xLTEtMjc3NDM_c5c1f332-826c-44f8-a8f8-c53924e462a1">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtNS0xLTEtMjc3NDM_adef1942-0119-4afd-9896-0a3a9ebe1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtMS0xLTEtMjc3NDM_9e265158-dfb7-4222-8f5d-ed02dd0f4921">68,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtMy0xLTEtMjc3NDM_dcb6b7f9-9e39-4c88-8d31-0474cfb52b22">30,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtNS0xLTEtMjc3NDM_e9c7f656-1770-4b2b-b02d-a019e1a6c5be">37,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtMS0xLTEtMjc3NDM_7e8e3e06-e091-4b4b-8001-11dee1416ec4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtMy0xLTEtMjc3NDM_d09a2056-67f0-4a5a-96cb-49bac7d0d4b2">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtNS0xLTEtMjc3NDM_af112bb2-6b7d-4e73-a2da-becdd511e586">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctMS0xLTEtMjc3NDM_c2706baf-26dd-43b1-b3f0-0dc4cdbb6eae">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctMy0xLTEtMjc3NDM_76ddfa3c-c1e4-47ea-bb4f-60b0056d9c46">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctNS0xLTEtMjc3NDM_79155849-bbc7-43f8-9169-dd633e1643ad">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:ProceedsFromIssuanceofCommonStockandWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktMS0xLTEtMjc3NDM_d246a34c-da2b-4cfc-90cb-96a25189f8fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:ProceedsFromIssuanceofCommonStockandWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktMy0xLTEtMjc3NDM_12b15fbb-54ea-40b1-8b31-4fa603bde56e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:ProceedsFromIssuanceofCommonStockandWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktNS0xLTEtMjc3NDM_0ddc56c4-cdd0-4415-bd85-0c6642ce863b">27,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtMS0xLTEtMjc3NDM_825e08f4-3cdd-46e8-bd79-c9afc20b9fe9">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtMy0xLTEtMjc3NDM_3c6bfcc1-b971-43ca-998d-fc1fcd7a3f4d">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtNS0xLTEtMjc3NDM_bfcdb125-d590-46c4-b066-cf3b5aaddabc">5,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br/>issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtMS0xLTEtMjc3NDM_e840e667-6ac3-42ce-bc58-c0df9061495a">174,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtMy0xLTEtMjc3NDM_91f0b7ac-d1c7-4842-bdea-5bd0cf47a69f">37,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtNS0xLTEtMjc3NDM_d97f695a-806e-48c1-bbef-5fd1d8371437">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItMS0xLTEtMjc3NDM_44e32ed6-d257-404f-bab1-f238fe09987b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItMy0xLTEtMjc3NDM_0b13d8c9-7dd5-4539-99e8-aeaa918cf89b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItNS0xLTEtMjc3NDM_2f7e9b1a-854d-4dab-99f0-001f7c4eb6cc">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock pursuant to ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtMS0xLTEtMjc3NDM_8b61d594-028a-4b7a-bcf2-c5cf1e30e692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtMy0xLTEtMjc3NDM_936e34bc-ef1f-469c-af68-e70012322998">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtNS0xLTEtMjc3NDM_f9a2f7e7-ca66-45e7-93fe-c41845925f5b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtMS0xLTEtMjc3NDM_48a70d8e-fa59-4862-8f3b-8cb8b3f154a8">176,129</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtMy0xLTEtMjc3NDM_b1a06b34-fb74-4ed4-abd3-73834ae98c94">38,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtNS0xLTEtMjc3NDM_dc746aa0-987f-46c3-af18-9328ea38cf5e">35,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtMS0xLTEtMjc3NDM_2f74ba01-d8b0-4a13-8a33-19880ed971c0">107,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtMy0xLTEtMjc3NDM_fd3f894e-5e61-4288-973a-b45746dafe34">7,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtNS0xLTEtMjc3NDM_8178d96c-c622-44f2-a2e2-0b2348d83cb5">2,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtMS0xLTEtMjc3NDM_930b9a7b-f53d-44cc-a095-595eb9adc2d6">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtMy0xLTEtMjc3NDM_28208a53-9917-4f6f-9b0a-9e1e4dca619b">48,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtNS0xLTEtMjc3NDM_6f33d0cf-a984-468e-93ea-ce1f618acbb1">50,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctMS0xLTEtMjc3NDM_dce16000-a845-4b75-8f84-65f81e9db6c0">162,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctMy0xLTEtMjc3NDM_1a05970e-c902-4ad3-899d-758b4937df3b">55,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctNS0xLTEtMjc3NDM_1b67f8d3-c9c3-40e3-94d5-0a0336f2f362">48,141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtMS0xLTEtNDgyNTU_05994ce0-d047-48cf-b74e-f500e49c6b0b">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtMy0xLTEtNDgyNTU_60ecc157-9105-4809-9734-6751d9425a04">52,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtNS0xLTEtNDgyNTU_09739e2d-5e6d-439c-bffc-1ede682db75d">48,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMS0xLTEtNDk1NzU_2bcc88b4-aeb4-4d1e-8c4e-29ed567422c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMy0xLTEtNDgyNTU_fd716fb0-dd6f-458f-af0f-9c4c00d9e17a">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtNS0xLTEtNDgyNTU_88b7a9b2-0b46-4482-9119-66c5f90cc940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term restricted cash </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtMS0xLTEtNDgyNTU_8fd097ca-f9ee-4d29-a600-04aaaf53333d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtMy0xLTEtNDgyNTU_ad304fb8-34a7-4edd-b0a9-3ab9c4597d2d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtNS0xLTEtNDgyNTU_28b55b85-e0f1-4a55-bfbb-9ec87d7ed5b8">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMS0xLTEtNDgyNTU_7f55a34b-6574-49a1-86f8-922d9951743a">162,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMy0xLTEtNDgyNTU_192bdcee-e361-4d64-9370-a13563759cdf">55,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtNS0xLTEtNDgyNTU_e96756bc-71ec-4fc3-aca8-7888bb62ebfa">48,141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktMS0xLTEtNDgzNDQ_626ee158-ddde-432d-8c7e-e7af4691280a">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktMy0xLTEtNDgzNDQ_7acd5551-a350-4013-84f1-53e374cfef93">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktNS0xLTEtNDgzNDQ_04298934-8aaf-4790-b9bb-619a6b950741">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets related to the adoption of ASC 842</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMS0xLTEtMjc3NDM_e66c45fc-ae85-4ccb-9265-2626bb962469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMy0xLTEtMjc3NDM_f19fb015-ec24-4185-8802-c9451009a82f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtNS0xLTEtMjc3NDM_46aecb11-5c2d-41a1-8580-da834233ff74">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMS0xLTEtMjk2NDA_c70d1f4c-f018-4509-b8af-ec8bad994859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMy0xLTEtMjk2NDA_931706f8-7230-4e9a-8040-020a07b4944b">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtNS0xLTEtMjk2NDA_1341fa1b-0dd4-4cab-9898-006b8b6d6157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deemed Dividend on adjustment of exercise price on certain warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtMS0xLTEtMjc3NDM_05e13490-8ff4-4d1e-878d-7a89bfdcc203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtMy0xLTEtMjc3NDM_064b3121-9836-44ff-97b9-21f5cd82cb7b">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtNS0xLTEtMjc3NDM_86d431f4-3a2b-4a71-a5be-99635c6134f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_82"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMTA5MzY_e6604ff1-8ac8-46a5-9392-f4bb6974e690" continuedAt="ibba5d0f8a1fe4a39813a038a48f32801" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="ibba5d0f8a1fe4a39813a038a48f32801"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with bacillus Calmette-Gu&#233;rin ("BCG"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 VISTA clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of <ix:nonFraction unitRef="patient" contextRef="idbcc2cd80c644c9bba710067ba49b410_I20180430" decimals="INF" name="sesn:NumberOfPatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNTQ5NzU1ODI4NzQ5NA_af879fd8-4d8c-4a2e-95ec-e27c4132c9c6">133</ix:nonFraction> patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#8220;CMC&#8221;), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued <ix:nonFraction unitRef="shares" contextRef="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930" decimals="-5" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjMxNA_6894dc74-7007-42f6-83bd-6e438155e9d7">4.0</ix:nonFraction> million shares of its common stock to the Selling Shareholders, which at that time represented approximately <ix:nonFraction unitRef="number" contextRef="i5fb4126fec9d47d299096c36c0f06713_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjQxOA_b0dca6c2-67a1-454c-bf36-889061f744c5">19.9</ix:nonFraction>% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i36e9d8387a934ec497a4731a279af3dc_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjk4Mg_42ee455f-d2d9-4a6d-b363-7d7ec4dd630e">12.5</ix:nonFraction> million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i533b84da1d2441468aadec080d52600b_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzExMQ_0a033b47-8eb2-454b-a808-f2e08e564190">7.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="if2334efa0613474c99d0b53f5f47619c_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzI1Nw_9fa571a7-9e60-4f13-9395-711d69599fc1">3.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <ix:nonFraction unitRef="number" contextRef="i7059bd4c3d114e288eb8029d693c5dd6_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzM2OQ_e086b366-a2ca-4482-8cc3-9230d5c29547">2</ix:nonFraction>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) <ix:nonNumeric contextRef="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzYzNQ_d995a7c1-c9e4-4c5a-a4e9-b1d581f65f19">fifteen years</ix:nonNumeric> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first <ix:nonNumeric contextRef="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzk5Nw_132de40a-e094-45d2-be74-1b7a7eb1b546" continuedAt="iff44311d7016422b8d292d6e3cf83d1e">seven </ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff44311d7016422b8d292d6e3cf83d1e">years</ix:continuation> following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&#160;31, 2021, none of these individuals are active employees or members of the Company's board of directors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDY0OQ_8d120f8d-ae45-4efb-981b-2dc23b20b96a">162.6</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDY4Mg_eff316ed-7c10-4609-9cee-3918a34125e3">316.3</ix:nonFraction> million. The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred negative cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities of $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc1Ng_a2784e9e-5c4f-49a5-8807-efd244278c91">68.9</ix:nonFraction> million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc2MA_7d6e60cf-d629-44dc-b9d7-563ce0cc5f1e">30.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc2Nw_2531fa83-d891-46fa-957d-4383eba0f5b7">37.5</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Since the Company&#8217;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to address the issues raised in the CRL it received for a BLA for Vicineum for the treatment of BCG unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete the follow-up stage of the ongoing Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, complete any additional clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">out-license agreements. See &#8220;Note 12. Stockholders&#8217; Equity&#8221; below for information regarding the Company&#8217;s recently completed equity financings. Management believes that the Company&#8217;s cash and cash equivalents as of December&#160;31, 2021 will be sufficient to fund the Company's current operating plan for at least the next twelve months from the date these consolidated financial statements were issued.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future success is dependent on its ability to develop, and if approved, commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon its ability to attain profitable operations. In order to commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company needs to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of its product candidates, raising additional capital, development and commercialization by its competitors of new technological innovations, protection of proprietary technology and market acceptance of its products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and the Company expects to seek additional funds through equity or debt financings or through additional outside of United States (&#8220;OUS&#8221;) business development partnerships, collaborations, licensing transactions or other sources. The Company may be unable to obtain equity or debt financings or enter into additional OUS business development partnerships, collaborations or licensing transactions at favorable terms, or at all, and, if necessary, may be required to implement cost reduction strategies. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will incur substantial expenses if and as it:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addresses the issues identified in the CRL it received from the FDA for its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Withdrawal Assessment Report, which the Company expects will include the completion of an additional Phase 3 clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeks marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintains, expands and protects its intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hires additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expands its operational, financial and management systems and personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducts research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and its other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeks to discover and develop additional product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-licenses or acquires the rights to other products, product candidates or technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, initiation, progress, timing, costs and results of laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and its other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on the Company&#8217;s business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s ability to establish additional OUS business development partnerships, collaborations or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for its product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities, including those associated with the manufacturing process and technology transfer to third-party manufacturers to facilitate such commercial-scale manufacturing of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the Company in-licenses or acquires rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA, EMA or comparable non-US regulatory authorities to require that the Company perform more studies or clinical trials than those that it currently expects to perform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s ability to achieve certain future regulatory, development and commercialization milestones under its out-license and OUS business development partnership agreements </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as the Company can generate substantial product revenues from commercial sales, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic collaborations, OUS business development partnership agreements, partnerships, alliances, and licensing arrangements. The Company does not have any committed external source of funds other than the amounts payable under the license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and the license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;). To the extent the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, strategic OUS business development partnerships, collaborations, alliances or licensing arrangements, the Company may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on the Company&#8217;s operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect the Company&#8217;s ability to raise additional capital in the future.</span></div></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_85"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxOQ_685e53f4-d18b-481d-9bc3-5d10787d13e6" continuedAt="ia4999b482cec4d51af7fb31604f9e2e5" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4999b482cec4d51af7fb31604f9e2e5" continuedAt="i195efad864d9459e927233899a3c2691">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i195efad864d9459e927233899a3c2691"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxNg_4e5588d3-cc94-4113-80d6-746889d436ca" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxNw_cfe9bd45-c01d-4370-a0fc-ab6139497ab3" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxOA_8aa20fb3-ce39-4b28-92e7-5ee07f6c6ff0" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div></ix:nonNumeric></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4Mzk_5d14b5b9-c387-485d-8ee0-2402c0b10a3a" continuedAt="ifbe4e2477f79461ebf644aeaf4a3caab" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ifbe4e2477f79461ebf644aeaf4a3caab" continuedAt="i0d13368947874d10b490a65b30d41614"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjI_6773808a-55e5-48d2-a0d9-88e693199802" continuedAt="i287f28ff538c4909a35720a57daf3d15" escape="true">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i287f28ff538c4909a35720a57daf3d15">The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzE3_7a6c87fe-383d-4fd6-88c0-40cb19c78f58">250,000</ix:nonFraction> per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&#160;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds.</ix:continuation> </span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDk_ea794164-6971-43cf-8f3e-4875b9f309ec" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of <ix:nonNumeric contextRef="id0d7d3d671d44f1fb8dc94865706738c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTM4OA_305cde46-1b1b-4f36-b4ee-e1cf56460954">five years</ix:nonNumeric> for lab equipment, <ix:nonNumeric contextRef="i0f42726b9d2d45519a3279adbdeaf414_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQxMA_c4c2f676-74a3-44b5-9426-7fa9046f0efc">four years</ix:nonNumeric> for furniture and fixtures, <ix:nonNumeric contextRef="ib16d8fcfc6064d57a72284ee2689a0c5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ0MQ_cee98dac-07d2-4338-9ae7-0db94adcf06d">three years</ix:nonNumeric> for computer equipment and software and the lesser of <ix:nonNumeric contextRef="i649bc58c14754d8497732ebb7fb60f40_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ5OA_4ddf5223-522c-4ba6-a21c-01a87c3ea95a">five years</ix:nonNumeric> or the remaining lease term for leasehold improvements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzU_7443fc48-60af-4f5f-bbac-8c2d65d18806" continuedAt="i0b429936ae5d4b8aa8e6b4daf01020ac" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i0d13368947874d10b490a65b30d41614" continuedAt="i03d93ed113ea48d2a857778460b73815"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b429936ae5d4b8aa8e6b4daf01020ac">In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application (&#8220;MAA&#8221;), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i5a2a6758069a4a888d0e5d69c12d58ab_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNDM5ODA0NjUzOTM3NA_c02efd29-01bb-4ba2-b5db-6bc5e7f85ba3">31.7</ix:nonFraction> million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company's intangible asset of Vicineum EU rights, this asset was not impaired as of September 30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (&#8220;POS&#8221;) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase 3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTcwNDI0MzAzMzYwNzE_4c16c954-3f23-4f74-9d3c-67ca22e61849">no</ix:nonFraction>t recognize any impairment charges during the year ended December&#160;31, 2020. </span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzE_a5c6aab4-51b2-4d7c-8a9f-15ccc078a7a8" continuedAt="ie778b4f275ab42d788125de08eff5351" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only <ix:nonFraction unitRef="unit" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5NjI_85cd7542-13ad-4d77-a33d-3cc6ea654fb9">one</ix:nonFraction> reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company&#8217;s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5NDg_2c08ed4f-7114-4293-bc18-3431a4d4af0c">13.1</ix:nonFraction>&#160;million was not impaired as of September 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was <ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NTM_0fbd0bee-2456-4a4c-9790-af997d841998">no</ix:nonFraction> goodwill impairment as of December&#160;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i03d93ed113ea48d2a857778460b73815" continuedAt="ic57c448309894de6b6a320984b9a8a1c"><ix:continuation id="ie778b4f275ab42d788125de08eff5351"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was <ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTc1Mg_1fa5dabd-517d-40c7-bd11-b8c8aa25b0af">no</ix:nonFraction> goodwill impairment during the year ended December&#160;31, 2020.</span></div></ix:continuation><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="sesn:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjU_c404c114-e2c1-4455-85e0-79bfdad93375" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company's revenue projection models are timing of product launch and probabilities of clinical and regulatory success ("POS"); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately <ix:nonFraction unitRef="number" contextRef="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NjM_28dc195a-1041-4f72-be4e-d4696f71814c">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibecee94376694fc393e30898f2ff86a2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1Njg_aac8409a-90e6-4f12-b167-bb277fd7512e">55</ix:nonFraction>% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NzM_6980510a-676e-4371-8807-38aaac3ceb96">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1Nzc_5e96845d-0dad-48e5-9066-28aa466f0dc6">2</ix:nonFraction>% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from <ix:nonFraction unitRef="number" contextRef="i028ccf70c10c4129a5d10bd536d297b3_I20201231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1ODE_1ba7af8a-e782-4c0b-a7ae-d59bb4a47392">8.8</ix:nonFraction>% as of December&#160;31, 2020, to <ix:nonFraction unitRef="number" contextRef="i2de469ec0aa540adac05ef95232f5a15_I20210331" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1ODc_034f23e7-f618-45b4-8323-03d6d708360e">7.8</ix:nonFraction>% as of March 31, 2021, <ix:nonFraction unitRef="number" contextRef="ib6a34442b9744cb6ae08c574b84b89b9_I20210630" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MzU_e78facfe-2a39-439b-85d2-5ee6ad94eee9">6.8</ix:nonFraction>% as of June 30, 2021, <ix:nonFraction unitRef="number" contextRef="i4609a0afbc594078808154f146946ab1_I20210930" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1OTk_ceb76db2-7c90-46e7-be7f-f88ed773c9bd">8.6</ix:nonFraction>% as of September 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1OTM_eef6d3c8-4728-4515-910b-0e17462e8300">9.3</ix:nonFraction>% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from <ix:nonFraction unitRef="number" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MDU_7ab5424e-5f5b-4f82-aecc-0a467a98cc19">8.4</ix:nonFraction>% as of December&#160;31, 2020, to <ix:nonFraction unitRef="number" contextRef="ia2453680b1ee48d49d18b917c46773a0_I20210331" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MTE_8c5487ad-b537-47a0-bfde-12dbb6625b3d">7.4</ix:nonFraction>% as of March 31, 2021, <ix:nonFraction unitRef="number" contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MTc_ff2b4afe-2186-4d11-a46f-12a9ce58fd8f">6.6</ix:nonFraction>% as of June 30, 2021, <ix:nonFraction unitRef="number" contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MjM_d95d7b5e-e1f5-4f32-aaf9-92becf224eeb">7.5</ix:nonFraction>% as of September 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2Mjk_16b69e59-ed1a-4544-ba11-cc8d13dedb6e">8.0</ix:nonFraction>% as of December&#160;31, 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDU_da5565b4-e26b-4d69-a4a4-1cecb027fc07" continuedAt="i5f96ae4ec1e34f768f7cb267b50aead0" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the optional transition method outlined in ASU No. 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842), Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&#160;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 840") guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i4b6d609604934e33aa33ca5fc59ce894_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfODQ3MA_08682c8c-532a-4ff3-abb1-fa2bbebf917c"><ix:nonFraction unitRef="usd" contextRef="i4b6d609604934e33aa33ca5fc59ce894_I20190101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfODQ3MA_b44d4d02-80fd-40f3-8916-eef1ca4c1b06">0.2</ix:nonFraction></ix:nonFraction> million on the Company&#8217;s consolidated balance sheet as of January 1, 2019. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ic57c448309894de6b6a320984b9a8a1c" continuedAt="i69578fc097d34816a88c634f445c6a2c"><ix:continuation id="i5f96ae4ec1e34f768f7cb267b50aead0"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on the Company&#8217;s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company&#8217;s financial statement disclosures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accounting policy election to use the short-term lease exception by asset class;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Election of the practical expedient package during transition, which includes:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess whether any expired or existing contracts are or contain leases;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess initial direct costs for any existing leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio as of the adoption date and as of December 31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2021, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company&#8217;s lease portfolio as of the adoption date were valued as of January 1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div></ix:continuation><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4Mzg_68c1d800-fb03-4527-9adf-c961e3aa90cc" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjM_1ef8bcfb-73b7-43fd-b7dc-a644b9fb0322" continuedAt="if30ae5a8df09419d97cea21db765793d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&#160;31, 2021, 2020 and 2019 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the &#8220;simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i69578fc097d34816a88c634f445c6a2c" continuedAt="ie4191a8e53c243bb9d2f3ebdc64c8931"><ix:continuation id="if30ae5a8df09419d97cea21db765793d"><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(generally <ix:nonNumeric contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQwODc_92084f93-1651-4897-8f2d-0144000000bf">four years</ix:nonNumeric>) and the original contractual term (<ix:nonNumeric contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQxMjY_c90bb293-9d9e-425a-bf8b-5b98fbc57fec">ten years</ix:nonNumeric>) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is <ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ3MzA_65ed8b91-5813-4420-a1b9-c43d0574ccd8">0</ix:nonFraction>% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div></ix:continuation><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzY_125fe576-e0c1-4395-a24a-4e3211d5f18b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2021 and 2020, the Company did not have any uncertain tax positions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDE_c4e97964-d7d3-4411-b6f6-6b8c1d933140" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                          distinct in the context of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4191a8e53c243bb9d2f3ebdc64c8931" continuedAt="i01fbe849109a4f97906fb5e357fe6a07">In December 2021, a $<ix:nonFraction unitRef="usd" contextRef="i537b107b17f34737a20ec184a594ae82_D20211201-20211231" decimals="-6" name="sesn:LicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5OTk_a5b21596-6c35-4076-981c-c807eaafbac3">20</ix:nonFraction>&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="i537b107b17f34737a20ec184a594ae82_D20211201-20211231" decimals="-6" name="sesn:LicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5ODY_b1063518-33dd-44b7-9602-1a7dfeacae92">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i537b107b17f34737a20ec184a594ae82_D20211201-20211231" name="sesn:LicenseAgreementMilestonePaymentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTcwMTE_70646b17-d4ff-4dd0-93e1-8cef01cf0991">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i695006bd273747aeb95e43b893e8b867_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzI5ODUzNTAxNjY3OQ_c5caa3f9-de7f-45c5-9f78-553872bb3834">20</ix:nonFraction>&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<ix:nonFraction unitRef="usd" contextRef="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzI5ODUzNTAxNjgwMg_2d6ef542-d325-488f-a8df-f4573102205b">20</ix:nonFraction>&#160;million was received. </ix:continuation></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01fbe849109a4f97906fb5e357fe6a07">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTQ5NzU1ODI0NDM4Ng_33f6a9e1-7734-430e-8088-02830519ab81">26.5</ix:nonFraction>&#160;million of license revenue related to the Roche, Qilu and MENA License Agreements during the year ended December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTQ5NzU1ODI0NDQwMg_2384a6cb-9234-453e-92f1-8b31ea1771d7">11.2</ix:nonFraction>&#160;million of license revenue related to the Qilu License Agreement during the year ended December 31, 2020.</ix:continuation> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85NC9mcmFnOjEwNTQyZThiNGRmNTQwMTA5N2ZiN2VmMGUwMzMzNzdiL3RleHRyZWdpb246MTA1NDJlOGI0ZGY1NDAxMDk3ZmI3ZWYwZTAzMzM3N2JfMzM0OQ_6c9c2e44-7608-454d-a239-3d824236c00c" continuedAt="i1983cbbac1ed46ffb0b2f760a46c78af" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="i1983cbbac1ed46ffb0b2f760a46c78af"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85NC9mcmFnOjEwNTQyZThiNGRmNTQwMTA5N2ZiN2VmMGUwMzMzNzdiL3RleHRyZWdpb246MTA1NDJlOGI0ZGY1NDAxMDk3ZmI3ZWYwZTAzMzM3N2JfMzM0OA_8e420737-a050-44d0-8ea2-b48d956480fd" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_97"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDAzOQ_768dfd06-eb00-4a85-8d77-c2d349b415e0" continuedAt="ib8df77c39d3240a1b755ba6b55afafb9" escape="true">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ib8df77c39d3240a1b755ba6b55afafb9" continuedAt="i435d468fd3b04536926c8c04f574da12"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NDA_7423ef5b-5642-4d7d-93a4-dde85bcf2cc9" continuedAt="i8fd0e2394fa0458a98bbee093bcf1ad2" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2021 and 2020 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="i8fd0e2394fa0458a98bbee093bcf1ad2" continuedAt="ibdba3b03dc6d4e76ab919d17aab4abbb">Level 3</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibdba3b03dc6d4e76ab919d17aab4abbb">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDA0MA_afd775d5-dfd3-4cd1-a719-1aa45172a908" continuedAt="iaa5c401233cf4a84ac7ddc2094cab294" escape="true">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i435d468fd3b04536926c8c04f574da12" continuedAt="i8906baf0e60b4719b742c2fbbc357b60"><ix:continuation id="iaa5c401233cf4a84ac7ddc2094cab294"><div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib942d47e8aca410e959ff68b5d97942f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC0xLTEtMS0yNzc0Mw_2f6104cc-996a-4686-985b-6a99ed01b75f">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3d4b0f71404387b7089a237b8a5500_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC0zLTEtMS0yNzc0Mw_9f8fbac0-4fea-4d26-a811-c75c9dceb116">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9280baa377514c5b8f3b86112af15bc1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC01LTEtMS0yNzc0Mw_deee05f7-c22a-42f7-9292-d0211cfae383">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e07a02a314fe58d21f5e73b65454b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC03LTEtMS0yNzc0Mw_e75d8d9c-c133-471b-9f99-418e4fda1970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2904e8fab3f54e409e119eb43ab1f654_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC05LTEtMS0yNzc0Mw_052eb447-85fb-4135-9a96-1701af5f8cc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib942d47e8aca410e959ff68b5d97942f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi0xLTEtMS0yNzc0Mw_b561be6d-bb69-41a1-9109-2c37fb7aa2bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3d4b0f71404387b7089a237b8a5500_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi0zLTEtMS0yNzc0Mw_ed2f70f5-e4b1-4309-9a30-c1d894b41de6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9280baa377514c5b8f3b86112af15bc1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi01LTEtMS0yNzc0Mw_c70996eb-fdb3-49c8-aa7c-df47bae062e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e07a02a314fe58d21f5e73b65454b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi03LTEtMS0yNzc0Mw_6e17a0db-b65b-4179-a3f0-6e209a2d7abf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2904e8fab3f54e409e119eb43ab1f654_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi05LTEtMS0yNzc0Mw_bf8d7a63-6604-49ce-a6c0-0538d40c2b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib942d47e8aca410e959ff68b5d97942f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy0xLTEtMS0yNzc0Mw_3e92c08a-89d0-4a0c-83c9-70361eedb084">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3d4b0f71404387b7089a237b8a5500_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy0zLTEtMS0yNzc0Mw_9a703a3d-17f0-45fa-9147-832b5427c89d">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9280baa377514c5b8f3b86112af15bc1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy01LTEtMS0yNzc0Mw_cce00826-d798-4122-8a8b-7839a2ac28e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e07a02a314fe58d21f5e73b65454b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy03LTEtMS0yNzc0Mw_be18999c-d583-4d8e-8055-278bfef1bea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2904e8fab3f54e409e119eb43ab1f654_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy05LTEtMS0yNzc0Mw_ef37d1a3-3440-41c9-861f-6bfa06983605">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC0xLTEtMS0yNzc0Mw_31a004b6-d28e-4d18-b217-0bcde89984b4">16,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5309a9a57784300b6ab55b4dbfaa087_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC0zLTEtMS0yNzc0Mw_ae51873c-01e4-4b48-b874-497ed5f92e34">16,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f21fbe1815427897b0c6ef0565f88f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC01LTEtMS0yNzc0Mw_6f4c2e60-7529-4867-8baa-e1eddd261659">16,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33449a16f50d42fda82fa03444b362a5_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC03LTEtMS0yNzc0Mw_447d6aef-1429-401d-aaf4-c5fc76e8a933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC05LTEtMS0yNzc0Mw_dc2a1d1f-0344-4f27-9fcb-3676f2832aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi0xLTEtMS0yNzc0Mw_540804c0-cea1-400b-b540-03a59d9a6ebf">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5309a9a57784300b6ab55b4dbfaa087_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi0zLTEtMS0yNzc0Mw_0431842b-d616-42ba-a199-7b7222769570">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f21fbe1815427897b0c6ef0565f88f_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi01LTEtMS0yNzc0Mw_5f9352af-a776-4420-a867-03108529dd9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33449a16f50d42fda82fa03444b362a5_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi03LTEtMS0yNzc0Mw_d2505ecb-eeb2-4c6a-b945-2b5e72ac1517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi05LTEtMS0yNzc0Mw_011d8e67-00d1-458f-adbc-fb071f990e1c">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy0xLTEtMS0yNzc0Mw_9a518215-c89d-4ea1-ba52-526d27770ffb">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5309a9a57784300b6ab55b4dbfaa087_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy0zLTEtMS0yNzc0Mw_cf8b2d48-2714-4bc9-befa-5106eb49f841">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f21fbe1815427897b0c6ef0565f88f_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy01LTEtMS0yNzc0Mw_b8a4f32f-ea42-4bd9-bde8-2a6b5c4e266f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33449a16f50d42fda82fa03444b362a5_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy03LTEtMS0yNzc0Mw_bebc9c23-8df7-4dbc-943b-3abaf4da05b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy05LTEtMS0yNzc0Mw_140baebe-ca1c-4136-b974-459644f8181a">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from <ix:nonFraction unitRef="number" contextRef="ib03bde29f9a84402bee0c3bc6cf735f5_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzg0ODI5MDczMDAxMA_96e4f383-ebfc-4ea2-95f2-eb2068d180c9">8.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i58772c205c8a4b93bd99d62ff3f8e8af_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NTY_0593a624-4442-4a62-a30b-bceb768a6bca">9.3</ix:nonFraction>% as of December&#160;31, 2021 and <ix:nonFraction unitRef="number" contextRef="i294acb7d2420400b8155b9d8ca59ecac_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjAyMg_4dcd7c38-e00d-411f-ad48-716cc41112fc">8.4</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i80a8c65717624d59b77914baa103c3bf_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjAyOA_2bca2bad-007f-4416-9609-2c1581063298">8.8</ix:nonFraction>% as of December&#160;31, 2020. There have been no changes to the valuation methods utilized during the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDA0MQ_609233e2-f0e6-44e5-8c82-6aa959eeac10" continuedAt="icb2456fcd5844c048201bda7a606daca" escape="true">The following table sets forth a summary by quarter of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i8906baf0e60b4719b742c2fbbc357b60" continuedAt="i183d6a8fb6784a0dba44f424ba67ead8"><ix:continuation id="icb2456fcd5844c048201bda7a606daca"><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMC0xLTEtMS0yNzc0Mw_4608251b-7b7b-40f9-a8fb-e8da3b1b5004">108,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9873482dcdab4f8e99687d14de08bf30_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMS0xLTEtMS0yNzc0Mw_061fab41-b98b-4a58-a6b0-15b2d03cad2d">48,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2453680b1ee48d49d18b917c46773a0_I20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMi0xLTEtMS0yNzc0Mw_3b022d13-2ede-4ceb-a3e9-13ffb4675c94">157,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ab9cefc27e4b67b11ffb55b439770b_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMy0xLTEtMS0yNzc0Mw_c27af503-1354-4d3e-9eac-659c1875838c">13,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNC0xLTEtMS0yNzc0Mw_0137421a-b009-41f4-9f04-161a39d83308">170,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic90b2409cd1e47e9a97d51b1bda3f754_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNS0xLTEtMS0yNzc0Mw_b28a0236-140a-4605-8f37-b13c8ab59b28">114,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNi0xLTEtMS0yNzc0Mw_7b8bd602-aeef-48f3-bdf9-7c81c43737e0">56,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNy0xLTEtMS0yNzc0Mw_7162395d-9a14-44ee-998d-632c5e9077c9">4,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfOC0xLTEtMS0yNzc0Mw_e7e6953b-de7b-407f-8bec-53c2ace4e031">52,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021, current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMTAtMS0xLTEtMjc3NDM_82599e7d-c96e-40fd-8542-d66a83aff52f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021, net of current portion</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMTEtMS0xLTEtMjc3NDM_65e6ac33-1175-4c42-aa1c-1a431df66de7">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i461f7c863e8845a1bf3aecbdde6819d0_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMC0xLTEtMS0zMDI3Ng_89337f78-097e-4c35-a783-4f88457bf005">108,840</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccafbadd781745f8a66ce65217af032c_D20210101-20211231" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMS0xLTEtMS0zMDI4NA_86832af2-5324-41dc-a4be-1707b5f89b2d">8,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccafbadd781745f8a66ce65217af032c_D20210101-20211231" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMi0xLTEtMS0zMDI5Mg_ad6469f9-4219-4413-9bac-cea1a8aa19d6">47,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208c2cdd76674e1490701e0cd5f02c0f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMy0xLTEtMS0zMDMxMA_4093d389-3124-4c5f-bb2e-7668c8073c5d">52,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i183d6a8fb6784a0dba44f424ba67ead8">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTA5OTUxMTYzNDE3Ng_0a9c0fb3-bd28-48d0-9c60-92ae775ff46f">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjk4MA_c6912ff7-f528-4d70-9683-cc0c9654886a">2</ix:nonFraction>% earnout is derived from the Company&#8217;s WACC, which has fluctuated from <ix:nonFraction unitRef="number" contextRef="i028ccf70c10c4129a5d10bd536d297b3_I20201231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzEwMA_7ae83321-ac68-4486-9508-6f2e2cb6cf88">8.8</ix:nonFraction>% as of December&#160;31, 2020, to <ix:nonFraction unitRef="number" contextRef="i2de469ec0aa540adac05ef95232f5a15_I20210331" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzEzMA_8121cf6c-6333-47ab-b549-a8ce6b90c583">7.8</ix:nonFraction>% as of March 31, 2021, <ix:nonFraction unitRef="number" contextRef="ib6a34442b9744cb6ae08c574b84b89b9_I20210630" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzE1NQ_e78a1cf8-bea4-4c56-8356-fb0c5b782922">6.8</ix:nonFraction>% as of June 30, 2021, <ix:nonFraction unitRef="number" contextRef="i4609a0afbc594078808154f146946ab1_I20210930" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzE3OQ_909cf822-16e8-494c-82d8-fb0ccab765d0">8.6</ix:nonFraction>% as of September 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzg0ODI5MDczMTU5NQ_564da084-42ab-4d1d-bfb2-eb4bd8366f4c">9.3</ix:nonFraction>% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from <ix:nonFraction unitRef="number" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ0MQ_abd5161f-48b9-4573-91ba-05b44fa22a01">8.4</ix:nonFraction>% as of December&#160;31, 2020, to <ix:nonFraction unitRef="number" contextRef="ia2453680b1ee48d49d18b917c46773a0_I20210331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ3MQ_b3dd341c-5899-41d5-b39c-defb295313c8">7.4</ix:nonFraction>% as of March 31, 2021, <ix:nonFraction unitRef="number" contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ5Ng_6528f9b2-59d9-4e23-83d5-1b6b892ebd28">6.6</ix:nonFraction>% as of June 30, 2021, <ix:nonFraction unitRef="number" contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzUyMA_6a13d7fd-fde7-41e6-94a7-a7e768945725">7.5</ix:nonFraction>% as of September 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NjM_f61c647f-318c-440e-be5f-1b5d07460998">8.0</ix:nonFraction>% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTcwNDI0MzAyNzQ5NzY_3dbc9b6f-21d3-4118-a572-b7866858adc1">56.8</ix:nonFraction> million for the year ended December&#160;31, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form, and the Company&#8217;s withdrawal of its MAA with EMA. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Incorporating the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#8217;s revenue projection models are timing of commercial product launch and probabilities of clinical and regulatory success; the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL and the Company&#8217;s withdrawal of its MAA. The Company plans to conduct an additional Phase 3 clinical trial in order to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which will lead to delays in the start of commercialization globally. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately <ix:nonFraction unitRef="number" contextRef="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5ODQ_e8f080e9-4caa-41f8-999b-2396e8948d5f">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibecee94376694fc393e30898f2ff86a2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5ODk_94b0c53b-ee74-4909-8519-3ad243c3e295">55</ix:nonFraction>% globally.</ix:continuation> Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_1294"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMTU0NDg3MjA5Njk1NA_3f893826-ea4b-4f5a-aec4-33f318ecfcb1" continuedAt="i4063b9e6833049349cce4488af91d3b1" escape="true">RECEIVABLES </ix:nonNumeric></span></div><ix:continuation id="i4063b9e6833049349cce4488af91d3b1" continuedAt="i7f3a4e3d5bd647d98a031256aa4919bf"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of December 31, 2021 is $<ix:nonFraction unitRef="usd" contextRef="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEwOA_09a50a2e-ea8b-45c2-b032-4890e61a345d">21.0</ix:nonFraction>&#160;million, comprised primarily of a $<ix:nonFraction unitRef="usd" contextRef="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEzNA_3e38b8bb-fcde-48b9-82a7-c97dcf7fcba6">20</ix:nonFraction>&#160;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE0Nw_b2f62b13-8133-4bef-a106-830ff3e58fcc">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i15fd8a9c40534aeaaf4598e6db3abbf6_D20211201-20211231" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE2Mg_5206b3da-fb31-4b10-8a5e-8d0dc52db337">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $<ix:nonFraction unitRef="usd" contextRef="i69a83c24db234a7e8561b517d543d5e4_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE2OA_fc225545-834f-4a3a-8019-3ac6acf44f39">20</ix:nonFraction>&#160;million was received. Additionally, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ia21f2148bbe744ea9737cdc30b3b639e_I20210630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xNzA0MjQzMDIzNTk5MQ_8b0a6c6e-0b27-4a2b-815b-fb7db0bb2e5a">0.9</ix:nonFraction>&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December 31, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEyNw_547e89e7-9ae7-49d3-bf3d-d6c180bab0ee">3.5</ix:nonFraction>&#160;million. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE4MQ_1d186cb8-2b4e-4aea-a3df-d400b5950ed5">3.4</ix:nonFraction>&#160;million to other receivables in the fourth quarter of 2021 for German VAT recovery related to drug substance sent to Baxter. The Company received a payment for $<ix:nonFraction unitRef="usd" contextRef="i34539641171840f78745ef893c090fa7_D20220101-20220131" decimals="-5" name="sesn:ProceedsFromValueAddedTaxRecovery" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE5NQ_3e9e4d0f-c6fa-4f2a-8ff7-5cd3763b0f44">1.8</ix:nonFraction>&#160;million in January 2022 and expects to collect the remaining balance.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f3a4e3d5bd647d98a031256aa4919bf">The accounts receivable and other receivable balances as of December 31, 2020 were de minims.</ix:continuation> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzIzNA_619a8025-11e3-4a7e-89b0-1da7551cbcd4" continuedAt="ib6f7c0a9013b4b80bed6ea8816a60fbb" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="ib6f7c0a9013b4b80bed6ea8816a60fbb" continuedAt="idf21fe5aa1d7413ca48b5e26c45f6df3"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzIzOQ_b7839ba6-6c80-42e0-9267-a05863c7580b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea343b4020f4cf29f1266e2dc6a6b09_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzItMS0xLTEtMjc3NDM_d38c3547-0fd2-460c-ad9c-bb5bc8e39491">569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib230fbf43aab492384091cb48ddd7af2_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzItMy0xLTEtMjc3NDM_6d0190e1-cb51-482a-8b86-e843f9a92638">570</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea35f777e5264bc1a11c1a5275407d2e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzMtMS0xLTEtMjc3NDM_4e1e9ed3-2fc3-49db-ab5e-f0cb94a4e15b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9439e6445a46079edce40b074a4cb1_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzMtMy0xLTEtMjc3NDM_9f784e7c-7d02-476e-8827-c4b3ff47c3eb">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1ae7c86aed4911bffc0db6ed1d7ca4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzQtMS0xLTEtMjc3NDM_45edb1a2-af3d-466a-ad3b-acf40931bcdf">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4126ae783347adb9e0ab895ddfa18d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzQtMy0xLTEtMjc3NDM_0e5cd4ee-ceb2-457c-841e-ae1cf1e9f04a">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e085c71b3d4eb89b00ee3fce28ada1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzUtMS0xLTEtMjc3NDM_152a371b-8542-4709-bb3d-4d83840aaf68">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1639a88a7f44d28ddedc2f01af5b1b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzUtMy0xLTEtMjc3NDM_dcdf47bc-bc7d-4dca-83bd-3b0ce1cf1f4c">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if671dcdd4df94af4a5b9fb93620a325b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzYtMS0xLTEtMjc3NDM_7bce8263-5e17-47b4-856e-773d7a015a20">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e5f96e4bd74651b225f0392286c025_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzYtMy0xLTEtMjc3NDM_85d444d3-bffb-4b2a-ad5a-2d14f2461d91">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzctMS0xLTEtMjc3NDM_7096aa13-b14b-40a0-9a9c-0ec9f1cdd715">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzctMy0xLTEtMjc3NDM_2d675c0c-e7c7-450e-98b9-11f1b82d3c13">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzgtMS0xLTEtMjc3NDM_327c2412-3695-4076-a16d-114d6f4d0577">966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzgtMy0xLTEtMjc3NDM_8aea25c9-573e-4b47-95d9-a2a767f14654">881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzktMS0xLTEtMjc3NDM_b373cdf7-172f-4567-bb55-9193226973f2">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzktMy0xLTEtMjc3NDM_58929297-3264-4666-8bb3-320365a66ea8">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf21fe5aa1d7413ca48b5e26c45f6df3">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE2OA_fd25404f-9821-4e53-9fa0-e1156e8989a5">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE3Mg_e3eeefc9-53b6-4f98-8ef6-01053cb26b32">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE3OQ_8d9f53af-68c4-48f5-8f84-4f665fef2e1a">0.2</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</ix:continuation> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzQ0Nw_331f5533-0791-4771-8328-730505aa14f2" continuedAt="ibb9a0940960f44e39a70d06783fc393a" escape="true">INTANGIBLES AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="ibb9a0940960f44e39a70d06783fc393a" continuedAt="id04c4c6753494a6bb7b8bf769d47fa54"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's consolidated balance sheet are the result of the Viventia Acquisition in September 2016. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzQ0OA_2d59a69d-481b-4611-8a8b-4ebd0ebdde01" continuedAt="idaa75f9575d340f2ac5725373da7746e" escape="true">The following table sets forth the composition of intangible assets as of December&#160;31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="idaa75f9575d340f2ac5725373da7746e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52b03759bf044b3b5e17cf2a7c4a0b9_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzMtMS0xLTEtMjc3NDM_ff93b3fa-ed06-4c3b-9893-ca4c85f3ab5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12322603449433985e3779be27b8eab_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzMtMy0xLTEtMjc3NDM_97b1ce3c-d910-411f-8408-05278e393029">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d622315903d4829a4f582cfffed067f_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzQtMS0xLTEtMjc3NDM_a76c8970-a2d2-49bf-8f29-672a073d2774">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425fb86623034e39aa2df73efd925f25_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzQtMy0xLTEtMjc3NDM_4cdd5a8a-5bf4-4b42-9056-16aa121823d7">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe412d00cd048258c144cd9ed556654_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzUtMS0xLTEtMjc3NDM_541b5eba-3656-4a13-a394-ef4a7bacf19c">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1e110f756945ed9233483c148b8a4a_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzUtMy0xLTEtMjc3NDM_0fabd042-1889-4a1f-b6ec-32acac6642a4">46,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="id04c4c6753494a6bb7b8bf769d47fa54" continuedAt="i4e7ac8915f4d4555957ed35b5c1a717e"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i65d83f49999a40659f8cb5c98716447b_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjA1NzQ_5f4fdc49-8a86-4d49-92e5-f3bb96e8f571">31.7</ix:nonFraction>&#160;million of impairment charges as of September 30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjMyOTc_4c16c954-3f23-4f74-9d3c-67ca22e61849">no</ix:nonFraction>t recognize any impairment charges during the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzU0OTc1NTgxNzM0NDc_05812bca-c78b-4387-adf4-82f58d499d88"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzU0OTc1NTgxNzM0NDc_381b5dd2-ad7e-4641-8e1f-666ffad548de">13.1</ix:nonFraction></ix:nonFraction>&#160;million as of December&#160;31, 2021 and 2020. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company's withdrawal of its MAA, a quantitative impairment analysis was conducted during the third quarter of 2021, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU4OTc_ed5ddec5-e381-4248-acda-9db0502458b7">13.1</ix:nonFraction>&#160;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately <ix:nonFraction unitRef="number" contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MTY_c5b58db6-7d25-466d-b62a-6d606c3baa1f">45</ix:nonFraction>%. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was <ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEyMDk0NjI3OTQ3NjAw_46390fca-693f-4d5d-9a2a-3eca1f36867f">no</ix:nonFraction> goodwill impairment as of December&#160;31, 2021. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from <ix:nonFraction unitRef="number" contextRef="ia43faec616e1467283e341842cd9d4ab_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MjU_28270a63-9b48-4906-80b8-ea028337fd73">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibecee94376694fc393e30898f2ff86a2_I20211231" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MzQ_9939a189-5e56-43eb-b28c-517e1b71d7e5">55</ix:nonFraction>% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e7ac8915f4d4555957ed35b5c1a717e">Based on the annual testing and quarterly reviews performed, the Company concluded that there was <ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjUzMzk_1fa5dabd-517d-40c7-bd11-b8c8aa25b0af">no</ix:nonFraction> goodwill impairment during the year ended</ix:continuation> December&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90ZXh0cmVnaW9uOjllOWQwY2ZkMDA0NTQ5Nzc5YzRhMmU0YzZjMjUyYTVkXzE4NzU_4c3721cd-2cfc-47f8-af42-070f0de68cdb" continuedAt="i89d6ae9216b84bd493fec8602df777a3" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i89d6ae9216b84bd493fec8602df777a3"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90ZXh0cmVnaW9uOjllOWQwY2ZkMDA0NTQ5Nzc5YzRhMmU0YzZjMjUyYTVkXzE4Nzk_b74a5883-6db9-4dba-a086-10343357f204" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzItMS0xLTEtMjc3NDM_d45200ca-7885-47cd-b382-a7f966f60619">1,841</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzItMy0xLTEtMjc3NDM_35f8c81a-35c0-4141-afc5-fca174e67f5b">1,372</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzMtMS0xLTEtMjc3NDM_0cfbbcec-0563-480a-99e3-94e6b96bb09c">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzMtMy0xLTEtMjc3NDM_ef40fd3d-1a61-4342-a92c-2808829bf2b0">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzQtMS0xLTEtMjc3NDM_72116434-bf65-4e4e-b910-a4ee29309b76">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzQtMy0xLTEtMjc3NDM_282a8404-3832-4cff-b613-2239630476bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzUtMS0xLTEtMjc3NDM_bfa3018a-124c-4e11-8cae-005e6da9e6a6">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzUtMy0xLTEtMjc3NDM_97de0620-58a1-456a-9baa-42e25063a572">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzYtMS0xLTEtMjc3NDM_cd0d71dc-5969-49da-bb1c-582f8b807c37">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzYtMy0xLTEtMjc3NDM_bbcbaa63-f88e-45f7-a3f9-222f84a64979">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzctMS0xLTEtMjc3NDM_5eb5bb18-dd0f-4c89-bbcb-45b455a756cb">8,255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzctMy0xLTEtMjc3NDM_13c611f4-4ce3-4ac8-9ba3-7c941988ef31">3,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzI4ODE_93963bda-ea0b-4424-9f90-aa9058e78405" continuedAt="if654d9468c214f5597c04394e0f68927" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="if654d9468c214f5597c04394e0f68927" continuedAt="iab24b3a355f94386b82971e65c6a7852"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, <ix:nonFraction unitRef="lawsuit" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMwOTU_c9f406a9-d055-4d0c-993b-b8236785b4b5">three</ix:nonFraction> substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The <ix:nonFraction unitRef="lawsuit" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMDU_5423c41e-43ba-467c-a834-ed54ece6c1fb">three</ix:nonFraction> complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The <ix:nonFraction unitRef="lawsuit" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMTU_d62740a2-625a-4d0c-8e11-4a1febf90081">three</ix:nonFraction> complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the <ix:nonFraction unitRef="lawsuit" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMjU_aedc41f6-d2c9-4140-98fd-2404ca1c9715">three</ix:nonFraction> cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants&#8217; response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant, but no defendant has yet been served. The <ix:nonFraction unitRef="lawsuit" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMzU_600a355b-9668-4de0-83f8-5b8dcf67dee9">three</ix:nonFraction> derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The <ix:nonFraction unitRef="lawsuit" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxNDU_f51f3929-deb3-42a0-8ffc-b07e4088c3ac">three</ix:nonFraction> derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iab24b3a355f94386b82971e65c6a7852"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_1172"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzA5Nw_739ee0de-025c-4509-8863-f8dcbf43ee4d" continuedAt="i39521ac584644431883e162113c537f6" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i39521ac584644431883e162113c537f6" continuedAt="i387da479d1d140c28b40eee483f42dc1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its <ix:nonFraction unitRef="sqft" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeasesAreaOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEwMg_3d0c34f2-8718-424f-a29a-aeb6fee4d29e">31,100</ix:nonFraction> square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional <ix:nonNumeric contextRef="i81e534a3b6984e9ca7a46fb4761feeec_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEyOQ_cb823a0e-f701-4256-83e5-0897114fb834">two years</ix:nonNumeric>, through September 2022, with a right to extend the lease for <ix:nonFraction unitRef="term" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="INF" name="sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzExNw_899d3252-1e39-48b3-8ddb-a4602c2b622b">one</ix:nonFraction> subsequent <ix:nonNumeric contextRef="i81e534a3b6984e9ca7a46fb4761feeec_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzE1OA_09622a00-c0c3-412a-bac3-e9de27b48058">three-year</ix:nonNumeric> term. The minimum monthly rent under this lease is CAD $<ix:nonFraction unitRef="cad" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4Njc4_c6f560ef-c85e-4904-9f3b-e11779fbd40b">18,100</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4Njg4_aa46e359-c968-499e-81eb-3b711b3abe54">14,300</ix:nonFraction> at exchange rates in effect on December&#160;31, 2021). In addition to rent expense, the Company expects to incur CAD $<ix:nonFraction unitRef="cad" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4NzQ1_e575234f-9c43-4b38-b42d-3288b583ee5a">18,200</ix:nonFraction> per month related to operating expenses (approximately $<ix:nonFraction unitRef="usd" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4NzU1_28d4dbf5-6e86-4632-9135-843647f906e3">14,300</ix:nonFraction> at exchange rates in effect on December&#160;31, 2021). Operating lease cost under this lease, including the related operating costs, were $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTA4_9db33a23-ae24-4e2d-bee8-76a98f5d683a">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTQw_43cffc2c-b41f-4758-91bf-0656fc66709a">0.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTcw_26ba0f83-b0a7-4b6c-b97e-a26ead905a3c">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NjAx_eecbb385-2fe8-4a56-9b8d-6e23f72087f6">0.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a">other assets</span></span> on the Company's consolidated balance sheets. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77">other current liabilities</span></span> and the long-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1">other liabilities</span></span> on the Company&#8217;s consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every <ix:nonNumeric contextRef="ie35eeadb1df94fb4940973f807cc6e7d_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDI3_b34c1b8f-e463-41bb-acc7-cc69d065f1b2">three months</ix:nonNumeric> to <ix:nonNumeric contextRef="i2d207bdc8bb44456958770de74b1eabe_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDQ2_78e53d5f-8b75-4260-a03e-6e8aff1a9df6">six months</ix:nonNumeric> and currently extend through June 2022 and May 2022, respectively. The minimum monthly rent for these office spaces is $<ix:nonFraction unitRef="usd" contextRef="i68866b76b55f41f7a5558f5272486883_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjQwNDM1_598bd5ee-84ff-4caf-9302-45b7cd7dd6bc">2,100</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4b8cf18e833d4913a7dc5dbc354f10c4_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjQwNDQ1_3f982f27-33f3-4538-abc4-60ed4e1be2d0">18,400</ix:nonFraction>, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzA5OA_ce2ea70f-aa89-4114-903f-eeab7a46f202" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&#160;31, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8yLTEtMS0xLTM5NjIy_8824d3d7-fa7f-4d83-a647-dd1b0a431a99">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8yLTMtMS0xLTQxMTc2_2cf518c9-969d-4f6d-a8e0-10cdcd34172d">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8zLTEtMS0xLTM5NjI1_bc303976-ba11-4fbb-9ad7-b252dad70350">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8zLTMtMS0xLTQxMTc5_2d132eaf-013d-470f-b5c1-d5177eec60f7">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF80LTEtMS0xLTQ5NDI3_0d9e6910-e320-43cb-a4cb-1c3c9afbc963">589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF80LTMtMS0xLTQ5NDI3_ccb1d5e5-6278-44d3-836c-baf2fa92c7cb">562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8xLTEtMS0xLTQ5NDMx_bc7e97f8-46dc-419d-93a2-8cc4ab35d7d8">0.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8xLTMtMS0xLTQ5NDMx_9c601c97-0d68-4107-a688-d2530dfdee08">1.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8yLTEtMS0xLTQ5NDMx_2e06c13a-7a45-4e26-9ece-30126280c8cf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8yLTMtMS0xLTQ5NDMx_8784130f-3af4-4a7b-831d-bcf7eaabfcc6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEwMA_2450b5dd-6506-4634-a7ee-729d50b3647f" continuedAt="ib5d243719d74443d874bb2e304e871ce" escape="true">The following table sets forth the Company's future minimum lease payments under non-cancelable leases as of December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i387da479d1d140c28b40eee483f42dc1"><ix:continuation id="ib5d243719d74443d874bb2e304e871ce"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Minimum Lease Payments:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments (2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8xLTEtMS0xLTQxMTg1_788b2a2b-e87e-44ee-993a-dd88f54dea5e">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8yLTEtMS0xLTQxMTg1_beb9503d-02b4-4807-b2ae-15da2a7babb1">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8zLTEtMS0xLTQ5NDQ5_b62254f8-67af-4c3d-9bbb-305464b98609">124</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="if1c5a63ddb584a0db5ee835d7440b255_112"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTM2_7e44bc56-57b4-42d2-86f1-a337909e9aac" continuedAt="i64847604ff5346e1b47b3fe12be3e462" escape="true">STOCKHOLDERS' EQUITY DEFICIT</ix:nonNumeric></span></div><ix:continuation id="i64847604ff5346e1b47b3fe12be3e462" continuedAt="i02fee32c97b046bf934f367942177039"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i16b4c01413da485fa2ac23775d55bed5_I20191130" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQyOTI_57301754-2b30-4d01-b6ed-62dd5a406a73">0.001</ix:nonFraction> per share, from time to time (the &#8220;ATM Offering&#8221;) for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i65be1969c492411ba4743fe748508e67_D20191101-20191130" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzMTI_e9cb6198-f620-45ab-9d93-917297cfdc51">35</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $<ix:nonFraction unitRef="usd" contextRef="id6ed6ecc802f45c586c3b6cfff6e28d2_D20201001-20201031" decimals="-5" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzNjY_273b1909-596b-48d8-9a9d-c882db3ef274">50.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibfb861283e22418081b9e629463e783d_D20210201-20210228" decimals="-5" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzNTE_f5aeefa2-82d4-474b-9a7d-c30a2653276b">34.5</ix:nonFraction>&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i072f60a137e94674991638220c6ed9ec_D20210601-20210731" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzOTI_75402b7e-436c-4934-9eed-ffd609b7b236">200</ix:nonFraction>&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <ix:nonFraction unitRef="number" contextRef="i65be1969c492411ba4743fe748508e67_D20191101-20191130" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQ0MTE_66932d0b-718e-4ec3-b309-11e928859972">3.0</ix:nonFraction>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $<ix:nonFraction unitRef="usd" contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNDc_8137ddee-77f1-42ac-996d-f00b12343ee7">175.0</ix:nonFraction> million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNTQ_46f34930-4686-4dee-9b79-f3148bf217ef">56.9</ix:nonFraction> million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNjA_758e79af-be69-4ab8-aef3-d137b82ac7a2">3.17</ix:nonFraction> per share during the year ended December&#160;31, 2021, compared to</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNjU_44ca959c-0202-4115-98e3-0a5ab800f8ce">38.0</ix:nonFraction> million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNzA_9d3a0855-a37c-4515-9db3-9708acf1df9c">33.4</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a weighted-average price of</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNzU_7c46c6b3-c8f2-4049-9d0f-ea79253773f0">1.17</ix:nonFraction></span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share during the year ended December&#160;31, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $<ix:nonFraction unitRef="usd" contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzODQ_e4a6a0fa-d67c-4fb1-ba49-20196ba8fe5b">5.4</ix:nonFraction> million and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NjI3OTA_9e68453e-1c08-4d70-85b0-1f80db0d52b5">1.2</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2019 Financing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company raised $<ix:nonFraction unitRef="usd" contextRef="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIyNTE_73e0daed-83fa-4f34-a7b5-f8527330ea41">27.8</ix:nonFraction> million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIyODc_383644e1-4dde-40e1-a2e0-a9cd2399dc77">20.4</ix:nonFraction> million shares of common stock and accompanying warrants to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIzNjU_e1b356d5-2ce9-4d27-984f-cb39cc10b653">20.4</ix:nonFraction> million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $<ix:nonFraction unitRef="usdPerShare" contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" decimals="2" name="sesn:CommonStockAndWarrantOrRightsPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzI1NDM_072bed4a-7755-4739-a7ae-71b8bb87cb61">1.47</ix:nonFraction>. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzI3MDM_64052909-36f1-4f63-87de-7552b8da026f">1.47</ix:nonFraction> per share, subject to adjustments as provided under the terms of such warrants, and had a <ix:nonNumeric contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTM3_94791cac-cb12-4618-a9f3-14ff128dfbdb">one-year</ix:nonNumeric> term that expired on June 21, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzM5MjA_bb83ea6d-02b2-4b9e-af48-f50576274e8b">5.0</ix:nonFraction> million shares of "blank check" preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzM5NjQ_81cfc0f3-616e-4f9c-ad11-95239a1aa7ea">0.001</ix:nonFraction> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_3ca3ebd3-ceb3-4889-9eaf-9abc99c50214"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_a6fac8ff-e9aa-4eb3-9005-f84aa39202c8"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_d2dedf03-e918-4c25-883e-d5fc0ebacf4e"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_ea01a3c4-a76d-4098-a784-c8b743d25bfe">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTA0NDU_1e7dd183-5f40-4b42-9bef-bb5f5e95df67">200</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTA0NTg_c348de83-c14b-49bd-9c2d-cf888e978f23">400</ix:nonFraction>&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxMzg_6ebfddf1-ebe8-4834-a0d7-2f87dc8dafbb"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxMzg_db6a0c66-ced2-4ce5-bc01-7eeb19fd5fa6">199</ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxNTk_4ee5e4f9-967d-4976-9eb1-20191f57d79c"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxNTk_e39cf994-80dc-4e30-b9eb-865d78a3fb90">140</ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of December&#160;31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTQx_e2d3a93c-58e5-45b5-9c7a-15385f9d3f74" continuedAt="ia4722139eff04e0e9245e60e56e4d057" escape="true">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i02fee32c97b046bf934f367942177039" continuedAt="i1d313d2300ce41b6a98f9d81b1bff38f"><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><ix:continuation id="ia4722139eff04e0e9245e60e56e4d057"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:67.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzItMS0xLTEtMjc3NDM_910551ff-0edd-4ace-b6e8-8ce8933428fb">199,464</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzItMy0xLTEtMjc3NDM_a27d7ee9-291a-4add-9b4a-3af4f3b3d8b6">140,450</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0d8f6abc7e49829c395d208a3436f2_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzQtMS0xLTEtMjc3NDM_6c3143f6-0678-466e-8f1f-018d1cbdb64a">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id916d4f7441d4a088be2fca47e276005_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzQtMy0xLTEtMjc3NDM_374d992d-1ae3-4701-a457-1fc525ae1f9b">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMS0xLTEtMjc3NDM_08d38973-b036-4532-8535-f59d6eed6280"><ix:nonFraction unitRef="shares" contextRef="ifc1156bb975047729b334bf2e3fa2fc6_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMS0xLTEtMjc3NDM_2cb9d910-4172-4a92-9f7e-16207187cdaa">15,703</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMy0xLTEtMjc3NDM_dafa9df4-9ca2-435c-91ec-c63628a4731b">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtNTM0MzA_56772896-3e55-466f-b924-dedd6bd06979"><ix:nonFraction unitRef="shares" contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtNTM0MzA_d80264ab-c6f1-432d-8ba1-4fc5db1e7474">3,041</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75020eb264af4e39a21665962a79801e_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMy0xLTEtNTM0MzA_4b97d569-fe12-470c-9bc5-50f38d8dcaed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f92707265b84c70ae5a42f1daae1378_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtMjc3NDM_30dfc1b1-9752-400b-ba96-9417a25ea788">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40e1aa3b61664f47b00658c43dfd99fb_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMy0xLTEtMjc3NDM_63bf073f-26a3-4fb6-b85e-2f8b79cf9394">4,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7858b2eb979a432a96faff9ead49ee39_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzctMS0xLTEtMjc3NDM_fe758fc7-3233-4288-b148-df3ce01d4ba6">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44d44dfab69545dabde220a346b37456_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzctMy0xLTEtMjc3NDM_d41b0414-1081-4ec8-9edd-143eca070f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzgtMS0xLTEtMjc3NDM_927d8cf2-97b0-4647-8862-d301aa2224f4">229,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzgtMy0xLTEtMjc3NDM_71869167-bb97-4d4c-948c-bcbbe5af8626">157,707</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="INF" name="sesn:NumberofVotesEntitledForEachShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzUxMDY_53e774c3-db66-417c-8e3c-847bd3c59c7d">one</ix:nonFraction> vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTQy_5bd98541-2eb0-486b-9ba3-3f44582bc53c" continuedAt="ib1b366df086a4b2794c0b74538a33289" escape="true">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ib1b366df086a4b2794c0b74538a33289"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i877528c6538245119864f9c0c2e52211_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMi0xLTEtMjc3NDM_aefb2aaa-9afa-42eb-b301-dc5786cdc184">1.47</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i466f369ef0774c33bd619700d8de5551_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtNi0xLTEtMjc3NDM_c2999a41-537e-4805-81fc-374ed4f6e7f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtOC0xLTEtMjc3NDM_317e127c-1712-4008-874b-5ad1a479fc8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTAtMS0xLTI3NzQz_359b4cf0-c66f-405e-909e-8e9036ae6c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTItMS0xLTI3NzQz_0e037dab-8c41-419e-a33a-cfe8ecf604bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i877528c6538245119864f9c0c2e52211_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTQtMS0xLTI3NzQz_5fdbf0cd-5273-4243-8008-03069bb9d96a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMi0xLTEtMjc3NDM_d53a4938-9c9e-403f-a842-84e559cfc33e">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31cacad06c024286911346564a7662f0_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItNi0xLTEtMjc3NDM_1a79f56f-c083-43f2-972e-934ced65baca">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItOC0xLTEtMjc3NDM_fba4d9fa-40de-4e61-a017-9c18cdf1089a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTAtMS0xLTI3NzQz_078aeb3f-caf2-4bbc-82bc-128015051945">1,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTItMS0xLTI3NzQz_949ebfa7-ed1d-4574-a367-31a573148621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTQtMS0xLTI3NzQz_9483ef98-0beb-4fb0-ba39-ff73c27316f8">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMi0xLTEtMjc3NDM_43411bfd-62c6-47b1-a430-0ce1cc7da529">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ae2e392a7c740b1988ab6b7b8b786d1_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtNi0xLTEtMjc3NDM_e4aab035-3916-446f-aa83-5ab38e2c4ee9">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtOC0xLTEtMjc3NDM_bc321b98-1943-4767-b1df-1c6b2c1b0af4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTAtMS0xLTI3NzQz_9139048e-0de8-49a5-bc08-442ffff09749">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTItMS0xLTI3NzQz_ec630fe7-d845-4311-a56b-a7be93357b82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTQtMS0xLTI3NzQz_4c5f1b17-e021-43ae-a126-6b6c14faab54">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie688301f8b994be195f31b42f85842e5_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMi0xLTEtMjc3NDM_faed7136-7dd6-438a-b55d-f4871ced7bba">11.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d5371af6c3e495888104af773d10b15_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtNi0xLTEtMjc3NDM_aebae70f-e477-4dc5-9a36-c208f713fa28">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtOC0xLTEtMjc3NDM_2f4b494e-7430-4bc5-a592-685b5ab9f4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTAtMS0xLTI3NzQz_077aed76-0531-4c0b-b787-7e2372788cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTItMS0xLTI3NzQz_7d1b3434-84ff-4c81-8d81-a833b92ab512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie688301f8b994be195f31b42f85842e5_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTQtMS0xLTI3NzQz_3b65d639-74dc-4aef-ad3d-8177afff248b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i174b4bb16b14432aaeeb74b47fc49556_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMi0xLTEtMjc3NDM_021065e4-676a-4d69-8777-d926571b80dc">11.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e67736b7d564e33bad48ed099f8786c_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtNi0xLTEtMjc3NDM_72775c32-c429-4fe7-bfd5-a37b423c2ebe">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic128bae021684a57b2549146b666bae9_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtOC0xLTEtMjc3NDM_bbd7cdb4-e8e3-43b3-8033-63bb38cdbffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic128bae021684a57b2549146b666bae9_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTAtMS0xLTI3NzQz_0aa9c38f-ae9a-4985-9733-20740c83598c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic128bae021684a57b2549146b666bae9_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTItMS0xLTI3NzQz_b6b0caa1-8e61-4c95-9554-d8e1661a199c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i174b4bb16b14432aaeeb74b47fc49556_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTQtMS0xLTI3NzQz_6dcede5a-f057-4588-9206-644832f44964">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtNi0xLTEtMjc3NDM_86590912-d088-4a89-b44c-8a7ce404965c">2,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtOC0xLTEtMjc3NDM_afca3ae4-daa8-48ef-92fa-a7f5f459edcd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTAtMS0xLTI3NzQz_acc08e48-28a1-4719-a791-adfe42b15595">2,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTItMS0xLTI3NzQz_e64bb57d-0d63-4331-a57b-411f1e5aa5a3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTQtMS0xLTI3NzQz_f0653ebc-5258-46c7-bd0c-b41ce413b32f">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzY4ODI_b2538625-e132-41df-b3ff-6e0696e87191">1.1</ix:nonFraction> million from the exercises of <ix:nonFraction unitRef="shares" contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzE3MDQyNDMwMjg1ODQ4_5c41e71d-53c9-4a9e-9cb4-ba4980643690">1.6</ix:nonFraction> million 2018 Warrants and <ix:nonFraction unitRef="shares" contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzE3MDQyNDMwMjg1ODY2_32a13328-c767-440f-8b94-7d7a6f124ba6">0.5</ix:nonFraction> million 2017 Warrants.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Modifications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i1d313d2300ce41b6a98f9d81b1bff38f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzc2ODI_a0c53eb4-adfe-4204-a6ca-b08e86aa9328">1.1</ix:nonFraction> million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzgwMDM_1d5c3655-8171-4437-8dda-543569741cf1">1.1</ix:nonFraction> million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="id470afa5cc9848b2a4b4f535d4b6c1f0_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg4MTI_1cc293e3-8973-4028-abc7-de95552be397">1.20</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i4ec6e4d46e284f0594c5222b5698833c_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQzOTgwNDY1NjY1ODA_ffa3ef42-1aa7-4fa3-a8c4-da265355ee9f">0.60</ix:nonFraction> per share of the Company's common stock, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg4ODc_72ddfcca-3acf-4e2a-8bfc-2b08fe51aac4">2.0</ix:nonFraction> million from the exercise of <ix:nonFraction unitRef="shares" contextRef="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg5MTE_2d2b27ac-860a-4ff6-b756-555d199675da">3.4</ix:nonFraction> million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $<ix:nonFraction unitRef="usdPerShare" contextRef="i1f9a990e22cc41d8af941ad8a743ae8d_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzkxNTI_1291e85c-1290-4c08-9f0f-80e65f007714">1.20</ix:nonFraction> to the lesser of (a) $<ix:nonFraction unitRef="usdPerShare" contextRef="icc016955920f4e64b8ed1852c953e88a_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzkxNzY_0f0aa094-14f6-4dd7-8759-3a82218dbc7e">0.95</ix:nonFraction> per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $<ix:nonFraction unitRef="usdPerShare" contextRef="iae3ad21e639847039d2f1b31b55bc122_I20200630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQzOTgwNDY1NjY1ODg_31e1df23-6a93-4a34-b93a-f7b1748dd031">0.55</ix:nonFraction>; as such, the Company recognized a deemed dividend of approximately $<ix:nonFraction unitRef="usd" contextRef="i0db3ec5f4dbd471f8ba45bdc77ad6b70_D20200101-20200630" decimals="-5" name="sesn:OtherDividendAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQyNTg_9a954fc7-9d2f-401c-94ff-40b2929f859f">0.1</ix:nonFraction>&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' (Deficit) Equity. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than <ix:nonFraction unitRef="number" contextRef="i1dda2c9095f1418e975214cb9c010492_D20191001-20191031" decimals="3" name="sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwMjM1_b799e79d-f1b9-4df3-b4c4-87f31d62e20f">50.1</ix:nonFraction>% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTUy_ad7ff1da-ba2d-46c5-8ee6-4bf9607c3cf0">0.80</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTU4_2793cb63-ab65-4ca2-b28f-b778369ea774">0.55</ix:nonFraction> per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $<ix:nonFraction unitRef="usdPerShare" contextRef="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExMjQ3_9073db12-96ee-4d9e-a540-ac65ed7cb195">0.80</ix:nonFraction> to the lesser of (a) $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExMjcx_6f8cc366-09b6-4939-8583-570c45bef617">0.55</ix:nonFraction> per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December 31, 2021, there has been no adjustment to the exercise price of these warrants.</span></div></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_115"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90ZXh0cmVnaW9uOjg5NjhlNzM5ZjM2MjQzMWViNjE0ODY2ODg0MDZhMGI3XzI2NTI_0de47367-445f-4cf0-b1cc-3fd8c4b9543b" continuedAt="i7b551d63c02d438fabcadf0aad1ace39" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i7b551d63c02d438fabcadf0aad1ace39" continuedAt="ic65ea764bd7b4097b98b96e9e43d299d"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ic65ea764bd7b4097b98b96e9e43d299d"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method was not applied for the twelve months ended December&#160;31, 2021, 2020 and 2019 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90ZXh0cmVnaW9uOjg5NjhlNzM5ZjM2MjQzMWViNjE0ODY2ODg0MDZhMGI3XzI2NTM_17f75c07-f177-4cae-8a58-5d989d57f860" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&#160;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:53.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i150fe7eff7ea4fdb9a21acd3372500e8_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItMS0xLTEtMjc3NDM_39a0808f-c9d2-42f1-991b-cbc252ad0fb9">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5156f45bd4749bab08cc813bedda252_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItMy0xLTEtMjc3NDM_e76a5d14-38e6-44ad-8d7a-457737977b18">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if90f693a8f7e416ba3582374b0255711_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItNS0xLTEtMjc3NDM_2909ea05-d786-4317-b624-39325a9fa0fe">22,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMS0xLTEtMjc3NDM_08d38973-b036-4532-8535-f59d6eed6280"><ix:nonFraction unitRef="shares" contextRef="ifc1156bb975047729b334bf2e3fa2fc6_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMS0xLTEtMjc3NDM_2cb9d910-4172-4a92-9f7e-16207187cdaa">15,703</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMy0xLTEtMjc3NDM_dafa9df4-9ca2-435c-91ec-c63628a4731b">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica1ef2678e204ea598c3a695c7bf3daa_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtNS0xLTEtMjc3NDM_af73c356-a304-4f6e-8966-302801591b55">6,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtMS0xLTEtMjc3NDM_ffa71af8-7574-4c20-a6f8-b6c8ffb594b1">15,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtMy0xLTEtMjc3NDM_e4d017ca-379f-48ca-8788-261f3bb5852c">12,394</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtNS0xLTEtMjc3NDM_b16b51bc-d679-47ec-bdfd-2e0addd079a1">29,131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_118"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTU_b27d7d5c-6561-442c-b226-22dd2b03cc22" continuedAt="id1dda67426ed4fd1b6959c2404bbe51b" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="id1dda67426ed4fd1b6959c2404bbe51b" continuedAt="i776285e607dc44d9b8d67e368ce989ca"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTE_357bbcb8-85d6-41a2-a41d-b4d589ef2c05" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItMS0xLTEtMjc3NDM_337bb4a4-5e78-4570-900d-22177a44ccb9">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b84bfa887d467f8571564e41e8618e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItMy0xLTEtMjc3NDM_40131021-58fb-46ff-a77f-93bb3dc55a75">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3279ce60c04cfdb6610631e4f95328_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItNS0xLTEtMjc3NDM_78d72139-f29c-44b9-91d3-1908cb1ff2de">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6966455303f44235a15aa41b9bdb897d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtMS0xLTEtMjc3NDM_233ec184-4205-404e-b0e0-c8602953579e">4,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8dfe926ee5f4392a3f17922b1910370_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtMy0xLTEtMjc3NDM_bda2f461-dd85-4b3b-9e50-b93abbbd4ed9">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33db38ac6691417da69866ecf8c6be7e_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtNS0xLTEtMjc3NDM_cf34d716-cfe8-4db9-b7fb-075db583b612">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtMS0xLTEtMjc3NDM_633b37c4-85dd-4e12-9513-3bb766bdce0a">5,143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtMy0xLTEtMjc3NDM_7d1a2ff3-adaa-4eae-a67d-d3e15f55c371">1,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtNS0xLTEtMjc3NDM_3e7ce7b9-480e-40ae-aaa3-11e79164b199">1,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <ix:nonFraction unitRef="shares" contextRef="i3155b0a68be6497d8886c0858eccfe59_D20190601-20190630" decimals="-5" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5NTM_7f397d5d-fd56-4455-a781-aa5cf2216c07">7.9</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by <ix:nonFraction unitRef="shares" contextRef="i9b59ed3d58ff421abae5edfb38249ce6_D20210501-20210531" decimals="-6" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5Nzc_1faa14ff-51ff-4546-a461-cb0bc6c9f11f">12</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <ix:nonFraction unitRef="shares" contextRef="ie05ac20284034cf78dcee6454eac36b6_I20211231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5OTM_36c99eb0-2bee-44a3-a63a-08abd1b2e085">8.9</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <ix:nonNumeric contextRef="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTE2_dda0d53f-8e02-418c-9648-50b542563c11">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="i9542ee3724344137b968a7e2f78a7249_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjkxMDY_e3a34e56-839b-4dd2-a02f-2cffbe2d36bd">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="i6565370c486e4b11b00a6d3e11fa682f_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjkwODk_ea415101-6e77-440a-bfbe-2274bac09b3d">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjg5NzM_a844a8a3-b635-44d9-95e9-f0c7ef043ab1">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="ie05ac20284034cf78dcee6454eac36b6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzMTYz_f608c282-7fb8-4e98-b36b-48376fbc2691">12.8</ix:nonFraction>&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i776285e607dc44d9b8d67e368ce989ca" continuedAt="ib4c0d1a54ea24444977605acddaa9fa5"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="id3fee83c1a8e4b838f1b1364ca7244be_I20211231" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk0ODY_5697cc46-5dcb-4e6a-95c7-7bcb2fe6d7b3">one</ix:nonFraction> share of the Company&#8217;s common stock. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1MzA3Njk_54200e50-1ab3-468c-943c-4a011f117b7d">0.5</ix:nonFraction>&#160;million for retention-related RSUs for the year ended December&#160;31, 2021. Additionally, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231" decimals="-5" name="sesn:ShareBasedPaymentArrangementExpenseOnCashBonus" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTE4_f8a0cdbb-4a94-4798-bfea-e6434cfcf962">0.6</ix:nonFraction>&#160;million in relation to the cash bonus portion of the retention program.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately <ix:nonFraction unitRef="number" contextRef="i5019c429efc54a3d939b95facb6113a9_I20211231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk1MTQ_84d6940c-d869-4b0f-9fd3-b45c6a765963">fifty</ix:nonFraction> percent of current base salary. Each PSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i5019c429efc54a3d939b95facb6113a9_I20211231" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk0OTQ_d1812718-027e-4b3c-9601-09947a368e6b">one</ix:nonFraction> share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As none of the retention milestones were met in the year ended December&#160;31, 2021 and achievement was deemed not probable, the Company did not record expenses for retention-related PSUs. As of December&#160;31, 2021, the unrecognized compensation expense for the retention-related PSUs, granted on October 1, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i7f275e89a3774f7cbca3fb8965e7a354_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzNDE0_0e54b0c3-fd3f-43ee-bbe8-b8adb21be1d4">0.4</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTA1_7f0bb4b7-f92b-4b90-bb0a-134cdf78c1a2" continuedAt="i3f3f7245d55f4e5c997ff592b6019f64" escape="true">A summary of the status of restricted stock units is presented below: </ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i3f3f7245d55f4e5c997ff592b6019f64"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"></td><td style="width:75.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75020eb264af4e39a21665962a79801e_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzEtMS0xLTEtNDk4ODc_0af45ba9-406e-4a90-85da-ed259cb407a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzItMS0xLTEtNDEyNTE_ad38eb0f-e78b-4d24-ad20-91465f17c271">2,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzMtMS0xLTEtNDEyNTE_92847b98-fede-4836-991b-512ca3b9f43e">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzQtMS0xLTEtNDEyNTE_56772896-3e55-466f-b924-dedd6bd06979"><ix:nonFraction unitRef="shares" contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzQtMS0xLTEtNDEyNTE_d80264ab-c6f1-432d-8ba1-4fc5db1e7474">3,041</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual life of unvested RSUs and PSUs as of December 31, 2021 is <ix:nonNumeric contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1NTA3Njc_1c50baf7-8259-4358-97fc-383961d622dd"><ix:nonNumeric contextRef="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1NTA3Njc_3d5b5c3f-0d63-4510-a5d1-3a733e187fbb">9.75</ix:nonNumeric></ix:nonNumeric> years. The Company did <ix:nonFraction unitRef="shares" contextRef="i30373a67e51d44d48f81e5dc9200383a_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTMx_41193f40-646d-48d3-82c4-a484608e1b8b"><ix:nonFraction unitRef="shares" contextRef="if99964945ffc46049f3cdcd6ac3fa481_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTMx_89bd10bc-200f-49ca-a17a-c27214aa05a4">no</ix:nonFraction></ix:nonFraction>t grant restricted stock units during the years ended December 31, 2020 and 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of <ix:nonNumeric contextRef="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzExNTY_4d6a45b1-b542-4bf2-892d-bb500b4edec8">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzExNTk_6dd553a0-c5ee-402b-a919-c45d33571c02">0.1</ix:nonFraction> million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <ix:nonFraction unitRef="shares" contextRef="if520d25ca9304b37b3cf574ce10e6659_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzIxNjU_57055c67-cc86-4818-af1c-6d59c8b43fb6">2.8</ix:nonFraction> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTI_19016efd-c1b8-4ac8-8179-78e19a38ed25" continuedAt="i6fc290ed65e546fca5fbd0f61fa139aa" escape="true">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2021, 2020 and 2019:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib4c0d1a54ea24444977605acddaa9fa5"><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i6fc290ed65e546fca5fbd0f61fa139aa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:41.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtMS0xLTEtMjc3NDM_4fb695d8-f96d-432b-bdb4-8116f61acbdd">3,942</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtMy0xLTEtMjc3NDM_af5a338a-5672-46b1-b946-f9bc81ba9069">2.12</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i04ad27b86d2646489f5ab053b12babde_D20180101-20181231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtNS0xLTEtMjc3NDM_c1af431e-c713-46cb-b3f4-03de97517791">9.14</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtNy0xLTEtMjc3NDM_946d63df-3b2f-4a9b-8a09-1abb6ab3a5e7">57</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzItMS0xLTEtMjc3NDM_72c04cd1-c468-436c-934a-700911e575d6">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzItMy0xLTEtMjc3NDM_d3b3cf70-d72c-413e-b1c2-b5ca851d10f0">1.02</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzMtMS0xLTEtMjc3NDM_584c1449-a173-4e86-965c-5eb271ff6357">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzMtMy0xLTEtMjc3NDM_7e0d9c39-c378-4032-af62-6152d71b3730">1.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzQtMS0xLTEtMjc3NDM_bb8d0f39-4f50-45f0-b2ca-e7535b38223f">1,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzQtMy0xLTEtMjc3NDM_afa21597-1064-43d5-a903-66e7a8ed164f">1.78</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtMS0xLTEtMjc3NDM_66cbf305-e0ef-427c-8021-e5ec776b7e3b">6,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtMy0xLTEtMjc3NDM_b9c521cd-7545-45da-91c0-62797951edf3">1.52</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtNS0xLTEtMjc3NDM_b48fde18-61db-4058-8b6f-9333c5a4800b">8.83</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtNy0xLTEtMjc3NDM_4cc96530-aa66-4f10-b59a-daf0fda028db">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzYtMS0xLTEtMjc3NDM_4b3841e4-d52f-4008-83a9-832fd0195c77">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzYtMy0xLTEtMjc3NDM_16d92292-6fe3-4122-af15-7130fb390083">0.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzctMS0xLTEtMjc3NDM_f2a9282c-51e0-4d92-ad77-f5ea652a117c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzctMy0xLTEtMjc3NDM_4e6c5364-1148-45b1-b441-6a965e9dd9bf">1.13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzgtMS0xLTEtMjc3NDM_bc2d3678-803a-4dfb-ad69-561685710fa7">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzgtMy0xLTEtMjc3NDM_c31b0853-16a8-4b93-8ee0-14860c31b5d3">1.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktMS0xLTEtMjc3NDM_11066062-e3db-45ef-95bd-de78ce7a14ae">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktMy0xLTEtMjc3NDM_12e67679-3e50-4533-a5a8-53d867e6854d">1.26</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktNS0xLTEtMjc3NDM_2176f3a1-16e3-4663-8089-777ad18ae62d">8.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktNy0xLTEtMjc3NDM_2a51f7c8-8320-44ba-a7ef-2351ea17524e">3,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEwLTEtMS0xLTI3NzQz_5fbfe593-ba80-446d-898e-667aab23d766">8,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEwLTMtMS0xLTI3NzQz_050d040f-73e9-4af7-9aa9-65dd15e4cc3d">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzExLTEtMS0xLTI3NzQz_5981ec71-4c8f-43d5-9e55-50dea1c0e5f8">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzExLTMtMS0xLTI3NzQz_0d078480-c179-45c8-b0d7-cde184a61258">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEyLTEtMS0xLTI3NzQz_61343905-a4eb-48a5-ad99-cf11f75d7a0f">2,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEyLTMtMS0xLTI3NzQz_22ea50e1-5302-4425-b3ab-e6fe21e5d1b4">3.70</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTEtMS0xLTI3NzQz_8ea95c32-8a3d-4175-810e-2295d18d848e">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTMtMS0xLTI3NzQz_4a09f860-8337-45b6-9981-483726e727b6">1.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTUtMS0xLTI3NzQz_9ff0ac61-c10b-49e2-81d4-3d9062f49e70">8.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTctMS0xLTI3NzQz_d7b14e7d-0431-4818-a98e-0fc70df2494d">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTEtMS0xLTI3NzQz_48d8c939-c9cc-4f20-9a62-36b8327d683b">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTMtMS0xLTI3NzQz_2aff1d20-bdb3-45da-8e13-380f8baf8d12">1.65</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTUtMS0xLTI3NzQz_e89ec540-10a7-4681-bed9-7e598477d0a7">7.41</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTctMS0xLTI3NzQz_621d72b9-fdb2-4448-9ab2-22349e84cb52">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzMTc3_54ef698f-abba-4e89-bb7d-fb71f8ea83ea">5.1</ix:nonFraction>&#160;million for the year ended 2021. The stock option related expenses were</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NDU_02263348-6907-486d-b8de-b16e19ec44fc">4.6</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NTI_8557f087-3ae3-4b3e-a899-55b265425390">1.8</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NjA_da286c26-cc58-4032-854d-74a7795db2c6">1.2</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the years ended December&#160;31, 2021, 2020 and 2019, respectively.  The RSU related expense was</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NDc4MDIzNjY0OTQ_54200e50-1ab3-468c-943c-4a011f117b7d">0.5</ix:nonFraction>&#160;million for the year ended December&#160;31, 2021. The Company did <ix:nonFraction unitRef="usd" contextRef="ia6a7749193cc45fc901d310757b0a9ff_D20200101-20201231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzOTg3_3db97a04-1c97-4468-a8c9-f9a48116feef"><ix:nonFraction unitRef="usd" contextRef="i65d8a19fb4244ecfaa96a4eff824e050_D20190101-20191231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzOTg3_a79266fa-2bfe-480e-8dcc-3093a85e8f0e">no</ix:nonFraction></ix:nonFraction>t record RSU related expenses for the years ended December 31, 2020 and 2019.  As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5Njk_c67aff2a-a40e-489d-ae65-a75a81234de9">10.4</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NzY_169da346-0358-46d5-b2f0-deab461a4e4a">2.7</ix:nonNumeric> years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTA_969a9284-3480-41de-8c6a-403507a2648e">2.16</ix:nonFraction></span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTQ_beb476de-a8eb-4189-8f0b-44e1d2f94987">0.56</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTg_30313e36-e370-41d6-ad0c-a8b3a2fd9b14">1.02</ix:nonFraction>, respectively. The total intrinsic value of stock options exercised for the years ended December&#160;31, 2021, 2020 and 2019 was de minimis.</span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NDc_19a2bfb9-873d-4103-a765-22711de56d68" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItMS0xLTEtMjc3NDM_65efe2c0-9add-42c6-944a-6828b471a122">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItMy0xLTEtMjc3NDM_aac145aa-6d15-47f0-b1a8-9bd22a6e3d8f">0.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItNS0xLTEtMjc3NDM_686a18d6-f807-471c-9c89-1086046fddb9">1.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ifc1156bb975047729b334bf2e3fa2fc6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtMS0xLTEtMjc3NDM_2185f3ea-22f8-45c6-ae81-77a4951cfe8a">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8645ab0e887d4a8bbf9664668f155fb6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtMy0xLTEtMjc3NDM_61c50b18-69b6-492e-af9d-537d4c21c75c">0.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i558d72c250fc4f3bb70e9309cb978078_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtNS0xLTEtMjc3NDM_4400ccfa-7208-4d06-8cd7-6484d8473ec5">1.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtMS0xLTEtMjc3NDM_8ae8262e-af93-4e14-9f8e-b0f80eacdbb6">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtMy0xLTEtMjc3NDM_c51e0daf-bcc2-42f4-ac46-40e824f0502f">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtNS0xLTEtMjc3NDM_0c9f6813-25a6-4e06-b3dc-6b4288c96255">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtMS0xLTEtMjc3NDM_ad46d9db-4f64-4db4-a568-7ae41b8394d6">0.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtMy0xLTEtMjc3NDM_c822a83e-fdad-4b87-a63e-ad694d82bab7">1.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtNS0xLTEtMjc3NDM_39191ac1-e412-4e5c-afdc-94d184d17a64">2.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtMS0xLTEtMjc3NDM_24708e79-e564-4aba-8461-8ed11561df42">74.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtMy0xLTEtMjc3NDM_62e4abfd-6f9e-419e-b0f3-491027340377">71.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtNS0xLTEtMjc3NDM_3415844d-410f-40d4-9b84-e0db664eeda2">78.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctMS0xLTEtMjc3NDM_48bb6acb-62b0-4bcb-b470-110abd404332">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctMy0xLTEtMjc3NDM_32887a4c-0702-4a30-afe9-b108b9c01861">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctNS0xLTEtMjc3NDM_98d729b7-d032-4a41-b423-79ba1ce5f540">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_124"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzI1MzU_1acd523e-d03f-4ae4-8b72-49ebc072b126" continuedAt="id037bb6e1d6f49eea4a63c5839ace616" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="id037bb6e1d6f49eea4a63c5839ace616" continuedAt="i0865547a51b040c5ab940904418c632f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <ix:nonFraction unitRef="shares" contextRef="i3408800d9ca34cbc9107500cccfb1efe_I20140228" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3MTI_8a2b1789-e134-492e-93d7-c1991ae1ce3b">0.2</ix:nonFraction>&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <ix:nonFraction unitRef="shares" contextRef="i19aa28ed63b64ecf8600a587af11639c_D20210501-20210531" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3Mzc_f08fafb3-79e5-407a-aec4-e3b044fe6fa8">2.3</ix:nonFraction>&#160;million the number of shares of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i0865547a51b040c5ab940904418c632f" continuedAt="if7ef32e3383640afa3cba130cd0ba6d4"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="i2265e9372ef14f33a95d480831dcfd36_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3NTQ_e9b22e89-c96d-4d10-b07f-4e4cee2c956f">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i256cad603adc478fbe2bb635d926f6d6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNTgyNzI_065af96b-282d-4303-b6cf-3ac6cb798501">2.3</ix:nonFraction>&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzE3MTM_e5affa62-7f28-4b8b-b2a0-b737eba59473">100</ix:nonFraction>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231" decimals="INF" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzE5MTI_8dd89fb0-95ca-4c20-8dec-e499164ff2e8">4,000</ix:nonFraction> per year. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if7ef32e3383640afa3cba130cd0ba6d4">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <ix:nonFraction unitRef="number" contextRef="i0714416d3dbb41bf905d3f30d60053a9_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIzMjM_935adc23-ae41-4405-878a-1d3b224b8b66">4</ix:nonFraction>% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2021, 2020 and 2019, respectively.</ix:continuation> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_127"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDA_c1e9a30a-afbc-45ba-a0fc-60ac00ae8d67" continuedAt="i9d6dfe31336d4d0cb61126d6db57e607" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i9d6dfe31336d4d0cb61126d6db57e607" continuedAt="ie06b98247c834fe3ac6e071b75f415cb"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NTU_56a7f71b-5213-4c34-87e2-c41eea4cf7c4" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b01c3a7a584c8c83ef29c8a5d2f83b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtMS0xLTEtMjc3NDM_d0b88f1d-b196-40fe-b671-673259e43c64">32,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cc2b6152b3a498aa18f90d825cf3988_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtMy0xLTEtMjc3NDM_5a88f9f5-4570-4f81-9b4f-766d56dd0bcc">35,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff556de6a08542a29c8cf9c6757a93ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtNS0xLTEtMjc3NDM_fab755ec-12ab-4abb-b378-eea07439def0">27,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtMS0xLTEtMjc3NDM_58ac6779-1629-4b0f-bbbf-f1bc84902577">24,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95faf853daed44049bbacea1c98c9719_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtMy0xLTEtMjc3NDM_beb33a98-ba3f-4602-b167-6cbdb0f65479">14,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fac383649084445a8d938fea7593c9f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtNS0xLTEtMjc3NDM_026e35c2-ef0c-456d-aa8a-121cc4502e5b">80,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtMS0xLTEtMjc3NDM_cef87955-0aef-4804-bdb6-9df1892e6f8d">8,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtMy0xLTEtMjc3NDM_ccaf83a0-53e3-4af2-b20b-e6c0a127e290">20,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtNS0xLTEtMjc3NDM_360e8447-7a24-402a-ba82-2fa2e552165d">107,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NTI_b7c8d363-1535-4b96-9941-83e3f03a010a" continuedAt="i9dfd9a285a75457b834bbb00e1fe90e8" escape="true">The Company's tax benefit (provision) is comprised of the following components (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ie06b98247c834fe3ac6e071b75f415cb" continuedAt="ib1263224392d42b092e54e778898fc96"><div style="text-align:justify"><ix:continuation id="i9dfd9a285a75457b834bbb00e1fe90e8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtMS0xLTEtMjc3NDM_8a891cfb-ca83-4865-912b-34b10cba0b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtMy0xLTEtMjc3NDM_84fef57f-e223-4640-94f4-fc93e824732a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtNS0xLTEtMjc3NDM_dc5e317b-7132-4830-9d43-3c130a7280d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtMS0xLTEtMjc3NDM_ddbb4f2a-2192-4625-b2e6-79c88acb4f5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtMy0xLTEtMjc3NDM_a15318a3-23bd-4f50-8dde-134ea677e873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtNS0xLTEtMjc3NDM_97d3c3ec-bbc7-471b-a125-f045072a222c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtMS0xLTEtMjc3NDM_fbd78772-6c1f-416b-971e-cb6f6140baa2">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtMy0xLTEtMjc3NDM_78a574d5-c94e-49f1-82bd-0d5127ecd8e2">1,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtNS0xLTEtMjc3NDM_d67ab485-e165-4644-b2ca-261232240b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtMS0xLTEtMjc3NDM_80d62ff3-6801-401b-95e6-56a2180b9197">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtMy0xLTEtMjc3NDM_69758ab0-aa75-4ac2-b736-930a6d3432ca">1,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtNS0xLTEtMjc3NDM_12ffa86a-70b9-46b8-bb2c-9e9bc071855c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtMS0xLTEtMjc3NDM_e85d1a07-2b1a-40e7-960c-931099bece97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtMy0xLTEtMjc3NDM_7d92c272-6860-401a-b32b-27ff42bf2b47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtNS0xLTEtMjc3NDM_30a0fd62-b98c-4923-9c95-80aefc1e8c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktMS0xLTEtMjc3NDM_8def22d1-3a63-43af-9b33-41961b439850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktMy0xLTEtMjc3NDM_80199037-1932-431b-97d3-48ce2aa93b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktNS0xLTEtMjc3NDM_09f5d096-5b26-4602-990f-9878adb9c4cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTEtMS0xLTI3NzQz_7800ab6a-5beb-4011-8f34-26c4d2133a57">8,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTMtMS0xLTI3NzQz_0e8b000e-cad0-40fa-b32e-d17ac845c983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTUtMS0xLTI3NzQz_ad773e5c-de13-429b-9399-8172e5e03333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTEtMS0xLTI3NzQz_2b3875ee-08c2-4164-83a7-a22438219db9">8,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTMtMS0xLTI3NzQz_36b52200-ad3e-43f9-a193-3400eea39022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTUtMS0xLTI3NzQz_1ea73fe4-96f2-4b70-951e-f743f9a2401c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 73pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTEtMS0xLTI3NzQz_e0747521-e657-4024-aaa4-d3f11b4f50b6">8,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTMtMS0xLTI3NzQz_c91fa86c-ec1c-4a96-a62d-d6ef59591251">1,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTUtMS0xLTI3NzQz_11e4feb4-0c7f-4439-a6df-33a17d11cee9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record current or deferred income tax or benefit for the year ended December 31, 2019.</span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDU_d9672778-2601-45cd-bd19-4fc992eaf06d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItMS0xLTEtMjc3NDM_190197df-b2b5-4796-a587-5156eeb161ae">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItMy0xLTEtMjc3NDM_10a44062-16ba-4961-8d32-649503ad755d">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItNS0xLTEtMjc3NDM_5b062622-f62e-4d40-bcd4-41e692564b32">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtMS0xLTEtMjc3NDM_64ea8c05-6c46-4a0c-9014-e3c2421e68e8">15.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtMy0xLTEtMjc3NDM_25aa62fb-84b4-4e5b-95b2-254df64c596a">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtNS0xLTEtMjc3NDM_c8db928a-0a05-47a2-a028-a4804baf3cbe">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtMS0xLTEtMjc3NDM_412fe960-fb48-4672-93c9-e0b4c6c04c54">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtMy0xLTEtMjc3NDM_789763d8-a001-46ba-bc4e-d3f9d094dc2a">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtNS0xLTEtMjc3NDM_aceb3015-d23f-442d-8909-e34e97f77309">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtMS0xLTEtMjc3NDM_b040c9d6-6445-4847-9bea-58515b221b10">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtMy0xLTEtMjc3NDM_fd490530-2667-409c-a99c-4f6f468a920c">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtNS0xLTEtMjc3NDM_7e13a3fe-b8d4-45fa-bb63-8d8f1a9ae8db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtMS0xLTEtMjc3NDM_23135495-964d-41b8-9769-92c774615620">178.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtMy0xLTEtMjc3NDM_edbc5082-c9ea-4f5e-a469-31f611309b06">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtNS0xLTEtMjc3NDM_1bc2f351-1e86-4d99-bcf1-1647a83b449d">18.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctMS0xLTEtMjc3NDM_08aa8c70-65b6-4112-a167-46196ebc9c48">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctMy0xLTEtMjc3NDM_3f56cc69-599a-47f9-9306-4b6c67b4f9ee">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctNS0xLTEtMjc3NDM_bcd8eef6-c4e0-48e6-a801-92437734fd73">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtMS0xLTEtMjc3NDM_3d9bd497-1917-465b-b6fd-dac07214d9b8">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtMy0xLTEtMjc3NDM_739adad7-61ed-48bd-9fea-3d61807d6b7a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtNS0xLTEtMjc3NDM_966ffbce-25db-47ff-9a20-c2e0538a53f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktMS0xLTEtMjc3NDM_098685b1-a2d8-4bf9-9044-6e93e3d50e89">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktMy0xLTEtMjc3NDM_a928c3c8-3c16-48d8-a249-5d81cf3c79db">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktNS0xLTEtMjc3NDM_482f0ea3-fd94-473e-9f2c-96d767bc3f24">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTEtMS0xLTI3NzQz_044ca513-47c0-482c-a587-6676d1755255">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTMtMS0xLTI3NzQz_9812ad41-03ae-4908-b4b9-fa95f5331818">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTUtMS0xLTI3NzQz_2aa965d7-250e-4da7-8892-319fc2cb01c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTEtMS0xLTI3NzQz_989248c7-8812-4080-9f72-2263528d9252">72.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTMtMS0xLTI3NzQz_5f202e7d-2276-49dd-8f72-c39963d566a1">37.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTUtMS0xLTI3NzQz_f71fb798-07df-4b5d-823f-443443cc2483">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTEtMS0xLTI3NzQz_53ee16e9-0377-4aa2-b0ee-18aef786c200">96.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTMtMS0xLTI3NzQz_b10c5702-a11d-4bff-8d9c-d6df5218944d">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTUtMS0xLTI3NzQz_f0acc336-a0e3-47da-9a62-35f21a7641c4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1Mzk_02fd80eb-6420-4c13-af65-a657fac522cc" continuedAt="i6d92ae806c3b4deeabc725e927fb8d7b" escape="true">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib1263224392d42b092e54e778898fc96" continuedAt="id29b3ee7b7084e5f94a0c90e8b369c3d"><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i6d92ae806c3b4deeabc725e927fb8d7b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtMS0xLTEtMjc3NDM_41874ceb-eae2-4218-a32e-95c60caec2ca">63,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtMy0xLTEtMjc3NDM_a7d387fe-ded0-4613-9eaf-9508c6834ae9">57,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtNS0xLTEtMzMwNDc_899a12a1-de4a-457a-8bbd-22b898f40cca">50,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtMS0xLTEtMjc3NDM_b7b4a9c7-c67e-4116-a6d7-62dd967131d0">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtMy0xLTEtMjc3NDM_3574bfd8-e83a-4127-9334-abf786633bc4">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtNS0xLTEtMzMwNDc_1ea65883-ab00-4298-b2c9-d77229592c13">4,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtMS0xLTEtMjc3NDM_c5505b89-d677-4611-a567-aa3d05d72077">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtMy0xLTEtMjc3NDM_3b5dfabf-c900-470c-907c-e1c153f8369a">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtNS0xLTEtMzMwNDc_9407d777-17a9-4884-b13b-b6662b34c554">2,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtMS0xLTEtMjc3NDM_523ffd9a-9132-4ecf-9fd1-0ee590dbf0f4">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtMy0xLTEtMjc3NDM_ccfaca49-8352-4244-abee-a856494f80d9">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtNS0xLTEtMzMwNDc_e43507d6-7bba-4959-b906-438f698303a9">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctMS0xLTEtMjc3NDM_477313b8-6e45-4303-ac3d-c591d64cd756">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctMy0xLTEtMjc3NDM_61ef5f1f-4b57-4b87-80ef-80b57b54767e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctNS0xLTEtMzMwNDc_283ad6b9-8772-43f6-8e4e-a3c3bc3fe2e7">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtMS0xLTEtMjc3NDM_fc760acb-bc0a-4e2e-9ce9-0343ed2f0a05">71,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtMy0xLTEtMjc3NDM_e59a37ce-2adc-4be5-9f1a-f286935dd616">65,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtNS0xLTEtNTAyNzg_ffbc12e5-d8d3-4995-8a63-d9da7bd2e183">57,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTEtMS0xLTI3NzQz_a9bac230-a183-490a-88c0-89452a0c7ec5">3,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTMtMS0xLTI3NzQz_534be684-7626-4de0-814e-f598b3a87e02">12,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTUtMS0xLTMzMDU4_4e60731a-9274-4b17-83f6-4f0711d99018">12,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTEtMS0xLTI3NzQz_95d4d839-52c8-4be8-998a-141bae1b4144">3,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTMtMS0xLTI3NzQz_ae61da26-5608-419a-aecc-3524673e7391">12,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTUtMS0xLTUwMjc4_b7ec587a-925d-4823-ae85-c8152750c983">12,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTEtMS0xLTI3NzQz_4665cd25-79e6-4131-8c1c-55964adfa678">71,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTMtMS0xLTI3NzQz_21e4ba14-f6d8-4ec5-b7f6-76ac61788979">65,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTUtMS0xLTMzMDY3_02c21fe3-80e9-4065-9b5c-bd2680c86274">57,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTEtMS0xLTI3NzQz_eebc79b5-61c8-4657-a985-6e3e9d14de50">3,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTMtMS0xLTI3NzQz_c464b6f9-efe6-42fe-a56d-15d368c042e6">12,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTUtMS0xLTUwMjc4_285c2812-1ee6-4b87-a44d-3846b74a0482">12,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;D credit carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjQ1_ab6395b8-a28b-4d91-8256-7eb7d0fd0734">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjYz_3f12769c-e720-40dc-aace-b94e08354012">65.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjgy_5158db8a-53ee-4a3e-8ed9-1a5aec83554e">57.7</ix:nonFraction> million have been established as of December&#160;31, 2021, 2020 and 2019, respectively.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzIxOTkwMjMyNjU4MDA_1e9d7313-0f76-4413-a2dc-f7695627d438">6.2</ix:nonFraction> million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzIxOTkwMjMyNjYwNTI_cea191ea-b59d-40f3-8a5d-9faa8a503a35">4.0</ix:nonFraction> million primarily relates to the potential future impairments or amortization associated with IPR&amp;D intangible assets, which is not deductible for tax purposes and cannot be considered as a source of income to realize deferred tax assets. As a result, the Company recorded the deferred tax liability with an offset to goodwill.</span></div><ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDk_4d0c8547-28ca-4a15-b648-5be74c0f54ff" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b0f304a6e34b6abcd67c26db8d37c6_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzItMS0xLTEtMjc3NDM_c31aadf1-0c5c-48fd-b2a5-adb50833094d">101.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6573654cd29340309dbe2c811248a720_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzMtMS0xLTEtMjc3NDM_19f9014d-f263-4b14-9a65-acbfcad7ab22">118.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda208642281438089144b87cd645d8d_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzQtMS0xLTEtMjc3NDM_a7d1c543-85f2-4385-b0ae-5b59de8aa431">138.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6b0fe41f5b4f79ac97691814a89591_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzUtMS0xLTEtMjc3NDM_4b4fe745-bfab-4a63-8a9f-d277d1268af3">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia696bc1cbc724e098ee3bd580cfb8b6c_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzYtMS0xLTEtMjc3NDM_840d4a5b-2ab7-492b-967b-3108c426e2f8">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24bd2e4f3be4ae1b8b83df732484432_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzgtMS0xLTEtMjc3NDM_0ba1f4a2-0f92-4028-a68f-37a4c406b17e">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb901b4a5ff4839828a1c82f4bea528_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzktMS0xLTEtMjc3NDM_f4154d1d-5dd4-4304-9477-f47f323d2f29">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878819bdb7ce45d78433cd5efbbd8d27_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzEwLTEtMS0xLTI3NzQz_75a83bcb-e450-40e8-9e1d-3e46323f406f">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="id29b3ee7b7084e5f94a0c90e8b369c3d"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $<ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="sesn:OperatingLossCarryforwardsDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzMxMDA_1ad8ccbf-ee8a-44de-be95-eedf2d2dc2b1">0.8</ix:nonFraction> million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2020 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.</span></div></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_130"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="sesn:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE4NTUx_b4367986-203d-448d-925a-3ee61b44e866" continuedAt="i7fe10af9fd2b46b9b3c69fdc0d909869" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i7fe10af9fd2b46b9b3c69fdc0d909869" continuedAt="i1dbfe7e2606e4d6d82567aaf4bf8b568"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i996be0ab5ebb4bf2948b029b33aae0b8_D20210101-20211231" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NzA_46b31acb-b551-41cd-80c9-e4b589c121f3">0.5</ix:nonFraction>&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a <ix:nonFraction unitRef="number" contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NTM_45f33d60-a3f1-4a64-bb15-2e455f0a33dd">4</ix:nonFraction>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <ix:nonFraction unitRef="number" contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2ODg_390dca06-1e02-46f7-ac3a-532899a7f600">10</ix:nonFraction>% or greater, provided that the royalty rate to Zurich may not be less than <ix:nonFraction unitRef="number" contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NDY_7f96f067-e986-469f-a207-09bbcba12dd7">2</ix:nonFraction>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc3MDY_1fca1d71-03f0-43d3-b25d-96df5de59886">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i810bedfc811b413cbc1b773410810321_D20200101-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5MzA_159be6b0-12fc-4c9e-882a-c7eb53e2758c">0.3</ix:nonFraction>&#160;million related to achievement of a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the year ended December 31, 2021 and 2020, respectively, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the twelve months ended December&#160;31, 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2021, the Company may be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODI5ODk_91bada3f-85b0-4bb1-a883-3395c6570f91">2.4</ix:nonFraction>&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<ix:nonFraction unitRef="usd" contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5NzY_ef474ea3-46a2-441b-9387-f6bf8cae4e08">2.7</ix:nonFraction>&#160;million at exchange rates in effect on December&#160;31, 2021). The Company is also required to pay up to a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i1dbfe7e2606e4d6d82567aaf4bf8b568" continuedAt="i4e7fcb7d37fb49a7a80e55ddc96cde95"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0Mjc_34644c48-842d-4727-b892-ab0ddb8c0cb5">3.5</ix:nonFraction>% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <ix:nonFraction unitRef="number" contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0MTY_cbd306f9-7547-4f23-9930-d2f2b1557ee9">1.5</ix:nonFraction>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;<ix:nonFraction unitRef="eur" contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="-3" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0MDE_553a1f9c-cfc5-4b5b-82a1-355703d884db">50,000</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="0" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5NjM_7b576a14-f2db-4230-a5d5-a031f245fe0b">56,625</ix:nonFraction> at exchange rates in effect as of December&#160;31, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODM5OTU_c94339fd-ea86-4eef-ad34-e707bf3e0cb3">0.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQwMDA_9e9a313e-9350-4c9b-911a-d523c14b02ed">0.9</ix:nonFraction>&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQyMjI_40612604-2ac5-4d7b-9d43-fa6ffa2c521f">0.5</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQyNDE_5da66ef8-7f45-47bb-8b32-19762fdc83a2">0.6</ix:nonFraction>&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="-4" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4NTM_3e694845-ac2f-4247-a3b1-ab579932aa05">0.25</ix:nonFraction>&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a <ix:nonFraction unitRef="number" contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4NzM_8bfaec35-cdf7-4363-9107-96c156bc28af">2.5</ix:nonFraction>% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <ix:nonFraction unitRef="number" contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4OTQ_f12511a0-b228-401f-9391-52c20ce22364">1.75</ix:nonFraction>% of net sales. In addition, the foregoing royalty rates are reduced by <ix:nonFraction unitRef="number" contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4ODM_049458ad-37f4-49a4-b5e8-7665b102b1ae">50</ix:nonFraction>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM2ODI_f8eee220-75c9-4a27-81ef-170af996ad4b">7.5</ix:nonFraction>&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAdditionalUpFrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4MjU_fabeb4df-7636-4d63-a722-adcb141a3065">262.5</ix:nonFraction>&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i7c28bbf66e0b4945bbdff22096e98ec1_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3MTE_7a252c73-f3ff-44db-a1c2-8d7006b9c5d1">197.5</ix:nonFraction>&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="i53830883489044f7a20fd0f2afe3ada7_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3NDE_ffc96ffa-a69c-4ff0-8d8c-4c468ef8612b">72.5</ix:nonFraction>&#160;million in development milestones, the next of which is $<ix:nonFraction unitRef="usd" contextRef="i536ac10f94b7496ebcf21cf333f739f3_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTY2_0ca4358e-e936-4824-a0ec-e81d2cc1a78e">30</ix:nonFraction>&#160;million for initiation of the first Phase III clinical trial, (ii) $<ix:nonFraction unitRef="usd" contextRef="i36fc4d06bbde4724b5f3f5d605df0dda_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3Njg_7a54c76d-77d0-48b3-bee2-21e200cc783d">50</ix:nonFraction>&#160;million in regulatory milestones and (iii) $<ix:nonFraction unitRef="usd" contextRef="ibf1e9a4c5180446d85e2e5552350fe42_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4NTM_c3754d4f-581b-4efc-a62f-47471ace49c9">75</ix:nonFraction>&#160;million in commercialization milestones. Additional amounts of up to $<ix:nonFraction unitRef="usd" contextRef="i672850f3381947678ce8bad19d353cfe_D20210101-20211231" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzM4NDgyOTA3NjQ2Mzk_1d9ebcd6-a6d7-418f-b633-c36529488477">65</ix:nonFraction>&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="i34be4d2750144c28965180b21ad35c2c_D20160901-20160930" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4ODA_3bc8218c-3ed1-48ef-9a1c-e5bda87f81fa">22.5</ix:nonFraction>&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $<ix:nonFraction unitRef="usd" contextRef="i58f3a5e587554717a5b2e59570cb1b71_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTc5_5a5e683b-7f7c-4fd2-8b96-ab5a9e55ed1c">20</ix:nonFraction>&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="i58f3a5e587554717a5b2e59570cb1b71_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTky_d32400c9-510e-481e-9707-846d09e54e0b">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i592275577a9d4f158b7f51ca29978045_D20210101-20211231" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjA3_d008f4a7-2870-47ea-84bc-43dab66ff329">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $<ix:nonFraction unitRef="usd" contextRef="i695006bd273747aeb95e43b893e8b867_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjEz_c5caa3f9-de7f-45c5-9f78-553872bb3834">20</ix:nonFraction>&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<ix:nonFraction unitRef="usd" contextRef="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjI2_2d6ef542-d325-488f-a8df-f4573102205b">20</ix:nonFraction>&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from <ix:nonFraction unitRef="number" contextRef="iced271cdb5d7466d9c7c148965459481_I20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5MzQ_f7c7ca7e-d344-4cb2-944e-4ae2c7d9e5b5">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i013a145bc60a457a851dd9b22eab7d0b_I20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5Mjk_74a8684e-bd01-40b9-8799-5e7fee26fe59">15</ix:nonFraction>% of net sales of potential future products containing EBI-031 and up to <ix:nonFraction unitRef="number" contextRef="id8f7872b3f9441f786d65989d956951c_I20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMDEwMjA_90106d6a-c665-46a4-ad9e-c35113548237">50</ix:nonFraction>% of these rates for net </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i4e7fcb7d37fb49a7a80e55ddc96cde95" continuedAt="ia7127aa114fb4593aba5377323c48b95"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for <ix:nonFraction unitRef="period" contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="INF" name="sesn:LicenseAgreementOptionPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjQ0_93bb2f11-7a09-42c2-b583-4513ca585c9c">two</ix:nonFraction> &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5NTg_3f71932f-22b9-4526-981f-5e332c251f30">135</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjUx_b3c7ede6-6383-4c4d-b7f7-8daad62b1e27">30</ix:nonNumeric> days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within <ix:nonNumeric contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjYw_242c3d74-1e19-4cca-8266-b82a758863d7">30</ix:nonNumeric> days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $<ix:nonFraction unitRef="usd" contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwMzA_1a5643bf-06b9-4f67-a666-1964506b79e2">265</ix:nonFraction>&#160;million, which amount would be reduced to $<ix:nonFraction unitRef="usd" contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwMDM_b404ac80-37e0-409e-8eb7-fccf4ecd4c2a">220</ix:nonFraction>&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwNTY_b2b2ec78-fcb7-4c4b-9075-bd999cfa042f">12</ix:nonFraction>&#160;million, and milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730" decimals="-6" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwODE_d340b8dc-2ba0-46cb-a41b-55e2bac12ae5">23</ix:nonFraction>&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a <ix:nonFraction unitRef="number" contextRef="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwOTg_59723fe1-4ba2-4974-a0bf-6448075ded86">12</ix:nonFraction>% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ia7127aa114fb4593aba5377323c48b95" continuedAt="i1895afb208f44db1b944149d86e034f5"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $<ix:nonFraction unitRef="usd" contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxMTc_262e8abf-7d74-4d9f-8e3a-5b4a2fde86c4">11.2</ix:nonFraction>&#160;million and was based on the up-front fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="i3854b11b1f004bb585ab8a3ed3e68622_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxNDQ_e2d6b05c-2e04-4948-a9f3-e25d67a5e374">12</ix:nonFraction>&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $<ix:nonFraction unitRef="usd" contextRef="i028e8f65759541db8dc7760918e71d52_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxNzE_0dfaecb2-6764-4ece-b2b7-c2871e090f2f">11.2</ix:nonFraction>&#160;million of the total $<ix:nonFraction unitRef="usd" contextRef="i028e8f65759541db8dc7760918e71d52_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyMDA_77615bbd-a7e0-4abf-bd69-1f3a942be962">11.2</ix:nonFraction>&#160;million transaction price was considered earned and the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i77d8a2af6cca4ab8b80ffdc3f2434161_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyMjk_daa2a2d4-348c-4c9d-8ab8-631268a96f18">11.2</ix:nonFraction>&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $<ix:nonFraction unitRef="usd" contextRef="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331" decimals="-6" name="sesn:BusinessCombinationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyODA_29fd2ff7-0b6c-4626-b08b-deacdbe2d1c1">3</ix:nonFraction>&#160;million milestone payment from Qilu, the first milestone payment out of the $<ix:nonFraction unitRef="usd" contextRef="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331" decimals="-6" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyNTY_0b8eab48-f015-4f46-8b49-8262b2aadc4a">23</ix:nonFraction>&#160;million in potential milestone payments. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQzMDU_10a7a7b6-125c-4ae9-be9b-e5e7a90abc2c">2.8</ix:nonFraction>&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i818c0861bdb74095a88cb8cfcda94efa_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjc5_d085c774-fa87-4821-ac81-c17aeaa4d9d7">0.9</ix:nonFraction>&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3fb1bcb7e3874976b1397e8d0fc3b469_D20201130-20201130" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQzODQ_3f68c78a-7438-4474-9b35-4ad312459c38">3</ix:nonFraction>&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $<ix:nonFraction unitRef="usd" contextRef="i1a168b0aa4c647e1997b38ac0934768d_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0MDk_8b590708-a3cd-4c21-be67-4305183b45cc">1.5</ix:nonFraction>&#160;million as of December 31, 2020 and was based on <ix:nonFraction unitRef="number" contextRef="i1a168b0aa4c647e1997b38ac0934768d_I20201231" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0Mjc_9d02c0ad-b085-45fc-95ee-ee39324c1c47">50</ix:nonFraction>% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($<ix:nonFraction unitRef="usd" contextRef="i5b79f0dfcd8c4696998a76eff4413ecf_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzExNTQ0ODcyMTg1NDU2_58c700ad-b375-438e-9f02-93a674990f5e">1.5</ix:nonFraction>&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as long-term deferred revenue as of December 31, 2021. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $<ix:nonFraction unitRef="usd" contextRef="i0ebdbf98df0844558086fd4461793449_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0NDU_cebbb13b-dabd-494d-b766-78cd7c9b20a0">1.5</ix:nonFraction>&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of December&#160;31, 2021, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement). Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i34d384e7e18448558f3f9903191a5912_I20210805" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0ODg_c4a654d6-5fda-4377-8a2f-29c943e194c0">1.5</ix:nonFraction>&#160;million. The Company is in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i1895afb208f44db1b944149d86e034f5" continuedAt="ib94d1beaddd54be7963be10e33b83014"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is eligible to receive additional regulatory and commercial milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i149c70a89b234c42b784e047bac76480_D20210805-20210805" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ1MTU_d9dfb2c3-07ea-4102-982a-4a7735b93d36">2.0</ix:nonFraction>&#160;million and is also entitled to receive a <ix:nonFraction unitRef="number" contextRef="i544162f98c2149b991bf17fc6d17e544_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ1MzM_a99e27e9-904f-4d40-9413-d2e5a9cd07ed">30</ix:nonFraction>% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of December&#160;31, 2021, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib94d1beaddd54be7963be10e33b83014"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</ix:continuation> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_133"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzE0NTE_7fc057fb-ea4e-42b5-93c7-77cf6deb561d" continuedAt="ia08581bf0e1d43ae82d702ea53379b8b" escape="true">RELATED-PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="ia08581bf0e1d43ae82d702ea53379b8b" continuedAt="ieb703b59db7d4ba8a8707b7ce014a0a7"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Winnipeg, Manitoba from an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019. For each of the years ended December&#160;31, 2021, 2020 and 2019, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i289b399c61c441cdbd3ee11d6f7a9ff8_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_2d4482c9-cc3a-4f5f-b2d0-24a6b7fb81e2"><ix:nonFraction unitRef="usd" contextRef="ida0bc936be4b4983b3016c269a7787db_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_4969f2d5-e078-4922-a550-b6e6a0c2d61f"><ix:nonFraction unitRef="usd" contextRef="i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_f15229b3-cb11-4f07-82e7-0fbcd985751f">0.3</ix:nonFraction></ix:nonFraction></ix:nonFraction> million of rent, which includes the related operating expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays fees under an intellectual property license agreement to Protoden Technologies Inc. ("Protoden"), a company owned by Clairmark, an affiliate of Mr. Dan. Pursuant to the agreement, the Company has an exclusive, perpetual, irrevocable and non-royalty bearing license, with the right to sublicense, to certain patents and technology to make, use and sell products that utilize such patents and technology. The annual fee is $<ix:nonFraction unitRef="usd" contextRef="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzc0NA_48098db3-4e0f-4e92-b434-ed07703f9957">0.1</ix:nonFraction> million. Upon expiration of the term on December 31, 2024, the licenses granted to the Company will require no further payments to Protoden. For each of the years ended December&#160;31, 2021, 2020 and 2019, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_2b9f8af3-3047-4374-bef5-2ea7eca26be3"><ix:nonFraction unitRef="usd" contextRef="ic637e93aa17d4ad6a3c0e4e24f9685b5_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_6230ad3d-60dd-42e6-bf4c-1dbb7201dbc7"><ix:nonFraction unitRef="usd" contextRef="i41763d631ab94cc3954f93769f016e8a_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_fb358299-49eb-4235-9233-9a3958acedd9">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million under this license agreement.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieb703b59db7d4ba8a8707b7ce014a0a7">Due to his retirement in July 2019, Mr. Dan was not deemed a related party during the twelve-month period ended December 31, 2020 and 2021; as such, only payments made through the nine month period ended September 30, 2019 are considered payments to a related party.</ix:continuation> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_1190"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xNzA0MjQzMDIzMTgwMw_6abdc339-b097-4a80-8157-1e37aa4e9629" continuedAt="i5777f489b9f64a83a2f24277dcef9ccf" escape="true">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i5777f489b9f64a83a2f24277dcef9ccf"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restructuring Plan included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="position" contextRef="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xMDk5NTExNjI4OTM3_547cb409-6bab-4767-a05e-0ddcdd2467be">18</ix:nonFraction> positions (or approximately <ix:nonFraction unitRef="number" contextRef="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xMDk5NTExNjI4OTMy_3c663bda-18b4-404c-84bd-7315b29ea92c">35</ix:nonFraction>% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xNzA0MjQzMDIzMTgwNA_d3572ad2-a300-4d59-bc3e-edc42f35e014" continuedAt="i9a14f078717e454396a0f126fdb64397" escape="true">The following is a summary of accrued restructuring costs related to the Restructuring Plan:</ix:nonNumeric></span></div><div><ix:continuation id="i9a14f078717e454396a0f126fdb64397"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ea168da84a45ce835565576cb8541c_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV8yLTEtMS0xLTMxODAy_1a1efc48-e788-4410-9c6e-470af48bae7f">2,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a50664b1a24d31b0f259776c76eef4_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV8zLTEtMS0xLTMxODAy_ea1690b4-ab92-447a-a532-c1bbc7fcdb4c">2,736</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77fcf675f74847e4ab66d5e451e81521_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV80LTEtMS0xLTMxODAy_7782ab3f-9597-4336-b749-d9a7919117b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV81LTEtMS0xLTMxODAy_67d91dff-b38c-460a-84c7-fbcc6a64d01e">5,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV82LTEtMS0xLTMxODAy_9a18663b-4742-416d-a1f5-27beb1f3f5ad">4,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV83LTEtMS0xLTMxODAy_2caf5d69-2d96-44bb-9867-a778112c30d6">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December&#160;31, 2021. The Company expects that substantially all of the accrued restructuring costs as of December&#160;31, 2021 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div></ix:continuation><div id="if1c5a63ddb584a0db5ee835d7440b255_136"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzIxMjc_0b9f0752-f471-4c15-bc57-2d175dcb74be" continuedAt="i2b7d3841246c49c2ad95b23b87474a50" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i2b7d3841246c49c2ad95b23b87474a50"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted the Company&#8217;s request for a Type C Meeting (&#8220;Type C Meeting&#8221;) to discuss the study protocol for an additional Phase 3 clinical trial that the Company plans to conduct for potential resubmission of a BLA for Vicineum&#8482; for the treatment of BCG-unresponsive NMIBC. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, the Company received written notice (the &#8220;Notice&#8221;) from Nasdaq indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice has no effect at this time on the listing of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;), which continues to trade on The Nasdaq Global Market under the symbol &#8220;SESN&#8221;. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company&#8217;s Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is not in compliance by July 25, 2022, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for, or fail to regain, compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist the Company&#8217;s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to actively monitor the closing bid price of the Company&#8217;s common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously announced, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#8220;Review&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Review took place over the course of <ix:nonNumeric contextRef="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228" name="sesn:ReviewPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTI1_fc9f9379-7ad4-469f-92d0-49252a2fb463">five months</ix:nonNumeric>, involved full cooperation from the Company&#8217;s management team, a review of more than <ix:nonFraction unitRef="document" contextRef="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228" decimals="INF" name="sesn:NumberOfDocumentsReviewed" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTMx_f220db26-35c5-4df5-b9af-50c30648ca4d">600,000</ix:nonFraction> documents, and <ix:nonFraction unitRef="interview" contextRef="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228" decimals="INF" name="sesn:NumberOfInterviews" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTQw_a13451ad-b933-49ed-8664-a08dbfc39f46">39</ix:nonFraction> interviews of current and former employees and consultants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is now complete.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Review, the Board continues to fully support the Company&#8217;s current management team and believes no changes or amendments relating to the Company&#8217;s prior disclosures to the SEC or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>exhibit41-fy2021form10xk.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie7829dce83044f74b3e4c1861268f9bb_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 4.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">REGISTERED PURSUANT TO SECTION 12 OF THE </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Sesen Bio, Inc. (&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is our common stock, $0.001 par value per share. </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">COMMON STOCK</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;The following description of our common stock summarizes provisions of our certificate of incorporation, as amended, our by-laws, as amended, and the Delaware General Corporation Law. For a complete description, refer to our certificate of incorporation, our by-laws and the amendments thereto, which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part, and to the applicable provisions of the Delaware General Corporation Law. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation authorizes us to issue up to 400,000,000 shares of common stock with a par value of $0.001 per share. As of February 21, 2022, there were 199,463,645 shares of common stock outstanding. The shares of common stock currently outstanding are fully paid and nonassessable.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Rights</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Voting Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. When a quorum is present at any meeting, a plurality of the votes properly cast for election to any office shall elect to such office and a majority of the votes properly cast upon any question other than an election to an office shall decide the question, except when a larger vote is required by law, by our certificate of incorporation or by our by-laws. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation and by-laws do not provide for cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. Subject to the preferences that may be applicable to any then outstanding preferred stock, the holders of our outstanding shares of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Liquidation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our then outstanding preferred stock. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Other Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The terms of our common stock do not include any preemptive, conversion or subscription rights, nor any redemption or sinking fund provisions. The common stock is not subject to future calls or assessments by us.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. Our board of directors is authorized to issue up to 5,000,000 shares of preferred stock in one or more series, with such rights, preferences and privileges as shall be determined by our board of directors. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of shares of any series of our preferred stock that we may classify and issue in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Anti-Takeover Effects of Our Certificate of Incorporation and By-laws and Delaware Law</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Staggered Board&#59; Removal of Directors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation and our bylaws divide our board of directors into three classes with staggered three-year terms. In addition, our certificate of incorporation and our bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of 75% of our shares of common stock present in person or by proxy and entitled to vote. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our certificate of incorporation provides that the authorized number of directors may be changed only by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">the authorized number of directors and fill vacancies </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Stockholder Action&#59; Special Meeting of Stockholders&#59; Advance Notice Requirements for Stockholder Proposals and Director Nominations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. Our certificate of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by the chairman of our board of directors, our chief executive officer or our board of directors. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock because even if the third party acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Super-Majority Voting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Delaware Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1)&#160;shares owned by persons who are directors and also officers and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">on or subsequent to the consummation of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least&#160;66-2&#47;3%&#160;of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;Section&#160;203 defines a business combination to include&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Transfer Agent and Registrar</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The transfer agent and registrar for our common stock is Computershare Trust Company,&#160;Inc.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Stock Market Listing</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our common stock is listed for trading on the Nasdaq Global Market under the symbol &#8220;SESN.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>exhibit108_formindemnifica.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idb3133470fb94b0ca6765496ec59dbc0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.8</font></div></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDEMNIFICATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Indemnification Agreement (&#8220;Agreement&#8221;) is made as of &#91; &#93;, 20&#91; &#93; by and between Sesen Bio, Inc., a Delaware corporation (the &#8220;Company&#8221;), and &#91; &#93; (the &#8220;Indemnitee&#8221;). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. </font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board of Directors of the Company (the &#8220;Board&#8221;) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Certificate of Incorporation of the Company (as the same may be amended from time to time, the &#8220;Certificate of Incorporation&#8221;) requires indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;). The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder&#59;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Indemnitee does not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;WHEREAS, Indemnitee is a representative of &#91; &#93; &#91;and its affiliated investment funds&#93; (the &#8220;Fund&#8221;), and has certain rights to indemnification and&#47;or insurance provided by the Fund which Indemnitee and the Fund intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company&#8217;s acknowledgement and agreement to the foregoing being a material condition to Indemnitee&#8217;s willingness to serve on the Board&#59;&#93; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Services to the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Indemnitee agrees to serve a&#91;n&#93; &#91;director&#93; &#91;officer&#93;  of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee&#8217;s employment with the Company (or of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the Company&#8217;s Bylaws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a&#91;n&#93; &#91;director&#93; &#91;officer&#93; of the Company, as provided in Section 16 hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">References to &#8220;agent&#8221; shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">A &#8220;Change in Control&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt">Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing forty percent (40%) or more of the combined voting power of the Company&#8217;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors&#59;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.34pt">Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.01pt">Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its ultimate parent, as applicable) more than 51% of the combined voting power of the voting securities of the surviving entity or its ultimate parent, as applicable, outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity or its ultimate parent, as applicable&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt">Liquidation or Sale of Assets. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; and</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Section 2(b), the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;&#8220;Exchange Act&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;&#8220;Person&#8221; shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act&#59; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;&#8220;Beneficial Owner&#8221; shall have the meaning given to such term in Rule 13d-3 under the Exchange Act&#59; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)&#160;&#160;&#160;&#160;&#8220;Corporate Status&#8221; describes the status of a person as a current or former director or officer of the Company or as a current or former director, manager, partner, officer, employee, agent, or trustee of any other entity or enterprise that such person is or was serving at the request of the Company.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(E)&#160;&#160;&#160;&#160;&#8220;Disinterested Director&#8221; shall mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(F)&#160;&#160;&#160;&#160;&#8220;Enterprise&#8221; shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or fiduciary.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(G)&#160;&#160;&#160;&#160;&#8220;Expenses&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee&#8217;s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(H)&#160;&#160;&#160;&#160;&#8220;Independent Counsel&#8221; shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent&#58; (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(I)&#160;&#160;&#160;&#160;The term &#8220;Proceeding&#8221; shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him (or a failure to take action by him) or of any action (or failure to act) on his part while acting pursuant to his Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(J)&#160;&#160;&#160;&#160;Reference to &#8220;other enterprise&#8221; shall include employee benefit plans&#59; references to &#8220;fines&#8221; shall include any excise tax assessed with respect to any employee benefit plan&#59; references to &#8220;serving at the request of the Company&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries&#59; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner &#8220;not opposed to the best interests of the Company&#8221; as referred to in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Indemnity in Third-Party Proceedings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the Bylaws, vote of its stockholders or disinterested directors or applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Indemnity in Proceedings by or in the Right of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;) or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Indemnification For Expenses of a Witness.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Partial Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Additional Indemnification.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of Section 8(a), the meaning of the phrase &#8220;to the fullest extent permitted by applicable law&#8221; shall include, but not be limited to&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt">to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.34pt">to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Exclusions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision in this Agreement &#91;but subject to Section 15(e), however&#93;, the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim made against Indemnitee&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision&#59; or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act)&#59; or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Advances of Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision of this Agreement to the contrary (other than Section 14(d)), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#8217;s ability to repay the Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with Section 14(d), advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Procedure for Notification and Defense of Claim.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company will be entitled to participate in the Proceeding at its own expense.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Procedure Upon Application for Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case&#58; (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee&#59; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company&#59; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section&#160;12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section&#160;2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&#160;11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#8217;s selection of Independent Counsel and&#47;or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&#160;12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Presumptions and Effect of Certain Proceedings.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law&#59; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and&#47;or information relating thereto&#59; and provided, further, that the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">nolo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The knowledge and&#47;or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Remedies of Indemnitee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section&#160;10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section&#160;5, 6 or 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section&#160;5 of this Agreement. The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&#160;14 shall be conducted in all respects as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">de</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">novo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If a determination shall have been made pursuant to Section&#160;12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&#160;14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims&#59; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Non-exclusivity&#59; Survival of Rights&#59; Insurance&#59; Subrogation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee &#91;(other than any rights of recovery of Indemnitee from a Fund Indemnitor or under any insurance provided by the Fund or its affiliates)&#93;, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;Except as provided for under Section 15(e) of this Agreement, the&#93; The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and&#47;or insurance provided by the Fund and certain of its affiliates (collectively, the &#8220;Fund Indemnitors&#8221;). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the Certificate of Incorporation or Bylaws (or any agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and&#47;or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms hereof.&#93;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Duration of Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement shall continue until and terminate upon the later of&#58; (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a &#91;director&#93; &#91;officer&#93; of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement &#91;or by a Fund Indemnitor pursuant to Section 15(e) of this Agreement, in either case,&#93; relating thereto. The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (a) the validity, legality and </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law&#59; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Enforcement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Modification and Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Notice by Indemnitee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If to the Company to&#58;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sesen Bio, Inc.<br>245 First Street, Suite 1800</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cambridge, MA 02142<br>Attention&#58;  Chief Financial Officer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to any other address as may have been furnished to Indemnitee by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Contribution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and&#47;or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company, on the one hand, and Indemnitee, on the other hand, as a result of the event(s) and&#47;or transaction(s) giving cause to such Proceeding&#59; and&#47;or (ii) the relative fault of the Company (and its other directors, officers, employees and agents), on the one hand, and Indemnitee, on the other hand, in connection with such event(s) and&#47;or transaction(s).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Applicable Law and Consent to Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably the Corporation Trust Center as its agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Identical Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Miscellaneous.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The remainder of this page is intentionally left blank.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div><div id="idb3133470fb94b0ca6765496ec59dbc0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties executed this Agreement as of the day and year first set forth above.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SESEN BIO, INC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Office&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INDEMNITEE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.871%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">Schedule of Material Differences to Exhibit 10.2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">The following directors and executive officers are parties to an Indemnification Agreement with the Company, each of which are substantially identical in all material respects to the representative Indemnification Agreement filed herewith as Exhibit 10.2 except as to the name of the signatory and the effective date of each signatory's Indemnification Agreement and the fund affiliation of each signatory, which are listed below. The actual Indemnification Agreements are omitted pursuant to Instruction 2 to Item 601 of Regulation S-K.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.242%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indemnitee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Effective Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fund Affiliation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wendy L. Dixon, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 22, 2014</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Daniel S. Lynch</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 11, 2014</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jane V. Henderson</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 11, 2014</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jay S. Duker</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 20, 2015</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leslie L. Dan</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">September 20, 2016</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stephen A. Hurly</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">September 20, 2016</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Richard F. Fitzgerald</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 23, 2018</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 7, 2018</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dennis Kim, M.D., MPH</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">December 3, 2018</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Glen MacDonald, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 26, 2019</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mark R. Sullivan</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 26, 2019</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Monica Forbes</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 26, 2019</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carrie L. Bourdow</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 24, 2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jason A. Keyes</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 24, 2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elly Ryu</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">July 20, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patricia M. Drake</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">July 20, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Peter K Honig, M.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">July 20, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael A.S. Jewett, M.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">July 20, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Minori Koshiji Rosales, M.D., Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>4
<FILENAME>exhibit1030-rsuandcashrete.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1864d489f6844aa3a8b8538e9e8ebb15_1"></div><div style="min-height:64.8pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sesen Bio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restricted Stock Unit and Cash Retention Award Agreement </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Granted Under 2014 Stock Incentive Plan</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICE OF GRANT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Restricted Stock Unit and Cash Retention Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made as of the Agreement Date between Sesen Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a Delaware corporation, and the Participant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.&#160;&#160;&#160;&#160;Agreement Date</font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:41.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2021</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.&#160;&#160;&#160;&#160;Participant Information</font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:41.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant Address&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.&#160;&#160;&#160;&#160;Grant Information</font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:41.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Restricted Stock Units&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amount of Cash Retention Award&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An amount equal 50% of Participant&#8217;s base salary as of September 30, 2022</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IV.&#160;&#160;&#160;&#160;Vesting Table</font></div><div><font><br></font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.346%"><tr><td style="width:1.0%"></td><td style="width:24.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Number of Restricted Stock Units that Vest</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amount of Cash Retention Award that Vests</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">September 30, 2022</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An amount equal 50% of Participant&#8217;s base salary as of September 30, 2022</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement includes this Notice of Grant and the following Exhibit, which is expressly incorporated by reference in its entirety herein&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A &#8211; General Terms and Conditions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Agreement Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SESEN BIO, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Thomas R. Cannell</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President &#38; CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; &#91;_____&#93;</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1864d489f6844aa3a8b8538e9e8ebb15_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i1864d489f6844aa3a8b8538e9e8ebb15_7"></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Stock Unit and Cash Retention Award Agreement</font></div><div style="margin-bottom:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2014 Stock Incentive Plan</font></div><div style="margin-bottom:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GENERAL TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Award of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Agreement and in the Company&#8217;s 2014 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an award with respect to the number of Restricted Stock Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the Notice of Grant that forms part of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each RSU represents the right to receive one share of common stock, $0.001 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon vesting of the RSU, subject to the terms and conditions set forth herein.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Grant of Cash Retention Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant a cash retention award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Retention Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which represents the right to receive a cash amount equal to the amount set forth in the Notice of Grant upon vesting of the Cash Retention Award, subject to the terms and conditions set forth herein.  </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The RSUs and the Cash Retention Award shall vest in accordance with the Vesting Table set forth in the Notice of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Table</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Upon the vesting of the RSUs, the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 8.  The Common Stock will be delivered to the Participant as soon as practicable following a vesting date, but in any event within fourteen (14) days following such vesting date.  Upon the vesting of the Cash Retention Award, the Company will pay to the Participant an amount in cash equal to the amount set forth in the Notice of Grant, subject to the payment of any taxes pursuant to Section 8, which amount will be payable to the Participant in a single lump sum on the next regular payroll date following the vesting date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Forfeiture of Unvested RSUs and Cash Retention Award Upon Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as otherwise provided in Sections 4(b) or (c), as applicable, in the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation, and the Cash Retention Award, to the extent unvested, shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to (i) the unvested RSUs or any Common Stock that may have been issuable with respect thereto, or (ii) the Cash Retention Award, to the extent unvested.  If the Participant provides services to a subsidiary of the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If the Participant&#8217;s employment with the Company and its subsidiaries is terminated by the Company or one of its subsidiaries without Cause (as defined below), then all of the RSUs that are unvested as of the time of such termination of employment shall become immediately and automatically vested as of the date of the Participant&#8217;s termination of employment, and the shares of Common Stock underlying such RSUs will be delivered to the Participant within fourteen (14) days following the date of the Participant&#8217;s termination of employment</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If, on or prior to March 31, 2022, the Participant&#8217;s employment with the Company and its subsidiaries is terminated by the Company or one of its subsidiaries without Cause, then the Pro-Rated Cash Retention Award (as defined below) shall become immediately and automatically vested as of the date of the Participant&#8217;s termination of employment.  For purposes of this Agreement, the term &#8220;Pro-Rated Cash Retention Award&#8221; shall mean the product of (i) the amount equal to 50% of Participant&#8217;s base salary on the date of Participant&#8217;s termination of employment, multiplied by (ii) a fraction, the numerator of which is the number of days during the period commencing on the Grant Date and ending on (and including) the date of the Participant&#8217;s termination of employment, and the denominator of which is the number of days during the period commencing on the Grant Date and ending on (and including) the Vesting Date set forth on the Notice of Grant.  If, on or following April 1, 2022 and prior to the Vesting Date set forth on the Notice of Grant, the Participant&#8217;s employment with the Company and its subsidiaries is terminated by the Company or one of its subsidiaries without Cause, then the amount equal to 50% of Participant&#8217;s base salary on the date of Participant&#8217;s termination of employment shall become immediately and automatically vested as of the date of the Participant&#8217;s termination of employment.  If all or a portion of the Cash Retention Award becomes vested pursuant to this Section 4(c), the Company shall pay to the Participant the amount that becomes vested (rounded to the nearest whole cent), subject to the payment of any taxes pursuant to Section 8, in a single lump sum within 30 days following the date of the Participant&#8217;s termination of employment. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in the Participant&#8217;s employment agreement with the Company or, if the Participant does not have an employment agreement with the Company, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Participant&#8217;s commission of one or more of the following&#58; (i) an act of material dishonesty involving the Company, embezzlement, or misappropriation of assets or property of the Company&#59; (ii) gross negligence or willful misconduct in connection with the performance of Participant&#8217;s duties, theft, fraud or breach of fiduciary duty to the Company&#59; (iii) Participant&#8217;s willful, sustained, or repeated failure to substantially perform the duties or obligations of your position (other than due to illness or injury)&#59; (iv) a violation of federal or state securities law&#59; (v) the conviction of a felony or any crime involving moral turpitude, including a plea of nolo contendere&#59; or (vi) a material breach of any of the Company&#8217;s written policies related to conduct, ethics, equal employment or harassment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively &#8220;transfer&#8221;) any RSUs or the Cash Retention Award, or any interest therein. The Company shall not be required to treat as the owner of any RSUs, issue any Common Stock to, or pay any cash amounts to, any transferee to whom such RSUs or Cash Retention Award have been transferred in violation of any of the provisions of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rights as a Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Acknowledgments&#59; No Section 83(b) Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#8217;s own tax advisors with respect to the award of RSUs and the Cash Retention Award, and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs and the Cash Retention Award.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s tax liability that may arise in connection with the acquisition, vesting, disposition and&#47;or payment of the RSUs and the Cash Retention Award.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code, as amended, is available with respect to RSUs or the Cash Retention Award.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting and&#47;or payment of the RSUs and the Cash Retention Award.  At such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock, the Participant shall execute the instructions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Automatic Sale Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as the means of satisfying such tax obligation with respect to the RSUs.  If the Participant does not execute the Automatic Sale Instructions prior to an applicable vesting date of the RSUs, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the RSUs then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company.  The Company shall not deliver any shares of Common Stock in respect of vested RSUs to the Participant until it is satisfied that all required withholdings have been made.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Authority of Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In making any decisions or taking any actions with respect to the matters covered by this Agreement, the Compensation Committee shall have all of the authority and discretion, and shall be subject to all of the protections, provided for in the Plan.  All decisions and actions by the Compensation Committee with respect to this Agreement shall be made in the Compensation Committee&#8217;s discretion and shall be final and binding on the Participant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs and the Cash Retention Award is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The RSUs and the Cash Retention Award awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations issued thereunder </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The delivery of shares of Common Stock on the vesting of the RSUs, and the payment of cash on the vesting of the Cash Retention Award, may not be accelerated or deferred unless permitted or required by Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Participant&#8217;s Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that he or she&#58; (i) has read this Agreement&#59; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant&#8217;s own choice or has voluntarily declined to seek such counsel&#59; (iii) understands the terms and consequences of this Agreement&#59; and (iv) is fully aware of the legal and binding effect of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby acknowledge that I have read this Agreement, have received and read the Plan, and understand and agree to comply with the terms and conditions of this Agreement and the Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT ACCEPTANCE</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; &#91;_____&#93;</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><div id="i1864d489f6844aa3a8b8538e9e8ebb15_10"></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Automatic Sale Instructions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of RSUs on such date shall be paid through an automatic sale of shares as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Upon any vesting of RSUs pursuant to Sections 3 or 4 hereof, as applicable, the Company shall sell, or arrange for the sale of, such number of shares of Common Stock issuable with respect to the RSUs that vest pursuant to Section 3 or Section 4, as applicable, as is sufficient to generate net proceeds sufficient to satisfy the Company&#8217;s minimum statutory withholding obligations with respect to the income recognized by the Participant upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the Company shall retain such net proceeds in satisfaction of such tax withholding obligations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Participant hereby appoints the President and Chief Executive Officer and Secretary of the Company, and either of them acting alone and with full power of substitution, to serve as his or her attorneys in fact to sell the Participant&#8217;s Common Stock in accordance with this Schedule A.  The Participant agrees to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the Shares pursuant to this Schedule A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Participant represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock.  The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a &#8220;binding contract&#8221; relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">_______________________________</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Participant Name&#58;  ________________</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;  __________________________</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>5
<FILENAME>exhibit1031-performancexba.htm
<DESCRIPTION>EX-10.31
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iba43394eb0144231a081e3fd2e08dddd_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sesen Bio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance-Based Restricted Stock Unit Agreement </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Granted Under 2014 Stock Incentive Plan</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICE OF GRANT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance-Based Restricted Stock Unit Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made as of the Agreement Date between Sesen Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a Delaware corporation, and the Participant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.&#160;&#160;&#160;&#160;Agreement Date</font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:29.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2021</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.&#160;&#160;&#160;&#160;Participant Information</font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:30.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant Address&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.&#160;&#160;&#160;&#160;Grant Information</font></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:42.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Restricted Stock Units&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement includes this Notice of Grant and the following Exhibit, which is expressly incorporated by reference in its entirety herein&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A &#8211; General Terms and Conditions</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Agreement Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SESEN BIO, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Thomas R. Cannell</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President &#38; CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; &#91;_____&#93;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="iba43394eb0144231a081e3fd2e08dddd_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance-Based Restricted Stock Unit Agreement</font></div><div style="margin-bottom:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2014 Stock Incentive Plan</font></div><div style="margin-bottom:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GENERAL TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Award of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Agreement and in the Company&#8217;s 2014 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an award with respect to the number of performance-based Restricted Stock Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the Notice of Grant that forms part of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each PSU represents the right to receive one share of common stock, $0.001 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon vesting of the PSU, subject to the terms and conditions set forth herein.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The PSUs may be earned based on the achievement of one or more of the performance milestones (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the table below.  The number of PSUs that may be earned based on the achievement of each Performance Milestone is set forth in the table below.  The determination of whether, and to what extent, each Performance Milestone has been achieved shall be made by the Compensation Committee in its sole discretion.  Any PSUs that are earned based on the achievement of the Performance Milestones shall vest on September 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">End Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Upon the vesting of the PSUs, the Company will deliver to the Participant, for each PSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7.  The Common Stock will be delivered to the Participant within fourteen (14) days of the End Date. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Milestones</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Weightings</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Number of PSUs that will be Earned Upon Achievement of Performance Milestone</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Clinical Performance Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Retention Performance Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Performance Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;&#9679;&#93;</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">The Clinical Performance Milestone shall be achieved if the timing for completing full patient enrollment for the new study to be determined based on regulatory feedback and as endorsed by the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is achieved.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">The Employee Retention Performance Milestone shall be achieved if 80% of the thirty-two (32) employees that are employed by the Company and its subsidiaries on the Grant Date remain employed by the Company and its subsidiaries on the End Date. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">The Financial Performance Milestone shall be achieved if the Company&#8217;s cash balance is no lower than 90% of the Board approved budget&#47;forecast as of both December 31, 2022 and June 30, 2023. </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Forfeiture of Unvested PSUs Upon Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as otherwise provided in Section 3(b), in the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without cause, all of the PSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested PSUs or any Common Stock that may have been issuable with respect thereto.  If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If, prior to the End Date, the Participant&#8217;s employment with the Company and its subsidiaries is terminated by the Company or one of its subsidiaries without Cause (as defined below), then each PSU that has become earned as of the time of such termination of employment based on the achievement of the applicable Performance Milestone, as determined by the Compensation Committee in its sole discretion, shall become immediately and automatically vested as of the date of the Participant&#8217;s termination of employment, and the shares of Common Stock underlying such PSU will be delivered to the Participant as soon as practicable following the date of the Participant&#8217;s termination of employment, but in any event within fourteen (14) of such date.  For purposes of this Agreement, the term &#8220;Cause&#8221; shall have the meaning specified in the Participant&#8217;s employment agreement with the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively &#8220;transfer&#8221;) any PSUs, or any interest therein. The Company shall not be required to treat as the owner of any PSUs or issue any Common Stock to any transferee to whom such PSUs have been transferred in violation of any of the provisions of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rights as a Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the PSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the PSUs.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Acknowledgments&#59; No Section 83(b) Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#8217;s own tax advisors with respect to the award of PSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the PSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s tax liability that may arise in connection with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 126831007v.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the acquisition, vesting and&#47;or disposition of the PSUs.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code, as amended, is available with respect to PSUs.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting  of the PSUs.  At such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock, the Participant shall execute the instructions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Automatic Sale Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as the means of satisfying such tax obligation.  If the Participant does not execute the Automatic Sale Instructions prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the PSUs then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company.  The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Authority of Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In making any decisions or taking any actions with respect to the matters covered by this Agreement, the Compensation Committee shall have all of the authority and discretion, and shall be subject to all of the protections, provided for in the Plan.  All decisions and actions by the Compensation Committee with respect to this Agreement shall be made in the Compensation Committee&#8217;s discretion and shall be final and binding on the Participant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the PSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The PSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations issued thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The delivery of shares of Common Stock on the vesting of the PSUs may not be accelerated or deferred unless permitted or required by Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Participant&#8217;s Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that he or she&#58; (i) has read this Agreement&#59; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant&#8217;s own choice or has voluntarily declined to seek such counsel&#59; (iii) understands the terms and consequences of this Agreement&#59; and (iv) is fully aware of the legal and binding effect of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby acknowledge that I have read this Agreement, have received and read the Plan, and understand and agree to comply with the terms and conditions of this Agreement and the Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 126831007v.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT ACCEPTANCE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; &#91;_____&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 126831007v.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Automatic Sale Instructions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of PSUs on such date shall be paid through an automatic sale of shares as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Upon any vesting of PSUs pursuant to Sections 2 or 3 hereof, as applicable, the Company shall sell, or arrange for the sale of, such number of shares of Common Stock issuable with respect to the PSUs that vest pursuant to Section 2 or Section 3, as applicable, as is sufficient to generate net proceeds sufficient to satisfy the Company&#8217;s minimum statutory withholding obligations with respect to the income recognized by the Participant upon the vesting of the PSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the Company shall retain such net proceeds in satisfaction of such tax withholding obligations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Participant hereby appoints the President and Chief Executive Officer and Secretary of the Company, and either of them acting alone and with full power of substitution, to serve as his or her attorneys in fact to sell the Participant&#8217;s Common Stock in accordance with this Schedule A.  The Participant agrees to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the Shares pursuant to this Schedule A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Participant represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock.  The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a &#8220;binding contract&#8221; relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Participant Name&#58;  ________________</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;  __________________________</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 126831007v.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>sesn-12312021x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i64b8250da04e4787951b4afbc5485805_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of Sesen Bio, Inc.</font></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:27.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viventia Bio Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Province of Ontario, Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viventia Bio USA&#160;Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Province of Ontario, Canada</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viventia Biotech (EU) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>exhibit231eyconsentforfy20.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i72cc5f8a3f9d4df7bfb517aa7f98fd58_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-195170) pertaining to the Eleven Biotherapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan, 2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Post-Effective Amendment No. 1 to Form S-1 on Form S-3 No. 333-201176) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(3)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-202677) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(4)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-210523) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(5)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-217686) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(6)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-217687) pertaining to the Eleven Biotherapeutics, Inc. Inducement Stock Option Awards&#59;</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(7)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Amendment No. 3 to Form S-1 No. 333-220809) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(8)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-3 No. 333-224682) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(9)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Pre-Effective Amendment No. 1 to Form S-3 No. 333-223750) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(10)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Post-Effective Amendment No. 1 to Form S-8 No. 333-224959) pertaining to the Sesen Bio, Inc.  2014 Stock Incentive Plan (formerly known as the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan)&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(11)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-231644) pertaining to the Sesen Bio, Inc. 2014 Stock Incentive Plan (formerly known as the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan) and Sesen Bio, Inc. Inducement Stock Option Awards&#59; and</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(12)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-234697) pertaining to the Sesen Bio, Inc. 2014 Stock Incentive Plan (formerly known as the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan) and Sesen Bio, Inc. Inducement Stock Option Awards</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(13)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-254264) pertaining to the Sesen Bio, Inc. Inducement Stock Option Awards</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(14)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-255941) pertaining to the Sesen Bio, Inc. 2014 Stock Incentive Plan (as amended effective May 3, 2021) and the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan (as amended effective May 3, 2021)</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(15)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-3 No. 333-255943) of Sesen Bio, Inc.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">of our reports dated February 28, 2022, with respect to the consolidated financial statements of Sesen Bio, Inc. and the effectiveness of internal control over financial reporting of Sesen Bio, Inc. included in this Annual Report (Form&#160;10-K) of Sesen Bio, Inc. for the year ended December&#160;31, 2021.</font></div><div style="margin-bottom:6pt;padding-left:4pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">February 28, 2022</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>sesn-12312021x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8033b827a45144ac816484136f4abb18_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Thomas R. Cannell, D.V.M., certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.777%"><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>sesn-12312021x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8b3cd5ce1e3c44f0aaa1693ff87409ee_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Monica Forbes, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:0.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>sesn-12312021x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i06fd148db7c5460598e6967e25bec4a1_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:0.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>sesn-12312021x10kex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0d6fdccaa2034549992739031e1cdcf4_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:0.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>sesn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sesn="http://www.sesenbio.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sesenbio.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sesenbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.sesenbio.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>1005007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION">
        <link:definition>2103102 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2107104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS">
        <link:definition>2108105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables">
        <link:definition>2309301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails">
        <link:definition>2412405 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
        <link:definition>2413406 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLES" roleURI="http://www.sesenbio.com/role/RECEIVABLES">
        <link:definition>2114106 - Disclosure - RECEIVABLES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLESDetails" roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails">
        <link:definition>2415407 - Disclosure - RECEIVABLES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>2116107 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>2317302 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail">
        <link:definition>2418408 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>2419409 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILL" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL">
        <link:definition>2120108 - Disclosure - INTANGIBLES AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLTables" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables">
        <link:definition>2321303 - Disclosure - INTANGIBLES AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails">
        <link:definition>2422410 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLNarrativeDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails">
        <link:definition>2423411 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES">
        <link:definition>2124109 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2325304 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails">
        <link:definition>2426412 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2127110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails">
        <link:definition>2428413 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.sesenbio.com/role/LEASES">
        <link:definition>2129111 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.sesenbio.com/role/LEASESTables">
        <link:definition>2330305 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails">
        <link:definition>2431414 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostsDetails" roleURI="http://www.sesenbio.com/role/LEASESLeaseCostsDetails">
        <link:definition>2432415 - Disclosure - LEASES - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESFutureMinimumLeasePaymentsDetails" roleURI="http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails">
        <link:definition>2433416 - Disclosure - LEASES - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2134112 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>2335306 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails">
        <link:definition>2436417 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails">
        <link:definition>2437418 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITCommonStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails">
        <link:definition>2438419 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails">
        <link:definition>2439420 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITWarrantsDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails">
        <link:definition>2440421 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails">
        <link:definition>2441422 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2142113 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2343307 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2444423 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2145114 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2346308 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
        <link:definition>2447424 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2448425 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
        <link:definition>2449426 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>2450427 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
        <link:definition>2451428 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2152115 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2453429 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sesenbio.com/role/INCOMETAXES">
        <link:definition>2154116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.sesenbio.com/role/INCOMETAXESTables">
        <link:definition>2355309 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofPretaxIncomeLossDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails">
        <link:definition>2456430 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofIncomeTaxProvisionsDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails">
        <link:definition>2457431 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails">
        <link:definition>2458432 - Disclosure - INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2459433 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2460434 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofCreditCarryforwardsDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails">
        <link:definition>2461435 - Disclosure - INCOME TAXES - Schedule of Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS">
        <link:definition>2162117 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails">
        <link:definition>2463436 - Disclosure - LICENSE AGREEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2164118 - Disclosure - RELATED-PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2465437 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIES" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES">
        <link:definition>2166119 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESTables" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables">
        <link:definition>2367310 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails">
        <link:definition>2468438 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails">
        <link:definition>2469439 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS">
        <link:definition>2170120 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2471440 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sesn_CommonStockAndWarrantOrRightsPricePerShare" abstract="false" name="CommonStockAndWarrantOrRightsPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationTable" abstract="true" name="OrganizationAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_AccruedRestructuringChargesRelatedCurrent" abstract="false" name="AccruedRestructuringChargesRelatedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestonePaymentTerm" abstract="false" name="LicenseAgreementMilestonePaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_XOMAIrelandLimitedMember" abstract="true" name="XOMAIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_EBI031Member" abstract="true" name="EBI031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_FirstIndicationMember" abstract="true" name="FirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ViciniumMember" abstract="true" name="ViciniumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLeasesAreaOfOfficeSpace" abstract="false" name="OperatingLeasesAreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_WarrantsExpiringJune2020Member" abstract="true" name="WarrantsExpiringJune2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" abstract="false" name="SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_SecondIndicationMember" abstract="true" name="SecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_SaleOfStockCommissionFixedRate" abstract="false" name="SaleOfStockCommissionFixedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_IL6Member" abstract="true" name="IL6Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" abstract="false" name="RightOfUseAssetRelatedToAdoptionOfAccountingStandard" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_FacilityinWinnipegManitolaMember" abstract="true" name="FacilityinWinnipegManitolaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" abstract="false" name="ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" abstract="false" name="LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ATMFacilityMember" abstract="true" name="ATMFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_DeferredTaxAssetsCapitalizedStartUpCosts" abstract="false" name="DeferredTaxAssetsCapitalizedStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchievementExpense" abstract="false" name="LicenseAgreementMilestoneAchievementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchieved" abstract="false" name="LicenseAgreementMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ViventiaBioInc.Member" abstract="true" name="ViventiaBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" abstract="false" name="ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodNewIssuesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" abstract="false" name="BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" abstract="true" name="CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RetentionProgramMember" abstract="true" name="RetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_OperatingLeaseOtherMonthlyOperatingExpenses" abstract="false" name="OperatingLeaseOtherMonthlyOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MENALicenseAgreementMember" abstract="true" name="MENALicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OtherDividendAndAdjustments" abstract="false" name="OtherDividendAndAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementAdditionalUpFrontFee" abstract="false" name="LicenseAgreementAdditionalUpFrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeaseMonthlyRent" abstract="false" name="OperatingLeaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" abstract="false" name="LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationLineItems" abstract="true" name="OrganizationAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_LicenseMaintenanceFees" abstract="false" name="LicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" abstract="false" name="LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" abstract="false" name="SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyRate" abstract="false" name="LicenseAgreementRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" abstract="false" name="SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" abstract="true" name="EczacibasiPharmaceuticalsMarketingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" abstract="false" name="SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" abstract="false" name="ShareBasedPaymentArrangementExpenseOnCashBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_NonCapitalLossCarryforwardMember" abstract="true" name="NonCapitalLossCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementProceedsFromMilestoneAchieved" abstract="false" name="LicenseAgreementProceedsFromMilestoneAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_NumberOfDocumentsReviewed" abstract="false" name="NumberOfDocumentsReviewed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" abstract="false" name="LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ProceedsFromIssuanceofCommonStockandWarrants" abstract="false" name="ProceedsFromIssuanceofCommonStockandWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharesOfCommonStockReservedForIssuanceAbstract" abstract="true" name="SharesOfCommonStockReservedForIssuanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_SaleOfStockAdditionalSharesAuthorizedForSale" abstract="false" name="SaleOfStockAdditionalSharesAuthorizedForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SupplementalLeaseInformationAbstract" abstract="true" name="SupplementalLeaseInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberOfLawsuits" abstract="false" name="NumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" abstract="false" name="LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" abstract="false" name="StockIssuedDuringPeriodExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestonePayment" abstract="false" name="LicenseAgreementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2022Member" abstract="true" name="WarrantsExpiringNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ReviewPeriod" abstract="false" name="ReviewPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" abstract="true" name="A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedMay2015Member" abstract="true" name="WarrantsExpiringNovember2024IssuedMay2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_IssuanceOfWarrantForCommonStock" abstract="false" name="IssuanceOfWarrantForCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantOrRightOutstandingRollForward" abstract="true" name="WarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_WeightedAverageCostOfCapital" abstract="false" name="WeightedAverageCostOfCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_DebtInstrumentIndexRateHighYield" abstract="false" name="DebtInstrumentIndexRateHighYield" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MicrometAGMember" abstract="true" name="MicrometAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_CommonStockSharesIssuedAndReservedForFuture" abstract="false" name="CommonStockSharesIssuedAndReservedForFuture" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_BusinessCombinationRoyaltyPaymentPercent" abstract="false" name="BusinessCombinationRoyaltyPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringMarch2023Member" abstract="true" name="WarrantsExpiringMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberOfInterviews" abstract="false" name="NumberOfInterviews" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_BusinessCombinationMilestonePayments" abstract="false" name="BusinessCombinationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_LicenseRevenueMember" abstract="true" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NetOperatingLossCarryforwardDomain" abstract="true" name="NetOperatingLossCarryforwardDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" abstract="false" name="SaleOfStockMaximumAggregateSalesPriceInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RoyaltyRevenuePercentage" abstract="false" name="RoyaltyRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_ProceedsFromValueAddedTaxRecovery" abstract="false" name="ProceedsFromValueAddedTaxRecovery" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementOptionPeriods" abstract="false" name="LicenseAgreementOptionPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" abstract="true" name="WarrantsExpiringNovember2024IssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLossCarryforwardsDecrease" abstract="false" name="OperatingLossCarryforwardsDecrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_StockIncentivePlan2009Member" abstract="true" name="StockIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberofVotesEntitledForEachShare" abstract="false" name="NumberofVotesEntitledForEachShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_QiluPharmaceuticalCoLtdMember" abstract="true" name="QiluPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NetOperatingLossCarryforwardAxis" abstract="true" name="NetOperatingLossCarryforwardAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_NumberOfPatients" abstract="false" name="NumberOfPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_MassachusettsAndPennsylvaniaMember" abstract="true" name="MassachusettsAndPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>sesn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38728ae6-e738-4668-bf0f-a4cd6cb817ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_f9d09c1a-7b85-4156-952a-b198a4fcd10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38728ae6-e738-4668-bf0f-a4cd6cb817ab" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_f9d09c1a-7b85-4156-952a-b198a4fcd10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16dd5b93-7e44-44e2-8489-e254aba5868a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38728ae6-e738-4668-bf0f-a4cd6cb817ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_16dd5b93-7e44-44e2-8489-e254aba5868a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_57e684b5-221a-480f-a865-395d94614e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4f39239-2517-428a-8536-168a6ea3fa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57e684b5-221a-480f-a865-395d94614e5d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4f39239-2517-428a-8536-168a6ea3fa74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c6286ff-1adb-47b0-902a-ad8c82e78fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57e684b5-221a-480f-a865-395d94614e5d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c6286ff-1adb-47b0-902a-ad8c82e78fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_b4e9fec3-7c04-432f-bd26-0c30fa770054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57e684b5-221a-480f-a865-395d94614e5d" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_b4e9fec3-7c04-432f-bd26-0c30fa770054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e14d00a7-4637-4e15-ba0d-9fdc82796b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57e684b5-221a-480f-a865-395d94614e5d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e14d00a7-4637-4e15-ba0d-9fdc82796b07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5dbc4fa3-432e-446c-ac4d-8639895bf706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57e684b5-221a-480f-a865-395d94614e5d" xlink:to="loc_us-gaap_RestrictedCashCurrent_5dbc4fa3-432e-446c-ac4d-8639895bf706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39205ff6-d464-4e96-a8ec-6646b44ad640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_b5e38d72-e308-4f20-b50c-d7ca146111db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39205ff6-d464-4e96-a8ec-6646b44ad640" xlink:to="loc_us-gaap_AssetsNoncurrent_b5e38d72-e308-4f20-b50c-d7ca146111db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_72c86b14-9031-4390-9ba5-ef27bedb668a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39205ff6-d464-4e96-a8ec-6646b44ad640" xlink:to="loc_us-gaap_AssetsCurrent_72c86b14-9031-4390-9ba5-ef27bedb668a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e22b7aaa-bf47-4c24-834f-a3d9bbc358a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc7df762-81d4-4785-9146-7656d02709e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e22b7aaa-bf47-4c24-834f-a3d9bbc358a3" xlink:to="loc_us-gaap_StockholdersEquity_cc7df762-81d4-4785-9146-7656d02709e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3514a739-90db-4c33-9608-aea7004e3482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e22b7aaa-bf47-4c24-834f-a3d9bbc358a3" xlink:to="loc_us-gaap_Liabilities_3514a739-90db-4c33-9608-aea7004e3482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_8fda4abd-830e-449f-ac00-d47a17c046cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d99cb1ab-b44a-48ee-9840-e4b9e59c3223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8fda4abd-830e-449f-ac00-d47a17c046cf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d99cb1ab-b44a-48ee-9840-e4b9e59c3223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7d529997-3691-4e84-b774-157a516b5e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8fda4abd-830e-449f-ac00-d47a17c046cf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7d529997-3691-4e84-b774-157a516b5e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3acb15a6-ff5c-49b2-9f15-23b3a841e35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8fda4abd-830e-449f-ac00-d47a17c046cf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3acb15a6-ff5c-49b2-9f15-23b3a841e35b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ae4e7aa-11ea-4646-882c-7a6082d8f376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8fda4abd-830e-449f-ac00-d47a17c046cf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ae4e7aa-11ea-4646-882c-7a6082d8f376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_be38e9c9-e883-478c-999f-36300facc4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bbf408aa-a6c0-4863-905a-19ec396dfead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_be38e9c9-e883-478c-999f-36300facc4d7" xlink:to="loc_us-gaap_AccountsPayableCurrent_bbf408aa-a6c0-4863-905a-19ec396dfead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_426e20cb-27b0-4ad0-90ed-fee04d775752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_be38e9c9-e883-478c-999f-36300facc4d7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_426e20cb-27b0-4ad0-90ed-fee04d775752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b2dd1c05-04fd-4e08-b4ca-2ffca4d8959e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_be38e9c9-e883-478c-999f-36300facc4d7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b2dd1c05-04fd-4e08-b4ca-2ffca4d8959e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8ccc5584-0bfa-44fb-935c-7ca7b833ffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_be38e9c9-e883-478c-999f-36300facc4d7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8ccc5584-0bfa-44fb-935c-7ca7b833ffa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2f5fef77-d974-4ef8-86c6-40149fa9619b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_be38e9c9-e883-478c-999f-36300facc4d7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2f5fef77-d974-4ef8-86c6-40149fa9619b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d347fa8-7d2d-4185-b70b-5662fc5d6551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e4125d8e-0f30-47bc-bdd1-646e27d78018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0d347fa8-7d2d-4185-b70b-5662fc5d6551" xlink:to="loc_us-gaap_CommonStockValue_e4125d8e-0f30-47bc-bdd1-646e27d78018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e4af151f-ab2f-49b7-8fec-2a65e22772d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0d347fa8-7d2d-4185-b70b-5662fc5d6551" xlink:to="loc_us-gaap_PreferredStockValue_e4af151f-ab2f-49b7-8fec-2a65e22772d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b2384b7c-ff68-4147-b3ed-12d7284cca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0d347fa8-7d2d-4185-b70b-5662fc5d6551" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b2384b7c-ff68-4147-b3ed-12d7284cca25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b70ce455-9f28-4300-bd73-0b3b70b57459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0d347fa8-7d2d-4185-b70b-5662fc5d6551" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b70ce455-9f28-4300-bd73-0b3b70b57459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6609aab7-927c-4fb2-98f0-e8db7a52177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:to="loc_us-gaap_Goodwill_6609aab7-927c-4fb2-98f0-e8db7a52177e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_270cb61c-656d-42fb-bb23-873f4f7b2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_270cb61c-656d-42fb-bb23-873f4f7b2a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_86c19a97-0312-4d81-800c-0ee6f0018fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_86c19a97-0312-4d81-800c-0ee6f0018fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_317f4d9c-4651-4199-a8a5-9f41f551e0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_317f4d9c-4651-4199-a8a5-9f41f551e0c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bab59aff-7353-4f5e-93b5-0af8409cc9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bab59aff-7353-4f5e-93b5-0af8409cc9da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0c7a26df-2895-4c80-968f-64f01a51adc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5f4eba30-7272-45ea-b08c-091e10260d37" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0c7a26df-2895-4c80-968f-64f01a51adc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f962c134-175b-468d-8bc4-b0a4bba8ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cd18dd5f-f756-4a07-a597-5186abb4d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f962c134-175b-468d-8bc4-b0a4bba8ba10" xlink:to="loc_us-gaap_NetIncomeLoss_cd18dd5f-f756-4a07-a597-5186abb4d6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_152f5a58-4a09-421b-81d4-17547eff4233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f962c134-175b-468d-8bc4-b0a4bba8ba10" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_152f5a58-4a09-421b-81d4-17547eff4233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_973c5e99-9a10-44c3-bec1-0e944eb10ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_65fa40a2-e8d7-45aa-a888-5c8b51451ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_973c5e99-9a10-44c3-bec1-0e944eb10ac2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_65fa40a2-e8d7-45aa-a888-5c8b51451ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_129db870-f834-4a29-9b64-34c39aaad48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_973c5e99-9a10-44c3-bec1-0e944eb10ac2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_129db870-f834-4a29-9b64-34c39aaad48b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4c3eafe0-0a75-4352-bfea-c730f5431fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_973c5e99-9a10-44c3-bec1-0e944eb10ac2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4c3eafe0-0a75-4352-bfea-c730f5431fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_002f0276-4da4-47c2-9a7f-866ada0fda83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_973c5e99-9a10-44c3-bec1-0e944eb10ac2" xlink:to="loc_us-gaap_RestructuringCharges_002f0276-4da4-47c2-9a7f-866ada0fda83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_50a04f8b-213d-402d-867b-78b6c6ff0fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_973c5e99-9a10-44c3-bec1-0e944eb10ac2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_50a04f8b-213d-402d-867b-78b6c6ff0fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7b6c1f6-f764-4ea8-a42f-6d693515f497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_a9cee540-149c-4934-a390-39a6013713cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d7b6c1f6-f764-4ea8-a42f-6d693515f497" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_a9cee540-149c-4934-a390-39a6013713cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dc9bd834-3b9d-40cf-880b-231c9803ecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d7b6c1f6-f764-4ea8-a42f-6d693515f497" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dc9bd834-3b9d-40cf-880b-231c9803ecc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ddf84ab3-45e5-4f9f-b8dc-884d898ba812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e1b1d5ce-8d75-4642-bd11-8bd2438a9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ddf84ab3-45e5-4f9f-b8dc-884d898ba812" xlink:to="loc_us-gaap_NetIncomeLoss_e1b1d5ce-8d75-4642-bd11-8bd2438a9ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_380daf8d-349b-4b8c-ab46-3f34afde4647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ddf84ab3-45e5-4f9f-b8dc-884d898ba812" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_380daf8d-349b-4b8c-ab46-3f34afde4647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_730d35ef-6b35-4ea4-b985-bc5101935eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3be7d5fc-75c1-4516-bb5f-5eebee95b034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_730d35ef-6b35-4ea4-b985-bc5101935eb7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3be7d5fc-75c1-4516-bb5f-5eebee95b034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbcaad62-0dde-4b99-83b5-6267aa556b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_730d35ef-6b35-4ea4-b985-bc5101935eb7" xlink:to="loc_us-gaap_OperatingIncomeLoss_cbcaad62-0dde-4b99-83b5-6267aa556b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9d06ce08-1866-4ce9-88e2-704d6f027fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ba0fbce8-4f98-41f2-a509-0456f84683f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9d06ce08-1866-4ce9-88e2-704d6f027fb5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ba0fbce8-4f98-41f2-a509-0456f84683f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_895fbc7f-2b7e-4b0e-9085-fa5c5fffe60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9d06ce08-1866-4ce9-88e2-704d6f027fb5" xlink:to="loc_us-gaap_OperatingExpenses_895fbc7f-2b7e-4b0e-9085-fa5c5fffe60b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49f91734-f333-44ee-919c-81ab1c23dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1ba7280-a89d-43ad-88a8-f7381bdd366a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49f91734-f333-44ee-919c-81ab1c23dd57" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1ba7280-a89d-43ad-88a8-f7381bdd366a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_932115ce-1925-4f7a-860b-a11995455c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49f91734-f333-44ee-919c-81ab1c23dd57" xlink:to="loc_us-gaap_RestrictedCashCurrent_932115ce-1925-4f7a-860b-a11995455c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5b442d4c-9216-45c5-a572-43c228b1fe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49f91734-f333-44ee-919c-81ab1c23dd57" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5b442d4c-9216-45c5-a572-43c228b1fe9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94563651-8de6-4dc0-bd5a-f8a44fdf7366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e3fb9ba8-8e93-4f1a-ae01-5232b52f013f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94563651-8de6-4dc0-bd5a-f8a44fdf7366" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e3fb9ba8-8e93-4f1a-ae01-5232b52f013f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromIssuanceofCommonStockandWarrants_8f733845-c2e6-401e-b7fe-68c796a72c9b" xlink:href="sesn-20211231.xsd#sesn_ProceedsFromIssuanceofCommonStockandWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94563651-8de6-4dc0-bd5a-f8a44fdf7366" xlink:to="loc_sesn_ProceedsFromIssuanceofCommonStockandWarrants_8f733845-c2e6-401e-b7fe-68c796a72c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_387a85b0-f5cf-46bd-8b68-b2ffe52cc003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94563651-8de6-4dc0-bd5a-f8a44fdf7366" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_387a85b0-f5cf-46bd-8b68-b2ffe52cc003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a8686f5b-d15e-4270-9090-dbba01956c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94563651-8de6-4dc0-bd5a-f8a44fdf7366" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a8686f5b-d15e-4270-9090-dbba01956c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7b8887ac-0bd4-492e-80ea-c98b7c05ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_94563651-8de6-4dc0-bd5a-f8a44fdf7366" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7b8887ac-0bd4-492e-80ea-c98b7c05ff9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_04e17795-cc73-4c14-8e86-19351f56d43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_04e17795-cc73-4c14-8e86-19351f56d43a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a4a7c525-b612-4871-8edb-533b024a44a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a4a7c525-b612-4871-8edb-533b024a44a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6a7b393a-1c0a-4a46-8aa9-94f079586be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_AssetImpairmentCharges_6a7b393a-1c0a-4a46-8aa9-94f079586be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_de68299d-8f68-4c86-b58f-c503fd33567a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_de68299d-8f68-4c86-b58f-c503fd33567a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_c7f60c23-6b10-436a-af0d-b8e5350d1a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_c7f60c23-6b10-436a-af0d-b8e5350d1a77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f08391b3-403d-4be3-a9a6-9d48bb8e2c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_NetIncomeLoss_f08391b3-403d-4be3-a9a6-9d48bb8e2c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4a05234e-de3f-4acf-a264-3a8854cb1a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4a05234e-de3f-4acf-a264-3a8854cb1a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e95882ab-ff80-4865-9b38-c6af32e5e101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e95882ab-ff80-4865-9b38-c6af32e5e101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1585ca3e-8087-47ad-8021-fba1e21c495a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_DepreciationAndAmortization_1585ca3e-8087-47ad-8021-fba1e21c495a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1de19de2-cc65-45a9-a747-e192b30dfa45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3918d47f-85a5-4542-94a6-816f29ae48f1" xlink:to="loc_us-gaap_ShareBasedCompensation_1de19de2-cc65-45a9-a747-e192b30dfa45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9df1a2e8-f8d8-4428-bdf0-03ed4523d915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af57921e-4d3f-4daa-9605-3c27843798bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9df1a2e8-f8d8-4428-bdf0-03ed4523d915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af57921e-4d3f-4daa-9605-3c27843798bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ffb3758-728b-4bdb-8500-b6ac06d0ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9df1a2e8-f8d8-4428-bdf0-03ed4523d915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ffb3758-728b-4bdb-8500-b6ac06d0ef5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81c9c1bf-13e6-4621-b468-e4ddc2c323f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9df1a2e8-f8d8-4428-bdf0-03ed4523d915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81c9c1bf-13e6-4621-b468-e4ddc2c323f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d60b618-302a-4728-86b6-93429e5a61f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76db295e-49a5-44e1-a824-43b76461cfa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d60b618-302a-4728-86b6-93429e5a61f8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76db295e-49a5-44e1-a824-43b76461cfa6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aba5b800-e49c-4f90-9b8a-6e28e548f252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_72fdd4f1-e57d-418b-bfa3-098619851595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aba5b800-e49c-4f90-9b8a-6e28e548f252" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_72fdd4f1-e57d-418b-bfa3-098619851595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d94e7bc4-48d0-423f-9388-df86403e2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aba5b800-e49c-4f90-9b8a-6e28e548f252" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d94e7bc4-48d0-423f-9388-df86403e2b17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" xlink:type="simple" xlink:href="sesn-20211231.xsd#PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c4d0c63d-592c-4802-ab31-c0fdd2627b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a3e1f86b-9544-4367-941c-70e42a1eb6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c4d0c63d-592c-4802-ab31-c0fdd2627b0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a3e1f86b-9544-4367-941c-70e42a1eb6c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb7e59a6-6594-4839-9e95-8db8358bfde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c4d0c63d-592c-4802-ab31-c0fdd2627b0d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb7e59a6-6594-4839-9e95-8db8358bfde9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ea492564-99cd-420a-bb26-128ee8a82702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_29d44084-2e2f-40c5-b861-4f49d8fdecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ea492564-99cd-420a-bb26-128ee8a82702" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_29d44084-2e2f-40c5-b861-4f49d8fdecd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4305f1ba-2ca0-4ea7-855f-aa205f33f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ea492564-99cd-420a-bb26-128ee8a82702" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4305f1ba-2ca0-4ea7-855f-aa205f33f6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_702af6bc-796e-4109-b888-0fe92b0112be" xlink:href="sesn-20211231.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ea492564-99cd-420a-bb26-128ee8a82702" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_702af6bc-796e-4109-b888-0fe92b0112be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_783c9470-0292-4827-88d1-961d3998c891" xlink:href="sesn-20211231.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ea492564-99cd-420a-bb26-128ee8a82702" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_783c9470-0292-4827-88d1-961d3998c891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_006f7f8c-1629-4992-9692-2b377572661a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ea492564-99cd-420a-bb26-128ee8a82702" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_006f7f8c-1629-4992-9692-2b377572661a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_86967139-c65b-464b-84c9-a733ebdf0469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9cbcc4d5-7356-4284-84a8-9fec51a650ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_86967139-c65b-464b-84c9-a733ebdf0469" xlink:to="loc_us-gaap_OperatingLeaseCost_9cbcc4d5-7356-4284-84a8-9fec51a650ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_4dfd486f-b316-4aa9-bf3e-a3a9eb599508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_86967139-c65b-464b-84c9-a733ebdf0469" xlink:to="loc_us-gaap_ShortTermLeaseCost_4dfd486f-b316-4aa9-bf3e-a3a9eb599508" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_92df71ee-a10b-496f-ae87-0275d091576b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_91095587-abff-488f-977d-958ee344c11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_92df71ee-a10b-496f-ae87-0275d091576b" xlink:to="loc_us-gaap_OperatingLeaseLiability_91095587-abff-488f-977d-958ee344c11c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c1644392-6864-420c-9607-2b9306607b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_92df71ee-a10b-496f-ae87-0275d091576b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c1644392-6864-420c-9607-2b9306607b3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_2f59295f-5d66-4e06-993d-9ac6d14b44f4" xlink:href="sesn-20211231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b304648-2e31-4e68-92d9-fc4cc84bb5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_2f59295f-5d66-4e06-993d-9ac6d14b44f4" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b304648-2e31-4e68-92d9-fc4cc84bb5d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_aed567e0-2c4f-4711-a032-fa6078dca9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_2f59295f-5d66-4e06-993d-9ac6d14b44f4" xlink:to="loc_us-gaap_CommonStockSharesIssued_aed567e0-2c4f-4711-a032-fa6078dca9dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9df0f025-ab28-421d-98b7-f6071fd58da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a04e864c-e6a8-4c2a-9abd-7e08b60b64a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9df0f025-ab28-421d-98b7-f6071fd58da2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a04e864c-e6a8-4c2a-9abd-7e08b60b64a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e643c6c2-eecf-4103-86d7-78ce9407b790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9df0f025-ab28-421d-98b7-f6071fd58da2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e643c6c2-eecf-4103-86d7-78ce9407b790" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d469ddc2-8f4d-4e79-a662-eefa518754c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a030afc0-88b3-4b64-b256-0c9796508cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d469ddc2-8f4d-4e79-a662-eefa518754c5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a030afc0-88b3-4b64-b256-0c9796508cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f4d1729b-d221-44c8-b468-92132769d396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d469ddc2-8f4d-4e79-a662-eefa518754c5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f4d1729b-d221-44c8-b468-92132769d396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1dab2d59-1cdc-4314-9b6a-ee2663b2c4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_329bdf8c-0d3d-4f9b-8039-34b409face1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1dab2d59-1cdc-4314-9b6a-ee2663b2c4a7" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_329bdf8c-0d3d-4f9b-8039-34b409face1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d788f4f-0edc-4bb9-8991-420da32c1268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1dab2d59-1cdc-4314-9b6a-ee2663b2c4a7" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d788f4f-0edc-4bb9-8991-420da32c1268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_df7805ed-6615-46f9-97c7-f1956c363025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1dab2d59-1cdc-4314-9b6a-ee2663b2c4a7" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_df7805ed-6615-46f9-97c7-f1956c363025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2c7f60cc-c1b0-4ed4-8f33-bb04f356262a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_54f1f894-c18f-4ef7-9daa-2df4df5fb5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2c7f60cc-c1b0-4ed4-8f33-bb04f356262a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_54f1f894-c18f-4ef7-9daa-2df4df5fb5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e00e3c42-c436-400d-9e40-3e13348005b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2c7f60cc-c1b0-4ed4-8f33-bb04f356262a" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e00e3c42-c436-400d-9e40-3e13348005b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_31ea626d-73e1-4bc3-bcc6-31fc272e5afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2c7f60cc-c1b0-4ed4-8f33-bb04f356262a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_31ea626d-73e1-4bc3-bcc6-31fc272e5afe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8d9c97d6-3718-497d-ad97-50807659e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8d9c97d6-3718-497d-ad97-50807659e5f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a54b7d78-4c0e-4117-9f67-8830d6600414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a54b7d78-4c0e-4117-9f67-8830d6600414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_446da6b4-74a9-4f53-9b8c-dcc4b94a12ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_446da6b4-74a9-4f53-9b8c-dcc4b94a12ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_08571902-ac2f-4fcc-9e57-56ad910f353d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_08571902-ac2f-4fcc-9e57-56ad910f353d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_bdd45cb4-1164-4709-8bbe-4d2d3d249b94" xlink:href="sesn-20211231.xsd#sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_bdd45cb4-1164-4709-8bbe-4d2d3d249b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_268cb789-9cb2-48ab-aad8-f388d9873703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_268cb789-9cb2-48ab-aad8-f388d9873703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1e0e516a-a475-4bd4-8060-7a521e07a324" xlink:href="sesn-20211231.xsd#sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1e0e516a-a475-4bd4-8060-7a521e07a324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fa997c82-fa19-4bf2-909a-a4090d741f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fa997c82-fa19-4bf2-909a-a4090d741f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dec242fe-a8b5-47f6-8a8d-76904e19645c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dec242fe-a8b5-47f6-8a8d-76904e19645c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3e964d11-9304-46de-8a43-ae6f765f2b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce928763-7dc9-42c0-b5a1-97fe8dca4c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3e964d11-9304-46de-8a43-ae6f765f2b01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ae6b07df-0b3b-4378-9d96-2eecae8d1258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_18282336-2926-42b9-b586-3f9a9ce84114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae6b07df-0b3b-4378-9d96-2eecae8d1258" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_18282336-2926-42b9-b586-3f9a9ce84114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_91dc5a6f-c560-49fc-b0cf-4b03f4275dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae6b07df-0b3b-4378-9d96-2eecae8d1258" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_91dc5a6f-c560-49fc-b0cf-4b03f4275dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_14959b06-d59a-4563-a5b1-cc415556260e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae6b07df-0b3b-4378-9d96-2eecae8d1258" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_14959b06-d59a-4563-a5b1-cc415556260e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_0a26acb6-4e6e-48d2-82f6-82e2dbda6c1f" xlink:href="sesn-20211231.xsd#sesn_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae6b07df-0b3b-4378-9d96-2eecae8d1258" xlink:to="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_0a26acb6-4e6e-48d2-82f6-82e2dbda6c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_453828bd-736d-4338-9d2c-a9d22fc24ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae6b07df-0b3b-4378-9d96-2eecae8d1258" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_453828bd-736d-4338-9d2c-a9d22fc24ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c87af743-8cb7-410c-9eea-dd2f2211e266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b2113fec-5910-4b57-8ff2-ea0a87a098ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c87af743-8cb7-410c-9eea-dd2f2211e266" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b2113fec-5910-4b57-8ff2-ea0a87a098ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_41afdf50-9939-4727-b635-6728795f2910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_29e41188-e0c3-483c-b764-21313596fd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_41afdf50-9939-4727-b635-6728795f2910" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_29e41188-e0c3-483c-b764-21313596fd44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8fb857a2-9fb7-4492-ae2e-38be890ad029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_41afdf50-9939-4727-b635-6728795f2910" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8fb857a2-9fb7-4492-ae2e-38be890ad029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8a808ce9-d9e8-4fe5-a91d-1a0ea9191161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_41afdf50-9939-4727-b635-6728795f2910" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8a808ce9-d9e8-4fe5-a91d-1a0ea9191161" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>sesn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ia4636b27f9234b07abcd0ce91b98d314_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_52c33954-3873-437f-8366-c64ffe6bfaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_52c33954-3873-437f-8366-c64ffe6bfaf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef11b1d3-7351-4186-8bce-1d6dc5596b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef11b1d3-7351-4186-8bce-1d6dc5596b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ae2e5033-6fc9-4a3f-89e0-d52b5bcfef83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ae2e5033-6fc9-4a3f-89e0-d52b5bcfef83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_370658b1-fd70-458f-a90f-f52852cb95ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_RestructuringCharges_370658b1-fd70-458f-a90f-f52852cb95ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58090188-2727-4ce5-ab79-a98e502a95ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58090188-2727-4ce5-ab79-a98e502a95ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1bac05f3-2524-47cf-8bb5-708b3d6c7e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1bac05f3-2524-47cf-8bb5-708b3d6c7e6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_eedf008d-3bff-4d38-9f5b-2b6ad4700525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_OperatingExpenses_eedf008d-3bff-4d38-9f5b-2b6ad4700525" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a0f9d53-d6b6-4adb-b075-3d22fbb74aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a0f9d53-d6b6-4adb-b075-3d22fbb74aa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_525455d5-5ad7-4d34-9fb2-9e2708d85f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_525455d5-5ad7-4d34-9fb2-9e2708d85f37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_5225ab0b-b81c-4e98-b4a0-5314455af123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_5225ab0b-b81c-4e98-b4a0-5314455af123" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad9a3652-6948-4b10-9236-747942bf0ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad9a3652-6948-4b10-9236-747942bf0ada" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae8c10c9-acc4-41bf-841f-6f0451518d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_NetIncomeLoss_ae8c10c9-acc4-41bf-841f-6f0451518d90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_24b3c808-86ae-434e-810b-397d187df5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_24b3c808-86ae-434e-810b-397d187df5c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_4da4f474-2516-49cd-a16e-7ba199127efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_4da4f474-2516-49cd-a16e-7ba199127efe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6bc39bfe-d23f-49db-86c8-9147ce82565f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6bc39bfe-d23f-49db-86c8-9147ce82565f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca5c957d-893d-4355-8ed7-c62fb317ad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca5c957d-893d-4355-8ed7-c62fb317ad7c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f897167f-1299-4e9b-ba07-b056d33fe9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_EarningsPerShareBasic_f897167f-1299-4e9b-ba07-b056d33fe9d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_20f0e572-5a21-4e04-b769-32e04152afdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_EarningsPerShareDiluted_20f0e572-5a21-4e04-b769-32e04152afdb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91cafcb5-6e90-4d71-a9a3-2173b891d1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91cafcb5-6e90-4d71-a9a3-2173b891d1fc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5e73da0-9ffe-4bfc-96b0-c6038bd14d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5e73da0-9ffe-4bfc-96b0-c6038bd14d08" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:to="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:to="loc_srt_ProductsAndServicesDomain_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23807835-d079-41a0-835b-9e6b161af479" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:to="loc_srt_ProductsAndServicesDomain_23807835-d079-41a0-835b-9e6b161af479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseRevenueMember_3bf2a504-98ec-41ae-8f08-fd3763b8dae2" xlink:href="sesn-20211231.xsd#sesn_LicenseRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_23807835-d079-41a0-835b-9e6b161af479" xlink:to="loc_sesn_LicenseRevenueMember_3bf2a504-98ec-41ae-8f08-fd3763b8dae2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i0c394f5c323f41e3a7c2999d057e1eb4_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d882bac1-6e8b-44c6-913a-6ab07fdc257e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d882bac1-6e8b-44c6-913a-6ab07fdc257e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1d7c5408-d5f5-4379-9324-ba85191cde8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_SharesOutstanding_1d7c5408-d5f5-4379-9324-ba85191cde8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_313cc08b-cdb2-4ca1-b674-0fc0803f4d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockholdersEquity_313cc08b-cdb2-4ca1-b674-0fc0803f4d78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f48fd4fd-f2bd-4693-86a0-02435943f078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_NetIncomeLoss_f48fd4fd-f2bd-4693-86a0-02435943f078" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_54f28f1c-3e3a-4500-98c8-306030b5c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_54f28f1c-3e3a-4500-98c8-306030b5c26d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07bd9d95-6d8a-4f60-8bba-891158569f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07bd9d95-6d8a-4f60-8bba-891158569f5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ac285bd1-5bee-4cc7-a083-f5ea8ebe64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ac285bd1-5bee-4cc7-a083-f5ea8ebe64b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08c3f898-6d7f-4c56-ab38-65708e2ccf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08c3f898-6d7f-4c56-ab38-65708e2ccf54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bff35868-c138-4007-9749-9934b2d9e82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bff35868-c138-4007-9749-9934b2d9e82f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_0137fe78-a1ef-4b4a-92a9-1f230d1e4056" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_0137fe78-a1ef-4b4a-92a9-1f230d1e4056" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_be269f31-81d5-4efe-9192-82782ef93422" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_be269f31-81d5-4efe-9192-82782ef93422" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c35a7a3d-1979-4e53-bd0a-1e46e6139942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c35a7a3d-1979-4e53-bd0a-1e46e6139942" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30c0e8f5-6081-4132-ae26-6cc02d7ccee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30c0e8f5-6081-4132-ae26-6cc02d7ccee5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_07b09c0a-9bed-4ba4-9aeb-25f9d34a6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa3c72f4-2c87-46b4-ab8f-d390132f5337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d882bac1-6e8b-44c6-913a-6ab07fdc257e" xlink:to="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e4729e5-178b-4ad9-8c0c-d26fecacfd48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:to="loc_us-gaap_EquityComponentDomain_2e4729e5-178b-4ad9-8c0c-d26fecacfd48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:to="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_da4975b3-a17e-498e-8b86-4b4be1c56874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:to="loc_us-gaap_CommonStockMember_da4975b3-a17e-498e-8b86-4b4be1c56874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_09056783-6eff-47c1-b0a9-b67c6282a7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_09056783-6eff-47c1-b0a9-b67c6282a7c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cb40a818-3704-4a5c-8f90-d7839c43801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:to="loc_us-gaap_RetainedEarningsMember_cb40a818-3704-4a5c-8f90-d7839c43801a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aab3f495-48d3-4456-9502-2483535b8eb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aab3f495-48d3-4456-9502-2483535b8eb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f65a7431-9b7d-49f7-89a0-ead49aace8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f65a7431-9b7d-49f7-89a0-ead49aace8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_f595e604-fc7a-4cc1-af34-c78284b784cb" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f65a7431-9b7d-49f7-89a0-ead49aace8f6" xlink:to="loc_sesn_ATMFacilityMember_f595e604-fc7a-4cc1-af34-c78284b784cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended" id="idc384c2608224b029c45c42481ac9617_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_477de774-6913-41ad-9501-c9862185cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1d1be784-0c82-4405-89e8-0b9b169c0c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_477de774-6913-41ad-9501-c9862185cb0e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1d1be784-0c82-4405-89e8-0b9b169c0c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_477de774-6913-41ad-9501-c9862185cb0e" xlink:to="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cc1662a-403a-4bf9-85a4-3b1290998a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cc1662a-403a-4bf9-85a4-3b1290998a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_5f31e7e3-0599-4156-a229-46d3800f7a0a" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cc1662a-403a-4bf9-85a4-3b1290998a16" xlink:to="loc_sesn_ATMFacilityMember_5f31e7e3-0599-4156-a229-46d3800f7a0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="i20a3cd44a8324d3e8f9e7a34717b3795_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfPatients_d0fc30ad-3559-413c-8fdf-6ffe28d3f709" xlink:href="sesn-20211231.xsd#sesn_NumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_NumberOfPatients_d0fc30ad-3559-413c-8fdf-6ffe28d3f709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_5ff5c21d-3b5f-4689-ab10-e0b2e7d25695" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_5ff5c21d-3b5f-4689-ab10-e0b2e7d25695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eec77b94-805e-4edb-b12b-5f555147e58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eec77b94-805e-4edb-b12b-5f555147e58b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_b02feeda-e0d4-41f7-a1d2-944c46cbeb53" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_b02feeda-e0d4-41f7-a1d2-944c46cbeb53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_fb2d41bc-4feb-4a87-a6f9-27c3cc909a26" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_fb2d41bc-4feb-4a87-a6f9-27c3cc909a26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_b0864e8a-9657-45be-be4c-6ddab47e147a" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_b0864e8a-9657-45be-be4c-6ddab47e147a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_02f8e3ff-d9d2-4234-856a-67721739a85e" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_02f8e3ff-d9d2-4234-856a-67721739a85e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed3bfeae-a5b8-4a61-b5f3-60e3c04a8630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed3bfeae-a5b8-4a61-b5f3-60e3c04a8630" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1c32fb3-1bb3-435d-9032-bb567efe4859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1c32fb3-1bb3-435d-9032-bb567efe4859" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d838c33a-b427-4f35-9156-5ecd9b03e8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d838c33a-b427-4f35-9156-5ecd9b03e8d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83478654-bd09-4608-b5b2-5ec5c3a51e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83478654-bd09-4608-b5b2-5ec5c3a51e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_b407f945-9b36-44b8-871b-bb6d2df09e84" xlink:href="sesn-20211231.xsd#sesn_ViventiaBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83478654-bd09-4608-b5b2-5ec5c3a51e6a" xlink:to="loc_sesn_ViventiaBioInc.Member_b407f945-9b36-44b8-871b-bb6d2df09e84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8804a802-94ac-48d6-bdba-fe2d2bbea149_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:to="loc_srt_ProductsAndServicesDomain_8804a802-94ac-48d6-bdba-fe2d2bbea149_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ef9ac00-0e0e-469d-8caa-eb6a1fd6df1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:to="loc_srt_ProductsAndServicesDomain_8ef9ac00-0e0e-469d-8caa-eb6a1fd6df1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_376ea89a-aa4c-4a5f-a851-943722364122" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8ef9ac00-0e0e-469d-8caa-eb6a1fd6df1d" xlink:to="loc_sesn_ViciniumMember_376ea89a-aa4c-4a5f-a851-943722364122" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_563da234-98db-4961-a0e6-fe8341ae4e33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_563da234-98db-4961-a0e6-fe8341ae4e33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5e4d34f-89e1-4759-af5c-361688f69b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5e4d34f-89e1-4759-af5c-361688f69b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_4b681c07-23af-4c07-87d6-d2bd22416e47" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5e4d34f-89e1-4759-af5c-361688f69b84" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_4b681c07-23af-4c07-87d6-d2bd22416e47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a4006a9b-c97e-4cb8-8709-7b61f7894147_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:to="loc_srt_SegmentGeographicalDomain_a4006a9b-c97e-4cb8-8709-7b61f7894147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:to="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0d6d0253-a92a-4c7c-8ff7-7033485e161a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:to="loc_country_US_0d6d0253-a92a-4c7c-8ff7-7033485e161a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6698bb47-c0e0-467e-89bd-2c67bd87ac5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:to="loc_srt_EuropeMember_6698bb47-c0e0-467e-89bd-2c67bd87ac5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_b98f83f9-6b87-49c2-abb2-f74949d6db63" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:to="loc_country_JP_b98f83f9-6b87-49c2-abb2-f74949d6db63" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="ic3edf0479f454b00b9f923b7cb9c769b_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_0c860d18-d828-4744-a96d-4f9f3bf1ae92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_0c860d18-d828-4744-a96d-4f9f3bf1ae92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7aed4a1f-05f5-484b-8639-b75c8389928e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7aed4a1f-05f5-484b-8639-b75c8389928e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2dfb983e-56d2-48c7-915e-8375edcf15c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2dfb983e-56d2-48c7-915e-8375edcf15c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32f733f9-2a10-49f4-a4a6-538140ffa087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32f733f9-2a10-49f4-a4a6-538140ffa087" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_7b0150bb-644a-4e7a-87e0-33143c325b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_NumberOfReportingUnits_7b0150bb-644a-4e7a-87e0-33143c325b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0affc524-bad5-4a95-8b66-07fb893d2941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_Goodwill_0affc524-bad5-4a95-8b66-07fb893d2941" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b6147506-6e62-471b-8a38-0dcfc5d5d4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b6147506-6e62-471b-8a38-0dcfc5d5d4de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_e942f94f-da25-49ce-b738-c11f1549dec1" xlink:href="sesn-20211231.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_e942f94f-da25-49ce-b738-c11f1549dec1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_1aea22a2-f09b-4c75-9d68-ccacbd225efa" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_1aea22a2-f09b-4c75-9d68-ccacbd225efa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_925937bf-39f1-4686-8453-1f1b8b814eb7" xlink:href="sesn-20211231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_WeightedAverageCostOfCapital_925937bf-39f1-4686-8453-1f1b8b814eb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DebtInstrumentIndexRateHighYield_0dd468e7-4f3f-4004-8184-45b326a1114d" xlink:href="sesn-20211231.xsd#sesn_DebtInstrumentIndexRateHighYield"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_DebtInstrumentIndexRateHighYield_0dd468e7-4f3f-4004-8184-45b326a1114d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f38d9c19-af00-4bbf-8e73-7dcb8ac00d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f38d9c19-af00-4bbf-8e73-7dcb8ac00d59" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b4cfbfea-a2ae-47f4-95f1-094a847e7bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_OperatingLeaseLiability_b4cfbfea-a2ae-47f4-95f1-094a847e7bbe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_485247f7-981e-4e14-a9df-9aa321718aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_485247f7-981e-4e14-a9df-9aa321718aed" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0ea55d09-7605-47bf-900c-0b15eeda4d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0ea55d09-7605-47bf-900c-0b15eeda4d8f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_721945ba-91ba-4ad0-9db8-e65f05dd14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_721945ba-91ba-4ad0-9db8-e65f05dd14e1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePayment_75ab2985-b4fc-46ce-8044-6d195c1155cb" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementMilestonePayment_75ab2985-b4fc-46ce-8044-6d195c1155cb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePaymentTerm_7c143b54-dc66-42d1-863a-0e41a2c44830" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestonePaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementMilestonePaymentTerm_7c143b54-dc66-42d1-863a-0e41a2c44830" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0871a37f-ddf9-4a84-a85c-a29502cc973f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0871a37f-ddf9-4a84-a85c-a29502cc973f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4861ed7a-15ad-46a9-bb72-19a78d2614c2" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4861ed7a-15ad-46a9-bb72-19a78d2614c2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2892c719-5de7-4a55-a2c3-97e96c99aadd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2892c719-5de7-4a55-a2c3-97e96c99aadd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aed0dc1b-767a-4bdb-b9ef-1510b69a1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_EquipmentMember_aed0dc1b-767a-4bdb-b9ef-1510b69a1ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_712bcf0e-6bfb-49e4-a5d7-9cbe0a1b9923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_712bcf0e-6bfb-49e4-a5d7-9cbe0a1b9923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_76c55ab6-7e52-4309-bf53-ff00f767c9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_ComputerEquipmentMember_76c55ab6-7e52-4309-bf53-ff00f767c9e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_97eb878d-cb86-4c21-b23b-929a5e0a989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_97eb878d-cb86-4c21-b23b-929a5e0a989e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cbeee939-d80b-4ddb-86f3-5b8a48787ebb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:to="loc_srt_ProductsAndServicesDomain_cbeee939-d80b-4ddb-86f3-5b8a48787ebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:to="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_c66c6c3b-b94b-439b-9e00-501d321dbf35" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:to="loc_sesn_ViciniumMember_c66c6c3b-b94b-439b-9e00-501d321dbf35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_84462782-cc88-4550-96a2-b0109d09b0af" xlink:href="sesn-20211231.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:to="loc_sesn_EBI031Member_84462782-cc88-4550-96a2-b0109d09b0af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:to="loc_srt_SegmentGeographicalDomain_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c10c64f7-df78-4590-912d-0aa431d44962" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:to="loc_srt_SegmentGeographicalDomain_c10c64f7-df78-4590-912d-0aa431d44962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3e709ab3-f236-43cc-a374-8c868c633217" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c10c64f7-df78-4590-912d-0aa431d44962" xlink:to="loc_country_US_3e709ab3-f236-43cc-a374-8c868c633217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9954582-b341-4386-8053-35d363410684_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9954582-b341-4386-8053-35d363410684_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_340ab38c-9a86-47e0-bbe3-c899b3d65db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_340ab38c-9a86-47e0-bbe3-c899b3d65db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_08bdd6ab-14de-41d2-bddc-0a53dd4095a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:to="loc_us-gaap_LicensingAgreementsMember_08bdd6ab-14de-41d2-bddc-0a53dd4095a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a9b5601-3095-4fe5-aa34-4b5156802d9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a9b5601-3095-4fe5-aa34-4b5156802d9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17814a6-6ad3-4b64-9547-0866e6e860f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17814a6-6ad3-4b64-9547-0866e6e860f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fca18506-e345-4475-8b13-43e0f2d9b31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17814a6-6ad3-4b64-9547-0866e6e860f9" xlink:to="loc_us-gaap_PerformanceSharesMember_fca18506-e345-4475-8b13-43e0f2d9b31b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79a5a9c0-8f57-40d2-b28c-bcbfa2a74b52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79a5a9c0-8f57-40d2-b28c-bcbfa2a74b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_96045b0e-42d3-4f54-9e4b-48a497480a02" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79a5a9c0-8f57-40d2-b28c-bcbfa2a74b52" xlink:to="loc_sesn_RocheMember_96045b0e-42d3-4f54-9e4b-48a497480a02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d5513f8-5940-4f65-b7b6-7bd6873b7f50_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d5513f8-5940-4f65-b7b6-7bd6873b7f50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_49b1a517-5bf3-43f5-b2a2-5b7848f9a725" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_49b1a517-5bf3-43f5-b2a2-5b7848f9a725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6fbe0859-c849-4d84-947d-d6f153fa73f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_49b1a517-5bf3-43f5-b2a2-5b7848f9a725" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6fbe0859-c849-4d84-947d-d6f153fa73f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_198a0f29-e8cc-4cf7-9da2-bc6f889f484d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:to="loc_srt_RangeMember_198a0f29-e8cc-4cf7-9da2-bc6f889f484d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:to="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_af1779a8-40e8-4d21-b410-61266ac1011a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:to="loc_srt_MinimumMember_af1779a8-40e8-4d21-b410-61266ac1011a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9910fdfe-4b56-40b4-a3bc-7353234db11f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:to="loc_srt_MaximumMember_9910fdfe-4b56-40b4-a3bc-7353234db11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0a33da55-24ca-4dc2-89f1-d89a376c4342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0a33da55-24ca-4dc2-89f1-d89a376c4342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4c8d7c34-d5a5-4118-97fd-50309ed2aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4c8d7c34-d5a5-4118-97fd-50309ed2aacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_e6f36f8e-e788-4a4f-a1e5-bdda6d30b369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4c8d7c34-d5a5-4118-97fd-50309ed2aacb" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_e6f36f8e-e788-4a4f-a1e5-bdda6d30b369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6058c7f8-f778-41ef-9181-d94b32a6dc3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6058c7f8-f778-41ef-9181-d94b32a6dc3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8166d84e-eb7d-440f-86e3-20b95bfe6c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8166d84e-eb7d-440f-86e3-20b95bfe6c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_183b130f-9dea-4903-b33b-cdadbf4474b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8166d84e-eb7d-440f-86e3-20b95bfe6c42" xlink:to="loc_us-gaap_SubsequentEventMember_183b130f-9dea-4903-b33b-cdadbf4474b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i90d103449553420f81ff348ceca8d7f9_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9717008-8214-4222-baa1-5988d568ad33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9717008-8214-4222-baa1-5988d568ad33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_419bf49b-e142-44e0-afb6-e68e03785ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9717008-8214-4222-baa1-5988d568ad33" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_419bf49b-e142-44e0-afb6-e68e03785ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_d39d460f-267e-424e-8a8f-0b12d2529eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_d39d460f-267e-424e-8a8f-0b12d2529eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92df22b4-2626-4d18-9467-6bf435041cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92df22b4-2626-4d18-9467-6bf435041cff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9d4cc62a-67ec-4433-88bb-045f08e5b9fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9d4cc62a-67ec-4433-88bb-045f08e5b9fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_89ec9fd4-7fdd-4fcd-8879-7c0716b5d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_89ec9fd4-7fdd-4fcd-8879-7c0716b5d45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_89ec9fd4-7fdd-4fcd-8879-7c0716b5d45c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75fced28-98cc-49cd-b165-49094a77cfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75fced28-98cc-49cd-b165-49094a77cfbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b1d5dbd3-65c1-4665-bba9-2a3dda0290cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b1d5dbd3-65c1-4665-bba9-2a3dda0290cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0766a7e-c4d6-4167-ae62-1b43ba90d417_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0766a7e-c4d6-4167-ae62-1b43ba90d417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2931512e-1397-41bb-9585-28044dc2e772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2931512e-1397-41bb-9585-28044dc2e772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fce2909e-021b-4820-9108-334343388471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2931512e-1397-41bb-9585-28044dc2e772" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fce2909e-021b-4820-9108-334343388471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d45bb67b-3448-4e6e-84bb-a6b264656cee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d45bb67b-3448-4e6e-84bb-a6b264656cee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5568c1d0-a98e-4120-b185-edd872ba7246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5568c1d0-a98e-4120-b185-edd872ba7246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7b804462-a62d-4a95-a325-53da756f82bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7b804462-a62d-4a95-a325-53da756f82bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_68d60042-e457-4365-9f57-7494cb7847f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_68d60042-e457-4365-9f57-7494cb7847f9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="ib0c5ce91b9a2461f8107aa875a29f006_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_37da468b-59e1-4335-a002-5a75dffbf450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_37da468b-59e1-4335-a002-5a75dffbf450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_ac66e097-22b2-4e21-87f8-1cca0c4520c8" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_ac66e097-22b2-4e21-87f8-1cca0c4520c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_eb6b407a-a14f-47b0-a6ad-8d7a496ebd3e" xlink:href="sesn-20211231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_sesn_WeightedAverageCostOfCapital_eb6b407a-a14f-47b0-a6ad-8d7a496ebd3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4ec2a712-8515-4c6d-abbd-dfdcf3324910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4ec2a712-8515-4c6d-abbd-dfdcf3324910" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_ed3ca09e-7f2b-4436-8b61-7d083964151d" xlink:href="sesn-20211231.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_ed3ca09e-7f2b-4436-8b61-7d083964151d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e63866db-00d2-4741-a8d2-20033bd45d21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e63866db-00d2-4741-a8d2-20033bd45d21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5eff4da1-7d6f-40a4-af25-21b4106bdf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5eff4da1-7d6f-40a4-af25-21b4106bdf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d03cb129-0b92-41a0-ba9c-9b520c126848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5eff4da1-7d6f-40a4-af25-21b4106bdf10" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d03cb129-0b92-41a0-ba9c-9b520c126848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:to="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e516b78-c569-4229-8748-a145fdf931e5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:to="loc_srt_RangeMember_3e516b78-c569-4229-8748-a145fdf931e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:to="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f355b5f-5186-4c95-9a35-9a227d7fd3bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:to="loc_srt_MinimumMember_7f355b5f-5186-4c95-9a35-9a227d7fd3bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_620fabaa-42dc-4616-9273-3f6daa515c3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:to="loc_srt_MaximumMember_620fabaa-42dc-4616-9273-3f6daa515c3f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended" id="iceb2493416df42e58c0d67edf7c179e7_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b19849e1-ee81-4750-b87c-96a2459afd27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b19849e1-ee81-4750-b87c-96a2459afd27" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_391ab53c-4ccd-4d5b-b1b5-108db88966be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_391ab53c-4ccd-4d5b-b1b5-108db88966be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_d5a53863-a5bd-4643-aaa5-9390d8ca9eb4" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_d5a53863-a5bd-4643-aaa5-9390d8ca9eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_d0236ffd-4a0c-47b0-b628-f1fcee8a7deb" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_d0236ffd-4a0c-47b0-b628-f1fcee8a7deb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2aeaf00-351c-4074-8c0e-fbf1fbbefdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b19849e1-ee81-4750-b87c-96a2459afd27" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db69104b-34f8-4c06-9298-3ebb33102e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db69104b-34f8-4c06-9298-3ebb33102e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1e0eed44-b2ee-404e-8e1a-c3c3cf882107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db69104b-34f8-4c06-9298-3ebb33102e93" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1e0eed44-b2ee-404e-8e1a-c3c3cf882107" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RECEIVABLESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended" id="i2702d9c329124b149e4de6988a18c1fa_RECEIVABLESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fd52c55a-b773-4787-a2e1-1de97ef555d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fd52c55a-b773-4787-a2e1-1de97ef555d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_13d6a41e-b387-460e-856d-0b1dfbaa7d8a" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_13d6a41e-b387-460e-856d-0b1dfbaa7d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_8095be19-a3b1-4dae-b72f-ec03081e8e3f" xlink:href="sesn-20211231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_8095be19-a3b1-4dae-b72f-ec03081e8e3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_50a28e7a-e21c-4bb9-a039-693b73dbf9c8" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_50a28e7a-e21c-4bb9-a039-693b73dbf9c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f3808fba-bde7-498d-8f06-c79f30dbe344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f3808fba-bde7-498d-8f06-c79f30dbe344" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_31b51389-b512-4da5-97df-f0422f28adce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_31b51389-b512-4da5-97df-f0422f28adce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromValueAddedTaxRecovery_3c4e508d-62f2-473f-a980-4b48bc32d470" xlink:href="sesn-20211231.xsd#sesn_ProceedsFromValueAddedTaxRecovery"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_ProceedsFromValueAddedTaxRecovery_3c4e508d-62f2-473f-a980-4b48bc32d470" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_610186e5-88f2-4d2d-8dc4-b09665698dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_610186e5-88f2-4d2d-8dc4-b09665698dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a72307f7-3cf5-49f8-bbdc-98ff53537e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_610186e5-88f2-4d2d-8dc4-b09665698dc7" xlink:to="loc_us-gaap_SubsequentEventMember_a72307f7-3cf5-49f8-bbdc-98ff53537e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:to="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03795dca-f06e-4833-b263-db5be230274b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03795dca-f06e-4833-b263-db5be230274b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_e9c6b699-b31a-40e1-a649-260bbbb07dd1" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:to="loc_sesn_RocheMember_e9c6b699-b31a-40e1-a649-260bbbb07dd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_fd75e875-e6d2-4fe4-9ebf-424cbcbb8485" xlink:href="sesn-20211231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_fd75e875-e6d2-4fe4-9ebf-424cbcbb8485" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" xlink:type="simple" xlink:href="sesn-20211231.xsd#PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" xlink:type="extended" id="icd4a0714b14143caa9c05df513c03dc5_PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_46d9f8fd-3d8a-42db-bb08-b1653cf5f239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_46d9f8fd-3d8a-42db-bb08-b1653cf5f239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba464af1-027f-44b9-bdd7-388eebd875a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba464af1-027f-44b9-bdd7-388eebd875a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2fefb36d-00df-4df4-bcf3-d997610ae711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2fefb36d-00df-4df4-bcf3-d997610ae711" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_965be303-14d5-40d6-8bc1-ceb2ee318305_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_965be303-14d5-40d6-8bc1-ceb2ee318305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aaaa5a0d-bba7-4ecd-bf97-a88199055663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_EquipmentMember_aaaa5a0d-bba7-4ecd-bf97-a88199055663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d248c45a-6b1a-49be-990a-a1b7b922e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d248c45a-6b1a-49be-990a-a1b7b922e8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_55d859ce-7baa-4a5b-b885-f9ed9efdf386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_ComputerEquipmentMember_55d859ce-7baa-4a5b-b885-f9ed9efdf386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_6f8cb307-cb02-4b58-8af4-099ea6423a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_6f8cb307-cb02-4b58-8af4-099ea6423a1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8813db97-6289-44cb-a624-e765ca4577ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8813db97-6289-44cb-a624-e765ca4577ac" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="extended" id="i08f729f805b240cfab41d06dbd148e5e_INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8bdd01f-46ff-4cd2-9465-434a97716fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_1b98aece-3cb6-46b4-8eb1-9b797987ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8bdd01f-46ff-4cd2-9465-434a97716fd2" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_1b98aece-3cb6-46b4-8eb1-9b797987ea64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8bdd01f-46ff-4cd2-9465-434a97716fd2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b57051ab-1a4f-486f-b088-0b2e9f57cd87_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:to="loc_srt_SegmentGeographicalDomain_b57051ab-1a4f-486f-b088-0b2e9f57cd87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:to="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1e38b1f9-31d2-4ccb-81e7-343947b25537" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:to="loc_country_US_1e38b1f9-31d2-4ccb-81e7-343947b25537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b1c6ccda-b914-4513-9b78-2f06be2ae6fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:to="loc_srt_EuropeMember_b1c6ccda-b914-4513-9b78-2f06be2ae6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c8e7d44-c1d4-4795-b9b3-fef529d32770_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:to="loc_srt_ProductsAndServicesDomain_3c8e7d44-c1d4-4795-b9b3-fef529d32770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4e253bad-0d2e-4863-a99c-9aca8c6e11d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:to="loc_srt_ProductsAndServicesDomain_4e253bad-0d2e-4863-a99c-9aca8c6e11d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_d2538ed3-3b10-44f0-bb5f-99110d99e92a" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4e253bad-0d2e-4863-a99c-9aca8c6e11d7" xlink:to="loc_sesn_ViciniumMember_d2538ed3-3b10-44f0-bb5f-99110d99e92a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cb40bff-4e5d-432d-b502-b07669fa8384_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cb40bff-4e5d-432d-b502-b07669fa8384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b7b591c-86c6-42a9-a475-4e2dcccdb819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b7b591c-86c6-42a9-a475-4e2dcccdb819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b5d0d6b2-7fb7-4ef0-a0c9-7469a809d750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b7b591c-86c6-42a9-a475-4e2dcccdb819" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b5d0d6b2-7fb7-4ef0-a0c9-7469a809d750" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INTANGIBLESANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="extended" id="ic12bf98c61414866af99e59e5688ffa2_INTANGIBLESANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_80fe6290-2145-44f4-bd2a-518f52600a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_80fe6290-2145-44f4-bd2a-518f52600a0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ec65c8a-f3da-49d1-ae17-dda3f05da456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_Goodwill_0ec65c8a-f3da-49d1-ae17-dda3f05da456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_27ccf664-44f6-4a0b-afd0-bc96ecf07fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_27ccf664-44f6-4a0b-afd0-bc96ecf07fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_07622c35-7944-4ea0-857d-15a6e400db78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_07622c35-7944-4ea0-857d-15a6e400db78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:to="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d92716ac-09e2-4949-a9b3-5a72f550b69f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:to="loc_srt_RangeMember_d92716ac-09e2-4949-a9b3-5a72f550b69f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:to="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1980764e-810f-41fb-b31c-798ad2430ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:to="loc_srt_MinimumMember_1980764e-810f-41fb-b31c-798ad2430ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6210025c-f0f0-419a-b67d-2991891af004" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:to="loc_srt_MaximumMember_6210025c-f0f0-419a-b67d-2991891af004" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended" id="ic67cb698e4924c91853cda9c15a40ec2_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_271c7fd9-5fcc-4649-8c59-0845dc08490a" xlink:href="sesn-20211231.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_271c7fd9-5fcc-4649-8c59-0845dc08490a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6279c9f3-fa2b-45b5-859c-50955345778f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6279c9f3-fa2b-45b5-859c-50955345778f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_6ca4eec0-16c2-4109-8e2c-3fe776539857" xlink:href="sesn-20211231.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_6ca4eec0-16c2-4109-8e2c-3fe776539857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d26e2eb3-7d4f-4eec-bc57-4ae4a0bcbfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d26e2eb3-7d4f-4eec-bc57-4ae4a0bcbfc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_43e0b7c2-e309-42c4-8062-e187fefa08bb" xlink:href="sesn-20211231.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_43e0b7c2-e309-42c4-8062-e187fefa08bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_4fe123bd-db83-466d-9886-bbc53ae5c8df" xlink:href="sesn-20211231.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_4fe123bd-db83-466d-9886-bbc53ae5c8df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9731ccd3-9493-425a-a07e-a31ffc532fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_ShortTermLeaseCost_9731ccd3-9493-425a-a07e-a31ffc532fe9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f7773179-0513-4e80-89c7-a70c87cc8c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseCost_f7773179-0513-4e80-89c7-a70c87cc8c57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0e91e4a4-8ed7-4dee-aabd-32ae2ab5eddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0e91e4a4-8ed7-4dee-aabd-32ae2ab5eddc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a06da408-9863-4fad-84e5-8f518795885d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a06da408-9863-4fad-84e5-8f518795885d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d51fa7bb-17d8-4dd5-913b-578d26fce6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d51fa7bb-17d8-4dd5-913b-578d26fce6f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:to="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1ad618fe-486d-407e-acc0-9d28e87e5011_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:to="loc_srt_SegmentGeographicalDomain_1ad618fe-486d-407e-acc0-9d28e87e5011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:to="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_281b691d-87ea-4f6a-99bf-d13eafe1b614" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_country_CA_281b691d-87ea-4f6a-99bf-d13eafe1b614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MassachusettsAndPennsylvaniaMember_5c5747a6-c17d-4967-ad09-0ecf4612326c" xlink:href="sesn-20211231.xsd#sesn_MassachusettsAndPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_sesn_MassachusettsAndPennsylvaniaMember_5c5747a6-c17d-4967-ad09-0ecf4612326c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_bf63bed6-ece6-4010-b92b-f1343559190d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_stpr_MA_bf63bed6-ece6-4010-b92b-f1343559190d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_1ef32233-d94a-4cce-bd25-ae87f1a778bd" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_stpr_PA_1ef32233-d94a-4cce-bd25-ae87f1a778bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:to="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aba1f478-c004-4a1b-99bc-d191c5a2b427_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:to="loc_srt_RangeMember_aba1f478-c004-4a1b-99bc-d191c5a2b427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:to="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0c8cf493-9e2b-46de-98a9-62bddb6e6893" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:to="loc_srt_MinimumMember_0c8cf493-9e2b-46de-98a9-62bddb6e6893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f24c8339-7c0a-477f-b636-22850443f0b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:to="loc_srt_MaximumMember_f24c8339-7c0a-477f-b636-22850443f0b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="extended" id="i21ee6f09e1d54deeba1cbc6858ac1ec4_STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d44ba0e-cb36-44c6-a755-182c6a7608b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d44ba0e-cb36-44c6-a755-182c6a7608b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_1eb7080a-7455-4fa7-b4da-2efed38f5fd0" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_1eb7080a-7455-4fa7-b4da-2efed38f5fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_ab22f0b7-3d93-4c6a-980f-9ff7e58f8a99" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_ab22f0b7-3d93-4c6a-980f-9ff7e58f8a99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_28e8142e-b612-43f9-b606-2fc780b8a6c4" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_28e8142e-b612-43f9-b606-2fc780b8a6c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cdadf42-73b9-4cc6-a5ef-55a1598fa2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cdadf42-73b9-4cc6-a5ef-55a1598fa2e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6736a87c-7c73-42e8-9863-a55c45b445e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6736a87c-7c73-42e8-9863-a55c45b445e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_2c32ba22-0fc2-45c7-b6de-b0eadc3b558a" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_2c32ba22-0fc2-45c7-b6de-b0eadc3b558a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_248859d8-8f83-4d32-a635-61f2d022303c" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_248859d8-8f83-4d32-a635-61f2d022303c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b6dd2a37-671a-4ed8-85d0-16e78ade8c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b6dd2a37-671a-4ed8-85d0-16e78ade8c09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_db6752f6-b2da-4dee-9155-deabdbf844cc" xlink:href="sesn-20211231.xsd#sesn_CommonStockAndWarrantOrRightsPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_db6752f6-b2da-4dee-9155-deabdbf844cc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6eafdc36-78bf-4a7e-946e-6da580cd6a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6eafdc36-78bf-4a7e-946e-6da580cd6a57" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_39e0eb80-8149-4e8e-b854-d500829ed580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_39e0eb80-8149-4e8e-b854-d500829ed580" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:to="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fc717b16-4c0b-4875-8143-d329ce9fb549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:to="loc_us-gaap_CreditFacilityDomain_fc717b16-4c0b-4875-8143-d329ce9fb549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6170ff95-1301-4072-ad0c-c54499598597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:to="loc_us-gaap_CreditFacilityDomain_6170ff95-1301-4072-ad0c-c54499598597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_3113d467-a245-472c-a573-acf86955eee2" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6170ff95-1301-4072-ad0c-c54499598597" xlink:to="loc_sesn_ATMFacilityMember_3113d467-a245-472c-a573-acf86955eee2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="extended" id="ifbccf099f95d482faca303266a9ee3af_STOCKHOLDERSEQUITYDEFICITCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5891c7e2-045c-45ec-85e0-633d64d458c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5891c7e2-045c-45ec-85e0-633d64d458c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_78cfbb0a-baf3-42da-99bf-a7e998508d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_CommonStockSharesIssued_78cfbb0a-baf3-42da-99bf-a7e998508d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_51a99b1b-98c0-408e-8cf2-273a91fa64db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_51a99b1b-98c0-408e-8cf2-273a91fa64db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_3f3f5e5e-8fdf-45c5-ba7c-9d5d03fa6d8a" xlink:href="sesn-20211231.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_3f3f5e5e-8fdf-45c5-ba7c-9d5d03fa6d8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_388572b8-761f-4a80-ab00-04aa48c22bbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:to="loc_us-gaap_EquityComponentDomain_388572b8-761f-4a80-ab00-04aa48c22bbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca6012ce-23a2-4755-8e06-147407aaa508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:to="loc_us-gaap_EquityComponentDomain_ca6012ce-23a2-4755-8e06-147407aaa508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3d3d0be1-c068-488f-8c9c-6383d5d27320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ca6012ce-23a2-4755-8e06-147407aaa508" xlink:to="loc_us-gaap_CommonStockMember_3d3d0be1-c068-488f-8c9c-6383d5d27320" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended" id="ib3ae6a39ed6e4d1ca387a987b1fbdd65_STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_99b4aaaa-0cb4-4845-b05d-7dc531fcd4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_99b4aaaa-0cb4-4845-b05d-7dc531fcd4d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:href="sesn-20211231.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39718321-57ed-4392-ae79-7b264164ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39718321-57ed-4392-ae79-7b264164ef9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_1bd47293-3d6d-4f77-ad81-9eb284f653e4" xlink:href="sesn-20211231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_1bd47293-3d6d-4f77-ad81-9eb284f653e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:to="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b390970-ca05-45a1-ad08-a42e38280ae6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b390970-ca05-45a1-ad08-a42e38280ae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4fa4b879-51f4-4451-ac22-f8da2646fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_WarrantMember_4fa4b879-51f4-4451-ac22-f8da2646fc04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aaa81f08-ece3-4561-99e2-d7a5aa844bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aaa81f08-ece3-4561-99e2-d7a5aa844bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b329a182-4666-46cf-b6dc-bb28bc28e065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b329a182-4666-46cf-b6dc-bb28bc28e065" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_3590532b-e68b-486e-9875-354c24e92ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_StockCompensationPlanMember_3590532b-e68b-486e-9875-354c24e92ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5d2836ba-d04b-4fbb-b872-720c3d3cfe55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_EmployeeStockMember_5d2836ba-d04b-4fbb-b872-720c3d3cfe55" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="extended" id="i5ac15b17a83a4d5ab09e52e9efe28b82_STOCKHOLDERSEQUITYDEFICITWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0f88d0c-2c69-44a2-9962-93a52e82c0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0f88d0c-2c69-44a2-9962-93a52e82c0fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:href="sesn-20211231.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2290b31e-897a-4fb0-bed3-53746c1d9864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2290b31e-897a-4fb0-bed3-53746c1d9864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_6ef09834-2988-4ca5-95c0-c2df64165606" xlink:href="sesn-20211231.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_6ef09834-2988-4ca5-95c0-c2df64165606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_7b1f0a5a-7e06-485f-a9c2-f3ad78ff97e5" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_7b1f0a5a-7e06-485f-a9c2-f3ad78ff97e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_ed79dcd2-8852-4d9e-834d-41ba972cfa7c" xlink:href="sesn-20211231.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_ed79dcd2-8852-4d9e-834d-41ba972cfa7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_15d424a3-3a43-49f0-a3ec-cc7993a85a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f33badae-335b-4bf7-952f-8fffbd4cdb03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f33badae-335b-4bf7-952f-8fffbd4cdb03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringJune2020Member_5e660edd-af37-458c-b566-3aaf85ee6a94" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringJune2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringJune2020Member_5e660edd-af37-458c-b566-3aaf85ee6a94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_020001d6-8219-4c26-b1e6-2239d7f11335" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_020001d6-8219-4c26-b1e6-2239d7f11335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_2c1345c2-4dc2-4c29-81e8-846d085aaca1" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_2c1345c2-4dc2-4c29-81e8-846d085aaca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_f4ca90fc-da7a-43b8-9ad9-74fab7b8eead" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_f4ca90fc-da7a-43b8-9ad9-74fab7b8eead" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_bbd22f91-27ae-47ab-85fe-f0339fc7f5a1" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_bbd22f91-27ae-47ab-85fe-f0339fc7f5a1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="extended" id="i39ff5806cf5040cf81761f8764a2a294_STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_f61a829a-58bf-4038-bac0-bf8491e1d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_f61a829a-58bf-4038-bac0-bf8491e1d7a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e801d6c1-82f8-4a5a-b6f3-a809a81ff27d" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e801d6c1-82f8-4a5a-b6f3-a809a81ff27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_dd896038-9a10-49d2-a9c0-9121ebb892a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_dd896038-9a10-49d2-a9c0-9121ebb892a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7d2a33d-dd48-49f0-bde8-5c45e5eca24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7d2a33d-dd48-49f0-bde8-5c45e5eca24e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments_eecb15d3-d662-4545-b6bb-5236d2cc9f51" xlink:href="sesn-20211231.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_sesn_OtherDividendAndAdjustments_eecb15d3-d662-4545-b6bb-5236d2cc9f51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_a3399fb5-3d75-4de1-8913-ea7248706446" xlink:href="sesn-20211231.xsd#sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_a3399fb5-3d75-4de1-8913-ea7248706446" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad7fc4ae-4c04-4644-8c04-7ea910f763ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad7fc4ae-4c04-4644-8c04-7ea910f763ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_8613a36f-6cc2-4a18-8473-1af8d31cf3e9" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_8613a36f-6cc2-4a18-8473-1af8d31cf3e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_e35522c4-38f8-4b2d-802a-651e5d9e864f" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_e35522c4-38f8-4b2d-802a-651e5d9e864f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_616ded75-e7e6-4296-b34f-4285406fe1eb" xlink:href="sesn-20211231.xsd#sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:to="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_616ded75-e7e6-4296-b34f-4285406fe1eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f61ca50b-e8f0-4092-9b7d-865529f36393_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:to="loc_us-gaap_EquityComponentDomain_f61ca50b-e8f0-4092-9b7d-865529f36393_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e714777-2d6b-4086-9bbb-e5e03543e3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:to="loc_us-gaap_EquityComponentDomain_2e714777-2d6b-4086-9bbb-e5e03543e3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9857a570-3d83-4b6a-9447-50ca6bd30270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e714777-2d6b-4086-9bbb-e5e03543e3f6" xlink:to="loc_us-gaap_CommonStockMember_9857a570-3d83-4b6a-9447-50ca6bd30270" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="i40e14a1505a8434ab035d98fe67ad1d8_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb7e1780-1b18-4856-a583-d9d4306d8a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_841fd610-3814-4be0-89ea-b3774a21fd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb7e1780-1b18-4856-a583-d9d4306d8a11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_841fd610-3814-4be0-89ea-b3774a21fd8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb7e1780-1b18-4856-a583-d9d4306d8a11" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a146389c-9b7f-4edb-86cd-f968a4724fb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a146389c-9b7f-4edb-86cd-f968a4724fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bb56bd92-6caf-4586-a952-5c7cb23f3c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:to="loc_us-gaap_WarrantMember_bb56bd92-6caf-4586-a952-5c7cb23f3c63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3035c288-15a3-45f4-af83-6387b7454cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3035c288-15a3-45f4-af83-6387b7454cab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended" id="i7e03642b462b4cb7960f3d871e22db5a_SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3d61ec-3f62-4d71-a0bb-768dc1fc31d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a0b2d92-46d7-40c3-bfdb-6ce90f1b6f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3d61ec-3f62-4d71-a0bb-768dc1fc31d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a0b2d92-46d7-40c3-bfdb-6ce90f1b6f8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3d61ec-3f62-4d71-a0bb-768dc1fc31d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c608fade-2ec7-486d-bfb5-e8d76ce07066_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c608fade-2ec7-486d-bfb5-e8d76ce07066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be3632f-6987-4029-b94d-9349e52e4093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be3632f-6987-4029-b94d-9349e52e4093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4f9b695-8150-414f-9210-b9472d77cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4f9b695-8150-414f-9210-b9472d77cc44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i8523767edfa04470ab6859f515097c73_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_b903bbaf-e6be-412c-90b1-7bf1b6f64e31" xlink:href="sesn-20211231.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_b903bbaf-e6be-412c-90b1-7bf1b6f64e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6ed6767b-3ac8-487f-9afe-73f2d91bd03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6ed6767b-3ac8-487f-9afe-73f2d91bd03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f9edc2b0-efee-45f5-870a-405ab532a8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f9edc2b0-efee-45f5-870a-405ab532a8c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_42066f6d-ce2a-42e4-a491-588db74e2b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_42066f6d-ce2a-42e4-a491-588db74e2b74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_662580cb-4a00-4ec5-9227-71589fb77a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_662580cb-4a00-4ec5-9227-71589fb77a6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3aad3be0-2ca5-4fcf-913c-31e2b6f825dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3aad3be0-2ca5-4fcf-913c-31e2b6f825dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_1707094d-0794-4ccd-9c02-71b04441df53" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_1707094d-0794-4ccd-9c02-71b04441df53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_10ba634c-61ba-473e-a6fd-02db27b5a68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_10ba634c-61ba-473e-a6fd-02db27b5a68a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_a83101e0-dc57-4f20-a09b-c37ea53d03be" xlink:href="sesn-20211231.xsd#sesn_ShareBasedPaymentArrangementExpenseOnCashBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_a83101e0-dc57-4f20-a09b-c37ea53d03be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_d3985af6-ae26-4931-aa1b-70d72aec3ab9" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_d3985af6-ae26-4931-aa1b-70d72aec3ab9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_38cda6c6-68a9-40ea-9d43-7a3d5eb77949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_38cda6c6-68a9-40ea-9d43-7a3d5eb77949" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_de2de09a-bea5-45d4-b611-3e5cc0822f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_de2de09a-bea5-45d4-b611-3e5cc0822f54" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7eba0a8f-6572-48fb-a757-6fa8861eace6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7eba0a8f-6572-48fb-a757-6fa8861eace6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8f063828-d8a6-411e-add3-1bb76baa748c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8f063828-d8a6-411e-add3-1bb76baa748c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90c559de-c461-4aca-8562-a997c0d2e476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90c559de-c461-4aca-8562-a997c0d2e476" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3102b3c2-815a-4f8d-819c-cf84bb9a9810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3102b3c2-815a-4f8d-819c-cf84bb9a9810" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec54e961-1694-43a2-915a-e211397db58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec54e961-1694-43a2-915a-e211397db58e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6c61a627-4976-4683-94cb-fb3e74582832_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:to="loc_us-gaap_VestingDomain_6c61a627-4976-4683-94cb-fb3e74582832_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:to="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2a8c099b-5665-49d3-9ede-1abda367f24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2a8c099b-5665-49d3-9ede-1abda367f24a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1e5887ac-dd73-4aa1-b4cd-ab7fedc1ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1e5887ac-dd73-4aa1-b4cd-ab7fedc1ca65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02c2c7a7-59c0-4630-b926-944bbf4a2353_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:to="loc_us-gaap_PlanNameDomain_02c2c7a7-59c0-4630-b926-944bbf4a2353_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:to="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_b827a75f-c94f-4ead-94af-44d6e90b1d34" xlink:href="sesn-20211231.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_b827a75f-c94f-4ead-94af-44d6e90b1d34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_bf3a3218-6aa2-4d97-af88-3c25813293db" xlink:href="sesn-20211231.xsd#sesn_RetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:to="loc_sesn_RetentionProgramMember_bf3a3218-6aa2-4d97-af88-3c25813293db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_018dd6bc-b939-4798-876f-a0e891ae0e7b" xlink:href="sesn-20211231.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:to="loc_sesn_StockIncentivePlan2009Member_018dd6bc-b939-4798-876f-a0e891ae0e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd830eba-c4e6-492a-b6fb-10091adb3be5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd830eba-c4e6-492a-b6fb-10091adb3be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a72eb49-8ab9-4c3f-8012-a6ad93544c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a72eb49-8ab9-4c3f-8012-a6ad93544c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ee74a489-093f-40f7-9a0d-9c191570a938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ee74a489-093f-40f7-9a0d-9c191570a938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0bcb7320-cdf7-4270-be06-bbde43b78299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:to="loc_us-gaap_PerformanceSharesMember_0bcb7320-cdf7-4270-be06-bbde43b78299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_f74811b4-d0c8-43e8-8c78-57652a649caa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:to="loc_us-gaap_GranteeStatusDomain_f74811b4-d0c8-43e8-8c78-57652a649caa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_05abaeb2-d8f1-47ef-a0ce-3fdcebcd81ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:to="loc_us-gaap_GranteeStatusDomain_05abaeb2-d8f1-47ef-a0ce-3fdcebcd81ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_26d64532-4a87-41e0-9357-c8080f8b7a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_05abaeb2-d8f1-47ef-a0ce-3fdcebcd81ba" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_26d64532-4a87-41e0-9357-c8080f8b7a4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended" id="ie1d8e663f8024be19d9130d13e6e98dd_SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e443e1-1bac-4082-9d56-7a2b7203fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e443e1-1bac-4082-9d56-7a2b7203fba4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6108eccd-27df-4898-8ed1-97c090ead3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6108eccd-27df-4898-8ed1-97c090ead3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358e0c4f-1030-4d1d-821d-528000e977a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358e0c4f-1030-4d1d-821d-528000e977a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12224ce9-839f-47e5-92ea-68ba3e0deb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e443e1-1bac-4082-9d56-7a2b7203fba4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:to="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995361ea-2f43-4ef9-a615-7c528c70145d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995361ea-2f43-4ef9-a615-7c528c70145d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6321c089-f5eb-42a3-ba0e-24c3b9cbc970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6321c089-f5eb-42a3-ba0e-24c3b9cbc970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8bf42f60-28f6-40b6-9040-6e59a363c917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:to="loc_us-gaap_PerformanceSharesMember_8bf42f60-28f6-40b6-9040-6e59a363c917" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended" id="idc5fc17ef3014fce84ca011e581878e1_SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_577acc72-67d9-4fb5-a413-f0c9ba4d8f38" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_577acc72-67d9-4fb5-a413-f0c9ba4d8f38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c01bed3c-253a-4956-9b17-dd952a0c7c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c01bed3c-253a-4956-9b17-dd952a0c7c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_879a16eb-103c-46f7-b6ca-67cdab2617d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_879a16eb-103c-46f7-b6ca-67cdab2617d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_03252f7e-9a24-4940-9206-446c542928b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_03252f7e-9a24-4940-9206-446c542928b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_af738a79-75ea-43f6-938f-7bc96fe00635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_af738a79-75ea-43f6-938f-7bc96fe00635" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_864f3d8d-e677-4870-9888-c2d148e83e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_864f3d8d-e677-4870-9888-c2d148e83e55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:to="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90c8d011-cbc1-46f7-982b-99bff5277848_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90c8d011-cbc1-46f7-982b-99bff5277848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d29ec8-d0b5-441c-9c66-237b10db78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d29ec8-d0b5-441c-9c66-237b10db78b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71ec4059-3f5b-4063-a792-f3ffebd2e426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d29ec8-d0b5-441c-9c66-237b10db78b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71ec4059-3f5b-4063-a792-f3ffebd2e426" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="i0d1c246099224ea7aa026f567e704d68_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_04c63e74-acea-4c28-91d6-db57123c7464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_04c63e74-acea-4c28-91d6-db57123c7464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_eeea3a0b-3a53-40b2-aea9-64b105b910b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_eeea3a0b-3a53-40b2-aea9-64b105b910b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_17ebab39-05e5-4fdf-9aca-d845fb6afd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_17ebab39-05e5-4fdf-9aca-d845fb6afd44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e48a7489-5f86-4897-9e9f-260687919f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e48a7489-5f86-4897-9e9f-260687919f32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dd01df1f-5bc7-4126-84f0-ab60478d6224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dd01df1f-5bc7-4126-84f0-ab60478d6224" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_e94d6303-df7b-4ab0-8555-76a47f4a3d9a" xlink:href="sesn-20211231.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_e94d6303-df7b-4ab0-8555-76a47f4a3d9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_70a4fd22-d166-41e0-be96-9493f76bb947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_70a4fd22-d166-41e0-be96-9493f76bb947" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:to="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_35057582-7325-4cd4-9e9c-341cc7acf0a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:to="loc_us-gaap_PlanNameDomain_35057582-7325-4cd4-9e9c-341cc7acf0a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c8bf88ae-51f9-4b39-8c55-b25db3968f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:to="loc_us-gaap_PlanNameDomain_c8bf88ae-51f9-4b39-8c55-b25db3968f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_5d4eba9c-724b-401b-ad9c-1836a84bb3ad" xlink:href="sesn-20211231.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c8bf88ae-51f9-4b39-8c55-b25db3968f97" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_5d4eba9c-724b-401b-ad9c-1836a84bb3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_04bd1604-3604-4ea3-9b10-33d43b227aae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_04bd1604-3604-4ea3-9b10-33d43b227aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_ff500ec7-b7c0-45c6-938c-29e5e5831669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:to="loc_us-gaap_DomesticPlanMember_ff500ec7-b7c0-45c6-938c-29e5e5831669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b69d67ec-317a-427a-88c9-a1b06bf0b47f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_ff500ec7-b7c0-45c6-938c-29e5e5831669" xlink:to="loc_country_US_b69d67ec-317a-427a-88c9-a1b06bf0b47f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8a1d44bf-7fad-483b-97c9-10ab3b0e6d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:to="loc_us-gaap_ForeignPlanMember_8a1d44bf-7fad-483b-97c9-10ab3b0e6d89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended" id="i54fb517d355f4c0c9a31f15165b76b30_INCOMETAXESComponentsofPretaxIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6626f6da-1fc7-42b1-a17d-24e37bf8ea12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6626f6da-1fc7-42b1-a17d-24e37bf8ea12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d8ea0166-c5a9-4861-9a88-8a8da59f0176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d8ea0166-c5a9-4861-9a88-8a8da59f0176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad16bab5-18c5-4b6e-afc9-ecf1d7fbe6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad16bab5-18c5-4b6e-afc9-ecf1d7fbe6eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:to="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f84e760c-e236-44e5-b530-e84dc6f9af47_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:to="loc_srt_SegmentGeographicalDomain_f84e760c-e236-44e5-b530-e84dc6f9af47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:to="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4f55c156-2d95-46b0-b7b5-8ffe58da6e56" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:to="loc_country_US_4f55c156-2d95-46b0-b7b5-8ffe58da6e56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_9d37422e-5546-46b4-b537-77dff42f9b07" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:to="loc_country_CA_9d37422e-5546-46b4-b537-77dff42f9b07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESScheduleofCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="extended" id="i48f235fe781f4a7daaf6df00199a820b_INCOMETAXESScheduleofCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6b59d4a4-8da5-46c0-bef4-0baf6ebf100d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6b59d4a4-8da5-46c0-bef4-0baf6ebf100d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_34f89339-7162-4fee-96e4-37411b03b587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_34f89339-7162-4fee-96e4-37411b03b587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:to="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2412e415-306a-437e-9514-a3c26d24e1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:to="loc_us-gaap_ResearchMember_2412e415-306a-437e-9514-a3c26d24e1b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NonCapitalLossCarryforwardMember_d1a0e2d6-6420-4123-af6f-62f439a2bb24" xlink:href="sesn-20211231.xsd#sesn_NonCapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:to="loc_sesn_NonCapitalLossCarryforwardMember_d1a0e2d6-6420-4123-af6f-62f439a2bb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCreditMember_dccc2dd5-bf83-40ee-b80f-a89e2c2217bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:to="loc_us-gaap_InvestmentCreditMember_dccc2dd5-bf83-40ee-b80f-a89e2c2217bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain_7a706bc9-f27a-469c-8bb1-0c65b6064af7_default" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:to="loc_sesn_NetOperatingLossCarryforwardDomain_7a706bc9-f27a-469c-8bb1-0c65b6064af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain_17728d7c-c112-405c-ac94-14fd5016fe70" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:to="loc_sesn_NetOperatingLossCarryforwardDomain_17728d7c-c112-405c-ac94-14fd5016fe70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IndefiniteMember_7a3d146c-1620-471a-96bc-1f1e3f9f717e" xlink:href="sesn-20211231.xsd#sesn_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_NetOperatingLossCarryforwardDomain_17728d7c-c112-405c-ac94-14fd5016fe70" xlink:to="loc_sesn_IndefiniteMember_7a3d146c-1620-471a-96bc-1f1e3f9f717e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_707486d7-4d4f-430e-95e2-46ca07897a5c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:to="loc_srt_SegmentGeographicalDomain_707486d7-4d4f-430e-95e2-46ca07897a5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:to="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_973e9a8f-0c01-4e7a-8474-bbba21eacfb5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:to="loc_country_US_973e9a8f-0c01-4e7a-8474-bbba21eacfb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_6c49e94b-efac-4f16-be1c-fb496e583ec0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:to="loc_country_CA_6c49e94b-efac-4f16-be1c-fb496e583ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f23002e7-b7b3-4507-af18-b4270ff9553d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:to="loc_us-gaap_DomesticCountryMember_f23002e7-b7b3-4507-af18-b4270ff9553d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d032c776-4776-4bd6-bb58-e31e1f7a71ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d032c776-4776-4bd6-bb58-e31e1f7a71ee" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LICENSEAGREEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="extended" id="ib923d75230bf4107802f9f9f4c6ce4f1_LICENSEAGREEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:href="sesn-20211231.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_e195a37f-5bbf-4eca-8717-83ab55703520" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_e195a37f-5bbf-4eca-8717-83ab55703520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_2bf18b66-c4ac-4fb0-b210-863cd9ca76b6" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_2bf18b66-c4ac-4fb0-b210-863cd9ca76b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_3d18b9a0-d638-4c57-b03a-89bf66720ea4" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_3d18b9a0-d638-4c57-b03a-89bf66720ea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_89ff7c55-dac9-4880-8aac-e12f71da60bb" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_89ff7c55-dac9-4880-8aac-e12f71da60bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_8c78f06f-350d-463c-ae3f-f9e1c0e379c7" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_8c78f06f-350d-463c-ae3f-f9e1c0e379c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_1f5e6e40-9794-4f5a-a14b-451e0d0ee755" xlink:href="sesn-20211231.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_1f5e6e40-9794-4f5a-a14b-451e0d0ee755" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a702bc48-2d78-4f2f-b50e-4517261c1430" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a702bc48-2d78-4f2f-b50e-4517261c1430" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_4ee860a4-5d29-4a76-b8df-b7588857110e" xlink:href="sesn-20211231.xsd#sesn_LicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseMaintenanceFees_4ee860a4-5d29-4a76-b8df-b7588857110e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_11426108-8928-48c1-b855-f653ccc3d071" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_11426108-8928-48c1-b855-f653ccc3d071" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_2460ddb1-734c-406e-819c-cd8919733a27" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_2460ddb1-734c-406e-819c-cd8919733a27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_2237b0b0-40e6-4260-9d04-bb6403c9fedf" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_2237b0b0-40e6-4260-9d04-bb6403c9fedf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_2367af10-2ff0-445a-bc9e-050ff3ea9b87" xlink:href="sesn-20211231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_2367af10-2ff0-445a-bc9e-050ff3ea9b87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_abb7eabd-ab1a-408c-abe6-06b2ba26b905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_abb7eabd-ab1a-408c-abe6-06b2ba26b905" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_eb2099a2-2e71-43d9-a594-142066f265ff" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_eb2099a2-2e71-43d9-a594-142066f265ff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_375e9594-49f5-4c78-974d-3f25c3eb02f7" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_375e9594-49f5-4c78-974d-3f25c3eb02f7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_82f33269-6814-4c08-a0dc-a8e3fa41932b" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_82f33269-6814-4c08-a0dc-a8e3fa41932b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_e0db6d27-0fe8-4f19-9872-c14d1ec7181f" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_e0db6d27-0fe8-4f19-9872-c14d1ec7181f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_9ee0ba09-7b5b-4f39-b35d-39f3f4309bcd" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_9ee0ba09-7b5b-4f39-b35d-39f3f4309bcd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_65ac7f5e-4d2e-4723-9be1-a329eda210d2" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_65ac7f5e-4d2e-4723-9be1-a329eda210d2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_a9488ea4-d5c7-4d7b-8fe2-2f37e4239281" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_a9488ea4-d5c7-4d7b-8fe2-2f37e4239281" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5b6823c6-d49c-4d48-8d49-ae16cdb2d300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5b6823c6-d49c-4d48-8d49-ae16cdb2d300" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_412ffc64-cef0-453d-be62-4aee566f302d" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_412ffc64-cef0-453d-be62-4aee566f302d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_a364841f-4534-4da9-af4b-1f5bee58e9e7" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_a364841f-4534-4da9-af4b-1f5bee58e9e7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b50d4b0d-3c6c-4447-827b-c354dbe992b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b50d4b0d-3c6c-4447-827b-c354dbe992b2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_ba5853f2-1aa1-4b2b-bbcb-722afdbc6d8a" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_ba5853f2-1aa1-4b2b-bbcb-722afdbc6d8a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_6d6758cc-ad42-43af-9b64-8b3cfba834ba" xlink:href="sesn-20211231.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_RoyaltyRevenuePercentage_6d6758cc-ad42-43af-9b64-8b3cfba834ba" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:href="sesn-20211231.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2951876-d807-405d-8734-c03e79e0eae5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2951876-d807-405d-8734-c03e79e0eae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_9e743ea5-ad7d-4c9d-816f-4c20b3ee3234" xlink:href="sesn-20211231.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_UniversityOfZurichMember_9e743ea5-ad7d-4c9d-816f-4c20b3ee3234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_c53c9baf-2d72-4af4-87aa-660d06ee2bf4" xlink:href="sesn-20211231.xsd#sesn_MicrometAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_MicrometAGMember_c53c9baf-2d72-4af4-87aa-660d06ee2bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_7f8d10a3-621c-4d90-9e11-841f3f05fae6" xlink:href="sesn-20211231.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_XOMAIrelandLimitedMember_7f8d10a3-621c-4d90-9e11-841f3f05fae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_beb64fea-72b6-49db-a200-3374c95e3262" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_RocheMember_beb64fea-72b6-49db-a200-3374c95e3262" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_7567ff33-8b44-481c-be9b-4460ef92c129" xlink:href="sesn-20211231.xsd#sesn_MENALicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_MENALicenseAgreementMember_7567ff33-8b44-481c-be9b-4460ef92c129" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d96d8a25-e244-4afc-a68b-f4a0b2443811" xlink:href="sesn-20211231.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d96d8a25-e244-4afc-a68b-f4a0b2443811" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ba47fe2-cd56-4753-9443-5c2584b69a84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ba47fe2-cd56-4753-9443-5c2584b69a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_46767412-188f-4589-8c20-0e72216a5aeb" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_46767412-188f-4589-8c20-0e72216a5aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_a324e49c-dd64-4ce0-aaf4-b18e93411695" xlink:href="sesn-20211231.xsd#sesn_FirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_FirstIndicationMember_a324e49c-dd64-4ce0-aaf4-b18e93411695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_2134c57b-a379-4687-994a-0f0943ce9409" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_2134c57b-a379-4687-994a-0f0943ce9409" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_b67765ca-d07d-473b-b854-645b21e10a5b" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_b67765ca-d07d-473b-b854-645b21e10a5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_5dc469e2-0ae9-40ec-9a1f-6abd03218f53" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_5dc469e2-0ae9-40ec-9a1f-6abd03218f53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f43b04b2-2d35-4b7c-811a-74a5705b2a98" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f43b04b2-2d35-4b7c-811a-74a5705b2a98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_cbc78af5-7c00-464d-aef2-d869b06576b9" xlink:href="sesn-20211231.xsd#sesn_SecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_SecondIndicationMember_cbc78af5-7c00-464d-aef2-d869b06576b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10eeb09c-b2b7-4744-8970-546e2489ff0b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:to="loc_srt_ProductsAndServicesDomain_10eeb09c-b2b7-4744-8970-546e2489ff0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:to="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_bc53145d-4d9d-4c9f-b56f-02235b4616a6" xlink:href="sesn-20211231.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:to="loc_sesn_EBI031Member_bc53145d-4d9d-4c9f-b56f-02235b4616a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member_d1fe95c6-0e0e-4db1-b445-070b9d41fc04" xlink:href="sesn-20211231.xsd#sesn_IL6Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:to="loc_sesn_IL6Member_d1fe95c6-0e0e-4db1-b445-070b9d41fc04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_76f91586-f045-4c99-90c8-d3b52b282612_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_76f91586-f045-4c99-90c8-d3b52b282612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1584c96d-eeea-4435-9ed7-e7e5c2aa9082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1584c96d-eeea-4435-9ed7-e7e5c2aa9082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2c9256d1-815e-40f0-89bf-e9990a5fb223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1584c96d-eeea-4435-9ed7-e7e5c2aa9082" xlink:to="loc_us-gaap_SubsequentEventMember_2c9256d1-815e-40f0-89bf-e9990a5fb223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5beca2c6-f701-4662-bdc1-1c8ea5721462_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:to="loc_srt_RangeMember_5beca2c6-f701-4662-bdc1-1c8ea5721462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:to="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3b95ae2-55d5-417c-9621-1b6b5a169011" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:to="loc_srt_MinimumMember_f3b95ae2-55d5-417c-9621-1b6b5a169011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bff80d5f-6b53-4e56-9acc-88fa4600edd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:to="loc_srt_MaximumMember_bff80d5f-6b53-4e56-9acc-88fa4600edd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87c797f1-304e-48b9-bb45-5155449b2579_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87c797f1-304e-48b9-bb45-5155449b2579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_631d8271-3d9b-4875-9f9c-c4e051cc422c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_631d8271-3d9b-4875-9f9c-c4e051cc422c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_a99856cf-e6ee-42ae-be51-fc2b0667e77c" xlink:href="sesn-20211231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_631d8271-3d9b-4875-9f9c-c4e051cc422c" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_a99856cf-e6ee-42ae-be51-fc2b0667e77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b229ab4f-895e-48e1-8cb2-902c218d3815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b229ab4f-895e-48e1-8cb2-902c218d3815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1e0a06d-cc6e-4bcb-bec1-417fb8b21cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1e0a06d-cc6e-4bcb-bec1-417fb8b21cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b6b87fc0-4161-4bd9-97cc-04aa5623d508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1e0a06d-cc6e-4bcb-bec1-417fb8b21cd7" xlink:to="loc_us-gaap_LicensingAgreementsMember_b6b87fc0-4161-4bd9-97cc-04aa5623d508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b42e59dd-3b1d-476f-8695-5215c01dafaf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:to="loc_srt_SegmentGeographicalDomain_b42e59dd-3b1d-476f-8695-5215c01dafaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a4e1c04f-1bc8-4a7c-ba78-2149d1286e48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:to="loc_srt_SegmentGeographicalDomain_a4e1c04f-1bc8-4a7c-ba78-2149d1286e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_2d87841c-07fb-4539-a408-b1896896fa55" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a4e1c04f-1bc8-4a7c-ba78-2149d1286e48" xlink:to="loc_country_TR_2d87841c-07fb-4539-a408-b1896896fa55" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="ia559e2c11c4f45ce8ea811d1b3196037_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_be5867b5-8fd9-4ed5-b9f4-2538bfe294ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_be5867b5-8fd9-4ed5-b9f4-2538bfe294ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4db448e0-4a81-480e-96fa-b127fc896d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4db448e0-4a81-480e-96fa-b127fc896d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cf15311e-6ef2-4231-a798-d204d73b2252_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:to="loc_us-gaap_RelatedPartyDomain_cf15311e-6ef2-4231-a798-d204d73b2252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:to="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_d1eba3c1-391b-49c5-973d-8689a197d624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:to="loc_us-gaap_MajorityShareholderMember_d1eba3c1-391b-49c5-973d-8689a197d624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_13d9d4b4-7d19-4429-974b-a16f0106fd47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:to="loc_srt_DirectorMember_13d9d4b4-7d19-4429-974b-a16f0106fd47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14b2f3c0-35ff-4e64-a730-7c23d897b73a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14b2f3c0-35ff-4e64-a730-7c23d897b73a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b56f2a0c-2f2b-4329-bde4-44c758586e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b56f2a0c-2f2b-4329-bde4-44c758586e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FacilityinWinnipegManitolaMember_4cfd4bde-40af-42cb-abfa-746c8fa5ce18" xlink:href="sesn-20211231.xsd#sesn_FacilityinWinnipegManitolaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b56f2a0c-2f2b-4329-bde4-44c758586e2e" xlink:to="loc_sesn_FacilityinWinnipegManitolaMember_4cfd4bde-40af-42cb-abfa-746c8fa5ce18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_64be6402-a990-4f03-819a-788d9ac9ebeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_64be6402-a990-4f03-819a-788d9ac9ebeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2aa31f5a-c438-4713-ab1d-cb155208911d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2aa31f5a-c438-4713-ab1d-cb155208911d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_a5c7d061-db2d-41eb-a5ab-6665668330ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2aa31f5a-c438-4713-ab1d-cb155208911d" xlink:to="loc_us-gaap_IntellectualPropertyMember_a5c7d061-db2d-41eb-a5ab-6665668330ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended" id="i49805f371f1540c0b7538c000d93eabe_RESTRUCTURINGANDRELATEDACTIVITIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4a2bc874-d3a3-4dc1-8cf1-f3322dd2d2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_RestructuringCharges_4a2bc874-d3a3-4dc1-8cf1-f3322dd2d2cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_614a6328-af98-4381-8310-e34f7bbe1e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_PaymentsForRestructuring_614a6328-af98-4381-8310-e34f7bbe1e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_13444135-2a4f-4906-b2fb-3ac18545cfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_RestructuringReserve_13444135-2a4f-4906-b2fb-3ac18545cfa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e0c67934-06a5-4a80-b15a-6c13d994f706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e0c67934-06a5-4a80-b15a-6c13d994f706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_6d8601c8-9712-4280-9440-2de2cc72c519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:to="loc_us-gaap_ContractTerminationMember_6d8601c8-9712-4280-9440-2de2cc72c519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_2c2163b4-ca2b-4622-a5df-fb651af6dbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:to="loc_us-gaap_OtherRestructuringMember_2c2163b4-ca2b-4622-a5df-fb651af6dbfd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="iaa3ea489e0994aa4bd3f9c2cf8af2219_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ReviewPeriod_7b99d5a8-2af9-476f-84e3-1ab3129fae5b" xlink:href="sesn-20211231.xsd#sesn_ReviewPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_sesn_ReviewPeriod_7b99d5a8-2af9-476f-84e3-1ab3129fae5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfDocumentsReviewed_902b9d63-d5ce-4049-b013-5121c53d80cb" xlink:href="sesn-20211231.xsd#sesn_NumberOfDocumentsReviewed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_sesn_NumberOfDocumentsReviewed_902b9d63-d5ce-4049-b013-5121c53d80cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfInterviews_f4f6e7cd-b6f7-46a5-9b67-df39a303fb20" xlink:href="sesn-20211231.xsd#sesn_NumberOfInterviews"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_sesn_NumberOfInterviews_f4f6e7cd-b6f7-46a5-9b67-df39a303fb20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_255bd2a5-6188-4ac0-94f0-d8806873c0b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_255bd2a5-6188-4ac0-94f0-d8806873c0b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_56e0d0bb-f310-4754-9756-0b412c8df025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_56e0d0bb-f310-4754-9756-0b412c8df025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8f20b738-2842-4bed-ba92-07c4d1bcadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_56e0d0bb-f310-4754-9756-0b412c8df025" xlink:to="loc_us-gaap_SubsequentEventMember_8f20b738-2842-4bed-ba92-07c4d1bcadaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>sesn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_e48a18ef-0fc4-4ab4-91a2-1f06dfee6fce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DebtInstrumentIndexRateHighYield_02e78330-94d8-4da9-ab2f-9e08d4fbc229_terseLabel_en-US" xlink:label="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Index rate, high-yield</link:label>
    <link:label id="lab_sesn_DebtInstrumentIndexRateHighYield_label_en-US" xlink:label="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Index Rate, High-Yield</link:label>
    <link:label id="lab_sesn_DebtInstrumentIndexRateHighYield_documentation_en-US" xlink:label="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Index Rate, High-Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DebtInstrumentIndexRateHighYield" xlink:href="sesn-20211231.xsd#sesn_DebtInstrumentIndexRateHighYield"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DebtInstrumentIndexRateHighYield" xlink:to="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_0ccef844-edeb-495a-9c61-0b836d00254a_terseLabel_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_label_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_documentation_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember" xlink:href="sesn-20211231.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_XOMAIrelandLimitedMember" xlink:to="lab_sesn_XOMAIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_827bce68-b2b3-4e17-a712-6117ab7d4e4a_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fa22f4e7-ddcb-48ff-b35d-c9ad835ec927_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_45170df0-9389-4ca4-a18a-851a4d99cf37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1b33287-be23-49d9-8783-ebec13c3dc42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cbc47185-0442-480f-93e4-33350be88c84_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1e53de64-636e-4098-91cf-afca1ee6430e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b34bd33b-1b99-43ae-bb0e-247d652735b3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AuditInformationAbstract_label_en-US" xlink:label="lab_sesn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_sesn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_sesn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AuditInformationAbstract" xlink:href="sesn-20211231.xsd#sesn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AuditInformationAbstract" xlink:to="lab_sesn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6b9ac4bc-d239-4668-a71d-a37e18b0090a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_49395a8a-d27f-42a5-a738-1ac82caae8ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5c91dd1a-5592-4fd6-b88a-85b370d98b07_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b1089a5a-08d6-4a1a-9fd3-2ad7e89cff9d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1ab83059-0f81-4072-baec-48155dfde21e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c7aac08f-a3f9-4695-bf92-2ce023f24cdf_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_48c6bcc1-2fc7-42c3-81d4-4d57e606917c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_85f4258c-27a8-4f8d-b25f-413693d3e77d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_22f604f3-d36e-4afa-ae8e-58fe236c5def_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price, discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6977ad17-6f62-420c-a508-a48f8c4e2555_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_cdb86516-cf88-4da1-9947-76537502f0cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7d181644-b350-42a9-8535-784f134b7c49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bdf93853-d63d-43f1-a9ed-22bfbec0544f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2f376988-f922-431f-8776-9ac88cb7b345_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f3ec1659-4375-4f38-9787-ddcb53ae1c2d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_6cdb5bf9-bce4-4ee1-b279-4d8ae2bec404_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received per award (in shares)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5afbec72-2905-449b-8e46-54205a30b768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractTerminationMember_c31b0528-b650-4710-b173-1da915014bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination costs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractTerminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember" xlink:to="lab_us-gaap_ContractTerminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_98747fa8-46c6-447f-8520-063f627575fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for sale (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f30bbea8-1291-4b71-85fe-2f8e0b3458d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_cc349872-4245-4e5a-bdce-b9882a2844d5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_cb547a82-30dc-47b9-8e9d-d8dcf32e44ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_8f1b6e6b-3c60-4091-8788-c8ade5c214df_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D intangible assets:</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ed35ae06-3e1e-4ba1-a3dc-49869022029d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_a12f1742-2978-4b7e-9ab7-7be0cef72072_terseLabel_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue, percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_label_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_documentation_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage" xlink:href="sesn-20211231.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RoyaltyRevenuePercentage" xlink:to="lab_sesn_RoyaltyRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4a2e7dc3-8cfb-4347-b4bc-4c8e2ed110b8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d1bbb748-f2d1-4017-9baf-f8e4b171cfad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8e91395c-a828-497b-8278-73509cdb65d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f72fc5c3-d228-4ba7-907a-c880d1eaac4e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fee for remaining term of lease</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_de140798-ca72-4f2f-aaf4-91acd3ac4b37_terseLabel_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option</link:label>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_label_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</link:label>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_documentation_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:href="sesn-20211231.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:to="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_2f822db4-950a-4c6e-9df7-f7237aa90b77_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementUpfrontFee" xlink:to="lab_sesn_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f58d50bc-b3a2-4534-9682-4c0cd00c684b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_704e8b8c-5ae8-4997-b0f8-ebcdbef27d64_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_221f9abd-0cad-4390-ac80-84a9fa0c0f23_terseLabel_en-US" xlink:label="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of securities issued</link:label>
    <link:label id="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_label_en-US" xlink:label="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Minimum Percentage of Securities Issued</link:label>
    <link:label id="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_documentation_en-US" xlink:label="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Minimum Percentage of Securities Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:href="sesn-20211231.xsd#sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:to="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c205490-8ae9-4323-9481-a83acc7788d2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_fce55cb4-9108-4269-8f2e-6b1689fc77f7_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party minimum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_82473e08-d535-4f08-ac6c-e62797082669_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCreditMember_4ba421e1-9c3c-4197-8ef9-7d9fbf0f74ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_InvestmentCreditMember_label_en-US" xlink:label="lab_us-gaap_InvestmentCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCreditMember" xlink:to="lab_us-gaap_InvestmentCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a9785c6-0bd9-4c98-b3d0-c127739a7b38_netLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_88446355-52cc-4713-9541-09978147d34f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_eabc48ab-6b26-4d26-8bc1-7fe32558be8d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5e9485e2-7f43-415d-b7e6-03dbdd48e533_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_e84e59fe-285d-41ad-97b9-cf07f9fa5964_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardDomain_7d435fde-cc30-43a7-a352-38717c028576_terseLabel_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Domain]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardDomain_label_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Domain]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardDomain_documentation_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Net Operating Loss Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NetOperatingLossCarryforwardDomain" xlink:to="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MassachusettsAndPennsylvaniaMember_c445d231-45c8-4d25-98b0-3af3a46158a2_terseLabel_en-US" xlink:label="lab_sesn_MassachusettsAndPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts And Pennsylvania</link:label>
    <link:label id="lab_sesn_MassachusettsAndPennsylvaniaMember_label_en-US" xlink:label="lab_sesn_MassachusettsAndPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts And Pennsylvania [Member]</link:label>
    <link:label id="lab_sesn_MassachusettsAndPennsylvaniaMember_documentation_en-US" xlink:label="lab_sesn_MassachusettsAndPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts And Pennsylvania</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MassachusettsAndPennsylvaniaMember" xlink:href="sesn-20211231.xsd#sesn_MassachusettsAndPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MassachusettsAndPennsylvaniaMember" xlink:to="lab_sesn_MassachusettsAndPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5c313c1d-6fe4-470a-b15f-97239883d314_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_210c9776-fa17-4c96-aa83-0d329f8a01ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_cdf10839-69f0-4b8c-a3ae-cf3abce2754c_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_label_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_documentation_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:href="sesn-20211231.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:to="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00add507-4cf9-4c21-b0dc-017e491add9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ebfddaa8-f02f-45ea-96a0-1a121fb45e4d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_448bd793-5d3e-43ff-b34c-5095ff8d4a97_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_38be870e-f51a-4f5e-ba53-fc63e2df383a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_b34f6e82-e394-4e41-9fa9-d57662ec1f0d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_ee2d6121-818a-40a4-9b91-8c82e06cc5d0_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on regulatory milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d03399c5-12bb-4765-8fbd-4b245fe61772_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7ca072d3-d478-48eb-bce9-b9a78ce3fe80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff9d74e9-04a2-427c-921e-f8133a0f8ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested grant restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec6a7b16-aad6-47a3-9e0b-423ac94d2e98_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6d211a14-5a51-4b11-b2d9-a70a78c055d4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLES AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ee8dc691-4220-4a86-a3ca-12b0f9880ee7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December&#160;31, 2021 and 2020; no shares issued and outstanding at December&#160;31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b6c542bb-91c2-42cf-bd81-ff6ab68ff447_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_843e4c8c-2170-4879-aebc-1942142ca937_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff17954d-a1e9-4faf-9979-ae00e20150a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9dcb5358-e0ba-47e0-89c6-359e77129760_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestonePayment_438229b0-3b40-4514-8560-255b0aaf0db1_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePayment_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePayment_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePayment" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestonePayment" xlink:to="lab_sesn_LicenseAgreementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a1b6fa65-4bfc-4996-b948-dd68f3ec8194_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e1ecc57d-5bce-465f-8219-aaa528755963_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_6ade9b2c-7aba-4568-828c-75d2186399eb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_925a9492-aa8d-4284-9e9a-a0eebfa2303d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e3971bb-6b08-41c2-80ed-ebfe8a9f6e90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7c824339-91c5-45d5-b495-852f26713ef2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_af9d40ef-b17d-4479-866d-c66d74f1694e_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party maximum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:to="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_23b64387-5523-463a-bdc2-ea2fd294d63b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_71a4cfff-9d43-4422-901d-ce3b23d72189_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_53bb70e4-a38a-4c5d-8b8c-d4aaa663b7ad_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_64147f7e-4ce6-40bc-aeca-3c8c382a9b49_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2d5d5e9e-e6b5-4018-9dbb-8438c6345b18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0e9968fb-3a60-4f20-8b0a-0a9620797790_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_11d0ca92-3fbb-4a67-a265-be741526e14f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_37407b9b-c49c-4df7-87f0-288367eb6063_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original number of shares subject to the option vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_08d4457e-feec-4b29-96f5-d6f3eec26351_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_5339d184-d2be-4b33-832c-18303d455d8c_terseLabel_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized start-up costs</link:label>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_label_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</link:label>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_documentation_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:href="sesn-20211231.xsd#sesn_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_9930a66e-a35c-46a3-a2ec-38da0881241d_terseLabel_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achieving clinical and regulatory milestones</link:label>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_label_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Achieving Clinical and Regulatory Milestones, Percentage</link:label>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_documentation_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Achieving Clinical and Regulatory Milestones, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:href="sesn-20211231.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:to="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_5201c0e5-b64d-4380-831f-6326c36acc90_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ca54ab29-4149-4c6c-9295-6cb3e1c3e07f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c6a43676-1fb6-4aa0-9558-24a8653272c9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e2008f98-f9e2-44fd-b632-f63119efb78f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration - short term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_2d59260c-dd34-4abb-a015-2efb37268a91_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment, percentage</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_label_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:to="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8f1df618-3f25-4555-ab3c-5fd604484ea8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c5d4c85-8e4c-4513-aa7d-97fefc3b087a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfInterviews_361b0eb0-2c01-47f7-8ed0-dceda6a58024_terseLabel_en-US" xlink:label="lab_sesn_NumberOfInterviews" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interviews</link:label>
    <link:label id="lab_sesn_NumberOfInterviews_label_en-US" xlink:label="lab_sesn_NumberOfInterviews" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Interviews</link:label>
    <link:label id="lab_sesn_NumberOfInterviews_documentation_en-US" xlink:label="lab_sesn_NumberOfInterviews" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Interviews</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfInterviews" xlink:href="sesn-20211231.xsd#sesn_NumberOfInterviews"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfInterviews" xlink:to="lab_sesn_NumberOfInterviews" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_560ce059-1be0-4d86-bc17-94c80f372eb4_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b8c70a32-0a50-4ce8-9f80-460c76f0a72d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_45db5f9b-ccb0-4460-b9be-a12ad5ff0aae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestonePaymentTerm_87f54160-f185-4e4f-a4f1-65d0a586d946_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment term</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePaymentTerm_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Term</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePaymentTerm_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePaymentTerm" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestonePaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestonePaymentTerm" xlink:to="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5c855c7d-cb02-4f39-9bb8-3daac7274900_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_dd84105a-0c75-45d6-812e-8c47e6d95d15_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c9e54cf2-293a-4308-8e63-f6b61dabf4c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets related to the adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_79cb85db-e30f-4afc-a16d-26384ab02017_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FirstIndicationMember_cc9cd1c5-5771-4921-bc19-632fb0173f25_terseLabel_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_label_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_documentation_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember" xlink:href="sesn-20211231.xsd#sesn_FirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FirstIndicationMember" xlink:to="lab_sesn_FirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6192f57b-0366-453a-a7f2-8c49075e159f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_667c64d2-7d2d-4e68-a95f-08c52423700c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_27153735-739f-4e62-94ce-37d5e3e0eb76_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_label_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009 [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member" xlink:href="sesn-20211231.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlan2009Member" xlink:to="lab_sesn_StockIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d21f41b7-96fc-45c4-8112-5d9a09f79ad4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_69f92c64-a893-4d92-8fda-e6d44375e59a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9cea0abb-7866-43c1-87d7-269e86f9a3d7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_04199674-6dfd-410f-a092-a947e93ce376_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfLawsuits_a650178f-1143-4e11-b8de-e9e0a348acd4_terseLabel_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_label_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_documentation_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits" xlink:href="sesn-20211231.xsd#sesn_NumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfLawsuits" xlink:to="lab_sesn_NumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1b1bb837-7768-47a1-8c9a-2954dc89d884_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_be5a8238-5951-45b3-9740-a9f43ecd18af_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_74fb46f9-a3ed-41e1-801e-adc02ca06b6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_8f8a3f19-851e-43fd-a97c-0d327f5db272_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3231376b-761c-4d05-9aa8-5d47571134d2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2a186d9d-2176-47c4-87f1-ec7f897130f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Lease Payments:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_8fdf4f7f-3e2f-47fc-b60d-117a4fa45655_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits and other credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_59914f6c-55e6-4af1-bf0d-e70346db6639_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ac5cbaff-2868-4724-8f2c-7616fe178ab3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2fc9fba1-6f30-4e1e-8e5d-726838175398_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c220334b-b49a-4fcd-83cd-458d2c903e8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_6afb42f2-8146-4f58-a7dc-35333b24db20_terseLabel_en-US" xlink:label="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance coverage limit</link:label>
    <link:label id="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_label_en-US" xlink:label="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits, at or Above FDIC Insurance Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:to="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cd60144e-514b-4029-8658-d7eccbd07c26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on the First Anniversary of Date of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ec132d58-2614-4bbf-a277-d80b8d1c9f4c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_39a8f0e8-7149-42e1-9d0d-0b02c8547306_terseLabel_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match per participating employee, maximum</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_label_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_documentation_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:href="sesn-20211231.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:to="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9778adf2-2b61-4978-8626-133c8636a97a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2451580d-f0be-41de-b114-9c93a7189653_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ad16083b-a38f-4428-8fcb-49b24886f81f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_ae712640-8c1b-4903-a171-da7f971330cb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_99596cc9-8a9e-424e-b325-bfe252d619b3_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_97aea507-71ba-49fa-b2a6-5c2900661533_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4c6eb108-14bd-40b1-8a0e-2b039523a8de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_db62cff3-42b7-446d-b518-e3f92fcc59f8_terseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:href="sesn-20211231.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df2d12ec-732a-4728-bf8d-d34788a2721d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b6be4387-eaa6-4fee-b582-ae86fd2806ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a36ad428-25d1-4c89-9188-baf2b9e9e007_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fa277fc4-ed5a-4ff9-bca7-dabaee70663a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_53c07677-0c63-48c2-94aa-c0e29451cc83_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_698623ef-5a92-44ab-8ffd-2eeaeef64609_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options and vesting of RSAs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_96262058-2092-4e96-b7f8-16e3c6edf204_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_2bfcf5cc-ebaf-47a5-b617-a5abb19fd17a_terseLabel_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_label_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Dividend And Adjustments</link:label>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_documentation_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Dividend And Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments" xlink:href="sesn-20211231.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OtherDividendAndAdjustments" xlink:to="lab_sesn_OtherDividendAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9075bc7f-7c21-4c73-a9e6-51f99e386820_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b52ef833-b8d7-4c27-80e3-4bca14a8b417_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value included in loss</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_428a65ba-c643-44a7-ab4c-bb106b9b7b57_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_label_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_documentation_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:to="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_9974e393-a640-4ce8-b49c-7ad03fb3ca27_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_2d03aadc-8e08-4a07-938b-6f06c16159b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a958f6a4-fe39-40b5-873d-d263c078b14e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d92f9358-24f2-4eec-a9f2-4743059b3fc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2d996510-db6f-41a2-b4b4-6b6e44a99af2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_e5fa9bdd-4459-4aad-88b1-2c07eda58254_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_af68020b-a552-4105-94fb-aa37df2faaeb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1a32675c-8a25-4096-bf9a-daa96009c6ed_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ContingentConsiderationPolicyTextBlock_10a11485-c6b8-40f0-a1e8-df85daab3527_terseLabel_en-US" xlink:label="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_sesn_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_sesn_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ContingentConsiderationPolicyTextBlock" xlink:href="sesn-20211231.xsd#sesn_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ContingentConsiderationPolicyTextBlock" xlink:to="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c8a73438-f440-4765-88b9-f6fa121adc2c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfDocumentsReviewed_b8764a26-4d83-494a-9704-d06baf6e4795_terseLabel_en-US" xlink:label="lab_sesn_NumberOfDocumentsReviewed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of documents reviewed</link:label>
    <link:label id="lab_sesn_NumberOfDocumentsReviewed_label_en-US" xlink:label="lab_sesn_NumberOfDocumentsReviewed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Documents Reviewed</link:label>
    <link:label id="lab_sesn_NumberOfDocumentsReviewed_documentation_en-US" xlink:label="lab_sesn_NumberOfDocumentsReviewed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Documents Reviewed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfDocumentsReviewed" xlink:href="sesn-20211231.xsd#sesn_NumberOfDocumentsReviewed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfDocumentsReviewed" xlink:to="lab_sesn_NumberOfDocumentsReviewed" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_f20c1a4e-6c34-403f-b9e8-bd1a2c2a692b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_d4c4b289-af0d-40d6-a0d9-d25f3a166026_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_5d7bf22d-91d9-463c-a988-50014a4897d4_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, option periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_label_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementOptionPeriods" xlink:to="lab_sesn_LicenseAgreementOptionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_7e874219-ce42-4679-b8e9-e4707cefd0de_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IL6Member_5b8509cc-4bcd-4bd7-abba-2fbf0a13fa0e_terseLabel_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6</link:label>
    <link:label id="lab_sesn_IL6Member_label_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6 [Member]</link:label>
    <link:label id="lab_sesn_IL6Member_documentation_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member" xlink:href="sesn-20211231.xsd#sesn_IL6Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IL6Member" xlink:to="lab_sesn_IL6Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bc85ac80-be42-45ca-808c-8b7025191998_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f47069a0-54c2-42a0-84f7-95c6c35b2edf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_fb5a48a4-d7b8-444a-ba13-f754928cccf5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5cb41b94-bd77-49bd-aa11-8a0b406a48f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ce43244b-1c22-405a-b513-f6f6299395db_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_d5d82cce-8cb9-4dcd-a6f6-8849f7e267a5_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:href="sesn-20211231.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0f8d388c-6733-4a93-b7f4-6c5f0b728ecd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_8c3a2208-00f0-4452-b132-063f5adb921a_terseLabel_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms" xlink:href="sesn-20211231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccountsReceivablePaymentTerms" xlink:to="lab_sesn_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_6923f862-0c3c-44fc-8cb0-0574bd2025fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_03908e32-03f2-41aa-bd09-5070a903c7e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_ea8c7add-62d6-45db-bd3b-0c9919ccafc5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restructuring costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ee12a29e-5663-491a-9f4e-4a1478f004a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Benefit (Provision)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_51adedcc-0bf7-435e-ab30-8a663ad8cfb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fe38330f-c6d0-4cdf-90fa-073f79a59faf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a633a169-97be-429f-8f5d-fd17eb41dfd7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5b235e13-fe62-470d-b6bc-e49e7d6012fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3bf84624-d810-45c9-87b7-9d9ce4080027_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a67810b6-b83b-4ad8-983e-fa9a4929668c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b81ab2df-8434-4dbc-b7d7-6cb2809f4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_b7bc2c8d-d607-45ad-a91a-5de04084ae41_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration - long term</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4150f17b-fbdd-4a9d-882c-03ab755a8b2e_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_a199f745-32c2-4c5d-82dc-b630de7a4799_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9c0a81d2-2a04-4f68-8498-25b07078611c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5091ff3d-982b-4698-97f4-0e10bcdb710c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3033b2b8-e09a-4c11-8da4-5084fd95d0b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e712a302-d9ed-491e-8fdc-b88db18342dc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0f755d40-c070-470a-8621-bf4442360ec7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at December&#160;31, 2021 and 2020; 199,463,645 and 140,449,647 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_1611dfaf-4276-4cbd-ae92-070eb8f246ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend on adjustment of exercise price of certain warrants</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84a6e362-3286-4cec-80b1-6ce1d703c867_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period unvested stock to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a993fa1e-8d4a-48c9-86ee-141b95046705_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_24f3614f-404e-42bd-939e-0990661cfca8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_8ed557d8-78a7-43ef-987e-173f015d2874_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a8e8f4f4-7d7d-4572-aabc-c34d4dd5aa51_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f602bc57-99c2-487d-a5bc-488485f69272_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_edc702ec-3e14-489a-b2dc-21fd4203ecc3_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fixed rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_label_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_documentation_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockCommissionFixedRate" xlink:to="lab_sesn_SaleOfStockCommissionFixedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_9e56ad6a-1c0b-43b5-9b74-5a3535457d36_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_34f106ea-6f84-4198-8573-8ccb1ee40429_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a1d2439a-62d8-4c12-9dc4-d42d50651397_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f2addb52-87a4-409a-b5a6-028b506ee8cd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_87dc21a0-7894-42e0-a5dc-8ae02d75b253_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_4c776331-7098-4aa3-b913-b09950d9810e_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_79de78f1-f377-42ae-866c-6cd81307fddb_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="sesn-20211231.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardAxis_01db4e35-6dd8-4759-9d5c-2dd1e604cb43_terseLabel_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Axis]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardAxis_label_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Axis]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardAxis_documentation_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardAxis" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis" xlink:to="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ReviewPeriod_0fd8f0eb-d1d9-4325-9fc3-f706f31fe75e_terseLabel_en-US" xlink:label="lab_sesn_ReviewPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Review period</link:label>
    <link:label id="lab_sesn_ReviewPeriod_label_en-US" xlink:label="lab_sesn_ReviewPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Review Period</link:label>
    <link:label id="lab_sesn_ReviewPeriod_documentation_en-US" xlink:label="lab_sesn_ReviewPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Review Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ReviewPeriod" xlink:href="sesn-20211231.xsd#sesn_ReviewPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ReviewPeriod" xlink:to="lab_sesn_ReviewPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3a4d444a-c63e-4325-9f69-ad2806b2e8f8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_e984ddd9-a10b-4b0c-9939-cc6eb77cc2ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_dd8a88a7-b87e-4818-9b99-5f223e6c57c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_03b6bca9-8fb4-4f2d-a85b-a0c049a4365a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_dd814ee6-61b8-4bba-90b4-feead515e390_terseLabel_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_label_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Contingent Consideration, Percent</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_documentation_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Contingent Consideration, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:href="sesn-20211231.xsd#sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:to="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2054e4e4-bba8-421b-9440-a5558b517ccf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d4f5508c-16f0-456b-9239-be47eefbd692_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a7a3ac4-192e-4379-b4d1-4c49bf3fe9a6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bf8b2fda-3559-4334-b3c6-0d97849d4bef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_420a823f-14e6-48a1-b2a1-688d34b4dcf7_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_09342584-a187-46f4-9e43-1615e043cc0b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, period to pay buyout option once exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_label_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:to="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_10b406f3-37cc-43e9-81fe-86246ee74ff7_totalLabel_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_label_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_documentation_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:href="sesn-20211231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:to="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_4413689b-139b-431e-b160-ba5cca35cf42_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECEIVABLES</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_321b3b6f-7b8b-494d-9948-8a101348923b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_003eb4e0-9b23-4ba0-a0ca-c47c3af886ae_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8054dfb8-46ec-415f-9efe-e9933071a91f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_dd26114c-7dd5-45b9-9f1f-3c0f9ab95bc4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f80774df-786b-4942-8afe-43429464dd3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2eed97a8-0bbd-4794-867d-86b5fcc62be2_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_841062be-d2ba-4029-be1e-52a39d5f0e4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7e9a72d3-c638-4705-aa2b-75e98cd9e563_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6f3549fd-658d-4353-8f3c-acadbd4a47f6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_ec907fcd-5672-427f-9e48-e7ffb97b64ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6fb61b88-3c1a-4229-a760-7a9ec8d20261_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_68bc7ea7-7770-407b-bca6-2467f1a146ad_verboseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_label_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent" xlink:href="sesn-20211231.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseMonthlyRent" xlink:to="lab_sesn_OperatingLeaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1d3c9475-1ea4-4e0f-8f8f-c09d4ac84d49_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3b8f7412-0bcf-4029-8f32-f42453761f31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_2f752e9d-30a6-45e4-bc79-cbfff0b538e1_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to the selling shareholders (in shares)</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_label_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:to="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_afad16cb-e8e5-4eeb-afa9-e9e26ed83b73_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c0b70350-d97b-4d45-b206-cc861aa26e52_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_fb2d8daf-a715-41e9-94f4-466d5375fc85_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d85c64f9-3b13-4d59-b8f0-619cb98adb21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b9773b3f-4518-44cc-88ca-79b1511a762a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING AND RELATED ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_86d7b245-767e-4e18-88e9-219e8b16dc40_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9abbbca1-58e2-4893-a66b-2051d9403be6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_7d6970eb-c006-4d5f-812e-8fd5e89ca70d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense in related party transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_54c703e4-258f-45ee-b5a9-1f261f030cd3_terseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:href="sesn-20211231.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_afea9f08-1c30-45d7-9303-1401e52ee295_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_879402ff-bf87-4439-81df-5a3232c6cda3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0e23113-37cb-44de-91fa-2b3d40acedfc_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_faecbe56-2e3f-4fab-b43d-5bfd889739ac_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyRate" xlink:to="lab_sesn_LicenseAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_08fb8dfd-e49c-458c-9e3b-9bca205fb7fc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_e4d1de6f-d50a-4b47-a278-62b35b2eefec_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_28cb8b00-9406-4480-88ed-8b5ca260ec4f_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_85458a1b-3ea8-4508-a29b-01d581db0562_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e2fc838d-80c2-4270-827e-aa05f29b4fce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1790f7dc-398d-4e41-8955-92bed55db00b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3ce64b74-b785-4c14-a1a3-2c8f7684f1b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_b363f3de-3b10-40bc-894a-33d082316229_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time milestone payment upon first sale of product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:to="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_1ddbec39-bc8d-4503-bac9-fa696ab37878_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of base salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_4bab916b-3c3e-4dde-877b-b418bc50579a_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_fff1a969-e876-464b-b61d-967a384de31e_verboseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrants</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringMarch2023Member" xlink:to="lab_sesn_WarrantsExpiringMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0695570b-3dcc-435f-bd82-847c3c8de598_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b331a55c-9002-43b6-ab63-52ded64aad6a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b7277a8-bb72-45a1-996e-88a09570625a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5d033def-d23d-47a7-882a-7650330225f9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_04cb26a0-6fd7-49cc-9eb0-11e03db5be62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_9f80f933-dbc5-49fe-a3d8-a708f9a26c6f_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b0edd380-f2a4-4124-9c70-8544bc9c24fd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfPatients_757b31b3-19f6-40f5-ab47-26c024370d05_terseLabel_en-US" xlink:label="lab_sesn_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_sesn_NumberOfPatients_label_en-US" xlink:label="lab_sesn_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:label id="lab_sesn_NumberOfPatients_documentation_en-US" xlink:label="lab_sesn_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfPatients" xlink:href="sesn-20211231.xsd#sesn_NumberOfPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfPatients" xlink:to="lab_sesn_NumberOfPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1c29d62f-ff42-4e10-883e-b0c004fa15bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ATMFacilityMember_8f14b870-f886-448d-b7bf-e59fc75de74e_terseLabel_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_label_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_documentation_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ATMFacilityMember" xlink:to="lab_sesn_ATMFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_efc667d2-e6f0-470b-8d13-14ff23fe11f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_684ad89d-ec25-4abd-b5d0-aed350ae44cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_65a083a4-5c79-4901-a161-0a12539ee7da_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_67c7d873-6e69-4c5f-9a92-3f1249afc296_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c677d69d-0497-4ba4-a6d9-c10421c2ad47_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e707c08a-d3ad-4955-a936-8a3a4e7fac0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RetentionProgramMember_8dccff3d-f27a-4bfd-9392-22c4479b5db0_terseLabel_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_label_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_documentation_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember" xlink:href="sesn-20211231.xsd#sesn_RetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RetentionProgramMember" xlink:to="lab_sesn_RetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_01df4b60-375a-48bd-8930-015c9b643615_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9b051be0-9459-4054-91b9-f45ded6e697e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f3efca40-cf70-497c-93e5-ad69a04a10f1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f35428fd-d711-4f6b-9332-1590832ac8b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SupplementalLeaseInformationAbstract_b8178b1f-5ed8-44cc-971c-6ccf7cf01be2_terseLabel_en-US" xlink:label="lab_sesn_SupplementalLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information:</link:label>
    <link:label id="lab_sesn_SupplementalLeaseInformationAbstract_label_en-US" xlink:label="lab_sesn_SupplementalLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Lease Information [Abstract]</link:label>
    <link:label id="lab_sesn_SupplementalLeaseInformationAbstract_documentation_en-US" xlink:label="lab_sesn_SupplementalLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Lease Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SupplementalLeaseInformationAbstract" xlink:href="sesn-20211231.xsd#sesn_SupplementalLeaseInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SupplementalLeaseInformationAbstract" xlink:to="lab_sesn_SupplementalLeaseInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringJune2020Member_72059515-1ede-447c-bfc9-7f5b8cbee7e0_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringJune2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring June 2020</link:label>
    <link:label id="lab_sesn_WarrantsExpiringJune2020Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringJune2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring June 2020 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringJune2020Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringJune2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring June 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringJune2020Member" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringJune2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringJune2020Member" xlink:to="lab_sesn_WarrantsExpiringJune2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0d7dd529-45d4-4312-92e7-de261a2cee6a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_23feffae-6c48-43d3-9048-96651e9e3f55_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a78c2f51-2349-4f6c-9f87-364911b3e272_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9de34908-c99e-40f8-ad52-df7f500e4fbf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_c0f7504b-5af4-46df-9a98-2ca97955df3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c982ae39-6d76-410a-91c5-002d73649129_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity (Deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_7e0bbc7b-b0b0-48a8-860e-1f2def8d2af1_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4c3dee9a-1d9e-4e9b-a68a-6fea70a2fb2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_d464cd5a-553e-4004-9965-ba11da5a0013_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current (provision)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_49197700-5208-4217-848c-383fe1581bd1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_62ac6f68-3dbc-4e0a-a6a8-414e846e8212_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_107ba03e-fc25-4534-ba54-755f0f28bf7b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5264397e-8c17-40ec-a00b-cd90edcf448d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_12adedd6-77b3-448b-985d-dd91f372d341_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fdee7581-edb0-4d44-b826-f015497c7a38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_2483f53c-4e3a-4717-b5f0-879c345074e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant under 2014 Stock Incentive Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_d48e6447-877d-4d12-9ea9-97855806d9e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_ac1943a2-6c76-4a70-b52a-b13f6ccb829b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, additional up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:to="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_16c238d6-b1d5-4125-a770-ef16f3b3f8a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6434230a-e631-4bbb-aa86-30b1674b8c7b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6657bc05-29d4-4427-805b-61021d9afedf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1076f9a4-6c73-4d30-848d-0a0129cfa371_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common stock under 2014 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_63af679d-f0e4-4572-8165-373d3692d29f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_816c3432-1ac6-4ee7-abd8-161e35217cb1_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value (in dollars per share)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_737c6a12-0ee9-42ae-ae7c-1a8c25f99ea7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_294b3dcf-c302-4263-8109-0a1480a12003_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_31b32c6f-56a3-4ecd-ad3b-027e89e75e7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting at End of Each Successive Three-Month Period Thereafter</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_da3e23a3-e085-4551-85ed-127ca1183332_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2df51c81-49bc-4168-9e9b-590d3ddd9bbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ec664c2-48b0-46e0-b6e8-447f04d1d610_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9f829b1e-e3ed-4e5e-97a3-587e02783a9a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_7732f3dd-903c-4039-9acc-a8e8d1ce6506_terseLabel_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_label_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_documentation_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare" xlink:href="sesn-20211231.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberofVotesEntitledForEachShare" xlink:to="lab_sesn_NumberofVotesEntitledForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_0f471fc3-2004-4282-8da6-aa08f7b32ed6_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration - short term</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_994f1e24-6bf6-4cc1-8eaa-2e6e23d1efdf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_decf7cc2-7e97-4cb2-aa67-62f1b7dcae6f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_fa6c0273-fd4d-4938-b6bc-f60609e7d90c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e838a58f-1af4-4e44-b905-52dbd5b6a4fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92bf8f15-a931-4e85-a8e4-46e682422adc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f514d03d-483e-4b72-be40-f452e6f35bb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b2912a66-8f7e-47e9-a136-2e5299b2f09d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d8732aea-53e8-4241-8295-5a07dc10a6a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e5f586d1-2d90-4b48-8368-918cd39f0bc5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d0e83059-4bd0-4c04-a428-4f03bd74282a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2972e07b-092d-469b-9d7d-85ad442d79ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_05d454fb-49e9-48bf-8bbe-18288458d442_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5dd4596-afd6-4120-b975-3bff4ec858a7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5b23b07f-d26f-4fc9-a52b-a66d87aed9c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e9ddc3b5-facb-44f8-a5a3-a8577dfc86d8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_9e10ba8c-eaf9-4531-84ab-cf419b3cf7e2_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_53bcccf6-b310-4026-8fc4-ff4d0428da52_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense related to cash bonus</link:label>
    <link:label id="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_label_en-US" xlink:label="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, On Cash Bonus</link:label>
    <link:label id="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_documentation_en-US" xlink:label="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, On Cash Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" xlink:href="sesn-20211231.xsd#sesn_ShareBasedPaymentArrangementExpenseOnCashBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" xlink:to="lab_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_700a1970-396e-43d9-ab25-751307611c44_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments (2022)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_715d49da-c373-4041-abd6-adb6b7ab83e6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1a479fc5-0e25-4f1d-8a51-f90d48c09a2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_49514528-c19a-4186-a580-76f85586f4df_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:href="sesn-20211231.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d09d585f-bb3e-4ac6-969f-c9c3cf53a59f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in warrant value</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_da19712a-a51d-4a92-b70e-903e6ee71724_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b8d16466-ebdd-4f6f-a5c3-d4009a0e1108_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f28f05d5-ffe9-4e22-b016-3e51c8105031_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_d6153a0a-aca1-4afa-8cb4-08f350cc5609_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_95e860eb-4e2d-4d0e-be1f-7a0441ed091e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_51a16e6e-1488-4f9e-ac65-819ad562b80b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance change</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c3c80207-72f2-41b4-b422-72326795fb11_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_55da8ba5-3386-4a68-8a56-09fc55778c71_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration - long term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9dea3def-b344-4846-aa5f-7cbb784c869a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants_77079dff-6fee-4f96-a78a-86bac0b54e43_terseLabel_en-US" xlink:label="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and common stock warrants, net of issuance costs</link:label>
    <link:label id="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants_label_en-US" xlink:label="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock and Warrants</link:label>
    <link:label id="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants_documentation_en-US" xlink:label="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromIssuanceofCommonStockandWarrants" xlink:href="sesn-20211231.xsd#sesn_ProceedsFromIssuanceofCommonStockandWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProceedsFromIssuanceofCommonStockandWarrants" xlink:to="lab_sesn_ProceedsFromIssuanceofCommonStockandWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_521ae69c-924b-49b3-b8a7-f857e0c62679_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_14008748-2acb-4d46-a749-b7c01363c7a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrants Outstanding and Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_53617de2-9b62-4608-9183-afb7abd67358_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b744274-cee5-45a3-899e-086e437097b4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_e7e93e46-6f45-43e3-be1f-1af72a968298_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_faada080-0935-458f-8261-eb95ecaee1bf_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_9097408a-d6f2-45cc-8f40-cae9ddc04f8b_terseLabel_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_label_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_documentation_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:href="sesn-20211231.xsd#sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_a131ae6e-f265-4e4a-b8f3-d295bf726809_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a16b53fc-f1a1-460f-a44d-903725b2d0bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_903ea148-0e04-4839-8662-de9efb96d6de_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_84e46846-dbd8-40a5-89ab-74101829581d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option cancellations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b28e7b1d-20f4-40a3-a455-db9482fee90c_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6a43b1fb-a442-412e-8f54-19962d88ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_f4c1dd2f-f700-4eb1-b98a-321e5d61e750_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_ca18857e-b3a7-4d61-b090-c48efa8c62a6_negatedTerseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Cancelled (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:href="sesn-20211231.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_061895c1-45b5-4645-9be5-53b31b66d5f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_63d35f80-5af7-4e6b-84c9-91d7f2659e55_terseLabel_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge related</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_label_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:href="sesn-20211231.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:to="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f74c9ada-a8b5-4d61-8810-15390a9681d4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_80320267-ea55-4cd8-8bd7-def245e95aab_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term property leases</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6eda1129-3410-4f43-a969-435753d39ead_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_f2214bf5-001f-45c1-af23-1ef279f73a16_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_edbb7637-7194-4982-807f-819d699f584b_terseLabel_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance for:</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_label_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_documentation_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:href="sesn-20211231.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:to="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_82a03360-f87e-45f3-8816-9fd0c01b4401_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_8431d482-837c-4d6e-af3a-24d3937b0a19_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_d5b2bdae-7882-4d4d-bf6c-c9429d5a7ac7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_ae605256-e649-42e0-8996-cca02e700f5a_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_ef511a9c-e488-4369-bd8d-3d35177d109d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cdba315f-573e-4321-8598-91b116f941c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_66dc6324-7929-40e8-8240-d6745ce7c2a4_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_b8c40df0-ecca-4ce1-a04e-48f531276863_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair value in excess of carrying amount</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_32327178-996b-41df-a4f1-cdea3a83281f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_00746122-9f5c-436b-a916-ec7fadf99f17_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SecondIndicationMember_57982bad-51ee-4e98-9c60-d3562b41e4a9_terseLabel_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_label_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_documentation_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember" xlink:href="sesn-20211231.xsd#sesn_SecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SecondIndicationMember" xlink:to="lab_sesn_SecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_48bf519d-2a5c-48da-a104-e396f92b899d_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_label_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationMilestonePayments" xlink:to="lab_sesn_BusinessCombinationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48e18ded-f6c9-4e60-953f-94de19e671b1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1b3f09f0-8f78-4667-a18a-f9c033914a26_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_af0c4c5d-e8b1-462d-acaa-d4ddd351d5d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d2a7172-ddfa-4cc6-9116-a082b1bba500_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f1af2c05-859f-4a80-8801-d0ac586010c7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_07861da3-2499-4397-b0df-4a210d399be3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_96d0606e-9d12-4e8b-876b-b48b794ee308_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4b22949b-7d6e-4ee7-a2af-c3bcaa4a88d0_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EBI031Member_79ae9c6b-6049-4eeb-93a6-165571691bf2_terseLabel_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031</link:label>
    <link:label id="lab_sesn_EBI031Member_label_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:label id="lab_sesn_EBI031Member_documentation_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member" xlink:href="sesn-20211231.xsd#sesn_EBI031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EBI031Member" xlink:to="lab_sesn_EBI031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_5817ceeb-7aec-43bb-bf2a-a9bf673a5e5d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_1e84fea5-e458-4ba8-98e4-8245cf1ee0ff_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_e5b35411-5b3e-4eb9-a7ee-1ef8af448141_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_3926d1ef-eaef-46c4-a97d-818f5c240955_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6f013a7d-4efa-4d26-845c-061a4a34064f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9eefcfcf-7b4e-4fda-b246-ede27fb996ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2036e8c8-3256-438f-9bc6-896253b79821_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4276717d-1d89-49f2-9dab-951c8a646e19_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_de8ee806-1995-417c-8bc9-6a7f85f3a32f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_0104af83-82ee-4c29-b996-c4401209c333_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8e22e71f-fd57-4918-ab74-6ab6ca6ea43f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_30187166-50a9-4eef-b0ec-076111c77b5c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_538e49cb-addc-4458-816f-0568ec44601b_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on development milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_aa026621-7aad-43a6-985a-47f0dbef23ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1e8df0a2-4cb8-480a-84e0-c7c781b5a646_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_18bfe47a-9eda-4cd8-8fbd-9b38d6984eaa_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protoden</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7bfa546c-128b-4af1-960b-3fc762b6e009_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8befeb90-d8f8-44f8-be83-f4413efb4227_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_49c93d42-3ebf-406f-9216-299883fdb5f5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9150201d-d6aa-4ccf-a2df-eea508d5ece2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_76b08284-48fd-43e5-b40b-e2d5d9a5c945_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_89e16dac-357d-41e1-ad8f-969fbd190561_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9b243842-b44b-4624-a13f-ac0cec9161a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Status of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0ee869eb-4659-4b68-9677-0d173421f662_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_156e21da-5250-41fb-9d14-c5c302c0f1c9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_6ecc8091-b784-4193-ab67-eb67fb35a130_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_5b621a0b-793b-4549-b525-eead7e1bd904_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesLineItems_65c1f3c7-ecd0-4b11-a303-dacd8af53ad5_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_label_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesLineItems" xlink:to="lab_sesn_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cd519002-1f81-4e0b-a80a-403df8f7a819_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a21961ea-f52d-4128-8a6e-e45c859a1fff_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4278296b-1d73-47de-90e0-099f8c095313_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_1f2ec05b-7ee9-480d-b231-9c44fda10598_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ae29ec9-d7b1-4071-8e43-e5b66c05f590_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_513c6657-7061-401d-9e96-8117c84f2fba_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_84dde6c2-94b2-41db-93a7-4494f4fd8b28_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7a0cb3ee-697a-4cf6-89b5-25844738a640_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7c4fac3-f919-4777-8f34-af5aadb84904_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_45684eed-437f-4463-9c1f-a5e3b7727040_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative cash flows from operating activities incurred</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_d02301f5-d5ea-4dc9-bcd7-ae3859ff47ff_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_682c9f99-5af8-4c27-b530-1d61a0a4175a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97721edb-94f4-42a9-94b4-45defe06b1ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_cc3d2194-2d14-422c-9b66-325daf0fa4bf_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_423c023f-448c-4bd4-afb3-120aa4bca729_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_797168b7-c53a-49ca-9af3-a74c85edcddb_verboseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e0a403e5-8f74-424c-adea-c45de48dfbb3_negatedTerseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_626c12d8-7d3c-4ba2-9248-200dac613de5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_8247eae6-bb01-4184-8ee9-0fc33fc7f9dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b8d5e352-21d5-4b15-a4f6-20e6adecc7ef_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3579cc90-ee88-44cd-8db9-4b74beaef74f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bfd761dc-6ea9-43e7-b6ca-e2c8897671e2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a62e4e2a-c8ed-4df6-ad8e-322b8e8698b2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3f7977cf-9451-45c4-b144-58ba0252db05_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_b32b14bc-77f1-415f-ba2f-7be8d79eef6b_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales of quarterly earn-out payments during earn-out periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:to="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_58c8d485-4052-4894-b517-c3c65f0f1c3d_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_4f9a40da-c4f7-43e9-8638-26f00d7fbb3a_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1f701e30-3b3f-49ab-ada0-df4622664b6b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_da709feb-8839-442b-98d1-f878ba50ea69_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance cost</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:to="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_11695b53-228b-40f2-bf2a-c7154000ada4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_b4c4c50c-3693-4041-a9d1-77421a446d5e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_46d06a23-4d80-4f64-80af-ad4b6983a9ce_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9f5937fa-eb30-4ab5-9a70-059d6a2ae2f2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_459d426c-a6ad-4964-829a-8fdbb2c6eb43_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and benefits costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_918f3f64-2157-4e87-bba2-47605cd6fe95_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1900fa82-c114-42a2-aa98-da820c2bcd41_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_a8667333-2180-4bd7-8f73-8c745eb74acc_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued</link:label>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_label_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Shares Authorized For Sale</link:label>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_documentation_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Shares Authorized For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:to="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_5d203cb6-da4c-435d-81c6-167a29096eef_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:to="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_16f2cd6d-1e41-440b-87d3-30bd78d260e8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_21a580f6-2914-4ed4-a659-2991b9a908a7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_ba5238a3-8d52-433b-b599-01af5fcb60d4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1e4ae7b-61ea-487b-b329-c45f6050b9e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1b85e7ff-25da-46bb-801c-5e4ccda8eed1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_74a6a4f4-aa81-4a36-8bd7-fed533a17337_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0808fe94-835d-4d91-a25a-3c89c1c9bdb3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IssuanceOfWarrantForCommonStock_db67373a-92da-4cbc-a371-b07c338eee95_terseLabel_en-US" xlink:label="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend on adjustment of exercise price on certain warrants</link:label>
    <link:label id="lab_sesn_IssuanceOfWarrantForCommonStock_label_en-US" xlink:label="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrant For Common Stock</link:label>
    <link:label id="lab_sesn_IssuanceOfWarrantForCommonStock_documentation_en-US" xlink:label="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrant For Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IssuanceOfWarrantForCommonStock" xlink:href="sesn-20211231.xsd#sesn_IssuanceOfWarrantForCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IssuanceOfWarrantForCommonStock" xlink:to="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_a3260022-0dc4-4850-8c87-41181d3207af_terseLabel_en-US" xlink:label="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrant Amendment, Amendment to Securities Purchase Agreement</link:label>
    <link:label id="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:href="sesn-20211231.xsd#sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:to="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_cf02630a-7df3-4b97-8e82-ff419cf2cd48_terseLabel_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_label_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement [Member]</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_documentation_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:href="sesn-20211231.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:to="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_33990846-aa51-46b3-a9f5-fd08b0f087a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Expected Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7113d7f2-80bf-4dcf-b88d-c1c8f5cf0e54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_25310028-dc43-4253-a0d6-a3df798539ba_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_fa98e011-cd57-433b-ab57-0cb9b9f3cfb2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f11f948e-2881-4735-bcee-dcea5ca206f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ed52dfb7-6f3e-44ac-ba98-5bac7374017e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6e5aa93e-4447-4508-8206-d83904e6dbbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_0ae0112e-3eb2-45ff-9f7b-1ddb40bd8aa7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b2c0466f-4fcc-4e02-b22b-7cd5f296b18d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_d77a1893-01dc-4e40-a356-5b9282e536d7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d3ec7506-1007-4193-928f-c8836a62068a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_106c4895-c36b-40db-a736-5293b6eb65bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare_2853d440-47b2-425d-a51b-bf7844c064cf_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and warrants price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare_label_en-US" xlink:label="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrant Or Rights, Price Per Share</link:label>
    <link:label id="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare_documentation_en-US" xlink:label="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrant Or Rights, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:href="sesn-20211231.xsd#sesn_CommonStockAndWarrantOrRightsPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:to="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_df24c49b-7eff-4bf7-b539-11a16329e96f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_bbe615e1-14c3-46a0-932a-662c24990c16_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to achievement of development milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:to="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_90945c18-5d3b-447a-9265-fe9254afa3d7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b8881d5c-5b66-41ff-8ef7-85f6ae1ea789_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fafc2b1-6df1-4b6f-9169-baaa6d793243_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_UniversityOfZurichMember_8909c702-688c-433d-86bf-bf92a270a377_terseLabel_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_label_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich [Member]</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember" xlink:href="sesn-20211231.xsd#sesn_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_UniversityOfZurichMember" xlink:to="lab_sesn_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_99e7c2e2-35c6-46b1-a188-dcc18c00478f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares under Option (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_7a066b59-732b-4f86-99cc-1cbb25cea84e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82ceddfa-b693-46fd-886d-4300c34b4011_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a9480962-45a6-4ebd-9ee7-a183b9041e40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_2a8f64cc-4a28-44ef-af3a-7c1c8f4aea8c_verboseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:href="sesn-20211231.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c636d7cc-d8aa-488a-a8e9-306492478201_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_12e2216f-7e27-42b5-a312-77f4d51eaf08_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_709f630c-911c-42f4-b8ca-5edb20e97347_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6a02c94e-86a5-4f07-919b-3a7138bad6c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fadedc7c-9266-425d-9aa7-17fbac12c385_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_8260305f-469d-49ff-afbf-dd458b76b201_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax Provision</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_064d9531-80df-4790-8a0c-cd854d0e8a2f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ed2da227-d668-45ba-9502-07187745770d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorityShareholderMember_a535ddab-6c52-412f-b248-830e87b31354_terseLabel_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Majority Shareholder</link:label>
    <link:label id="lab_us-gaap_MajorityShareholderMember_label_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Majority Shareholder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorityShareholderMember" xlink:to="lab_us-gaap_MajorityShareholderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_68dd6faa-f836-43b0-85e7-5f7fe5332728_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9212b93b-b313-4bb2-9ea2-718b91adc4af_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d6dd59ab-3e79-4e21-8747-a0b2d7b09140_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RocheMember_493c4d75-70e6-465c-b102-9633e75bf056_terseLabel_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_sesn_RocheMember_label_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_sesn_RocheMember_documentation_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RocheMember" xlink:to="lab_sesn_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8de0b951-905f-4c58-ab71-d09a0cdd416f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_eafc6708-ecb1-4f30-a5dd-f71e2233765b_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:to="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1a33dce7-f815-4f15-9137-53d246ec1229_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_cc8af557-b289-4f15-82c9-53bf1efcfb4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_1c4bf7dc-eee6-4837-9736-e4271258c6af_terseLabel_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:href="sesn-20211231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:to="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_03c32eba-68ab-4c53-9108-2ddb55fe71ee_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5cd84488-16d9-43a0-89cf-7d1983f3a6d7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7d2b7478-0b47-44b8-bccb-1861ca9ecdfd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_847e6eba-8210-42f2-9bf1-16457aedfddb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_577d52aa-158e-4ea5-b947-46dda94d3671_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_5d904f1c-4194-4e74-a3c5-7e1530822698_terseLabel_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average cost of capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_label_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital" xlink:href="sesn-20211231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WeightedAverageCostOfCapital" xlink:to="lab_sesn_WeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16e6a795-53c9-4840-be7a-d8139d5c1473_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_027e6b18-4cfd-4f40-ba63-6a09e6a38315_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_751081be-7484-421e-8e2c-70effab58344_terseLabel_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:href="sesn-20211231.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:to="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViventiaBioInc.Member_12c623f7-d3c5-4cfb-b74a-a9aed366a825_terseLabel_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio Inc.</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_label_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc. [Member]</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_documentation_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member" xlink:href="sesn-20211231.xsd#sesn_ViventiaBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViventiaBioInc.Member" xlink:to="lab_sesn_ViventiaBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseRevenueMember_92ddb5a1-b001-4d4d-b5c6-6bdc2f675a05_terseLabel_en-US" xlink:label="lab_sesn_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_sesn_LicenseRevenueMember_label_en-US" xlink:label="lab_sesn_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue [Member]</link:label>
    <link:label id="lab_sesn_LicenseRevenueMember_documentation_en-US" xlink:label="lab_sesn_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseRevenueMember" xlink:href="sesn-20211231.xsd#sesn_LicenseRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseRevenueMember" xlink:to="lab_sesn_LicenseRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLossCarryforwardsDecrease_533ae810-db6e-44b9-9d80-21f27bf05def_terseLabel_en-US" xlink:label="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforward reduced amount</link:label>
    <link:label id="lab_sesn_OperatingLossCarryforwardsDecrease_label_en-US" xlink:label="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Decrease</link:label>
    <link:label id="lab_sesn_OperatingLossCarryforwardsDecrease_documentation_en-US" xlink:label="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLossCarryforwardsDecrease" xlink:href="sesn-20211231.xsd#sesn_OperatingLossCarryforwardsDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLossCarryforwardsDecrease" xlink:to="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9fe579b-0229-4962-b4f6-50f6606e3f11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_007ddf6b-2941-4c3d-99ba-bd8e813779a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_72bccea7-bdc0-4fed-82a8-869241ffb6a0_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_78be3839-972f-4a97-88be-a14fc4947e5d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_e0aef066-3774-43a8-beff-e5d44d185918_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_d7b503ec-5427-4b67-900b-737bc4292c88_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment obligation, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_76b91395-8208-4bdb-ace2-5ab81283c16a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a76f47e-dfc3-4382-b870-ae38848ba0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b8c5db9a-6271-406b-86ad-a800111d1d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1081c077-5646-4081-a900-23027d440eeb_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_59937c60-777e-4894-ba4d-95dc8c324718_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60069d78-cb7b-471f-9bbe-91a7b2a4c56a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_2570272a-3cc1-4cdb-9737-523506190732_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credit carryforwards</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_c406bd50-0764-4d28-85fe-8db5e1ea90a7_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_658a2f50-aeb4-4716-b95b-5ae9ac376c64_verboseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_62d3bf33-c3ca-4c71-b568-8b497762fa0a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseMaintenanceFees_b1ed2a8b-2b74-40c4-a84d-2d2451980592_terseLabel_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_label_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_documentation_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees" xlink:href="sesn-20211231.xsd#sesn_LicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseMaintenanceFees" xlink:to="lab_sesn_LicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0a549450-f20a-4718-bbb8-9b42828828a3_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_bfeeee01-1d44-409b-be6e-0a798bd17b8d_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_d856b74b-e0fb-4175-9be4-cdea2337a70f_terseLabel_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="sesn-20211231.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_1947e4ea-ddb0-4626-88f8-408394677d88_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_7eca27fe-9d90-4c5a-b00f-59a7e7de9f69_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_987a9ce7-c437-41a7-8059-de425efbb08b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_5cc166b5-32b5-4bce-8de5-133f99d326b0_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_030cf9ba-a539-44b5-b1e9-7580cd77b5e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Pre-tax Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e0b2fb0e-60c1-4462-af8d-7cbc371f932b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecd78f2b-9c6e-4ff3-94f3-15bf3c84a074_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_251aefa0-feb0-436a-9638-63b25257174c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2e77014-88a0-4935-a53a-e86595758700_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_1f16dfcc-b2a2-4b42-934e-ca74d6f37567_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7b9d94df-a692-428a-bb2a-fccc5a1b0a3f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of units issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8f9d42fa-d63c-4281-b9ab-a1b1e36520e2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_48790d40-e608-47da-8d55-aa77c15d5e61_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States:</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_606bcc34-d098-48e9-94d4-adbc75338945_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_521b087c-fa23-4093-ae0a-5154e1e02119_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_793ef6f0-2d46-4360-9863-9547b930efb1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_af9d9ea8-244b-43cc-b842-b2f09f46e472_terseLabel_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_label_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_documentation_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:href="sesn-20211231.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:to="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProceedsFromValueAddedTaxRecovery_45f61060-5f9a-40e5-9951-0a29d1e500c9_terseLabel_en-US" xlink:label="lab_sesn_ProceedsFromValueAddedTaxRecovery" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from value added tax recovery</link:label>
    <link:label id="lab_sesn_ProceedsFromValueAddedTaxRecovery_label_en-US" xlink:label="lab_sesn_ProceedsFromValueAddedTaxRecovery" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Value Added Tax Recovery</link:label>
    <link:label id="lab_sesn_ProceedsFromValueAddedTaxRecovery_documentation_en-US" xlink:label="lab_sesn_ProceedsFromValueAddedTaxRecovery" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Value Added Tax Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromValueAddedTaxRecovery" xlink:href="sesn-20211231.xsd#sesn_ProceedsFromValueAddedTaxRecovery"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProceedsFromValueAddedTaxRecovery" xlink:to="lab_sesn_ProceedsFromValueAddedTaxRecovery" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a63d1d93-53fc-454d-b0e7-0d25b72508fa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a822dc1c-913d-44e0-8970-3ca256344548_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bfa5e726-fa65-4b22-a6a4-15eccf727c68_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c9a4d25-4786-4c5a-9d0e-f4b838965e3b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_6e2feaad-348d-485f-9508-1fced3abcf8b_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_bfcffbdf-ddab-4140-bea6-84394c29a06a_verboseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2022Member" xlink:to="lab_sesn_WarrantsExpiringNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_289e3b76-f083-4390-aa46-8a094f29236f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b8301bd7-ac8e-4a36-b972-b414a78404d5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FacilityinWinnipegManitolaMember_02a97534-80a7-4c91-b908-3d163da63a1c_terseLabel_en-US" xlink:label="lab_sesn_FacilityinWinnipegManitolaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility in Winnipeg, Manitola</link:label>
    <link:label id="lab_sesn_FacilityinWinnipegManitolaMember_label_en-US" xlink:label="lab_sesn_FacilityinWinnipegManitolaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility in Winnipeg, Manitola [Member]</link:label>
    <link:label id="lab_sesn_FacilityinWinnipegManitolaMember_documentation_en-US" xlink:label="lab_sesn_FacilityinWinnipegManitolaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility in Winnipeg, Manitola [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FacilityinWinnipegManitolaMember" xlink:href="sesn-20211231.xsd#sesn_FacilityinWinnipegManitolaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FacilityinWinnipegManitolaMember" xlink:to="lab_sesn_FacilityinWinnipegManitolaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dcaad9da-fc7d-4e44-a3e3-60f1c32065c5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_aea8081b-a259-48d7-94d4-cbb0ad29a3c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fa45caf3-ae12-4ff7-9c18-1ef2dfbdb822_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a994bd70-33c3-47ae-835d-0ca3c5da9003_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock awards and vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7d90687b-e7f7-4c13-a958-9ad3f28a9638_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_0d137f7e-0a9b-469a-b411-1ae35e744622_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under first option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8e851a5-4cdc-4849-9942-3c91457780c1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding for diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_113d6452-4311-402f-be17-b0dba1a0dcdd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6d440200-c2e7-45c6-bdd8-02de5dbda88a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_3433d8d7-c347-4423-89aa-0e41b59e7279_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTextBlock" xlink:to="lab_sesn_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_916c452d-2ab4-4601-a234-ba43d2782d15_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_f960d772-9de3-4eb4-be41-64613e3c33b9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f09be31e-93cd-45db-b33e-947cc6098292_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_80e4ba26-7bea-409a-85df-abb3a1fa3fa9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY DEFICIT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_837c6ff1-9a7a-4dad-b499-2743512b3a65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7e6ec445-5dfd-4bb9-bb1d-ea908a038edd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_13613f97-4099-4979-9944-2eac7e05a616_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3be483e1-dde2-4cfd-bc7b-9103b11f3f13_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b909540f-b0fc-42b9-8c24-7db460a75555_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c48975-d930-417b-aadb-bb12992db802_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_224b8dc2-c332-4c65-af13-7790b93ee41f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0a50ac9f-9630-4bcf-942f-793ad1a55e80_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_122e3496-d200-44ff-8ab5-c50e6c859a63_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_45e540c6-8bad-4059-85f5-4f37ce4efd86_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56407797-a0db-42f7-a587-61b9ca2c27f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_c5115046-ca99-47c9-a844-6a2cf94904bb_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bc3f4d71-887b-42be-bb71-b2891c2c4349_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_340f7918-c74f-4818-94f8-767ee0106027_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common stock under 2014 ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_91d95f19-997f-4807-bd97-befb2f5cd668_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average stock price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ae1f4237-582c-487a-8083-ba1c885292c6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_85cf14af-ba56-4780-87ec-c0fc3cd8c913_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_07ef4320-9e3c-480a-a906-f0c85ab01ced_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b3d59b2c-1922-444c-8716-cb90e7abbac7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_41d88b7b-858c-49be-b332-9724e786c56d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d7808394-73a1-4e37-9330-c05794ad8cd9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b37c52af-3aef-4b84-8a23-c207039b5857_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_d0a1fd9b-e787-4e48-b87c-432a3e35639e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for sale under 2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e7f0c4bc-182b-4c5e-b23a-ea93314f2dea_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesTable_3fd9a856-cbd8-4557-abf3-46e1750124c8_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_label_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesTable" xlink:to="lab_sesn_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MicrometAGMember_48a93f07-fcd4-4a7f-8436-45bdb8685b07_terseLabel_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:label id="lab_sesn_MicrometAGMember_label_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG [Member]</link:label>
    <link:label id="lab_sesn_MicrometAGMember_documentation_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember" xlink:href="sesn-20211231.xsd#sesn_MicrometAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MicrometAGMember" xlink:to="lab_sesn_MicrometAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_53619ebe-d00a-4006-a7b8-605e8c698835_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_03641fc2-4f80-4c15-a3be-cd29c482afcb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_f42cffa1-3d66-43f8-8105-8899e81e3403_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NonCapitalLossCarryforwardMember_ae86d163-1430-4631-bcaf-abed563ff98a_terseLabel_en-US" xlink:label="lab_sesn_NonCapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-capital loss carryforwards</link:label>
    <link:label id="lab_sesn_NonCapitalLossCarryforwardMember_label_en-US" xlink:label="lab_sesn_NonCapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Capital Loss Carryforward [Member]</link:label>
    <link:label id="lab_sesn_NonCapitalLossCarryforwardMember_documentation_en-US" xlink:label="lab_sesn_NonCapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NonCapitalLossCarryforwardMember" xlink:href="sesn-20211231.xsd#sesn_NonCapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NonCapitalLossCarryforwardMember" xlink:to="lab_sesn_NonCapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IndefiniteMember_c622a5c4-ea9f-4c82-b8d0-77a069016d05_terseLabel_en-US" xlink:label="lab_sesn_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_sesn_IndefiniteMember_label_en-US" xlink:label="lab_sesn_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_sesn_IndefiniteMember_documentation_en-US" xlink:label="lab_sesn_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IndefiniteMember" xlink:href="sesn-20211231.xsd#sesn_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IndefiniteMember" xlink:to="lab_sesn_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_573fd076-ed46-4037-aa7b-71db73d0f457_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_7beb34a5-7d9b-4368-b45d-78eed8d5ed89_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which quarterly earn-outs are payable after date of net sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:to="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9b70a1cd-50de-4aae-91c1-efeeca08b162_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock pursuant to ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ddb70182-d0f0-4a4b-a077-4970e3f6a051_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_cb4122fa-5204-4ecd-891c-f6445c62b3b1_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, amount payable upon achievement of specified milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_label_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:to="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_95172694-f732-4322-9031-977a6aa75047_terseLabel_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_label_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_documentation_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:href="sesn-20211231.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:to="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViciniumMember_cf58ccca-354a-4fb9-8b44-80ce33439770_terseLabel_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:label id="lab_sesn_ViciniumMember_label_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:label id="lab_sesn_ViciniumMember_documentation_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViciniumMember" xlink:to="lab_sesn_ViciniumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32152c79-96c9-47fc-a62c-06a04340a80b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_4d02fc22-6c1f-4794-a5e3-3b820d07b396_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_7fa80e4d-f54d-4fae-a08c-aed188e8b986_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty payment, reduction, conditions not met</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:to="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e7b2b825-d1f0-4ca5-bbe3-b38025737e97_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_777bc491-cee7-406d-814f-8bafc80c1bfa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_b5abcd52-77fd-435d-9433-3b2548cbf23f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_69ad0cd0-2fd0-45ce-919e-65457cb01062_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_f4a89769-452f-451f-9941-5987919351c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_49877a75-73f1-474b-a819-5d47bf14da94_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9682415b-e0f6-495d-ab84-0e68c30ac24f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592d7165-2a03-4b1a-aced-e5742ea9eeaf_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MENALicenseAgreementMember_afe1e745-2b7b-4c89-bc62-45d8ea19b183_terseLabel_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_label_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement [Member]</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_documentation_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember" xlink:href="sesn-20211231.xsd#sesn_MENALicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MENALicenseAgreementMember" xlink:to="lab_sesn_MENALicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_af7daffd-ddd8-4238-adb6-46a314aba134_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_0069032b-99de-40c2-a1ae-387fbaaf9bdb_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b283623-26ea-45e9-961a-bf7e1435d083_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2cb58062-fb52-4c67-8cf5-1b080d4c6cc7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_3d729911-0d16-44b1-88b4-08e0eda0c322_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_label_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:to="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_919abf94-0bde-4d23-aca8-a82101d68d43_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost, including related operating cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_21d02eef-4698-4067-a851-17149e3b2c9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (including related operating costs)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_dda9de4f-ac55-4c37-a079-589931d2ef19_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on commercialization milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6d7aab62-51ca-4e90-bee9-10cfcd5d00fd_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_982c091a-6923-4103-857e-d7f26830d409_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8306e39b-f580-42e1-a84e-edcd4a5802f3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED-PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_7466aa04-c7f1-4f3b-8533-adfc5e08936b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution retirement plan, maximum employee contribution deferred</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af2a1883-4147-4306-a063-bfbb14cf4b44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_036520cf-d615-46f4-a436-43f6809a87a6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred benefit (provision)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_be7f1f61-9895-406b-a920-2318670346dc_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related operating expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_label_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:href="sesn-20211231.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:to="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>sesn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/Cover" xlink:type="simple" xlink:href="sesn-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_57c0a643-a048-4af5-90e8-97d618de6463" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentType_57c0a643-a048-4af5-90e8-97d618de6463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e3dd3f58-605e-4db7-ba6c-a5f015c06fec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentAnnualReport_e3dd3f58-605e-4db7-ba6c-a5f015c06fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b65808e1-c33c-47ff-b407-c1cd51c3737a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentPeriodEndDate_b65808e1-c33c-47ff-b407-c1cd51c3737a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_00839588-01d6-43c6-89c8-a46c297c2d39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_CurrentFiscalYearEndDate_00839588-01d6-43c6-89c8-a46c297c2d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a269936a-272a-4705-b382-6bc75c8899a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentTransitionReport_a269936a-272a-4705-b382-6bc75c8899a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_024619f0-07dc-4d46-885d-97c0856e55ba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityFileNumber_024619f0-07dc-4d46-885d-97c0856e55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cc896791-1fe7-43bb-a3f7-16b45b673d23" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityRegistrantName_cc896791-1fe7-43bb-a3f7-16b45b673d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d380795a-c23b-4ea8-9e8a-125c1b26aec4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d380795a-c23b-4ea8-9e8a-125c1b26aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ae0a8721-2e5a-4cca-a88b-dd76e9481769" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityTaxIdentificationNumber_ae0a8721-2e5a-4cca-a88b-dd76e9481769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0b6027a6-8236-49a7-b725-9a246886b4a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityAddressAddressLine1_0b6027a6-8236-49a7-b725-9a246886b4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c351b399-6cc4-49cc-80db-0646e8cce44e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityAddressAddressLine2_c351b399-6cc4-49cc-80db-0646e8cce44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_596c4450-d7e8-43db-ba4e-ed277b7413d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityAddressCityOrTown_596c4450-d7e8-43db-ba4e-ed277b7413d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e09b73f7-334d-4864-977f-20658db20eaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityAddressStateOrProvince_e09b73f7-334d-4864-977f-20658db20eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_73b1f6c8-cb40-4ea5-bd8e-0a846e6ee6ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityAddressPostalZipCode_73b1f6c8-cb40-4ea5-bd8e-0a846e6ee6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f37bc835-8ba6-4d3f-8988-4687984a636f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_CityAreaCode_f37bc835-8ba6-4d3f-8988-4687984a636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_88691023-bc18-4918-bfd6-72126f162d5a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_LocalPhoneNumber_88691023-bc18-4918-bfd6-72126f162d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e8ab4f29-8117-4215-82f4-dbd8255af065" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_Security12bTitle_e8ab4f29-8117-4215-82f4-dbd8255af065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_49a14467-3a8d-48e2-9387-41f70ebdfd34" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_TradingSymbol_49a14467-3a8d-48e2-9387-41f70ebdfd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4504f6ba-48cf-47e4-a812-57967310f820" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_SecurityExchangeName_4504f6ba-48cf-47e4-a812-57967310f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7fcc76e2-76d7-4fbf-9a2f-16a5100f51a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7fcc76e2-76d7-4fbf-9a2f-16a5100f51a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_26ad37dd-aa75-4f8c-af11-536db55f29f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityVoluntaryFilers_26ad37dd-aa75-4f8c-af11-536db55f29f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_93eff43f-047f-438c-a7cc-a65739be7b32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityCurrentReportingStatus_93eff43f-047f-438c-a7cc-a65739be7b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6598cf87-083d-4c60-816d-3d8628a76ffc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityInteractiveDataCurrent_6598cf87-083d-4c60-816d-3d8628a76ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_14ea743b-3cd2-4277-b24f-9849d4fb6fa5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityFilerCategory_14ea743b-3cd2-4277-b24f-9849d4fb6fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e6d21c9f-34dc-45a5-8b60-f66aa741fc5a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntitySmallBusiness_e6d21c9f-34dc-45a5-8b60-f66aa741fc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2a6ea484-2d2a-41f7-9b87-1b4b8c0ddc82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityEmergingGrowthCompany_2a6ea484-2d2a-41f7-9b87-1b4b8c0ddc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bc02268b-1304-4758-a5aa-acc21f651f39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bc02268b-1304-4758-a5aa-acc21f651f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_934be519-659e-4677-a53f-717aef004c5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityShellCompany_934be519-659e-4677-a53f-717aef004c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_b434c09c-e395-48eb-93bc-fbc8a552e5b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityPublicFloat_b434c09c-e395-48eb-93bc-fbc8a552e5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e24ae024-c6ce-41b3-a8cb-7ded766a1c51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e24ae024-c6ce-41b3-a8cb-7ded766a1c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_68a8ba37-bf88-485d-a5dd-7ee7237e6d5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_68a8ba37-bf88-485d-a5dd-7ee7237e6d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1af5cc78-d7cd-456e-9f12-12654925f58a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_EntityCentralIndexKey_1af5cc78-d7cd-456e-9f12-12654925f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_95f08965-d2c1-48d0-ad4b-7ea05b378f4f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentFiscalYearFocus_95f08965-d2c1-48d0-ad4b-7ea05b378f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_57666b0b-c633-4fe8-940c-53f793277d72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_57666b0b-c633-4fe8-940c-53f793277d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b8041127-d810-42f4-bd7f-d3e74be207b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa0b96f2-8cd9-4b7a-85e2-87b7f83288cd" xlink:to="loc_dei_AmendmentFlag_b8041127-d810-42f4-bd7f-d3e74be207b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/AuditInformation" xlink:type="simple" xlink:href="sesn-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AuditInformationAbstract_67f69869-2933-4838-9b63-271aeb12cf97" xlink:href="sesn-20211231.xsd#sesn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c377d77c-b305-4503-b435-18cc007b7be3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_AuditInformationAbstract_67f69869-2933-4838-9b63-271aeb12cf97" xlink:to="loc_dei_AuditorFirmId_c377d77c-b305-4503-b435-18cc007b7be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_3995ef81-d2aa-4e9f-9c4d-8103599dd0cf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_AuditInformationAbstract_67f69869-2933-4838-9b63-271aeb12cf97" xlink:to="loc_dei_AuditorName_3995ef81-d2aa-4e9f-9c4d-8103599dd0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_da52c770-81cb-4d1c-bda1-a6de6a25a6cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_AuditInformationAbstract_67f69869-2933-4838-9b63-271aeb12cf97" xlink:to="loc_dei_AuditorLocation_da52c770-81cb-4d1c-bda1-a6de6a25a6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1ccab24b-1427-45a9-9c9f-19fa0b9c0f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2cd08434-014b-4611-ac32-0a7dc4bc930d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1ccab24b-1427-45a9-9c9f-19fa0b9c0f2f" xlink:to="loc_us-gaap_AssetsAbstract_2cd08434-014b-4611-ac32-0a7dc4bc930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2cd08434-014b-4611-ac32-0a7dc4bc930d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_304afcca-3455-47af-b68d-d7ff75875f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_304afcca-3455-47af-b68d-d7ff75875f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cc2c1aae-c294-47e0-8d1e-9e3586907d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cc2c1aae-c294-47e0-8d1e-9e3586907d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_30aa6dc4-8f96-480d-9052-dec4cb0ee0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_30aa6dc4-8f96-480d-9052-dec4cb0ee0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dd8ef23c-7e9b-4ba9-afbc-10f9f3d03932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dd8ef23c-7e9b-4ba9-afbc-10f9f3d03932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_04befb88-03cf-4b99-8384-8c1435dce6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:to="loc_us-gaap_RestrictedCashCurrent_04befb88-03cf-4b99-8384-8c1435dce6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d279b312-7da7-4fae-8cbb-9f17f3e9a871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd1a10ba-7201-43ae-89de-8abab8e73589" xlink:to="loc_us-gaap_AssetsCurrent_d279b312-7da7-4fae-8cbb-9f17f3e9a871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2cd08434-014b-4611-ac32-0a7dc4bc930d" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_06880312-9e70-48e2-8a1d-12feb46302d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_06880312-9e70-48e2-8a1d-12feb46302d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cda8f4fa-c6c6-47ca-bf79-cea303d42296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cda8f4fa-c6c6-47ca-bf79-cea303d42296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0eba8aea-3861-4bc2-9b9b-c645137cdf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0eba8aea-3861-4bc2-9b9b-c645137cdf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_87ba0f0b-7f8b-400e-9d52-aa0b3e3090b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_Goodwill_87ba0f0b-7f8b-400e-9d52-aa0b3e3090b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8df8389b-2b8c-44ed-8946-27d232724cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8df8389b-2b8c-44ed-8946-27d232724cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_154f2951-67cc-4dfc-8fd6-bfe0383e62b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_154f2951-67cc-4dfc-8fd6-bfe0383e62b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_c864f4bb-b51b-4300-b071-742fe50e6c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54b848d0-abaf-4969-854d-e6e8e7093efb" xlink:to="loc_us-gaap_AssetsNoncurrent_c864f4bb-b51b-4300-b071-742fe50e6c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ec147dc3-1598-42e7-b633-8f0b83de312a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2cd08434-014b-4611-ac32-0a7dc4bc930d" xlink:to="loc_us-gaap_Assets_ec147dc3-1598-42e7-b633-8f0b83de312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1ccab24b-1427-45a9-9c9f-19fa0b9c0f2f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_23dc5619-182f-45bb-9371-2485dd5181cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:to="loc_us-gaap_AccountsPayableCurrent_23dc5619-182f-45bb-9371-2485dd5181cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d426ceda-ef02-4bd5-a2a5-b35aa06d15a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d426ceda-ef02-4bd5-a2a5-b35aa06d15a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f31d877b-3ad5-447d-8a5d-fb01627ba172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f31d877b-3ad5-447d-8a5d-fb01627ba172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fd649d13-4436-46c4-b8b8-4d98191a0893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fd649d13-4436-46c4-b8b8-4d98191a0893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ad9441e-729e-4141-8dd6-0f9068bf3351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ad9441e-729e-4141-8dd6-0f9068bf3351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_79958a17-c761-4234-8565-8281a6793101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0d6308d9-936b-47b5-970a-8666c403958a" xlink:to="loc_us-gaap_LiabilitiesCurrent_79958a17-c761-4234-8565-8281a6793101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d53becab-849c-4a9f-85da-f032ee5f85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d53becab-849c-4a9f-85da-f032ee5f85ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_da4f2bfd-5409-45c8-98a0-4165a6e3b304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_da4f2bfd-5409-45c8-98a0-4165a6e3b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_990bf49d-40de-4619-8645-af6202773613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_990bf49d-40de-4619-8645-af6202773613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_346d3a09-92bc-45af-8651-5ff0b2929e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_346d3a09-92bc-45af-8651-5ff0b2929e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3f0f99e8-b48a-4d37-be8c-0bc62c72be0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad3e4955-34b2-4f90-8d90-5f3768383e4c" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3f0f99e8-b48a-4d37-be8c-0bc62c72be0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_915add8c-faa0-40fe-9511-e07eab2dfb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:to="loc_us-gaap_Liabilities_915add8c-faa0-40fe-9511-e07eab2dfb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e8575ef2-5fe7-45c7-abcc-2a8da383db93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:to="loc_us-gaap_PreferredStockValue_e8575ef2-5fe7-45c7-abcc-2a8da383db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c7ec3728-93d1-448f-b77d-3edac5695f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:to="loc_us-gaap_CommonStockValue_c7ec3728-93d1-448f-b77d-3edac5695f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3b4ca649-6964-4a20-8d42-93c5f9fbc823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3b4ca649-6964-4a20-8d42-93c5f9fbc823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09ab183e-b206-43e6-ac3c-973ee183924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09ab183e-b206-43e6-ac3c-973ee183924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1bc7d4ba-2b4d-4ab6-8a3c-5ee07c52bc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e52224d4-a792-4ad0-8522-a1963ef8f47d" xlink:to="loc_us-gaap_StockholdersEquity_1bc7d4ba-2b4d-4ab6-8a3c-5ee07c52bc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ca2299c1-7a10-4e66-b5eb-9b7fbba5eaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b2a8b56-7854-4b3e-95ca-5f153476b072" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ca2299c1-7a10-4e66-b5eb-9b7fbba5eaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f2a0ebc-e452-4e4b-9092-94d4b2008709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f2a0ebc-e452-4e4b-9092-94d4b2008709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c0d3235b-2b09-4d60-a9a6-4abd4d99ac10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c0d3235b-2b09-4d60-a9a6-4abd4d99ac10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e1f57ec2-ae9c-456e-a64d-9e562fc4582b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e1f57ec2-ae9c-456e-a64d-9e562fc4582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_887b090b-55b5-4ca6-ac28-9cbf2927827a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_887b090b-55b5-4ca6-ac28-9cbf2927827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_61641750-8ee5-4ad9-ba18-93511d4d7531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_61641750-8ee5-4ad9-ba18-93511d4d7531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_95b6de39-0f40-475a-bb21-9f795cf1f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_95b6de39-0f40-475a-bb21-9f795cf1f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ed53f9ce-1b76-4a19-ad30-ee6f95ff79fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_CommonStockSharesIssued_ed53f9ce-1b76-4a19-ad30-ee6f95ff79fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14cc7d2a-8c63-40c8-8c54-5e72c119e947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f2eed38-6445-4f9e-9010-37ec5e15523c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14cc7d2a-8c63-40c8-8c54-5e72c119e947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9d921ba3-9532-48de-af3a-2e8c1beb645f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d921ba3-9532-48de-af3a-2e8c1beb645f" xlink:to="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:to="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23807835-d079-41a0-835b-9e6b161af479" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1e0ae770-7f8a-4e85-ac24-b6cbe9c68616" xlink:to="loc_srt_ProductsAndServicesDomain_23807835-d079-41a0-835b-9e6b161af479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseRevenueMember_3bf2a504-98ec-41ae-8f08-fd3763b8dae2" xlink:href="sesn-20211231.xsd#sesn_LicenseRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_23807835-d079-41a0-835b-9e6b161af479" xlink:to="loc_sesn_LicenseRevenueMember_3bf2a504-98ec-41ae-8f08-fd3763b8dae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5a208cf1-840d-446a-bf7c-18dff0f7d762" xlink:to="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_52c33954-3873-437f-8366-c64ffe6bfaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_52c33954-3873-437f-8366-c64ffe6bfaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef11b1d3-7351-4186-8bce-1d6dc5596b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef11b1d3-7351-4186-8bce-1d6dc5596b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ae2e5033-6fc9-4a3f-89e0-d52b5bcfef83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ae2e5033-6fc9-4a3f-89e0-d52b5bcfef83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_370658b1-fd70-458f-a90f-f52852cb95ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_RestructuringCharges_370658b1-fd70-458f-a90f-f52852cb95ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58090188-2727-4ce5-ab79-a98e502a95ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58090188-2727-4ce5-ab79-a98e502a95ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1bac05f3-2524-47cf-8bb5-708b3d6c7e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1bac05f3-2524-47cf-8bb5-708b3d6c7e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_eedf008d-3bff-4d38-9f5b-2b6ad4700525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e51b70f6-7cc9-4912-8f66-be78def006dc" xlink:to="loc_us-gaap_OperatingExpenses_eedf008d-3bff-4d38-9f5b-2b6ad4700525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a0f9d53-d6b6-4adb-b075-3d22fbb74aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a0f9d53-d6b6-4adb-b075-3d22fbb74aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_525455d5-5ad7-4d34-9fb2-9e2708d85f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_525455d5-5ad7-4d34-9fb2-9e2708d85f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_5225ab0b-b81c-4e98-b4a0-5314455af123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_5225ab0b-b81c-4e98-b4a0-5314455af123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad9a3652-6948-4b10-9236-747942bf0ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad9a3652-6948-4b10-9236-747942bf0ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae8c10c9-acc4-41bf-841f-6f0451518d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_NetIncomeLoss_ae8c10c9-acc4-41bf-841f-6f0451518d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_24b3c808-86ae-434e-810b-397d187df5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_24b3c808-86ae-434e-810b-397d187df5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_4da4f474-2516-49cd-a16e-7ba199127efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_4da4f474-2516-49cd-a16e-7ba199127efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6bc39bfe-d23f-49db-86c8-9147ce82565f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6bc39bfe-d23f-49db-86c8-9147ce82565f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca5c957d-893d-4355-8ed7-c62fb317ad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca5c957d-893d-4355-8ed7-c62fb317ad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f897167f-1299-4e9b-ba07-b056d33fe9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_EarningsPerShareBasic_f897167f-1299-4e9b-ba07-b056d33fe9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_20f0e572-5a21-4e04-b769-32e04152afdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_EarningsPerShareDiluted_20f0e572-5a21-4e04-b769-32e04152afdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91cafcb5-6e90-4d71-a9a3-2173b891d1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91cafcb5-6e90-4d71-a9a3-2173b891d1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5e73da0-9ffe-4bfc-96b0-c6038bd14d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_637beca0-d109-486f-a4dd-300ca9a0c4ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5e73da0-9ffe-4bfc-96b0-c6038bd14d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_884f4d0b-af6d-49cf-aae7-b6c84bc3ae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_884f4d0b-af6d-49cf-aae7-b6c84bc3ae5d" xlink:to="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e4729e5-178b-4ad9-8c0c-d26fecacfd48" xlink:to="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_da4975b3-a17e-498e-8b86-4b4be1c56874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:to="loc_us-gaap_CommonStockMember_da4975b3-a17e-498e-8b86-4b4be1c56874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_09056783-6eff-47c1-b0a9-b67c6282a7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_09056783-6eff-47c1-b0a9-b67c6282a7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cb40a818-3704-4a5c-8f90-d7839c43801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_494effd5-948e-429b-9a7c-3e2beea549a7" xlink:to="loc_us-gaap_RetainedEarningsMember_cb40a818-3704-4a5c-8f90-d7839c43801a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f65a7431-9b7d-49f7-89a0-ead49aace8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aab3f495-48d3-4456-9502-2483535b8eb5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f65a7431-9b7d-49f7-89a0-ead49aace8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_f595e604-fc7a-4cc1-af34-c78284b784cb" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f65a7431-9b7d-49f7-89a0-ead49aace8f6" xlink:to="loc_sesn_ATMFacilityMember_f595e604-fc7a-4cc1-af34-c78284b784cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d882bac1-6e8b-44c6-913a-6ab07fdc257e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72e194f3-2840-4f91-90e1-f041ca0edef7" xlink:to="loc_us-gaap_StatementLineItems_d882bac1-6e8b-44c6-913a-6ab07fdc257e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d882bac1-6e8b-44c6-913a-6ab07fdc257e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1d7c5408-d5f5-4379-9324-ba85191cde8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_SharesOutstanding_1d7c5408-d5f5-4379-9324-ba85191cde8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_313cc08b-cdb2-4ca1-b674-0fc0803f4d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockholdersEquity_313cc08b-cdb2-4ca1-b674-0fc0803f4d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f48fd4fd-f2bd-4693-86a0-02435943f078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_NetIncomeLoss_f48fd4fd-f2bd-4693-86a0-02435943f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_54f28f1c-3e3a-4500-98c8-306030b5c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_54f28f1c-3e3a-4500-98c8-306030b5c26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07bd9d95-6d8a-4f60-8bba-891158569f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07bd9d95-6d8a-4f60-8bba-891158569f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ac285bd1-5bee-4cc7-a083-f5ea8ebe64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ac285bd1-5bee-4cc7-a083-f5ea8ebe64b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08c3f898-6d7f-4c56-ab38-65708e2ccf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08c3f898-6d7f-4c56-ab38-65708e2ccf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bff35868-c138-4007-9749-9934b2d9e82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bff35868-c138-4007-9749-9934b2d9e82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_0137fe78-a1ef-4b4a-92a9-1f230d1e4056" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_0137fe78-a1ef-4b4a-92a9-1f230d1e4056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_be269f31-81d5-4efe-9192-82782ef93422" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_be269f31-81d5-4efe-9192-82782ef93422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c35a7a3d-1979-4e53-bd0a-1e46e6139942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c35a7a3d-1979-4e53-bd0a-1e46e6139942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30c0e8f5-6081-4132-ae26-6cc02d7ccee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30c0e8f5-6081-4132-ae26-6cc02d7ccee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_07b09c0a-9bed-4ba4-9aeb-25f9d34a6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_SharesOutstanding_07b09c0a-9bed-4ba4-9aeb-25f9d34a6fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa3c72f4-2c87-46b4-ab8f-d390132f5337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca2105a9-d0da-49aa-8ae4-1ba6c2785138" xlink:to="loc_us-gaap_StockholdersEquity_fa3c72f4-2c87-46b4-ab8f-d390132f5337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_96e59f79-ac66-4205-b638-13f4efcb4a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_96e59f79-ac66-4205-b638-13f4efcb4a56" xlink:to="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cc1662a-403a-4bf9-85a4-3b1290998a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5e79ed9f-dfd9-4ae0-9a3f-62219f2de721" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cc1662a-403a-4bf9-85a4-3b1290998a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_5f31e7e3-0599-4156-a229-46d3800f7a0a" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cc1662a-403a-4bf9-85a4-3b1290998a16" xlink:to="loc_sesn_ATMFacilityMember_5f31e7e3-0599-4156-a229-46d3800f7a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_477de774-6913-41ad-9501-c9862185cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d8ed246-d7ad-4798-9880-ac4ba9d6505a" xlink:to="loc_us-gaap_StatementLineItems_477de774-6913-41ad-9501-c9862185cb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1d1be784-0c82-4405-89e8-0b9b169c0c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_477de774-6913-41ad-9501-c9862185cb0e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1d1be784-0c82-4405-89e8-0b9b169c0c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f5c60c50-8ce8-48f5-aa2f-cd43bb74d8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f5c60c50-8ce8-48f5-aa2f-cd43bb74d8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0614699-4c13-4928-9cea-70cd30a6bf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f5c60c50-8ce8-48f5-aa2f-cd43bb74d8dd" xlink:to="loc_us-gaap_NetIncomeLoss_d0614699-4c13-4928-9cea-70cd30a6bf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f5c60c50-8ce8-48f5-aa2f-cd43bb74d8dd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_529e5b71-4665-4066-a7ea-cda43fc750ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:to="loc_us-gaap_DepreciationAndAmortization_529e5b71-4665-4066-a7ea-cda43fc750ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_af6ead52-ff44-4a64-958e-a0ae1a73c855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:to="loc_us-gaap_ShareBasedCompensation_af6ead52-ff44-4a64-958e-a0ae1a73c855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dd896f1e-5cc9-4707-a901-b64b8a2214ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dd896f1e-5cc9-4707-a901-b64b8a2214ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4eccf234-acc2-4ae5-b4b7-728fad35e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:to="loc_us-gaap_AssetImpairmentCharges_4eccf234-acc2-4ae5-b4b7-728fad35e65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d04408d-a6f3-4314-863e-b66bc08708f0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6093330a-a19f-49b7-9ed5-78d82e3dd6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6093330a-a19f-49b7-9ed5-78d82e3dd6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_104e143a-9a8c-4e16-a0a1-a11d420fc48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_104e143a-9a8c-4e16-a0a1-a11d420fc48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0ace1eff-0a7a-462d-9ccd-75a13e7564d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0ace1eff-0a7a-462d-9ccd-75a13e7564d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcf74d47-89e5-4a92-adbe-a6baf01fd40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcf74d47-89e5-4a92-adbe-a6baf01fd40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_d2c6361f-2567-45a7-b63e-e7701be73452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7ac55b0-e156-425c-90d8-529cb26f7e76" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_d2c6361f-2567-45a7-b63e-e7701be73452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_991c8764-51f2-43f6-a0e8-3af99254c25c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f5c60c50-8ce8-48f5-aa2f-cd43bb74d8dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_991c8764-51f2-43f6-a0e8-3af99254c25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_83213ff6-f9d3-4829-8135-cb934aa55298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_83213ff6-f9d3-4829-8135-cb934aa55298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a1bfc30-afbf-4f47-9c40-1c44bffe3f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_83213ff6-f9d3-4829-8135-cb934aa55298" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a1bfc30-afbf-4f47-9c40-1c44bffe3f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_824b53c0-8477-44b2-9116-465adbca9c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_83213ff6-f9d3-4829-8135-cb934aa55298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_824b53c0-8477-44b2-9116-465adbca9c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromIssuanceofCommonStockandWarrants_42b8425c-b5c0-4c2f-b77a-934e40c1dd0d" xlink:href="sesn-20211231.xsd#sesn_ProceedsFromIssuanceofCommonStockandWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:to="loc_sesn_ProceedsFromIssuanceofCommonStockandWarrants_42b8425c-b5c0-4c2f-b77a-934e40c1dd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_2bfbadc2-ba72-4040-819a-76ab993c357e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_2bfbadc2-ba72-4040-819a-76ab993c357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35ece14a-7f28-4226-b33b-1a3448811c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_35ece14a-7f28-4226-b33b-1a3448811c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b541a68a-772c-4f46-938a-86127706fdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b541a68a-772c-4f46-938a-86127706fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_75ec6260-3900-4494-a7d4-cb91505e2456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9362a83f-ac4b-4665-a694-9552214672f8" xlink:to="loc_us-gaap_ProceedsFromStockPlans_75ec6260-3900-4494-a7d4-cb91505e2456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_501df3eb-99dd-4990-b06d-b871df7fdc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_501df3eb-99dd-4990-b06d-b871df7fdc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2c53fb1-1e7d-4298-8340-e29527855772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2c53fb1-1e7d-4298-8340-e29527855772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0fd22f74-f735-4a9f-bfd0-dc4367a81552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0fd22f74-f735-4a9f-bfd0-dc4367a81552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eea9184a-785e-46de-a765-872b7aee8489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eea9184a-785e-46de-a765-872b7aee8489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_db2dcb9e-c3a9-4c74-b883-4e29806f1462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_db2dcb9e-c3a9-4c74-b883-4e29806f1462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ddec5d9-d3e1-4bda-a811-34a1620bc165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_db2dcb9e-c3a9-4c74-b883-4e29806f1462" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ddec5d9-d3e1-4bda-a811-34a1620bc165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4fff80c2-38e1-446e-9fd0-d01087095ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_db2dcb9e-c3a9-4c74-b883-4e29806f1462" xlink:to="loc_us-gaap_RestrictedCashCurrent_4fff80c2-38e1-446e-9fd0-d01087095ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_efec1218-d55e-45e7-b659-83b0a14dfb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_db2dcb9e-c3a9-4c74-b883-4e29806f1462" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_efec1218-d55e-45e7-b659-83b0a14dfb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f1f6038-fa65-4893-9d79-9c4ccd8f791a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_db2dcb9e-c3a9-4c74-b883-4e29806f1462" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f1f6038-fa65-4893-9d79-9c4ccd8f791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2f0ca44a-8b7e-447d-9215-4e7e681587db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2f0ca44a-8b7e-447d-9215-4e7e681587db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_77fd8016-de04-44a1-9f29-a5bd20fe54db" xlink:href="sesn-20211231.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2f0ca44a-8b7e-447d-9215-4e7e681587db" xlink:to="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_77fd8016-de04-44a1-9f29-a5bd20fe54db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_aad392a5-9733-43ac-83bd-f66375706ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_aad392a5-9733-43ac-83bd-f66375706ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e982c3d9-22d4-446a-9c6d-020a2184ea87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_aad392a5-9733-43ac-83bd-f66375706ac9" xlink:to="loc_us-gaap_OperatingLeasePayments_e982c3d9-22d4-446a-9c6d-020a2184ea87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6dad1ee5-eadd-4e43-b382-267340920408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_aad392a5-9733-43ac-83bd-f66375706ac9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6dad1ee5-eadd-4e43-b382-267340920408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_be3da3c9-5545-4c70-958d-df8b800c5bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d17cc380-2f50-44d3-bd38-2c28cca3f2d4" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_be3da3c9-5545-4c70-958d-df8b800c5bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IssuanceOfWarrantForCommonStock_a2548402-82ec-45ae-aded-76d65646e31f" xlink:href="sesn-20211231.xsd#sesn_IssuanceOfWarrantForCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_be3da3c9-5545-4c70-958d-df8b800c5bd0" xlink:to="loc_sesn_IssuanceOfWarrantForCommonStock_a2548402-82ec-45ae-aded-76d65646e31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="sesn-20211231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b80f648-cb8b-4112-aaec-8db4ee1df7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_bafecf62-dac2-44a9-b636-928e1bfc4155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b80f648-cb8b-4112-aaec-8db4ee1df7aa" xlink:to="loc_us-gaap_NatureOfOperations_bafecf62-dac2-44a9-b636-928e1bfc4155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6b7f43f-c4c8-4bae-b5b1-6d3176395172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6b7f43f-c4c8-4bae-b5b1-6d3176395172" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83478654-bd09-4608-b5b2-5ec5c3a51e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c0f3ff0-4699-40de-a5a8-ef52f8c78eac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83478654-bd09-4608-b5b2-5ec5c3a51e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_b407f945-9b36-44b8-871b-bb6d2df09e84" xlink:href="sesn-20211231.xsd#sesn_ViventiaBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83478654-bd09-4608-b5b2-5ec5c3a51e6a" xlink:to="loc_sesn_ViventiaBioInc.Member_b407f945-9b36-44b8-871b-bb6d2df09e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ef9ac00-0e0e-469d-8caa-eb6a1fd6df1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8804a802-94ac-48d6-bdba-fe2d2bbea149" xlink:to="loc_srt_ProductsAndServicesDomain_8ef9ac00-0e0e-469d-8caa-eb6a1fd6df1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_376ea89a-aa4c-4a5f-a851-943722364122" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8ef9ac00-0e0e-469d-8caa-eb6a1fd6df1d" xlink:to="loc_sesn_ViciniumMember_376ea89a-aa4c-4a5f-a851-943722364122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5e4d34f-89e1-4759-af5c-361688f69b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_563da234-98db-4961-a0e6-fe8341ae4e33" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5e4d34f-89e1-4759-af5c-361688f69b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_4b681c07-23af-4c07-87d6-d2bd22416e47" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5e4d34f-89e1-4759-af5c-361688f69b84" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_4b681c07-23af-4c07-87d6-d2bd22416e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a4006a9b-c97e-4cb8-8709-7b61f7894147" xlink:to="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0d6d0253-a92a-4c7c-8ff7-7033485e161a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:to="loc_country_US_0d6d0253-a92a-4c7c-8ff7-7033485e161a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6698bb47-c0e0-467e-89bd-2c67bd87ac5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:to="loc_srt_EuropeMember_6698bb47-c0e0-467e-89bd-2c67bd87ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_b98f83f9-6b87-49c2-abb2-f74949d6db63" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed9fd452-c1fc-4861-a9c7-eedaffd1522e" xlink:to="loc_country_JP_b98f83f9-6b87-49c2-abb2-f74949d6db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_86d8317b-c4e2-4eee-8111-3c023066eed5" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfPatients_d0fc30ad-3559-413c-8fdf-6ffe28d3f709" xlink:href="sesn-20211231.xsd#sesn_NumberOfPatients"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_NumberOfPatients_d0fc30ad-3559-413c-8fdf-6ffe28d3f709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_5ff5c21d-3b5f-4689-ab10-e0b2e7d25695" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_5ff5c21d-3b5f-4689-ab10-e0b2e7d25695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eec77b94-805e-4edb-b12b-5f555147e58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_eec77b94-805e-4edb-b12b-5f555147e58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_b02feeda-e0d4-41f7-a1d2-944c46cbeb53" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_b02feeda-e0d4-41f7-a1d2-944c46cbeb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_fb2d41bc-4feb-4a87-a6f9-27c3cc909a26" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_fb2d41bc-4feb-4a87-a6f9-27c3cc909a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_b0864e8a-9657-45be-be4c-6ddab47e147a" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_b0864e8a-9657-45be-be4c-6ddab47e147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_02f8e3ff-d9d2-4234-856a-67721739a85e" xlink:href="sesn-20211231.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_02f8e3ff-d9d2-4234-856a-67721739a85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed3bfeae-a5b8-4a61-b5f3-60e3c04a8630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed3bfeae-a5b8-4a61-b5f3-60e3c04a8630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1c32fb3-1bb3-435d-9032-bb567efe4859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1c32fb3-1bb3-435d-9032-bb567efe4859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d838c33a-b427-4f35-9156-5ecd9b03e8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_06d90af2-a5ca-4545-976c-8ae618049f9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d838c33a-b427-4f35-9156-5ecd9b03e8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="sesn-20211231.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_35998f25-631d-4153-97ca-1152192f49e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_baecdde5-a9fc-4d35-a99d-6cd42e0bb146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35998f25-631d-4153-97ca-1152192f49e6" xlink:to="loc_us-gaap_BasisOfAccounting_baecdde5-a9fc-4d35-a99d-6cd42e0bb146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b83947df-4791-494f-82d1-4bbbc48500cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_444679e0-de6a-4fb1-abd8-44deb1c8b653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b83947df-4791-494f-82d1-4bbbc48500cc" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_444679e0-de6a-4fb1-abd8-44deb1c8b653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ac478286-d835-49ce-add4-7e7095e0ffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_UseOfEstimates_ac478286-d835-49ce-add4-7e7095e0ffd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_5f9dae6f-1122-4301-9d03-b1942fcf84b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_5f9dae6f-1122-4301-9d03-b1942fcf84b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_11dc05f5-7991-464c-8255-5d4e3ea34803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_11dc05f5-7991-464c-8255-5d4e3ea34803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3c0f07de-f030-495c-b5f1-d9acbae1380a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3c0f07de-f030-495c-b5f1-d9acbae1380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6d1b00ca-5ff7-4ae1-b82d-c46b9549f72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6d1b00ca-5ff7-4ae1-b82d-c46b9549f72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1a1108ab-d0ff-461c-b73b-edc39c70cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1a1108ab-d0ff-461c-b73b-edc39c70cb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a0611130-5888-4e27-8580-73abd8f57f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a0611130-5888-4e27-8580-73abd8f57f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ContingentConsiderationPolicyTextBlock_b0118dab-03f7-472c-8c15-dce557b81519" xlink:href="sesn-20211231.xsd#sesn_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_sesn_ContingentConsiderationPolicyTextBlock_b0118dab-03f7-472c-8c15-dce557b81519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c85b6d21-847f-408f-aa38-bbc72449ca96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c85b6d21-847f-408f-aa38-bbc72449ca96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_476e4aba-f9ef-4c54-9d8f-961dd2cc0be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_476e4aba-f9ef-4c54-9d8f-961dd2cc0be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_987f61ff-fb10-43a1-a3a4-b420af68c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_987f61ff-fb10-43a1-a3a4-b420af68c87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_096cb72f-2e29-49e5-9605-57e6c745ed3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_096cb72f-2e29-49e5-9605-57e6c745ed3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8854cc2f-409e-4335-a004-4040e77ab467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8854cc2f-409e-4335-a004-4040e77ab467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_803582e0-3319-4f67-9d7d-cea48244ce7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_803582e0-3319-4f67-9d7d-cea48244ce7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3bb0716c-2b2c-4e38-98e6-4b5c1e3410ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827b2a2e-bac9-43ff-9c79-0001c54dd460" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3bb0716c-2b2c-4e38-98e6-4b5c1e3410ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2c9b1e60-5ddc-446c-8ab8-8c55ecda9cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2c9b1e60-5ddc-446c-8ab8-8c55ecda9cac" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2892c719-5de7-4a55-a2c3-97e96c99aadd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aed0dc1b-767a-4bdb-b9ef-1510b69a1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_EquipmentMember_aed0dc1b-767a-4bdb-b9ef-1510b69a1ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_712bcf0e-6bfb-49e4-a5d7-9cbe0a1b9923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_712bcf0e-6bfb-49e4-a5d7-9cbe0a1b9923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_76c55ab6-7e52-4309-bf53-ff00f767c9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_ComputerEquipmentMember_76c55ab6-7e52-4309-bf53-ff00f767c9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_97eb878d-cb86-4c21-b23b-929a5e0a989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b57467fb-8f30-4d73-a420-7c7b6db7d237" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_97eb878d-cb86-4c21-b23b-929a5e0a989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cbeee939-d80b-4ddb-86f3-5b8a48787ebb" xlink:to="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_c66c6c3b-b94b-439b-9e00-501d321dbf35" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:to="loc_sesn_ViciniumMember_c66c6c3b-b94b-439b-9e00-501d321dbf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_84462782-cc88-4550-96a2-b0109d09b0af" xlink:href="sesn-20211231.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_510c8541-fc07-4408-bb5e-984a72cbbac2" xlink:to="loc_sesn_EBI031Member_84462782-cc88-4550-96a2-b0109d09b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c10c64f7-df78-4590-912d-0aa431d44962" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4ae6ba16-5a4c-4ba1-a8a2-522a185d61b1" xlink:to="loc_srt_SegmentGeographicalDomain_c10c64f7-df78-4590-912d-0aa431d44962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3e709ab3-f236-43cc-a374-8c868c633217" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c10c64f7-df78-4590-912d-0aa431d44962" xlink:to="loc_country_US_3e709ab3-f236-43cc-a374-8c868c633217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9954582-b341-4386-8053-35d363410684" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_340ab38c-9a86-47e0-bbe3-c899b3d65db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_340ab38c-9a86-47e0-bbe3-c899b3d65db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_08bdd6ab-14de-41d2-bddc-0a53dd4095a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1b7d467b-0cc6-480e-9afa-12efbee37295" xlink:to="loc_us-gaap_LicensingAgreementsMember_08bdd6ab-14de-41d2-bddc-0a53dd4095a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17814a6-6ad3-4b64-9547-0866e6e860f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9a9b5601-3095-4fe5-aa34-4b5156802d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17814a6-6ad3-4b64-9547-0866e6e860f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fca18506-e345-4475-8b13-43e0f2d9b31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17814a6-6ad3-4b64-9547-0866e6e860f9" xlink:to="loc_us-gaap_PerformanceSharesMember_fca18506-e345-4475-8b13-43e0f2d9b31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79a5a9c0-8f57-40d2-b28c-bcbfa2a74b52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6f36ef7b-329a-4f40-b03d-36cd3e3dfd94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79a5a9c0-8f57-40d2-b28c-bcbfa2a74b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_96045b0e-42d3-4f54-9e4b-48a497480a02" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79a5a9c0-8f57-40d2-b28c-bcbfa2a74b52" xlink:to="loc_sesn_RocheMember_96045b0e-42d3-4f54-9e4b-48a497480a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_49b1a517-5bf3-43f5-b2a2-5b7848f9a725" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7d5513f8-5940-4f65-b7b6-7bd6873b7f50" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_49b1a517-5bf3-43f5-b2a2-5b7848f9a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6fbe0859-c849-4d84-947d-d6f153fa73f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_49b1a517-5bf3-43f5-b2a2-5b7848f9a725" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6fbe0859-c849-4d84-947d-d6f153fa73f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_198a0f29-e8cc-4cf7-9da2-bc6f889f484d" xlink:to="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_af1779a8-40e8-4d21-b410-61266ac1011a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:to="loc_srt_MinimumMember_af1779a8-40e8-4d21-b410-61266ac1011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9910fdfe-4b56-40b4-a3bc-7353234db11f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e95e2a0d-3653-4123-95fa-2186ea9cd210" xlink:to="loc_srt_MaximumMember_9910fdfe-4b56-40b4-a3bc-7353234db11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4c8d7c34-d5a5-4118-97fd-50309ed2aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0a33da55-24ca-4dc2-89f1-d89a376c4342" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4c8d7c34-d5a5-4118-97fd-50309ed2aacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_e6f36f8e-e788-4a4f-a1e5-bdda6d30b369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4c8d7c34-d5a5-4118-97fd-50309ed2aacb" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_e6f36f8e-e788-4a4f-a1e5-bdda6d30b369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8166d84e-eb7d-440f-86e3-20b95bfe6c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6058c7f8-f778-41ef-9181-d94b32a6dc3f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8166d84e-eb7d-440f-86e3-20b95bfe6c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_183b130f-9dea-4903-b33b-cdadbf4474b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8166d84e-eb7d-440f-86e3-20b95bfe6c42" xlink:to="loc_us-gaap_SubsequentEventMember_183b130f-9dea-4903-b33b-cdadbf4474b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c4b5145-b678-42fe-a91f-e1846fe12e5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_0c860d18-d828-4744-a96d-4f9f3bf1ae92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_0c860d18-d828-4744-a96d-4f9f3bf1ae92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7aed4a1f-05f5-484b-8639-b75c8389928e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7aed4a1f-05f5-484b-8639-b75c8389928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2dfb983e-56d2-48c7-915e-8375edcf15c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2dfb983e-56d2-48c7-915e-8375edcf15c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32f733f9-2a10-49f4-a4a6-538140ffa087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32f733f9-2a10-49f4-a4a6-538140ffa087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_7b0150bb-644a-4e7a-87e0-33143c325b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_NumberOfReportingUnits_7b0150bb-644a-4e7a-87e0-33143c325b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0affc524-bad5-4a95-8b66-07fb893d2941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_Goodwill_0affc524-bad5-4a95-8b66-07fb893d2941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b6147506-6e62-471b-8a38-0dcfc5d5d4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b6147506-6e62-471b-8a38-0dcfc5d5d4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_e942f94f-da25-49ce-b738-c11f1549dec1" xlink:href="sesn-20211231.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_e942f94f-da25-49ce-b738-c11f1549dec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_1aea22a2-f09b-4c75-9d68-ccacbd225efa" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_1aea22a2-f09b-4c75-9d68-ccacbd225efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_925937bf-39f1-4686-8453-1f1b8b814eb7" xlink:href="sesn-20211231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_WeightedAverageCostOfCapital_925937bf-39f1-4686-8453-1f1b8b814eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DebtInstrumentIndexRateHighYield_0dd468e7-4f3f-4004-8184-45b326a1114d" xlink:href="sesn-20211231.xsd#sesn_DebtInstrumentIndexRateHighYield"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_DebtInstrumentIndexRateHighYield_0dd468e7-4f3f-4004-8184-45b326a1114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f38d9c19-af00-4bbf-8e73-7dcb8ac00d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f38d9c19-af00-4bbf-8e73-7dcb8ac00d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b4cfbfea-a2ae-47f4-95f1-094a847e7bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_OperatingLeaseLiability_b4cfbfea-a2ae-47f4-95f1-094a847e7bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_485247f7-981e-4e14-a9df-9aa321718aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_485247f7-981e-4e14-a9df-9aa321718aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0ea55d09-7605-47bf-900c-0b15eeda4d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0ea55d09-7605-47bf-900c-0b15eeda4d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_721945ba-91ba-4ad0-9db8-e65f05dd14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_721945ba-91ba-4ad0-9db8-e65f05dd14e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePayment_75ab2985-b4fc-46ce-8044-6d195c1155cb" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestonePayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementMilestonePayment_75ab2985-b4fc-46ce-8044-6d195c1155cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePaymentTerm_7c143b54-dc66-42d1-863a-0e41a2c44830" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestonePaymentTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementMilestonePaymentTerm_7c143b54-dc66-42d1-863a-0e41a2c44830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0871a37f-ddf9-4a84-a85c-a29502cc973f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0871a37f-ddf9-4a84-a85c-a29502cc973f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4861ed7a-15ad-46a9-bb72-19a78d2614c2" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5595e0f9-ee02-44b6-87cd-bf40aa1633e1" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_4861ed7a-15ad-46a9-bb72-19a78d2614c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="sesn-20211231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_a81e9477-6266-4025-9383-b02cbcc3463d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b29ac961-93ab-486f-87c7-f00fd92cbd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_a81e9477-6266-4025-9383-b02cbcc3463d" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b29ac961-93ab-486f-87c7-f00fd92cbd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b3a4c4c9-116f-4c69-b562-4e6fb648ad75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_20a3d5fd-17e7-424d-984a-3f13eba3fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b3a4c4c9-116f-4c69-b562-4e6fb648ad75" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_20a3d5fd-17e7-424d-984a-3f13eba3fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_60a01c35-0d64-4c6e-aedc-8441dd109951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5af771cb-ca4b-42b3-9e4c-cf067880c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60a01c35-0d64-4c6e-aedc-8441dd109951" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5af771cb-ca4b-42b3-9e4c-cf067880c38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_c0a68d12-6399-4ecd-b24d-631df5caaa81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60a01c35-0d64-4c6e-aedc-8441dd109951" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_c0a68d12-6399-4ecd-b24d-631df5caaa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_27d035c7-ffec-400a-9494-c6b0f405439d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_27d035c7-ffec-400a-9494-c6b0f405439d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_89ec9fd4-7fdd-4fcd-8879-7c0716b5d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9d4cc62a-67ec-4433-88bb-045f08e5b9fc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_89ec9fd4-7fdd-4fcd-8879-7c0716b5d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_89ec9fd4-7fdd-4fcd-8879-7c0716b5d45c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75fced28-98cc-49cd-b165-49094a77cfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75fced28-98cc-49cd-b165-49094a77cfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b1d5dbd3-65c1-4665-bba9-2a3dda0290cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_00f8273e-b193-4572-b5da-781954834cc8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b1d5dbd3-65c1-4665-bba9-2a3dda0290cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2931512e-1397-41bb-9585-28044dc2e772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0766a7e-c4d6-4167-ae62-1b43ba90d417" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2931512e-1397-41bb-9585-28044dc2e772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fce2909e-021b-4820-9108-334343388471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2931512e-1397-41bb-9585-28044dc2e772" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fce2909e-021b-4820-9108-334343388471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d45bb67b-3448-4e6e-84bb-a6b264656cee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5568c1d0-a98e-4120-b185-edd872ba7246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5568c1d0-a98e-4120-b185-edd872ba7246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7b804462-a62d-4a95-a325-53da756f82bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7b804462-a62d-4a95-a325-53da756f82bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_68d60042-e457-4365-9f57-7494cb7847f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc23219-f31f-48df-8078-1e203c8ee2b7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_68d60042-e457-4365-9f57-7494cb7847f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccf80d94-1291-4323-bc07-a6ce34b44afa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9717008-8214-4222-baa1-5988d568ad33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9717008-8214-4222-baa1-5988d568ad33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_419bf49b-e142-44e0-afb6-e68e03785ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9717008-8214-4222-baa1-5988d568ad33" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_419bf49b-e142-44e0-afb6-e68e03785ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e81d762-5c81-40d5-9c47-6f0a40e031a2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_d39d460f-267e-424e-8a8f-0b12d2529eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_d39d460f-267e-424e-8a8f-0b12d2529eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92df22b4-2626-4d18-9467-6bf435041cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f793793-db39-447c-a0a3-d59fd10b69eb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92df22b4-2626-4d18-9467-6bf435041cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b90b01fc-4d65-49a7-b735-1e91019f9559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b90b01fc-4d65-49a7-b735-1e91019f9559" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5eff4da1-7d6f-40a4-af25-21b4106bdf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e63866db-00d2-4741-a8d2-20033bd45d21" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5eff4da1-7d6f-40a4-af25-21b4106bdf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d03cb129-0b92-41a0-ba9c-9b520c126848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5eff4da1-7d6f-40a4-af25-21b4106bdf10" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d03cb129-0b92-41a0-ba9c-9b520c126848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:to="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e516b78-c569-4229-8748-a145fdf931e5" xlink:to="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f355b5f-5186-4c95-9a35-9a227d7fd3bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:to="loc_srt_MinimumMember_7f355b5f-5186-4c95-9a35-9a227d7fd3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_620fabaa-42dc-4616-9273-3f6daa515c3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e298780e-fd8a-47c4-be68-e3e5635aceb3" xlink:to="loc_srt_MaximumMember_620fabaa-42dc-4616-9273-3f6daa515c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f86439c0-48eb-4b73-9f43-04050e8841d6" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_37da468b-59e1-4335-a002-5a75dffbf450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_37da468b-59e1-4335-a002-5a75dffbf450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_ac66e097-22b2-4e21-87f8-1cca0c4520c8" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_ac66e097-22b2-4e21-87f8-1cca0c4520c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_eb6b407a-a14f-47b0-a6ad-8d7a496ebd3e" xlink:href="sesn-20211231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_sesn_WeightedAverageCostOfCapital_eb6b407a-a14f-47b0-a6ad-8d7a496ebd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4ec2a712-8515-4c6d-abbd-dfdcf3324910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4ec2a712-8515-4c6d-abbd-dfdcf3324910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_ed3ca09e-7f2b-4436-8b61-7d083964151d" xlink:href="sesn-20211231.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_afb0d89b-6023-41a4-b607-7837f3ce3a8d" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_ed3ca09e-7f2b-4436-8b61-7d083964151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25220009-9c78-446d-9b80-3920cde9a59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_2dff2242-e05b-48ba-b341-4294d1b801dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25220009-9c78-446d-9b80-3920cde9a59c" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_2dff2242-e05b-48ba-b341-4294d1b801dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43261f43-8e61-43dc-bd60-50d5a799ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_2dff2242-e05b-48ba-b341-4294d1b801dc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43261f43-8e61-43dc-bd60-50d5a799ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0096f5e7-fbbe-4d58-9d8f-d0b5630ebecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_2dff2242-e05b-48ba-b341-4294d1b801dc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0096f5e7-fbbe-4d58-9d8f-d0b5630ebecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96ab5042-aa4b-4fdd-a8e6-f4d5eb5fd02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_2dff2242-e05b-48ba-b341-4294d1b801dc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96ab5042-aa4b-4fdd-a8e6-f4d5eb5fd02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ef29f1b8-726c-4176-a2c1-3009dd1e79fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25220009-9c78-446d-9b80-3920cde9a59c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ef29f1b8-726c-4176-a2c1-3009dd1e79fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_462550b1-ed57-4deb-b1d2-6761f122161b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25220009-9c78-446d-9b80-3920cde9a59c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_462550b1-ed57-4deb-b1d2-6761f122161b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_550a1fc1-fa0f-4b68-8d91-fedac82b2a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_550a1fc1-fa0f-4b68-8d91-fedac82b2a4e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db69104b-34f8-4c06-9298-3ebb33102e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffaaad1-066a-4b4c-a06f-e87e0a0f64ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db69104b-34f8-4c06-9298-3ebb33102e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1e0eed44-b2ee-404e-8e1a-c3c3cf882107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db69104b-34f8-4c06-9298-3ebb33102e93" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1e0eed44-b2ee-404e-8e1a-c3c3cf882107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b19849e1-ee81-4750-b87c-96a2459afd27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce638d15-d5d3-433b-a7ef-9041b4dafef7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b19849e1-ee81-4750-b87c-96a2459afd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b19849e1-ee81-4750-b87c-96a2459afd27" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_391ab53c-4ccd-4d5b-b1b5-108db88966be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_391ab53c-4ccd-4d5b-b1b5-108db88966be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_d5a53863-a5bd-4643-aaa5-9390d8ca9eb4" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_d5a53863-a5bd-4643-aaa5-9390d8ca9eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_d0236ffd-4a0c-47b0-b628-f1fcee8a7deb" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_d0236ffd-4a0c-47b0-b628-f1fcee8a7deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2aeaf00-351c-4074-8c0e-fbf1fbbefdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_8c0524ab-43d8-477b-842e-aba851c68901" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2aeaf00-351c-4074-8c0e-fbf1fbbefdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="simple" xlink:href="sesn-20211231.xsd#RECEIVABLES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_8729575f-0630-416d-8e2c-266ffd673a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_84e10039-9dc8-4c84-b27d-264b3dc8055a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_8729575f-0630-416d-8e2c-266ffd673a3f" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_84e10039-9dc8-4c84-b27d-264b3dc8055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RECEIVABLESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_15234eeb-3d22-48f3-85cd-e1fc5c1f87a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_15234eeb-3d22-48f3-85cd-e1fc5c1f87a2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_610186e5-88f2-4d2d-8dc4-b09665698dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a3a9324f-0f67-42bf-8cc7-bd31c7b9b3ce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_610186e5-88f2-4d2d-8dc4-b09665698dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a72307f7-3cf5-49f8-bbdc-98ff53537e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_610186e5-88f2-4d2d-8dc4-b09665698dc7" xlink:to="loc_us-gaap_SubsequentEventMember_a72307f7-3cf5-49f8-bbdc-98ff53537e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:to="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_03795dca-f06e-4833-b263-db5be230274b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_e9c6b699-b31a-40e1-a649-260bbbb07dd1" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:to="loc_sesn_RocheMember_e9c6b699-b31a-40e1-a649-260bbbb07dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_fd75e875-e6d2-4fe4-9ebf-424cbcbb8485" xlink:href="sesn-20211231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b353810b-a05e-4432-9819-f3b372cf26d8" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_fd75e875-e6d2-4fe4-9ebf-424cbcbb8485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97e50f55-24b0-44b8-9154-327fa16bd5bd" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fd52c55a-b773-4787-a2e1-1de97ef555d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fd52c55a-b773-4787-a2e1-1de97ef555d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_13d6a41e-b387-460e-856d-0b1dfbaa7d8a" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_13d6a41e-b387-460e-856d-0b1dfbaa7d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_8095be19-a3b1-4dae-b72f-ec03081e8e3f" xlink:href="sesn-20211231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_8095be19-a3b1-4dae-b72f-ec03081e8e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_50a28e7a-e21c-4bb9-a039-693b73dbf9c8" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_50a28e7a-e21c-4bb9-a039-693b73dbf9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f3808fba-bde7-498d-8f06-c79f30dbe344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f3808fba-bde7-498d-8f06-c79f30dbe344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_31b51389-b512-4da5-97df-f0422f28adce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_31b51389-b512-4da5-97df-f0422f28adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromValueAddedTaxRecovery_3c4e508d-62f2-473f-a980-4b48bc32d470" xlink:href="sesn-20211231.xsd#sesn_ProceedsFromValueAddedTaxRecovery"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb73c403-9ac6-49ad-912c-fd444f3fcf05" xlink:to="loc_sesn_ProceedsFromValueAddedTaxRecovery_3c4e508d-62f2-473f-a980-4b48bc32d470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="sesn-20211231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_56e6f19c-969a-475f-8034-a265ca3c15fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b001de30-89df-4d35-9d09-c64e7ef083d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_56e6f19c-969a-475f-8034-a265ca3c15fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b001de30-89df-4d35-9d09-c64e7ef083d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dfef9061-ad2e-4f0a-9400-d1bb0c80f10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_15ab95d5-49a2-419f-8c3b-b2e4882b50b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dfef9061-ad2e-4f0a-9400-d1bb0c80f10b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_15ab95d5-49a2-419f-8c3b-b2e4882b50b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" xlink:type="simple" xlink:href="sesn-20211231.xsd#PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7623e9a2-4cd9-4cca-8ed3-01d48ed64f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7623e9a2-4cd9-4cca-8ed3-01d48ed64f06" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_965be303-14d5-40d6-8bc1-ceb2ee318305" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aaaa5a0d-bba7-4ecd-bf97-a88199055663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_EquipmentMember_aaaa5a0d-bba7-4ecd-bf97-a88199055663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d248c45a-6b1a-49be-990a-a1b7b922e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d248c45a-6b1a-49be-990a-a1b7b922e8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_55d859ce-7baa-4a5b-b885-f9ed9efdf386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_ComputerEquipmentMember_55d859ce-7baa-4a5b-b885-f9ed9efdf386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_6f8cb307-cb02-4b58-8af4-099ea6423a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_6f8cb307-cb02-4b58-8af4-099ea6423a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8813db97-6289-44cb-a624-e765ca4577ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fea7a15-5b62-47c9-9132-c207324f4232" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8813db97-6289-44cb-a624-e765ca4577ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb8415ac-b9a3-4373-8c4d-412d27d37b29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_46d9f8fd-3d8a-42db-bb08-b1653cf5f239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_46d9f8fd-3d8a-42db-bb08-b1653cf5f239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba464af1-027f-44b9-bdd7-388eebd875a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba464af1-027f-44b9-bdd7-388eebd875a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2fefb36d-00df-4df4-bcf3-d997610ae711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8fe426c0-fff9-4d7b-b317-42075de3b4b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2fefb36d-00df-4df4-bcf3-d997610ae711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fb041ed6-5919-4438-bc6a-f5f1da3c2f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1aadc02e-c0d0-456e-baa7-d51f95f655fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fb041ed6-5919-4438-bc6a-f5f1da3c2f37" xlink:to="loc_us-gaap_DepreciationAndAmortization_1aadc02e-c0d0-456e-baa7-d51f95f655fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL" xlink:type="simple" xlink:href="sesn-20211231.xsd#INTANGIBLESANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7327cbfd-5f0f-4b75-bfd1-802bb167771b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e9eafde9-62ac-4ffc-91a4-ef81a448d01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7327cbfd-5f0f-4b75-bfd1-802bb167771b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e9eafde9-62ac-4ffc-91a4-ef81a448d01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#INTANGIBLESANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6fbb73a-ae90-4d8a-90dc-69c2ce506ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9291b89c-1870-4da9-8d51-db0e4fe84848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6fbb73a-ae90-4d8a-90dc-69c2ce506ba0" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9291b89c-1870-4da9-8d51-db0e4fe84848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f73c5dbe-168a-4eff-b383-87a6d8bb647e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f73c5dbe-168a-4eff-b383-87a6d8bb647e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b57051ab-1a4f-486f-b088-0b2e9f57cd87" xlink:to="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1e38b1f9-31d2-4ccb-81e7-343947b25537" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:to="loc_country_US_1e38b1f9-31d2-4ccb-81e7-343947b25537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b1c6ccda-b914-4513-9b78-2f06be2ae6fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6a780a5e-b34d-4959-afcd-9de4160cef90" xlink:to="loc_srt_EuropeMember_b1c6ccda-b914-4513-9b78-2f06be2ae6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4e253bad-0d2e-4863-a99c-9aca8c6e11d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c8e7d44-c1d4-4795-b9b3-fef529d32770" xlink:to="loc_srt_ProductsAndServicesDomain_4e253bad-0d2e-4863-a99c-9aca8c6e11d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_d2538ed3-3b10-44f0-bb5f-99110d99e92a" xlink:href="sesn-20211231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4e253bad-0d2e-4863-a99c-9aca8c6e11d7" xlink:to="loc_sesn_ViciniumMember_d2538ed3-3b10-44f0-bb5f-99110d99e92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b7b591c-86c6-42a9-a475-4e2dcccdb819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cb40bff-4e5d-432d-b502-b07669fa8384" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b7b591c-86c6-42a9-a475-4e2dcccdb819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b5d0d6b2-7fb7-4ef0-a0c9-7469a809d750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3b7b591c-86c6-42a9-a475-4e2dcccdb819" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b5d0d6b2-7fb7-4ef0-a0c9-7469a809d750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8bdd01f-46ff-4cd2-9465-434a97716fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1d057380-5835-48e8-bbc0-50d8febbf0d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8bdd01f-46ff-4cd2-9465-434a97716fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_1b98aece-3cb6-46b4-8eb1-9b797987ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8bdd01f-46ff-4cd2-9465-434a97716fd2" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_1b98aece-3cb6-46b4-8eb1-9b797987ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INTANGIBLESANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bdb31738-1623-4ea5-bb89-8cef67ba33cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bdb31738-1623-4ea5-bb89-8cef67ba33cc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:to="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d92716ac-09e2-4949-a9b3-5a72f550b69f" xlink:to="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1980764e-810f-41fb-b31c-798ad2430ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:to="loc_srt_MinimumMember_1980764e-810f-41fb-b31c-798ad2430ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6210025c-f0f0-419a-b67d-2991891af004" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e320c327-119a-4bc5-ba93-607b7cca7696" xlink:to="loc_srt_MaximumMember_6210025c-f0f0-419a-b67d-2991891af004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73bcb2fb-1f7e-44e0-b647-1f92fead87e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_80fe6290-2145-44f4-bd2a-518f52600a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_80fe6290-2145-44f4-bd2a-518f52600a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ec65c8a-f3da-49d1-ae17-dda3f05da456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_Goodwill_0ec65c8a-f3da-49d1-ae17-dda3f05da456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_27ccf664-44f6-4a0b-afd0-bc96ecf07fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_27ccf664-44f6-4a0b-afd0-bc96ecf07fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_07622c35-7944-4ea0-857d-15a6e400db78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_85c3a8f2-3585-428c-8bc1-3c441296cce8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_07622c35-7944-4ea0-857d-15a6e400db78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="sesn-20211231.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dc9c8dbf-c91b-46e2-b81b-8c3bb42bc3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5dace12e-d314-40e7-b038-29d34874d027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dc9c8dbf-c91b-46e2-b81b-8c3bb42bc3ac" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5dace12e-d314-40e7-b038-29d34874d027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_34bc3e42-8194-44cf-b3ec-87795b193f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cb382a0d-a4c3-4849-a11a-50a32d13b169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_34bc3e42-8194-44cf-b3ec-87795b193f03" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cb382a0d-a4c3-4849-a11a-50a32d13b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_76b6253d-fb71-4cf2-b138-11a9347518cf" xlink:href="sesn-20211231.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_76b6253d-fb71-4cf2-b138-11a9347518cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_992273fb-083e-4cb5-9454-f8bca30d6181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_992273fb-083e-4cb5-9454-f8bca30d6181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_692718c4-6f77-4653-9d2e-8465dc45de8e" xlink:href="sesn-20211231.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_692718c4-6f77-4653-9d2e-8465dc45de8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ccf83bf3-7806-4353-9e71-16ba603f4b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ccf83bf3-7806-4353-9e71-16ba603f4b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19cb67e9-e21e-4ed7-826f-fcd30ebcb1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19cb67e9-e21e-4ed7-826f-fcd30ebcb1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dc6fed79-37b1-4829-b965-40b0a8ab04f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85308c38-dbee-4e42-a3cd-2bba602768f7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dc6fed79-37b1-4829-b965-40b0a8ab04f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sesn-20211231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea217aad-b339-423b-a72c-9deeda35e5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c7aee736-3ae9-4d5d-98ef-f5a513f79c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea217aad-b339-423b-a72c-9deeda35e5f7" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c7aee736-3ae9-4d5d-98ef-f5a513f79c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e786fd1-00da-4f27-93e3-dd150ba6ddee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits_8ed63053-5b73-4489-8cac-12620f8ccc62" xlink:href="sesn-20211231.xsd#sesn_NumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e786fd1-00da-4f27-93e3-dd150ba6ddee" xlink:to="loc_sesn_NumberOfLawsuits_8ed63053-5b73-4489-8cac-12620f8ccc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASES" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0ba5898a-2772-4039-a20d-2022bceb2309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e02c01be-bc1c-4cc1-b67e-70ecc14f7eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ba5898a-2772-4039-a20d-2022bceb2309" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e02c01be-bc1c-4cc1-b67e-70ecc14f7eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c0ae50d0-b14e-4f24-9926-0dc8f484a617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f94167cb-4c9e-4802-8652-ed8df26cd276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0ae50d0-b14e-4f24-9926-0dc8f484a617" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f94167cb-4c9e-4802-8652-ed8df26cd276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_796ed602-8768-4bc3-b758-a95d7dcc8162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0ae50d0-b14e-4f24-9926-0dc8f484a617" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_796ed602-8768-4bc3-b758-a95d7dcc8162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e0ad0a29-5dc4-4eef-9e20-97d3bc587ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e0ad0a29-5dc4-4eef-9e20-97d3bc587ddf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:to="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1ad618fe-486d-407e-acc0-9d28e87e5011" xlink:to="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_281b691d-87ea-4f6a-99bf-d13eafe1b614" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_country_CA_281b691d-87ea-4f6a-99bf-d13eafe1b614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MassachusettsAndPennsylvaniaMember_5c5747a6-c17d-4967-ad09-0ecf4612326c" xlink:href="sesn-20211231.xsd#sesn_MassachusettsAndPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_sesn_MassachusettsAndPennsylvaniaMember_5c5747a6-c17d-4967-ad09-0ecf4612326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_bf63bed6-ece6-4010-b92b-f1343559190d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_stpr_MA_bf63bed6-ece6-4010-b92b-f1343559190d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_1ef32233-d94a-4cce-bd25-ae87f1a778bd" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fd533d7f-35bc-4942-8883-3db552a99427" xlink:to="loc_stpr_PA_1ef32233-d94a-4cce-bd25-ae87f1a778bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:to="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aba1f478-c004-4a1b-99bc-d191c5a2b427" xlink:to="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0c8cf493-9e2b-46de-98a9-62bddb6e6893" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:to="loc_srt_MinimumMember_0c8cf493-9e2b-46de-98a9-62bddb6e6893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f24c8339-7c0a-477f-b636-22850443f0b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39b7c1e0-bf5f-4372-8dcf-b4279f64a3b5" xlink:to="loc_srt_MaximumMember_f24c8339-7c0a-477f-b636-22850443f0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_36534d98-b684-4be4-abb0-78e43ee714b2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_271c7fd9-5fcc-4649-8c59-0845dc08490a" xlink:href="sesn-20211231.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_271c7fd9-5fcc-4649-8c59-0845dc08490a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6279c9f3-fa2b-45b5-859c-50955345778f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6279c9f3-fa2b-45b5-859c-50955345778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_6ca4eec0-16c2-4109-8e2c-3fe776539857" xlink:href="sesn-20211231.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_6ca4eec0-16c2-4109-8e2c-3fe776539857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d26e2eb3-7d4f-4eec-bc57-4ae4a0bcbfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d26e2eb3-7d4f-4eec-bc57-4ae4a0bcbfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_43e0b7c2-e309-42c4-8062-e187fefa08bb" xlink:href="sesn-20211231.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_43e0b7c2-e309-42c4-8062-e187fefa08bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_4fe123bd-db83-466d-9886-bbc53ae5c8df" xlink:href="sesn-20211231.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_4fe123bd-db83-466d-9886-bbc53ae5c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9731ccd3-9493-425a-a07e-a31ffc532fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_ShortTermLeaseCost_9731ccd3-9493-425a-a07e-a31ffc532fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f7773179-0513-4e80-89c7-a70c87cc8c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseCost_f7773179-0513-4e80-89c7-a70c87cc8c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0e91e4a4-8ed7-4dee-aabd-32ae2ab5eddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0e91e4a4-8ed7-4dee-aabd-32ae2ab5eddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a06da408-9863-4fad-84e5-8f518795885d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a06da408-9863-4fad-84e5-8f518795885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d51fa7bb-17d8-4dd5-913b-578d26fce6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35c3c484-7642-498e-9b5b-1de7ccf33678" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d51fa7bb-17d8-4dd5-913b-578d26fce6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_113cbd27-b09b-4ca0-bb18-661bdd259749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_8e20dd80-84c8-47ca-8e27-657e716fac78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_113cbd27-b09b-4ca0-bb18-661bdd259749" xlink:to="loc_us-gaap_LeaseCostAbstract_8e20dd80-84c8-47ca-8e27-657e716fac78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e79fe830-239e-4e38-b05b-4b26a88137b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_8e20dd80-84c8-47ca-8e27-657e716fac78" xlink:to="loc_us-gaap_OperatingLeaseCost_e79fe830-239e-4e38-b05b-4b26a88137b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_96ef9a32-e514-4280-b8fc-6d326564062d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_8e20dd80-84c8-47ca-8e27-657e716fac78" xlink:to="loc_us-gaap_ShortTermLeaseCost_96ef9a32-e514-4280-b8fc-6d326564062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a18bc7a1-d216-401d-b6be-00cd25757fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_8e20dd80-84c8-47ca-8e27-657e716fac78" xlink:to="loc_us-gaap_LeaseCost_a18bc7a1-d216-401d-b6be-00cd25757fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SupplementalLeaseInformationAbstract_e1d90763-2cd1-4c95-90bd-1c7843e5db0f" xlink:href="sesn-20211231.xsd#sesn_SupplementalLeaseInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_113cbd27-b09b-4ca0-bb18-661bdd259749" xlink:to="loc_sesn_SupplementalLeaseInformationAbstract_e1d90763-2cd1-4c95-90bd-1c7843e5db0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6e983827-754b-4230-8e36-565e198f2165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SupplementalLeaseInformationAbstract_e1d90763-2cd1-4c95-90bd-1c7843e5db0f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6e983827-754b-4230-8e36-565e198f2165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_084ecc9c-2877-451f-800a-0c6218c26ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SupplementalLeaseInformationAbstract_e1d90763-2cd1-4c95-90bd-1c7843e5db0f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_084ecc9c-2877-451f-800a-0c6218c26ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LEASESFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_929f0e7d-786f-4191-a436-fc538642bf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0dc35851-c60c-415a-b3ef-1b76f5acd5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_929f0e7d-786f-4191-a436-fc538642bf84" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0dc35851-c60c-415a-b3ef-1b76f5acd5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6351401d-ee9b-44ed-85ac-9956e10c25d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0dc35851-c60c-415a-b3ef-1b76f5acd5dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6351401d-ee9b-44ed-85ac-9956e10c25d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d844c6bc-cc5d-4dd5-8638-5f55b7342edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0dc35851-c60c-415a-b3ef-1b76f5acd5dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d844c6bc-cc5d-4dd5-8638-5f55b7342edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_10c64c91-fa32-40c3-9e3f-4836e24e71a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0dc35851-c60c-415a-b3ef-1b76f5acd5dc" xlink:to="loc_us-gaap_OperatingLeaseLiability_10c64c91-fa32-40c3-9e3f-4836e24e71a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ce8c21ba-ab2f-41fa-9c32-4030186c6ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_37476a62-a63a-4eb5-af2a-a9771232ecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ce8c21ba-ab2f-41fa-9c32-4030186c6ad0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_37476a62-a63a-4eb5-af2a-a9771232ecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_769afd02-5aec-44d1-80da-3d4f7d7f9923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_d9bd7e76-f540-4fb6-86d0-b0e5e49d8533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_769afd02-5aec-44d1-80da-3d4f7d7f9923" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_d9bd7e76-f540-4fb6-86d0-b0e5e49d8533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3e9e7ccc-4084-4279-ab0a-c7045bb359be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_769afd02-5aec-44d1-80da-3d4f7d7f9923" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3e9e7ccc-4084-4279-ab0a-c7045bb359be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8a7399f9-275b-4175-830b-8d39f87d3972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8a7399f9-275b-4175-830b-8d39f87d3972" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:to="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6170ff95-1301-4072-ad0c-c54499598597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fc717b16-4c0b-4875-8143-d329ce9fb549" xlink:to="loc_us-gaap_CreditFacilityDomain_6170ff95-1301-4072-ad0c-c54499598597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_3113d467-a245-472c-a573-acf86955eee2" xlink:href="sesn-20211231.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6170ff95-1301-4072-ad0c-c54499598597" xlink:to="loc_sesn_ATMFacilityMember_3113d467-a245-472c-a573-acf86955eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c28d5dde-a249-4149-bc78-af95ae3d12b2" xlink:to="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d44ba0e-cb36-44c6-a755-182c6a7608b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d44ba0e-cb36-44c6-a755-182c6a7608b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_1eb7080a-7455-4fa7-b4da-2efed38f5fd0" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_1eb7080a-7455-4fa7-b4da-2efed38f5fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_ab22f0b7-3d93-4c6a-980f-9ff7e58f8a99" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_ab22f0b7-3d93-4c6a-980f-9ff7e58f8a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_28e8142e-b612-43f9-b606-2fc780b8a6c4" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_28e8142e-b612-43f9-b606-2fc780b8a6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cdadf42-73b9-4cc6-a5ef-55a1598fa2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cdadf42-73b9-4cc6-a5ef-55a1598fa2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6736a87c-7c73-42e8-9863-a55c45b445e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6736a87c-7c73-42e8-9863-a55c45b445e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_2c32ba22-0fc2-45c7-b6de-b0eadc3b558a" xlink:href="sesn-20211231.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_2c32ba22-0fc2-45c7-b6de-b0eadc3b558a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_248859d8-8f83-4d32-a635-61f2d022303c" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_248859d8-8f83-4d32-a635-61f2d022303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b6dd2a37-671a-4ed8-85d0-16e78ade8c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b6dd2a37-671a-4ed8-85d0-16e78ade8c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_db6752f6-b2da-4dee-9155-deabdbf844cc" xlink:href="sesn-20211231.xsd#sesn_CommonStockAndWarrantOrRightsPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_db6752f6-b2da-4dee-9155-deabdbf844cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6eafdc36-78bf-4a7e-946e-6da580cd6a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6eafdc36-78bf-4a7e-946e-6da580cd6a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_39e0eb80-8149-4e8e-b854-d500829ed580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26d9339f-9b1d-4e29-9dee-72b255d47737" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_39e0eb80-8149-4e8e-b854-d500829ed580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ab11da0f-3bc5-44a4-8ca1-ea93517c13c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a5c3ab07-2bd7-4db1-b08f-63b3131b59b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab11da0f-3bc5-44a4-8ca1-ea93517c13c8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a5c3ab07-2bd7-4db1-b08f-63b3131b59b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9fb36c07-64df-485b-9417-ba79f3bd9723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab11da0f-3bc5-44a4-8ca1-ea93517c13c8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9fb36c07-64df-485b-9417-ba79f3bd9723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6b8a72d0-7379-4acf-b1c3-ffc1362098aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab11da0f-3bc5-44a4-8ca1-ea93517c13c8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6b8a72d0-7379-4acf-b1c3-ffc1362098aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3dd78a42-a53d-49c0-ae32-ebe7abd05896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab11da0f-3bc5-44a4-8ca1-ea93517c13c8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3dd78a42-a53d-49c0-ae32-ebe7abd05896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_221365bc-81e6-41b6-9cbe-19b040967b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_221365bc-81e6-41b6-9cbe-19b040967b92" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca6012ce-23a2-4755-8e06-147407aaa508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_388572b8-761f-4a80-ab00-04aa48c22bbc" xlink:to="loc_us-gaap_EquityComponentDomain_ca6012ce-23a2-4755-8e06-147407aaa508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3d3d0be1-c068-488f-8c9c-6383d5d27320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ca6012ce-23a2-4755-8e06-147407aaa508" xlink:to="loc_us-gaap_CommonStockMember_3d3d0be1-c068-488f-8c9c-6383d5d27320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa78c6e1-7bc5-4ce0-bd8f-8ec23fd5ee62" xlink:to="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5891c7e2-045c-45ec-85e0-633d64d458c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5891c7e2-045c-45ec-85e0-633d64d458c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_78cfbb0a-baf3-42da-99bf-a7e998508d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_CommonStockSharesIssued_78cfbb0a-baf3-42da-99bf-a7e998508d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_51a99b1b-98c0-408e-8cf2-273a91fa64db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_51a99b1b-98c0-408e-8cf2-273a91fa64db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_3f3f5e5e-8fdf-45c5-ba7c-9d5d03fa6d8a" xlink:href="sesn-20211231.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8606ff21-e17c-448d-b797-2353ef265ce4" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_3f3f5e5e-8fdf-45c5-ba7c-9d5d03fa6d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_42f16a09-ad32-4fe6-af0b-3449047cbc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_42f16a09-ad32-4fe6-af0b-3449047cbc4a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:to="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1b390970-ca05-45a1-ad08-a42e38280ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4fa4b879-51f4-4451-ac22-f8da2646fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_WarrantMember_4fa4b879-51f4-4451-ac22-f8da2646fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aaa81f08-ece3-4561-99e2-d7a5aa844bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aaa81f08-ece3-4561-99e2-d7a5aa844bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b329a182-4666-46cf-b6dc-bb28bc28e065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b329a182-4666-46cf-b6dc-bb28bc28e065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_3590532b-e68b-486e-9875-354c24e92ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_StockCompensationPlanMember_3590532b-e68b-486e-9875-354c24e92ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5d2836ba-d04b-4fbb-b872-720c3d3cfe55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9120275-fed4-4a7b-9ae1-6243d9dc2824" xlink:to="loc_us-gaap_EmployeeStockMember_5d2836ba-d04b-4fbb-b872-720c3d3cfe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e16349bc-630a-4e6a-b780-ce00d839e9c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_99b4aaaa-0cb4-4845-b05d-7dc531fcd4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_99b4aaaa-0cb4-4845-b05d-7dc531fcd4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:href="sesn-20211231.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920d468f-9411-4f16-8985-e7dfde886b1b" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39718321-57ed-4392-ae79-7b264164ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39718321-57ed-4392-ae79-7b264164ef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_1bd47293-3d6d-4f77-ad81-9eb284f653e4" xlink:href="sesn-20211231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_d04757a5-5082-48b4-ac47-59ecd328b31e" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_1bd47293-3d6d-4f77-ad81-9eb284f653e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d226a723-6877-4b99-b227-02272384d951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d226a723-6877-4b99-b227-02272384d951" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f33badae-335b-4bf7-952f-8fffbd4cdb03" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringJune2020Member_5e660edd-af37-458c-b566-3aaf85ee6a94" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringJune2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringJune2020Member_5e660edd-af37-458c-b566-3aaf85ee6a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_020001d6-8219-4c26-b1e6-2239d7f11335" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_020001d6-8219-4c26-b1e6-2239d7f11335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_2c1345c2-4dc2-4c29-81e8-846d085aaca1" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_2c1345c2-4dc2-4c29-81e8-846d085aaca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_f4ca90fc-da7a-43b8-9ad9-74fab7b8eead" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_f4ca90fc-da7a-43b8-9ad9-74fab7b8eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_bbd22f91-27ae-47ab-85fe-f0339fc7f5a1" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a487f03d-ecd3-49d1-a5f2-a04afe52b4ff" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_bbd22f91-27ae-47ab-85fe-f0339fc7f5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45f941e0-a4fc-4eeb-b388-bc06db4b7dec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0f88d0c-2c69-44a2-9962-93a52e82c0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0f88d0c-2c69-44a2-9962-93a52e82c0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:href="sesn-20211231.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_49c2119e-8e7f-436f-bdec-1cdfd399b945" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2290b31e-897a-4fb0-bed3-53746c1d9864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2290b31e-897a-4fb0-bed3-53746c1d9864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_6ef09834-2988-4ca5-95c0-c2df64165606" xlink:href="sesn-20211231.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_6ef09834-2988-4ca5-95c0-c2df64165606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_7b1f0a5a-7e06-485f-a9c2-f3ad78ff97e5" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_7b1f0a5a-7e06-485f-a9c2-f3ad78ff97e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_ed79dcd2-8852-4d9e-834d-41ba972cfa7c" xlink:href="sesn-20211231.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_ed79dcd2-8852-4d9e-834d-41ba972cfa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_15d424a3-3a43-49f0-a3ec-cc7993a85a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_9b003a1e-db92-4002-879d-d65a00448e8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_15d424a3-3a43-49f0-a3ec-cc7993a85a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1544b6a3-238d-4c80-89b4-9283168de5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1544b6a3-238d-4c80-89b4-9283168de5ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ad7fc4ae-4c04-4644-8c04-7ea910f763ac" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_8613a36f-6cc2-4a18-8473-1af8d31cf3e9" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_8613a36f-6cc2-4a18-8473-1af8d31cf3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_e35522c4-38f8-4b2d-802a-651e5d9e864f" xlink:href="sesn-20211231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_e35522c4-38f8-4b2d-802a-651e5d9e864f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_616ded75-e7e6-4296-b34f-4285406fe1eb" xlink:href="sesn-20211231.xsd#sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0945b868-487b-445f-b865-b292806e494d" xlink:to="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_616ded75-e7e6-4296-b34f-4285406fe1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e714777-2d6b-4086-9bbb-e5e03543e3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f61ca50b-e8f0-4092-9b7d-865529f36393" xlink:to="loc_us-gaap_EquityComponentDomain_2e714777-2d6b-4086-9bbb-e5e03543e3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9857a570-3d83-4b6a-9447-50ca6bd30270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e714777-2d6b-4086-9bbb-e5e03543e3f6" xlink:to="loc_us-gaap_CommonStockMember_9857a570-3d83-4b6a-9447-50ca6bd30270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5d7896c2-cdc2-47f7-ab52-80345f03df67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_f61a829a-58bf-4038-bac0-bf8491e1d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_f61a829a-58bf-4038-bac0-bf8491e1d7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e801d6c1-82f8-4a5a-b6f3-a809a81ff27d" xlink:href="sesn-20211231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_e801d6c1-82f8-4a5a-b6f3-a809a81ff27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_dd896038-9a10-49d2-a9c0-9121ebb892a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_dd896038-9a10-49d2-a9c0-9121ebb892a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7d2a33d-dd48-49f0-bde8-5c45e5eca24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7d2a33d-dd48-49f0-bde8-5c45e5eca24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments_eecb15d3-d662-4545-b6bb-5236d2cc9f51" xlink:href="sesn-20211231.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_sesn_OtherDividendAndAdjustments_eecb15d3-d662-4545-b6bb-5236d2cc9f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_a3399fb5-3d75-4de1-8913-ea7248706446" xlink:href="sesn-20211231.xsd#sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d842ae7b-b0ea-4ce4-9b39-b73164dd3d75" xlink:to="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_a3399fb5-3d75-4de1-8913-ea7248706446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="sesn-20211231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45dbf3b5-90de-4644-acfa-fb3d72e3ea78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_30218353-4b98-4d49-a7cf-2d6e09daee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45dbf3b5-90de-4644-acfa-fb3d72e3ea78" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_30218353-4b98-4d49-a7cf-2d6e09daee1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="sesn-20211231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_db1f71c6-1fa1-4711-a44e-0b8eb4c89fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0ff029c9-1a07-4174-916e-adeb1870010a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db1f71c6-1fa1-4711-a44e-0b8eb4c89fb7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0ff029c9-1a07-4174-916e-adeb1870010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_72c4caa4-196e-43d1-9c98-4adcc39b4713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_72c4caa4-196e-43d1-9c98-4adcc39b4713" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a146389c-9b7f-4edb-86cd-f968a4724fb5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bb56bd92-6caf-4586-a952-5c7cb23f3c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:to="loc_us-gaap_WarrantMember_bb56bd92-6caf-4586-a952-5c7cb23f3c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3035c288-15a3-45f4-af83-6387b7454cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5508d88-2dfe-4351-b8ba-5f099a6c4c4d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3035c288-15a3-45f4-af83-6387b7454cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb7e1780-1b18-4856-a583-d9d4306d8a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fca345db-636c-4ea6-86ed-463a361b0ccd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb7e1780-1b18-4856-a583-d9d4306d8a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_841fd610-3814-4be0-89ea-b3774a21fd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb7e1780-1b18-4856-a583-d9d4306d8a11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_841fd610-3814-4be0-89ea-b3774a21fd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1e4c176-4f0d-4744-9826-54808f6d09d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cfad98c2-4526-417c-acc5-c667b734590b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1e4c176-4f0d-4744-9826-54808f6d09d8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cfad98c2-4526-417c-acc5-c667b734590b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_662e6287-a1a5-450f-9bf5-c26cf5ccd086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b9b5aafb-dc28-472e-afc2-2a0e5c10fd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_662e6287-a1a5-450f-9bf5-c26cf5ccd086" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b9b5aafb-dc28-472e-afc2-2a0e5c10fd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_42c03432-2a70-499e-b04d-746c34982ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_662e6287-a1a5-450f-9bf5-c26cf5ccd086" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_42c03432-2a70-499e-b04d-746c34982ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1ea9739f-e914-4867-bd29-7f4782f40aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_662e6287-a1a5-450f-9bf5-c26cf5ccd086" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1ea9739f-e914-4867-bd29-7f4782f40aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4519066c-0956-4537-9367-c2105f2cc9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_662e6287-a1a5-450f-9bf5-c26cf5ccd086" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4519066c-0956-4537-9367-c2105f2cc9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6030eafe-cb32-43f2-88d3-ce4ffcf7df65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6030eafe-cb32-43f2-88d3-ce4ffcf7df65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c608fade-2ec7-486d-bfb5-e8d76ce07066" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be3632f-6987-4029-b94d-9349e52e4093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2be3632f-6987-4029-b94d-9349e52e4093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4f9b695-8150-414f-9210-b9472d77cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e775593b-6a13-4977-98ab-d9137f6246cd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4f9b695-8150-414f-9210-b9472d77cc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3d61ec-3f62-4d71-a0bb-768dc1fc31d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc638ba-e0fb-4c7f-b05d-cc94959a8249" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3d61ec-3f62-4d71-a0bb-768dc1fc31d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a0b2d92-46d7-40c3-bfdb-6ce90f1b6f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3d61ec-3f62-4d71-a0bb-768dc1fc31d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a0b2d92-46d7-40c3-bfdb-6ce90f1b6f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_05c3c482-5621-4bcc-9abc-76268d52c0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_05c3c482-5621-4bcc-9abc-76268d52c0a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_6c61a627-4976-4683-94cb-fb3e74582832" xlink:to="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2a8c099b-5665-49d3-9ede-1abda367f24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2a8c099b-5665-49d3-9ede-1abda367f24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1e5887ac-dd73-4aa1-b4cd-ab7fedc1ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d9f4151e-7f2e-420e-b3b1-13532253f5a1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1e5887ac-dd73-4aa1-b4cd-ab7fedc1ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_02c2c7a7-59c0-4630-b926-944bbf4a2353" xlink:to="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_b827a75f-c94f-4ead-94af-44d6e90b1d34" xlink:href="sesn-20211231.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_b827a75f-c94f-4ead-94af-44d6e90b1d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_bf3a3218-6aa2-4d97-af88-3c25813293db" xlink:href="sesn-20211231.xsd#sesn_RetentionProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:to="loc_sesn_RetentionProgramMember_bf3a3218-6aa2-4d97-af88-3c25813293db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_018dd6bc-b939-4798-876f-a0e891ae0e7b" xlink:href="sesn-20211231.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33bc7b59-bd5e-4eb4-9490-5cdd407a7641" xlink:to="loc_sesn_StockIncentivePlan2009Member_018dd6bc-b939-4798-876f-a0e891ae0e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dd830eba-c4e6-492a-b6fb-10091adb3be5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a72eb49-8ab9-4c3f-8012-a6ad93544c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a72eb49-8ab9-4c3f-8012-a6ad93544c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ee74a489-093f-40f7-9a0d-9c191570a938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ee74a489-093f-40f7-9a0d-9c191570a938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0bcb7320-cdf7-4270-be06-bbde43b78299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a09008d-964b-48c9-ae75-4058ffc70292" xlink:to="loc_us-gaap_PerformanceSharesMember_0bcb7320-cdf7-4270-be06-bbde43b78299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_05abaeb2-d8f1-47ef-a0ce-3fdcebcd81ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_f74811b4-d0c8-43e8-8c78-57652a649caa" xlink:to="loc_us-gaap_GranteeStatusDomain_05abaeb2-d8f1-47ef-a0ce-3fdcebcd81ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_26d64532-4a87-41e0-9357-c8080f8b7a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_05abaeb2-d8f1-47ef-a0ce-3fdcebcd81ba" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_26d64532-4a87-41e0-9357-c8080f8b7a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c631cab-3d4d-45ed-8495-8a70cb0f0f08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_b903bbaf-e6be-412c-90b1-7bf1b6f64e31" xlink:href="sesn-20211231.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_b903bbaf-e6be-412c-90b1-7bf1b6f64e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6ed6767b-3ac8-487f-9afe-73f2d91bd03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6ed6767b-3ac8-487f-9afe-73f2d91bd03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f9edc2b0-efee-45f5-870a-405ab532a8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f9edc2b0-efee-45f5-870a-405ab532a8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_42066f6d-ce2a-42e4-a491-588db74e2b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_42066f6d-ce2a-42e4-a491-588db74e2b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_662580cb-4a00-4ec5-9227-71589fb77a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_662580cb-4a00-4ec5-9227-71589fb77a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3aad3be0-2ca5-4fcf-913c-31e2b6f825dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3aad3be0-2ca5-4fcf-913c-31e2b6f825dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_1707094d-0794-4ccd-9c02-71b04441df53" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_1707094d-0794-4ccd-9c02-71b04441df53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_10ba634c-61ba-473e-a6fd-02db27b5a68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_10ba634c-61ba-473e-a6fd-02db27b5a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_a83101e0-dc57-4f20-a09b-c37ea53d03be" xlink:href="sesn-20211231.xsd#sesn_ShareBasedPaymentArrangementExpenseOnCashBonus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus_a83101e0-dc57-4f20-a09b-c37ea53d03be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_d3985af6-ae26-4931-aa1b-70d72aec3ab9" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_d3985af6-ae26-4931-aa1b-70d72aec3ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_38cda6c6-68a9-40ea-9d43-7a3d5eb77949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_38cda6c6-68a9-40ea-9d43-7a3d5eb77949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_de2de09a-bea5-45d4-b611-3e5cc0822f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_de2de09a-bea5-45d4-b611-3e5cc0822f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7eba0a8f-6572-48fb-a757-6fa8861eace6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7eba0a8f-6572-48fb-a757-6fa8861eace6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8f063828-d8a6-411e-add3-1bb76baa748c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8f063828-d8a6-411e-add3-1bb76baa748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90c559de-c461-4aca-8562-a997c0d2e476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90c559de-c461-4aca-8562-a997c0d2e476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3102b3c2-815a-4f8d-819c-cf84bb9a9810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3102b3c2-815a-4f8d-819c-cf84bb9a9810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec54e961-1694-43a2-915a-e211397db58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf9f679-d2af-42a1-b090-b41ec335b014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec54e961-1694-43a2-915a-e211397db58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fc7f79d-6807-4caf-871d-888051026bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fc7f79d-6807-4caf-871d-888051026bec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:to="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_995361ea-2f43-4ef9-a615-7c528c70145d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6321c089-f5eb-42a3-ba0e-24c3b9cbc970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6321c089-f5eb-42a3-ba0e-24c3b9cbc970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8bf42f60-28f6-40b6-9040-6e59a363c917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46cbcc05-c283-4e40-8de6-221b7a1d3b2d" xlink:to="loc_us-gaap_PerformanceSharesMember_8bf42f60-28f6-40b6-9040-6e59a363c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e443e1-1bac-4082-9d56-7a2b7203fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7135fa98-a818-47e3-953a-3eb28b667625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e443e1-1bac-4082-9d56-7a2b7203fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e443e1-1bac-4082-9d56-7a2b7203fba4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6108eccd-27df-4898-8ed1-97c090ead3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6108eccd-27df-4898-8ed1-97c090ead3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358e0c4f-1030-4d1d-821d-528000e977a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358e0c4f-1030-4d1d-821d-528000e977a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12224ce9-839f-47e5-92ea-68ba3e0deb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17e6b205-26cf-41b4-b199-80a2e48dfaa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12224ce9-839f-47e5-92ea-68ba3e0deb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bf22579-1160-4620-9df9-38acb26bfca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bf22579-1160-4620-9df9-38acb26bfca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a8253fb-43fd-49c0-bd4f-3a1724f8fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a8253fb-43fd-49c0-bd4f-3a1724f8fa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_106d0ff1-2728-42bc-bb62-03b57066cc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_106d0ff1-2728-42bc-bb62-03b57066cc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f0acead-5d31-416c-88aa-414ce55ffded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6f0acead-5d31-416c-88aa-414ce55ffded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4501f5f7-757d-4e44-88d6-dbd83dcb2af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4501f5f7-757d-4e44-88d6-dbd83dcb2af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a82ab3f3-7f4b-4842-a8b6-2978f1db1b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fbd2f1d0-199f-4bd3-ab0d-7bde42aaf489" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a82ab3f3-7f4b-4842-a8b6-2978f1db1b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e332dfdf-726b-4dbb-9d39-61df5b8559b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bf22579-1160-4620-9df9-38acb26bfca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e332dfdf-726b-4dbb-9d39-61df5b8559b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bf22579-1160-4620-9df9-38acb26bfca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9a2acd0e-4f85-4ece-9343-9f5f1e02925b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9a2acd0e-4f85-4ece-9343-9f5f1e02925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8b77f7d-624d-40c9-8e3d-84b5545fd57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8b77f7d-624d-40c9-8e3d-84b5545fd57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ceb7c733-63b2-4043-b411-2b8c5df96971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ceb7c733-63b2-4043-b411-2b8c5df96971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_849dcddb-9daf-4a54-84f3-1a5721e84311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_849dcddb-9daf-4a54-84f3-1a5721e84311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ebfe303d-b34c-467a-a0f5-c35e306f517b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4ddb63f-9e50-4360-ab3d-3db08b4cf036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ebfe303d-b34c-467a-a0f5-c35e306f517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c77cedda-373e-4250-b77f-46829c898a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bf22579-1160-4620-9df9-38acb26bfca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c77cedda-373e-4250-b77f-46829c898a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_262412e3-de39-4aad-b99b-2ea8dae13c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bf22579-1160-4620-9df9-38acb26bfca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_262412e3-de39-4aad-b99b-2ea8dae13c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52a47b66-9505-4c98-b0f8-deaf5eed351a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_262412e3-de39-4aad-b99b-2ea8dae13c24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52a47b66-9505-4c98-b0f8-deaf5eed351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_958a3c4c-8209-48b9-953e-5aa312aea43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_262412e3-de39-4aad-b99b-2ea8dae13c24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_958a3c4c-8209-48b9-953e-5aa312aea43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d3b2e54e-d5d1-4949-8441-65e8cc1c0376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_262412e3-de39-4aad-b99b-2ea8dae13c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d3b2e54e-d5d1-4949-8441-65e8cc1c0376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e949e5d7-88fa-40ca-a8e0-c1bec5a32df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_262412e3-de39-4aad-b99b-2ea8dae13c24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e949e5d7-88fa-40ca-a8e0-c1bec5a32df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_942c0959-f131-4c23-837a-9519db6bf8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_942c0959-f131-4c23-837a-9519db6bf8e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:to="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d29ec8-d0b5-441c-9c66-237b10db78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_90c8d011-cbc1-46f7-982b-99bff5277848" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d29ec8-d0b5-441c-9c66-237b10db78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71ec4059-3f5b-4063-a792-f3ffebd2e426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d29ec8-d0b5-441c-9c66-237b10db78b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71ec4059-3f5b-4063-a792-f3ffebd2e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c0f4043-4d64-48fc-a634-c983bc75a268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_577acc72-67d9-4fb5-a413-f0c9ba4d8f38" xlink:href="sesn-20211231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_577acc72-67d9-4fb5-a413-f0c9ba4d8f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c01bed3c-253a-4956-9b17-dd952a0c7c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c01bed3c-253a-4956-9b17-dd952a0c7c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_879a16eb-103c-46f7-b6ca-67cdab2617d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_879a16eb-103c-46f7-b6ca-67cdab2617d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_03252f7e-9a24-4940-9206-446c542928b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_03252f7e-9a24-4940-9206-446c542928b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_af738a79-75ea-43f6-938f-7bc96fe00635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_af738a79-75ea-43f6-938f-7bc96fe00635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_864f3d8d-e677-4870-9888-c2d148e83e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06ede827-c7a6-4d1f-a456-bc7120feb1db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_864f3d8d-e677-4870-9888-c2d148e83e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="sesn-20211231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0373c780-2f49-4077-a171-4f9740e4c02d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_73d762e6-9fdb-4e8c-9e6a-e8c662d77b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0373c780-2f49-4077-a171-4f9740e4c02d" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_73d762e6-9fdb-4e8c-9e6a-e8c662d77b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_467445ef-d5a4-4657-990c-2be754eee377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_467445ef-d5a4-4657-990c-2be754eee377" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:to="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c8bf88ae-51f9-4b39-8c55-b25db3968f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_35057582-7325-4cd4-9e9c-341cc7acf0a9" xlink:to="loc_us-gaap_PlanNameDomain_c8bf88ae-51f9-4b39-8c55-b25db3968f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_5d4eba9c-724b-401b-ad9c-1836a84bb3ad" xlink:href="sesn-20211231.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c8bf88ae-51f9-4b39-8c55-b25db3968f97" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_5d4eba9c-724b-401b-ad9c-1836a84bb3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_04bd1604-3604-4ea3-9b10-33d43b227aae" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_ff500ec7-b7c0-45c6-938c-29e5e5831669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:to="loc_us-gaap_DomesticPlanMember_ff500ec7-b7c0-45c6-938c-29e5e5831669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b69d67ec-317a-427a-88c9-a1b06bf0b47f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_ff500ec7-b7c0-45c6-938c-29e5e5831669" xlink:to="loc_country_US_b69d67ec-317a-427a-88c9-a1b06bf0b47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8a1d44bf-7fad-483b-97c9-10ab3b0e6d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_001850f7-69f5-4aa8-b942-2233d0f2bfe9" xlink:to="loc_us-gaap_ForeignPlanMember_8a1d44bf-7fad-483b-97c9-10ab3b0e6d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4143f164-9bbe-4b1d-8f52-97ade34e0df1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_04c63e74-acea-4c28-91d6-db57123c7464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_04c63e74-acea-4c28-91d6-db57123c7464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_eeea3a0b-3a53-40b2-aea9-64b105b910b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_eeea3a0b-3a53-40b2-aea9-64b105b910b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_17ebab39-05e5-4fdf-9aca-d845fb6afd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_17ebab39-05e5-4fdf-9aca-d845fb6afd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e48a7489-5f86-4897-9e9f-260687919f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e48a7489-5f86-4897-9e9f-260687919f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dd01df1f-5bc7-4126-84f0-ab60478d6224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dd01df1f-5bc7-4126-84f0-ab60478d6224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_e94d6303-df7b-4ab0-8555-76a47f4a3d9a" xlink:href="sesn-20211231.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_e94d6303-df7b-4ab0-8555-76a47f4a3d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_70a4fd22-d166-41e0-be96-9493f76bb947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_51b5c1d5-fd31-4acd-bc9d-8139335a6773" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_70a4fd22-d166-41e0-be96-9493f76bb947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef64130c-f606-43b6-83ff-f5b6996b617a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_aecf17b9-b42c-45a6-93be-9c47ef9b0e31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef64130c-f606-43b6-83ff-f5b6996b617a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_aecf17b9-b42c-45a6-93be-9c47ef9b0e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_db443b70-71b8-4938-b6a0-f7333a12e20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c7d5febf-8816-41cb-9b08-405cc12a8afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db443b70-71b8-4938-b6a0-f7333a12e20c" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c7d5febf-8816-41cb-9b08-405cc12a8afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_437af01e-90f9-4827-a297-b25dd49e2390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db443b70-71b8-4938-b6a0-f7333a12e20c" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_437af01e-90f9-4827-a297-b25dd49e2390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9d4e3256-a558-4c4d-9179-401189631b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db443b70-71b8-4938-b6a0-f7333a12e20c" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9d4e3256-a558-4c4d-9179-401189631b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_93a397e8-503f-4ff6-a127-29634f7693dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db443b70-71b8-4938-b6a0-f7333a12e20c" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_93a397e8-503f-4ff6-a127-29634f7693dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_58ea997d-296e-4f75-b42f-3869416b27f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db443b70-71b8-4938-b6a0-f7333a12e20c" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_58ea997d-296e-4f75-b42f-3869416b27f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b42a0f4-6e06-4b37-901d-dff9015dab00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b42a0f4-6e06-4b37-901d-dff9015dab00" xlink:to="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:to="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f84e760c-e236-44e5-b530-e84dc6f9af47" xlink:to="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4f55c156-2d95-46b0-b7b5-8ffe58da6e56" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:to="loc_country_US_4f55c156-2d95-46b0-b7b5-8ffe58da6e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_9d37422e-5546-46b4-b537-77dff42f9b07" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_348c2c5d-ba73-41c4-ae80-b7962e35595a" xlink:to="loc_country_CA_9d37422e-5546-46b4-b537-77dff42f9b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_51ef7c29-ddf9-416b-a332-48ed4217a521" xlink:to="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6626f6da-1fc7-42b1-a17d-24e37bf8ea12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6626f6da-1fc7-42b1-a17d-24e37bf8ea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d8ea0166-c5a9-4861-9a88-8a8da59f0176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d8ea0166-c5a9-4861-9a88-8a8da59f0176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad16bab5-18c5-4b6e-afc9-ecf1d7fbe6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_78710dcd-7602-4750-b48c-c092223dea3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad16bab5-18c5-4b6e-afc9-ecf1d7fbe6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b55f7fd4-3db5-4af4-b476-bdb7a032f126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_acce179f-7158-4b38-9ceb-db67b6c0b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b55f7fd4-3db5-4af4-b476-bdb7a032f126" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_acce179f-7158-4b38-9ceb-db67b6c0b8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_20a68390-08bc-43bd-80a2-9f8b2af0f5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_acce179f-7158-4b38-9ceb-db67b6c0b8ad" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_20a68390-08bc-43bd-80a2-9f8b2af0f5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_75934feb-3c9a-4bca-8f23-93d9346ab74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_acce179f-7158-4b38-9ceb-db67b6c0b8ad" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_75934feb-3c9a-4bca-8f23-93d9346ab74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a2c93495-a653-4e9b-a9bc-1fa6256aa230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_acce179f-7158-4b38-9ceb-db67b6c0b8ad" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a2c93495-a653-4e9b-a9bc-1fa6256aa230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7a0f862-800e-43c7-bb2e-2f649dbf3bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_acce179f-7158-4b38-9ceb-db67b6c0b8ad" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7a0f862-800e-43c7-bb2e-2f649dbf3bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_28c072a9-11de-40ea-bff9-6d9d63aa11d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b55f7fd4-3db5-4af4-b476-bdb7a032f126" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_28c072a9-11de-40ea-bff9-6d9d63aa11d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f143764b-022c-465a-97e2-0cb654c4cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_28c072a9-11de-40ea-bff9-6d9d63aa11d0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f143764b-022c-465a-97e2-0cb654c4cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7ac6b958-d9c3-46a4-8008-d090fd513ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_28c072a9-11de-40ea-bff9-6d9d63aa11d0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7ac6b958-d9c3-46a4-8008-d090fd513ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e7143153-b62a-48f3-8a0a-fde1fd5527bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_28c072a9-11de-40ea-bff9-6d9d63aa11d0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e7143153-b62a-48f3-8a0a-fde1fd5527bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65ef1bcc-b20b-4dbd-89df-f5de84ce20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_28c072a9-11de-40ea-bff9-6d9d63aa11d0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65ef1bcc-b20b-4dbd-89df-f5de84ce20ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9eb5f371-9231-4974-beb2-636cc8cdca91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b55f7fd4-3db5-4af4-b476-bdb7a032f126" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9eb5f371-9231-4974-beb2-636cc8cdca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_314e898c-6607-45ef-a740-38222e49ed0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314e898c-6607-45ef-a740-38222e49ed0e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8173aaff-13ad-420c-a2e1-244afa955a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8173aaff-13ad-420c-a2e1-244afa955a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_174dd559-5ef6-4102-bdd3-7e52196ed8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_174dd559-5ef6-4102-bdd3-7e52196ed8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4883e6b2-4f48-482f-91b1-1398e26a6bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4883e6b2-4f48-482f-91b1-1398e26a6bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1902a525-6367-48c4-b4a5-76bfddd47c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1902a525-6367-48c4-b4a5-76bfddd47c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_a017d449-4c56-45b3-b873-2df05f5257a3" xlink:href="sesn-20211231.xsd#sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_a017d449-4c56-45b3-b873-2df05f5257a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1be087bc-ae05-404c-8eb9-1b009de5de90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1be087bc-ae05-404c-8eb9-1b009de5de90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_9b2d3628-b851-44a6-8160-7912ad9fa8bc" xlink:href="sesn-20211231.xsd#sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_9b2d3628-b851-44a6-8160-7912ad9fa8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_afdde60b-6709-4692-a106-02457eab105a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_afdde60b-6709-4692-a106-02457eab105a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2a2ce419-dcb2-420b-b45f-fdd00bebcc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2a2ce419-dcb2-420b-b45f-fdd00bebcc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_f2842b31-761a-4a6f-8300-811888e8b124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_f2842b31-761a-4a6f-8300-811888e8b124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_605d3c69-c6ee-4bc1-89c7-1df0ccf79cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7d568407-1f48-4b94-b53d-c8323ede3a70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_605d3c69-c6ee-4bc1-89c7-1df0ccf79cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c87ba28e-a3d9-4714-bdde-46de7d6c6bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c87ba28e-a3d9-4714-bdde-46de7d6c6bcb" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac527015-bd57-492d-be78-23d29b9e8d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac527015-bd57-492d-be78-23d29b9e8d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_74cff44b-5b4b-4ab1-94b0-3bb0dc9c73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_74cff44b-5b4b-4ab1-94b0-3bb0dc9c73c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_56821899-6b91-4044-8c8d-7cf6bddb1568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_56821899-6b91-4044-8c8d-7cf6bddb1568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_90b16ee1-4f1e-4407-b9de-b1844ed4723a" xlink:href="sesn-20211231.xsd#sesn_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:to="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_90b16ee1-4f1e-4407-b9de-b1844ed4723a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6d2b6e9d-b4da-47a7-ab40-c7d3208d01d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6d2b6e9d-b4da-47a7-ab40-c7d3208d01d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2923bf97-a926-4ab0-a4e8-77ae1912caa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d8a71a2b-f661-4ec2-89f3-2a2badcbe9ed" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2923bf97-a926-4ab0-a4e8-77ae1912caa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3d26a5f6-cb51-4a5c-be9b-d25cea4b4e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c87ba28e-a3d9-4714-bdde-46de7d6c6bcb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3d26a5f6-cb51-4a5c-be9b-d25cea4b4e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_d0566c57-18c7-45d3-a6b4-f0092cccf348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3d26a5f6-cb51-4a5c-be9b-d25cea4b4e4e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_d0566c57-18c7-45d3-a6b4-f0092cccf348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_af1ecf6b-228a-430b-9a13-2af67e323799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3d26a5f6-cb51-4a5c-be9b-d25cea4b4e4e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_af1ecf6b-228a-430b-9a13-2af67e323799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d188da49-7bb8-4e30-ae9b-ff27df4ddc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3d26a5f6-cb51-4a5c-be9b-d25cea4b4e4e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d188da49-7bb8-4e30-ae9b-ff27df4ddc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7793c799-f0b1-4a04-8b4f-0945eb22b3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3d26a5f6-cb51-4a5c-be9b-d25cea4b4e4e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7793c799-f0b1-4a04-8b4f-0945eb22b3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b3ba7b5a-f176-4b83-a291-a0a887e2abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_970764a6-d272-4d2d-8f1b-954888812aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3ba7b5a-f176-4b83-a291-a0a887e2abc8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_970764a6-d272-4d2d-8f1b-954888812aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_62d628d0-0991-4474-8c74-189192cd8dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3ba7b5a-f176-4b83-a291-a0a887e2abc8" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_62d628d0-0991-4474-8c74-189192cd8dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bf8ea742-ae89-471f-ae07-b7e01fac62c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3ba7b5a-f176-4b83-a291-a0a887e2abc8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bf8ea742-ae89-471f-ae07-b7e01fac62c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLossCarryforwardsDecrease_09d05759-246b-4fc5-867a-33eb1738773f" xlink:href="sesn-20211231.xsd#sesn_OperatingLossCarryforwardsDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3ba7b5a-f176-4b83-a291-a0a887e2abc8" xlink:to="loc_sesn_OperatingLossCarryforwardsDecrease_09d05759-246b-4fc5-867a-33eb1738773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#INCOMETAXESScheduleofCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_caa8ccb3-a6b8-4098-aa03-480f364e4f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_caa8ccb3-a6b8-4098-aa03-480f364e4f6b" xlink:to="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_59e6fb3d-9a80-4d49-b93a-b79a09f3e23b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2412e415-306a-437e-9514-a3c26d24e1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:to="loc_us-gaap_ResearchMember_2412e415-306a-437e-9514-a3c26d24e1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NonCapitalLossCarryforwardMember_d1a0e2d6-6420-4123-af6f-62f439a2bb24" xlink:href="sesn-20211231.xsd#sesn_NonCapitalLossCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:to="loc_sesn_NonCapitalLossCarryforwardMember_d1a0e2d6-6420-4123-af6f-62f439a2bb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCreditMember_dccc2dd5-bf83-40ee-b80f-a89e2c2217bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bcdbb669-e509-46e4-a9d4-a46ca6adeed8" xlink:to="loc_us-gaap_InvestmentCreditMember_dccc2dd5-bf83-40ee-b80f-a89e2c2217bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain_17728d7c-c112-405c-ac94-14fd5016fe70" xlink:href="sesn-20211231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis_7a706bc9-f27a-469c-8bb1-0c65b6064af7" xlink:to="loc_sesn_NetOperatingLossCarryforwardDomain_17728d7c-c112-405c-ac94-14fd5016fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IndefiniteMember_7a3d146c-1620-471a-96bc-1f1e3f9f717e" xlink:href="sesn-20211231.xsd#sesn_IndefiniteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_NetOperatingLossCarryforwardDomain_17728d7c-c112-405c-ac94-14fd5016fe70" xlink:to="loc_sesn_IndefiniteMember_7a3d146c-1620-471a-96bc-1f1e3f9f717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_707486d7-4d4f-430e-95e2-46ca07897a5c" xlink:to="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_973e9a8f-0c01-4e7a-8474-bbba21eacfb5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:to="loc_country_US_973e9a8f-0c01-4e7a-8474-bbba21eacfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_6c49e94b-efac-4f16-be1c-fb496e583ec0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cae3823b-c150-4c71-bf6c-a10abe8c0e0e" xlink:to="loc_country_CA_6c49e94b-efac-4f16-be1c-fb496e583ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e9287e65-9b4b-4cde-9fd3-3b3d3d8f2e54" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f23002e7-b7b3-4507-af18-b4270ff9553d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:to="loc_us-gaap_DomesticCountryMember_f23002e7-b7b3-4507-af18-b4270ff9553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d032c776-4776-4bd6-bb58-e31e1f7a71ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aec1e145-8391-4493-af20-a9fd1588e48f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d032c776-4776-4bd6-bb58-e31e1f7a71ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:href="sesn-20211231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_43687b64-f7ba-4d9d-a464-f2ba25839f4c" xlink:to="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6b59d4a4-8da5-46c0-bef4-0baf6ebf100d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6b59d4a4-8da5-46c0-bef4-0baf6ebf100d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_34f89339-7162-4fee-96e4-37411b03b587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_a998f20f-6317-4adc-bee0-6d22df4a77f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_34f89339-7162-4fee-96e4-37411b03b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="sesn-20211231.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6c73944-4c68-4948-9cea-19afc0b0d024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock_4ae455d0-1cea-4131-bded-d71377da50f8" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6c73944-4c68-4948-9cea-19afc0b0d024" xlink:to="loc_sesn_LicenseAgreementTextBlock_4ae455d0-1cea-4131-bded-d71377da50f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#LICENSEAGREEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b784114-7fbd-46bf-b6d9-4764597e9c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:href="sesn-20211231.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b784114-7fbd-46bf-b6d9-4764597e9c6c" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f2951876-d807-405d-8734-c03e79e0eae5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_9e743ea5-ad7d-4c9d-816f-4c20b3ee3234" xlink:href="sesn-20211231.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_UniversityOfZurichMember_9e743ea5-ad7d-4c9d-816f-4c20b3ee3234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_c53c9baf-2d72-4af4-87aa-660d06ee2bf4" xlink:href="sesn-20211231.xsd#sesn_MicrometAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_MicrometAGMember_c53c9baf-2d72-4af4-87aa-660d06ee2bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_7f8d10a3-621c-4d90-9e11-841f3f05fae6" xlink:href="sesn-20211231.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_XOMAIrelandLimitedMember_7f8d10a3-621c-4d90-9e11-841f3f05fae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_beb64fea-72b6-49db-a200-3374c95e3262" xlink:href="sesn-20211231.xsd#sesn_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_RocheMember_beb64fea-72b6-49db-a200-3374c95e3262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_7567ff33-8b44-481c-be9b-4460ef92c129" xlink:href="sesn-20211231.xsd#sesn_MENALicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_MENALicenseAgreementMember_7567ff33-8b44-481c-be9b-4460ef92c129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d96d8a25-e244-4afc-a68b-f4a0b2443811" xlink:href="sesn-20211231.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cab8e0d-2b46-48cc-8a86-006df22f4965" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d96d8a25-e244-4afc-a68b-f4a0b2443811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ba47fe2-cd56-4753-9443-5c2584b69a84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_46767412-188f-4589-8c20-0e72216a5aeb" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_46767412-188f-4589-8c20-0e72216a5aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_a324e49c-dd64-4ce0-aaf4-b18e93411695" xlink:href="sesn-20211231.xsd#sesn_FirstIndicationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_FirstIndicationMember_a324e49c-dd64-4ce0-aaf4-b18e93411695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_2134c57b-a379-4687-994a-0f0943ce9409" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_2134c57b-a379-4687-994a-0f0943ce9409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_b67765ca-d07d-473b-b854-645b21e10a5b" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_b67765ca-d07d-473b-b854-645b21e10a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_5dc469e2-0ae9-40ec-9a1f-6abd03218f53" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_5dc469e2-0ae9-40ec-9a1f-6abd03218f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f43b04b2-2d35-4b7c-811a-74a5705b2a98" xlink:href="sesn-20211231.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f43b04b2-2d35-4b7c-811a-74a5705b2a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_cbc78af5-7c00-464d-aef2-d869b06576b9" xlink:href="sesn-20211231.xsd#sesn_SecondIndicationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18289a5b-0a44-4eb9-a89b-0bbc2ac4d632" xlink:to="loc_sesn_SecondIndicationMember_cbc78af5-7c00-464d-aef2-d869b06576b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_10eeb09c-b2b7-4744-8970-546e2489ff0b" xlink:to="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_bc53145d-4d9d-4c9f-b56f-02235b4616a6" xlink:href="sesn-20211231.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:to="loc_sesn_EBI031Member_bc53145d-4d9d-4c9f-b56f-02235b4616a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member_d1fe95c6-0e0e-4db1-b445-070b9d41fc04" xlink:href="sesn-20211231.xsd#sesn_IL6Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03cc4fd6-fb6d-42d2-adfb-7a0765690f35" xlink:to="loc_sesn_IL6Member_d1fe95c6-0e0e-4db1-b445-070b9d41fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1584c96d-eeea-4435-9ed7-e7e5c2aa9082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_76f91586-f045-4c99-90c8-d3b52b282612" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1584c96d-eeea-4435-9ed7-e7e5c2aa9082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2c9256d1-815e-40f0-89bf-e9990a5fb223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1584c96d-eeea-4435-9ed7-e7e5c2aa9082" xlink:to="loc_us-gaap_SubsequentEventMember_2c9256d1-815e-40f0-89bf-e9990a5fb223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5beca2c6-f701-4662-bdc1-1c8ea5721462" xlink:to="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3b95ae2-55d5-417c-9621-1b6b5a169011" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:to="loc_srt_MinimumMember_f3b95ae2-55d5-417c-9621-1b6b5a169011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bff80d5f-6b53-4e56-9acc-88fa4600edd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_06c789f9-3172-41c5-8f14-620114f5f091" xlink:to="loc_srt_MaximumMember_bff80d5f-6b53-4e56-9acc-88fa4600edd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_631d8271-3d9b-4875-9f9c-c4e051cc422c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87c797f1-304e-48b9-bb45-5155449b2579" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_631d8271-3d9b-4875-9f9c-c4e051cc422c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_a99856cf-e6ee-42ae-be51-fc2b0667e77c" xlink:href="sesn-20211231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_631d8271-3d9b-4875-9f9c-c4e051cc422c" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_a99856cf-e6ee-42ae-be51-fc2b0667e77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1e0a06d-cc6e-4bcb-bec1-417fb8b21cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b229ab4f-895e-48e1-8cb2-902c218d3815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1e0a06d-cc6e-4bcb-bec1-417fb8b21cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b6b87fc0-4161-4bd9-97cc-04aa5623d508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1e0a06d-cc6e-4bcb-bec1-417fb8b21cd7" xlink:to="loc_us-gaap_LicensingAgreementsMember_b6b87fc0-4161-4bd9-97cc-04aa5623d508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a4e1c04f-1bc8-4a7c-ba78-2149d1286e48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b42e59dd-3b1d-476f-8695-5215c01dafaf" xlink:to="loc_srt_SegmentGeographicalDomain_a4e1c04f-1bc8-4a7c-ba78-2149d1286e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_2d87841c-07fb-4539-a408-b1896896fa55" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a4e1c04f-1bc8-4a7c-ba78-2149d1286e48" xlink:to="loc_country_TR_2d87841c-07fb-4539-a408-b1896896fa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:href="sesn-20211231.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_5e057b89-a6d3-4ae0-b7cf-aafeb8030734" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_e195a37f-5bbf-4eca-8717-83ab55703520" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_e195a37f-5bbf-4eca-8717-83ab55703520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_2bf18b66-c4ac-4fb0-b210-863cd9ca76b6" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_2bf18b66-c4ac-4fb0-b210-863cd9ca76b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_3d18b9a0-d638-4c57-b03a-89bf66720ea4" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_3d18b9a0-d638-4c57-b03a-89bf66720ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_89ff7c55-dac9-4880-8aac-e12f71da60bb" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_89ff7c55-dac9-4880-8aac-e12f71da60bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_8c78f06f-350d-463c-ae3f-f9e1c0e379c7" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_8c78f06f-350d-463c-ae3f-f9e1c0e379c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_1f5e6e40-9794-4f5a-a14b-451e0d0ee755" xlink:href="sesn-20211231.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_1f5e6e40-9794-4f5a-a14b-451e0d0ee755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a702bc48-2d78-4f2f-b50e-4517261c1430" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a702bc48-2d78-4f2f-b50e-4517261c1430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_4ee860a4-5d29-4a76-b8df-b7588857110e" xlink:href="sesn-20211231.xsd#sesn_LicenseMaintenanceFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseMaintenanceFees_4ee860a4-5d29-4a76-b8df-b7588857110e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_11426108-8928-48c1-b855-f653ccc3d071" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_11426108-8928-48c1-b855-f653ccc3d071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_2460ddb1-734c-406e-819c-cd8919733a27" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_2460ddb1-734c-406e-819c-cd8919733a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_2237b0b0-40e6-4260-9d04-bb6403c9fedf" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_2237b0b0-40e6-4260-9d04-bb6403c9fedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_2367af10-2ff0-445a-bc9e-050ff3ea9b87" xlink:href="sesn-20211231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_2367af10-2ff0-445a-bc9e-050ff3ea9b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_abb7eabd-ab1a-408c-abe6-06b2ba26b905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_abb7eabd-ab1a-408c-abe6-06b2ba26b905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_eb2099a2-2e71-43d9-a594-142066f265ff" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_eb2099a2-2e71-43d9-a594-142066f265ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_375e9594-49f5-4c78-974d-3f25c3eb02f7" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_375e9594-49f5-4c78-974d-3f25c3eb02f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_82f33269-6814-4c08-a0dc-a8e3fa41932b" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_82f33269-6814-4c08-a0dc-a8e3fa41932b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_e0db6d27-0fe8-4f19-9872-c14d1ec7181f" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_e0db6d27-0fe8-4f19-9872-c14d1ec7181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_9ee0ba09-7b5b-4f39-b35d-39f3f4309bcd" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_9ee0ba09-7b5b-4f39-b35d-39f3f4309bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_65ac7f5e-4d2e-4723-9be1-a329eda210d2" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_65ac7f5e-4d2e-4723-9be1-a329eda210d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_a9488ea4-d5c7-4d7b-8fe2-2f37e4239281" xlink:href="sesn-20211231.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_a9488ea4-d5c7-4d7b-8fe2-2f37e4239281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5b6823c6-d49c-4d48-8d49-ae16cdb2d300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5b6823c6-d49c-4d48-8d49-ae16cdb2d300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_412ffc64-cef0-453d-be62-4aee566f302d" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_412ffc64-cef0-453d-be62-4aee566f302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_a364841f-4534-4da9-af4b-1f5bee58e9e7" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_a364841f-4534-4da9-af4b-1f5bee58e9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b50d4b0d-3c6c-4447-827b-c354dbe992b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b50d4b0d-3c6c-4447-827b-c354dbe992b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_ba5853f2-1aa1-4b2b-bbcb-722afdbc6d8a" xlink:href="sesn-20211231.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_ba5853f2-1aa1-4b2b-bbcb-722afdbc6d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_6d6758cc-ad42-43af-9b64-8b3cfba834ba" xlink:href="sesn-20211231.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_44bdf91b-f768-4d6f-b441-1209d6f449ed" xlink:to="loc_sesn_RoyaltyRevenuePercentage_6d6758cc-ad42-43af-9b64-8b3cfba834ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="sesn-20211231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_caa44d39-0c0c-4e4d-b110-7cec0c08d412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_63e1914c-6e98-47a3-be09-54ca74c1e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_caa44d39-0c0c-4e4d-b110-7cec0c08d412" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_63e1914c-6e98-47a3-be09-54ca74c1e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_cf6aeb2f-a39d-4c47-a898-f17ce87a7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_cf6aeb2f-a39d-4c47-a898-f17ce87a7d39" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cf15311e-6ef2-4231-a798-d204d73b2252" xlink:to="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_d1eba3c1-391b-49c5-973d-8689a197d624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:to="loc_us-gaap_MajorityShareholderMember_d1eba3c1-391b-49c5-973d-8689a197d624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_13d9d4b4-7d19-4429-974b-a16f0106fd47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2325495a-817a-4e30-976b-c126b41e06a7" xlink:to="loc_srt_DirectorMember_13d9d4b4-7d19-4429-974b-a16f0106fd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b56f2a0c-2f2b-4329-bde4-44c758586e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_14b2f3c0-35ff-4e64-a730-7c23d897b73a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b56f2a0c-2f2b-4329-bde4-44c758586e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FacilityinWinnipegManitolaMember_4cfd4bde-40af-42cb-abfa-746c8fa5ce18" xlink:href="sesn-20211231.xsd#sesn_FacilityinWinnipegManitolaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b56f2a0c-2f2b-4329-bde4-44c758586e2e" xlink:to="loc_sesn_FacilityinWinnipegManitolaMember_4cfd4bde-40af-42cb-abfa-746c8fa5ce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2aa31f5a-c438-4713-ab1d-cb155208911d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_64be6402-a990-4f03-819a-788d9ac9ebeb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2aa31f5a-c438-4713-ab1d-cb155208911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_a5c7d061-db2d-41eb-a5ab-6665668330ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2aa31f5a-c438-4713-ab1d-cb155208911d" xlink:to="loc_us-gaap_IntellectualPropertyMember_a5c7d061-db2d-41eb-a5ab-6665668330ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7fad6f53-adef-4e58-b49a-67d91d461c2b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_be5867b5-8fd9-4ed5-b9f4-2538bfe294ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_be5867b5-8fd9-4ed5-b9f4-2538bfe294ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4db448e0-4a81-480e-96fa-b127fc896d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06a84348-f530-4f28-a184-05039e3cc68a" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4db448e0-4a81-480e-96fa-b127fc896d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="simple" xlink:href="sesn-20211231.xsd#RESTRUCTURINGANDRELATEDACTIVITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_972d34c2-672a-4211-8561-bc75d0f4ca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_10c8e7b4-af3d-4c80-9663-a47cf29944d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_972d34c2-672a-4211-8561-bc75d0f4ca0c" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_10c8e7b4-af3d-4c80-9663-a47cf29944d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="simple" xlink:href="sesn-20211231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c355c050-b822-4a13-a5a7-ddf08ffcc90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_920451b5-cf8e-4119-93be-df0fe3cfbe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c355c050-b822-4a13-a5a7-ddf08ffcc90b" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_920451b5-cf8e-4119-93be-df0fe3cfbe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6b973e81-172b-44ca-b012-51e0bd89e25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_22239e46-1f8d-4ca0-b392-c707d7703b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6b973e81-172b-44ca-b012-51e0bd89e25e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_22239e46-1f8d-4ca0-b392-c707d7703b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_5d2c88c0-fe22-4501-84e3-947a1ecffb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6b973e81-172b-44ca-b012-51e0bd89e25e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_5d2c88c0-fe22-4501-84e3-947a1ecffb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4c158e7a-4795-4653-a874-2db7601e6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4c158e7a-4795-4653-a874-2db7601e6dfb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_51b1c1f5-8fc4-47c1-a35a-056a3f83ff67" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e0c67934-06a5-4a80-b15a-6c13d994f706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e0c67934-06a5-4a80-b15a-6c13d994f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_6d8601c8-9712-4280-9440-2de2cc72c519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:to="loc_us-gaap_ContractTerminationMember_6d8601c8-9712-4280-9440-2de2cc72c519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_2c2163b4-ca2b-4622-a5df-fb651af6dbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_528c620d-0b38-44bb-8560-e50f8b66c202" xlink:to="loc_us-gaap_OtherRestructuringMember_2c2163b4-ca2b-4622-a5df-fb651af6dbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_369926d9-9906-42fd-b6dd-6c19afc2f8ee" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4a2bc874-d3a3-4dc1-8cf1-f3322dd2d2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_RestructuringCharges_4a2bc874-d3a3-4dc1-8cf1-f3322dd2d2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_614a6328-af98-4381-8310-e34f7bbe1e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_PaymentsForRestructuring_614a6328-af98-4381-8310-e34f7bbe1e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_13444135-2a4f-4906-b2fb-3ac18545cfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_593e0f07-0976-4068-92a7-6808dc97dab2" xlink:to="loc_us-gaap_RestructuringReserve_13444135-2a4f-4906-b2fb-3ac18545cfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_adf0d39b-a70a-48d2-9a6b-791927213c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a4ecbd53-b71f-4a30-a9c6-60b35bd91cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_adf0d39b-a70a-48d2-9a6b-791927213c38" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a4ecbd53-b71f-4a30-a9c6-60b35bd91cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20211231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b239bc0c-ce5f-4cf5-a267-3318a2d61a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b239bc0c-ce5f-4cf5-a267-3318a2d61a26" xlink:to="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_56e0d0bb-f310-4754-9756-0b412c8df025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_255bd2a5-6188-4ac0-94f0-d8806873c0b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_56e0d0bb-f310-4754-9756-0b412c8df025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8f20b738-2842-4bed-ba92-07c4d1bcadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_56e0d0bb-f310-4754-9756-0b412c8df025" xlink:to="loc_us-gaap_SubsequentEventMember_8f20b738-2842-4bed-ba92-07c4d1bcadaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b42c379e-ec06-477c-9f16-59ae916f5b43" xlink:to="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ReviewPeriod_7b99d5a8-2af9-476f-84e3-1ab3129fae5b" xlink:href="sesn-20211231.xsd#sesn_ReviewPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_sesn_ReviewPeriod_7b99d5a8-2af9-476f-84e3-1ab3129fae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfDocumentsReviewed_902b9d63-d5ce-4049-b013-5121c53d80cb" xlink:href="sesn-20211231.xsd#sesn_NumberOfDocumentsReviewed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_sesn_NumberOfDocumentsReviewed_902b9d63-d5ce-4049-b013-5121c53d80cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfInterviews_f4f6e7cd-b6f7-46a5-9b67-df39a303fb20" xlink:href="sesn-20211231.xsd#sesn_NumberOfInterviews"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c2e77643-369d-4ac2-a1bc-49b76df0c005" xlink:to="loc_sesn_NumberOfInterviews_f4f6e7cd-b6f7-46a5-9b67-df39a303fb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>sesn-20211231_g1.jpg
<TEXT>
begin 644 sesn-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UO<F=A;B!6
M87IQ=65Z    !9 #  (    4   0J) $  (    4   0O)*1  (    #-34
M )*2  (    #-34  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C(Z,#(Z,C<@,3$Z,3,Z,3@ ,C R,CHP
M,CHR-R Q,3HQ,SHQ.    $T ;P!R &< 80!N "  5@!A 'H <0!U &4 >@
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" ++ T(# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M\._\^6J?]^H__BZ\/HH_L;"=G]X>SB>X?\+J\._\^6J?]^H__BZ/^%U>'?\
MGRU3_OU'_P#%UX?11_8V$[/[P]G$]P_X75X=_P"?+5/^_4?_ ,71_P +J\._
M\^6J?]^H_P#XNO#Z*/[&PG9_>'LXGN'_  NKP[_SY:I_WZC_ /BZ/^%U>'?^
M?+5/^_4?_P 77A]%']C83L_O#V<3W#_A=7AW_GRU3_OU'_\ %T?\+J\._P#/
MEJG_ 'ZC_P#BZ\/HH_L;"=G]X>SB>X?\+J\._P#/EJG_ 'ZC_P#BZ/\ A=7A
MW_GRU3_OU'_\77A]%']C83L_O#V<3W#_ (75X=_Y\M4_[]1__%T?\+J\._\
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M!J/[.R[FY>;7_$') ]2_X75X=_Y\M4_[]1__ !='_"ZO#O\ SY:I_P!^H_\
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M_"ZO#O\ SY:I_P!^H_\ XNO#Z*/[&PG9_>'LXGN'_"ZO#O\ SY:I_P!^H_\
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MPQ::/=)JGB3P](%MM2M\36V,&"9<EA[9W#C\1D$8\>E\:^()H]022_RNI?\
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M'7Q[7VO\3EM'^'.J+J-FE[;'RM]O([H'_?)CE"&&#@\'M7S[]E\*?]"=9?\
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MUO)%*Q)8[U!."23QCJW4' U_LOA3_H3K+_P-NO\ X[1]E\*?]"=9?^!MU_\
M':2RVJE;E_'_ ((>RF49OC+JA^($'B*STVTM[2"S_LY=+^]$;7.?+)XYS@Y
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M$36YEM/[2:/RQ$@4#>J9.2 >,>G-'V7PI_T)UE_X&W7_ ,=H^R^%/^A.LO\
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M_%=)KG7[;7_#T6K:#K5Z;XZ;)=-&UO*6!RDRC/8 \<X[98&_]E\*?]"=9?\
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MO_CM'V7PI_T)UE_X&W7_ ,=H^I8C^7\5_F'L9'E5%>J_9?"G_0G67_@;=?\
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MP8Q1LX#/MZX'4XR,X]:/KV*_Y^/[PYI=SD_^%6>%O^?6X_\  AJ/^%6>%O\
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M ,"&H_X59X6_Y];C_P "&KL**/KV*_Y^/[PYI=SC_P#A5GA;_GUN/_ AJ/\
MA5GA;_GUN/\ P(:NPHH^O8K_ )^/[PYI=SC_ /A5GA;_ )];C_P(:C_A5GA;
M_GUN/_ AJ["BCZ]BO^?C^\.:7<X__A5GA;_GUN/_  (:C_A5GA;_ )];C_P(
M:NPHH^O8K_GX_O#FEW./_P"%6>%O^?6X_P# AJ/^%6>%O^?6X_\  AJ["BCZ
M]BO^?C^\.:7<X_\ X59X6_Y];C_P(:C_ (59X6_Y];C_ ,"&KL**/KV*_P"?
MC^\.:7<X_P#X59X6_P"?6X_\"&H_X59X6_Y];C_P(:NPHH^O8K_GX_O#FEW.
M/_X59X6_Y];C_P "&H_X59X6_P"?6X_\"&KL**/KV*_Y^/[PYI=SC_\ A5GA
M;_GUN/\ P(:C_A5GA;_GUN/_  (:NPHH^O8K_GX_O#FEW./_ .%6>%O^?6X_
M\"&H_P"%6>%O^?6X_P# AJ["H!)<2R3K;112&$@%6EVL<J#TQ[XZ]J/KV*_Y
M^/[PYI=SEO\ A5GA;_GUN/\ P(:C_A5GA;_GUN/_  (:NL9;T;@L-N[JN[8)
MSD^G\/?!H9;T;@L-N[JN[8)SD^G\/?!H^NXK_GX_O#FEW.3_ .%6>%O^?6X_
M\"&H_P"%6>%O^?6X_P# AJZQEO1N"PV[NJ[M@G.3Z?P]\&AEO1N"PV[NJ[M@
MG.3Z?P]\&CZ[BO\ GX_O#FEW.3_X59X6_P"?6X_\"&H_X59X6_Y];C_P(:NL
M9;T;@L-N[JN[8)SD^G\/?!H9;T;@L-N[JN[8)SD^G\/?!H^NXK_GX_O#FEW.
M3_X59X6_Y];C_P "&H_X59X6_P"?6X_\"&KK&6]&X+#;NZKNV"<Y/I_#WP:&
M6]&X+#;NZKNV"<Y/I_#WP:/KN*_Y^/[PYI=SD_\ A5GA;_GUN/\ P(:C_A5G
MA;_GUN/_  (:NL9;T;@L-N[JN[8)SD^G\/?!H9;T;@L-N[JN[8)SD^G\/?!H
M^NXK_GX_O#FEW.3_ .%6>%O^?6X_\"&H_P"%6>%O^?6X_P# AJZQEO1N"PV[
MNJ[M@G.3Z?P]\&AEO1N"PV[NJ[M@G.3Z?P]\&CZ[BO\ GX_O#FEW.3_X59X6
M_P"?6X_\"&IJ?"_PLX)^R7 P2.+ANU=<RWHW!8;=W5=VP3G)]/X>^#31%>QA
MU6*W=QE]@G.><X_A]C1]=Q7_ #\?WAS2[G*_\*L\+?\ /K<?^!#4?\*L\+?\
M^MQ_X$-76,MZ-P6&W=U7=L$YR?3^'O@T,MZ-P6&W=U7=L$YR?3^'O@T?7<5_
MS\?WAS2[G)_\*L\+?\^MQ_X$-1_PJSPM_P ^MQ_X$-76,MZ-P6&W=U7=L$YR
M?3^'O@T,MZ-P6&W=U7=L$YR?3^'O@T?7<5_S\?WAS2[G)_\ "K/"W_/K<?\
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M6\3Z8-<DTA3>2W<+I'*(;">2.-G 9=TBH47A@<D\=ZV526UA6/.=?.OD7O\
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MHHN LFI0%9,B=E*\*EO(&SSWQ]/3ZT2:E 5DR)V4KPJ6\@;//?'T]/K2447
M634H"LF1.RE>%2WD#9Y[X^GI]:)-2@*R9$[*5X5+>0-GGOCZ>GUI**+@+)J4
M!63(G92O"I;R!L\]\?3T^M$FI0%9,B=E*\*EO(&SSWQ]/3ZTE%%P%DU* K)D
M3LI7A4MY V>>^/IZ?6B34H"LF1.RE>%2WD#9Y[X^GI]:2BBX"R:E 5DR)V4K
MPJ6\@;//?'T]/K2/J=NR2?Z]UVX"I!(&SSGG'T],>M%1P_=;_?;^=%P)9-2@
M*R9$[*5X5+>0-GGOCZ>GUHDU* K)D3LI7A4MY V>>^/IZ?6DHHN LFI0%9,B
M=E*\*EO(&SSWQ]/3ZT2:E 5DR)V4KPJ6\@;//?'T]/K2447 634H"LF1.RE>
M%2WD#9Y[X^GI]:)-2@*R9$[*5X5+>0-GGOCZ>GUI**+@+)J4!63(G92O"I;R
M!L\]\?3T^M(^IV[+)_KW7;C:D$@;/?G'T],>M%1Q=9/]_P#H*+@2R:E 5DR)
MV4KPJ6\@;//?'T]/K1)J4!63(G92O"I;R!L\]\?3T^M)11<!9-2@*R9$[*5X
M5+>0-GGOCZ>GUHDU* K)D3LI7A4MY V>>^/IZ?6DHHN LFI0%9,B=E*\*EO(
M&SSWQ]/3ZT2:E 5DR)V4KPJ6\@;//?'T]/K2447 634H"LF1.RE>%2WD#9Y[
MX^GI]:9-J'G*\5H'9F&W+1NFSU))Q[8 Y_HZHX_]=+]1_(47 6*(1*>2S,<L
M[=6/J:?112 **** "BBB@ JU;?ZL_6JM6K;_ %9^M $M%%% #9&VH21GVJ'S
MU_YYBI)_]2U5* )_/7_GF*//7_GF*@HH G\]?^>8H\]?^>8J"B@"?SU_YYBC
MSU_YYBH** )_/7_GF*//7_GF*@HH G\]?^>8H\]?^>8K*AUO2KG3IK^WU.SE
MLX"PEN8[A&CCV\MN8' QWSTIUAJ^FZKO_LO4+6]\L*7^SSK)M##*D[2<9'(]
M13LP-/SU_P">8H\]?^>8JE]MM1?BQ^TP_:S%YPM_,'F&/.-^WKMR<9Z9J:D!
M/YZ_\\Q1YZ_\\Q4%% $_GK_SS%'GK_SS%59IXK:WDGN)$BAB4O))(P544#))
M)X  [UE0^+_#=Q&SV_B'2I4569F2]C8 * 6)PW0 @GTR*=F]@-_SU_YYBCSU
M_P">8JM'(DL:R1.KHX#*RG(8'H0:=2 G\]?^>8H\]?\ GF*@HH G\]?^>8H\
M]?\ GF*@HH G\]?^>8H\]?\ GF*@HH G\]?^>8H\]?\ GF*@HH G\]?^>8H\
M]?\ GF*@JA-KVD6VJ1Z9<:K917\N/+M)+A%E?/3"$Y.?I3LV!K>>O_/,4>>O
M_/,5D7^OZ-I=W%:ZGJUC9W$P!CAN+E(W<$X& 2">>*-2U_1]&DB35]6L;!YL
MF-;JY2(OCKC<1GJ*+,#7\]?^>8H\]?\ GF*@HI 3^>O_ #S%'GK_ ,\Q4%%
M$_GK_P \Q1YZ_P#/,5!10!/YZ_\ /,4>>O\ SS%05%;W,%Y )K2>.>(DJ'B<
M,I()!&1Z$$'W% %SSU_YYBCSU_YYBH** )_/7_GF*//7_GF*@HH G\]?^>8H
M\]?^>8J"B@"?SU_YYBCSU_YYBH*B@NH+I7:UGCF5':-C&X8*ZG#*<="""".Q
M% %SSU_YYBCSU_YYBH** )_/7_GF*//7_GF*@HH G\]?^>8H\]?^>8J"B@"?
MSU_YYBCSU_YYBH** )_/7_GF*//7_GF*@HH G\]?^>8H\]?^>8J"B@"?SU_Y
MYBCSU_YYBH** )_/7_GF*//7_GF*@HH G\]?^>8H\]?^>8J"N0\2_$.R\,ZP
M=/NK*>9_+60/&5Q@_7Z5K2I3K2Y::NQI-[';>>O_ #S%'GK_ ,\Q7F?_  N3
M2_\ H&WGYK_C1_PN32_^@;>?FO\ C75_9V+_ )&/DEV/3//7_GF*//7_ )YB
MO,_^%R:7_P! V\_-?\:/^%R:7_T#;S\U_P :/[.Q?\C#DEV/3//7_GF*//7_
M )YBO,_^%R:7_P! V\_-?\:/^%R:7_T#;S\U_P :/[.Q?\C#DEV/3//7_GF*
M//7_ )YBO,_^%R:7_P! V\_-?\:/^%R:7_T#;S\U_P :/[.Q?\C#DEV/3//7
M_GF*//7_ )YBO,_^%R:7_P! V\_-?\:/^%R:7_T#;S\U_P :/[.Q?\C#DEV/
M3//7_GF*//7_ )YBO,_^%R:7_P! V\_-?\:/^%R:7_T#;S\U_P :/[.Q?\C#
MDEV/3//7_GF*;'<JP.(@,,17FO\ PN32_P#H&WGYK_C34^,.EH#_ ,2V\.6)
MZKW_ !H_L[%_R,.278].\]?^>8H\]?\ GF*\S_X7)I?_ $#;S\U_QH_X7)I?
M_0-O/S7_ !H_L[%_R,.278],\]?^>8H\]?\ GF*\S_X7)I?_ $#;S\U_QH_X
M7)I?_0-O/S7_ !H_L[%_R,.278],\]?^>8H\]?\ GF*\S_X7)I?_ $#;S\U_
MQH_X7)I?_0-O/S7_ !H_L[%_R,.278],\]?^>8IJ7*L6Q$!AL?6O-?\ A<FE
M_P#0-O/S7_&FI\8=+4M_Q+;P[FSU7_&C^SL7_(PY)=CT[SU_YYBCSU_YYBO,
M_P#A<FE_] V\_-?\:/\ A<FE_P#0-O/S7_&C^SL7_(PY)=CTSSU_YYBCSU_Y
MYBO,_P#A<FE_] V\_-?\:/\ A<FE_P#0-O/S7_&C^SL7_(PY)=CTSSU_YYBC
MSU_YYBO,_P#A<FE_] V\_-?\:/\ A<FE_P#0-O/S7_&C^SL7_(PY)=CTSSU_
MYYBFK<J7<>4!M(Y]>*\U_P"%R:7_ - V\_-?\::OQATM7=O[-O/F.>J\<?6C
M^SL7_(PY)=CT[SU_YYBCSU_YYBO,_P#A<FE_] V\_-?\:/\ A<FE_P#0-O/S
M7_&C^SL7_(PY)=CTSSU_YYBCSU_YYBO/-/\ BUI%[?Q6\MK<6RR-CS9"NU?K
MBN[1UD0.A#*PR".]<U:A5HNU2-A--;ECSU_YYBCSU_YYBH**Q$3^>O\ SS%2
MQ.'7(&.:IU:MO]6?K0!+1110!'/_ *EJJ5;G_P!2U5* "BBB@ HHHH ***BN
M;F&SM9;FY<1PPH7=SV Y)H EHJ@^MZ='JEGILMR([V^B>:W@=2K.JXW'!'!&
MX<'!Z^AQ>=UCC9Y&"HHRS,< #UIV8'DOBOP1K4OC2;2M%4IX:\4S)<:LR*?]
M'>,[I,$?=,F%Y[G-3:W%XFM];UV#3X]731(]1TU-MGY@9+,0@2BV Y^_MW>7
MSUKTRWU"WNS#]F9Y$GA$\<BQ-Y;(<8._&W/(XSG'.*HMXGTP:Y)I"F\ENX72
M.40V$\D<;. R[I%0HO# Y)X[ULJDMK"L><Z^=?(O?^$8'B<67_"/7'V;S_M/
MF_:/M@Q]_P"??LSMS\VS':FZE;>,;-==M-)DUEK-9M-D\R5III/*9&^T^42P
M=CN"Y1&!&2!MS7K5S=065K)<WD\=O!$I:265PJH!U))X K/TOQ+INL3"*S:Z
M1V3S$6ZLIK?S%XR4\Q%W 9&<9QD9ZBA5';8+' 0R>(-,NO#]PUYKFIZ;%<WR
M3LNGW,;;7A!A5HG9Y657W /)R/7&&.7I5AXLO["W759?$D;1>%99!BXN8F-Z
M)GV;B""TFW'RGDC'!%>H'Q9H8T.^U@:@C6%A))%<S(C-Y;(VUA@#)P?0'(P1
MD5+-XDT>"ZTNWDOXO-U;)L53+>> N[(QGC'.3QR/6GSR[ <?X2C\0V_BC1WU
M!]6E@OO#RSZA]K,C1QWFY#C!^6-L%AM ' Y&>:?J_P +$U:+3T?5VB^QB13M
MM\^:KR,Y4_-T^;!'M7H%4=7UJQT.UCN-1>54EE6&,10/,SNW10J*6)./2H]I
M*]XA8GL+7[#IMM:;]_D1+'NQC=M &<=NE3USUSXXT:S2%KI-5B$[!(]^C7@W
M,20%_P!5]XD<#J?QJ\_B+3(AIWVB=[9M3E,-I'<0/$\CX)P5905X!^\!V]1F
M'&789IT5!!>V]S<7$$+YEMG"2H5*E21D'GJ"#P1P>?0U/4@%%%% !1110 44
M44 %>7^++.^;Q=K36\&J3/-%8/9VL5BSVMY-%(S!990AV!6VDG>@P3G(XKU"
MBKC+E=P.,L+B/0-0UNWUG2KZXGO[MYEN;>PDN4NXFXC0LBL%V+^[VOM QD<'
M-5#/<^'KW7W;3+F*\OWCELKM=,EOHS$(U @98#E=A#C!(7YMP)R:[ZHKBX2U
MC#R+(P+JF(HFD.6( X4$XYY/0#DX I\_D(XS4)?%,WP^'D:5#8RKIL$NRPGD
M2>.0!&>)(0G &'4 .3P!CFL:1=<UO49F5O$$%A+?WKH!]HMF\L6T1B'\+*OF
M D#C)R.Y!]1HH52W0+'FMA8>*=2M-1OFN=5@U2'2[9K&*65XH6N6M2'RA^5C
MO(R#P& Z<YH1IK$7A;='J6NWTGVF.4:>^GZE:O)^[(:$SEWD3)PV_=Y89<$8
M;CU6>X2W\OS!(?,<1KY<3/@GUV@X'N< >M257M'V"QY4MWKEQKFJCP[)J\FK
M1ZE<Q@3O*]G'"+?**=Y,(;S"F-OS>ORYI9H];ETV:/0V\2I;O#8K<->&X$ZW
M!ND\TQF3YL>5OW[/W>,8_BKT&3^R_#-G>7TG^C03W'G7#_,^Z1RJ9QR>3M''
M%6IM1M;?4;6QFEVW-V',*;2=X0 MSC QD=:?M.R \]":S;75C"QUFZBMM6N8
MH[-FNU,T!E79(URO78,X$K%74D=0#4FE:?XID_LX23ZD+?499XM0:>=U>U6*
MY=XV0'E?,CS'D8XV'L*]#GGCM;:6>=ML42%W;&< #)/%5'US3X]/LKY[C%M?
M/$EN^QOG:4@(,8R,Y'7&.^*GG;V0''^!8M=77KF37M1OFN&247%E-8W*PAA+
M\KI,[M#]WHL87*MR,KQ6DM_$\7B*>[L)-4:674[V"-)GD-NL(M&:([#\@7S@
MN&QU.,]J](HI>TUO8+'E,L>NRZ:\>BMXD2)X+);QKLSB9;DW47F&,OSCR_,W
M[/W>,8XS74:#_P )#:V-U:+:M/;0W]S&DU_>2B=8-^4*;D8R\$X+,.@YKKJ*
M'4NK6"QY!;:?XIBT**9KGQ&]S'HMG>;'FF):\\TAU(/).P &/H0<LI;YJU'N
M->_MF:QDFUNV$=SJ;O=1VD\L<<3J3;LN 5DVY^5!G!&,"O2Z*KVM^@6/,K,7
M\D6EIK<7B*UT[R)D\RREO9'>X#J%E<<SJI7)5)/E7D'/!.;=6'B.*XEC6ZU/
M2+"2_P!2D2>UT^ZN&65KIF1S'"ZD@H<J7#(><CD5Z_11[7R"PB$F-2QR<#)V
MXS^!Z4M%%8C"L^+7=,F\03Z''=H=3MX%N)+8@AA&QP&&1@C/!QG&1G&16A7F
M6NC0QX\UV;4O$6EZ+J,<-FVG74M]"LL$RK+NW1E@VPJZAE8 ,K<=B.BA255M
M/M^J0F['9S>+]$@M?/:\9P;J6S2.*"2262:-BKJD:J7?:5.2H(P,].:KW?CO
M0K&P^V73WZ0*2)&_LNZ)@(QQ(!'F,D,I < D,",@@UYOX=\16>BSP:[?:GH%
MQ=F?4!<Z?;ZU:ET6XN!*KPLT@4] "&*D@@]1M/0>)/&^B>)? .J6T>JZ/:7<
MX"P6LVL6ID8 J<L5D**<AN QX .025':\$HS4;-J^]UW]/QV)YM#JIO'&A6L
M<+W<]U;>=DA;C3[B-D4$ NZL@*("RC>P"\]:N0>)-+N-;.DI-*MW\^T26TB)
M+L(#A)&4(Y7/(4DCGT->=>,_$6BW>I:C+I6NZ'?)JVBOI)/]KVR"U<LV)'#.
M"4Q(2=N6^0#'/"2^+M%U#Q5;P76LV]K8:?:M:V.HV^KZ?G>Z[7N#F8L/E "C
M8?O$D= $L&G%-)[/^K6_K<.8],M]:TZZGOXK>\B=].;9=X/$)V[L$].G)].]
M9DOCOPY#!9SMJ.Z&\B\^*2."1U6+<%\QRJD1IDXW/M'7G@UYKI.F^%()=;TZ
M?XB00Z9-<V\D++J6GDW02)=QD&PALOD,&'S8R=V234MH]'/@W1],_P"$TL+6
M^N+(Z=JLO]KV)C2U)):-EPVX@,X0I@_.Q9^!5K T[ZM].GE?M_6PN9GKZ>*=
M*DU273A+.+J-9&"-:2J)?+.'$;%<2E2>0A8U!_PFNA"QDNFN+A!'<+;- ]E.
MMQYK ,J" IYA)4Y&%Z9/0&N+;Q]HDWCQ;NYN+,V&F020Z>\>L6!61F'SRMFX
M##(545<<9);&?ESAK7A^XLM7OUURTL[HW\=[I<)UVR-VDJQ",EY6>1-AW.,,
M9-J$A5^ZHA8)?:3Z=5U?I_PVH^8]:T[4+75M.AOM/F$UO.NY' (_ @\@@\$$
M @@@@$59KG/ 2V47A"W@L-9M-9:)Y#=7=I,DB-<2.99.5X'S2$XXX(XKHZ\^
MK%0FXK9,I;!11168PKQ#XL_\CM_V[1_S->WUXA\6?^1V_P"W:/\ F:]C)O\
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M!YO^^E_QKZ$Q1BC^W,3_ "Q^Y_YA[61\]_\ " ^*/^@/-_WTO^-'_" ^*/\
MH#S?]]+_ (U]"8HQ1_;F)_EC]S_S#VLCY[_X0'Q1_P! >;_OI?\ &D'@+Q.>
MFD3'_@2_XU]"XJ*$?*W^^W\Z/[<Q/\L?N?\ F'M9'@'_  @/BC_H#S?]]+_C
M1_P@/BC_ * \W_?2_P"-?0F*,4?VYB?Y8_<_\P]K(^>_^$!\4?\ 0'F_[Z7_
M !H_X0'Q1_T!YO\ OI?\:^A,48H_MS$_RQ^Y_P"8>UD?/?\ P@/BC_H#S?\
M?2_XT?\ " ^*/^@/-_WTO^-?0F*,4?VYB?Y8_<_\P]K(^>_^$!\4?] >;_OI
M?\:0> O$YSC2)CCK\R_XU]"XJ*(',G^__04?VYB?Y8_<_P#,/:R/ /\ A ?%
M'_0'F_[Z7_&C_A ?%'_0'F_[Z7_&OH3%&*/[<Q/\L?N?^8>UD?/?_" ^*/\
MH#S?]]+_ (T?\(#XH_Z \W_?2_XU]"8HQ1_;F)_EC]S_ ,P]K(^>_P#A ?%'
M_0'F_P"^E_QH_P"$!\4?] >;_OI?\:^A,48H_MS$_P L?N?^8>UD?/?_  @/
MBC_H#S?]]+_C2?\ "!>)R2!I$V1U^9?\:^A<5%&/WTOU'\A1_;F)_EC]S_S#
MVLCP#_A ?%'_ $!YO^^E_P :/^$!\4?] >;_ +Z7_&OH3%&*/[<Q/\L?N?\
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M7_Y^IO\ OPU'_"TO"_\ S]3?]^&H^IXG_GW+[F'++L=Q]I/]T4?:3_=%</\
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MH+(O;.,UF7WA*[U+Q1=7$J6EI8WEO+;7LUI,ZRWT;1E$62/;M#)N.)-S' P
M V!>L;7Q(+6+2]4CTN2T5/)EO8II!),F,?ZG8 C$?]-& ]^E:M1MH(DL/%::
MG)%)9:1J<FG3.%BU(1Q^2X)P&"[_ #=I/&[9C'S9V_-2_P#"6V'_  BD?B#R
MKC[))(L83:OF9:41#C./O'/7I^50:-9^)=)M;/2673)[*T"1+?F:02M"N ,P
M!-N_:-N?,QGYL?P5A+\,;1/!T-HNFZ0-<CN(YC?B ;CBX$A_>;-V=@(_3I1:
M%]0.AL/&NDZC%K36YF$NBR3)<P.@#D1EE+*,X*DHP!SU!!P:V;&[CU#3[>\A
M#+'<1+*@<8(# $9]^:XNZ\ W4VA:@+:Y@MM9:ZOYK2Y4DH8KB1V\F7C)4AAG
MKM8!AD@9Z_2+233]$L;.8JTEO;QQ.4.02J@''MQ2DH_9 N4445F,**** "BB
MB@ HHHH **** "BBB@# D\70*L\]OIFHW6GV\A26_@C0Q+M.'(4L)'"G.2BL
M.#C.#5_3]:M-3OKJVM"S_95B<R<;'61=RE2#SQ6-!I/B'2]-DT?2SISV99Q!
M>3R.)8(V8G!B"D2%<G!WKGC..24LO#^I>&IY/^$?BM+R&6UMX-M[=/"T?DIL
M!RL;[LC'I@COG@ GT[QK9:LT/V"QOI4>&.:5PJ8MUD+!-XWYY*GE0P Y) R:
MGT#Q5;>(+B>*WADC,2JX+LN&4@8(Y^8<_>7<A_A9JQX_!M]9?V'#8/:9TQ8E
M.I%GCG**V9(]@!#H_/!8;<YY(S78QQ1Q%S%&J%VW/M4#<WJ?4\4 /HHHH **
M** "BBB@ KQ#XL_\CM_V[1_S->WUXA\6?^1V_P"W:/\ F:]C)O\ >UZ,TI_$
M<31117VQTA1110 4444 :=IH;SZ<+^[O;73[5Y#'%)<ESYK 9;:J*S$#C)QC
MD#.:C.B:@\ER+.WDOHK7F2>T0RQA<9#%@.!CGG!'.<$&KL6I:=?:#:Z;J[75
MLUB[F">VB67<CG+*RLR\@C(8'N1CO6EI?B/1[!+-!_:42Z9>M=6XB"?Z5E5&
M).1L.4ZC=A6*\XR>.52K&[2N_P /+[_P^1-V8$6@ZO-#'+#I5[)'+CRW2W<J
M^>F#CG.*0:)JIMYYQIEX8;=F6:06[[8BOW@QQ@$=\]*Z.Z\9P3Z9-;1K<0F3
M25LA'& L:2>=O; W<*5X]>V*WKWQ/IIM;3Q%B[Q_:%T\$'EKF5C!&I#MN^49
M] V1FLI8BO%ZPWO_ %\Q79PMSX9U2"X:*&UDO#'!'<2-:QM(L:.F\;CCCC^1
MI;GPOK=K)91R:;<M)?1^9 B1,S,.3C '4 9([ C.*Z@>/+0VRPPO<6+Q&WDC
MN18PW+!D@$;#:[ +RN0P.<$\<U7@\7Z:LT%Q*+GSGTD:;.#:12JA&")%#-A\
MD %2!P3S0JV)ZQ_/M_7Y!>1@:1X6U;6=0>TMK.5&B9DFDEB<) P!)#D [3QC
M![U-KGAY-'T72KH745Q+>"0R^3.DB(1C"@J>HS@^^0/4[]GXUT_[?!<ZG<7\
M\EI<R3(\5G%&+G?"L?SH' 5EVX!&<CTKAGGEDACB>5VBBSY:%B53/7 [9K2G
M*O.I>6B7X[]?N8U=L91117:4%%%% !1110!Z;\/OB"86CTC7)24)VP3L>G^R
M?\__ %_4X"&\PJ<@OD$=^!7SCH6A7GB'4DL[%"23\[D<(/4U]!:%IYTO2H[-
MIWG,/RF20Y)X%?&9Q0H4JJ=-ZO='-423T-&BBBO$,PHHHH **** "HX_]=+]
M1_(5)4<?^NE^H_D* )**** "BBB@ HHHH *M6W^K/UJK5JV_U9^M $M%%% $
M<_\ J6JI5R8$Q$#FJNQO[I_*@!M%.V-_=/Y4;&_NG\J &T4[8W]T_E1L;^Z?
MRH ;7+:]'>6OC"RO[3R=\NFW-E;M<,5C6X9HGC#$ D!O+;U^Z!WKJ]C?W3^5
M&QO[I_*FG9@>=CX<ZCIUO;G3-<FO)OLD]E<QWWEI&\<JLS,#''N+"4A_F+<;
MAD9S2_\ "":I;A9K-K!I;==+,$+2,B,UMN$BE@AV@@C! /09 KT/8W]T_E1L
M;^Z?RJ_:2%8Y?1O#NI6EU=W%QJ<EI]HU%[QK:S,<D<JLJ#8[21;NJD?*5X/K
MTXF[\+7OA;X?^1)H.@Q74<UC&;^TN&\VZ?[;"0)/W"D*>YW-C X->O;&_NG\
MJ-C?W3^5"J-,+'$6GA;6K"^;7K9K :O)<7#RV1D?[.T4IBS&)=FX,/)1]^SE
MBPVX.1:U+1/$'B.2P34[FVTJWM[C[4PTZ7SI Z >4-TL6UAN+,<H,%5 !^]7
M6[&_NG\J-C?W3^5+G>XS@].\"7MG?65K=7,.H:/9W%RZ"Y/[UXIXBK1LJH$P
M'9NF!M;&!CG8T?PM%H?B5[C38H+?3%TN"Q@@C)W(8Y)7)/'0B0<Y))SGU/2;
M&_NG\J-C?W3^5#G)@<W;^#;2V\63:XMYJ#-)$B"%K^X90RN[$G,A!4[\!"-J
MX.!R:H>)?"L^J>+(=4_L31-:MTLOLWD:I*5V/OW;E_<R#IQVKL]C?W3^5&QO
M[I_*A3=[@8;:5='QE'K.8?+736M3'O.[S#(K^GW>.O7VKG+?P-JEB]GK)UQY
M-5@NVO;B"0QK:DRX$Z!A'YFW9PI8G&Q3@8X[_8W]T_E1L;^Z?RH4V@.4\+:-
M9W,,NK7EE;S22ZC<W=A-)$K/%&[_ "LC$97> &X[,,^E=33MC?W3^5&QO[I_
M*ID[NX#:*=L;^Z?RHV-_=/Y4@&T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_
M*@!M%.V-_=/Y4;&_NG\J &T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_*@!M
M%.V-_=/Y4;&_NG\J &T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_*@!M%.V-
M_=/Y4;&_NG\J &T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_*@!M%.V-_=/Y
M4;&_NG\J &T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_*@!M%.V-_=/Y4;&_
MNG\J &T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_*@!M%.V-_=/Y4;&_NG\J
M &T4[8W]T_E1L;^Z?RH ;13MC?W3^5&QO[I_*@!M>3?$;PMK6L^+#<Z9I\MQ
M"($3>I &1GU/O7K>QO[I_*C8W]T_E73AL3/#5/:0W\RHR<7<^>O^$!\4?] >
M;_OI?\:/^$!\4?\ 0'F_[Z7_ !KZ%V-_=/Y4;&_NG\J]3^W,3_+'[G_F7[61
M\]?\(#XH_P"@/-_WTO\ C1_P@/BC_H#S?]]+_C7T+L;^Z?RHV-_=/Y4?VYB?
MY8_<_P#,/:R/GK_A ?%'_0'F_P"^E_QH_P"$!\4?] >;_OI?\:^A=C?W3^5&
MQO[I_*C^W,3_ "Q^Y_YA[61\]?\ " ^*/^@/-_WTO^-'_" ^*/\ H#S?]]+_
M (U]"[&_NG\J-C?W3^5']N8G^6/W/_,/:R/GK_A ?%'_ $!YO^^E_P :/^$!
M\4?] >;_ +Z7_&OH78W]T_E1L;^Z?RH_MS$_RQ^Y_P"8>UD?/7_" ^*/^@/-
M_P!]+_C1_P (#XH_Z \W_?2_XU]"[&_NG\J-C?W3^5']N8G^6/W/_,/:R/GK
M_A ?%'_0'F_[Z7_&D'@+Q.>FD3'_ ($O^-?0VQO[I_*HX8W"ME&'SGM[T?VY
MB?Y8_<_\P]K(^?O^$!\4?] >;_OI?\:/^$!\4?\ 0'F_[Z7_ !KZ%V-_=/Y4
M;&_NG\J/[<Q/\L?N?^8>UD?/7_" ^*/^@/-_WTO^-'_" ^*/^@/-_P!]+_C7
MT+L;^Z?RHV-_=/Y4?VYB?Y8_<_\ ,/:R/GK_ (0'Q1_T!YO^^E_QJ6U^'?B6
MXNHXI=-D@1VPTKD84>O!KZ V-_=/Y4;&_NG\J3SS$M;+[G_F'M)&+X:\-6?A
MK35MK109",R2GJYK4BZR?[_]!4VQO[I_*HXHW!DRC#+^GL*\6<Y3DY2=VS(=
M13MC?W3^5&QO[I_*I ;13MC?W3^5&QO[I_*@!M%.V-_=/Y4;&_NG\J &U''_
M *Z7ZC^0J;8W]T_E4:1N)9<HW)&./:@!U%.V-_=/Y4;&_NG\J &T4[8W]T_E
M1L;^Z?RH ;13MC?W3^5&QO[I_*@!M6K;_5GZU7V-_=/Y58MP1&<C'/>@"6BB
MB@#!\:ZS<^'_  ?>ZG8",W$'E[/,7*_-(JG(^A->3?\ "X_$W]RQ_P"_)_\
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M2.FV.U+$A>-S!6)4$Y.<'Y1N]0.>*RYI7BKZ=&]]B?<)?^%Q^)O[EC_WY/\
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MTK/^Q6G_ #Z6_P#WZ7_"O:P&9K"4G3<;W=]_0TC/E5CY@HKZ?^Q6G_/I;_\
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M^E_PH_MZ/_/O\?\ @![7R/F"BOI_[%:?\^EO_P!^E_PH^Q6G_/I;_P#?I?\
M"C^WH_\ /O\ '_@![7R/F"BOI_[%:?\ /I;_ /?I?\*/L5I_SZ6__?I?\*/[
M>C_S[_'_ ( >U\CY@HKZ?^Q6G_/I;_\ ?I?\*/L5I_SZ6_\ WZ7_  H_MZ/_
M #[_ !_X >U\CY@HKZ?^Q6G_ #Z6_P#WZ7_"C[%:?\^EO_WZ7_"C^WH_\^_Q
M_P" 'M?(^8**^G_L5I_SZ6__ 'Z7_"C[%:?\^EO_ -^E_P */[>C_P ^_P ?
M^ 'M?(^8**^G_L5I_P ^EO\ ]^E_PH^Q6G_/I;_]^E_PH_MZ/_/O\?\ @![7
MR/F"BOI_[%:?\^EO_P!^E_PIO]GV1<.;*VW $ ^2N0#U[>PH_MZ/_/O\?^ '
MM?(^8J*^G_L5I_SZ6_\ WZ7_  H^Q6G_ #Z6_P#WZ7_"C^WH_P#/O\?^ 'M?
M(^8**^G_ +%:?\^EO_WZ7_"C[%:?\^EO_P!^E_PH_MZ/_/O\?^ 'M?(^8**^
MG_L5I_SZ6_\ WZ7_  H^Q6G_ #Z6_P#WZ7_"C^WH_P#/O\?^ 'M?(^8**^G_
M +%:?\^EO_WZ7_"C[%:?\^EO_P!^E_PH_MZ/_/O\?^ 'M?(^8**^G_L5I_SZ
M6_\ WZ7_  H^Q6G_ #Z6_P#WZ7_"C^WH_P#/O\?^ 'M?(^8*UM#\3ZQX;:<Z
M+>?9OM&WS?W:/NVYQ]X'U/YU]$_8K3_GTM_^_2_X4?8K3_GTM_\ OTO^%3/.
MZ<X\LZ5UZ_\  %[1/H>&Z9XUEMI-7U74)[JZUR\MOLUO)M41Q*2,MUX(QP N
M./>LNV\7:Y9Z!)HMM?&/3Y%96A$:<AOO#=C=SGUKZ&^Q6G_/I;_]^E_PH^Q6
MG_/I;_\ ?I?\*Q6;4%?]UVZKIM;3H+VB['@7_"?>)REFO]K28LB#"=B9&%V\
MG&6X/\6<]ZCO/&WB&_N)9[O46D>:T>S?]T@!B<Y9<!<#.!R.>!S7T#]BM/\
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MQU/-?2'V*T_Y]+?_ +]+_A1]BM/^?2W_ ._2_P"%5'.*$7>-%)_+_(?M%V/
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MVOD?,%%?3_V*T_Y]+?\ []+_ (4R.TM6+[K6 [6P/W2\#\J/[>C_ ,^_Q_X
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M )]+?_OTO^%'V*T_Y]+?_OTO^%']O1_Y]_C_ , /:^1\P45]/_8K3_GTM_\
MOTO^%'V*T_Y]+?\ []+_ (4?V]'_ )]_C_P ]KY'S!7N'P5_Y$N[_P"P@_\
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MI(S1.$:!(VC+-,22 AVG(KH;GQ9H]GJ*6-W<O%<-Y8<&!RD+2?<620 HC$]
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M_A33)](\,VMI> +<9>650V=C2.SE<]\%L?A6Q6<K7LAA1114@%%%% !1110
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MJB@#BKSP5J=Y)=ZF=8DAU1[L7=O FPVZ-'E85+&/S,;.&P0/F;@]^T0L44R
M*V/F"G(!^O>EHH **** "BBB@ HHHH *\0^+/_([?]NT?\S7M]>:>._ FL^(
M_$IOM/$ A\E8_P!Y)M)(SVQ[UZF5U84<2I5'969<&D]3R6BNV_X5-XD_Z<_^
M_P ?\*/^%3>)/^G/_O\ '_"OJ_[1PG_/Q&_/'N<YI>K1V=K<V-]:"\L;HJTD
M8DV.CJ&VNC8(4C<>H(()&*N0:[IEO:W=A%I,PL+N-!*/MG[\NK[E;?LV^HQL
MZ>_-:_\ PJ;Q)_TY_P#?X_X4?\*F\2?].?\ W^/^%92Q>!D[N?XL7-$B3X@,
M+Z*X;35Q%>-<(BS$83R!"J9(/(50=W?T%2Z=XATZX\*7L.J6VY;:TM+=;=+H
M1O<[9G<D$J2/O\@ \#J,\'_"IO$G_3G_ -_C_A1_PJ;Q)_TY_P#?X_X5BZN7
MM64TMNKZ.XKP _$FYD)$MM+&L@G$K6MT89/WD@=2CA25*X [Y&<]:JV_C?[,
M\$HMKNXN+6]-U;SW-[YC8945T<[ 7R%."-I&>^*M?\*F\2?].?\ W^/^%'_"
MIO$G_3G_ -_C_A357+5M)?>QW@5)/&44_P!HAN[?4[NTN A*76I^;)&R/N78
MYCX7D@@@Y]:PM:U+^V-<O=1\KR?M4S2^7NW;<G.,X&:ZC_A4WB3_ *<_^_Q_
MPH_X5-XD_P"G/_O\?\*TIXK 4W>,U][_ *Z I11Q-%=M_P *F\2?].?_ '^/
M^%:.A_"74/[4C;7'A6T7EEBDW%_;IQ6DLSPD8M\]Q\\3+\#>!9?$-PMW?*T>
MGQGD]#*?0>U>U64$=M;"&! D:,551V&:DMK:*TMT@MHUCBC&%51@ 40_=;_?
M;^=?'XS&5,74YI;=%V.>4G)DE%%%<1(4444 %%%% !4<763_ '_Z"I*CBZR?
M[_\ 04 24444 %%%% !1110 5''_ *Z7ZC^0J2HX_P#72_4?R% $E%%% !11
M10 4444 %6K;_5GZU5JU;?ZL_6@"6BBB@!DH+1$ 9-5O*?\ NFG:EJ$6EZ?+
M>7"NT<>,A ">2!W(]:P/^%@:5_S[WG_?"_\ Q5:PHU)J\5<Y*V-P^'ERU9I,
MW?*?^Z:/*?\ NFL+_A8&E?\ /O>?]\+_ /%4?\+ TK_GWO/^^%_^*J_JU;^4
MP_M3!?\ /Q&[Y3_W31Y3_P!TUA?\+ TK_GWO/^^%_P#BJ/\ A8&E?\^]Y_WP
MO_Q5'U:M_*']J8+_ )^(W?*?^Z:/*?\ NFL+_A8&E?\ /O>?]\+_ /%4?\+
MTK_GWO/^^%_^*H^K5OY0_M3!?\_$;OE/_=-'E/\ W36%_P + TK_ )][S_OA
M?_BJ/^%@:5_S[WG_ 'PO_P 51]6K?RA_:F"_Y^(W?*?^Z:/*?^Z:PO\ A8&E
M?\^]Y_WPO_Q5'_"P-*_Y][S_ +X7_P"*H^K5OY0_M3!?\_$;OE/_ '31Y3_W
M36%_PL#2O^?>\_[X7_XJC_A8&E?\^]Y_WPO_ ,51]6K?RA_:F"_Y^(W?*?\
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MG_?"_P#Q5'_"P-*_Y][S_OA?_BJ/JU;^4/[4P7_/Q&[Y3_W31Y3_ -TUA?\
M"P-*_P"?>\_[X7_XJC_A8&E?\^]Y_P!\+_\ %4?5JW\H?VI@O^?B-WRG_NFC
MRG_NFL+_ (6!I7_/O>?]\+_\51_PL#2O^?>\_P"^%_\ BJ/JU;^4/[4P7_/Q
M&[Y3_P!TT>4_]TUA?\+ TK_GWO/^^%_^*H_X6!I7_/O>?]\+_P#%4?5JW\H?
MVI@O^?B-WRG_ +IH\I_[IK"_X6!I7_/O>?\ ?"__ !5'_"P-*_Y][S_OA?\
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M\+_\51_PL#2O^?>\_P"^%_\ BJ/JU;^4/[4P7_/Q&[Y3_P!TT>4_]TUA?\+
MTK_GWO/^^%_^*H_X6!I7_/O>?]\+_P#%4?5JW\H?VI@O^?B-WRG_ +IID4,B
MJV4(^<G]:Q?^%@:5_P ^]Y_WPO\ \51_PL#2O^?>\_[X7_XJCZM6_E#^U,%_
MS\1N^4_]TT>4_P#=-87_  L#2O\ GWO/^^%_^*H_X6!I7_/O>?\ ?"__ !5'
MU:M_*']J8+_GXC=\I_[IH\I_[IK"_P"%@:5_S[WG_?"__%4?\+ TK_GWO/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;)VMN. <XZ9_E6]I<2+XITUHM$GTM=T@)E=V\SY#_> Z?UK66]M-6U^33=1
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M]Q70Z3:KI.A:[;W<)FC@E8-&6V^8NT8Y'3(Q5'Q:?-T/2Y;#:-,VX1 .5;'
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M9>TO1V^?ZZA1115G,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7H?P__P"0!/\ ]?3?
M^@K7GE>A_#__ ) $_P#U]-_Z"M<6-_@GO9!_OJ]&=31117AGZ"8GC'_D4[S_
M (!_Z&M>75W/Q;U>[T'X6ZOJ6G&,7,'D[#+&LB\S(IRK @\$U\T?\+>\5_\
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M_B:/^%O>*_\ GKI__@M@_P#B:/:/L'^KM7_GXON/7J*\A_X6]XK_ .>NG_\
M@M@_^)H_X6]XK_YZZ?\ ^"V#_P")H]H^P?ZNU?\ GXON/7J*\A_X6]XK_P">
MNG_^"V#_ .)H_P"%O>*_^>NG_P#@M@_^)H]H^P?ZNU?^?B^X]>HKR'_A;WBO
M_GKI_P#X+8/_ (FC_A;WBO\ YZZ?_P""V#_XFCVC[!_J[5_Y^+[CUZBO(?\
MA;WBO_GKI_\ X+8/_B:/^%O>*_\ GKI__@M@_P#B:/:/L'^KM7_GXON/7JD@
MN9[63S+::2%\8W1L5./J*\=_X6]XK_YZZ?\ ^"V#_P")H_X6]XK_ .>NG_\
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M_P""V#_XFCVC[!_J[5_Y^+[CUZBO(?\ A;WBO_GKI_\ X+8/_B:/^%O>*_\
MGKI__@M@_P#B:/:/L'^KM7_GXON/7J*\A_X6]XK_ .>NG_\ @M@_^)H_X6]X
MK_YZZ?\ ^"V#_P")H]H^P?ZNU?\ GXON/7J*\A_X6]XK_P">NG_^"V#_ .)H
M_P"%O>*_^>NG_P#@M@_^)H]H^P?ZNU?^?B^X]>HKR'_A;WBO_GKI_P#X+8/_
M (FC_A;WBO\ YZZ?_P""V#_XFCVC[!_J[5_Y^+[CUZBO(?\ A;WBO_GKI_\
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M7J*\A_X6]XK_ .>NG_\ @M@_^)H_X6]XK_YZZ?\ ^"V#_P")H]H^P?ZNU?\
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M_P#2B.OCVO4P?\-^I$MPHHHKL)/<OAC\/="U_P"'=AJ=SX2_MZ]GU0VUP_\
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MG/.<@$'B/XEW_B+2+C3ET30M)BNY5ENGTRQ\I[@J21O8L2<$Y]<TXPG?WOS
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M'_"L_!/_ $*^F_\ ?FNHJ*WN$NH!+$)%4DC$L31MP2#\K 'MP<<CD<&CGGW
MYS_A6?@G_H5]-_[\T?\ "L_!/_0KZ;_WYKJ**/:3[@<O_P *S\$_]"OIO_?F
MC_A6?@G_ *%?3?\ OS7444>TGW Y?_A6?@G_ *%?3?\ OS1_PK/P3_T*^F_]
M^:ZBBCVD^X'+_P#"L_!/_0KZ;_WYH_X5GX)_Z%?3?^_-=15:PU*UU.*62QE\
MU(9Y+=SM(Q)&Q1QR.S C/3THYY]V!@?\*S\$_P#0KZ;_ -^:/^%9^"?^A7TW
M_OS7444>TGW Y?\ X5GX)_Z%?3?^_-'_  K/P3_T*^F_]^:ZBBCVD^X'+_\
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M3S_[:R__ )^?@_\ (O?\*S\$_P#0KZ;_ -^:/^%9^"?^A7TW_OS5'_A.;O\
MY]8?S-'_  G-W_SZP_F:/J^)_I_\$/[:R_\ Y^?@_P#(O?\ "L_!/_0KZ;_W
MYH_X5GX)_P"A7TW_ +\U1_X3F[_Y]8?S-'_"<W?_ #ZP_F:/J^)_I_\ !#^V
MLO\ ^?GX/_(O?\*S\$_]"OIO_?FC_A6?@G_H5]-_[\U1_P"$YN_^?6'\S1_P
MG-W_ ,^L/YFCZOB?Z?\ P0_MK+_^?GX/_(O?\*S\$_\ 0KZ;_P!^:/\ A6?@
MG_H5]-_[\U1_X3F[_P"?6'\S1_PG-W_SZP_F:/J^)_I_\$/[:R__ )^?@_\
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M5GX)_P"A7TW_ +\U1_X3F[_Y]8?S-'_"<W?_ #ZP_F:/J^)_I_\ !#^VLO\
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M2BL?0/$UGXA@CDM8IX#-:Q7<:3A0SQ2#*L-I/0@J1U!'H5)V*333LP"BBBD
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M?#L^NQB%K"1EGDFM-A$N]E7S-V0#U!+9Z"F2^,M#CDLBNH6\MK>),Z7L4Z-
M@B W[GW8'7_'%/VD^B"QR \(ZA;75BEOHJR)9ZM<R6L,RP/90VTDJMDH7W1L
M "R-&I*G((P2*DTKP+J4?]G>='';P7$LZZQ"6!,T:W+SVY&TX/+$'_9<CM78
M7OBO0K#0QJ\^K67V%PWE3BY39,1GY48G#-\I& >U59_&^B6T6D^;<JMQJQM_
MLUGYB>?MF("L4W9V@GDC/0]:7--K8-#!\"^%;W1->N;K4X=1^V.DJS79:T^S
M769=RM\@$S/CD&0';EAGIFM)X,U8>(I]2L;9;6[N-3O2;X2+N6W>T98SP<[?
M-VG:.01G'>NW7Q#HKF["ZO8,;*18KK%RG[AV;:JOS\I+# !Y)XJ9-6TZ32O[
M3CU"U;3PA?[6LRF+:.IWYQ@8/.:GGE>]@/-)?!6I76FO!9>'_P"RH&@LH;JU
M\^+_ $R5+J)WFRC$':BO\[$.V[IP*ZC0="UG2[&ZLK1K.QL%O[EHK1K?S,P,
M^Y!&5D58QR>"IQGH*VK;Q/H%[<V]O9ZYIMQ-=*6@BBNXV:8 D$J <L 58<?W
M3Z4^'Q%HMRMT;?6+"46:>9<F.Z1O(3&=SX/RC )R:;G-JS0'F-M\.-1M]"B2
M/2%6\BT6S"#STXOXY26?.[&\+@!_[OR@XXK4?PUK!UF:&;2;QK);G4YC=6MQ
M"K2)<J=@CRX(<9(RP !P<XYKMQXGT!H+:==<TTQ7;F.WD%W'MF<'!5#GYCD@
M8%6(-8TRYU!["VU&TFO(U+O;1SJTBJ&VDE0<@!N#[\4W4GU06//K/PG=QQ:6
M-:\*0ZA80P30BQMDMXFA<NNV=X]XB$C*#ED8D'[N,D"CJ/@35[N[=[^SU">R
M:[U!TATZ2T\Z)I+DR1S*9_E4E"/F4JZD#U./6Z*7MI!81,B-=Q8G R6QG\<<
M4M%%8C"LE/$NGMXJE\/L9([U(5F7>H"2@Y.%.>6 &2/3)&<'&M7$:K:V3^(M
M;&II?[;F.V^SS6>G7,CP2QAR)%=(RN1O&,$]P>XK:E",FT^WZH3-C_A+[-SY
M5K:WEU=M<SVR6L*+YCF%]CODL%" ]V(Z@=3BDU'Q6VEZ8]]=Z#JHBA_UX @S
M%R,9S+ALY!RA8=B000.0T<WNC&/45^T76I^;<_:(VT>^CBGCFE\SAA 2C C/
MW6')'H:UM8UB77?"=]8W5K=6]W<X$:1Z5?/&B@J>7, +'@G.T=0,'&3TNA%3
M22NK^?\ 6W]=!7->\\8PZ?Q?:5J,,B1-<3QXB<V\ (!E?;(1MY/"DM\IXXJS
M>^*])L-4CL)[C,S6[W3>6-PCB52VYL>H!P!DG%<MXDN?[1O[F?2X[X"_TYM.
MN/M&D7H,2%B?,0"$[B S_*<#IS5.\T;2%U.WN-&.OV.([@2S?8M19Q*\:HDB
MKLVY&T9' P%'0##C0@TG)-;A<Z;_ (3RS%G-+)INHQRQ?9\6[+$7<3MMC((D
M*\G/5@1CI5B_\70::56[TV_5UMS=72*L;&TAW;=\A#X(X8X0L<*>*X[356QM
M;I)/#T,L%Q'!&VF?V9>_9W9-VZ=B;4_.25&-O\()8D4KZ;9W&AZ5IUPFJ*T,
M;07=Q#INHHWV<MN^SJ!&-Z?P#?D!1PN3Q3H4T]4[?\ +G97?BD66K0V,^D:@
M/M'F&&=6@:-U1=S/Q)N"XQU Z@=32P^*X9/"LWB"?3KZVLH[872"7RB\L97<
M"H5SCCLQ%9$>J6XUS4M3GM+Z9FMUM;& Z1>!5C W,&/D<;GZX#8"K]*QEBC/
MAWQ'9PV$^FG5HMD%E:Z3>FW@;R]I?/V=>6.,X0=!U-0J,6M8]N_S_KR"YZ7&
MXDB5USA@",TZJ6DWL5[8*T*7""/$9%Q;20$D =%D521SUQC\JNUPM-.S*"BB
MBD 5Y[XO_P"1BE_W%_E7H5>>^+_^1BE_W%_E7;@OXQX.?_[D_5&)1117N'Y\
M%%%% !1110 4444 %%%% !1110 5);0-=745O'@/*X1<],DXJ.E1VC=71BK*
M<A@<$'UH>V@XVOKL:\=AIUU?OI]J;D3\K'.[+L=P.Z8RH.#W..*1/#=Y+'"T
M4D#M*(VV!CE%D^Z3D8[=LFH6UJ4O)-';6T5U(I5KE%8.<]2!G:"?4 =35FPU
MT_:HDO B0;849T4DJ(^5/?OC/!XZ"N=^U2NCTXO"3E:?X::=/^"_Q9$^@/&B
MR/?6BP,BL)B7"_,2%'W<Y.">G !SBI#X<N!&!(T<#IYK2M)(2 J;<G 7_:SU
M.?;O)?ZO$)LQ^7?"95:=)3(\8=2=I0MA^F>IQ\Q'(JM)XAO94D641.9%E5F*
MG.)-N>_;:,4E[5ZCDL'!M/\ #U_R_6X__A'+E9)5EN+>/8S $ESOPGF$C"G^
M$YYQ61720:Q;7-G-]NN/*\_/VB*/>K':@5-F.#G'(<X^E<W5TW-WYCGQ4*,5
M%TMG?KKY7_K\@HHHK8X@HHHH **** "BBB@ HHHH **** "MG0=>DTJ8)(2]
MLQ^9?3W%8U:.CZ/-JUT$0;8E^^_8"L:ZINF_:;'?E\L1'$1^K?%_6_D>D03Q
MW,*RP,'1AD$5)4%E90V%JL%NNU5'7N?>IZ^<?D?IZO;7<*M6W^K/UJK5JV_U
M9^M R6BBB@".?_4M52KDW,+8JIM/H?RH 2BEVGT/Y4;3Z'\J $HI=I]#^5&T
M^A_*@!*Y_P 8Q.=,LKL<Q6.HV]U/[1*XW-]%!W'V4UT.T^A_*C:?0_E33L[@
M<-J+^)/"-KJ$_AS3+;7;&[N7NHP)66:U:4EG)15;SD#'=A2&^; !QFL^V\"7
MDS:9=V5RK0QI9.[7<3P2R-%>-<2MY97*;MQVJ>1G!QC->D[3Z'\J-I]#^57[
M1K85CB?#'A/5]'\16\]ZUD;&RM+NVA>*9VEE\ZY2569"@"X"D$!FY_2>#P-!
M)K^L:GJ>9VNKU+JTC%U+Y:%8416>+(0N&4D'!(^4YXXZ_:?0_E1M/H?RI<\K
MW&><6G@7Q!I=A8IIMS9QR0Z39V%PL=P\/G>7([2@2+&60,'X<#<"3C!YJ;PO
MX"O]+LY$U4:?+)_8L&G1F-FD >)Y3NRR# .Z-O8CV!/H.T^A_*C:?0_E3=23
M0K'G"?#F]CTYX8SIZR_V5IMFC#.!);RF20_=Z'@CN2.0*8W@?Q/=:IJ-[J%Q
M87$LRV[1M+=2.LK071F1'C\L"-"C!2%S@KNPY8FO2MI]#^5&T^A_*G[606."
MUCP;J&L:M#J5U86;^=:_9KK3X]9N;>)")FD#J\<8\S=O)(9!R!@]2:EQ\/M8
MNFNK.22P6P,6JI#,)7:5C>-N7<FP!=AXR&.>O'2O2-I]#^5&T^A_*E[22"QY
M]-X/UZ[U%=4G73$NH8[$QVPN)'BD>WDE8AG,8*@AP0=IPPZ'',FI^&?$^J>)
M-,OY!IT5I:3K/]E2^DVQ,4E27"B$"1F\P-N;!&TJ,;F)[W:?0_E1M/H?RH]H
MPL</X3T:XTS6=*LY)(I6T705L+MX6RGG,T;!02 <A8R<$ X=3CD5V]+M/H?R
MHVGT/Y5,I<SN,2BEVGT/Y4;3Z'\JD!**7:?0_E1M/H?RH 2BEVGT/Y4;3Z'\
MJ $HI=I]#^5&T^A_*@!*QO%.CW&N:3#:VCQH\=[;7!,I(&V.9)&' /.%./>M
MK:?0_E1M/H?RIIV=P//['X=3""*UOY+80'3;VTF,!;=YDUPLJ.O Y4*3G@AL
M8]:AU7P3XDGL=*M[6]M+H6\L=Y>>=</;B:[$ZRO(0D;;@0&4*>%X.#@8]&VG
MT/Y4;3Z'\JOVDKW%8X6'PAK NU_>6MMI\6JPWT-D+IYQ%M+F4JYC4C>6!\OD
M*0<, <"";X<3Q:2\-I>"6:'48[BT0SR6P6VC+[+;S(_G0*)9"&&<$C@UZ#M/
MH?RHVGT/Y4>TD%CD;SPO=2?#EM#T^VMK.YWK(L+WTL\8(G$AS,Z;SGGDKP3C
MH*RY/!GB/[=+J]C=6-EJ<\EW/L21GB@DDBCC3:6C^;_5;F8J.6Z''/H6T^A_
M*C:?0_E0JC0'FECX&\0V%J7C339KC-_&L5QJ$T@6.Y*-O\UHBQD4IM.5^8$G
M(Z5/#X'UJTDLX83I\MO]ITZZN9WG=9(VMDC1HT7RR'4B/<"67EFX[UZ)M/H?
MRHVGT/Y4_:R"QYC;?#.\AT1],DBM9GC,$27T^J7$WG0QW4<I5H'4I&2J=%)&
M[T!..S\2Z))JF@FTTY;>.9+F*[2.88BE=)EE*O@'AB#DX/)S@]#M[3Z'\J-I
M]#^52ZDF[L9PFK>'?%&JZYI-X4TV"ULYXKEK*._D")())#(W$(\PLK(<MC:0
MV!R6JB/AQJ2Z7;6Z36*O;V+Q[<L4EE^V)<J&^7[C;"K'K\QX->D[3Z'\J-I]
M#^5/VDEL*QP.N>#M1US4(]1N].L7,MJ]K=:?'K-S;Q-E]P?S8XP7R,AE9,=.
M>.>@\-^'_P"QCJ+SI;M+=:C<722(,L%D(QDD9SA5!Z]!R<5O;3Z'\J-I]#^5
M)S;5AB44NT^A_*C:?0_E4 )12[3Z'\J-I]#^5 "44NT^A_*C:?0_E0 E%+M/
MH?RHVGT/Y4 )12[3Z'\J-I]#^5 "44NT^A_*C:?0_E0 E%+M/H?RHVGT/Y4
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M>4?_ '\%>A[3Z'\J-I]#^5'UVL']@8+L_O///^$0U;_GE'_W\%'_  B&K?\
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M\Z;3IO(NEV,OEOC.,D 'ZC(JE#XU\.W'BQ_#4.J1/JZ EK8*W89(#8VD@<D
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M#0\TLO#GCJZU3PKI]QHW]CZ?H4\?VB:VU1/LMVD; [O(4;MS8R">Y.0,\6/
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M,R]0.I IFJ>-'TC1WU&\\-:T(H<_:5 M]T'3&<S /D,#E"PZ@D$$#A]#EO\
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MIP1T(KNO#&O/?I]EN59I4'$@&<CWKD-.TZ?4[I8;=<_WF[**]%TO2X-*M1%
M,M_&_=C7F8Z=.W+U_(^LX?H8E2=5.T/S]/3O\B[1117DGV85''_KI?J/Y"I*
MCC_UTOU'\A0!)1110 4444 %%%% !5JV_P!6?K56K5M_JS]: ):*** (Y_\
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M*=Y;_P!T_E1Y;_W3^5 #:*=Y;_W3^5'EO_=/Y4 -HIWEO_=/Y4>6_P#=/Y4
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MY_9/^_8_QKK/+?\ NG\J/+?^Z?RK;ZS6_F./^R\%_P ^T<G_ ,(+#_S^R?\
M?L?XT?\ ""P_\_LG_?L?XUUGEO\ W3^5'EO_ '3^5'UFM_,']EX+_GVCD_\
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M +I_*F)%()9"4;!(QQ[4 +13O+?^Z?RH\M_[I_*@!M%.\M_[I_*CRW_NG\J
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M/RID=U(P;)'#$=/>N'_X3F[_ .?6'\S35\;72 XM8>23U-'U.O\ R_B@_MO
M?\_/PE_D=[Y[^H_*CSW]1^5<)_PG-W_SZP_F:/\ A.;O_GUA_,T?4Z_\OXH/
M[;P'_/S\)?Y'=^>_J/RH\]_4?E7"?\)S=_\ /K#^9H_X3F[_ .?6'\S1]3K_
M ,OXH/[;P'_/S\)?Y'=^>_J/RH\]_4?E7"?\)S=_\^L/YFC_ (3F[_Y]8?S-
M'U.O_+^*#^V\!_S\_"7^1W?GOZC\J9'=2L7R1PV!Q7#_ /"<W?\ SZP_F::O
MC:Z7=BUA^8Y/)H^IU_Y?Q0?VW@/^?GX2_P CO?/?U'Y4>>_J/RKA/^$YN_\
MGUA_,T?\)S=_\^L/YFCZG7_E_%!_;> _Y^?A+_([OSW]1^5'GOZC\JQ]%UN'
M5[?(PDZCYT_J*TZYI1<79GJTZD*D%.#NF2^>_J/RH\]_4?E45%(LE\]_4?E3
M$NI#)("1A2,<>U-J./\ UTOU'\A0!9\]_4?E1Y[^H_*HJ* )?/?U'Y4>>_J/
MRJ*B@"7SW]1^5'GOZC\JBHH E\]_4?E4T+ET);UJI5JV_P!6?K0!+1110!'/
M_J6JI5N?_4M52@#EOB1X8O?&'@6]T73)8(KF=HRKW#%4&UU8Y(!/0>E>?_\
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M" 3G!XZ?6L.Q^'_B7PW:WNE>%[JPAT>34EN8T^T/!<20$'? TJQEEYP X);
MZBND\(^*CJUKI\-X?,FNK:22.YRF)WB?9* $+( "RE=K-D$\_*:ZJCGG!<K
M\ET7X6Z[9:7':7TVFL8-!O=*C9)G;<\SEE8YC&  Q!Z].^:6Z^%^OO"YAN-.
M>7RM*51)-(H9K52'R=AP">AP?<"O6:*/;2O<+'FUO\/];778-9FDT])SK<FI
MRVL<S^6BF'RU57V LQ."25%0S^ O$NK:#XHM=872AJ.N_/\ ;H[R1_+"$&*$
M(81B, 8SN)R2<'MZ?12]K(+'F=QX!U_4]>NM4U$Z7$UUK6G:@\,4\DBB.W3:
MZY,8R3VXP>^*FN?AWJ,JZH8I;%9;SQ)#JJ/N8$0H5.TG;][AL#ISUYKT:BCV
ML@L>2:K\._&>KZM>7E_?Z=<O/9WEFLCW<J@1RC$6(A%M3: ,@$D\DDFNF\(>
M$]6TS7QJNLFQA:+2+?3(X;*5Y!((R2979D3GH ,' [UVM%#JR:L%@HHHK(84
M444 %%%% !6%XJTO4-2ATV325MI)[&_CNC'<S-$KJJL"-RHQ!^8=JW:*:=G<
M#B=6\*ZUX@,U[J+6-M=[K6.WMH)7DCCBCN8YI"TA0%F;R^!M & .<DUCMX'\
M62:K=ZA=3:==W$DUG,'EOI1YAM[EI0,>3B-2C!<+D KGYBQ->G45:J-:"L>:
MW/PYU":X-[/':W;W9N_MFGC4[BTA"SR!]JR1+EQQA@RX8G.!TK0/@[55NIK>
M'[&E@^LP:FDHN7\U J1JT>W9CC82&W<\9 KL=1U&UTJPDO+^3RH(\ D*6))(
M50% )8DD   DD@"L#5?B!HVG:'+?PO-=2B&>2.T2VE$I,7WPZ["T0!P"S@ 9
M&:I2G+8-"?PAI.H:)I$&F:A:Z>$L8$MH+JUE8O<(N1N="@V$\$@,W):N;C^'
M-XMJD;_V>7%AJENQYYDNI=R-]WH%R&/7G R*Z>/QGHQD2*>X:*8IN?\ <R-&
MK>7YIC\P+L+A,MMSNP,XJ&W^(7ABZ:(0ZD3YSQJA-M*H_>$!&)*\(Q( <_*3
MQG-).:=T@T.8NO /B74M0<:A?6C6QTVXT])1<R$QI+%&% A\L+@/&<G=N</R
M?E5:U-4\/>(=2AL[J.QT:UOH$N+=X8[N3RG26%4\S=Y((8%0-FW& /FKIM-U
MZPU6[N;6T>9;BU"F6&XMI(' 8D*P$BJ2IVM@C(X-:-#J2Z@>87_P^\2OHMYI
M]C>V:Q7UK#;3I]IDBW;+3R<EEC)(#@-M& X&&."0>K\->')]-U+4[_4HK0SW
MLEO*GDDN8RELD1&XJ#U$F#Z-VR17244G4DU8+!11168PHHHH **** "N9;QK
M;P>/)?#=[:O HCA,-\6S')+)N(B/'RL0A*Y.&P1P< ]-7$:MIDC>(-?^U>&M
M4U>RU6WMX&\AK5$'EACN5GN%?.7X.U2I3()X-=%",)-J?;O;JOT$[EF#QO<:
MA.;'2=)6XU(W=W"(I+GRXDBMYC$TKR;"5!.,*%8Y..@+!VN^)O$6A>'YM4G\
M/V#"U!-PG]JL >1M,9$!+#YL'<$((. 1ACRNE:)X@T2UMYK#2M>;5H)KES>7
M,=@Z7"3R^8R2QB[7=S@AE93D9Z$J=;4F\2:UX3OM)U;0-8DN+SK/#%8QQQ %
M<!8S>$X^7/+DY8\@8 [72H*:MRN-]==;7]>WS)N[%_5/&>JZ.TL5YH=K)<6=
MF^HWR6VH,RQ6RMC*%HE+R'#D(0H^3[W(JQI?C+^UO&VH:%;1Z>(K((Q=K\BX
ME5X4D#K!Y?W,R!<[O\*P?$MGK.NWDL]IX=URQ^V6+:=? BQD,MN6SA#]K&QQ
MN<!CN'S'Y3@5-C7Y_$FGW]YX9U,V>E&1K&VMXK*.12T9CP\K7K;@%)X"KD[3
MVQ4^RHN'2]GUZ].OR]-PN[FAJ'CW[#X2OM:^PPC[+JKZ;LGN_+C^6Y\CS&DV
M':O\1X.!Z]:TI?$LEM:^'Y);>VF;6;M;<-:7?FQ(&BDE#H^P;P1&.P^]GMSS
MUC+XET?2KJWTCP[J27%QJ-Q>&6ZALY45996D*;5O5.1N W;NW3GBO:Z;J-II
M/AZRC\,:[_Q)KXWK-_H $S,DH90HNL(NZ8D#G  '/6DZ-&SVW?7I;3KW_,+L
MZ*[\2:K9>+;72I],T_[+<++,;E=1??#!&!F61#" HR5&-YY/7 )J+3_B!IU]
M;ZM<^1/';V%REO#E29+QGC5T\M.IW;QM'<8/%4$6\FU?5K[5?!>KZ@NH1QVZ
MP3?8"D4"#_5X-R0V79F)P,Y Q\HK+L/"^FV=_JLTOPPFN+>^GCFBMFM-,V6X
M6)4VC_2".2&;@#ES]2U2H./O;V6S6]]=W\NV@79W?AK6AXC\,:?K"0&W6^@6
M81%MQ0,,XS@9K3KF_A_I1T+P79:4VG3V#6:B(B=(4:<X!,N(I)%&XD]6SD'/
MJ>DKAK**J24-KZ>A2V"BBBLAA7GOB_\ Y&*7_<7^5>A5Y[XO_P"1BE_W%_E7
M;@OXQX.?_P"Y/U1B4445[A^?!1110 4444 %%%% !5JRLA=+-+++Y-O;KNDD
MV[CR<  =R3]![U5JU97HM5FBEB\ZWN%VR1[MIX.00>Q!^H]JF5[:&M+DY_?V
M_JWROOY%A='-VD;Z3*;H,_EE'01NK8)&1DC!"G!S2+H.HM-Y0A3<0I!\Y-IW
M$A<-G!)(/ ]*FM-;BT^6'[%9E84?S) \NYY&PP&6  P W QZUHZ1J*36\:F2
M*%HUB@.^5%*@,S><-_!(W8V@9]"*PE*K%7Z'HTJ.$JM1;=_+;Y77]6,1](O4
MMVF:)2BKO.V12VW.-VT')7/\6,5/<>'K^$RLD+&*,L,NR*QVC)^4,>@],U)+
MK,:K(L<1DF%N;1;C?A6CSC=LQG<5]_PJ6X\3>?>Q7'V3;Y;3';YF<^8@7T[8
MS[T^:MT7]?>1[/!).\G?3_@].F_Y,S;G2KRTM1<7$:I&2%_UBE@2,X*@Y!QS
MR*J5T/B!XY;"+R[U)/+D"A$=&\X; /-.WY@?EQAR3SVZ5SU:4Y.4;LYL52A2
MJ\L-O,****T.4**** "BBB@ HHHH FM+N:RN%FMW*NI[5Z'HFMPZM;\86=1\
MZ?U%><11//*L<2EG8X %=_X?\/IID0FG :Y8<_[%>9CE3LF_B/J^'I8GG<5_
M#Z^OEY]S<HHHKR3[0*CC_P!=+]1_(5)4<?\ KI?J/Y"@"2BBB@ HHHH ****
M "K5M_JS]:JU:MO]6?K0!+1110!'/_J6JI5R52T9 Y-5_)D_N_K0!'14GDR?
MW?UH\F3^[^M $=%2>3)_=_6CR9/[OZT 1T5)Y,G]W]:/)D_N_K0!'14GDR?W
M?UH\F3^[^M $=87B2TE:[T74X(WE_LR^\V6.-2S-&\4D3$*.21Y@;CG -=#Y
M,G]W]:/)D_N_K33LP.'LOAS;Z:5FL;I(;N66X%_,MOC[;!-([F-P&^\H8!7R
M2-O0@E::_P /KB[M4CU/6A/)9V:VFG2Q6@C, 5TD#R#<1(VZ*+.-@PIX&>.Z
M\F3^[^M'DR?W?UJ_:2[BL<9J_@N^UZ&].J:O;_:+O2Y=.+VUDR(H=PP?:TK'
MC&,9Y]JET_P1!IOBZXUB!-+D6XN7N6:;30UW&[K@A+C>,+G)P5)P2,XQCKO)
MD_N_K1Y,G]W]:7/*UAG/WEI+?>-M-G1'6#3;>9Y)&4@.\FU553T;A7)]/E]>
M-RI/)D_N_K1Y,G]W]:ENX$=%2>3)_=_6CR9/[OZT@(Z*D\F3^[^M'DR?W?UH
M CHJ3R9/[OZT>3)_=_6@".BI/)D_N_K1Y,G]W]: (Z*D\F3^[^M'DR?W?UH
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MR9/[OZT>3)_=_6IE)R=V,CHJ3R9/[OZT>3)_=_6D!'14GDR?W?UH\F3^[^M
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MZF44 /\ .D_O4>=)_>IE% #_ #I/[U'G2?WJ910 _P Z3^]1YTG]ZF44 /\
M.D_O4>=)_>IE% #_ #I/[U'G2?WJ910 _P Z3^]1YTG]ZF44 /\ .D_O4>=)
M_>IE% #_ #I/[U'G2?WJ97,ZWXHN-+U1[6.")U5006SGD5<*<JCY8[F&(Q%+
M#0]I5=E_78ZGSI/[U'G2?WJX;_A.;O\ Y]8?S-'_  G-W_SZP_F:W^IU_P"7
M\4>=_;> _P"?GX2_R.Y\Z3^]1YTG]ZN&_P"$YN_^?6'\S1_PG-W_ ,^L/YFC
MZG7_ )?Q0?VW@/\ GY^$O\CN?.D_O4>=)_>KAO\ A.;O_GUA_,T?\)S=_P#/
MK#^9H^IU_P"7\4']MX#_ )^?A+_([GSI/[U'G2?WJX;_ (3F[_Y]8?S-'_"<
MW?\ SZP_F:/J=?\ E_%!_;> _P"?GX2_R.Y\Z3^]1YTG]ZN&_P"$YN_^?6'\
MS1_PG-W_ ,^L/YFCZG7_ )?Q0?VW@/\ GY^$O\CN?.D_O4>=)_>KAO\ A.;O
M_GUA_,T?\)S=_P#/K#^9H^IU_P"7\4']MX#_ )^?A+_([GSI/[U,BGE96RY.
M&(_6N)_X3F[_ .?6'\S35\;72 XM8>23U-'U.O\ R_B@_MO ?\_/PE_D=WYT
MG]ZCSI/[U<-_PG-W_P ^L/YFC_A.;O\ Y]8?S-'U.O\ R_B@_MO ?\_/PE_D
M=SYTG]ZCSI/[U<-_PG-W_P ^L/YFC_A.;O\ Y]8?S-'U.O\ R_B@_MO ?\_/
MPE_D=SYTG]ZCSI/[U<-_PG-W_P ^L/YFI+?QO*UP@N;:-8B?F*$Y%#PE9*_+
M^14<YP$FDJGX/_([7SI/[U,CGE8OESPV!4<$\=S"LL#!T89!%$763_?_ *"N
M4]8G\Z3^]1YTG]ZF44 /\Z3^]1YTG]ZF44 /\Z3^]1YTG]ZF44 /\Z3^]3$G
ME,D@+G (Q^5%1Q_ZZ7ZC^0H G\Z3^]1YTG]ZF44 /\Z3^]1YTG]ZF44 /\Z3
M^]1YTG]ZF44 /\Z3^]5B!BR$L<G-5*M6W^K/UH EHHHH CG_ -2U5*MS_P"I
M:JE ')Z#\/-+\/\ C;5_$=H<RZEC;#LPMN3S)M/^TP![8Z5R&A? UM)UC3;F
MX\113V^GW8NUCATJ.&9V!) ,X8N5SV)(QZ<$>MUF:WJCZ>+*WM0IO-0N5MH-
MZEE!VL[L0"#@(CGKR0!QG-:JI/HQ6.9C^&OVSQ%>ZAXGUNXUNWFLVL(+62(0
M^5 S;BK.A!D/ ^;@]SGM6U3X264L;6NA7O\ 9>GRZ?\ V=-;/$UQB+SO-S&S
M."C%B>3N'(XXK<T_Q=&O@>X\0ZYY<,=O/<H_E# (CN'B0#)ZD*O4@9/85G0?
M$_1[L17,4K);(ET;A D<[ PK&V \4K+R)!C;OSG&5((-)U;Z= T)+GX:Z:_B
MK3-<L;BYMIK2[:[N$:>6473E N>7PIX&2!R!@\51D^%LFH7NL7'B#Q)=ZFU]
MIYTVV)@2)K:#>7 8K_K6!Q\Q SSGJ,2M\3(M/N]0&O6$NGK'<0P6MM-)!'*Q
M:'S"7=I?*' .,L.P^\<5=M_B5H]W/;K;6U]+;SBU)NQ&GE1?:&*QAB6SG<,'
M ./IS1^]0:$WAKPE?:-K][JVIZK#?SW5K!;8ALS %$0(#',CY)SST%;6MZ'I
MWB'2Y-/U>UBN8'!P)(U?RV((WKN! 89.#VJK=:Q<0^-M.T=$C-O=65Q<.Q!W
MAHWB  .<8_>'/'I6*WC[['>W]M>:=<7<L>H3VUM'8HNYHXH8Y6+%W !P[=QG
M&.N,Q[\G<#<TCPSIN@^'_P"R-'MXK:+R1&SI$JM*VP+YC[0-S$ 9/>N'U#X)
M6&H_#_3- DU(QW^G!ECU-+?!=&D+E&CW<KD\#=P1D=2#TEOX\T^35O*D:7['
M,(3#<>0%2/S(3*N]MY)W!3CY1@\<Y!J%?B?H7]LVFF2K/#<7*Q$K*T2M$TB;
MT1H]^_)!7E5(&\ D<XI>U3NO4-#.USX5_P!L_P#"5?\ $X\G_A(8[-/^/7=]
MG^S[>?OC=NV^V,]ZV?#_ (*3PQXDO;W1[I+?2[V)/,TN.#;&DRC'FH0V%R!R
M-O/K45O\1+2YTZPNXM&U4#4FC%BDBPQFXWJS?*S2!01L(P6!/& 003$?'=P/
M$<>E6^DW6H;[JZB9X$CCV+#MR 'E^;[X);CCHN3P_P!XU9_U_5@T)=$^'>E:
M9X@U75[Z"SU*ZOK\WL$LUFOF6ASD*KG)X/.1CFLB+X5SVEG9QV.NI'/!#>V\
MDLEEO#QW+ECA?,&UESP<D'N.U=9H?BBQ\12,NFI.R);Q3O(Z!50R D1GG.\
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M =YC_P!YOSH\Q_[S?G3:* '>8_\ >;\ZC260RR@NV 1CGVIU1Q_ZZ7ZC^0H
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M (S%22^T#C/.>_4'<C\<VTP6&#2=2DU W4EJ=/"Q"961%=B29!&%"NASO_B
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M3-<2M$#&JA7\C?Y><H"< $\\\YJ"U\"7*WKWE]JT<UQ)<75Q)Y5H8U)FA2+
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MU=O?#44<DNVZ"29F,<*0G:?+&3R6)'ZUDRZM<O"\$;;("I15V@LL><A-^-Q
M],TZ36[^6422S[F&_G8H^^,-V[BGRUNY"JX))IP?3_@]>W_#(FU/14TVQBF-
MPTCR, %\O"L-H8LK9^9>0,XK*K7U?4;&]MP+>)_.$F5=XPI2/;@(2&)?H/F/
M/%9%:4^9Q][<YL4J2JVI;?>%%%%:'*%%%% "H[1N'0E64Y!':N]\-Z__ &E'
M]GN?^/A!]['#"N)L;&?4+I8+=2S,>3Z5Z+I&D0:3:A(QND;[[^M>;CI4[6?Q
M'U?#U/$\[FG:GU\WY?YFA1117D'V@5'%UD_W_P"@J2HXNLG^_P#T% $E%%%
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M=*OK:1+V[OIYYA<>?=,T8DF:950LP"!>%10 % P.0>:Z_P M_P"ZWY4>6_\
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M +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\
MW6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4
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M +K?E1Y;_P!UORH ;4<?^NE^H_D*F\M_[K?E3$BD$DA*-@D8X]J %HIWEO\
MW6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4
M-JU;?ZL_6J_EO_=;\JL6X*QG((Y[T 2T444 %%%<!=:EJ?A2YLT==L-Q>ZK=
M2P94^=&HDFC^;!VYX/'/KZ548\P'?T5S?A/Q5/XBDN8;W3EL)X8+>Y5$N/.!
MBF4LF3M7##:00,@=B:R(/B)=/:+<W>EV-G#<_:?L<LVI,$8P2[&$I\K,>>2N
MT/G&#@XR^25[ =W17GFF^/\ 5M<U33/L6F006=QIMY<7*RW#+)&\%PL+;<Q9
M..H#*N=W.TK@KH?Q)GU"YTBR@T:^O%FMK,WET$D=HGGB5P28X?*( =2S%H^I
M(7 Q3]G(5ST*BO,)_BAJ]QX=-U9Z);6MS<6UO<VOF7ID'ER3B%BV(QM8,01C
M<"&R>A4];8>);NY\6S:'>V-M9R06Z2L6NV+3%E!8PJ8P)(U8E2VX$$<J,C(Z
M<EN%SHJ*Y*7QK<0>*+RPDTN/^S[34+?3WNUNB9?-FC1D/E;,;<R*I._/?%9,
M7Q,U%]!TK4'\-;&UE5>QB2YEGW+L9GWB*%W7&T8PC9#@G;A@%[.3"YZ'17#1
M_$.>?_1)=%GL=1EBCGCM9Y=DBP-$SO*0R?*49'0C!&[;S\U1VOQ"N/[%CU :
M8;BPL[6S?4;F6Z43*TT:/\B+&%DVK(K,<Q]3M'&*?LY!<[VBN*'Q"D>)#!HD
MMQ))_:6V&&7<[&SDV84;>2_7 Y'0;JSV^(-Y'?6NH,MI<:6VF&ZN([*Y\Q(U
M%RL;2B1HU8E%)+(0N,,.HH]G(+GHM%<CJ/B^\/PPU3Q1IEG&K16\\]DLLN1)
M&I.R4X'=1O"]P0,C/$(\:ZK;WMU;7FAP,NFV,-[J$\%_N$:/YGW%,:ER!%G'
MR]_0;ER2&=I17G#?%*]3P]<ZG-X>6V\E4DBCNI;F$72LC-MB+6V7D&TE@JE0
M/FWX!(GF^(6H6EQKU[-IL4FE6,-H;94F;SWDGP(P45&^\S@'!)4#A6)I^RF*
MYZ!17 S>/M6NM)\JQT%[;5F@NYF2\>6".**$+^]4R0AWR98\ QKD[@< 9.O'
MXG?3?!NA:QJX#V]S! ;Z[)V^1OCSYA4#!!<J#C&-V>U)PDAG3T5YX_Q*.H:+
M'<66GW-K*CVXO4,R+):-)=1Q(ARCJ2REF/ .WH02"*MKXS\67DND.EC8[KK6
MKVS6V2ZP)DB2?"NQBRFTQJ=RY+8Z#.VJ]E(5STVBN:_X2\3^ K/Q+9P6ZB[@
MBF2"\N&C&7 ^0%(W9GR<!54EC@#DUS&N?$C4KOP8][X:L%@N/['34IYKB<#[
M*'<HH1=C"5LI)P0HPH]<"53DPN>F45P4OQ/$.I:HIT*]DTW3VN(OMD44IW2P
M\,K$QB)06#*")6.0,@9XLVGCJ_\ ^$BAT75M%@MKI[Y+1S!?&94W6SSALF-<
MGY-N/?.>.7[.789VE%<!8_$R6^GT2./2[8G6(QLC2]=I()#'(ZB0>5M56\L@
M$MN/)"D*V*-C\3M73PWHT]UH7V_4M1LGO_)L3/(#"-N,!(&*N2^ I^48YDY%
M'LIBN>FT5B:QK\]DNF0Z;I_VJ^U239!#<RFW5 $+L9&VL5P!T"DYP/4C%LO'
MM]JFIVVGZ9H*RW/ERM>K)>A!;M%/Y,JJ=AWX;)4\;@.=M2H2:N,[6BN+\5>,
M)_#'B*4R![BSCTKSEM43)DG:XCBCY"EL9< X!X.0I/%-M?'U[-)I45UH1TY[
MZZDMGEOY)K>$,I7:(V> ,S.K9576/<590<BG[.5KB.VHK \-^))M?&H[[.&U
MDLYS$+8W#&=>N/-1D7RR0 1@L"#D$CD\?;>-O%<]GH-VUC8M)>W%Z&MH[HA)
MDB5R-SF+*;=O&T-NP,XR<"IR8'I]%<'%\34FU"SB2PAD@OM.^W0M'=,TD?\
MHXG"2KY>U"1G&'8XP=N#QK>$?%L_B22>*\TU=/FCM;:\14N?.#13JQ3)VKAA
ML;(&1TY-#A)*[&=-17"1?$IGFU2U&FP3W=I);16WV2\9X;EYY6B4>8T2XPRG
M<0& P0"2"*S(OB1K&GM=6=YI+:IJGVV[Q;6GFR+##"8QM5HX&9B3( "R*/[S
M#C+]E(5STZBN'N/B'<)<120Z)_Q+I+U[ 2SW)CG$JP-*?W6P@*-A7E@<_P .
M.L<OQ)D%EYT.FVJO_9EG?A+B]==_V@2?NDV1.S./+X 7YL]L<GLY=AG>45YU
M#\2;YGU'5)-,B.C6^CV.H1H)V^T;KA7*KM"$'+ *>1@+D;MV!T>A^([S6M O
M[JZTR?2[BU9T598I563"!@Z>;'&Q'..4'*GJ,$ITY+<#HJ*\ET+QQX@LO#GV
MW6)YYY[O1K>]LUU*.!0\K,JR2(;< "!?-B.U\28STYKK]1_M?PIX?U#6KG7+
MG639V4DSVUQ;PI&65204,:*R+D<[B^%]^:;IM.PCJZ*Y&WN[O1]9TZWU7Q-<
MWUYJ2L([9]/"V<C;&?;%+''E"-N1OD<[0>"2&$_C&PN=7\&&VGT-=1O)MJM;
MV\D;K;L00TBF4QAB@)*YP2VW@=0N749T]%<)=1:X?'6FZ7'XHU>UM;ZQN;MX
M3#9L\#(\05 QA;@"0@Y+$X'S'NA\<:G=PP7":2;6R?61IR3QWJ%G9;KR3N1H
MCA6&3QSPPRO#%^S?05SO**\[A^(-WJTMO#:I;VSQ:S:VLLMI,;B&XAE5CE'>
M-"0<?> QP"&.:UO$GBR?0-:N(XK2>\6'35N3$K@1C,XC+L%C9P%!+$C=A0?D
M)YH]G*]@N==17-ZUX@DM?!=OJ\;1EIIK1=UA<K(A$L\:?)(T9#+A^NT$CIM.
M"*GAKQQ/KNL0V=UI2V4=U%=26LJW7FEQ;SB)]R[!MR6!')[].,KD=KC.OHKS
MU/%>OQ^/=7TX0176+R.RT^S-RL<('V=9WED?R2X.T]BPRVW;QO-#5O'^J32[
M]/<V#1VZI<6Q5)/*N$U"*WE 8K\PP7 /&00< ]*]E(5SU&BN*;QY?XCN(=!6
M2RO9Y[73G%Y^\N)X@Y"NFS$:OY4F&#,>%R!GA+3XG:?J>HM9Z9:O*TDL*VDD
MC[$N$9=TS@X) B ;=D=0!WS4^SD%SMJ*Y/4?'^G021G2'M=7MWL;V[,]K=JR
M!K=8R8\J",GS!SGC'0YJKI_Q N+S4BLND1Q:>+RWL6N%O"THEFA213Y?E@;<
MR!2=V>^*.25KC.VHKF]9\47&F^)8-(@L;=O.M6GCGN[IH%F<;OW49$;!G& 2
MI*D*V0&P<<Y8?$?4[7PQX=U#6['3Y)-52!G2VO)#,$E=$$HB\G 4&09W. "0
MH9BP!%3DU= >CT5YS-\5I(;F_0:/#*EJPB6.*\>2<2M<>1''+$L),98Y; +'
M:. QXKJO#FN:CKMK'<W.D-I\>9$E6=I4<.K84HDD2%D9>=QVD=-O<#A)*[ W
M**\YUY-3TK6M1OM,MWT1-2U#3K+[7%';[IP]QLDD"Y<,V'^^ZJ<;1M.,U<U7
MQ%?>!M0ECU34+C7;.33YKN,2Q1K<1R1O&FT^4BJ48R@ [<@@]<X#]FWL([JB
MN"3XE7%O;B76/#]Q8H[30PLYE03W"HKQQH)HHV/F N 2!\T9&"""8+[XC7\C
M:O:6>BW,/V2"YC^WQQRR)!<10ECDF$1;-P*@[R2<94 \'LY!<]$HKA[+QY=_
M98;J?35ETR&:VLKR_-P%E$\JQC<L(3!0/*@)W \DA2!S4D^*%U:Z/_:-YH""
M*=)GLE@OM[2^5,L3*^Z-=A.X$8W X.2.Y[.07/0Z*X5/B+<V]ULU?0UM;>*]
MFL+F:*\$NR9(&G&Q=BEE*+U.TACC!ZU!9_$S4+RRAE3PQ/')=7%M#:^>\T,4
MGG!L$R20+RNT;@H888%2W2CV<@N>@T5PVA>-=7U_Q/IUO!IMK!8S6,TUR'NF
M+I)'/Y3;<1X8!E(&=N023C !-0\8ZEI'CK4+6:W6ZTF-M.A+>8$:V:XD>/<H
M"DOEMN02, <>E'LY7L%SN:*X)/B5(UMK;#2X)Y-),!,EK=22V[1RLZF0R>2&
M"IY;%BJ.!CKP<:7B?7=3M?#.CWVCM:&ZO+ZSC*I/O@E61U#*)=A.P@X#A<XY
M [4N25[,9U=%>=W'Q3N(6%K!X<N;O4H3.+RTMC+-L\J3RR(VCA;<6ZC>(QZD
M&G7?Q3>"769+?P]=SV&FI=;;K9,@>2W!W*[&'RT4E74$.QR!E1G ?LI]A7/0
MJ*P_#GB&?6IM1MKVQ6RNK"9$=$G\U65XED4[MJ\X?!&."#@D<UQLGQ,U"&\3
M5KBP$>CW&D-=V-K'*99;AGN8HH6<"/,9/F#*J7P&/!(Q25.3=@/3J*\NU7XA
MZS'-IMY<6$^D6,$=[<WT.UEDN%MPC!4$\"L48.O.$.21E=N6U(/B%J]S):6B
M>%94O[NY>")+B6:WB8+"9=P>6!&/W2I^3@],YI^RE:X7.]HKA9OB'?VVGZKJ
M%UX=V6>G3M9EDO/,>2XWQHB;%0G:6D W#<1@X4\9@NOB!J]SHLL>GZ"]KJHM
MKN=Q>/+!'#'"%Q*GF0AY,F1, QJ,A@2,9)[.07/0:*Y>37;F'0?"MQ*\CS:E
M/;13-&47<7B+$D%#QD=%VGT(Z&'P9XWG\4O"MYI2Z>;G3HM0M]EUYVZ-V92&
M^1=I!7MG((Z'(I<CM<9UU%<=+X[FBNFE?25_LDZA+IL5T+K]ZT\>Y3F+;@(7
M1E#;B>AV@'B+3_'&LZE8Z-)%X<@CN-;B6>S274L1^5Y7F,SL(R5(RH "MG<#
MQS@]G(#MJ*\R\,?$R_O++0[6;2[K5+B6UM&U"[A@E^1IOX@L<1CPH^9MS)QG
M .,5U7A3Q'J/B33VOYM&2RM'4FV878D:4AV5@5VC;]T$')R#V/%.5.4=Q7.C
MHK@]"\::_?Z3IHFTFPFU+4Y[GR%6^9(EBB=@Q=O*)4CY5 "MGJ2.<3Z[XNOI
M_A7/X@T");:\8>7MG<9@<2^4^#M8,58'&1@XS[4>SE>P7.UHKB+7QO<V:0MJ
M5B9-,6\?3&U%KE6G>XCW*[-$L:KL+HZA@0>AV 'BQ9^,M2DM]'N;_0XK:VUF
MYABM&2^\Q@DD<DFYU\L , B_*"1\_P![BE[.0SKZ*XW1O'LNL:GI=L=-ALX]
M0A>59;FZ9?,*NZE(<1E9'&P,RED(# @$ XDUWQU)I/BE=&LM%NM2,<<,MT]O
M%,YB65V4;0D3*2 C,=[(,#@DY .25[ ==17C>G^.?%B:E'>ZQ,&L?+O[EK2T
MFB)<PW0MTA&Z $+N91DODY+%EQL/777CO4;*_&DSZ% =8-Y!;B&*_)@*S1RL
MDGFF,' ,+AALR,9&[@&G2DA7.VHK@$\;^(;>;Q#/J.A6XATH6Z>1#=/(\;R)
M&S%]L1RBB1F9ER0$X0\FNAO_ !%+9^$X-7B&FS23",JHOG:&4MT$4B1,TA)(
M"A4RV>!4N$D,WJ*\^'Q1DEAL[JWT3=9RZ=9ZA<2/=[7A2XF:+:J[#O*E<]5!
M&>AP#9A\6ZKJ7C+2(;6VCMM%N+R]M?,,P:6Y,"LI)39\BB1&P0Y)QR!FG[.7
M45SN****S&%%%% !1110 50U+1-/U>2%]1M_.:%9$C.]EVB1"C]".JDCV[5?
MKS,>-_%G_".Z;J(M-.F?6+P6MI';P$F$@RY+^9,BON$8 &],%CRV #<8M[ =
M[I^AZ?I5Q)-86_E220Q0.V]FRD0(C')/0,>>ISSFN9T+X;Z9;:/)#KD)N[N5
MY]TBWDQ6-'G,H$66'E'A"2@7)7J>M5I_&7B+27MI?$>EQZ?$VGR3>0L7FF[N
M8XY':)94D*PG:@8!@^X;@&R#B"Y\<:YI<0CO#I=[--;65Y'+:Q.L<<<]TD+*
MP+L6^5B5?(!VGY>.;49]&+0Z.W\">'[5;86]M<I]E>5XF%_<;AYK!I%)WY96
M8 E3E2<G')J:V\':+97%I-907%J]I##;Q_9[V:-7CB&(UD57 EP./G#<<5S:
M^,/$6I>((])TE=+C=[G4HO,N(I& 6V>)4&%<<GS"">W4#C:6W'C/Q!%X5N/$
M,4>GS6\MR;2VM(XF\RW<W(A5I7:55; W$C]V <#<!E@<L^X'1_\ "#^'OL*V
M?]GX@6T%FJB>0%8@^\ '=D$, 0V<^]6K/PWIUCJ*7T8NYKF./RXWNKZ:X\L8
M .T2.P4D*,D8)[DY-<W%XE\4VTVCKX@T^'2H+FZ-M/<-;B;>[.!"NV.=O)W@
MD;BT@#8!QD9O^(]?U2UUIM.TB73K9H=-EU&2:_1G6148+L 5UVCG+/D[<K\I
MS2M+:X!9>"X!XTU;7M3'GF>\BN;*,7$FR,I;I%N:+(0OE6PV"0".1VT'\(Z*
M^AV.D"U>.TT_;]D\JXDCD@*@@%9%8.#@D9W<@D&N4L/B!K%_K%M+]EM(-+FN
MK*W-N\;_ &@?:;59>7W;049@"-IR..",G7\3>)-4L-5N[32GT^W6PTIM3F>_
M1F$RAF&Q=K+L V'<YW8W+\IIM3NE<-#>70M.!C9K<R2QVK68FED:24PL064R
M,2S9*@Y))XJA_P (/X>\RV86#!;>.&)8A<2B.18?]5YB;MLI7 P7#$8'I7,Q
M>/M;GUO,5E:?V>;VVM$M71EN"9K-9QERVT%7./N\@]L9,&D>-_%&J16)(T^%
M-6GAAL[N?39X8D+0/,_#2YFX4(I4JK$[@3C%')-=0.L_X0C01J4U_';W,5S-
MYI+Q7TZ;#*09"@#@1EB 25 )(S575/!5K_9$UOH$:VMU<0M9R74L\C.()9 T
M[9.XO(1N(9N2V,L*Y6Y^(.K)FYAM[1[NWM)XRV^7[/-)'?16Y=5#XVD,2"06
M4\;B <SZCXZ\46]N]I96]E<ZE#=7EMOBL)I5N)(A&T:+$LFZ/<)#EV8JNSG[
MPP^6?<-#T*72[*;1WTJ2W0V#VYMF@Z*8BNW;],<55TSPUI>D&8V<$K-<0I!*
MUS<R7#/&A<JI,C,2!YC_ (''0 "GKVJ:I9W6BZ9ITEDE[J4KQM=7,+-$FR)G
M;$8<$D[>!OX&3DXYX;PEXR\67EEI.G:;8G4FALK6:\GN"K/*)78,^]YT8!0I
M(PLFX@C*]:E1DXWN!VC_  ]\.R6"63V]ZUM&1Y41U.YQ" C)M3]Y\B%'92JX
M4C (.!B8^!O#[*Z/:3,DMHMG(C7DQ62)00NX%\,RYX<Y8=B,"N5F^(6O+I<C
M1Z=;M=VMU%I=UB([1>M*5.W?(@*; K %QGS4&X8.89O%GB2PUCS-5MELKZ33
MX(?L\\G^C1227IA6=E21@!M*L0&)_AW?Q57+4[AH=C<^"M%O+**VNEOYEB9R
MDKZG<F90X =?-\S?M( RN[:<#BM(Z18-H@TA[5)-/6 6X@DRR^6!@*<\G@=>
MM<4?%_B*37$T&*?24O([Z:VFU!K21K=U6W6<83S058;MK NV,9[X%"#XC^(-
M0\FYL;33([9SIT?E2B1F9[LE 0X(&U6PV=I+#CCK2Y)OJ&AZ!=^']+OH[E+F
MS1A=SQ7$Y!*F22(H8R2"#P8TXZ<>YJM;^$=%M=5&HP6THN%NGNUS=2LB3.KJ
M[K&6VJ6$CYP!DG)Y (XM_'WBN>>+2]*TJUO=5C:]$IC0+'.;>;RP%$DZ; <@
MDYD*Y'RM4EUXW\2?;[J&./3X(FN[NPMU,+O+%)%:F<.QW[6^Z5V@<\'/:CDG
MM<#LG\*Z.WAVVT(6TD>GVGE_9TBN)$>+804*R*P<$$=<YJA+\.O#,VFP6#65
MP+:")H%1+^X0M&6W>6Q#@N@/(5B0,G &:K6FOZCI/PDAU[498-0NTTZ.XWA#
M"C;D!!<EFZ9RS#KR<#I7/^(M;\17-P/#LVHVJ3+J&GK->Z=%-"LD4[-^[^6;
M>C QY)#_ #*P^[DY(J=]&!VTGA#19;R\N'MI2+X-]JMQ=2BWFW+M8M#N\LDC
MJ=N<\]>:QK#X=V,%_J@N_/ELI[B"XLB-0N#<0M'%Y9/FEMXZL!AC\IQTXI?&
M.L7'@Z[MM=3[5=6+P-92VBNSCSN6@8#L6?,9/?>F3A:P[36-;\/:A)HLMS'<
M:E(NFQ/>7LLTL:37#W#2,4,F-H*;55=F<J"< 8(J5KI@=3;_  ]\-6ES8SVM
MC-"]@8S;B.]G55,>0A*A]K$!F&2#D,0>#BG+X"\/QV\$$,%Y"ML[M;M#J-RC
MP!P RHZR!D0X'R A> <5SEYXE\0Z=XBNM.#:>]\]QI]J9RDYA F,^7$1EPI
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M-1AL+6.^EC$4ETD*B5T&,*7QDC@<9["HUT+2%U*?45TJR%]<(8YKH6Z>;*N
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MR;=_O7,"+Q3-IL\5B=>767TV_75#<-,L(N"A\G[.6^0'?C:8>-N=W.*2BWU
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M3(;8/E(_BQVI\D5UZ@>B5#<WEO:>5]IF2,S2"*,,>7<]% [G@GZ GH*\FO\
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MHA?:6P78(HP 3RS ?C7/:MX7?6/'\%]="\CL8],>'S;2_DMF\TRJ0I\IU8C
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M#:'BA56 P!C('HJC_@(]*5X:JP%NBBBLQA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %"^T+2-4NH+G4]+LKRXMCF"6XMTD>(YSE202.0#Q5^BBBX!
M1110 4444 %1):V\=U+<QP1I/,%6654 9PN=H)ZG&3C/3)J6B@ HHHH ****
M "BBB@ HHHH BAM;>V>9K>".)IY/-E,:!3(^ -S8ZG"@9/8#TJ6BB@ HHHH
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M>2:)D<*)Y%C=D.49XPP1RIY!8$C QTHYH7V Y)_B?<QQ"Z?0XQ97%@]_9O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sesn-20211231_g2.jpg
<TEXT>
begin 644 sesn-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJXGU+Q!!IMOJ7A[^Q[9K'4A-;%_.N)&7S)9'V9<95 6.P+CGH/\ @K'_ ,%
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MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ",TK 1PQK NU>%]*D!S2;*4#%, HHHH **** "BBB@ HHHH **** "BBB@
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M1_P_@^$'_0F_M#?^&FUS_P"1Z^V** /B?_A_!\(/^A-_:&_\--KG_P CT?\
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M ?$__#^#X0?]";^T-_X:;7/_ )'H_P"'\'P@_P"A-_:&_P##3:Y_\CU]L44
M?$__  _@^$'_ $)O[0W_ (:;7/\ Y'H_X?P?"#_H3?VAO_#3:Y_\CU]L44 ?
M$_\ P_@^$'_0F_M#?^&FUS_Y'H_X?P?"#_H3?VAO_#3:Y_\ (]?;%% 'Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Q[_P %]_\ E#Q\?O\ L6__ &XAK["KX]_X+[_\H>/C
M]_V+?_MQ#0!]-?!'_DC'A'_L"V?_ *(2NHKE_@C_ ,D8\(_]@6S_ /1"5U%
M!1110 $XH!S5/7_$%CX5T:YU'4KNWL-/LXVFN+FXD$<,$:C+.[,0%4#DDG I
MND^(;/Q!I%MJ&GW$-[8WD0GM[F!Q+#-&1E75ER"I'((X(H O9S14:W(('#')
MX(% N@1]V0>N5Z4 245']H7RB_S;1GM0;I=H(5R&&00N:/,.MB3.:,\U"MVH
M8JVX$>HQ61IOQ*\/ZUXOU#P_9ZWI-YK^DQQRWVFPW<;WEDDG^K>6('>BMV+
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M_P (?5?_ )-K[5I&;:N: /BO_A5__!0#_HK'[,/_ (0^J_\ R;1_PJ__ (*
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M44 ?#?\ P2H_Y/:_;F_[*I:?^F:SK[C9MJD^E?#G_!*C_D]K]N;_ +*I:?\
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MY%F4$E"R\@-C(J/PU\9O"_C+3]4O-)U[1=1L]#N)+34KBWOHY(=/FC_UD<K
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M -N:_(^V_AY\:O"7Q>\*?VYX3\2Z#XGT?G-[I5_%=VXQG(+QD@$8Z&N=T_\
M;&^%.IZMH]C#\2/ <EYXAD,.EP+KUL9=1<,5*Q+ORYW C YR"*^4KKP-X;^
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M -C1XG_],DE 'W4.M% ZT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]U8D5%J__!.KX2WW[+UY\'[?PVVE^!KZ:.ZNK:QNY(;BYG299O-DGSYC.TB
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M#CXV?#V\TXW2^)-#2VT^^TB\W#9;26\,KK)$ZDE7 !&,$FN4\5_M=^-_C_\
MM/\ Q"\#>"?B)X)^$OAWX5O!IU]J^KVUO?7VMZG)&)6B2*:55CMT1DRX#,Q)
M (QQ4HM:?,(Z^\OZZ'KO[9FE?!_2_@II6@_%33[-?"-]JEEH^E0QVTNZUO78
M):B!H!OA8,!M=2 N.M<[^RQ\%_@YX ^/OC*U\+_\)%KWQ&\)6T&GZQJOB*ZO
M=1O+&WF'F1V\-S<Y4QD#)$3=0-V37RC^T7^UUJ7[57[)NCVOB--%7QA\/?C7
MHWAK6Y-&E\[3[UX[I&CN8#N;"2HRG;N.T[ADXKU;XL_MJ^/O!^H_MF26.J:7
M;O\ !_1+.]\./_9L+/;2/:/*3*3_ *X;E& _2E"+;<7UDU_Y+%_J'+=Q4>J7
M_I4E^A[?X;_X)L_"OPQX?\+Z79Z?K"V?@_QI/X]TT/JDS,FJS.[N['.6C+2-
M^[/RCBO0OA=^S9X5^#OQ \=>)M#M[N+5?B+J,>J:T\UT\J2SI$(E**>(QL X
M7C/-?$WBG]J+]I?X$?LT?#?XY>,/%W@?6-%\03Z)#K'@RRT 6^V#4&CC$L=]
MYC-YH\Q7V[0@R1VKTOXF_M;>-/C#^UUXT^&/@CQ[X0^%>A_#>UM'U7Q!J]M!
M?7>J7MRID6VMX9I414C129'()RR@5I/FW?5M?-)-_H3S.SOY7^;=OQ/9_"G[
M OPM\,? 36/AB_AT:OX+UW4KK5KRPU.X>Z\RXN)C/(X<G<I$AW*5(*8&"*A^
M#?\ P3_^'/P5\?0^*K.W\0:]XFLX&M;#4_$.MW.K7&EPMPT=NT[MY2L.#M&2
M  2:YO\ X)W?M=ZS^TM8>/M \5'09O&'PQUYM U*^T.7?INKIL62&[A&YBHD
MC8;ER0&5L<5](4K2C9O=I/Y-714I<S:>NK3^_7\1$3RUP*6BBI **** /A3_
M (()?\D&^-__ &73QC_Z5K2_\%'_ /E*7^P?_P!C1XG_ /3))2?\$$O^2#?&
M_P#[+IXQ_P#2M:7_ (*/_P#*4O\ 8/\ ^QH\3_\ IDDH ^ZAUHH'6B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "FC[].IO1J /G?_@J#^U[X
M6_8>_8N\:>/O&6A1>+-+@6/3K?0'C61=<N;AEBAMF5@PPSMSD'"@\5^7]S\1
M/VJ/V3OV;(_&'B_]B_X!6_[/6BW=OXMO_">DV\8N[##[UNQ#YSO]HCRK%I(V
M Q]U0,C])_\ @KI^P[JO_!0K]B7Q-\/O#^JPZ+XHCN[77/#]W,/W*ZA:2B:(
M.0,A6(VEN<9!Y (KX>^+7Q,_X*+_ +6'P*U/X WW[/\ X4\&7VO:;_8>N^.Y
M-55].>W=0D\L*[RI8IG^]N!. #BHI_'=;Z6+Z:[=3]3/V>?C+H7[17P6\)>/
M/#,LDOA_Q?I5OJ^GEUVMY,T8=0P[,,X(]J[BO+_V._V?K/\ 9-_9@^'_ ,,[
M&Z>_M_ NAVNBI<N,&?R8PA?'7YB":]0K6=N9V,*?PA1114F@4A4'L/RI:* $
MVC'0?E2[1Z444 )M'H*4#!HHH *^/?\ @OO_ ,H>/C]_V+?_ +<0U]A5\>_\
M%]_^4/'Q^_[%O_VXAH ^FO@C_P D8\(_]@6S_P#1"5U%<O\ !'_DC'A'_L"V
M?_HA*ZB@ HHIL@)3CKZ>M #MU)D#TKY2_;M_X*.77[%WQ(T/0H_"$/B)=:TY
MK_SVU(VIAVRE-FT1MGIG.:\3_P"'\%]_T3&W_P#!^W_QFC4#]&MU&ZOSE_X?
MP7W_ $3&W_\ !^W_ ,9H_P"'\%]_T3&W_P#!^W_QFG9A<_1H'-%? _P?_P""
MS]Y\6OBYX7\*M\.[>Q_X2+5(]/-R-:,I@W]'"^2,X],U]\4@"BBB@ HQ110
M4444 %%%% !UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /AO_@E1_R>U^W-_P!E
M4M/_ $S6=?<4AQ&W&:^'?^"5'_)[7[<W_95+3_TS6=?<E 'YN_\ !07_ ()W
M_%CX_?M;^(O%?A?0]/OM$U"ULH;>:74X;=]T4"JX*L=WW@>U>-_\.B_CU_T+
M6C_^#NW_ ,:_8:BM/:- ?CS_ ,.B_CU_T+6C_P#@[M_\:/\ AT7\>O\ H6M'
M_P#!W;_XU^PU%'M&!^//_#HOX]?]"UH__@[M_P#&C_AT7\>O^A:T?_P=V_\
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M_P#AI-;_ /C%'_#]OX4_]$]_:1_\-)K?_P 8K[3V^]&WWH ^+/\ A^W\*?\
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MAG_@H_\ \I2_V#_^QH\3_P#IDDH ^ZAUHH'6B@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U
M^E?"_P#P4?\ ^4I?[!__ &-'B?\ ],DE?=#]*^%_^"C_ /RE+_8/_P"QH\3_
M /IDDH ^ZAUHH'6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@4445F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH :_2OA?_@H__P I2_V#_P#L:/$__IDDK[H?I7PO_P %'_\
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M^4/'Q^_[%O\ ]N(:^PJ^/?\ @OO_ ,H>/C]_V+?_ +<0T ?37P1_Y(QX1_[
MMG_Z(2NHKE_@C_R1CPC_ -@6S_\ 1"5U% !1110!^7G_  73_P"3A/ O_8NR
M?^E+5\35]L_\%T_^3A/ O_8NR?\ I2U?$U;0V(EN%%%%4(]%_8[_ .3NOAA_
MV,MI_,U^Z]?A1^QW_P G=?##_L9;3^9K]UZSJ;F@4445F 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_2OA?\
MX*/_ /*4O]@__L:/$_\ Z9)*^Z'Z5\+_ /!1_P#Y2E_L'_\ 8T>)_P#TR24
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[PQ9VMU9DSPJ3'(D893M)'!K])Z^/?\ @OO_ ,H>/C]_V+?_ +<0U)1]-?!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA-:^./!/C[4M"\.>!CX:L9+'4(H;V.&UM))S;^:/-5L&7SU*[MW&W%>]1?\
M!4NUN?V@H?##:/H,.@+XTC^'MQ.OB>%M;36"%5V73B@+6:7#& S"3>2I<1[/
MFKT/7OV%_"_BG]GSXG?#>XU3Q%'HOQ4U?4=8U&<2Q?:K.>]F$T@@)CVJJLH*
M;E8@=2:QM$_X)P^$/"WQK;QA:ZCK4:W&LGQ%<Z7Y%EY5YJ;(%>Z:Y\C[6 [?
MO&A$PB+\[!3B[1C&7;7_ ,EO_P"W6_IG)K:_GI][_P"!_6AY!'_P6*URY^&>
MK^)+/X<Z-J<T.HV6EVNAVWBY5U>RN[G4$LA::G;R0+)9W"^8)?E66(JK@2Y
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MA_\ ':/^&Z?@C_T6+X5_^%98?_': /5**\K_ .&Z?@C_ -%B^%?_ (5EA_\
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MI?\ /U\5/_"@A_\ D>OFG_B*]^,?_1$_AQ_X4EW_ /&:/^(KWXR?]$3^'/\
MX4=W_P#&:.5ARL^EO^(1_P#92_Y^OBI_X4$/_P CT?\ $(_^RE_S]?%3_P *
M"'_Y'KQ'P7_P<P?'OQ[\,_B%XML/@E\+?[)^&5C8ZCK*S>*+R.9X;V\6S@\A
M?LY\P^:PW<C KF7_ .#KGXR1D@_!/X<\,5Y\17B]..AA[]12Y6%F?2G_ !"/
M_LI?\_7Q4_\ "@A_^1Z/^(1_]E+_ )^OBI_X4$/_ ,CU\T_\17OQC_Z(G\./
M_"DN_P#XS1_Q%>_&/_HB?PX_\*2[_P#C-/E8<K/I;_B$?_92_P"?KXJ?^%!#
M_P#(]'_$(_\ LI?\_7Q4_P#"@A_^1Z^8=2_X.T/B]I.GW%U-\$_ASY-I$TTH
M7Q'=EMJ@DX'D^U=I\=?^#E7X_?L[?%*Z\'^(O@G\*SK-G8Z?J$OV3Q3>30^7
M>VD5W#M8P LWERH" , @\GK2LPLSVK_B$?\ V4O^?KXJ?^%!#_\ (]'_ !"/
M_LI?\_7Q4_\ "@A_^1Z^:?\ B*]^,?\ T1/X<?\ A27?_P 9H_XBO?C'_P!$
M3^''_A27?_QFGRL.5GTM_P 0C_[*7_/U\5/_  H(?_D>C_B$?_92_P"?KXJ?
M^%!#_P#(]?-/_$5[\8_^B)_#C_PI+O\ ^,U?T/\ X.FOC9XBM]:DMO@G\-=N
M@Z1-K=SO\2W8S;Q2P0N%_<\MNN(L#TW>E'*PY6?0_P#Q"/\ [*7_ #]?%3_P
MH(?_ )'H_P"(1_\ 92_Y^OBI_P"%!#_\CU\TG_@Z]^,>3_Q9/X<=?^ADN^G;
M_ECZ8H_XBO?C'_T1/X<?^%)=_P#QFCE8<K/I<?\ !I!^RF#_ ,?7Q4_\*"'_
M .1Z^M/^"=/_  3!^&W_  2^\!^(_#GPSE\22:=XIU1=6O?[9ODNI!,L*0C8
M5C3"[4'&#SGGM7Y:?\17OQC_ .B)_#C_ ,*2[_\ C-*O_!UW\9&;_DB?PX_\
M*2[_ /C-'*PY6?KS^W#^Q;X-_P""@?[..L?"WQZVL1^&=<GMKBY.EW*V]R&M
MYTGCVNRL -\:Y^4Y&:^&Q_P:/_LI*N/M7Q4_\*"'_P"1Z^=]?_X.G/C9X:;2
MQ=?!/X:_\3C2;36K?9XEO#_H]U'YD6[]S]X+P1V-4?\ B*]^,?\ T1/X<?\
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M%=_&0CCX)_#?J!\WB2["C)QR?)XKJ/'_ /P<P?'KX:> ?A_XDU3X)_"T:?\
M$O1GUW1EB\47C2BW2=[=A,I@&Q]\;?*">,<TN5ARL]N_XA'_ -E+_GZ^*G_A
M00__ "/1_P 0C_[*7_/U\5/_  H(?_D>OFG_ (BOOC&3_P D3^'&/^QCN_\
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MKWXQ6YDV_!7X:R+&Y0.OB.\V2<X#*3 #@@AAD X(R!G@LPLSZ6_XA'_V4O\
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M@'X/_">/_A;&I:;9Z=X:TNQ\%QQZSI.H(46(R7"J7=E(/&]_,W8(.37ZT_\
M!5K]O!O^"<?['.N?$JU\/MXIUB.]M=(TC2RQ6.YO;J010B0K\VP,<D+\Q' Y
M-?"GA+XB?\%$-,US_A+-%_8Y^ >GZUJ<2S_VC;SZ=;7L@*\;Y/M DS@]&.1T
M-%/?YI_<[FBERN,UT=_PL._8^^%%YH7_  6:^ .G:?\ #VT\*>,O OP5,WQ9
MU#2-*CT_3+N]O(8?(1DA"Q^:)%ES\H.2>H45^P&>:\[_ &9)O%>K_!#PGJGQ
M T+3/#OQ%U+2K63Q-8V)1X;6]$?[V)75F#HCDA3N/%>B5<WK;S?XMO\ 70QC
M&VOI^"L%%%%04%%%% !39CB)OI3J&7<,'I0&O0^!?C7_ ,$%? 'Q9^('CB^T
MOXA?$SP#X/\ BI>B^\<^#M U".'2?$4W&6.4WP[L98(?FR<^E?:WPH^'&B_"
M+P#HOAGP[8P:7H6@64=A86D(^2WAC4*BCZ "NA\A?[O?-*L:H>!2M967E^&P
M2U?SO]^_WA)$)1SG\*^/?^"^D03_ ((\_'T\_P#(M#J<_P#+Q#7V)7Q[_P %
M]_\ E#Q\?O\ L6__ &XAI@?37P3&[X,^$=V6/]BV>2>_[A*Z?8*YCX(_\D8\
M(_\ 8%L__1"5U% ";!1L%+10 FP4;!2T4 )L%&P4M% ";!1L%+10 FP4;!2T
M4 )L%&P4M% ";!1L%+10 FP4;!2T4 )L%&P4M% ";!1L%+10 FP4;!2T4 )L
M%&P4M% ";!1L%+10 FP4;!2T4 )L%&P4M% ";!1L%+10 FP4QX59E./F'0]Z
MDJ&:<12<YZ4 ?RA_MU_)^WA\=%^;Y?B#K8ZG_G\DKR[?]?S-??\ ^U9_P1%_
M:?\ BI^UA\5?%6A_#2.[T3Q-XPU35=.N#KVGQ_:+>:Y=XY-K3AEW*0<$ C-<
M'_PX)_:R_P"B6Q_^%'IO_P D57,5S'QYO^OYFD+9_/OS7V)_PX)_:R_Z);'_
M .%'IO\ \D4?\.#/VLD^;_A5D;;>0/\ A(M-Y]O^/BCF#F/._P!E4;/V&?VR
M"H"M_P (MX3P0,$?\5'$*^?U.U!M 7V4;?Y5]V7/_!.GXR?L.?\ !/C]JC5O
MBAX0_P"$9T_Q/H'AFQTZ7^U+6\^T30^(89)%Q#(Q7"NI!/!S7PF/NBBX7%W_
M %_,T;_K^9I**HHS/&3?\4AJW_7C<#.>WEO7TW_P5?\ E_;V\1?]BKX2'7K_
M ,4]8?R_K7S'XR_Y%'5O^O*?_P!%/7TY_P %8/\ D_;Q%_V*WA+_ -1ZPH ^
M>-_U_,T;_K^9I** %W_7\S74_"R1O[-^)7/'_"O-2;!YY&HZ3_C_ )XKE:ZG
MX6?\@[XE?]D[U+_TXZ10!S#-@X]...*3?]?S-#_?/UI* %W_ %_,TZ%LS+U^
M\.],IT'^O3_>% '3?%5LGP&>_P#PKWP\<XZDVIS7,;_K^9KI_BIT\!_]D\\.
M_P#I*U<O0 N_Z_F:-_U_,TE% '5_"$_Z1XZ]1X UD@XY4^99\CWXKE%?Y1]/
M6NJ^$/\ Q\>._P#LG^L_^C+.N57[M "[_K^9HW_7\S244 .4[G7ZCKS7O?[7
M?'[*'['QY.?AI?=3_P!1F\KP2/[X^H_G7O?[7G_)IW['O_9-+[_T\WE '@2'
M"_Q?F:7?]?S-(.@^E% "[_K^9KZ+_P""3J[OVY+#U_X0OQ9R>2/^)-/T/6OG
M.OHS_@DW_P GQV'_ &)7BO\ ],T] 'S7H+?\22U]HAW_ ,^M6=_U_,U4T'_D
M"6O_ %R']*M4 +O^OYFD)R&ZYP!G)XHH[-^']: .K\2G_BPW@'_:U/7LYYS^
M_AKE=Y/MVP.!74^)?^2#_#__ +"FN_\ I1#7*CI0 N_Z_F:-_P!?S-)10!V'
M[.[9_:(\!_\ 8;BX/.?DDKB[ [;4?4CTZ,U=I^SO_P G$> _^PW%_P"@25Q5
MC_QZCZM_Z$U $V_Z_F:-_P!?S-)10 N_Z_F:ZG6_^3??!_3Y?$NM\X]8[6N5
MKJM;_P"3??"'_8RZU_Z+M: .6W_7\S1O^OYFDHH 7?\ 7\S7>_LHMG]K7X2C
M=C/C321R3C'VI.OM_7%<#7??LH<_M8_"@?\ 4YZ3_P"E<= 'V%_P5-M- _9:
M_P""C/Q9\=:M_9?B;Q]X@UJ.Z\*:)Y@N+31(_L\:C4KX9P9%96\J#U&YN,5\
M.V=IXH^._P 24MX%U;Q5XU\67I "[I[S4+F3K@=SU)(PH48X4"OH;_@JQX*U
M;XA_\%@/C!H&@:9=:MK>M>)X;:SM+:+S)+B5K6 !0/YL> !DG K%\;>-=+_8
MD\,ZCX#\!ZG;ZI\5-6A:Q\7^,+27S(]!0\2:3ID@_CS\LUPN,D,D9P&- !XV
M\:Z7^Q'X7U+P1X#U*UU7XI:M ]CXQ\8V,H:'0H&^632=-D'&[JL]RO4C8A !
M:O)?@3\"=9^/7B[^Q=%:RL;.RMFO-4U.]D\G3="LTY:XN)?X$49('5S\J E@
M*/@/\#-6^/OB\Z1HK6=C96,#:AJVKW;>3I^A6:_+)<W,G\,8Z8^\Y^502175
M?'+XYZ+%X,7X:_#5;JQ^'&GSK<W][.OEZAXUO%Z7MWC[D"](;?[L8Y.7)( /
MOCXJ+X%7_@V8\16_P[76IO#MEXRCMTO=5 CN-9G&HP^9="(<PI*3E8LEE3 )
MR2*^ ?@1\"-.\6>'[[QUXXOKO0?A?H$_DW=[;J/MNOSD9&F:>#]ZX=0Q9N4A
M4L[G@ _??[.VC>#]8_X-GM4C\=ZUJ6C>%[7QO)<W3:;;B6\O?+U*)EM8L_*C
MS,-GF-\J;BQZ&OSH^/\ ^T#J'QSUVQN)K*S\/>%_#\#67ASPY9,?L'AZTR6*
M)N^],WWI)F^:5^O&!0)!\?OC[J'QWURS=K&S\.^&?#L!L?#?ANS8_8?#UKD8
M49_UDC@9EG?+R.V2<8 [OX:_#'0OV?/A_IOQ.^)FFPZO>:LOVOP7X)NB4;76
M!(34M0 PR:>AW84C?<, !\F26?#?X9Z%^SSX&TOXE?$K3(=7U#6$^U>"O!-T
M#'_;I'"ZE?)]Z/3E8;DC.#.RXP$!)\N\=>._$WQY^)UQKNMW-]XG\5^)+I$+
MI$7FNI'^6*W@B'W4P B1)A4"*HXH&>^?\$[OB;KOQ?\ ^"O/P9\4^*-3EU;7
MM7\90&ZN9=J!F\IP$C0<(B*%58T 54P .*_IW1,(/I7\\?\ P3<T'0OV./\
M@H'\'/"=W9Z3XG^,7B#Q!#9:^\@%Q9> +9T;=9Q$?+)J,G"RR [8,%%RV2/Z
M'(SF-><\=?6LV9B[!1L%+10 UU^7ZU\+_P#!1_\ Y2F?L'_]C1XG_P#3))7W
M0_2OA?\ X*/_ /*4O]@__L:/$_\ Z9)* /NH=:*!UHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHH/2@#Y<_P""OG[,7C3]L7]AKQ7\/? .
MF^&=1\2ZW<6?D#7G:*UMECG5S/'(!E)H]N]&7)#@=J^/M$^&G_!6+PUH5KIL
M/CKX&W$=G;+;Q375I#+,^Q< N_EC>V!R<"O=/^#BCXO>)O@Y_P $R/$%YX;\
M07GA-M9\0:1H>IZQ:.R2Z?I]U=I'<2!EP5'EL02"",G!%?F)XP_X)I^"]!^(
M_P"T/X5M_P!I;XBVMQ\/?!.F^-_A_J-YXJ"VGBFQFLWEEWD'+@3(8E,+!L2
MG)%33^*QIRW7]=TOS9^]/[+\GC*;]G_P6WQ$O-'U#QVVD6Y\07.E;?L,M]L'
MG&';QLWYQCC%>A5\\_\ !+37]!\6?\$]/@CJ'AF#4K7P_-X,TR33X=0G$]U%
M$;=,++(/ON.06[XSUS7T-6U6/+-HQC+FBI=PHHHK,H**** "BBB@ HHHH *^
M/?\ @OO_ ,H>/C]_V+?_ +<0U]A5\>_\%]_^4/'Q^_[%O_VXAH ^FO@C_P D
M8\(_]@6S_P#1"5U%<O\ !'_DC'A'_L"V?_HA*ZB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *"N[J,T44 %%%% !01D444 ?$__!PZBI_P2&^*N% ^?2.@_P"HM9U_
M.&.@'?TK^HS_ (*K?LG^(OVX/V%/&GPQ\)WFDZ?KWB5K'[-<:F[K:Q>1>P7#
M[RB.W*1,!@=2*_)\?\&M'QXP1_PG'PI W'&;N_.!V_Y=?S]Z /S3Q1BOTL_X
MA9OCQ_T//PG_ / J_P#_ )&H_P"(6;X\?]#S\)__  *O_P#Y&JN8KF/R_P#&
M0_XI#5O^O*X_]%/7TY_P5@_Y/V\1?]BMX2_]1ZPKZ9\0?\&K7QZU/P]J%K'X
MX^$WFW5K+ A:ZO\ :I=6&3_HWO7SU_P68\(W'@+_ (*5^.M"NGBENM%T3PQ8
M3/%DQN\6@V2,5R <$J<9'2A.X)GS'11CZ_E1CZ_E5%!74_"S_D'?$K_LG>I?
M^G'2*Y;'U_*NJ^%@_P")=\2O^R=ZE_Z<=(H Y9_OGZTE*WWC]:2@ IT'^O3_
M 'A3:=!_KT_WA0!TWQ4Z> _^R>>'?_25JY>NH^*G3P'_ -D\\._^DK5R] !1
M110!U7PA_P"/CQW_ -D_UG_T99URJ_=KJ_A#_K_'?_9/]9_]&6=<HOW: "BB
MB@!T?WQ]1_.O>_VO/^33OV/?^R:7W_IYO*\$C^^/J/YU[W^UY_R:=^Q[_P!D
MTOO_ $\WE '@0Z#Z44#H/I10 5]&?\$F_P#D^.P_[$KQ7_Z9IZ^<Z^C/^"3?
M_)\=A_V)7BO_ -,T] 'S3H/_ "!+7_KD/Z5:JKH/_($M?^N0_I5J@ H[-^']
M:*.S?A_6@#JO$O\ R0?X?_\ 84UW_P!*(:Y4=*ZKQ+_R0?X?_P#84UW_ -*(
M:Y4=* "BBB@#L/V=_P#DXCP'_P!AN+_T"2N*L?\ CU'U;_T)J[7]G?\ Y.(\
M!_\ 8;B_] DKBK'_ (]1]6_]":@"6BBB@ KJM;_Y-]\(?]C+K7_HNUKE:ZK6
M_P#DWWPA_P!C+K7_ *+M: .5HHHH *[[]DY]G[6WPG.-W_%9:3D$9R/M2=/?
MIS]:X&N^_90./VLOA/\ ]CGI/_I7'0!]A?\ !7?X]>'_ -GO]M_XUZ;\-9K]
MOB'XTOA'XI\4S0^5/H5L;:)6TW3QU4NH!EN1\Q#[%QR:^+_@3\"-7^/'BYM%
MT7[)9V.FVS7NKZK>/Y5AH=C'_K+FXDZ!!G@#EV("\XKZ4_X*-? K6?V@O^"P
M?QVTG2I+.PL['5EOM8U>_?RM/T*R2U@\RZN)/X47C '+L549)P?%_CG\=M%E
M\&1_#?X;QW>G?#C3[A;J^NKA?)O_ !G?1Y O+O'*PJ2WDVX^6-<$@N20 'QT
M^.>B_P#"&1_#7X9K=6?PYLK@7-]>W">7J'C>\7@7MY_=A0Y,-O\ =C4Y.7)Q
M7^ OP$TWQ5X;O/'GCR^O/#_PPT*<6UU>08%]KUWC<NG6"MQ),1PSGY8%;<V<
M %/@'\!-.\3^&KWQ]X\O+KP_\+M!N/)NKF$#[=XAO,9&G:>IX:<K@L_*0KAF
MYQG$^/?Q\U#X\>)+.22UM?#_ (;\/P?8?#OA^Q.VQT"T/S^7&/XY6^])*WS2
M-EB>B@ _1KXK?&#_ (7-_P &R?B+5H_#^B>$]+M?&$5CI^D:7%MM].M(M1A$
M<;LWS2N!]^5_F=B6Z$"OAWX<?#+0_P!GGP5IOQ*^)6EKJVH:NOVOP5X(N\[M
M9 8^7J.H*/F33T885&PUP5 X0,:^\_@W>0_ /_@VAFUKQMX$;Q!;OXI&J:7I
M6J!X;>\,FH1FTN9$X,D <!MG <+CH:_+KQQXX\4?'7XE7&M:U=7WB;Q=XFND
M4F./S9KR5\)'##$GRA.D:1)@ # 'J"0[QOXW\4_'OXEW.L:Q<WWB3Q7XHNEB
M=HHS)-=2L1''!!&HX PJ1QJ %08 [U[/?ZE:_P#!/_2[G3=-N+.^^/5] \&I
MZG;LL]K\.H7 \RTMG&4?5&4XDE'%N&9%R^2$U&_M?V!-+N-*TF:VO_CM?PFV
MU+5+=Q<V_P .X9$PUI;/TEU)D)669<B$'8N'W$>1_!+X,>)/V@?B+:>&?"]J
M+K4KQ'NIY[B<+!I]NHW375S,W$<2<L\CGGIDL:!GLG_!(#PCJGB[_@J#\%X]
M)T^_U)]+\1C4KTPQ-,;:VC1C+<3-_"N67YSR3]:_J%7A:_G@_8$^-^@_";]O
M?X*_"?X0WTEQX=NO%]L/%OBU8S#=>.)T5L1)GYH]-B8$QPGF0_.V> /Z'H!M
MA4'TK,S'4444 -?I7PO_ ,%'_P#E*7^P?_V-'B?_ -,DE?=#]*^%_P#@H_\
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M"N0^!7P(/Q8.IZUKFJ-X7\ >&=CZ_KICW>46/RVULG_+6ZE(PL:]!EF.T9H
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M/]>G^\* .F^*G3P'_P!D\\._^DK5R]=1\5.G@/\ [)YX=_\ 25JY>@ HHHH
MZKX0_P#'QX[_ .R?ZS_Z,LZY5?NBNJ^$/_'QX[_[)_K/_HRSKE5^[0 4444
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M$CL/%'AQ0/F^R[B(=03C=Y;&.7'"ENE?"GBGX3_$O]H3XX_M%>)/V:?^%/\
MQ#\/_M&6%KI'BRS\<O/IOB#X<W,-I]C9)[*2,RLFTM(L3A?F5<9&&)'22ML/
M1Q=S]9?#NMVGB72[/4+"ZM[RQOHEGMIH)%DAN(V&Y9$9>&# @AAU!K4KRO\
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M[!__ &-'B?\ ],DE 'W4.M% ZT4 %%%% !1110 4444 %%%% !1110 4444
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MN?\ 0"\9?^%/=?XT<P<Q_/)75ZT,_L^^#_\ :\2ZT1_W[M:_?#_B&P_9<_Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME:CS*/SE_P""LG_!27XB_L=_&/P3HD?@^\70KCQ%::E;WVA>(+<W.LZ;"/\
M38KVW<*UK!N9!YS$Q_,,L*^XOV<O&7BCXA?"33=9\9>&-/\ !^O:@#++I=EJ
MR:M#;QDGRR+E%5)"R;22HQDX!/6I?%/[.O@CQSX@U'5M:\+Z'JVI:MI#^'[N
MYN[-)9)]/=MSVK$CF(MR5[FND\*>%K'P3X;L=(TRWCL]-TR".UM+>,82WBC4
M*B*/15  ]A2IJT'?>XJDFYKM8T$&!2TA.#2!Z?,ACJ***8#7Z5\+_P#!1_\
MY2E_L'_]C1XG_P#3))7W0_2OA?\ X*/_ /*4O]@__L:/$_\ Z9)* /NH=:*!
MUHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^/?^"^__*'CX_?]BW_[<0U]A5\>_P#!??\
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M,U]='D4WR5SG%";3NA]#&O;W2_AQX2>ZNI]/TG1M&M=TLAVVUK:1(O)_NH@
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M9 KXI_X)Y>";.Q_;0G\3ZO\ #_4O!?B+Q#\.-/2S-^EW=S/'%.ZR+]LE0;L
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MXQ?"VWN(=(M(Y8G\66"M$PA0%2#+D$'@CVKI/^&[O@;_ -%H^%/_ (5VG_\
MQVL%?^"8/[-I'S?L_P#P9S_V)FG_ /QFC_AU_P#LU_\ 1O\ \&?_  B]._\
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M^BT?"G_PKM/_ /CM8/\ PZ__ &:_^C?_ (,_^$7IW_QJC_AU_P#LU_\ 1O\
M\&?_  B]._\ C5 &]_PW=\#?^BT?"G_PKM/_ /CM'_#=WP-_Z+1\*?\ PKM/
M_P#CM8/_  Z__9K_ .C?_@S_ .$7IW_QJC_AU_\ LU_]&_\ P9_\(O3O_C5
M&]_PW=\#?^BT?"G_ ,*[3_\ X[1_PW=\#?\ HM'PI_\ "NT__P".U@_\.O\
M]FO_ *-_^#/_ (1>G?\ QJC_ (=?_LU_]&__  9_\(O3O_C5 &]_PW=\#?\
MHM'PI_\ "NT__P".T?\ #=WP-_Z+1\*?_"NT_P#^.U@_\.O_ -FO_HW_ .#/
M_A%Z=_\ &J/^'7_[-?\ T;_\&?\ PB]._P#C5 &]_P -W? W_HM'PI_\*[3_
M /X[1_PW=\#?^BT?"G_PKM/_ /CM8/\ PZ__ &:_^C?_ (,_^$7IW_QJC_AU
M_P#LU_\ 1O\ \&?_  B]._\ C5 &]_PW=\#?^BT?"G_PKM/_ /CM'_#=WP-_
MZ+1\*?\ PKM/_P#CM8/_  Z__9K_ .C?_@S_ .$7IW_QJC_AU_\ LU_]&_\
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MU_\ LU_]&_\ P9_\(O3O_C5 &]_PW=\#?^BT?"G_ ,*[3_\ X[1_PW=\#?\
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M .$7IW_QJC_AU_\ LU_]&_\ P9_\(O3O_C5 &]_PW=\#?^BT?"G_ ,*[3_\
MX[1_PW=\#?\ HM'PI_\ "NT__P".U@_\.O\ ]FO_ *-_^#/_ (1>G?\ QJC_
M (=?_LU_]&__  9_\(O3O_C5 &]_PW=\#?\ HM'PI_\ "NT__P".T?\ #=WP
M-_Z+1\*?_"NT_P#^.U@_\.O_ -FO_HW_ .#/_A%Z=_\ &J/^'7_[-?\ T;_\
M&?\ PB]._P#C5 &]_P -W? W_HM'PI_\*[3_ /X[1_PW=\#?^BT?"G_PKM/_
M /CM8/\ PZ__ &:_^C?_ (,_^$7IW_QJC_AU_P#LU_\ 1O\ \&?_  B]._\
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M^BT?"G_PKM/_ /CM8/\ PZ__ &:_^C?_ (,_^$7IW_QJC_AU_P#LU_\ 1O\
M\&?_  B]._\ C5 &]_PW=\#?^BT?"G_PKM/_ /CM'_#=WP-_Z+1\*?\ PKM/
M_P#CM8/_  Z__9K_ .C?_@S_ .$7IW_QJC_AU_\ LU_]&_\ P9_\(O3O_C5
M&]_PW=\#?^BT?"G_ ,*[3_\ X[1_PW=\#?\ HM'PI_\ "NT__P".U@_\.O\
M]FO_ *-_^#/_ (1>G?\ QJC_ (=?_LU_]&__  9_\(O3O_C5 &]_PW=\#?\
MHM'PI_\ "NT__P".T?\ #=WP-_Z+1\*?_"NT_P#^.U@_\.O_ -FO_HW_ .#/
M_A%Z=_\ &J/^'7_[-?\ T;_\&?\ PB]._P#C5 &]_P -W? W_HM'PI_\*[3_
M /X[1_PW=\#?^BT?"G_PKM/_ /CM8/\ PZ__ &:_^C?_ (,_^$7IW_QJC_AU
M_P#LU_\ 1O\ \&?_  B]._\ C5 &]_PW=\#?^BT?"G_PKM/_ /CM'_#=WP-_
MZ+1\*?\ PKM/_P#CM8/_  Z__9K_ .C?_@S_ .$7IW_QJC_AU_\ LU_]&_\
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M7:?_ /':Q=5_:H_9UUGQKIOB>X^*GP?EU_1X9;:SOF\6V'FP128\R,$3?=;
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M_"G_ ,*[3_\ X[0/V[?@:,'_ (7-\*.!@'_A+M/_ /CM8G_#K_\ 9K_Z-_\
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M7_T;_P#!G_PC-._^-4?\.O\ ]FO_ *-_^#/_ (1>G?\ QJG<5E_7J;3?MU_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP,<U\X?LG^&+[Q=_P7U_;FT715V:IK7@G5[>T6,["]S*ENB'TW%B.3]:\/\
M^"%VB^*+7]G_ ,:>'],_;"L?V;=4\):[,^N>&-0T*TN'N72)(WNC)<31NV6B
M=2@!*F,8^\*CFYH*K#K"]OF9./+*2E]F:C]ZN?KY^S__ ,%AO /[5/[!_C;X
MX>!;34+P> =.N[C5O#=\5MK^TN;>$R^1(R[@JR#&V0 C&3C*L!\J^%/^#H6;
MXD?LZV/C/PC^SMXZ\7ZM;Q2W?B:RTJ\,VF^%;=7(3S[W[.-\KHIDV+%A5P2>
M:\=_X)U_!?X<>#?V%_VV/%7PP^-&O?%O3?$7AN\CUN>[\#S>';6/4!;W,ADA
M=Y&6;<'?(7A0R_WA7T1_P:]Z=;Q?\$6X&6WB5KK5=6:X.T?OSM5?F_O?* .>
MPJZEHPJU(_947]Z=S%RY90C+[3FON2L;'QC_ ."Q5O\ M@_\$?O'OQ/^#7P]
M\7>*[ZXCNO#&MZ+#<"VU#PJ);63SM0=T5]T,*$2AEP&&.5(./'_^#4;]I3XA
M>)O@1?> =4\$^+-8\&P:A?ZO'\1[[47N+.YNCY"?V<JR*6WJ!NSYA')X%>/_
M /!O7&O_  Z'_;0^7.(=2P .O_$KG_SQ7TA_P:/^-M'F_P"":LV@C5=,;7(?
M%VHW4FG"[1KR*)H[8+*8\[Q&QSAMN.#SFNF=&,)RBM?=B_O6I:?-A(S>CYVO
MN/U4E)VM_G-?ST?\%:_"VM_\%>?^"NWQ.\ ^%[IIM'_9_P#AYJ+0A,,MS>V\
M(GD3/W?WEQ-%%D\X1@.E?NI^UW\?]/\ V5_V9/'/Q$U5E6Q\'Z+<ZHP+;?->
M.-C&@/\ >9]J@=RP'>OY_/\ @C/J_P"V+X#T[X@?&CX._!CPK\3%^+M]+'K.
ML>('<++*EQ++.L2K-'^[,D[@\$?*!CBN!1YJK:WBG][5K_B;1]RES/J_RU9^
MG7_!L]^UO+^TY_P2\\,Z9=77VC7?AC._A>\$F6<PH%DMI&)ZDP2(./[N.U<?
M\9_^#EOP]\!?VH_C1\+]:^&.M7NH_"^X:PT;^RM1%Y>>+[O?$!%';B(&$!':
M1FW.56,G:<U\A_\ !O5XZ\7?L*_\%9OB%\"/B1H/_"%ZI\3K%]0&BALV]E?1
MF2[@6'YF&QK:290<DXB0&O3/^"8NBV6K_P#!TU^U-<7EK;W<VFVNJSV<DL8=
MK20S::A>,G[K%&9<CG#$=Z[+*I6C-+1INWHM?Q,8+V?-"6KC)7]'JOP9]!?%
MS_@XLL_@+J?[./\ PF'PIU'0]/\ CIH,6O:G)+JCFZ\)(TQB,1M_LX>Y?(7
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M52D_-67Y'8?#[_@XT.@_&CPCX2^.G[/OQ"^!MGX]O$L]!UG4YQ=6MP7941Y
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ME;TQV/H>*K_\&Z'P9T/]H?6?VUO _B>SCOM!\5:R^GWL+("-DDUT,@'^(9#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M".N>7]MLC/);LS1NLB,LD;*ZE64$%6!KT=A1M-#C=)+H&M[LX#]EW]F;P?\
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MZ/K7B)64RZE!+-97%T% "B9H70R@ 8PV>*Z/QQ:^#?\ @G#^QIX@O/!/@O\
MLOPYX'TV>ZL=!\/Z;)-+=3X.Q$BC5GD=Y"N6P2<\\"O=@#@T<XZ5G*%X>S[@
MI6DIOH?GO_P;[_L,^(OV=O@+XD^*7Q%T^33_ (H?'35I/$NK6L\.R;2X)&+0
MVS \@X.\J>A.*_0JF@<TZMI3<GKTT^XF,;7\]0HHHJ2@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sesn-20211231_g3.jpg
<TEXT>
begin 644 sesn-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME?7%?%__  <'?-_P1\^-2\[CIEKP.O\ Q_VU<N(ERTV_-&U!\U2*/F_]DO\
MX*&?M/?M#?\ !)_Q9^TR?%WP_?5O";:E<?\ "+MX3\FQOK6R*F3-P+@RHYC\
MPC /*@8.:^FO^"*W_!4VW_X*J?L\ZMXHN?#4?A7Q1X9U#^S-9LH)FGM69D$D
M<L+L =CJ<[3RI!SUK\V_^"<GPV^.WQ6_X-W/&6B_#6^\#V_AN_O=8.J020W
MUZ]M0X:]A@=B;=9)(PP3<N/FP<9S7V9_P;7_ !I_9Y\9_LEZAX5^!^EZ_P"'
M=4\/W*77BC3O$$R7&JSW,R#;<R3)\LL;!=JD8"[2N!BO0G&/M:T+;6:7;S_K
MJ<\?X=.?=M'Z14445SF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWV+/#?>W#&,$=:5;7#?>^GM3C\<I_P QG*-X*'9W^9^3O[;/_!,SX]?LZ?\
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M[KWCGQ%XZAAM8WM+NSM+6P$=S%,S3/<31D<1\!%;/MUK[(V?+BF"VVXQCY<
M?_JK.4>9-,=.7+JC\I/^"7?PN_:(_8<_X);Z_P#!V]_9_P#%D_Q%O+K53I=R
M=5TAM'_TL8BEN)?M9=0A.658VR!COFO1/^#?[_@C5XD_X)@^%/%GB+X@:II=
M]X^\<)#;2VFFRM-;:5:0LS)"92!YLA=V8L   0!G&:_1F2+S$*YZ^U$<;(>O
M &.E:>TESRJ]9*S]".5<BI]$[_,?1114E!1110 4444 %%%% !1110 4444
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M_P#"OL?_ (Y0!]&45\Y_\/=_V6O^CB/@S_X5]C_\<H_X>[_LM?\ 1Q'P9_\
M"OL?_CE 'T917SG_ ,/=_P!EK_HXCX,_^%?8_P#QRC_A[O\ LM?]'$?!G_PK
M['_XY0!]&45\Y_\ #W?]EK_HXCX,_P#A7V/_ ,<H_P"'N_[+7_1Q'P9_\*^Q
M_P#CE 'T917SG_P]W_9:_P"CB/@S_P"%?8__ !RC_A[O^RU_T<1\&?\ PK['
M_P".4 ?1E%?.?_#W?]EK_HXCX,_^%?8__'*/^'N_[+7_ $<1\&?_  K['_XY
M0!]&45\Y_P##W?\ 9:_Z.(^#/_A7V/\ \<H_X>[_ ++7_1Q'P9_\*^Q_^.4
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MZ/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\
MAC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X
M/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\
M1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?A
MM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3
M-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\
M;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTF
MB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S
M;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC
M7X/_ /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_
M /1*?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*
M?AM_X3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_
MX3-E_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E
M_P#&Z/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&
MZ/\ AC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\
MAC7X/_\ 1*?AM_X3-E_\;KTFB@#S;_AC7X/_ /1*?AM_X3-E_P#&Z/\ AC7X
M/_\ 1*?AM_X3-E_\;KTFC.: /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1
M*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM
M_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$
MS9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_
M !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO
M2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:*
M/-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^
M&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@
M_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]
M$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&
MW_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,
MV7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_Q
MNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_A
MC7X/_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/
M_P#1*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1
M*?AM_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM
M_P"$S9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$
MS9?_ !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_
M !NO2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO
M2:* /-O^&-?@_P#]$I^&W_A,V7_QNC_AC7X/_P#1*?AM_P"$S9?_ !NO2:*
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M]NO]CVQPD: *HY)X ZU][U\+?\$IO^3[/V[/^RGV/_IGMJ /NFBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^2/^"\'_*'_ /:"_P"Q2G_]#2OK>ODC_@O!_P H?_V@O^Q2G_\ 0TH
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M55HNFWS=-/R_S-.26WS^X_3X2J?XA5&V\6:7>ZM<:?#J5A-?68!N+:.X5IH
M>F] <KGW%?-?_!.#]M;5/VDO^"<7AOXP>.VTK3[YK"]N=5EL\1VQ6TEE1I<;
MF5=RQ;B Q4$\'&*_,W_@G-^T.=!_X*'>&?C!=-XKT>^_:COM8TC7KG4-"N+>
MQM"SEM%,-Q*@@G CC PC'._D4IKDJ2I2W2_';]"=X<Z_KN?N!<>/-#M([YI=
M:TF)=,95O&>[C46A;[HDR?D)[!L9K3CN(YHU9'5E8 AE.00>A%?@E:? /Q%K
M_P"S!I[ZEXV%]_PFW[2[:?KROX?LY6U9HKIE5[@LN9]I4;8G^0<+T%?4/P-_
MX*E?&CQU\9-&OH-+N=8\&WGC*_\ "-QX8M_"36T>FV=H7C6[34"WSW!*!I(0
MI55/RCBKE3:?+U_R46__ $I&-.LJG-R]/RNU^C/U-:55/6AID3JRCOUK\R_A
M5^V=\5OVD_@5;^+-0^,?PQT&U^*ECXBL]/\ !D=@L>M:&UHMPJ?89-S-<3J(
MMT@G"@!N,'%>2? ?]N+XO?";]FW]GSX<Z+XPU*\OO%7@:_\ %]QXE@\)#Q!>
MR>1)LBT]80V-A8EI)GRX4GIC-9:\S@]U;]?\C:/O-)=;_I_F?L7<:C;VEN\T
MLT44,8+.[L%5 .I)/  QUHT_4K?5[&.ZM+B&ZMIEWQRPN'CD'J&'!'TK\HM;
M_P""A'QB_:Q\%^)M!UC4/!OP<AT+X02>*=<T_6-.6;_A(KB<W%N8T>24&&V4
M1A@8V+;I "<5]N_\$I&7_AVY\$MBJJMX0L& 'W>8@>/;T]O6M'3DKWZ.P3]Q
MI/JD_O/H8'-%(O2EJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"OJ1D6V9HP"R*6&>F0*_.;]BO]LW]N#]N
MK]FW0/BEX/\ "_[+.F^&_$TEV+*#5[W7([Q%@NIK9O,6,2("6A8\.>".E?HY
M>_\ 'K)_N-_*OB+_ (-P_P#E#C\)?^NFL_\ IYOJ -3^U/\ @H-_T!?V/_\
MP8^(?_C5']J?\%!O^@+^Q_\ ^#'Q#_\ &J^SJ* /C'^U/^"@W_0%_8__ /!C
MXA_^-4?VI_P4&_Z O['_ /X,?$/_ ,:K[.HH ^,?[4_X*#?] 7]C_P#\&/B'
M_P"-4?VI_P %!O\ H"_L?_\ @Q\0_P#QJOLZB@#XQ_M3_@H-_P! 7]C_ /\
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M_C5']J?\%!O^@+^Q_P#^#'Q#_P#&J^SJ* /C'^U/^"@W_0%_8_\ _!CXA_\
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MJ?\ !0;_ * O['__ (,?$/\ \:K[.HH ^,?[4_X*#?\ 0%_8_P#_  8^(?\
MXU1_:G_!0;_H"_L?_P#@Q\0__&J^SJ* /C'^U/\ @H-_T!?V/_\ P8^(?_C5
M:G_!-+]L;XJ?M)_$?XY>"_BQHW@+2_$_P;\36>@R2>$'NI+&\$UFET6W7+;R
M1O49VKT/!KZZKX4_X)6?\G_?MW?]E)TS_P!,UO0!]UU\+?\ !*;_ )/L_;L_
M[*?8_P#IGMJ^Z:^%O^"4W_)]G[=G_93['_TSVU 'W31110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?)'
M_!>#_E#_ /M!?]BE/_Z&E?6]?)'_  7@_P"4/_[07_8I3_\ H:4 ?07[-G_)
MNO@'_L7-._\ 2:.NUKBOV;/^3=? /_8N:=_Z31UVM ",,BN?^*?PK\/_ !L^
M'^J>%?%FCV'B#P[K4/V>_P!.O8_,M[N/.=KKW&0#^%=#12:N!Y7?_L5_"W4]
M+\66<_@'PK-:^.K6VL?$,+68*:S;VR!((YA_&L:JJJ#V%&M_L6_"_P 3?$#1
M?%6I?#WP;J'B/P[#%;Z9J,^EQO<6<<0 B56(_@P-A.2N.*]4HJN9AY,\]TW]
MEOP#H_AWQ7I-MX-\-1Z7XXOIM3U^R^Q(T&L74N/,FG4@AG;: 6// /6N=T__
M ()^_!G2OA'?> [?X9^#8_!^H7"W=SI0T]/)N9E(*2.<%F=2!ALY';%>R44@
MU/&[C_@G]\&;GPUJVBO\,?!1TK6[Q=0O+<::JK/<A0@GXY$FT %P0Q P<U8\
M:?L)?!_XB^ =%\+ZY\-?!>I>'_#?.EV,NF1B&P]1'@94-_$,X;OFO7**!6_K
MU.'\;?L]>#_B-\*;GP)K7AG0]0\%W5LEG)HKVX%D\"8*Q^6N $4J,*..*9XX
M_9S\%?$D^&!X@\*Z%JL?@FX6ZT#[1;[_ .R)53RPT/\ <81_+D=N,5W=-F_U
M9J9:*XSRN7]D#X7)\$O^%;MX"\+OX!,DDHT)K%6LTD>1I&D5.JN9&9MP(.6)
MR*J']A'X.W7@SP[X?D^&?@L:/X0N3=Z+:#3$5-/F((:1,<[FR=Q).[/.:\K_
M ."C7[0'Q$^%7QE_9W\(_#_7]-\.M\4O%MSH>JW-YI::@%@6T>4,J,00ZLN1
MA@,XSD9%>%?"G_@KIX[^&WP-UAO'$WPS\0^(/#?Q#U?P0^K:YKA\+)JD=F5*
M7 BCM[A?-8-AE0*O&1Z5?*Y1<GW_ ,C24&E?^NO^1]L77P+^%OPL^ EYX"ET
M'PEX=^'%XDMI<Z1(D=KI<B7#,9(RK$+B1F8D \DU:\1_LR_#SQK\//#?AG4O
M"?A_4/"_A&>TO-!T^2 -;Z7);#_1I(0.%,?&TCH*^)?B=\;_  #_ ,%#?A3I
M.I>+;?X4Z_X\L8M8/A'P3+XV:Y\+Z])'"$EFGN'M8QYL2L6 *93:"#U(]N_X
M(K^)E\4_\$S?A5/'?:IJ30Z?+:R2W^6D#1W$B/&K9;?$I&U'R=R!341IN7-S
M/4QJ2Y;(]DA_8Z^&4.C6NG#P+X973[/Q ?%4%N+4;(M6+ES>@?\ /8L<[NN:
M73OV-?A?HWQGN/B)9^ /"-OXVN6,DFM+IT8NRY^](&Q@.1P7 #'U->GKT_PH
MJGKJ]P44KV/,_"O['GPQ\"_$76O%FC?#_P (Z;XD\1*Z:GJ=OIL:7-X'&'#,
M!_&/O8QN[YKG[_\ X)S_  /U7X=V_A.Z^%G@N?PW9WDNH6VGO8*8;>>4[I&C
M'5 QZJI"GTKVRB@H\K^(7[$_PI^+%OHL7B3X<^"M8C\-VCV.E)<Z5&RV%NZ[
M6A0  ",KQLZ>U=UX ^'^C_"SP7IOAWP[IMGH^AZ- MK8V-K'Y<%I$HPL:+_"
MH[#M6U10 B\"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPS\<>,E\,^*-#T#_ (2:\^VV<R6<=ESAA<;?+9SM($8)8GH*ODE>R_F:_P#
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M$IO^3[/V[/\ LI]C_P"F>VK[IKX6_P""4W_)]G[=G_93['_TSVU 'W31110
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M75(?#_A70=)BUO4)M6OUM[-%6[NYL>;.XQS(V!D]\5^37_#F[_@H[_T>HO\
MX/\ 5O\ XS1_PYN_X*._]'J+_P"#_5O_ (S1Y%<SM8_5;XO?LK_#OX_>&8=%
M\;>"O#/BC2;:9;F&TU#3HI8HI5Z2*-O#=N.U==X;\)Z=X.\/6>DZ18V>EZ7I
M\0@M;2TA6&&WC P%1%   '85^/?_  YN_P""CO\ T>HO_@_U;_XS1_PYN_X*
M._\ 1ZB_^#_5O_C-!)^R@0A0HQ@=*,M_LU^-?_#F[_@H[_T>HO\ X/\ 5O\
MXS1_PYN_X*._]'J+_P"#_5O_ (S0!^RF6_V:1Y&C&2/RK\;/^'-W_!1W_H]1
M?_!_JW_QFA?^"./_  4;C/S?MJ+[#^WM6Y_\@T ?LE"[,6#;?E_#/X5)7CO[
M!'PA^(?P&_91\(^$_BMXQ'Q \?:/;O%JOB 7$MQ_:3F1V5M\H#G"%1R!TKV*
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (KW_ (]9?]QOY5\1?\&X?_*''X2_]=-9_P#3S?5]NWO_
M !ZR?[C?RKXB_P"#</\ Y0X_"7_KIK/_ *>;Z@#[7UG_ )!-Y_UP;_T$U_'=
MI?\ QXI]3_,U_8EJ*&>*2'M,A4_0@C\Z_-6R_P"#6OX"16RK_P )=\6#UY_M
M*R&>?^O;I0!^#]%?O+_Q"W_ 7_H;OBQ_X,K+_P"1:/\ B%O^ O\ T-WQ8_\
M!E9?_(M:&A^#5%?O+_Q"W_ 7_H;OBQ_X,K+_ .1:/^(6_P" O_0W?%C_ ,&5
ME_\ (M 'X-5Z-^QQ_P GF_!G_L?-$_\ 2V*OV?\ ^(6_X"_]#=\6/_!E9?\
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MPK\#OA;X;\1:-X9FGT_4]-\-VMO=6D@9-KQR*@96'J#619][?LW?\F[> ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17O\
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M:;XBB>,/N*CY%F3.'5,#/8=[E[VW;^O\OE<Q^%J[Z_U]^_SL>3_\'-/[27Q
M_9M^ 7PCO_A_XV\2^";S5?'%O97UQHU[):R74!QF)RG+*?0\5]/?&W_@J+\'
M?V5OB]X2^'7Q%\47'AWQ%XHT%]=@N;JU?[ EK$C%Y);G[B'*,,$Y)QZBOBO_
M (.T3_QC;\%/^RA6A_45S_\ P48\ :+\3_\ @X?_ &/]&\1:;9ZOI4GA1IY+
M2[C\R&5XVG=-ZG@X8 X/&0*PPVO-%]9M?^2)FF)DHQA)=(7_ /)['W3^QO\
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KW_CUD_W&_E7Q%_P;
MA_\ *''X2_\ 736?_3S?5]NWO_'K)_N-_*OB+_@W#_Y0X_"7_KIK/_IYOJ /
MMJ_@:X@D11RZ,H)Z#((Y_P#K5^8L'_!";X@11!3XY\'$C/(MKGG\\_SK]0J*
M /S _P"'%7Q _P"AX\'_ /@/<?X4?\.*OB!_T/'@_P#\![C_  K]/Z*OVC _
M,#_AQ5\0/^AX\'_^ ]Q_A1_PXJ^('_0\>#__  'N/\*_3^BG[20'Y@?\.*OB
M!_T/'@__ ,![C_"MOX7?\$4O'7@/XJ^%]?N/&7A&XM]!UBTU*6*.WG\R5(9E
MD**2, D#%?I)14N3>C ;'RO-<+\:_@'X;_:&\/VNC^,-.EU?1['4H-62U$\D
M,4T]N^^(2*C#S$#8.QLHV!D<5WE(<YJ0O8\L_:9_8^^'/[9'@ >%?B=X.TWQ
M9H\;B:!+K<LEG*!@202H0\+@9&Y"IZ59_9S_ &4_A]^R3\/(_"?PV\(Z5X0T
M&*0S&VL4*F>0X!DED)+R2''+.68^M>D_-3ATH3:>@I6DK,\;_:T_86^&7[<?
MA[1=)^)_AMO$FF^']075+"$7UQ:"&Y7&V0F%TW=!PV1[4WQM^PA\+_B+^TGX
M/^+VL>&/MGQ"\ V;6&@ZHU_<K]AA8,"GE*XC?[S<LI/->S'I2 $5.UK='?YC
ME[UK]#QSQG^PO\,O'_[4_AOXU:QX::\^)7@^T?3](UC[=<)]C@<-N40JXB;(
M=AED)Y-<3^TY_P $BOV=_P!LKQ['XH^)/PIT+Q%X@CD4OJ(:6UFNPO"B;R77
MSE'3#@BOIJBCE6EBN9[GB_C_ /8%^$OQ(_9;G^"^H>!],M_AC<QK"_A_36?3
M[<*KAQAH&1P=PR2&!))SFNV^&/P3\-_!OX4:7X&\.Z5%8^%=#L%TVST]F:>.
M.W4;1&2Y)88X^8DFNQYI""35W=G'N9\OP_W=3Y3LO^"(W[*VF_$Z/QE#\$/!
MJ:[%<"Z0>5(;-9LY\S[,7\C=GG.RNV_:P_X)L?!3]MV729OB;\/])\27>A[5
ML;OS)+.ZMD#;A&LT+))Y>?X-VWVKW@4,,BI^SRE?:YCY[^''_!+OX%_!KXUZ
M'\1/"/P^L?#/BWP[I1T2QN-,N[BWABM#DM&T"R"*3)).YT+$]37(?%__ ((B
M?LN?'?XDS>+/$GP:\.7&N74OGW4UK+/90W[GEFGAAD6.3/?<I[U]8J,4HSFF
MG;4.ECSZY_9@\ 7/P47X;R>"?#,G@!+86O\ PCW]GQ_V<8AT7RMN..H/7/.:
M\I_9Z_X)#?LX_LK_ !+7QAX#^$?AG0?$D);R-0/F7,MEGK]G$K.(<_[ 7J:^
MF*#1>SYD'2Q'''MC QBOG']IS_@DE^SO^V'XY7Q-\1OA3X<\0>(-ZL^H#S;6
MXN=GW1,867S1V^?/%?26314\MY<S#5*R./\ @Y\%/"_[/GP^L?"W@GPWH_A7
MP]IR[;;3M-MUAAA]>%X)]6/)KS/X)?\ !-?X+_LX_M#^)OBQX-\$VNC^/O&0
M<:MJ:74\OG^8P:3;&[LD>Y@"=BC->]MTI,9'-5>5^;J*R4>5'C?[5'[!'PC_
M &V]/LK/XI> =#\6QZ=N-G<7*,EW9;NHBGC*R)G'16Q4/P(_X)^_!_\ 9>^%
M6L>#?A_X!T3POX?\0120:I#9*RS:BCJ5;S9R3*YPQY+9&>#7M7S T#<!4QND
MTNNX[MM2_E/+?V0_V-?AU^PU\*SX+^&/AW_A&?#?VJ2\^Q_;9[L^:^-S;YG=
M^<#C=BNX\?\ @33?B3X1U;0=9M?MVCZY:26-[;EV4312*4=<J01E21D$&MP4
M4ZGO_$"T/A./_@VR_8Q@,+#X,6\C6X4(9/$&IOP.@.;C&*^GO@1^QY\,OV9?
MAC<>#/ ?@70?#/A>\#"ZT^UMP8[W<I1O.+9,F5)!WD\&O3J*25H\G0#Y,\,_
M\$0OV6?!=]XBN--^#N@VLGBB&:WO0D]P4B652LGV=#(5MLJ2,PA".V*[N/\
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M4I__ $-*^MZ^2/\ @O!_RA__ &@O^Q2G_P#0TH ^@OV;/^3=? /_ &+FG?\
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M;_\ .*-_^<5\9_\ #EK1_P#HX[]K[_PZ5Q_\;H_X<M:/_P!''?M??^'2N/\
MXW0!]F;_ /.*-_\ G%?&?_#EK1_^CCOVOO\ PZ5Q_P#&Z/\ ARUH_P#T<=^U
M]_X=*X_^-T ?9F__ #BC?_G%?&?_  Y:T?\ Z.._:^_\.E<?_&Z/^'+6C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)3?\$2/%W["7[6^N?%WXG?&>X^*OC#5-";P_823I.9A;%HVD:66XED=R/+B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS$ 5O1K*7[V6SBS.K%QCR=3[QC.:?38QS3JB]R@HHHH **** "BBB@ HHHH
M*^2/^"\'_*'_ /:"_P"Q2G_]#2OK>ODC_@O!_P H?_V@O^Q2G_\ 0TH ^@OV
M;/\ DW7P#_V+FG?^DT==K7%?LV?\FZ^ ?^Q<T[_TFCKM: "BBB@#Y-_X+2?\
MF277_8<L/_1AK\E>_P"?\S7ZU?\ !:3_ ),DNO\ L.6'_HPU^2O?\_YFM:>Q
M$MPHHHJQ$6H?\>,G^[_[,*_H%^'7_(AZ%_V#K?\ ]%K7\_6H?\>,G^[_ .S"
MOZ!?AU_R(>A?]@ZW_P#1:UG4W W****S- HHHH **** "BBB@ HHHH ****
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M=K0 4444 ?)O_!:3_DR2Z_[#EA_Z,-?DKW_/^9K]:O\ @M)_R9)=?]ARP_\
M1AK\E>_Y_P S6M/8B6X44458B/4#_H,G^[_[,*_H$^'7_(AZ%_V#K?\ ]%K7
M\_>H?\>,G^[_ .S"OZ!/AU_R(>A?]@ZW_P#1:UG4W W****S- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX6_X)3?\
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M^T]X5_9$^%%SXT\9?VY_8EI/%;2?V3H]UJMSOD;:N(+='D(SU(7 ')Q7YO\
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M1]0\1:E#J&DW4EG=1C1[IO+EC.UAD)@X/<51_P"'OOP)_P"AFU/_ ,$EW_\
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MV'+#_P!&&OR5[_G_ #-:T]B);A1115B(M0_X\9/]W_V85],_\%6_^3FO#_\
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M'Y=,N()[?P];6^NVGV)8@(;74XV$L-K*8=SQ.LC?,0'%0?#_ /X(A^!_AO\
MM$KXPL=8TV;PTOBB7QA%HUWX7LY[Z*^DD,I5=1<EQ )"7"A X/ D XK[G\I=
MNW:,>E B5>BKZ]*I5)7)MI;^NWZ$-JFV7YN6P1TZ?_6JQ2*BH/E&*6HU&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSE/IHUYM-K\C"52$;03W/NA#VIU-5OFIU8QVN4%%%%4 4444 %%%% !1110
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M,(LKF^CF2./[6LZL6@D3R\@)GKU-?"?_ !$A_M-?]&1>,O\ OUK'_P KZ/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]!>OF;4/^/&3_=_]F%?3/_!5O_DYKP__ -B;IO\ Z"]9]0/FNBBBM "O8/\
M@GW_ ,GQ?"__ +#'_M)Z\?KV#_@GW_R?%\+_ /L,?^TGH XW]H;_ ).(^(/_
M &,E_P#^CFKD:Z[]H;_DXCX@_P#8R7__ *.:N1H *#THH/2@#[?_ ."%'_)>
MO'G_ & 8/_1XK]/:_,+_ ((4?\EZ\>?]@&#_ -'BOT]K&>Y40J*:-I&_V?K@
MU+2,VW_Z]24-17"\G-+AO:@2<4&3'\+4 &&]J,-[4Z@G H ;AO:C#>U!EP>A
MIP.30 W#>U&&]J=36DVG[I[<T &&]J,-[4@FS[$G ![T_- #<-[48;VIU#':
M* (YED=,*=ON#R*(8V0DMCGT_P _K2^;\W3C.,@TY7W4 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .-_:&_Y.(^(/_8R7_\ Z.:N1KKOVAO^3B/B#_V,E_\ ^CFKD: "@]**#TH
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M?MV?]E/L?_3/;5]TU\+?\$IO^3[/V[/^RGV/_IGMJ /NFBBB@ HHHH ****
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M-4<;?/CTJ2L$:;ZA1113 **** "BBB@ HHHH *^2/^"\'_*'_P#:"_[%*?\
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M?^17U+_KTE_] -9E'Y9:/_JK'_KI%_.OU='2ORBT?_56/_72+^=?JZ.E:3Z
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M1<>1+[74SE*&MCK?V'?VF;C]K/X"V/C"XA\.QS33S6LIT/5UU2QF:-L"6*4
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M4I__ $-*^MZ^2/\ @O!_RA__ &@O^Q2G_P#0TH ^@OV;/^3=? /_ &+FG?\
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M,F!\Z8=LH>#43YM.7NK^EU?[U<I=?1GSE\'O^"H'B#_A$?&D?CKX7ZY?^+O
M/CFY\$:C;^!1'J-K(T=NEQ'>#[3+"RQO'(JX)9@P/&.:\]_;X_X*96'BO]G)
M/"MA/XJ^">M?$1M3L#J7B9[;2K[3[&TLS///;/'/(HFD9X[>+#[]\C$ ;0:^
ME+__ ()I?!WQ#>^+I/$'@FQ\7Q^-/$\GC"^AUW_38(=2>!+9I84;B,>4BKM'
MOSDUN:'^P;\)/"/POUKP;HOP[\+Z'H&O)<"[MK&PCC^:>+RI9$;!*2%?XAZ
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M_P /-/\ @JU_T1_Q-_X:J;_&OWX)P>M&[ZT!S>1^ _\ P\V_X*M?]$?\3?\
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M/^)O_#53?XU^_.T^M)G'K0'/Y'X#_P##S3_@JU_T1_Q-_P"&JF_QH_X>:?\
M!5K_ *(_XF_\-5-_C7[\;J3=]:!\WD?@1_P\T_X*M?\ 1'_$W_AJIO\ &C_A
MYI_P5:_Z(_XF_P##53?XU^_ .32[3ZT"Y_(_ ;_AYI_P5:_Z(_XF_P##53?X
MT?\ #S3_ (*M?]$?\3?^&JF_QK]^#\O>C=0'-Y'X#_\ #S3_ (*M?]$?\3?^
M&JF_QH_X>:?\%6O^B/\ B;_PU4W^-?OON^M+N^M ^;R/P'_X>:?\%6O^B/\
MB;_PU4W^-'_#S3_@JU_T1_Q-_P"&JF_QK]^=I]:0C ZT"Y_(_ ?_ (>:?\%6
MO^B/^)O_  U4W^-'_#S3_@JU_P!$?\3?^&JF_P :_??=]:4')ZT!S>1^ _\
MP\T_X*M?]$?\3?\ AJIO\:/^'FG_  5:_P"B/^)O_#53?XU^_&T^M!.T]: Y
M_(_ ?_AYI_P5:_Z(_P")O_#53?XT?\/-/^"K7_1'_$W_ (:J;_&OWXW?6C=]
M:!\WD?@/_P /-/\ @JU_T1_Q-_X:J;_&C_AYI_P5:_Z(_P")O_#53?XU^_ ;
M-+@^M N?R/P&_P"'FG_!5K_HC_B;_P -5-_C1_P\T_X*M?\ 1'_$W_AJIO\
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M0/\ $C2M2&E0EE)F^S0J))<$ ;5()S[5^K#PK(VXCYO6ODG_ (+MKY'_  2
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M ,.YHO\ \11_PW#^UK_T9%=?^'<T7_XBOLO8/0?E1L'H/RH ^-/^&X?VM?\
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M\!:YJTFA6>H#X@V1DDO8]VZ(P_9_,&-C?,5QQ7#G_@[CS_S;?K'_ (6UM_\
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M>TOP+X%_9<U;6/$VL)++:VK^/K*W$B1+O<[Y+<*,+D\D=/6OQ+ &>E?9/_!
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MYB/S8/WHM/C8$2S_ ,8S&G))!RARL_93X2?\%HOCI\<_V=F^+'A?]CW4=0\
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M?!/@G4K75?'.I0M9^+/%MI)F*T3HVEZ=(.D8Y$T_\9RJG;G-<I7*S]&O&?\
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M_'/PY^S-^W_?>)/"RRZC\:]6\)Z?9VE]=6H^Q^";0-<#[3;ALB:^FWL%<C;
MJ[N79:_,?X;?#/Q)\=?B/8^'?#MG>>(/$>N3,\0>8MN;EI9YI&/RHN79Y78
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M_P .YHO_ ,17V7L'H/RHV#T'Y4 ?&@_;@_:T)'_&$=UUY_XNYHO'_CE>>?\
M!$/Q3XC\;?M.?MH:MXN\)OX%\2W_ ,1["6_T!]2BU)M,?^R+<!/M$0$<F5 ;
M*C'S8ZBOT-**>U?#'_!*?G]N[]NL_P#53K ?^4>VH ^Z:*** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "ORS_X.N/^31/A3_V/Z?\ IMOJ_4RORS_X.N/^31/A3_V/Z?\
MIMOJ /PW/6B@]:*T- K-\:_\B7K/_7A/_P"BVK2K-\:_\B7K/_7A/_Z+:@#[
MT_X. ?\ D[OX7?\ 9'/#_P#Z47]?#M?<7_!P#_R=W\+O^R.>'_\ THOZ^':
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MO-\+/^RNZC_[<5\64 %%%% %77_^1?OO^O=__037TQ_P5>_Y/6N/^Q/\,?\
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MFO :]^_:S_Y,W_8Y_P"Q!UO_ -/US7@- !1110!Z3^QC_P GI?!;_L?=%_\
M2R*N_P#^"NW_ "E'^.W_ &,I_P#2>*N _8Q_Y/2^"W_8^Z+_ .ED5=__ ,%=
MO^4H_P =O^QE/_I/%0!\[GK10>M%  OWA7T1_P $Z?\ C[_: _[(CX@_]&6M
M?.Z_>%?1'_!.G_C[_: _[(CX@_\ 1EK0!\YV?_'G#_US6I*CM/\ CSA_ZYK4
ME !1110!]I_$;_E7F^%G_97=1_\ ;BOBROM/XC?\J\WPL_[*[J/_ +<5\64
M%%%% %77_P#D7[[_ *]W_P#037TQ_P %7O\ D]:X_P"Q/\,?^FN&OF?7_P#D
M7[[_ *]W_P#037TQ_P %7O\ D]:X_P"Q/\,?^FN&@#YQ'2B@=**  =:^R/\
M@@&-W_!6/X<\9_XE^JX_\!:^-QUK[(_X( G'_!67X<9_Z!^J_P#I)0 []KCX
M(Z)\-_VR?C1\3OBK932>')O'.I#PUX6$AAO?&TZLHW,?O1Z<G_+28@;\&-.2
M37R]\9?C1X@^/GC^Z\2>(KJ.ZU*\"6\%M;1>3:V-NF%@M+:)<B*%!M55 Y[Y
M9LGTW_@I]XXUCX@_\%$/C%/KFJ7VM36'BFYTNS-PQD>*VBVK';H!_" <;5]<
MC)-:&F:9:_\ !/\ TRUU;6+>UU#X[7T"S:9I4\:S6_P_B=<I>7*<A]0=2&B@
M.1"#O?Y\8 #2M(L_V!=,@U;6K>WU#XYZC")]'TFXB66W^'\4H^2\NT.5?42I
MS%"?]0,,X+$ >*:#H'B+XQ_$6WL=-@U+Q'XJ\27F$7>9KJ_N';+.SG.">2[M
MPJY)Z4W0O#_B'XQ_$"WL;"WU+Q)XH\37>T N9KK4IY22[NS=2QR6<G  SFO6
M_&?CC2_V6O#U]X(\#ZE#JGC75HS9>+O&%J_R0KU?3--<<K'QB68?-)@J#MY(
M!^RG_!/GX?6?PC_X(4Z_H-CX@T_Q-)IV@^(5N;S3LBUCN<3F6&.0G#B-\IY@
M^5BI(K\'?V;_ ():M\>)K>QLKBVTS3=+T]+[7-;OLQV.BV@49FF;IST6,?.[
M8QFOW'_X(TZ78ZK_ ,$!I+*\OH](T^ZTKQ#%<7AB+)9HSW :38.2%!S@<\5^
M+7Q2^-&EW/P^T[X=_#^.;3/AQHJQSR23?+>^*;I% -_>>H;_ )8PGB)<'[Q)
M&9F6OC7\:=*U'PK#X ^']O=:7\-]*N%N)'G 6]\4W8&W[=>8YY_Y90_<C!Z;
MLD3_ +/G[/6F>+?#5_X^^(%Y<>'_ (5^'9Q'=7$'_'WXANL9&G6.?OS-P&E&
M5C4DGD4O[/W[/&F^*_#-[\0?B#?77A_X5Z#/Y-Q=0#;>>(;OJ-.L0?\ 62L.
M'DQB('.16'^T1^T'J7Q\\16#S65KX=\+^';<VGAOPY9-ML= ML_=0=Y6^])*
M<ER?2M#0J_M/_M ZE\?M1@:2SM?#_A;PW;"Q\.>'+'*V.A6N<A5'\<K#!EE?
MYF;O@5^R7_!>+Q3X'\%_L@_ 'Q%XLT^X\1WVCW:2Z#H94_V?JEVVFX'VN1?F
M$,:GS"J<N5"\ FOR=\%> =%_9W\ V/Q*^(FGQ:IJ&HJ+GP=X/NOE;6,, +Z]
M'5;)6!PO!FP ,KDU^E__  <Q_:O$_P"RG^S>T=GYU]JVLE8[:SBY>2332?+C
M0>IX 'L*!=3\BO'/CCQ)\:_B-<:UK5U>:_XDUZY1#LB!EN)!\D=O#&O"(.%2
M-!A1@"O>))K7_@G#I+P0-9ZA^T1?PB.6==LUO\,89%Y5"<A]596/4%;<$$_/
MT+FYMO\ @G#I$EO;O8WW[0U];;)IU"SV_P ,XI%!*(#E9-493U/%N#G[YP/#
M?AG\,O$7QS^)%GX9\-V-QK'B+6Y795DFR>[O<3S.?DC7YWDE=N "2:!C?A?\
M-/$GQS^(MEX=\-V=YKGB36YGE DDRQY+2W$\K9"1J,R22N< 9)-?;/\ P31^
M+>A_ [_@H;\'?AG\+=0AU1-4\0_9_&WC2./Y_%+I!(3966X;H=-C=01_%.5#
M$A0JU\Y?%'XIZ#\&/ .I_"_X7ZDNIQZHOD^,_&< *2>*G'6RLSPT6FH0,\YN
M2NYOEP#Z-_P1%^#/B+XD?\%'_AGKFDZ>)-%\#ZN+K5K^640VUJCP.D<09L!I
M7)PL2Y8X.!@&BUQ-'OW_  73^ -U\;O^"L/B"ZN]4M_"_@GPQX&T>\\2^);M
M3]GTB$RW04*!S/=2G*10+\SMZ $U\,_'[X_VOQ$TO3/!_@_39O"OPN\+2-/H
MVD.W^E7DY&QM3U CB6\D7)QRL2_(@ !)^Q_^#E_XJ^(=:_;ZA\$W&I.WA70?
M#>G:K:Z:JB.,7DK7*M</M ,DFQ<*SDE 6"[<DU\D? WX':+;>"_^%E?$R2^L
M_AS9W#6UAIMI+Y&I^.;Z/'^AVA(/EQ*"//NN0@RJY<@4D"&_!'X&Z+#X(;XF
M?$XWEC\-[*=H+#3[1U34O'%\HRUC9L>5MU(7S[HY$2DA<N0*Y/X[_';6OCWX
MQ37-<6QT^ST^V33M*T>Q4Q:9H5BG,5I;+_#&F<D_>=P22Q.:/CG\==:^/OC)
M=>UI;&PMM/MA9:3I6G1FWTW0;-#\EI;1_P ,:]6/WI&)9LL23ZAX1\):;^Q9
MX=T[QEXTTVSU?XGZO E]X1\)Z@@DM_#\#\PZOJT7(8D?-;VC8R<22#: "QGZ
MH_\ !LG\!=>^"?P:^)MSXA:SL]4\4ZAINI1Z+YO_ !,M-MC;R""6ZA(_<^<A
MWHC?,5&2!D5^H<0VQ@>E?DO_ ,&L'BO5/'.A?M#:YKNH7FK:UK'B73;J]OKJ
M0O->2M;29=B>Y&..@& .!7ZTH=R#Z5$MS-BT444@"OA;_@E-_P GV?MV?]E/
ML?\ TSVU?=-?"W_!*;_D^S]NS_LI]C_Z9[:@#[IHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\K_ &O=7\3^&?V7?B'J7@O4M+TOQ=I^A7MWHUYJ4L4=
MG:721,T;RM-F-8P1\Q?Y0,YKU2O(?VX?@+>_M0_LB?$[X=:?>1Z??>-?#M[H
M]M</]V*26(HA?U4DX/;&:QKJ3A[I=-VDF?BU^S9\?/\ @IW^WW\/5\8>%/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ(_X)T_\??[0'_9$?$'_ *,M: /G.T_X\X?^N:U)4=I_QYP_]<UJ2@ HHHH
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M-Y\?[G1IUM;?0?"OA^P2U\-^'K4;;31+$*-J@?Q2MP7E^\Q)[<5F9EG]H?\
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M9X&,-7Q+_P .>OVHO^B'^-/SMO\ X[5(I'S;17TE_P .>OVHO^B'^-/SMO\
MX[1_PYZ_:B_Z(?XT_.V_^.U11C_\$J_^4G_[/?\ V.L'_I+=5\_V_P#R\?\
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M  OWA7T1_P $Z?\ C[_: _[(CX@_]&6M?.Z_>%?1'_!.G_C[_: _[(CX@_\
M1EK0!\YVG_'G#_US6I*CM/\ CSA_ZYK4E !1110!]I_$;_E7F^%G_97=1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFF_L3Z!IWBWQ=IMIJOQ7U2W2]\*^%KZ+S(?#43#,6JZG$>DQ^_;VS9ZB208
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M.^'K8[H])MS;2$[G_P"6DTA >20\LQ'0  ?IU&,1KVXZ5^4W_!K#\,=>\(?
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M_P %\_\ E$-\:O\ L&VG_IPM: /YJV^^WUHH;[[?6BM#0*5/OCZTE*GWQ]:
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MS1-2CU:Q2>&1)[>15:*9&W+,I&0RGN"".::N_P @+E?)'_!>#_E#_P#M!?\
M8I3_ /H:5];U\D?\%X/^4/\ ^T%_V*4__H:4 ?07[-G_ ";KX!_[%S3O_2:.
MNUKBOV;/^3=? /\ V+FG?^DT==K0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4UXA)UIU% #1$H%'EC_ ":=
M10 WRQ_DT-&"O?\ .G4'I0!^%/\ P=6C'[8'PEZC_BCKP<$]/MHK\P:_3_\
MX.K_ /D\+X2_]B=>?^EHK\P*KF*3"BBBJ*/2?V,?^3TO@M_V/NB_^ED5=_\
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M*^ /[/K_ !>GU'5M5U1?"OP_\+JDWB#Q'-'YB6:G[L$"''GW<C?+' O))R<
M$T 'P&_9];XPSZGJFJZFOA;X>^$T6;Q)XCGCW)I\9X2&%1_K;N7E8HER2W+8
M49J7X_?'V/XH1Z5X9\-Z8WA7X:^%BW]A^'_,#O([</>WCKQ/>RJ 6D/" [$P
M <K\>_C_ !_%6WTKPSX:TEO"?PV\+LR^']!63S) SC#7EV__ "VO)<$NY^5
M=B8 .=?X)_!/0-%\#+\4?BA#=1^!//:'1-$BE\F^\>W:8W00G[T5FG'FW.,
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MO0_^":GQ0U[XR?\ !8#X+^(O$E\;_5;[Q( T@3RH;>-+:58[>%!PD2+@*@
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M )/L_;L_[*?8_P#IGMJ^Z:^%O^"4W_)]G[=G_93['_TSVU 'W31110 4444
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(YVHQQGCI2T4
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M(-?M.?'35=/M;+_A4WAGP/X70VOAGPS:Z]<M:Z7!R-\C?9?WUP^=SS$!F)]
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MP@IP&/SHH)"BBB@ KX6_X)3?\GV?MV?]E/L?_3/;5]TU\+?\$IO^3[/V[/\
MLI]C_P"F>VH ^Z:*** "BBB@ HHHH **** "BBB@ HHHH **** "OCS]O_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MURII=0E[S3?06BBBF!'.KLPV]*_+']K+_@DO\3/'G[8.I>-?!O\ PFUG\/\
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MV;/^3=? /_8N:=_Z31UVM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?"W_!*;_D^
MS]NS_LI]C_Z9[:ONFOA;_@E-_P GV?MV?]E/L?\ TSVU 'W31110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?)'_!>#_E#_\ M!?]BE/_ .AI7UO7R1_P7@_Y0_\ [07_ &*4_P#Z&E '
MT%^S9_R;KX!_[%S3O_2:.NUKBOV;/^3=? /_ &+FG?\ I-'7:T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNNF^(6D6/C>P\.W&K6,>N:E;R7=MI[2J+B>%" \JIG)520">V17P/^U5\8O
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M> /&/PZ^$-C<^$S\25UCQM\&=,UGQ9+!=7EUJ5[.-0M%O9U\PMY=Z;-K@ (
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M?^"PGPI\1_&[_@F7\:O"?A'1;[Q!XDU_PY+9Z?IUF@:XNY&=/E0$@$X!/X4
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M4:7_ /)M 'VM17Q3_P /:O'7_1F/[57_ (*-+_\ DVC_ (>U>.O^C,?VJO\
MP4:7_P#)M 'VM17Q3_P]J\=?]&8_M5?^"C2__DVC_A[5XZ_Z,Q_:J_\ !1I?
M_P FT ?:U%?%/_#VKQU_T9C^U5_X*-+_ /DVC_A[5XZ_Z,Q_:J_\%&E__)M
M'VM17Q3_ ,/:O'7_ $9C^U5_X*-+_P#DVC_A[5XZ_P"C,?VJO_!1I?\ \FT
M?:U%?%/_  ]J\=?]&8_M5?\ @HTO_P"3:/\ A[5XZ_Z,Q_:J_P#!1I?_ ,FT
M ?:U%?%/_#VKQU_T9C^U5_X*-+_^3:/^'M7CK_HS']JK_P %&E__ ";0!]K4
M5\4_\/:O'7_1F/[57_@HTO\ ^3:/^'M7CK_HS']JK_P4:7_\FT ?:U%?%/\
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MBHWB^4[>#C@CM7Q;_P /:O'7_1F/[57_ (*-+_\ DVC_ (>U^.O^C,?VJ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^P[_ ,$%OB%X'_;2\%^-M'\)Z;XJ2/0M M-1BCU#7C+LF2&"2-W"IYZLQW$
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MT:-LDS>3"$DYRJ#.1FOW6_;Q_:4M?V.OV//B'\3;Z3;'X.T6YOX4P&,LX0K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844622968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sesen Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SESN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders ("2022 Proxy Statement"), which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843404104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843644360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 162,636<span></span>
</td>
<td class="nump">$ 52,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">21,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">3,482<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">18,476<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">205,605<span></span>
</td>
<td class="nump">62,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,064<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">35,142<span></span>
</td>
<td class="nump">59,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">240,747<span></span>
</td>
<td class="nump">122,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,853<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,255<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,568<span></span>
</td>
<td class="nump">18,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">12,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">57,469<span></span>
</td>
<td class="nump">114,001<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">69,037<span></span>
</td>
<td class="nump">132,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December&#160;31, 2021 and 2020; no shares issued and outstanding at December&#160;31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at December&#160;31, 2021 and 2020; 199,463,645 and 140,449,647 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">487,768<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(316,257)<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">171,710<span></span>
</td>
<td class="num">(9,227)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 240,747<span></span>
</td>
<td class="nump">$ 122,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843616728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844806264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 26,544<span></span>
</td>
<td class="nump">$ 11,236<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">25,312<span></span>
</td>
<td class="nump">29,191<span></span>
</td>
<td class="nump">24,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,393<span></span>
</td>
<td class="nump">14,302<span></span>
</td>
<td class="nump">12,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">5,528<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(56,840)<span></span>
</td>
<td class="num">(11,180)<span></span>
</td>
<td class="nump">71,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,093<span></span>
</td>
<td class="nump">32,313<span></span>
</td>
<td class="nump">108,491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(8,549)<span></span>
</td>
<td class="num">(21,077)<span></span>
</td>
<td class="num">(108,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss Before Taxes</a></td>
<td class="num">(8,609)<span></span>
</td>
<td class="num">(20,952)<span></span>
</td>
<td class="num">(107,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">8,273<span></span>
</td>
<td class="num">(1,445)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss After Taxes</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
<td class="num">(107,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss After Taxes</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
<td class="num">(107,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend on adjustment of exercise price of certain warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(22,544)<span></span>
</td>
<td class="num">(107,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (336)<span></span>
</td>
<td class="num">$ (22,544)<span></span>
</td>
<td class="num">$ (107,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">182,323<span></span>
</td>
<td class="nump">118,221<span></span>
</td>
<td class="nump">90,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding for diluted (in shares)</a></td>
<td class="nump">182,323<span></span>
</td>
<td class="nump">118,221<span></span>
</td>
<td class="nump">90,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_LicenseRevenueMember', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 26,544<span></span>
</td>
<td class="nump">$ 11,236<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839720744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Facility</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,456,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 44,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (186,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(107,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock awards and vesting of restricted stock awards (in shares)</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options and vesting of RSAs</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of common stock under 2014 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of common stock under 2014 ESPP</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,772,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercise of common stock warrants</a></td>
<td class="nump">5,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,410,000<span></span>
</td>
<td class="nump">2,062,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">27,833<span></span>
</td>
<td class="nump">$ 1,936<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">27,812<span></span>
</td>
<td class="nump">$ 1,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,801,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">(26,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(293,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock awards and vesting of restricted stock awards (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options and vesting of RSAs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of common stock under 2014 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of common stock under 2014 ESPP</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercise of common stock warrants</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,369,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">(9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 5,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock awards and vesting of restricted stock awards (in shares)</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options and vesting of RSAs</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">2,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercise of common stock warrants</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,932,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (316,257)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Exercise Of Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844547848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844678440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (336)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
<td class="num">$ (107,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">5,143<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(56,840)<span></span>
</td>
<td class="num">(11,180)<span></span>
</td>
<td class="nump">71,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Intangibles impairment charge</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (net)</a></td>
<td class="num">(24,493)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(17,964)<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(5,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(249)<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(4,424)<span></span>
</td>
<td class="num">(2,035)<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,878)<span></span>
</td>
<td class="num">(30,837)<span></span>
</td>
<td class="num">(37,521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProceedsFromIssuanceofCommonStockandWarrants', window );">Proceeds from issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">5,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">174,962<span></span>
</td>
<td class="nump">37,958<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from sale of common stock pursuant to ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">176,129<span></span>
</td>
<td class="nump">38,113<span></span>
</td>
<td class="nump">35,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">107,247<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
<td class="num">(2,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">55,409<span></span>
</td>
<td class="nump">48,141<span></span>
</td>
<td class="nump">50,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
<td class="nump">48,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">162,636<span></span>
</td>
<td class="nump">52,389<span></span>
</td>
<td class="nump">48,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long term restricted cash</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
<td class="nump">48,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Right-of-use assets related to the adoption of ASC 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IssuanceOfWarrantForCommonStock', window );">Deemed Dividend on adjustment of exercise price on certain warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IssuanceOfWarrantForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrant For Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IssuanceOfWarrantForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProceedsFromIssuanceofCommonStockandWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProceedsFromIssuanceofCommonStockandWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Related To Adoption of Accounting Standard</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842018632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with bacillus Calmette-Gu&#233;rin ("BCG"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 VISTA clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#8220;CMC&#8221;), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&#160;31, 2021, none of these individuals are active employees or members of the Company's board of directors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had cash and cash equivalents of $162.6 million and an accumulated deficit of $316.3 million. The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred negative cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities of $68.9 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.8 million and $37.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Since the Company&#8217;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to address the issues raised in the CRL it received for a BLA for Vicineum for the treatment of BCG unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete the follow-up stage of the ongoing Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, complete any additional clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">out-license agreements. See &#8220;Note 12. Stockholders&#8217; Equity&#8221; below for information regarding the Company&#8217;s recently completed equity financings. Management believes that the Company&#8217;s cash and cash equivalents as of December&#160;31, 2021 will be sufficient to fund the Company's current operating plan for at least the next twelve months from the date these consolidated financial statements were issued.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future success is dependent on its ability to develop, and if approved, commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon its ability to attain profitable operations. In order to commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company needs to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of its product candidates, raising additional capital, development and commercialization by its competitors of new technological innovations, protection of proprietary technology and market acceptance of its products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and the Company expects to seek additional funds through equity or debt financings or through additional outside of United States (&#8220;OUS&#8221;) business development partnerships, collaborations, licensing transactions or other sources. The Company may be unable to obtain equity or debt financings or enter into additional OUS business development partnerships, collaborations or licensing transactions at favorable terms, or at all, and, if necessary, may be required to implement cost reduction strategies. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will incur substantial expenses if and as it:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addresses the issues identified in the CRL it received from the FDA for its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Withdrawal Assessment Report, which the Company expects will include the completion of an additional Phase 3 clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeks marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintains, expands and protects its intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hires additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expands its operational, financial and management systems and personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducts research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and its other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeks to discover and develop additional product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-licenses or acquires the rights to other products, product candidates or technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, initiation, progress, timing, costs and results of laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and its other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on the Company&#8217;s business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s ability to establish additional OUS business development partnerships, collaborations or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for its product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities, including those associated with the manufacturing process and technology transfer to third-party manufacturers to facilitate such commercial-scale manufacturing of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the Company in-licenses or acquires rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA, EMA or comparable non-US regulatory authorities to require that the Company perform more studies or clinical trials than those that it currently expects to perform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s ability to achieve certain future regulatory, development and commercialization milestones under its out-license and OUS business development partnership agreements </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as the Company can generate substantial product revenues from commercial sales, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic collaborations, OUS business development partnership agreements, partnerships, alliances, and licensing arrangements. The Company does not have any committed external source of funds other than the amounts payable under the license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and the license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;). To the extent the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, strategic OUS business development partnerships, collaborations, alliances or licensing arrangements, the Company may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on the Company&#8217;s operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect the Company&#8217;s ability to raise additional capital in the future.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403845846600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATIONThe accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403841983832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&#160;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application (&#8220;MAA&#8221;), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company's intangible asset of Vicineum EU rights, this asset was not impaired as of September 30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (&#8220;POS&#8221;) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase 3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any impairment charges during the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company&#8217;s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company's revenue projection models are timing of product launch and probabilities of clinical and regulatory success ("POS"); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the optional transition method outlined in ASU No. 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842), Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&#160;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 840") guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $0.2 million on the Company&#8217;s consolidated balance sheet as of January 1, 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on the Company&#8217;s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company&#8217;s financial statement disclosures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accounting policy election to use the short-term lease exception by asset class;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Election of the practical expedient package during transition, which includes:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess whether any expired or existing contracts are or contain leases;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess initial direct costs for any existing leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio as of the adoption date and as of December 31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2021, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company&#8217;s lease portfolio as of the adoption date were valued as of January 1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&#160;31, 2021, 2020 and 2019 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the &#8220;simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2021 and 2020, the Company did not have any uncertain tax positions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                          distinct in the context of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div>In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company recorded $20&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. The Company recognized $26.5&#160;million of license revenue related to the Roche, Qilu and MENA License Agreements during the year ended December 31, 2021 and $11.2&#160;million of license revenue related to the Qilu License Agreement during the year ended December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842203416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403925722168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2021 and 2020 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 8.0% to 9.3% as of December&#160;31, 2021 and 8.4% to 8.8% as of December&#160;31, 2020. There have been no changes to the valuation methods utilized during the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary by quarter of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021, current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021, net of current portion</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108,840</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s WACC, which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $56.8 million for the year ended December&#160;31, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form, and the Company&#8217;s withdrawal of its MAA with EMA. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Incorporating the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#8217;s revenue projection models are timing of commercial product launch and probabilities of clinical and regulatory success; the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL and the Company&#8217;s withdrawal of its MAA. The Company plans to conduct an additional Phase 3 clinical trial in order to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which will lead to delays in the start of commercialization globally. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842069880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">RECEIVABLES</a></td>
<td class="text">RECEIVABLES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of December 31, 2021 is $21.0&#160;million, comprised primarily of a $20&#160;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $20&#160;million was received. Additionally, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $0.9&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December 31, 2021 is $3.5&#160;million. The Company recorded $3.4&#160;million to other receivables in the fourth quarter of 2021 for German VAT recovery related to drug substance sent to Baxter. The Company received a payment for $1.8&#160;million in January 2022 and expects to collect the remaining balance.</span></div>The accounts receivable and other receivable balances as of December 31, 2020 were de minims.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842206648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense was $0.1 million, $0.1 million and $0.2 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842185528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLES AND GOODWILL</a></td>
<td class="text">INTANGIBLES AND GOODWILL<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's consolidated balance sheet are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any impairment charges during the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1&#160;million as of December&#160;31, 2021 and 2020. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company's withdrawal of its MAA, a quantitative impairment analysis was conducted during the third quarter of 2021, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 45%. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from 45% to 55% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div>Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842193848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403841982552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants&#8217; response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842036152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three-year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,300 at exchange rates in effect on December&#160;31, 2021). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,300 at exchange rates in effect on December&#160;31, 2021). Operating lease cost under this lease, including the related operating costs, were $0.3&#160;million and $0.3&#160;million for the year ended December&#160;31, 2021 and $0.3&#160;million and $0.3&#160;million for the year ended December&#160;31, 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a">other assets</span></span> on the Company's consolidated balance sheets. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77">other current liabilities</span></span> and the long-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1">other liabilities</span></span> on the Company&#8217;s consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three months to six months and currently extend through June 2022 and May 2022, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,400, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&#160;31, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">562</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's future minimum lease payments under non-cancelable leases as of December&#160;31, 2021 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Minimum Lease Payments:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments (2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842167192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY DEFICIT</a></td>
<td class="text">STOCKHOLDERS' EQUITY DEFICIT<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time (the &#8220;ATM Offering&#8221;) for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $35&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50.0&#160;million and $34.5&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $175.0 million of net proceeds from the sale of 56.9 million shares of common stock at a weighted-average price of $3.17 per share during the year ended December&#160;31, 2021, compared to</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.0 million of net proceeds from the sale of 33.4 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a weighted-average price of</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.17</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share during the year ended December&#160;31, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2019 Financing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company raised $27.8 million of net proceeds from the sale of 20.4 million shares of common stock and accompanying warrants to purchase an additional 20.4 million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $1.47. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $1.47 per share, subject to adjustments as provided under the terms of such warrants, and had a one-year term that expired on June 21, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of December&#160;31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,450</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company received proceeds of $1.1 million from the exercises of 1.6 million 2018 Warrants and 0.5 million 2017 Warrants.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Modifications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $1.1 million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $1.1 million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $1.20 to $0.60 per share of the Company's common stock, resulting in proceeds of $2.0 million from the exercise of 3.4 million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $1.20 to the lesser of (a) $0.95 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $0.55; as such, the Company recognized a deemed dividend of approximately $0.1&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' (Deficit) Equity. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than 50.1% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $0.80 to $0.55 per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $0.80 to the lesser of (a) $0.55 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December 31, 2021, there has been no adjustment to the exercise price of these warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842058488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method was not applied for the twelve months ended December&#160;31, 2021, 2020 and 2019 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&#160;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:53.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403925722168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 8.9&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 12.8&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. The Company recorded an expense of $0.5&#160;million for retention-related RSUs for the year ended December&#160;31, 2021. Additionally, the Company expensed $0.6&#160;million in relation to the cash bonus portion of the retention program.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As none of the retention milestones were met in the year ended December&#160;31, 2021 and achievement was deemed not probable, the Company did not record expenses for retention-related PSUs. As of December&#160;31, 2021, the unrecognized compensation expense for the retention-related PSUs, granted on October 1, 2021, was $0.4&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A summary of the status of restricted stock units is presented below: </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:75.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual life of unvested RSUs and PSUs as of December 31, 2021 is 9.75 years. The Company did not grant restricted stock units during the years ended December 31, 2020 and 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately 2.8 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2021, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.14</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $5.1&#160;million for the year ended 2021. The stock option related expenses were</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.6 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the years ended December&#160;31, 2021, 2020 and 2019, respectively.  The RSU related expense was</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.5&#160;million for the year ended December&#160;31, 2021. The Company did not record RSU related expenses for the years ended December 31, 2020 and 2019.  As of December&#160;31, 2021, there was $10.4 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.7 years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2021, 2020 and 2019 were $2.16</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.56 and $1.02, respectively. The total intrinsic value of stock options exercised for the years ended December&#160;31, 2021, 2020 and 2019 was de minimis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.02</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403845878072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&#160;31, 2021, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div>The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842170216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,952)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(107,500)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 73pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record current or deferred income tax or benefit for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,631&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,724)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,969)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;D credit carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $71.8 million, $65.6 million and $57.7 million have been established as of December&#160;31, 2021, 2020 and 2019, respectively.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $6.2 million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability of $4.0 million primarily relates to the potential future impairments or amortization associated with IPR&amp;D intangible assets, which is not deductible for tax purposes and cannot be considered as a source of income to realize deferred tax assets. As a result, the Company recorded the deferred tax liability with an offset to goodwill.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $0.8 million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2020 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844540360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.5&#160;million and $0.3&#160;million related to achievement of a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the year ended December 31, 2021 and 2020, respectively, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the twelve months ended December&#160;31, 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2021, the Company may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&#160;million at exchange rates in effect on December&#160;31, 2021). The Company is also required to pay up to a </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;50,000 (approximately $56,625 at exchange rates in effect as of December&#160;31, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as long-term deferred revenue as of December 31, 2021. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of December&#160;31, 2021, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement). Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company is in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of December&#160;31, 2021, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842002568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED-PARTY TRANSACTIONS</a></td>
<td class="text">RELATED-PARTY TRANSACTIONS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Winnipeg, Manitoba from an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019. For each of the years ended December&#160;31, 2021, 2020 and 2019, the Company paid $0.3 million of rent, which includes the related operating expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays fees under an intellectual property license agreement to Protoden Technologies Inc. ("Protoden"), a company owned by Clairmark, an affiliate of Mr. Dan. Pursuant to the agreement, the Company has an exclusive, perpetual, irrevocable and non-royalty bearing license, with the right to sublicense, to certain patents and technology to make, use and sell products that utilize such patents and technology. The annual fee is $0.1 million. Upon expiration of the term on December 31, 2024, the licenses granted to the Company will require no further payments to Protoden. For each of the years ended December&#160;31, 2021, 2020 and 2019, the Company paid $0.1 million under this license agreement.</span></div>Due to his retirement in July 2019, Mr. Dan was not deemed a related party during the twelve-month period ended December 31, 2020 and 2021; as such, only payments made through the nine month period ended September 30, 2019 are considered payments to a related party.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842040472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING AND RELATED ACTIVITIES</a></td>
<td class="text">RESTRUCTURING AND RELATED ACTIVITIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,736</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December&#160;31, 2021. The Company expects that substantially all of the accrued restructuring costs as of December&#160;31, 2021 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842067080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted the Company&#8217;s request for a Type C Meeting (&#8220;Type C Meeting&#8221;) to discuss the study protocol for an additional Phase 3 clinical trial that the Company plans to conduct for potential resubmission of a BLA for Vicineum&#8482; for the treatment of BCG-unresponsive NMIBC. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, the Company received written notice (the &#8220;Notice&#8221;) from Nasdaq indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice has no effect at this time on the listing of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;), which continues to trade on The Nasdaq Global Market under the symbol &#8220;SESN&#8221;. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company&#8217;s Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is not in compliance by July 25, 2022, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for, or fail to regain, compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist the Company&#8217;s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to actively monitor the closing bid price of the Company&#8217;s common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously announced, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#8220;Review&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Review took place over the course of five months, involved full cooperation from the Company&#8217;s management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is now complete.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Review, the Board continues to fully support the Company&#8217;s current management team and believes no changes or amendments relating to the Company&#8217;s prior disclosures to the SEC or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844666584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</a></td>
<td class="text">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit RiskThe Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&#160;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application (&#8220;MAA&#8221;), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company's intangible asset of Vicineum EU rights, this asset was not impaired as of September 30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (&#8220;POS&#8221;) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase 3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company&#8217;s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company's revenue projection models are timing of product launch and probabilities of clinical and regulatory success ("POS"); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the optional transition method outlined in ASU No. 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842), Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&#160;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 840") guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $0.2 million on the Company&#8217;s consolidated balance sheet as of January 1, 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on the Company&#8217;s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company&#8217;s financial statement disclosures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accounting policy election to use the short-term lease exception by asset class;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Election of the practical expedient package during transition, which includes:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess whether any expired or existing contracts are or contain leases;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;An entity need not reassess initial direct costs for any existing leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio as of the adoption date and as of December 31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2021, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company&#8217;s lease portfolio as of the adoption date were valued as of January 1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&#160;31, 2021, 2020 and 2019 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the &#8220;simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2021 and 2020, the Company did not have any uncertain tax positions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                          distinct in the context of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2021 and 2020 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div>Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839439768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</a></td>
<td class="text">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):<div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Contingent Consideration Liability</a></td>
<td class="text">The following table sets forth a summary by quarter of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021 (in thousands):<div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021, current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021, net of current portion</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108,840</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842207480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Composition of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844575848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Composition of Intangible Assets</a></td>
<td class="text">The following table sets forth the composition of intangible assets as of December&#160;31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842014664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843076168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&#160;31, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">562</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases</a></td>
<td class="text">The following table sets forth the Company's future minimum lease payments under non-cancelable leases as of December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Minimum Lease Payments:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments (2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843081736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock</a></td>
<td class="text">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,450</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding and Warrant Activity</a></td>
<td class="text">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2021 (in thousands):<div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403925772008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&#160;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:53.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843589032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of the Status of Restricted Stock Units</a></td>
<td class="text">A summary of the status of restricted stock units is presented below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:75.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2021, 2020 and 2019:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.14</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.02</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842217432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Pre-tax Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,952)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(107,500)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Benefit (Provision)</a></td>
<td class="text">The Company's tax benefit (provision) is comprised of the following components (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 73pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Expected Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,631&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,724)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,969)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Credit Carryforwards</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842017784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following is a summary of accrued restructuring costs related to the Restructuring Plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,736</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403840058136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>patient</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfPatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,636<span></span>
</td>
<td class="nump">$ 52,389<span></span>
</td>
<td class="nump">$ 48,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,257<span></span>
</td>
<td class="nump">315,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Negative cash flows from operating activities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,878<span></span>
</td>
<td class="nump">$ 30,837<span></span>
</td>
<td class="nump">$ 37,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare', window );">Shares of common stock issued to the selling shareholders (in shares) | shares</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales', window );">Period during which quarterly earn-outs are payable after date of net sales</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations', window );">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods', window );">Percentage of net sales of quarterly earn-out payments during earn-out periods</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403834703320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit', window );">Insurance coverage limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,064,000<span></span>
</td>
<td class="nump">$ 13,064,000<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="nump">$ 13,064,000<span></span>
</td>
<td class="nump">13,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DebtInstrumentIndexRateHighYield', window );">Index rate, high-yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="nump">0.084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.066<span></span>
</td>
<td class="nump">0.074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,544,000<span></span>
</td>
<td class="nump">$ 11,236,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestonePaymentTerm', window );">Milestone payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | United States | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_EBI031Member', window );">EBI-031 | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_EBI031Member', window );">EBI-031 | Roche | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_EBI031Member', window );">EBI-031 | Roche | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_EBI031Member', window );">EBI-031 | Roche | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DebtInstrumentIndexRateHighYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Index Rate, High-Yield</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DebtInstrumentIndexRateHighYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestonePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestonePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Probability of Achieving Clinical and Regulatory Milestones, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116652737&amp;loc=d3e64164-112818<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403834743592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,382<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,382<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,382<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 99,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403834827016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.080<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="nump">0.066<span></span>
</td>
<td class="nump">0.074<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="nump">0.084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">$ (4,600)<span></span>
</td>
<td class="num">$ (114,000)<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="nump">$ 48,160<span></span>
</td>
<td class="num">$ (56,840)<span></span>
</td>
<td class="num">$ (11,180)<span></span>
</td>
<td class="nump">$ 71,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="nump">0.084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.093<span></span>
</td>
<td class="nump">0.088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Probability of Achieving Clinical and Regulatory Milestones, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839883400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 56,600<span></span>
</td>
<td class="nump">$ 170,600<span></span>
</td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="nump">$ 108,840<span></span>
</td>
<td class="nump">$ 108,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value included in loss</a></td>
<td class="num">(4,600)<span></span>
</td>
<td class="num">(114,000)<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">48,160<span></span>
</td>
<td class="num">(56,840)<span></span>
</td>
<td class="num">$ (11,180)<span></span>
</td>
<td class="nump">$ 71,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">$ 56,600<span></span>
</td>
<td class="nump">$ 170,600<span></span>
</td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">108,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 99,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403845717976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 108,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">108,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent', window );">Change in fair value of contingent consideration - short term</a></td>
<td class="num">(8,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent', window );">Change in fair value of contingent consideration - long term</a></td>
<td class="num">(47,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403834627592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,011<span></span>
</td>
<td class="nump">$ 21,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Increase in other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProceedsFromValueAddedTaxRecovery', window );">Proceeds from value added tax recovery</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProceedsFromValueAddedTaxRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Value Added Tax Recovery</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProceedsFromValueAddedTaxRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839491128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(966)<span></span>
</td>
<td class="num">(881)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and Equipment, Net</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403925659288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839505592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details) - IPR&amp;D intangible assets: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 46,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">European Union | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839885128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="nump">13,064,000<span></span>
</td>
<td class="nump">13,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842943832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Components of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="nump">$ 1,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll-related expenses</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedRestructuringChargesRelatedCurrent', window );">Restructuring charge related</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 8,255<span></span>
</td>
<td class="nump">$ 3,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedRestructuringChargesRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Restructuring Charges Related, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedRestructuringChargesRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403845876952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfLawsuits', window );">Number of lawsuits</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403845778536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term property leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,000<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost, including related operating cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,000<span></span>
</td>
<td class="nump">$ 301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeasesAreaOfOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="nump">31,100<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption', window );">Renewal option | term</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses', window );">Related operating expenses</a></td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sesn_MassachusettsAndPennsylvaniaMember', window );">Massachusetts And Pennsylvania | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sesn_MassachusettsAndPennsylvaniaMember', window );">Massachusetts And Pennsylvania | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Monthly Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseOtherMonthlyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeasesAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeasesAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sesn_MassachusettsAndPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sesn_MassachusettsAndPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842965096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease (including related operating costs)</a></td>
<td class="nump">$ 327<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term property leases</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SupplementalLeaseInformationAbstract', window );"><strong>Supplemental Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SupplementalLeaseInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Lease Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SupplementalLeaseInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403925718136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum Lease Payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments (2022)</a></td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing present value adjustment</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839782456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockAndWarrantOrRightsPricePerShare', window );">Stock and warrants price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale', window );">Additional shares to be issued</a></td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockCommissionFixedRate', window );">Commission fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAndWarrantOrRightsPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock And Warrant Or Rights, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAndWarrantOrRightsPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Shares Authorized For Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockAdditionalSharesAuthorizedForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockCommissionFixedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fixed Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockCommissionFixedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Sales Price In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403846390360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843032728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberofVotesEntitledForEachShare', window );">Number of votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberofVotesEntitledForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Entitled For Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberofVotesEntitledForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843634744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockSharesIssuedAndReservedForFuture', window );">Total shares of common stock issued and reserved for issuance (in shares)</a></td>
<td class="nump">229,640,000<span></span>
</td>
<td class="nump">157,707,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">2,247,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">3,041,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for grant under 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">8,933,000<span></span>
</td>
<td class="nump">4,863,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for sale under 2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockSharesIssuedAndReservedForFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issued And Reserved For Future</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockSharesIssuedAndReservedForFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Reserved For Issuance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharesOfCommonStockReservedForIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403840162296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="num">(2,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringJune2020Member', window );">Warrants, Expiring June 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">Warrants, Expiring March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">Warrants, Expiring November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="num">(475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member', window );">Warrants, Expiring November 2024, Issued May 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 11.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member', window );">Warrants, Expiring November 2024, Issued November 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Expirations During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringJune2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringJune2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839279880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 5,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Increase in warrant value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OtherDividendAndAdjustments', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,059<span></span>
</td>
<td class="nump">238,110<span></span>
</td>
<td class="nump">6,772,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">2018 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">2018 Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">2017 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">2017 Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember', window );">2018 Warrant Amendment, Amendment to Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued', window );">Minimum percentage of securities issued</a></td>
<td class="nump">50.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember', window );">2018 Warrant Amendment, Amendment to Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Minimum Percentage of Securities Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherDividendAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Dividend And Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherDividendAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839559320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">15,902<span></span>
</td>
<td class="nump">12,394<span></span>
</td>
<td class="nump">29,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">22,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839563224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 5,143<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="nump">$ 1,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 4,170<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
<td class="nump">$ 1,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403838547400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="nump">10,147,000<span></span>
</td>
<td class="nump">6,236,000<span></span>
</td>
<td class="nump">3,942,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,143,000<span></span>
</td>
<td class="nump">$ 1,757,000<span></span>
</td>
<td class="nump">$ 1,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,482,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember', window );">2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember', window );">Retention Program | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus', window );">Expense related to cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember', window );">Retention Program | Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary', window );">Percent of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member', window );">Stock Incentive Plan 2009 | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting on the First Anniversary of Date of Grant | 2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting at End of Each Successive Three-Month Period Thereafter | 2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedPaymentArrangementExpenseOnCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Expense, On Cash Bonus</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedPaymentArrangementExpenseOnCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_RetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403936132648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,482,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">3,041,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403838537080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares under Option (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
<td class="nump">3,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">8,273<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(2,683)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
<td class="nump">3,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">7,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.32<span></span>
</td>
<td class="nump">0.87<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.23<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">3.70<span></span>
</td>
<td class="nump">1.04<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">8 years 10 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
<td class="text">9 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life (in years), Exercisable</a></td>
<td class="text">7 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 3,160<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839050424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value (in dollars per share)</a></td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.60%<span></span>
</td>
<td class="nump">71.50%<span></span>
</td>
<td class="nump">78.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843547672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution retirement plan, maximum employee contribution deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee', window );">Discretionary match per participating employee, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Common stock purchase price, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403843619048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Pre-tax Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total Loss Before Income Taxes</a></td>
<td class="num">$ (8,609)<span></span>
</td>
<td class="num">$ (20,952)<span></span>
</td>
<td class="num">$ (107,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-tax income (loss) U.S.</a></td>
<td class="num">(32,757)<span></span>
</td>
<td class="num">(35,529)<span></span>
</td>
<td class="num">(27,468)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Pre-tax income (loss) Canada</a></td>
<td class="nump">$ 24,148<span></span>
</td>
<td class="nump">$ 14,577<span></span>
</td>
<td class="num">$ (80,032)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403844755528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Income Tax Provisions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current Tax Provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,445)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current (provision)</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,445)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred tax provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">8,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit (provision)</a></td>
<td class="nump">8,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">$ 8,273<span></span>
</td>
<td class="num">$ (1,445)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839493464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">United States federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Impact of foreign rate differential</a></td>
<td class="num">(15.90%)<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock option cancellations</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent', window );">Contingent consideration</a></td>
<td class="nump">178.20%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">General business credits and other credits</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Other</a></td>
<td class="num">(13.80%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Foreign taxes</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in valuation allowance</a></td>
<td class="num">(72.30%)<span></span>
</td>
<td class="num">(37.70%)<span></span>
</td>
<td class="num">(7.90%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate</a></td>
<td class="nump">96.10%<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Contingent Consideration, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839385400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 63,381<span></span>
</td>
<td class="nump">$ 57,935<span></span>
</td>
<td class="nump">$ 50,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">71,849<span></span>
</td>
<td class="nump">65,631<span></span>
</td>
<td class="nump">57,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">IPR&amp;D</a></td>
<td class="num">(3,969)<span></span>
</td>
<td class="num">(12,528)<span></span>
</td>
<td class="num">(12,528)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(3,969)<span></span>
</td>
<td class="num">(12,528)<span></span>
</td>
<td class="num">(12,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(71,849)<span></span>
</td>
<td class="num">(65,631)<span></span>
</td>
<td class="num">(57,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net Deferred Tax Liability</a></td>
<td class="num">$ (3,969)<span></span>
</td>
<td class="num">$ (12,528)<span></span>
</td>
<td class="num">$ (12,528)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Start Up Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839438280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 71,849<span></span>
</td>
<td class="nump">$ 65,631<span></span>
</td>
<td class="nump">$ 57,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance change</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">$ 12,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLossCarryforwardsDecrease', window );">NOL carryforward reduced amount</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLossCarryforwardsDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Decrease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLossCarryforwardsDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403840040920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Credit Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States: | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 118.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States: | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">138.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NetOperatingLossCarryforwardAxis=sesn_IndefiniteMember', window );">Indefinite | United States: | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credit carryforwards | United States: | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credit carryforwards | United States: | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credit carryforwards | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=sesn_NonCapitalLossCarryforwardMember', window );">Non-capital loss carryforwards | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">31.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember', window );">Investment tax credit carryforwards | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NetOperatingLossCarryforwardAxis=sesn_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NetOperatingLossCarryforwardAxis=sesn_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=sesn_NonCapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=sesn_NonCapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403828790776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>period</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,236,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationRoyaltyPaymentPercent', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationMilestonePayments', window );">Business combination, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember', window );">Micromet AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent', window );">License agreement, royalty payment, reduction, conditions not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,625<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember', window );">XOMA Ireland Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementUpfrontFee', window );">License agreement, up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAdditionalUpFrontFee', window );">License agreement, additional up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementOptionPeriods', window );">License agreement, option periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod', window );">License agreement, buyout amount under first option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised', window );">License agreement, period to pay buyout option once exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod', window );">License agreement, buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct', window );">Buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | IL-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | First Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on commercialization milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Second Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember', window );">MENA License Agreement | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Long-term Purchase Commitment, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Royalty Payment Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAdditionalUpFrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Additional Up-Front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAdditionalUpFrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Amount Payable Upon Achievement of Specified Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under First Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchievementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achievement Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchievementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementOptionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Option Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementOptionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty On Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty on Net Product Sales, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Period to Pay Buyout Option Once Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Up-front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RoyaltyRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RoyaltyRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MicrometAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_IL6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_IL6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403839738664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Facility in Winnipeg, Manitola</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Rent expense in related party transaction</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Protoden | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Rent expense in related party transaction</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Annual fee for remaining term of lease</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sesn_FacilityinWinnipegManitolaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sesn_FacilityinWinnipegManitolaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403841984392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 30, 2021 </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403828783592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">$ 5,528<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(4,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and benefits costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">2,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">2,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140403842959048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2022 </div>
<div>interview </div>
<div>document</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ReviewPeriod', window );">Review period</a></td>
<td class="text">5 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfDocumentsReviewed', window );">Number of documents reviewed | document</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfInterviews', window );">Number of interviews | interview</a></td>
<td class="nump">39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfDocumentsReviewed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Documents Reviewed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfDocumentsReviewed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfInterviews">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Interviews</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfInterviews</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ReviewPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Review Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ReviewPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>sesn-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sesn="http://www.sesenbio.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sesn-20211231.xsd" xlink:type="simple"/>
    <context id="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i92f97507a36b49449af460f15366dc07_I20220221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-02-21</instant>
        </period>
    </context>
    <context id="i8984440967a74e3abe0feaafbe79712a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c88f9a9af124db29eb627c2bb0fd0e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i51b5ef8f93c04e62a666090e00118055_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if30a5968b1a146dbb7ffcec09da88262_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bf44be67ed84033b15e86e3de2e9088_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4c1773348a6144f8927754151f83c6b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic78f2f0a6b1d4a20ad7e12e40d1cacd4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i707ab57c26dd479d83f5e95b7b236b54_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i21d87267df014bc9b3e806eba7f1b0f5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i56d90314fd70472fa324352884486d5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3412d8401e304f0aae1eecacbcdbab85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf8c7f863b2f43bb922132621a9e5cda_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc289b8985ac49eb80e78ca2748e4a96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4d96180f8d6e4e14983b270d1c6668aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06678b0cf6c04477b759eb44801366df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id593ab74c6634403b9f73b261b779b5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1cd661b638041f898d4ddc61a940fa7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iededb75b8b3d41909c578b96949d296b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0b663c4ccd24528baa91746670f2709_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92612297cd0642f585229a45cac68bd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i548b9f86fcd54ebe9243040061933762_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i449b028e12ab447dbe3d1ff217dca3f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6cc5cde3c2444458bf73121a4a8d8f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c9ad583a050492ebb28f616a7b10aaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bdadfe711654c368dce057e84bccbf9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d93ef4c012e45c7b10ee227a4cdf96d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbcc2cd80c644c9bba710067ba49b410_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i5fb4126fec9d47d299096c36c0f06713_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i36e9d8387a934ec497a4731a279af3dc_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i533b84da1d2441468aadec080d52600b_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="if2334efa0613474c99d0b53f5f47619c_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i7059bd4c3d114e288eb8029d693c5dd6_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="id0d7d3d671d44f1fb8dc94865706738c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f42726b9d2d45519a3279adbdeaf414_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib16d8fcfc6064d57a72284ee2689a0c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i649bc58c14754d8497732ebb7fb60f40_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a2a6758069a4a888d0e5d69c12d58ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibecee94376694fc393e30898f2ff86a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i028ccf70c10c4129a5d10bd536d297b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2de469ec0aa540adac05ef95232f5a15_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6a34442b9744cb6ae08c574b84b89b9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4609a0afbc594078808154f146946ab1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2453680b1ee48d49d18b917c46773a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i02b5f8ea9c52413084c453c81936288b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4b6d609604934e33aa33ca5fc59ce894_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i537b107b17f34737a20ec184a594ae82_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i695006bd273747aeb95e43b893e8b867_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ib942d47e8aca410e959ff68b5d97942f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f3d4b0f71404387b7089a237b8a5500_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9280baa377514c5b8f3b86112af15bc1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a8e07a02a314fe58d21f5e73b65454b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2904e8fab3f54e409e119eb43ab1f654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5309a9a57784300b6ab55b4dbfaa087_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6f21fbe1815427897b0c6ef0565f88f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33449a16f50d42fda82fa03444b362a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib03bde29f9a84402bee0c3bc6cf735f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58772c205c8a4b93bd99d62ff3f8e8af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i294acb7d2420400b8155b9d8ca59ecac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80a8c65717624d59b77914baa103c3bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9873482dcdab4f8e99687d14de08bf30_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0ab9cefc27e4b67b11ffb55b439770b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic90b2409cd1e47e9a97d51b1bda3f754_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i461f7c863e8845a1bf3aecbdde6819d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccafbadd781745f8a66ce65217af032c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i208c2cdd76674e1490701e0cd5f02c0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15fd8a9c40534aeaaf4598e6db3abbf6_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69a83c24db234a7e8561b517d543d5e4_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ia21f2148bbe744ea9737cdc30b3b639e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i34539641171840f78745ef893c090fa7_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i3ea343b4020f4cf29f1266e2dc6a6b09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib230fbf43aab492384091cb48ddd7af2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea35f777e5264bc1a11c1a5275407d2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a9439e6445a46079edce40b074a4cb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf1ae7c86aed4911bffc0db6ed1d7ca4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c4126ae783347adb9e0ab895ddfa18d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1e085c71b3d4eb89b00ee3fce28ada1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c1639a88a7f44d28ddedc2f01af5b1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if671dcdd4df94af4a5b9fb93620a325b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76e5f96e4bd74651b225f0392286c025_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if52b03759bf044b3b5e17cf2a7c4a0b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic12322603449433985e3779be27b8eab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d622315903d4829a4f582cfffed067f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i425fb86623034e39aa2df73efd925f25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fe412d00cd048258c144cd9ed556654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f1e110f756945ed9233483c148b8a4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65d83f49999a40659f8cb5c98716447b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia43faec616e1467283e341842cd9d4ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81e534a3b6984e9ca7a46fb4761feeec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie35eeadb1df94fb4940973f807cc6e7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sesn:MassachusettsAndPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d207bdc8bb44456958770de74b1eabe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sesn:MassachusettsAndPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68866b76b55f41f7a5558f5272486883_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b8cf18e833d4913a7dc5dbc354f10c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16b4c01413da485fa2ac23775d55bed5_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i65be1969c492411ba4743fe748508e67_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="id6ed6ecc802f45c586c3b6cfff6e28d2_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ibfb861283e22418081b9e629463e783d_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i072f60a137e94674991638220c6ed9ec_D20210601-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifd395e5e95f84b618c6884bc4356ae1a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="icf0d8f6abc7e49829c395d208a3436f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id916d4f7441d4a088be2fca47e276005_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc1156bb975047729b334bf2e3fa2fc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3950633399b7426dbfabb5690ebcde85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75020eb264af4e39a21665962a79801e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f92707265b84c70ae5a42f1daae1378_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40e1aa3b61664f47b00658c43dfd99fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7858b2eb979a432a96faff9ead49ee39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44d44dfab69545dabde220a346b37456_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i877528c6538245119864f9c0c2e52211_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i466f369ef0774c33bd619700d8de5551_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31cacad06c024286911346564a7662f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8512f475d73400cabc282795a6d7b65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ae2e392a7c740b1988ab6b7b8b786d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie688301f8b994be195f31b42f85842e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d5371af6c3e495888104af773d10b15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i174b4bb16b14432aaeeb74b47fc49556_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e67736b7d564e33bad48ed099f8786c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic128bae021684a57b2549146b666bae9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id470afa5cc9848b2a4b4f535d4b6c1f0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4ec6e4d46e284f0594c5222b5698833c_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i1f9a990e22cc41d8af941ad8a743ae8d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icc016955920f4e64b8ed1852c953e88a_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="iae3ad21e639847039d2f1b31b55bc122_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0db3ec5f4dbd471f8ba45bdc77ad6b70_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1dda2c9095f1418e975214cb9c010492_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i150fe7eff7ea4fdb9a21acd3372500e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5156f45bd4749bab08cc813bedda252_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if90f693a8f7e416ba3582374b0255711_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica1ef2678e204ea598c3a695c7bf3daa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46b84bfa887d467f8571564e41e8618e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd3279ce60c04cfdb6610631e4f95328_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6966455303f44235a15aa41b9bdb897d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8dfe926ee5f4392a3f17922b1910370_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33db38ac6691417da69866ecf8c6be7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3155b0a68be6497d8886c0858eccfe59_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9b59ed3d58ff421abae5edfb38249ce6_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ie05ac20284034cf78dcee6454eac36b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9542ee3724344137b968a7e2f78a7249_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6565370c486e4b11b00a6d3e11fa682f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3fee83c1a8e4b838f1b1364ca7244be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5019c429efc54a3d939b95facb6113a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f275e89a3774f7cbca3fb8965e7a354_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30373a67e51d44d48f81e5dc9200383a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if99964945ffc46049f3cdcd6ac3fa481_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if520d25ca9304b37b3cf574ce10e6659_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04ad27b86d2646489f5ab053b12babde_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6a7749193cc45fc901d310757b0a9ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65d8a19fb4244ecfaa96a4eff824e050_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8645ab0e887d4a8bbf9664668f155fb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i558d72c250fc4f3bb70e9309cb978078_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3408800d9ca34cbc9107500cccfb1efe_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="i19aa28ed63b64ecf8600a587af11639c_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i2265e9372ef14f33a95d480831dcfd36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i256cad603adc478fbe2bb635d926f6d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0714416d3dbb41bf905d3f30d60053a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2b01c3a7a584c8c83ef29c8a5d2f83b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2cc2b6152b3a498aa18f90d825cf3988_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff556de6a08542a29c8cf9c6757a93ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95faf853daed44049bbacea1c98c9719_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4fac383649084445a8d938fea7593c9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92b0f304a6e34b6abcd67c26db8d37c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sesn:NetOperatingLossCarryforwardAxis">sesn:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6573654cd29340309dbe2c811248a720_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibda208642281438089144b87cd645d8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied6b0fe41f5b4f79ac97691814a89591_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia696bc1cbc724e098ee3bd580cfb8b6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id24bd2e4f3be4ae1b8b83df732484432_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sesn:NonCapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bb901b4a5ff4839828a1c82f4bea528_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i878819bdb7ce45d78433cd5efbbd8d27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i996be0ab5ebb4bf2948b029b33aae0b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i810bedfc811b413cbc1b773410810321_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7e35e96c504045f9b37880d11d241235_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i7c28bbf66e0b4945bbdff22096e98ec1_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i53830883489044f7a20fd0f2afe3ada7_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i536ac10f94b7496ebcf21cf333f739f3_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i36fc4d06bbde4724b5f3f5d605df0dda_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ibf1e9a4c5180446d85e2e5552350fe42_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i672850f3381947678ce8bad19d353cfe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34be4d2750144c28965180b21ad35c2c_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i58f3a5e587554717a5b2e59570cb1b71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i592275577a9d4f158b7f51ca29978045_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iced271cdb5d7466d9c7c148965459481_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i013a145bc60a457a851dd9b22eab7d0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8f7872b3f9441f786d65989d956951c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i3854b11b1f004bb585ab8a3ed3e68622_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i028e8f65759541db8dc7760918e71d52_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i77d8a2af6cca4ab8b80ffdc3f2434161_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i818c0861bdb74095a88cb8cfcda94efa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3fb1bcb7e3874976b1397e8d0fc3b469_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i1a168b0aa4c647e1997b38ac0934768d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b79f0dfcd8c4696998a76eff4413ecf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ebdbf98df0844558086fd4461793449_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34d384e7e18448558f3f9903191a5912_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i149c70a89b234c42b784e047bac76480_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="i544162f98c2149b991bf17fc6d17e544_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i289b399c61c441cdbd3ee11d6f7a9ff8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida0bc936be4b4983b3016c269a7787db_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic637e93aa17d4ad6a3c0e4e24f9685b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i41763d631ab94cc3954f93769f016e8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="id7ea168da84a45ce835565576cb8541c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3a50664b1a24d31b0f259776c76eef4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77fcf675f74847e4ab66d5e451e81521_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="patient">
        <measure>sesn:patient</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="unit">
        <measure>sesn:unit</measure>
    </unit>
    <unit id="lawsuit">
        <measure>sesn:lawsuit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>sesn:term</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="vote">
        <measure>sesn:vote</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="period">
        <measure>sesn:period</measure>
    </unit>
    <unit id="position">
        <measure>sesn:position</measure>
    </unit>
    <unit id="document">
        <measure>sesn:document</measure>
    </unit>
    <unit id="interview">
        <measure>sesn:interview</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF80LTEtMS0xLTI3NzQz_b1cafb70-0236-46f1-927a-370b6de93ff0">0001485003</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF82LTEtMS0xLTI3NzQz_c84400d1-661a-4620-9218-07b869194b37">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF83LTEtMS0xLTI3NzQz_32bcc5a1-6f95-4f5e-80b7-25f21a6959fc">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF84LTEtMS0xLTI3NzQz_dfe63572-2a68-4e09-81e4-5e258c5a6c54">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU1_a6c761d5-68cf-42a9-b4fd-faed8f67b32d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YTM1Y2EzN2RjNmJhNDZkZmIzY2JjZTExMTkyOTBkM2UvdGFibGVyYW5nZTphMzVjYTM3ZGM2YmE0NmRmYjNjYmNlMTExOTI5MGQzZV8wLTAtMS0xLTI3NzQz_c84a5ab5-a563-43b9-8324-260d98be02d2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMzI_fcaaccff-09d5-41c6-944d-38736053795e">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMzI_e7873fde-901b-4d61-8e24-6c478ac53fdb">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZDQ5NTY0NjEzNWU0NGE2ZDg5MDc2ODBlNTUxY2NhZmUvdGFibGVyYW5nZTpkNDk1NjQ2MTM1ZTQ0YTZkODkwNzY4MGU1NTFjY2FmZV8wLTAtMS0xLTI3NzQz_665c98bd-9886-49ee-bbfc-28ce5b9adce3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjQ4_27f8cf8f-da43-42a7-9f73-ddb7fcfeb15b">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU2_62f92caa-d49c-488c-a00c-5ce0e4229385">Sesen Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZTcyYjU2ZGFlNDhkNDI3ZDg2YWVkYzU1ODM0ZDk0NTkvdGFibGVyYW5nZTplNzJiNTZkYWU0OGQ0MjdkODZhZWRjNTU4MzRkOTQ1OV8wLTAtMS0xLTI3NzQz_e874d3c3-2832-4288-a249-c96e0c820d36">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZTcyYjU2ZGFlNDhkNDI3ZDg2YWVkYzU1ODM0ZDk0NTkvdGFibGVyYW5nZTplNzJiNTZkYWU0OGQ0MjdkODZhZWRjNTU4MzRkOTQ1OV8wLTEtMS0xLTI3NzQz_eb3b8bb8-4600-4e44-8dbb-3eb3d880e98e">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfNA_a773c3f5-b938-438a-b199-ecb2343a65cc">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfOA_b8cf61d2-8655-4c8c-9bd3-340f47b125be">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfMTE_9b57684f-64a7-40ed-9cbd-543c31abb206">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfMTU_2f4ca687-9b17-4a55-a3ca-0fd87f5f1dbe">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTEtMS0xLTI3NzQz_1a2b7128-bfc9-4f63-9770-6d0777d9b378">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zNTQ_f2535667-b01b-48f7-af7f-3e630019618d">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU3_c979bd1b-4156-429a-a7fd-76005eac7013">444-8550</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTAtMS0xLTI3NzQz_c81bb2cc-7b3a-48af-b584-404fe7af72a8">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTEtMS0xLTI3NzQz_7adb4571-21ef-4baa-8ebe-ccefc9e1c0d6">SESN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTItMS0xLTI3NzQz_bf36588e-c49d-4b3d-84fe-c9e0889784c2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU4_88753fa5-8075-444f-91cb-b7ddd1d8f103">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU5_fa9b099f-96bb-4f9f-8c2f-42f60a5bd0b7">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjQ5_74b4a2c7-ecbc-4270-8547-99876a796b8e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjUy_dabd669a-3947-4afd-ba9f-1a68902cf177">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8wLTAtMS0xLTQ1ODk4_06a99ac2-7f5c-482c-b2be-56f0e4225d06">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8wLTMtMS0xLTI3NzQz_67a6cd17-d59f-49aa-9e45-6ef3dee348ea">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8xLTMtMS0xLTI3NzQz_5b1fec30-ad64-4d0e-b6e3-9d54a9cf535c">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjUw_39384eab-cfbc-4aac-a40f-7f1c8c860f3b">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMjA5NDYyNzkwOTI4NQ_678a1f04-ef23-46e7-9caf-a58cdcc6cf82">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18yNzYy_0836b742-a1f0-4baf-9b93-e5b311f7dc80"
      unitRef="usd">870700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i92f97507a36b49449af460f15366dc07_I20220221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18yNzc4_3bb00bd5-780a-416b-b9b8-7b5a417a8531"
      unitRef="shares">199463645</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMjA5NDYyNzkwOTI4Ng_9a693323-2ff3-443a-8e84-4bbf582acbdc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders ("2022 Proxy Statement"), which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8zNy9mcmFnOjI2MTg4NGZjNTE3ZDRiMmQ5NDEwOWVkMThkOWFhNTk2L3RleHRyZWdpb246MjYxODg0ZmM1MTdkNGIyZDk0MTA5ZWQxOGQ5YWE1OTZfNDM5ODA0NjU0OTcxMA_2f495277-264d-4d37-988f-cb6f8f3951e8">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV81OC9mcmFnOjcxYjA3ZmRlZDJlNDRiOTBhZjQwYzg0MWQxNjk1OTI1L3RhYmxlOmY5OGE5ZGRhMGI0NjQ2OTlhZmVmNWQ3MWFiODlkMDNiL3RhYmxlcmFuZ2U6Zjk4YTlkZGEwYjQ2NDY5OWFmZWY1ZDcxYWI4OWQwM2JfMS0wLTEtMS01MDgyMy90ZXh0cmVnaW9uOmNmNjA0ODY1ODcyZDQ2NTdhMWVlMTliYTQyNmQ1ODIzXzE3MDQyNDMwMjMwNjA0_2bcd8e6a-5ae6-410f-9889-4b49b81396dd">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82MS9mcmFnOjMzOWI5ZWEwZjRlYzRjMmRhYTIxMjE2ZTBkMWQwMzllL3RleHRyZWdpb246MzM5YjllYTBmNGVjNGMyZGFhMjEyMTZlMGQxZDAzOWVfNTQ5NzU1ODE4MjI0MQ_2f495277-264d-4d37-988f-cb6f8f3951e8">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82MS9mcmFnOjMzOWI5ZWEwZjRlYzRjMmRhYTIxMjE2ZTBkMWQwMzllL3RleHRyZWdpb246MzM5YjllYTBmNGVjNGMyZGFhMjEyMTZlMGQxZDAzOWVfNTQ5NzU1ODE4MjIxOA_5c2af772-bd81-4ce8-94a0-10f6f6e071d7">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNC0xLTEtMS0yNzc0Mw_c427a9bc-4398-4ef3-8f58-10f5d3af827b"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNC0zLTEtMS0yNzc0Mw_4a4c21e5-2107-47b1-9fcb-f7d1467d39d7"
      unitRef="usd">52389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0xLTEtMS0zNjQwNw_a7b9d6ad-5951-462d-9a61-1eba04d83d01"
      unitRef="usd">21011000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0zLTEtMS0zNjQxNA_bcd87d43-6a0c-4c3c-b40b-68f67e95768d"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0xLTEtMS0zNjM5Mg_d8f40cd3-57ca-4850-826f-21827656413d"
      unitRef="usd">3482000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0zLTEtMS0zNjQwMA_b97cb8c1-15bc-4c35-8f59-2b19673cb9e0"
      unitRef="usd">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0xLTEtMS0yNzc0Mw_bab830d3-76c0-4fab-b042-3a16fb3b3769"
      unitRef="usd">18476000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0zLTEtMS0yNzc0Mw_81b98b70-5430-41d5-813d-c8a6106f7910"
      unitRef="usd">7478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0xLTEtMS0yNzc0Mw_d6b304cc-5443-4437-a395-b5b1ccabccdf"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0zLTEtMS0yNzc0Mw_77fa4435-9db0-4b39-85f3-97190de5fd80"
      unitRef="usd">3000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNy0xLTEtMS0yNzc0Mw_8936dd71-817f-41c7-8b54-6960fd135b98"
      unitRef="usd">205605000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNy0zLTEtMS0yNzc0Mw_e4202f41-88e5-4a17-837d-97f9b1f779f3"
      unitRef="usd">62867000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOC0xLTEtMS0yNzc0Mw_59a08bda-a49e-4583-9695-d226cdda8fae"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOC0zLTEtMS0yNzc0Mw_554f5813-c2a0-40dd-8a33-6fa4431cf774"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOS0xLTEtMS0yNzc0Mw_844b6939-b618-4972-9566-acf19ce6db2b"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOS0zLTEtMS0yNzc0Mw_310f0dc9-8e74-46b1-a209-be8249e68b67"
      unitRef="usd">123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTAtMS0xLTEtMjc3NDM_10f2a147-b8ec-4bf0-8d1e-b19149602e70"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTAtMy0xLTEtMjc3NDM_9901ff4e-a4d6-415b-82d9-633b567f4e8f"
      unitRef="usd">46400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTEtMS0xLTEtMjc3NDM_0cceaafe-4039-457e-9ab7-3e69fecdd7e9"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTEtMy0xLTEtMjc3NDM_6b1a01cd-c124-4a32-847c-e2b7e51e7d1c"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMS0xLTEtMzY0MzI_95d8eb86-b49a-49ac-939b-97622e614abe"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMy0xLTEtMzY0MzI_b70b091a-ab51-45ce-ae83-dda1a33c1bdf"
      unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTItMS0xLTEtMjc3NDM_3edd6372-023a-4b7b-8904-4f043278c195"
      unitRef="usd">123000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTItMy0xLTEtMjc3NDM_df61253c-b48b-4dca-a8d8-9f3596f4f44d"
      unitRef="usd">349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMS0xLTEtNDU5MTY_ea3f63b6-27bc-49e9-ae14-b212795582fc"
      unitRef="usd">35142000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMy0xLTEtNDU5MTY_1aa3503e-2e1b-436d-8d6b-ac08e9ea4f60"
      unitRef="usd">59956000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTMtMS0xLTEtMjc3NDM_d1a59f29-614b-418d-ae12-32936860f87f"
      unitRef="usd">240747000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTMtMy0xLTEtMjc3NDM_0ca21761-d016-46af-a4ff-a668808490ea"
      unitRef="usd">122823000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMS0xLTEtMjc3NDM_cb4e35d5-87fc-4f06-9eda-8e5f6a45bcd6"
      unitRef="usd">2853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMy0xLTEtMjc3NDM_7b180eb3-4419-4779-833c-c84915adbe0e"
      unitRef="usd">3102000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTctMS0xLTEtMjc3NDM_e5b34edc-f33c-4648-8497-ac38515bf7b6"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTctMy0xLTEtMjc3NDM_5509dae4-daf4-4ca3-9776-2e5ee525fd8e"
      unitRef="usd">3973000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMS0xLTEtMjc3NDM_8509c057-18e1-4ea8-9461-9677407a1bb7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMy0xLTEtMjc3NDM_6a4eb248-2c79-4a54-ac4f-b434bb8a5157"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTktMS0xLTEtMjc3NDM_82599e7d-c96e-40fd-8542-d66a83aff52f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTktMy0xLTEtMjc3NDM_7ed8e5f0-c603-4675-bad9-785c3c747cad"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjAtMS0xLTEtMjc3NDM_b25e04c8-fd46-4cd3-9968-3a0969126359"
      unitRef="usd">460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjAtMy0xLTEtMjc3NDM_e9c24e21-395f-4a3e-8027-2ac0d98db33e"
      unitRef="usd">489000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjEtMS0xLTEtMjc3NDM_b2981b03-40e0-4590-aaed-b37def878f1c"
      unitRef="usd">11568000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjEtMy0xLTEtMjc3NDM_aa67bdb0-c6e5-4e8a-8c72-271da2cb6fe2"
      unitRef="usd">18049000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjItMS0xLTEtMjc3NDM_65e6ac33-1175-4c42-aa1c-1a431df66de7"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjItMy0xLTEtMjc3NDM_e7dc99ea-b63d-429f-9d74-b8e81420deec"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjMtMS0xLTEtMjc3NDM_442efe3d-b5fb-40a3-b753-6400745aaf46"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjMtMy0xLTEtMjc3NDM_e38547cd-b141-4cce-9ece-89ac51114611"
      unitRef="usd">12528000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMS0xLTEtMjg1OTk_b8be25c0-6618-4ba5-bab5-4a4d780c64da"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMy0xLTEtMjg1OTk_e8d5edad-5f91-4ea9-a618-30238607de6f"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjUtMS0xLTEtMjc3NDM_0302ef1f-e7ee-4433-9b30-3fa35dc78464"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjUtMy0xLTEtMjc3NDM_2793571b-61de-4cb6-9a21-31ea20e3bd36"
      unitRef="usd">118000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzUtMS0xLTEtNDU5MjU_ed727ce2-d46d-464a-a206-d8dd46de763d"
      unitRef="usd">57469000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzUtMy0xLTEtNDU5MjU_d4469eee-cdb0-4ba0-aba1-d43e0238252f"
      unitRef="usd">114001000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjYtMS0xLTEtMjc3NDM_748cc669-cff2-44fd-b6a7-4b8d116bd301"
      unitRef="usd">69037000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjYtMy0xLTEtMjc3NDM_12c6c89c-c044-4564-90db-537661134ba0"
      unitRef="usd">132050000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDU3_1d9b135f-a2f7-402a-9a19-c06b3ac7d9d5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDU3_6c5638a7-e0d4-49d8-9187-9342a31d7ce2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDY5_269149d2-8053-4019-a81e-dceb9665154e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDY5_33659c5f-5b3a-4b9a-b171-d8446bebbf32"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_08295af6-3c58-4b06-9087-309fbe303a0e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_4c71215a-6af9-49de-9a7f-5d4af64adcd8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_a5dd636f-cdd3-4297-b4d7-47a6259e9b6c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_ce04d179-b392-43ad-bf37-88ceebac556b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMS0xLTEtMjc3NDM_e65004aa-68fc-4735-9cee-e65cbe12a4e9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMy0xLTEtMjc3NDM_0fa3adb4-da87-4cf1-91b7-2dba042dc67a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTEw_b7333fe5-ebb1-4092-94c3-1732fa3bf01c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTEw_c87da43c-0c21-481f-aa37-34fc4e5bab2c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTI0_e162648c-5e3b-416c-982f-4a7289978736"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTM4_53157d89-23c4-4111-aa61-8e18478057d8"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTUy_3b9be6e7-fe7a-486f-8e8e-db3038c67d8e"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTUy_5b7fec1c-08e6-44f5-8777-245e46e8b4fb"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTY2_6220807b-42e8-4ba2-b416-e8db52fdd5ea"
      unitRef="shares">140449647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTY2_94a15690-7b20-40d7-9593-a3652f00f6c9"
      unitRef="shares">140449647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMS0xLTEtMjc3NDM_8f1def5d-5d0e-4622-aeac-71e32d7e30aa"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMy0xLTEtMjc3NDM_1944510f-9c70-4093-b7a1-f0e3c019ccc3"
      unitRef="usd">140000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzEtMS0xLTEtMjc3NDM_dce7ddbd-ddba-430e-97df-4992a957f8b9"
      unitRef="usd">487768000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzEtMy0xLTEtMjc3NDM_c8520221-5a8e-40e3-a0de-c062cc686a21"
      unitRef="usd">306554000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMS0xLTEtMjc3NDM_4bad118f-4fde-4308-abf8-393008d50f1d"
      unitRef="usd">-316257000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMy0xLTEtMjc3NDM_e193fe34-734c-412d-9837-a2776339e3ad"
      unitRef="usd">-315921000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzMtMS0xLTEtMjc3NDM_0aebd621-5b03-483e-85d1-571240e4420c"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzMtMy0xLTEtMjc3NDM_cdebca43-7523-4204-aa7c-18c34d8db849"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzQtMS0xLTEtMjc3NDM_215ce228-ddec-4b04-86eb-13e10be191d1"
      unitRef="usd">240747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzQtMy0xLTEtMjc3NDM_8d46905d-802b-45d0-b9e7-1a77b7f59f0f"
      unitRef="usd">122823000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2c88f9a9af124db29eb627c2bb0fd0e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy0xLTEtMS0yNzc0Mw_955fb855-c58e-4bfa-9ace-a99aa19e0bf2"
      unitRef="usd">26544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i51b5ef8f93c04e62a666090e00118055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy0zLTEtMS0yNzc0Mw_16df42d7-7146-46e4-97ba-9a05a36458cd"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if30a5968b1a146dbb7ffcec09da88262_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy01LTEtMS0yNzc0Mw_5002f366-8174-44ce-b294-71e4e562802f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS0xLTEtMS00OTU2Ng_23098667-9591-4937-83f1-dacafd809cbd"
      unitRef="usd">26544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS0zLTEtMS00OTU2Ng_6055c3ad-dfc3-46cb-a6c4-9e4acc90370f"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS01LTEtMS00OTU2Ng_4cb1108d-f125-4155-95f3-e2d304705bc0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi0xLTEtMS0yNzc0Mw_42ce0de9-3533-4ea1-9139-6b74e6c1d8c3"
      unitRef="usd">25312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi0zLTEtMS0yNzc0Mw_7dc08a3f-7377-40d5-8a19-a05f120f9650"
      unitRef="usd">29191000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi01LTEtMS0yNzc0Mw_963e0199-8cfc-495a-bf9e-ce6a187478b8"
      unitRef="usd">24663000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0xLTEtMS0yNzc0Mw_51a694aa-6d20-4749-a926-f1e319b15cb9"
      unitRef="usd">29393000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0zLTEtMS0yNzc0Mw_00cf2429-5bd3-4839-96cb-cd579a2ef70c"
      unitRef="usd">14302000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy01LTEtMS0yNzc0Mw_7ff00aa0-16f6-4158-aed8-e035cc5152dc"
      unitRef="usd">12208000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0xLTEtMS0yODc1NQ_2b61f082-346c-4222-8618-f70f5e35bf5b"
      unitRef="usd">5528000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0zLTEtMS0yODc2NA_8b21c6cf-0a07-4a7c-ae38-b24204c51d3a"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy01LTEtMS0yODc3NQ_6fa850d5-494f-4988-9660-730f38dc1ce9"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0xLTEtMS0yODc1NQ_32f72440-6dd6-409a-82ba-ac13c02fdaa8"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0zLTEtMS0yODc2NA_416cdf83-25f6-42c0-89c7-1557dc00280c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC01LTEtMS0yODc3NQ_02d2f742-73a5-41a6-b029-e1adcf936907"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0xLTEtMS0yNzc0Mw_4d7b5ef8-8022-4e30-9680-ae521d60b66a"
      unitRef="usd">-56840000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0zLTEtMS0yNzc0Mw_6a424469-d5f6-418c-ad15-9ff42c6f356c"
      unitRef="usd">-11180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC01LTEtMS0yNzc0Mw_1abdfbb5-4d5c-4c5c-b6d0-7b68769e255f"
      unitRef="usd">71620000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS0xLTEtMS0yNzc0Mw_ee232fc0-ca17-43e6-bd27-214e3d65dcb4"
      unitRef="usd">35093000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS0zLTEtMS0yNzc0Mw_a08fbb26-310d-4620-8aed-c3a9f300ea64"
      unitRef="usd">32313000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS01LTEtMS0yNzc0Mw_e1a1a786-4bd4-4e36-bf82-caa16699eae5"
      unitRef="usd">108491000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMS0xLTEtMjg4Mzg_2a57fedd-7b70-48d4-95c8-18156f874987"
      unitRef="usd">-8549000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMy0xLTEtMjg4Mzg_dc25e598-9f3c-4e37-965d-58d5080796fb"
      unitRef="usd">-21077000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItNS0xLTEtMjg4Mzg_62d0caf4-f1a6-443f-8b5f-e023e1102da2"
      unitRef="usd">-108491000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMS0xLTEtMjc3NDM_d5b0b77a-67d7-4795-a490-81757f154f4c"
      unitRef="usd">-60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMy0xLTEtMjc3NDM_5843c52a-969f-44df-b9a1-c3aa3bef953f"
      unitRef="usd">125000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItNS0xLTEtMjc3NDM_78d61d9e-3813-4f34-ad93-66e143c60428"
      unitRef="usd">991000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtMS0xLTEtMjc3NDM_317e8a05-f1db-409f-b803-08067796d34f"
      unitRef="usd">-8609000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtMy0xLTEtMjc3NDM_97bd15c2-b4d2-4803-bcd7-1459d5cd6d43"
      unitRef="usd">-20952000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtNS0xLTEtMjc3NDM_bd40abd1-a5a9-4f7c-83f9-2a0a1c5b4325"
      unitRef="usd">-107500000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtMS0xLTEtMjc3NDM_31d95823-0302-4b16-a6d6-6067ff7e0b42"
      unitRef="usd">-8273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtMy0xLTEtMjc3NDM_0c026e21-1b23-40ef-bc8c-8c77f4b10966"
      unitRef="usd">1445000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtNS0xLTEtMjc3NDM_ffb1cdd7-8f42-434e-9d29-f0c5673f8b07"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMS0xLTEtMjc3NDM_2bccea8f-4ed7-49ee-8933-ecc3d24d2c4f"
      unitRef="usd">-336000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMS0xLTEtMjc3NDM_56134193-a39d-41e8-8ff0-ae0549d50a63"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMy0xLTEtMjc3NDM_04753fc1-0ac6-42f6-92f5-fad075f64c9d"
      unitRef="usd">-22397000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMy0xLTEtMjc3NDM_8912388c-6614-49a0-b6dd-a1ca15a101b1"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtNS0xLTEtMjc3NDM_87ae26ff-1706-4b89-b019-5642bf12a078"
      unitRef="usd">-107500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtNS0xLTEtMjc3NDM_deeb1d50-7a0b-4d9f-b50d-a61f59e0471f"
      unitRef="usd">-107500000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjkwMTY_e723fb68-6ad4-4f06-add1-7481211c3a48"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjkwMTY_41e471dd-fe89-401b-8aef-f8424acb3f1d"
      unitRef="usd">147000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjkwMTY_6a1d3f93-5f57-424a-9d07-72a84f7d6bb0"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjg5NTk_c31311e3-afb6-46ab-8f98-ff2e5f631ce3"
      unitRef="usd">-336000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjg5NTk_d68d798a-ac66-41c1-b88c-01af6aa6e050"
      unitRef="usd">-336000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjg5NTk_1273d8ad-2140-4818-9fc3-9d93b11e7538"
      unitRef="usd">-22544000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjg5NTk_1f1094e7-68f8-4613-829d-201f8de3ba76"
      unitRef="usd">-22544000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjg5NTk_2b71b8f9-23f3-40c5-b330-bd8d69923958"
      unitRef="usd">-107500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjg5NTk_ff4267d8-8cda-4854-b2b6-ab069eab48c7"
      unitRef="usd">-107500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMS0xLTEtNDU5MzI_3dcf45b4-e36a-449a-932f-9b63593d2eca"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMS0xLTEtNDU5MzI_53ac7a66-f9e5-4afb-9bf1-38ccab2df4ab"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMy0xLTEtNDU5MzI_3c4f7391-f1d5-4da7-b520-56ef98bef3a4"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMy0xLTEtNDU5MzI_d983829a-90ea-4972-944c-431a1a41098e"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtNS0xLTEtNDU5MzI_658eef7f-2a55-44a0-97a0-09863d992453"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtNS0xLTEtNDU5MzI_f1f23e88-9297-4dc3-bd9b-6ae0912d5102"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMS0xLTEtMjc3NDM_00f6e191-d783-4e19-a795-d0600cac7ce6"
      unitRef="shares">182323000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMS0xLTEtMjc3NDM_e23418f5-5b57-418a-ace3-372e3dcf1383"
      unitRef="shares">182323000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMy0xLTEtMjc3NDM_407116ad-e5f4-447d-b5e1-be5a416f8acc"
      unitRef="shares">118221000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMy0xLTEtMjc3NDM_980ba4b3-48c5-45e5-b7f4-89b8496cd6f9"
      unitRef="shares">118221000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtNS0xLTEtMjc3NDM_0d5ab724-813f-4c2f-a2b4-b7bf4a214c01"
      unitRef="shares">90929000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtNS0xLTEtMjc3NDM_e59ad112-ea24-4477-a261-d79c6a223c2c"
      unitRef="shares">90929000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i0bf44be67ed84033b15e86e3de2e9088_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi0xLTEtMS0yNzc0Mw_d8de166f-d74f-40d7-beaa-231d93ce2dfd"
      unitRef="shares">77456180</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0bf44be67ed84033b15e86e3de2e9088_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi0zLTEtMS0yNzc0Mw_d6df409d-5a6a-4920-b7f6-69374d78c30d"
      unitRef="usd">77000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c1773348a6144f8927754151f83c6b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi01LTEtMS0yNzc0Mw_ce36fcae-ec5c-4a27-aac1-f7bf3478a8ca"
      unitRef="usd">230154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic78f2f0a6b1d4a20ad7e12e40d1cacd4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi03LTEtMS0yNzc0Mw_bf9a07ab-5f3f-4a38-8bb6-1bf5e8cc92ac"
      unitRef="usd">-186024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi05LTEtMS0yNzc0Mw_72b5258f-8f1b-4293-937c-3a492010c054"
      unitRef="usd">44207000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i21d87267df014bc9b3e806eba7f1b0f5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMy03LTEtMS0yNzc0Mw_1f9ed555-7dd4-4e70-ab39-7c68abb6fe62"
      unitRef="usd">-107500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMy05LTEtMS0yNzc0Mw_a603efe2-732f-4aad-bea5-f8087731ffd3"
      unitRef="usd">-107500000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNC01LTEtMS0yNzc0Mw_12660377-b858-4bd2-be4e-bd92916fd95e"
      unitRef="usd">1237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNC05LTEtMS0yNzc0Mw_1eb2604e-106e-4043-84e3-59de920ae204"
      unitRef="usd">1237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS0xLTEtMS0yNzc0Mw_1a93878f-a49b-4015-8fde-b9e66f953768"
      unitRef="shares">89812</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS01LTEtMS0yNzc0Mw_1c894e25-0507-4318-82d6-c588aeea5774"
      unitRef="usd">98000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS05LTEtMS0yNzc0Mw_427ec341-3f9f-49d6-b111-5a0429b86e46"
      unitRef="usd">98000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi0xLTEtMS0yNzc0Mw_90564f58-e4b2-483f-aff9-1c6f44a97385"
      unitRef="shares">10283</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi01LTEtMS0yNzc0Mw_369444d3-db77-4313-8f21-3cf80028417f"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi05LTEtMS0yNzc0Mw_b17e1780-368b-4447-96f8-6d6907ef24be"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0wLTEtMS0yNzc0My90ZXh0cmVnaW9uOjk3MjRkYTM0MWE2NzQ3ZjU4ZmE2ZmEzMTI3ZWIyZDRlXzU0OTc1NTgxMzg5Nzc_bca1c4c5-3009-4445-a3ba-cdb96b0e4b6f"
      unitRef="usd">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0xLTEtMS0yNzc0Mw_ba4eb62f-c69f-40d9-a98a-a0e3856629dd"
      unitRef="shares">20410000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0zLTEtMS0yNzc0Mw_17b2ac41-f411-49c1-ad97-68938a4ae7f8"
      unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy01LTEtMS0yNzc0Mw_be098684-13ae-416e-8ade-7e8e116107e8"
      unitRef="usd">27812000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy05LTEtMS0yNzc0Mw_52773094-3822-469b-a122-e95ebca7d79c"
      unitRef="usd">27833000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC0xLTEtMS0yOTA5MQ_a7843989-92a6-4ffe-b266-8b4535e5e841"
      unitRef="shares">6772928</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i56d90314fd70472fa324352884486d5d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC0zLTEtMS0yOTA5MQ_253644d0-9e5a-4bee-b711-54bf4e431c72"
      unitRef="usd">7000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC01LTEtMS0yOTA5MQ_d622f749-1bf2-4ee9-be5c-c43acd825d37"
      unitRef="usd">5474000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC05LTEtMS00NjI5Ng_0460dbf6-f1d7-4a3f-9299-b82c37e0b3c4"
      unitRef="usd">5481000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0wLTEtMS00MDA5MC90ZXh0cmVnaW9uOjE3NzdjOWZiZTc4ZDRiNWY5YTkzYzdiNWRiOTBlMjZkXzU0OTc1NTgxMzg5NzA_f4ccd4c5-09a3-4375-b3d6-850eed18226c"
      unitRef="usd">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0xLTEtMS00MDEwMw_cd42b65f-9887-4fcc-9158-f209317d54f8"
      unitRef="shares">2062206</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0zLTEtMS00MDEwMw_eed521c3-1624-4950-853e-0dafd4c016ba"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3412d8401e304f0aae1eecacbcdbab85_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS01LTEtMS00MDEwMw_7aecef4a-82b7-4a13-b6b6-69b5afc951d8"
      unitRef="usd">1934000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS05LTEtMS00MDEwMw_a4f9db66-3149-4558-af30-4e602c28a880"
      unitRef="usd">1936000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0xLTEtMS0yNzc0Mw_f66eb284-a3c0-49e8-8a1c-17097970459d"
      unitRef="shares">106801409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0zLTEtMS0yNzc0Mw_1d029cd5-6867-4940-b6cc-b2683b6a94bb"
      unitRef="usd">107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf8c7f863b2f43bb922132621a9e5cda_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS01LTEtMS0yNzc0Mw_9f6a90f8-6d08-4bd5-a267-bdc7a2cd4606"
      unitRef="usd">266717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc289b8985ac49eb80e78ca2748e4a96_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS03LTEtMS0yNzc0Mw_7e791209-b185-411d-aa27-f422a4a4d640"
      unitRef="usd">-293524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS05LTEtMS0yNzc0Mw_51ea597f-6777-4161-a3f8-1fcdea91a821"
      unitRef="usd">-26700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i06678b0cf6c04477b759eb44801366df_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTAtNy0xLTEtMjc3NDM_9be35b65-90dc-4ab6-8b27-24f5d4c3031a"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTAtOS0xLTEtMjc3NDM_9b936e69-5c10-416d-aa8a-8a0c1fa3655c"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTEtNS0xLTEtMjc3NDM_f54e199f-81f4-476b-97a9-adf5523061c0"
      unitRef="usd">1757000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTEtOS0xLTEtMjc3NDM_e4394c68-598b-4aa8-a2b9-628040a7433a"
      unitRef="usd">1757000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItMS0xLTEtMjc3NDM_8316c5ad-c741-4ac4-b579-a2c193aa60c4"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItNS0xLTEtMjc3NDM_8d4022d9-2425-45d5-a0f9-704643f9e8c6"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItOS0xLTEtMjc3NDM_71a89f3d-8225-4bf7-8eee-928483c99d56"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtMS0xLTEtMjc3NDM_a2dc0553-3da5-471b-8094-60ad8c892ea5"
      unitRef="shares">28186</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtNS0xLTEtMjc3NDM_0f49d931-1667-4f3c-a423-d7510c4e690d"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtOS0xLTEtMjc3NDM_472263cf-8a80-46ee-b6d3-df70c6ce5294"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtMS0xLTEtMjc3NDM_c7c23d14-0649-4b66-a65a-e69ae40d100c"
      unitRef="shares">238110</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtNS0xLTEtMjc3NDM_982d13f9-c08b-42d3-9cfe-18a6ff18aa34"
      unitRef="usd">131000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtOS0xLTEtMjc3NDM_58497511-c2d4-4a37-af8e-7b449681343a"
      unitRef="usd">131000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjo5MGI5OTljN2E5YmI0MGFkYmJmNDE0OWQxM2FiZTg3N181NDk3NTU4MTM4OTcw_2fe6374a-3877-44fe-8e57-b85b10de254b"
      unitRef="usd">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMS0xLTEtMjc3NDM_3053161d-fcce-47c7-a668-fe03c3bd7c88"
      unitRef="shares">33369942</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMy0xLTEtMjc3NDM_a34928b1-b773-4ca5-aab0-b527b7ee4357"
      unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id593ab74c6634403b9f73b261b779b5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtNS0xLTEtMjc3NDM_e9adfaaf-5135-4176-a5d9-7fe9c5200622"
      unitRef="usd">37925000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib1cd661b638041f898d4ddc61a940fa7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtOS0xLTEtMjc3NDM_a692a336-248b-4794-bf07-58bfcdd16666"
      unitRef="usd">37958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="iededb75b8b3d41909c578b96949d296b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctMS0xLTEtMjc3NDM_e61031a6-0c23-464b-98a7-c3d680d4f222"
      unitRef="shares">140449647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iededb75b8b3d41909c578b96949d296b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctMy0xLTEtMjc3NDM_416b73ae-2865-472e-9c0c-1b066ce07d4f"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0b663c4ccd24528baa91746670f2709_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctNS0xLTEtMjc3NDM_7246dd05-ac7a-4709-8ef4-5baf31e6d2af"
      unitRef="usd">306554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92612297cd0642f585229a45cac68bd8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctNy0xLTEtMjc3NDM_8cd11026-c01d-42d7-9d7c-982bf3c328c5"
      unitRef="usd">-315921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctOS0xLTEtMjc3NDM_e32d68c3-9324-4966-a8fd-08ae0d465efc"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i548b9f86fcd54ebe9243040061933762_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTgtNy0xLTEtMjc3NDM_413445d8-ae7c-4195-8ee3-fdbc722d2979"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTgtOS0xLTEtMjc3NDM_9e48b881-7af3-4170-94a7-80d91309bbd5"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTktNS0xLTEtMjc3NDM_5f3e7a6f-9101-4b75-9cf6-92895e40db8e"
      unitRef="usd">5143000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTktOS0xLTEtMjc3NDM_67d1491e-1f16-4b31-8592-30bf402af3d6"
      unitRef="usd">5143000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtMS0xLTEtMjc3NDM_30e7adb0-5730-443e-a3fb-107974f6713a"
      unitRef="shares">33610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtNS0xLTEtMjc3NDM_5760d775-5236-4dc5-94ee-ff5284307bb9"
      unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtOS0xLTEtMjc3NDM_978870f2-0b0e-4c6a-b9c7-74a30271ec30"
      unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItMS0xLTEtMjc3NDM_70634e9b-dc1a-4252-8c46-09104de4b620"
      unitRef="shares">2048059</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItMy0xLTEtMjc3NDM_6eb55470-c445-46bc-b0c6-e7e7ba3831fd"
      unitRef="usd">2000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItNS0xLTEtMjc3NDM_821c27fe-e77b-4b57-b61d-ab4758801d0c"
      unitRef="usd">1124000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItOS0xLTEtMjc3NDM_98bdaf4c-8725-471f-82c0-e298da2a55ac"
      unitRef="usd">1126000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjpmOGE0ODQyNGRlMTc0OWRhYTRjZmQ0ZTlmMzI0MmRiYl81NDk3NTU4MTM4OTcw_0f8c243f-4365-409b-9730-4495e08a44a9"
      unitRef="usd">5400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMS0xLTEtMjc3NDM_2bfa1b11-a74a-4a37-9f8a-8235625ba313"
      unitRef="shares">56932329</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMy0xLTEtMjc3NDM_56f1d63b-26fe-4e42-87cd-d91a2a35c81b"
      unitRef="usd">57000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i449b028e12ab447dbe3d1ff217dca3f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtNS0xLTEtMjc3NDM_248893e3-3ac4-417c-a76e-dbcc2b9e7cf7"
      unitRef="usd">174905000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie6cc5cde3c2444458bf73121a4a8d8f5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtOS0xLTEtMjc3NDM_3ca3ae41-9308-4d3e-b627-d28a001e83da"
      unitRef="usd">174962000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i8c9ad583a050492ebb28f616a7b10aaf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtMS0xLTEtMjc3NDM_3f2cc55c-f99b-47a8-b60f-55e6f92e1a1e"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8c9ad583a050492ebb28f616a7b10aaf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtMy0xLTEtMjc3NDM_9e743bab-60bd-4b9e-9097-d67fafda6000"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bdadfe711654c368dce057e84bccbf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtNS0xLTEtMjc3NDM_1a2bb20f-a76e-4e4d-a414-cf0247dd97e3"
      unitRef="usd">487768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d93ef4c012e45c7b10ee227a4cdf96d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtNy0xLTEtMjc3NDM_8c4c463c-3ac7-4e13-8b03-ad8290be25c4"
      unitRef="usd">-316257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtOS0xLTEtMjc3NDM_e53fad47-f051-4162-8219-cc92542fc001"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy0xLTEtMS0yNzc0Mw_f2026e3a-01f0-4c12-8d50-6b5d724f02f8"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy0zLTEtMS0yNzc0Mw_b1a1b020-a960-42c8-9466-fe83d0f3c939"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy01LTEtMS0yNzc0Mw_3a75e822-882d-43c1-9954-cf92a0f73969"
      unitRef="usd">-107500000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS0xLTEtMS0yNzc0Mw_12a2d367-6a47-435b-9453-8f32fc679950"
      unitRef="usd">85000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS0zLTEtMS0yNzc0Mw_1c60d6fa-02ed-493c-bbe6-67e51acbe170"
      unitRef="usd">122000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS01LTEtMS0yNzc0Mw_5c3b0749-d686-4766-a077-5b167faead5b"
      unitRef="usd">219000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi0xLTEtMS0yNzc0Mw_5860771b-d0f6-47b3-b3cf-0aa68cd86686"
      unitRef="usd">5143000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi0zLTEtMS0yNzc0Mw_426d5422-5114-4ff7-876c-051d288731cb"
      unitRef="usd">1757000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi01LTEtMS0yNzc0Mw_dffced38-f9ca-4e4f-9683-864022efa08e"
      unitRef="usd">1237000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy0xLTEtMS0yNzc0Mw_4d7b5ef8-8022-4e30-9680-ae521d60b66a"
      unitRef="usd">-56840000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy0zLTEtMS0yNzc0Mw_6a424469-d5f6-418c-ad15-9ff42c6f356c"
      unitRef="usd">-11180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy01LTEtMS0yNzc0Mw_1abdfbb5-4d5c-4c5c-b6d0-7b68769e255f"
      unitRef="usd">71620000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS0xLTEtMS0yOTUyMg_b29b8dd9-602b-4add-907a-c4d61f9bb04f"
      unitRef="usd">31700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS0zLTEtMS0yOTUyMg_1e993444-5cd6-4412-95ad-db2a346ef5c6"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS01LTEtMS0yOTUyMg_bb57271f-fa75-413b-a99c-06f2cba56eeb"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMS0xLTEtMjk1NDY_e1e4b669-0055-4b1d-9530-644253d17ea2"
      unitRef="usd">24493000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMy0xLTEtMjk1NDY_0ed09fc7-a32d-4d19-815c-d1a80e6a1dd2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtNS0xLTEtMjk1NDY_a5f849b5-5e1f-4aeb-87f2-0428320a4920"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtMS0xLTEtMjc3NDM_e02ebc7a-4030-4011-93ef-b6e68a960c95"
      unitRef="usd">17964000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtMy0xLTEtMjc3NDM_dba15542-e519-4f19-be1a-48ce4bc867da"
      unitRef="usd">1304000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtNS0xLTEtMjc3NDM_b1a6ecc7-78b5-4455-b406-1c00f301116a"
      unitRef="usd">5188000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMS0xLTEtMjc3NDM_d61428c7-520f-49f2-a3d4-565e37959c0f"
      unitRef="usd">-249000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMy0xLTEtMjc3NDM_7fda028b-4e8f-4ebf-9777-ba02918f59a8"
      unitRef="usd">1200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtNS0xLTEtMjc3NDM_997c8d4c-746a-4520-b946-3b99346ef320"
      unitRef="usd">535000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItMS0xLTEtMjc3NDM_eb281b58-4173-4f3e-9dfe-691580192494"
      unitRef="usd">-4424000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItMy0xLTEtMjc3NDM_4d42d619-addb-4549-93e5-d67ce3d8ba1b"
      unitRef="usd">-2035000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItNS0xLTEtMjc3NDM_e97ce54e-6a23-4e82-a0d9-2fcee3b7a2a8"
      unitRef="usd">1556000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtMS0xLTEtMjc3NDM_52d8c648-ddf2-45d1-94d2-720da1dc4633"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtMy0xLTEtMjc3NDM_c5c1f332-826c-44f8-a8f8-c53924e462a1"
      unitRef="usd">3000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtNS0xLTEtMjc3NDM_adef1942-0119-4afd-9896-0a3a9ebe1147"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtMS0xLTEtMjc3NDM_9e265158-dfb7-4222-8f5d-ed02dd0f4921"
      unitRef="usd">-68878000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtMy0xLTEtMjc3NDM_dcb6b7f9-9e39-4c88-8d31-0474cfb52b22"
      unitRef="usd">-30837000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtNS0xLTEtMjc3NDM_e9c7f656-1770-4b2b-b02d-a019e1a6c5be"
      unitRef="usd">-37521000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtMS0xLTEtMjc3NDM_7e8e3e06-e091-4b4b-8001-11dee1416ec4"
      unitRef="usd">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtMy0xLTEtMjc3NDM_d09a2056-67f0-4a5a-96cb-49bac7d0d4b2"
      unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtNS0xLTEtMjc3NDM_af112bb2-6b7d-4e73-a2da-becdd511e586"
      unitRef="usd">136000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctMS0xLTEtMjc3NDM_c2706baf-26dd-43b1-b3f0-0dc4cdbb6eae"
      unitRef="usd">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctMy0xLTEtMjc3NDM_76ddfa3c-c1e4-47ea-bb4f-60b0056d9c46"
      unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctNS0xLTEtMjc3NDM_79155849-bbc7-43f8-9169-dd633e1643ad"
      unitRef="usd">-136000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sesn:ProceedsFromIssuanceofCommonStockandWarrants
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktMS0xLTEtMjc3NDM_d246a34c-da2b-4cfc-90cb-96a25189f8fa"
      unitRef="usd">0</sesn:ProceedsFromIssuanceofCommonStockandWarrants>
    <sesn:ProceedsFromIssuanceofCommonStockandWarrants
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktMy0xLTEtMjc3NDM_12b15fbb-54ea-40b1-8b31-4fa603bde56e"
      unitRef="usd">0</sesn:ProceedsFromIssuanceofCommonStockandWarrants>
    <sesn:ProceedsFromIssuanceofCommonStockandWarrants
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktNS0xLTEtMjc3NDM_0ddc56c4-cdd0-4415-bd85-0c6642ce863b"
      unitRef="usd">27833000</sesn:ProceedsFromIssuanceofCommonStockandWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtMS0xLTEtMjc3NDM_825e08f4-3cdd-46e8-bd79-c9afc20b9fe9"
      unitRef="usd">1126000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtMy0xLTEtMjc3NDM_3c6bfcc1-b971-43ca-998d-fc1fcd7a3f4d"
      unitRef="usd">131000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtNS0xLTEtMjc3NDM_bfcdb125-d590-46c4-b066-cf3b5aaddabc"
      unitRef="usd">5481000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtMS0xLTEtMjc3NDM_e840e667-6ac3-42ce-bc58-c0df9061495a"
      unitRef="usd">174962000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtMy0xLTEtMjc3NDM_91f0b7ac-d1c7-4842-bdea-5bd0cf47a69f"
      unitRef="usd">37958000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtNS0xLTEtMjc3NDM_d97f695a-806e-48c1-bbef-5fd1d8371437"
      unitRef="usd">1936000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItMS0xLTEtMjc3NDM_44e32ed6-d257-404f-bab1-f238fe09987b"
      unitRef="usd">42000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItMy0xLTEtMjc3NDM_0b13d8c9-7dd5-4539-99e8-aeaa918cf89b"
      unitRef="usd">13000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItNS0xLTEtMjc3NDM_2f7e9b1a-854d-4dab-99f0-001f7c4eb6cc"
      unitRef="usd">98000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtMS0xLTEtMjc3NDM_8b61d594-028a-4b7a-bcf2-c5cf1e30e692"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtMy0xLTEtMjc3NDM_936e34bc-ef1f-469c-af68-e70012322998"
      unitRef="usd">11000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtNS0xLTEtMjc3NDM_f9a2f7e7-ca66-45e7-93fe-c41845925f5b"
      unitRef="usd">8000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtMS0xLTEtMjc3NDM_48a70d8e-fa59-4862-8f3b-8cb8b3f154a8"
      unitRef="usd">176129000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtMy0xLTEtMjc3NDM_b1a06b34-fb74-4ed4-abd3-73834ae98c94"
      unitRef="usd">38113000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtNS0xLTEtMjc3NDM_dc746aa0-987f-46c3-af18-9328ea38cf5e"
      unitRef="usd">35356000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtMS0xLTEtMjc3NDM_2f74ba01-d8b0-4a13-8a33-19880ed971c0"
      unitRef="usd">107247000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtMy0xLTEtMjc3NDM_fd3f894e-5e61-4288-973a-b45746dafe34"
      unitRef="usd">7268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtNS0xLTEtMjc3NDM_8178d96c-c622-44f2-a2e2-0b2348d83cb5"
      unitRef="usd">-2301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtMS0xLTEtMjc3NDM_930b9a7b-f53d-44cc-a095-595eb9adc2d6"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtMy0xLTEtMjc3NDM_28208a53-9917-4f6f-9b0a-9e1e4dca619b"
      unitRef="usd">48141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtNS0xLTEtMjc3NDM_6f33d0cf-a984-468e-93ea-ce1f618acbb1"
      unitRef="usd">50442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctMS0xLTEtMjc3NDM_dce16000-a845-4b75-8f84-65f81e9db6c0"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctMy0xLTEtMjc3NDM_1a05970e-c902-4ad3-899d-758b4937df3b"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctNS0xLTEtMjc3NDM_1b67f8d3-c9c3-40e3-94d5-0a0336f2f362"
      unitRef="usd">48141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtMS0xLTEtNDgyNTU_05994ce0-d047-48cf-b74e-f500e49c6b0b"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtMy0xLTEtNDgyNTU_60ecc157-9105-4809-9734-6751d9425a04"
      unitRef="usd">52389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtNS0xLTEtNDgyNTU_09739e2d-5e6d-439c-bffc-1ede682db75d"
      unitRef="usd">48121000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMS0xLTEtNDk1NzU_2bcc88b4-aeb4-4d1e-8c4e-29ed567422c5"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMy0xLTEtNDgyNTU_fd716fb0-dd6f-458f-af0f-9c4c00d9e17a"
      unitRef="usd">3000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtNS0xLTEtNDgyNTU_88b7a9b2-0b46-4482-9119-66c5f90cc940"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtMS0xLTEtNDgyNTU_8fd097ca-f9ee-4d29-a600-04aaaf53333d"
      unitRef="usd">20000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtMy0xLTEtNDgyNTU_ad304fb8-34a7-4edd-b0a9-3ab9c4597d2d"
      unitRef="usd">20000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtNS0xLTEtNDgyNTU_28b55b85-e0f1-4a55-bfbb-9ec87d7ed5b8"
      unitRef="usd">20000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMS0xLTEtNDgyNTU_7f55a34b-6574-49a1-86f8-922d9951743a"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMy0xLTEtNDgyNTU_192bdcee-e361-4d64-9370-a13563759cdf"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtNS0xLTEtNDgyNTU_e96756bc-71ec-4fc3-aca8-7888bb62ebfa"
      unitRef="usd">48141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktMS0xLTEtNDgzNDQ_626ee158-ddde-432d-8c7e-e7af4691280a"
      unitRef="usd">174000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktMy0xLTEtNDgzNDQ_7acd5551-a350-4013-84f1-53e374cfef93"
      unitRef="usd">154000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktNS0xLTEtNDgzNDQ_04298934-8aaf-4790-b9bb-619a6b950741"
      unitRef="usd">153000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <us-gaap:OperatingLeasePayments
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMS0xLTEtMjc3NDM_e66c45fc-ae85-4ccb-9265-2626bb962469"
      unitRef="usd">0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMy0xLTEtMjc3NDM_f19fb015-ec24-4185-8802-c9451009a82f"
      unitRef="usd">0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtNS0xLTEtMjc3NDM_46aecb11-5c2d-41a1-8580-da834233ff74"
      unitRef="usd">236000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMS0xLTEtMjk2NDA_c70d1f4c-f018-4509-b8af-ec8bad994859"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMy0xLTEtMjk2NDA_931706f8-7230-4e9a-8040-020a07b4944b"
      unitRef="usd">290000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtNS0xLTEtMjk2NDA_1341fa1b-0dd4-4cab-9898-006b8b6d6157"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sesn:IssuanceOfWarrantForCommonStock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtMS0xLTEtMjc3NDM_05e13490-8ff4-4d1e-878d-7a89bfdcc203"
      unitRef="usd">0</sesn:IssuanceOfWarrantForCommonStock>
    <sesn:IssuanceOfWarrantForCommonStock
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtMy0xLTEtMjc3NDM_064b3121-9836-44ff-97b9-21f5cd82cb7b"
      unitRef="usd">147000</sesn:IssuanceOfWarrantForCommonStock>
    <sesn:IssuanceOfWarrantForCommonStock
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtNS0xLTEtMjc3NDM_86d431f4-3a2b-4a71-a5be-99635c6134f0"
      unitRef="usd">0</sesn:IssuanceOfWarrantForCommonStock>
    <us-gaap:NatureOfOperations
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMTA5MzY_e6604ff1-8ac8-46a5-9392-f4bb6974e690">DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio, Inc. ("Sesen" or the &#x201c;Company&#x201d;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#x2019;s most advanced product candidate, Vicineum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with bacillus Calmette-Gu&#xe9;rin ("BCG"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 VISTA clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#x201c;CMC&#x201d;), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (&#x201c;CRL&#x201d;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Viventia Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#x201c;Selling Shareholders&#x201d;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#x201c;Clairmark&#x201d;) (the &#x201c;Share Purchase Agreement&#x201d;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#x201c;Viventia Acquisition&#x201d;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#x201c;Purchased Product&#x201d;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&#160;31, 2021, none of these individuals are active employees or members of the Company's board of directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had cash and cash equivalents of $162.6 million and an accumulated deficit of $316.3 million. The Company in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;curred negative cash flows from operating acti&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vities of $68.9 million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30.8 million and $37.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Since the Company&#x2019;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to address the issues raised in the CRL it received for a BLA for Vicineum for the treatment of BCG unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete the follow-up stage of the ongoing Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, complete any additional clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercialization partnership and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;out-license agreements. See &#x201c;Note 12. Stockholders&#x2019; Equity&#x201d; below for information regarding the Company&#x2019;s recently completed equity financings. Management believes that the Company&#x2019;s cash and cash equivalents as of December&#160;31, 2021 will be sufficient to fund the Company's current operating plan for at least the next twelve months from the date these consolidated financial statements were issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Funding Requirements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future success is dependent on its ability to develop, and if approved, commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon its ability to attain profitable operations. In order to commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company needs to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of its product candidates, raising additional capital, development and commercialization by its competitors of new technological innovations, protection of proprietary technology and market acceptance of its products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and the Company expects to seek additional funds through equity or debt financings or through additional outside of United States (&#x201c;OUS&#x201d;) business development partnerships, collaborations, licensing transactions or other sources. The Company may be unable to obtain equity or debt financings or enter into additional OUS business development partnerships, collaborations or licensing transactions at favorable terms, or at all, and, if necessary, may be required to implement cost reduction strategies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will incur substantial expenses if and as it:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;addresses the issues identified in the CRL it received from the FDA for its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the European Medicines Agency&#x2019;s (&#x201c;EMA&#x201d;) Withdrawal Assessment Report, which the Company expects will include the completion of an additional Phase 3 clinical trial;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;seeks marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;establishes and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;maintains, expands and protects its intellectual property portfolio;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;hires additional clinical, regulatory, quality control, scientific and management personnel;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;expands its operational, financial and management systems and personnel;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;conducts research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and its other product candidates;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;seeks to discover and develop additional product candidates; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;in-licenses or acquires the rights to other products, product candidates or technologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's future capital requirements will depend on many factors, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the scope, initiation, progress, timing, costs and results of laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and its other product candidates;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the ongoing COVID-19 pandemic and its impact on the Company&#x2019;s business;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company&#x2019;s ability to establish additional OUS business development partnerships, collaborations or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for its product candidates;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the costs and timing of the implementation of commercial-scale manufacturing activities, including those associated with the manufacturing process and technology transfer to third-party manufacturers to facilitate such commercial-scale manufacturing of Vicineum;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company&#x2019;s obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the extent to which the Company in-licenses or acquires rights to other products, product candidates or technologies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the outcome, timing and cost of regulatory review by the FDA, EMA and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA, EMA or comparable non-US regulatory authorities to require that the Company perform more studies or clinical trials than those that it currently expects to perform;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company&#x2019;s ability to achieve certain future regulatory, development and commercialization milestones under its out-license and OUS business development partnership agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the effect of competing technological and market developments; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until such time, if ever, as the Company can generate substantial product revenues from commercial sales, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic collaborations, OUS business development partnership agreements, partnerships, alliances, and licensing arrangements. The Company does not have any committed external source of funds other than the amounts payable under the license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#x201c;Roche&#x201d;) and the license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;). To the extent the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#x2019;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, strategic OUS business development partnerships, collaborations, alliances or licensing arrangements, the Company may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on the Company&#x2019;s operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect the Company&#x2019;s ability to raise additional capital in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <sesn:NumberOfPatients
      contextRef="idbcc2cd80c644c9bba710067ba49b410_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNTQ5NzU1ODI4NzQ5NA_af879fd8-4d8c-4a2e-95ec-e27c4132c9c6"
      unitRef="patient">133</sesn:NumberOfPatients>
    <sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare
      contextRef="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjMxNA_6894dc74-7007-42f6-83bd-6e438155e9d7"
      unitRef="shares">4000000</sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i5fb4126fec9d47d299096c36c0f06713_I20160930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjQxOA_b0dca6c2-67a1-454c-bf36-889061f744c5"
      unitRef="number">0.199</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i36e9d8387a934ec497a4731a279af3dc_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjk4Mg_42ee455f-d2d9-4a6d-b363-7d7ec4dd630e"
      unitRef="usd">12500000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i533b84da1d2441468aadec080d52600b_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzExMQ_0a033b47-8eb2-454b-a808-f2e08e564190"
      unitRef="usd">7000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="if2334efa0613474c99d0b53f5f47619c_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzI1Nw_9fa571a7-9e60-4f13-9395-711d69599fc1"
      unitRef="usd">3000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods
      contextRef="i7059bd4c3d114e288eb8029d693c5dd6_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzM2OQ_e086b366-a2ca-4482-8cc3-9230d5c29547"
      unitRef="number">0.02</sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods>
    <sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales
      contextRef="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzYzNQ_d995a7c1-c9e4-4c5a-a4e9-b1d581f65f19">P15Y</sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales>
    <sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations
      contextRef="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzk5Nw_132de40a-e094-45d2-be74-1b7a7eb1b546">P7Y</sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDY0OQ_8d120f8d-ae45-4efb-981b-2dc23b20b96a"
      unitRef="usd">162600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDY4Mg_eff316ed-7c10-4609-9cee-3918a34125e3"
      unitRef="usd">-316300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc1Ng_a2784e9e-5c4f-49a5-8807-efd244278c91"
      unitRef="usd">-68900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc2MA_7d6e60cf-d629-44dc-b9d7-563ce0cc5f1e"
      unitRef="usd">-30800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc2Nw_2531fa83-d891-46fa-957d-4383eba0f5b7"
      unitRef="usd">-37500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:BasisOfAccounting
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxOQ_685e53f4-d18b-481d-9bc3-5d10787d13e6">BASIS OF PRESENTATIONThe accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxNg_4e5588d3-cc94-4113-80d6-746889d436ca">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxNw_cfe9bd45-c01d-4370-a0fc-ab6139497ab3">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxOA_8aa20fb3-ce39-4b28-92e7-5ee07f6c6ff0">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4Mzk_5d14b5b9-c387-485d-8ee0-2402c0b10a3a">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&#160;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application (&#x201c;MAA&#x201d;), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company's intangible asset of Vicineum EU rights, this asset was not impaired as of September 30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (&#x201c;POS&#x201d;) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#x2019;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#x2019;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase 3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize any impairment charges during the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's consolidated balance sheets is the result of the Company&#x2019;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#x2019;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#x2019;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company&#x2019;s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#x2019;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company's revenue projection models are timing of product launch and probabilities of clinical and regulatory success ("POS"); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#x2019;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#x2019;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#x2019;s estimated weighted-average cost of capital (&#x201c;WACC&#x201d;), which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2019, the Company adopted ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) using the optional transition method outlined in ASU No. 2018-11,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842), Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&#160;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 840") guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $0.2 million on the Company&#x2019;s consolidated balance sheet as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of this guidance did not have a material impact on the Company&#x2019;s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company&#x2019;s financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Accounting policy election to use the short-term lease exception by asset class;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Election of the practical expedient package during transition, which includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&#160;&#160;&#160;An entity need not reassess whether any expired or existing contracts are or contain leases;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&#160;&#160;&#160;An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&#160;&#160;&#160;An entity need not reassess initial direct costs for any existing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio as of the adoption date and as of December 31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#x2019;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#x2019;s consolidated balance sheet. As of December&#160;31, 2021, the Company did not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company&#x2019;s lease portfolio as of the adoption date were valued as of January 1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#x2019;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#x2019;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each grant of options during the years ended December&#160;31, 2021, 2020 and 2019 was determined using the following methods and assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the &#x201c;simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividend Yield. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2021 and 2020, the Company did not have any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1)   Identification of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2)  Determination of whether the promised goods or services are performance obligations including whether they are                          distinct in the context of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3)  Measurement of the transaction price, including the constraint on variable consideration&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4)  Allocation of the transaction price to the performance obligations&#x37e; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5)  Recognition of revenue when or as the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development and Regulatory Milestones and Other Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#x2019;s estimate of milestones and royalties approximates the standalone selling price of the license.&lt;/span&gt;&lt;/div&gt;In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company recorded $20&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. The Company recognized $26.5&#160;million of license revenue related to the Roche, Qilu and MENA License Agreements during the year ended December 31, 2021 and $11.2&#160;million of license revenue related to the Qilu License Agreement during the year ended December 31, 2020.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjI_6773808a-55e5-48d2-a0d9-88e693199802">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit RiskThe Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&#160;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzE3_7a6c87fe-383d-4fd6-88c0-40cb19c78f58"
      unitRef="usd">250000</us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDk_ea794164-6971-43cf-8f3e-4875b9f309ec">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id0d7d3d671d44f1fb8dc94865706738c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTM4OA_305cde46-1b1b-4f36-b4ee-e1cf56460954">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0f42726b9d2d45519a3279adbdeaf414_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQxMA_c4c2f676-74a3-44b5-9426-7fa9046f0efc">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib16d8fcfc6064d57a72284ee2689a0c5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ0MQ_cee98dac-07d2-4338-9ae7-0db94adcf06d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i649bc58c14754d8497732ebb7fb60f40_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ5OA_4ddf5223-522c-4ba6-a21c-01a87c3ea95a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzU_7443fc48-60af-4f5f-bbac-8c2d65d18806">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application (&#x201c;MAA&#x201d;), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company's intangible asset of Vicineum EU rights, this asset was not impaired as of September 30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (&#x201c;POS&#x201d;) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#x2019;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#x2019;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase 3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i5a2a6758069a4a888d0e5d69c12d58ab_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNDM5ODA0NjUzOTM3NA_c02efd29-01bb-4ba2-b5db-6bc5e7f85ba3"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTcwNDI0MzAzMzYwNzE_4c16c954-3f23-4f74-9d3c-67ca22e61849"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzE_a5c6aab4-51b2-4d7c-8a9f-15ccc078a7a8">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's consolidated balance sheets is the result of the Company&#x2019;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#x2019;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#x2019;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company&#x2019;s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#x2019;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5NjI_85cd7542-13ad-4d77-a33d-3cc6ea654fb9"
      unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:Goodwill
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5NDg_2c08ed4f-7114-4293-bc18-3431a4d4af0c"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NTM_0fbd0bee-2456-4a4c-9790-af997d841998"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTc1Mg_1fa5dabd-517d-40c7-bd11-b8c8aa25b0af"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <sesn:ContingentConsiderationPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjU_c404c114-e2c1-4455-85e0-79bfdad93375">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company's revenue projection models are timing of product launch and probabilities of clinical and regulatory success ("POS"); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#x2019;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#x2019;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#x2019;s estimated weighted-average cost of capital (&#x201c;WACC&#x201d;), which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</sesn:ContingentConsiderationPolicyTextBlock>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NjM_28dc195a-1041-4f72-be4e-d4696f71814c"
      unitRef="number">0.45</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="ibecee94376694fc393e30898f2ff86a2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1Njg_aac8409a-90e6-4f12-b167-bb277fd7512e"
      unitRef="number">0.55</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NzM_6980510a-676e-4371-8807-38aaac3ceb96"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1Nzc_5e96845d-0dad-48e5-9066-28aa466f0dc6"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i028ccf70c10c4129a5d10bd536d297b3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1ODE_1ba7af8a-e782-4c0b-a7ae-d59bb4a47392"
      unitRef="number">0.088</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i2de469ec0aa540adac05ef95232f5a15_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1ODc_034f23e7-f618-45b4-8323-03d6d708360e"
      unitRef="number">0.078</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="ib6a34442b9744cb6ae08c574b84b89b9_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MzU_e78facfe-2a39-439b-85d2-5ee6ad94eee9"
      unitRef="number">0.068</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i4609a0afbc594078808154f146946ab1_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1OTk_ceb76db2-7c90-46e7-be7f-f88ed773c9bd"
      unitRef="number">0.086</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1OTM_eef6d3c8-4728-4515-910b-0e17462e8300"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MDU_7ab5424e-5f5b-4f82-aecc-0a467a98cc19"
      unitRef="number">0.084</sesn:DebtInstrumentIndexRateHighYield>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="ia2453680b1ee48d49d18b917c46773a0_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MTE_8c5487ad-b537-47a0-bfde-12dbb6625b3d"
      unitRef="number">0.074</sesn:DebtInstrumentIndexRateHighYield>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MTc_ff2b4afe-2186-4d11-a46f-12a9ce58fd8f"
      unitRef="number">0.066</sesn:DebtInstrumentIndexRateHighYield>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MjM_d95d7b5e-e1f5-4f32-aaf9-92becf224eeb"
      unitRef="number">0.075</sesn:DebtInstrumentIndexRateHighYield>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2Mjk_16b69e59-ed1a-4544-ba11-cc8d13dedb6e"
      unitRef="number">0.080</sesn:DebtInstrumentIndexRateHighYield>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDU_da5565b4-e26b-4d69-a4a4-1cecb027fc07">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2019, the Company adopted ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) using the optional transition method outlined in ASU No. 2018-11,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842), Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&#160;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 840") guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $0.2 million on the Company&#x2019;s consolidated balance sheet as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of this guidance did not have a material impact on the Company&#x2019;s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company&#x2019;s financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Accounting policy election to use the short-term lease exception by asset class;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Election of the practical expedient package during transition, which includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&#160;&#160;&#160;An entity need not reassess whether any expired or existing contracts are or contain leases;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&#160;&#160;&#160;An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&#160;&#160;&#160;An entity need not reassess initial direct costs for any existing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio as of the adoption date and as of December 31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#x2019;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#x2019;s consolidated balance sheet. As of December&#160;31, 2021, the Company did not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company&#x2019;s lease portfolio as of the adoption date were valued as of January 1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4b6d609604934e33aa33ca5fc59ce894_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfODQ3MA_08682c8c-532a-4ff3-abb1-fa2bbebf917c"
      unitRef="usd">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4b6d609604934e33aa33ca5fc59ce894_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfODQ3MA_b44d4d02-80fd-40f3-8916-eef1ca4c1b06"
      unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4Mzg_68c1d800-fb03-4527-9adf-c961e3aa90cc">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjM_1ef8bcfb-73b7-43fd-b7dc-a644b9fb0322">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#x2019;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#x2019;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each grant of options during the years ended December&#160;31, 2021, 2020 and 2019 was determined using the following methods and assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the &#x201c;simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividend Yield. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQwODc_92084f93-1651-4897-8f2d-0144000000bf">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQxMjY_c90bb293-9d9e-425a-bf8b-5b98fbc57fec">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ3MzA_65ed8b91-5813-4420-a1b9-c43d0574ccd8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzY_125fe576-e0c1-4395-a24a-4e3211d5f18b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2021 and 2020, the Company did not have any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDE_c4e97964-d7d3-4411-b6f6-6b8c1d933140">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1)   Identification of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2)  Determination of whether the promised goods or services are performance obligations including whether they are                          distinct in the context of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3)  Measurement of the transaction price, including the constraint on variable consideration&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4)  Allocation of the transaction price to the performance obligations&#x37e; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5)  Recognition of revenue when or as the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development and Regulatory Milestones and Other Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#x2019;s estimate of milestones and royalties approximates the standalone selling price of the license.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sesn:LicenseAgreementMilestonePayment
      contextRef="i537b107b17f34737a20ec184a594ae82_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5OTk_a5b21596-6c35-4076-981c-c807eaafbac3"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestonePayment>
    <sesn:LicenseAgreementMilestonePayment
      contextRef="i537b107b17f34737a20ec184a594ae82_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5ODY_b1063518-33dd-44b7-9602-1a7dfeacae92"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestonePayment>
    <sesn:LicenseAgreementMilestonePaymentTerm
      contextRef="i537b107b17f34737a20ec184a594ae82_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTcwMTE_70646b17-d4ff-4dd0-93e1-8cef01cf0991">P30D</sesn:LicenseAgreementMilestonePaymentTerm>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i695006bd273747aeb95e43b893e8b867_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzI5ODUzNTAxNjY3OQ_c5caa3f9-de7f-45c5-9f78-553872bb3834"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzI5ODUzNTAxNjgwMg_2d6ef542-d325-488f-a8df-f4573102205b"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTQ5NzU1ODI0NDM4Ng_33f6a9e1-7734-430e-8088-02830519ab81"
      unitRef="usd">26500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTQ5NzU1ODI0NDQwMg_2384a6cb-9234-453e-92f1-8b31ea1771d7"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85NC9mcmFnOjEwNTQyZThiNGRmNTQwMTA5N2ZiN2VmMGUwMzMzNzdiL3RleHRyZWdpb246MTA1NDJlOGI0ZGY1NDAxMDk3ZmI3ZWYwZTAzMzM3N2JfMzM0OQ_6c9c2e44-7608-454d-a239-3d824236c00c">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85NC9mcmFnOjEwNTQyZThiNGRmNTQwMTA5N2ZiN2VmMGUwMzMzNzdiL3RleHRyZWdpb246MTA1NDJlOGI0ZGY1NDAxMDk3ZmI3ZWYwZTAzMzM3N2JfMzM0OA_8e420737-a050-44d0-8ea2-b48d956480fd">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDAzOQ_768dfd06-eb00-4a85-8d77-c2d349b415e0">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s consolidated balance sheets approximated their fair values as of December&#160;31, 2021 and 2020 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 8.0% to 9.3% as of December&#160;31, 2021 and 8.4% to 8.8% as of December&#160;31, 2020. There have been no changes to the valuation methods utilized during the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary by quarter of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108,840&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - short term &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company&#x2019;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#x2019;s WACC, which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $56.8 million for the year ended December&#160;31, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form, and the Company&#x2019;s withdrawal of its MAA with EMA. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Incorporating the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#x2019;s revenue projection models are timing of commercial product launch and probabilities of clinical and regulatory success; the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL and the Company&#x2019;s withdrawal of its MAA. The Company plans to conduct an additional Phase 3 clinical trial in order to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which will lead to delays in the start of commercialization globally. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#x2019;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NDA_7423ef5b-5642-4d7d-93a4-dde85bcf2cc9">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s consolidated balance sheets approximated their fair values as of December&#160;31, 2021 and 2020 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDA0MA_afd775d5-dfd3-4cd1-a719-1aa45172a908">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands):&lt;div style="margin-bottom:13pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib942d47e8aca410e959ff68b5d97942f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC0xLTEtMS0yNzc0Mw_2f6104cc-996a-4686-985b-6a99ed01b75f"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f3d4b0f71404387b7089a237b8a5500_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC0zLTEtMS0yNzc0Mw_9f8fbac0-4fea-4d26-a811-c75c9dceb116"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9280baa377514c5b8f3b86112af15bc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC01LTEtMS0yNzc0Mw_deee05f7-c22a-42f7-9292-d0211cfae383"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3a8e07a02a314fe58d21f5e73b65454b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC03LTEtMS0yNzc0Mw_e75d8d9c-c133-471b-9f99-418e4fda1970"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2904e8fab3f54e409e119eb43ab1f654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC05LTEtMS0yNzc0Mw_052eb447-85fb-4135-9a96-1701af5f8cc8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib942d47e8aca410e959ff68b5d97942f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi0xLTEtMS0yNzc0Mw_b561be6d-bb69-41a1-9109-2c37fb7aa2bf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3f3d4b0f71404387b7089a237b8a5500_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi0zLTEtMS0yNzc0Mw_ed2f70f5-e4b1-4309-9a30-c1d894b41de6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i9280baa377514c5b8f3b86112af15bc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi01LTEtMS0yNzc0Mw_c70996eb-fdb3-49c8-aa7c-df47bae062e0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3a8e07a02a314fe58d21f5e73b65454b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi03LTEtMS0yNzc0Mw_6e17a0db-b65b-4179-a3f0-6e209a2d7abf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i2904e8fab3f54e409e119eb43ab1f654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi05LTEtMS0yNzc0Mw_bf8d7a63-6604-49ce-a6c0-0538d40c2b2f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib942d47e8aca410e959ff68b5d97942f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy0xLTEtMS0yNzc0Mw_3e92c08a-89d0-4a0c-83c9-70361eedb084"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3f3d4b0f71404387b7089a237b8a5500_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy0zLTEtMS0yNzc0Mw_9a703a3d-17f0-45fa-9147-832b5427c89d"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9280baa377514c5b8f3b86112af15bc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy01LTEtMS0yNzc0Mw_cce00826-d798-4122-8a8b-7839a2ac28e1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3a8e07a02a314fe58d21f5e73b65454b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy03LTEtMS0yNzc0Mw_be18999c-d583-4d8e-8055-278bfef1bea3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2904e8fab3f54e409e119eb43ab1f654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy05LTEtMS0yNzc0Mw_ef37d1a3-3440-41c9-861f-6bfa06983605"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC0xLTEtMS0yNzc0Mw_31a004b6-d28e-4d18-b217-0bcde89984b4"
      unitRef="usd">16374000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib5309a9a57784300b6ab55b4dbfaa087_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC0zLTEtMS0yNzc0Mw_ae51873c-01e4-4b48-b874-497ed5f92e34"
      unitRef="usd">16374000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic6f21fbe1815427897b0c6ef0565f88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC01LTEtMS0yNzc0Mw_6f4c2e60-7529-4867-8baa-e1eddd261659"
      unitRef="usd">16374000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i33449a16f50d42fda82fa03444b362a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC03LTEtMS0yNzc0Mw_447d6aef-1429-401d-aaf4-c5fc76e8a933"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC05LTEtMS0yNzc0Mw_dc2a1d1f-0344-4f27-9fcb-3676f2832aae"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi0xLTEtMS0yNzc0Mw_540804c0-cea1-400b-b540-03a59d9a6ebf"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib5309a9a57784300b6ab55b4dbfaa087_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi0zLTEtMS0yNzc0Mw_0431842b-d616-42ba-a199-7b7222769570"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ic6f21fbe1815427897b0c6ef0565f88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi01LTEtMS0yNzc0Mw_5f9352af-a776-4420-a867-03108529dd9c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i33449a16f50d42fda82fa03444b362a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi03LTEtMS0yNzc0Mw_d2505ecb-eeb2-4c6a-b945-2b5e72ac1517"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi05LTEtMS0yNzc0Mw_011d8e67-00d1-458f-adbc-fb071f990e1c"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy0xLTEtMS0yNzc0Mw_9a518215-c89d-4ea1-ba52-526d27770ffb"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib5309a9a57784300b6ab55b4dbfaa087_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy0zLTEtMS0yNzc0Mw_cf8b2d48-2714-4bc9-befa-5106eb49f841"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic6f21fbe1815427897b0c6ef0565f88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy01LTEtMS0yNzc0Mw_b8a4f32f-ea42-4bd9-bde8-2a6b5c4e266f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i33449a16f50d42fda82fa03444b362a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy03LTEtMS0yNzc0Mw_bebc9c23-8df7-4dbc-943b-3abaf4da05b2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy05LTEtMS0yNzc0Mw_140baebe-ca1c-4136-b974-459644f8181a"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib03bde29f9a84402bee0c3bc6cf735f5_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzg0ODI5MDczMDAxMA_96e4f383-ebfc-4ea2-95f2-eb2068d180c9"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i58772c205c8a4b93bd99d62ff3f8e8af_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NTY_0593a624-4442-4a62-a30b-bceb768a6bca"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i294acb7d2420400b8155b9d8ca59ecac_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjAyMg_4dcd7c38-e00d-411f-ad48-716cc41112fc"
      unitRef="number">0.084</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i80a8c65717624d59b77914baa103c3bf_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjAyOA_2bca2bad-007f-4416-9609-2c1581063298"
      unitRef="number">0.088</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDA0MQ_609233e2-f0e6-44e5-8c82-6aa959eeac10">The following table sets forth a summary by quarter of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021 (in thousands):&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108,840&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - short term &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMC0xLTEtMS0yNzc0Mw_4608251b-7b7b-40f9-a8fb-e8da3b1b5004"
      unitRef="usd">108840000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9873482dcdab4f8e99687d14de08bf30_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMS0xLTEtMS0yNzc0Mw_061fab41-b98b-4a58-a6b0-15b2d03cad2d"
      unitRef="usd">48160000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia2453680b1ee48d49d18b917c46773a0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMi0xLTEtMS0yNzc0Mw_3b022d13-2ede-4ceb-a3e9-13ffb4675c94"
      unitRef="usd">157000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia0ab9cefc27e4b67b11ffb55b439770b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMy0xLTEtMS0yNzc0Mw_c27af503-1354-4d3e-9eac-659c1875838c"
      unitRef="usd">13600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNC0xLTEtMS0yNzc0Mw_0137421a-b009-41f4-9f04-161a39d83308"
      unitRef="usd">170600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ic90b2409cd1e47e9a97d51b1bda3f754_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNS0xLTEtMS0yNzc0Mw_b28a0236-140a-4605-8f37-b13c8ab59b28"
      unitRef="usd">-114000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNi0xLTEtMS0yNzc0Mw_7b8bd602-aeef-48f3-bdf9-7c81c43737e0"
      unitRef="usd">56600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNy0xLTEtMS0yNzc0Mw_7162395d-9a14-44ee-998d-632c5e9077c9"
      unitRef="usd">-4600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfOC0xLTEtMS0yNzc0Mw_e7e6953b-de7b-407f-8bec-53c2ace4e031"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMTAtMS0xLTEtMjc3NDM_82599e7d-c96e-40fd-8542-d66a83aff52f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMTEtMS0xLTEtMjc3NDM_65e6ac33-1175-4c42-aa1c-1a431df66de7"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i461f7c863e8845a1bf3aecbdde6819d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMC0xLTEtMS0zMDI3Ng_89337f78-097e-4c35-a783-4f88457bf005"
      unitRef="usd">108840000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent
      contextRef="iccafbadd781745f8a66ce65217af032c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMS0xLTEtMS0zMDI4NA_86832af2-5324-41dc-a4be-1707b5f89b2d"
      unitRef="usd">-8985000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent
      contextRef="iccafbadd781745f8a66ce65217af032c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMi0xLTEtMS0zMDI5Mg_ad6469f9-4219-4413-9bac-cea1a8aa19d6"
      unitRef="usd">-47855000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i208c2cdd76674e1490701e0cd5f02c0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMy0xLTEtMS0zMDMxMA_4093d389-3124-4c5f-bb2e-7668c8073c5d"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTA5OTUxMTYzNDE3Ng_0a9c0fb3-bd28-48d0-9c60-92ae775ff46f"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjk4MA_c6912ff7-f528-4d70-9683-cc0c9654886a"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i028ccf70c10c4129a5d10bd536d297b3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzEwMA_7ae83321-ac68-4486-9508-6f2e2cb6cf88"
      unitRef="number">0.088</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i2de469ec0aa540adac05ef95232f5a15_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzEzMA_8121cf6c-6333-47ab-b549-a8ce6b90c583"
      unitRef="number">0.078</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="ib6a34442b9744cb6ae08c574b84b89b9_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzE1NQ_e78a1cf8-bea4-4c56-8356-fb0c5b782922"
      unitRef="number">0.068</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i4609a0afbc594078808154f146946ab1_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzE3OQ_909cf822-16e8-494c-82d8-fb0ccab765d0"
      unitRef="number">0.086</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzg0ODI5MDczMTU5NQ_564da084-42ab-4d1d-bfb2-eb4bd8366f4c"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ0MQ_abd5161f-48b9-4573-91ba-05b44fa22a01"
      unitRef="number">0.084</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia2453680b1ee48d49d18b917c46773a0_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ3MQ_b3dd341c-5899-41d5-b39c-defb295313c8"
      unitRef="number">0.074</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ5Ng_6528f9b2-59d9-4e23-83d5-1b6b892ebd28"
      unitRef="number">0.066</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzUyMA_6a13d7fd-fde7-41e6-94a7-a7e768945725"
      unitRef="number">0.075</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NjM_f61c647f-318c-440e-be5f-1b5d07460998"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTcwNDI0MzAyNzQ5NzY_3dbc9b6f-21d3-4118-a572-b7866858adc1"
      unitRef="usd">-56800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5ODQ_e8f080e9-4caa-41f8-999b-2396e8948d5f"
      unitRef="number">0.45</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="ibecee94376694fc393e30898f2ff86a2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5ODk_94b0c53b-ee74-4909-8519-3ad243c3e295"
      unitRef="number">0.55</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMTU0NDg3MjA5Njk1NA_3f893826-ea4b-4f5a-aec4-33f318ecfcb1">RECEIVABLES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts receivable balance as of December 31, 2021 is $21.0&#160;million, comprised primarily of a $20&#160;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $20&#160;million was received. Additionally, i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $0.9&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other receivable balance as of December 31, 2021 is $3.5&#160;million. The Company recorded $3.4&#160;million to other receivables in the fourth quarter of 2021 for German VAT recovery related to drug substance sent to Baxter. The Company received a payment for $1.8&#160;million in January 2022 and expects to collect the remaining balance.&lt;/span&gt;&lt;/div&gt;The accounts receivable and other receivable balances as of December 31, 2020 were de minims.</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEwOA_09a50a2e-ea8b-45c2-b032-4890e61a345d"
      unitRef="usd">21000000</us-gaap:AccountsReceivableNetCurrent>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEzNA_3e38b8bb-fcde-48b9-82a7-c97dcf7fcba6"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE0Nw_b2f62b13-8133-4bef-a106-830ff3e58fcc"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:AccountsReceivablePaymentTerms
      contextRef="i15fd8a9c40534aeaaf4598e6db3abbf6_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE2Mg_5206b3da-fb31-4b10-8a5e-8d0dc52db337">P30D</sesn:AccountsReceivablePaymentTerms>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i69a83c24db234a7e8561b517d543d5e4_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE2OA_fc225545-834f-4a3a-8019-3ac6acf44f39"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia21f2148bbe744ea9737cdc30b3b639e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xNzA0MjQzMDIzNTk5MQ_8b0a6c6e-0b27-4a2b-815b-fb7db0bb2e5a"
      unitRef="usd">900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEyNw_547e89e7-9ae7-49d3-bf3d-d6c180bab0ee"
      unitRef="usd">3500000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE4MQ_1d186cb8-2b4e-4aea-a3df-d400b5950ed5"
      unitRef="usd">3400000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <sesn:ProceedsFromValueAddedTaxRecovery
      contextRef="i34539641171840f78745ef893c090fa7_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE5NQ_3e9e4d0f-c6fa-4f2a-8ff7-5cd3763b0f44"
      unitRef="usd">1800000</sesn:ProceedsFromValueAddedTaxRecovery>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzIzNA_619a8025-11e3-4a7e-89b0-1da7551cbcd4">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of property and equipment, net as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense was $0.1 million, $0.1 million and $0.2 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzIzOQ_b7839ba6-6c80-42e0-9267-a05863c7580b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of property and equipment, net as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3ea343b4020f4cf29f1266e2dc6a6b09_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzItMS0xLTEtMjc3NDM_d38c3547-0fd2-460c-ad9c-bb5bc8e39491"
      unitRef="usd">569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib230fbf43aab492384091cb48ddd7af2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzItMy0xLTEtMjc3NDM_6d0190e1-cb51-482a-8b86-e843f9a92638"
      unitRef="usd">570000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea35f777e5264bc1a11c1a5275407d2e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzMtMS0xLTEtMjc3NDM_4e1e9ed3-2fc3-49db-ab5e-f0cb94a4e15b"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a9439e6445a46079edce40b074a4cb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzMtMy0xLTEtMjc3NDM_9f784e7c-7d02-476e-8827-c4b3ff47c3eb"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idf1ae7c86aed4911bffc0db6ed1d7ca4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzQtMS0xLTEtMjc3NDM_45edb1a2-af3d-466a-ad3b-acf40931bcdf"
      unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1c4126ae783347adb9e0ab895ddfa18d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzQtMy0xLTEtMjc3NDM_0e5cd4ee-ceb2-457c-841e-ae1cf1e9f04a"
      unitRef="usd">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic1e085c71b3d4eb89b00ee3fce28ada1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzUtMS0xLTEtMjc3NDM_152a371b-8542-4709-bb3d-4d83840aaf68"
      unitRef="usd">32000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c1639a88a7f44d28ddedc2f01af5b1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzUtMy0xLTEtMjc3NDM_dcdf47bc-bc7d-4dca-83bd-3b0ce1cf1f4c"
      unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if671dcdd4df94af4a5b9fb93620a325b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzYtMS0xLTEtMjc3NDM_7bce8263-5e17-47b4-856e-773d7a015a20"
      unitRef="usd">293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i76e5f96e4bd74651b225f0392286c025_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzYtMy0xLTEtMjc3NDM_85d444d3-bffb-4b2a-ad5a-2d14f2461d91"
      unitRef="usd">293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzctMS0xLTEtMjc3NDM_7096aa13-b14b-40a0-9a9c-0ec9f1cdd715"
      unitRef="usd">1009000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzctMy0xLTEtMjc3NDM_2d675c0c-e7c7-450e-98b9-11f1b82d3c13"
      unitRef="usd">1004000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzgtMS0xLTEtMjc3NDM_327c2412-3695-4076-a16d-114d6f4d0577"
      unitRef="usd">966000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzgtMy0xLTEtMjc3NDM_8aea25c9-573e-4b47-95d9-a2a767f14654"
      unitRef="usd">881000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzktMS0xLTEtMjc3NDM_b373cdf7-172f-4567-bb55-9193226973f2"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzktMy0xLTEtMjc3NDM_58929297-3264-4666-8bb3-320365a66ea8"
      unitRef="usd">123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE2OA_fd25404f-9821-4e53-9fa0-e1156e8989a5"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE3Mg_e3eeefc9-53b6-4f98-8ef6-01053cb26b32"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE3OQ_8d9f53af-68c4-48f5-8f84-4f665fef2e1a"
      unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzQ0Nw_331f5533-0791-4771-8328-730505aa14f2">INTANGIBLES AND GOODWILL&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets on the Company's consolidated balance sheet are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum United States rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treatment of NMIBC, the Company&#x2019;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#x2019;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#x2019;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#x2019;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize any impairment charges during the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1&#160;million as of December&#160;31, 2021 and 2020. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company's withdrawal of its MAA, a quantitative impairment analysis was conducted during the third quarter of 2021, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 45%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#x2019;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from 45% to 55% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. &lt;/span&gt;&lt;/div&gt;Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzQ0OA_2d59a69d-481b-4611-8a8b-4ebd0ebdde01">The following table sets forth the composition of intangible assets as of December&#160;31, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum United States rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="if52b03759bf044b3b5e17cf2a7c4a0b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzMtMS0xLTEtMjc3NDM_ff93b3fa-ed06-4c3b-9893-ca4c85f3ab5f"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ic12322603449433985e3779be27b8eab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzMtMy0xLTEtMjc3NDM_97b1ce3c-d910-411f-8408-05278e393029"
      unitRef="usd">31700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i7d622315903d4829a4f582cfffed067f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzQtMS0xLTEtMjc3NDM_a76c8970-a2d2-49bf-8f29-672a073d2774"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i425fb86623034e39aa2df73efd925f25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzQtMy0xLTEtMjc3NDM_4cdd5a8a-5bf4-4b42-9056-16aa121823d7"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i6fe412d00cd048258c144cd9ed556654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzUtMS0xLTEtMjc3NDM_541b5eba-3656-4a13-a394-ef4a7bacf19c"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i9f1e110f756945ed9233483c148b8a4a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzUtMy0xLTEtMjc3NDM_0fabd042-1889-4a1f-b6ec-32acac6642a4"
      unitRef="usd">46400000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i65d83f49999a40659f8cb5c98716447b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjA1NzQ_5f4fdc49-8a86-4d49-92e5-f3bb96e8f571"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjMyOTc_4c16c954-3f23-4f74-9d3c-67ca22e61849"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzU0OTc1NTgxNzM0NDc_05812bca-c78b-4387-adf4-82f58d499d88"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzU0OTc1NTgxNzM0NDc_381b5dd2-ad7e-4641-8e1f-666ffad548de"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU4OTc_ed5ddec5-e381-4248-acda-9db0502458b7"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i02b5f8ea9c52413084c453c81936288b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MTY_c5b58db6-7d25-466d-b62a-6d606c3baa1f"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEyMDk0NjI3OTQ3NjAw_46390fca-693f-4d5d-9a2a-3eca1f36867f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ia43faec616e1467283e341842cd9d4ab_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MjU_28270a63-9b48-4906-80b8-ea028337fd73"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ibecee94376694fc393e30898f2ff86a2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MzQ_9939a189-5e56-43eb-b28c-517e1b71d7e5"
      unitRef="number">0.55</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjUzMzk_1fa5dabd-517d-40c7-bd11-b8c8aa25b0af"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90ZXh0cmVnaW9uOjllOWQwY2ZkMDA0NTQ5Nzc5YzRhMmU0YzZjMjUyYTVkXzE4NzU_4c3721cd-2cfc-47f8-af42-070f0de68cdb">ACCRUED EXPENSES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,973&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90ZXh0cmVnaW9uOjllOWQwY2ZkMDA0NTQ5Nzc5YzRhMmU0YzZjMjUyYTVkXzE4Nzk_b74a5883-6db9-4dba-a086-10343357f204">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,973&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzItMS0xLTEtMjc3NDM_d45200ca-7885-47cd-b382-a7f966f60619"
      unitRef="usd">1841000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzItMy0xLTEtMjc3NDM_35f8c81a-35c0-4141-afc5-fca174e67f5b"
      unitRef="usd">1372000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzMtMS0xLTEtMjc3NDM_0cfbbcec-0563-480a-99e3-94e6b96bb09c"
      unitRef="usd">2967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzMtMy0xLTEtMjc3NDM_ef40fd3d-1a61-4342-a92c-2808829bf2b0"
      unitRef="usd">1892000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzQtMS0xLTEtMjc3NDM_72116434-bf65-4e4e-b910-a4ee29309b76"
      unitRef="usd">1497000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzQtMy0xLTEtMjc3NDM_282a8404-3832-4cff-b613-2239630476bd"
      unitRef="usd">0</sesn:AccruedRestructuringChargesRelatedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzUtMS0xLTEtMjc3NDM_bfa3018a-124c-4e11-8cae-005e6da9e6a6"
      unitRef="usd">1941000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzUtMy0xLTEtMjc3NDM_97de0620-58a1-456a-9baa-42e25063a572"
      unitRef="usd">684000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzYtMS0xLTEtMjc3NDM_cd0d71dc-5969-49da-bb1c-582f8b807c37"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzYtMy0xLTEtMjc3NDM_bbcbaa63-f88e-45f7-a3f9-222f84a64979"
      unitRef="usd">25000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzctMS0xLTEtMjc3NDM_5eb5bb18-dd0f-4c89-bbcb-45b455a756cb"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzctMy0xLTEtMjc3NDM_13c611f4-4ce3-4ac8-9ba3-7c941988ef31"
      unitRef="usd">3973000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzI4ODE_93963bda-ea0b-4424-9f90-aa9058e78405">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#x2019;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#x2019; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#x201c;Securities Litigation&#x201d;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#x201c;Lead Plaintiffs&#x201d;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#x201c;Amended Complaint&#x201d;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants&#x2019; response to the Amended Complaint is due to be filed on March 7, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#x2019;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#x2019;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#x2019;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#x2019;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#x2019; fees. On October 18, 2021, the court consolidated the two federal cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#x201c;Federal Derivative Litigation&#x201d;). On December 22, 2021, the court entered a joint stipulation among the parties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sesn:NumberOfLawsuits
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMwOTU_c9f406a9-d055-4d0c-993b-b8236785b4b5"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMDU_5423c41e-43ba-467c-a834-ed54ece6c1fb"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMTU_d62740a2-625a-4d0c-8e11-4a1febf90081"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMjU_aedc41f6-d2c9-4140-98fd-2404ca1c9715"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMzU_600a355b-9668-4de0-83f8-5b8dcf67dee9"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxNDU_f51f3929-deb3-42a0-8ffc-b07e4088c3ac"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzA5Nw_739ee0de-025c-4509-8863-f8dcbf43ee4d">LEASES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for operating leases under ASC Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three-year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,300 at exchange rates in effect on December&#160;31, 2021). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,300 at exchange rates in effect on December&#160;31, 2021). Operating lease cost under this lease, including the related operating costs, were $0.3&#160;million and $0.3&#160;million for the year ended December&#160;31, 2021 and $0.3&#160;million and $0.3&#160;million for the year ended December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The asset component of the Company&#x2019;s operating leases is recorded as operating lease right-of-use assets and reported within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a"&gt;other assets&lt;/span&gt;&lt;/span&gt; on the Company's consolidated balance sheets. The short-term lease liability is recorded in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77"&gt;other current liabilities&lt;/span&gt;&lt;/span&gt; and the long-term lease liability is recorded in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1"&gt;other liabilities&lt;/span&gt;&lt;/span&gt; on the Company&#x2019;s consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three months to six months and currently extend through June 2022 and May 2022, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,400, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December&#160;31, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease (including related operating costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term property leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;562&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Supplemental Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's future minimum lease payments under non-cancelable leases as of December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Minimum Lease Payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments (2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sesn:OperatingLeasesAreaOfOfficeSpace
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEwMg_3d0c34f2-8718-424f-a29a-aeb6fee4d29e"
      unitRef="sqft">31100</sesn:OperatingLeasesAreaOfOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i81e534a3b6984e9ca7a46fb4761feeec_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEyOQ_cb823a0e-f701-4256-83e5-0897114fb834">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzExNw_899d3252-1e39-48b3-8ddb-a4602c2b622b"
      unitRef="term">1</sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i81e534a3b6984e9ca7a46fb4761feeec_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzE1OA_09622a00-c0c3-412a-bac3-e9de27b48058">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4Njc4_c6f560ef-c85e-4904-9f3b-e11779fbd40b"
      unitRef="cad">18100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4Njg4_aa46e359-c968-499e-81eb-3b711b3abe54"
      unitRef="usd">14300</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4NzQ1_e575234f-9c43-4b38-b42d-3288b583ee5a"
      unitRef="cad">18200</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4NzU1_28d4dbf5-6e86-4632-9135-843647f906e3"
      unitRef="usd">14300</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <us-gaap:ShortTermLeaseCost
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTA4_9db33a23-ae24-4e2d-bee8-76a98f5d683a"
      unitRef="usd">300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTQw_43cffc2c-b41f-4758-91bf-0656fc66709a"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTcw_26ba0f83-b0a7-4b6c-b97e-a26ead905a3c"
      unitRef="usd">300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NjAx_eecbb385-2fe8-4a56-9b8d-6e23f72087f6"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie35eeadb1df94fb4940973f807cc6e7d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDI3_b34c1b8f-e463-41bb-acc7-cc69d065f1b2">P3M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2d207bdc8bb44456958770de74b1eabe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDQ2_78e53d5f-8b75-4260-a03e-6e8aff1a9df6">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i68866b76b55f41f7a5558f5272486883_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjQwNDM1_598bd5ee-84ff-4caf-9302-45b7cd7dd6bc"
      unitRef="usd">2100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i4b8cf18e833d4913a7dc5dbc354f10c4_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjQwNDQ1_3f982f27-33f3-4538-abc4-60ed4e1be2d0"
      unitRef="usd">18400</sesn:OperatingLeaseMonthlyRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzA5OA_ce2ea70f-aa89-4114-903f-eeab7a46f202">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December&#160;31, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease (including related operating costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term property leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;562&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Supplemental Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8yLTEtMS0xLTM5NjIy_8824d3d7-fa7f-4d83-a647-dd1b0a431a99"
      unitRef="usd">327000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8yLTMtMS0xLTQxMTc2_2cf518c9-969d-4f6d-a8e0-10cdcd34172d"
      unitRef="usd">301000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8zLTEtMS0xLTM5NjI1_bc303976-ba11-4fbb-9ad7-b252dad70350"
      unitRef="usd">262000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8zLTMtMS0xLTQxMTc5_2d132eaf-013d-470f-b5c1-d5177eec60f7"
      unitRef="usd">261000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF80LTEtMS0xLTQ5NDI3_0d9e6910-e320-43cb-a4cb-1c3c9afbc963"
      unitRef="usd">589000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF80LTMtMS0xLTQ5NDI3_ccb1d5e5-6278-44d3-836c-baf2fa92c7cb"
      unitRef="usd">562000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8xLTEtMS0xLTQ5NDMx_bc7e97f8-46dc-419d-93a2-8cc4ab35d7d8">P0Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8xLTMtMS0xLTQ5NDMx_9c601c97-0d68-4107-a688-d2530dfdee08">P1Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8yLTEtMS0xLTQ5NDMx_2e06c13a-7a45-4e26-9ece-30126280c8cf"
      unitRef="number">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8yLTMtMS0xLTQ5NDMx_8784130f-3af4-4a7b-831d-bcf7eaabfcc6"
      unitRef="number">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEwMA_2450b5dd-6506-4634-a7ee-729d50b3647f">The following table sets forth the Company's future minimum lease payments under non-cancelable leases as of December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Minimum Lease Payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments (2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8xLTEtMS0xLTQxMTg1_788b2a2b-e87e-44ee-993a-dd88f54dea5e"
      unitRef="usd">129000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8yLTEtMS0xLTQxMTg1_beb9503d-02b4-4807-b2ae-15da2a7babb1"
      unitRef="usd">5000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8zLTEtMS0xLTQ5NDQ5_b62254f8-67af-4c3d-9bbb-305464b98609"
      unitRef="usd">124000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTM2_7e44bc56-57b4-42d2-86f1-a337909e9aac">STOCKHOLDERS' EQUITY DEFICIT&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company entered into an Open Market Sale Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time (the &#x201c;ATM Offering&#x201d;) for an aggregate sales price of up to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $35&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50.0&#160;million and $34.5&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#x2019;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $175.0 million of net proceeds from the sale of 56.9 million shares of common stock at a weighted-average price of $3.17 per share during the year ended December&#160;31, 2021, compared to&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$38.0 million of net proceeds from the sale of 33.4 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock at a weighted-average price of&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.17&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per share during the year ended December&#160;31, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.2 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the year ended December&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 2019 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company raised $27.8 million of net proceeds from the sale of 20.4 million shares of common stock and accompanying warrants to purchase an additional 20.4 million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $1.47. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $1.47 per share, subject to adjustments as provided under the terms of such warrants, and had a one-year term that expired on June 21, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following approval by the Company&#x2019;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were issued and outstanding as of December&#160;31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#x2019;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 815-40")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jun-2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jun-2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company received proceeds of $1.1 million from the exercises of 1.6 million 2018 Warrants and 0.5 million 2017 Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Modifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $1.1 million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $1.1 million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $1.20 to $0.60 per share of the Company's common stock, resulting in proceeds of $2.0 million from the exercise of 3.4 million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $1.20 to the lesser of (a) $0.95 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $0.55; as such, the Company recognized a deemed dividend of approximately $0.1&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' (Deficit) Equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than 50.1% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $0.80 to $0.55 per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $0.80 to the lesser of (a) $0.55 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December 31, 2021, there has been no adjustment to the exercise price of these warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i16b4c01413da485fa2ac23775d55bed5_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQyOTI_57301754-2b30-4d01-b6ed-62dd5a406a73"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="i65be1969c492411ba4743fe748508e67_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzMTI_e9cb6198-f620-45ab-9d93-917297cfdc51"
      unitRef="usd">35000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockAdditionalSharesAuthorizedForSale
      contextRef="id6ed6ecc802f45c586c3b6cfff6e28d2_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzNjY_273b1909-596b-48d8-9a9d-c882db3ef274"
      unitRef="usd">50000000</sesn:SaleOfStockAdditionalSharesAuthorizedForSale>
    <sesn:SaleOfStockAdditionalSharesAuthorizedForSale
      contextRef="ibfb861283e22418081b9e629463e783d_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzNTE_f5aeefa2-82d4-474b-9a7d-c30a2653276b"
      unitRef="usd">34500000</sesn:SaleOfStockAdditionalSharesAuthorizedForSale>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="i072f60a137e94674991638220c6ed9ec_D20210601-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzOTI_75402b7e-436c-4934-9eed-ffd609b7b236"
      unitRef="usd">200000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockCommissionFixedRate
      contextRef="i65be1969c492411ba4743fe748508e67_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQ0MTE_66932d0b-718e-4ec3-b309-11e928859972"
      unitRef="number">0.030</sesn:SaleOfStockCommissionFixedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNDc_8137ddee-77f1-42ac-996d-f00b12343ee7"
      unitRef="usd">175000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNTQ_46f34930-4686-4dee-9b79-f3148bf217ef"
      unitRef="shares">56900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNjA_758e79af-be69-4ab8-aef3-d137b82ac7a2"
      unitRef="usdPerShare">3.17</sesn:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNjU_44ca959c-0202-4115-98e3-0a5ab800f8ce"
      unitRef="usd">38000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNzA_9d3a0855-a37c-4515-9db3-9708acf1df9c"
      unitRef="shares">33400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNzU_7c46c6b3-c8f2-4049-9d0f-ea79253773f0"
      unitRef="usdPerShare">1.17</sesn:SaleOfStockWeightedAveragePricePerShare>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzODQ_e4a6a0fa-d67c-4fb1-ba49-20196ba8fe5b"
      unitRef="usd">5400000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NjI3OTA_9e68453e-1c08-4d70-85b0-1f80db0d52b5"
      unitRef="usd">1200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIyNTE_73e0daed-83fa-4f34-a7b5-f8527330ea41"
      unitRef="usd">27800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIyODc_383644e1-4dde-40e1-a2e0-a9cd2399dc77"
      unitRef="shares">20400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIzNjU_e1b356d5-2ce9-4d27-984f-cb39cc10b653"
      unitRef="shares">20400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sesn:CommonStockAndWarrantOrRightsPricePerShare
      contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzI1NDM_072bed4a-7755-4739-a7ae-71b8bb87cb61"
      unitRef="usdPerShare">1.47</sesn:CommonStockAndWarrantOrRightsPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzI3MDM_64052909-36f1-4f63-87de-7552b8da026f"
      unitRef="usdPerShare">1.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ifd395e5e95f84b618c6884bc4356ae1a_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTM3_94791cac-cb12-4618-a9f3-14ff128dfbdb">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzM5MjA_bb83ea6d-02b2-4b9e-af48-f50576274e8b"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzM5NjQ_81cfc0f3-616e-4f9c-ad11-95239a1aa7ea"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_3ca3ebd3-ceb3-4889-9eaf-9abc99c50214"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_a6fac8ff-e9aa-4eb3-9005-f84aa39202c8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_d2dedf03-e918-4c25-883e-d5fc0ebacf4e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_ea01a3c4-a76d-4098-a784-c8b743d25bfe"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTA0NDU_1e7dd183-5f40-4b42-9bef-bb5f5e95df67"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTA0NTg_c348de83-c14b-49bd-9c2d-cf888e978f23"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxMzg_6ebfddf1-ebe8-4834-a0d7-2f87dc8dafbb"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxMzg_db6a0c66-ced2-4ce5-bc01-7eeb19fd5fa6"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxNTk_4ee5e4f9-967d-4976-9eb1-20191f57d79c"
      unitRef="shares">140000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxNTk_e39cf994-80dc-4e30-b9eb-865d78a3fb90"
      unitRef="shares">140000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTQx_e2d3a93c-58e5-45b5-9c7a-15385f9d3f74">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzItMS0xLTEtMjc3NDM_910551ff-0edd-4ace-b6e8-8ce8933428fb"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzItMy0xLTEtMjc3NDM_a27d7ee9-291a-4add-9b4a-3af4f3b3d8b6"
      unitRef="shares">140450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="icf0d8f6abc7e49829c395d208a3436f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzQtMS0xLTEtMjc3NDM_6c3143f6-0678-466e-8f1f-018d1cbdb64a"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id916d4f7441d4a088be2fca47e276005_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzQtMy0xLTEtMjc3NDM_374d992d-1ae3-4701-a457-1fc525ae1f9b"
      unitRef="shares">2247000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMS0xLTEtMjc3NDM_08d38973-b036-4532-8535-f59d6eed6280"
      unitRef="shares">15703000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ifc1156bb975047729b334bf2e3fa2fc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMS0xLTEtMjc3NDM_2cb9d910-4172-4a92-9f7e-16207187cdaa"
      unitRef="shares">15703000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMy0xLTEtMjc3NDM_dafa9df4-9ca2-435c-91ec-c63628a4731b"
      unitRef="shares">10147000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtNTM0MzA_56772896-3e55-466f-b924-dedd6bd06979"
      unitRef="shares">3041000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtNTM0MzA_d80264ab-c6f1-432d-8ba1-4fc5db1e7474"
      unitRef="shares">3041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i75020eb264af4e39a21665962a79801e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMy0xLTEtNTM0MzA_4b97d569-fe12-470c-9bc5-50f38d8dcaed"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4f92707265b84c70ae5a42f1daae1378_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtMjc3NDM_30dfc1b1-9752-400b-ba96-9417a25ea788"
      unitRef="shares">8933000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i40e1aa3b61664f47b00658c43dfd99fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMy0xLTEtMjc3NDM_63bf073f-26a3-4fb6-b85e-2f8b79cf9394"
      unitRef="shares">4863000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7858b2eb979a432a96faff9ead49ee39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzctMS0xLTEtMjc3NDM_fe758fc7-3233-4288-b148-df3ce01d4ba6"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i44d44dfab69545dabde220a346b37456_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzctMy0xLTEtMjc3NDM_d41b0414-1081-4ec8-9edd-143eca070f7c"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzgtMS0xLTEtMjc3NDM_927d8cf2-97b0-4647-8862-d301aa2224f4"
      unitRef="shares">229640000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzgtMy0xLTEtMjc3NDM_71869167-bb97-4d4c-948c-bcbbe5af8626"
      unitRef="shares">157707000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:NumberofVotesEntitledForEachShare
      contextRef="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzUxMDY_53e774c3-db66-417c-8e3c-847bd3c59c7d"
      unitRef="vote">1</sesn:NumberofVotesEntitledForEachShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTQy_5bd98541-2eb0-486b-9ba3-3f44582bc53c">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2021 (in thousands):&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jun-2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jun-2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i877528c6538245119864f9c0c2e52211_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMi0xLTEtMjc3NDM_aefb2aaa-9afa-42eb-b301-dc5786cdc184"
      unitRef="usdPerShare">1.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i466f369ef0774c33bd619700d8de5551_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtNi0xLTEtMjc3NDM_c2999a41-537e-4805-81fc-374ed4f6e7f3"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtOC0xLTEtMjc3NDM_317e127c-1712-4008-874b-5ad1a479fc8d"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTAtMS0xLTI3NzQz_359b4cf0-c66f-405e-909e-8e9036ae6c11"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTItMS0xLTI3NzQz_0e037dab-8c41-419e-a33a-cfe8ecf604bc"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i877528c6538245119864f9c0c2e52211_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTQtMS0xLTI3NzQz_5fdbf0cd-5273-4243-8008-03069bb9d96a"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMi0xLTEtMjc3NDM_d53a4938-9c9e-403f-a842-84e559cfc33e"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i31cacad06c024286911346564a7662f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItNi0xLTEtMjc3NDM_1a79f56f-c083-43f2-972e-934ced65baca"
      unitRef="shares">1705000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItOC0xLTEtMjc3NDM_fba4d9fa-40de-4e61-a017-9c18cdf1089a"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTAtMS0xLTI3NzQz_078aeb3f-caf2-4bbc-82bc-128015051945"
      unitRef="shares">1573000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTItMS0xLTI3NzQz_949ebfa7-ed1d-4574-a367-31a573148621"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTQtMS0xLTI3NzQz_9483ef98-0beb-4fb0-ba39-ff73c27316f8"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMi0xLTEtMjc3NDM_43411bfd-62c6-47b1-a430-0ce1cc7da529"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6ae2e392a7c740b1988ab6b7b8b786d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtNi0xLTEtMjc3NDM_e4aab035-3916-446f-aa83-5ab38e2c4ee9"
      unitRef="shares">487000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtOC0xLTEtMjc3NDM_bc321b98-1943-4767-b1df-1c6b2c1b0af4"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTAtMS0xLTI3NzQz_9139048e-0de8-49a5-bc08-442ffff09749"
      unitRef="shares">475000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTItMS0xLTI3NzQz_ec630fe7-d845-4311-a56b-a7be93357b82"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTQtMS0xLTI3NzQz_4c5f1b17-e021-43ae-a126-6b6c14faab54"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie688301f8b994be195f31b42f85842e5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMi0xLTEtMjc3NDM_faed7136-7dd6-438a-b55d-f4871ced7bba"
      unitRef="usdPerShare">11.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9d5371af6c3e495888104af773d10b15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtNi0xLTEtMjc3NDM_aebae70f-e477-4dc5-9a36-c208f713fa28"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtOC0xLTEtMjc3NDM_2f4b494e-7430-4bc5-a592-685b5ab9f4e1"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTAtMS0xLTI3NzQz_077aed76-0531-4c0b-b787-7e2372788cc5"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTItMS0xLTI3NzQz_7d1b3434-84ff-4c81-8d81-a833b92ab512"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie688301f8b994be195f31b42f85842e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTQtMS0xLTI3NzQz_3b65d639-74dc-4aef-ad3d-8177afff248b"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i174b4bb16b14432aaeeb74b47fc49556_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMi0xLTEtMjc3NDM_021065e4-676a-4d69-8777-d926571b80dc"
      unitRef="usdPerShare">11.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7e67736b7d564e33bad48ed099f8786c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtNi0xLTEtMjc3NDM_72775c32-c429-4fe7-bfd5-a37b423c2ebe"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="ic128bae021684a57b2549146b666bae9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtOC0xLTEtMjc3NDM_bbd7cdb4-e8e3-43b3-8033-63bb38cdbffd"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ic128bae021684a57b2549146b666bae9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTAtMS0xLTI3NzQz_0aa9c38f-ae9a-4985-9733-20740c83598c"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="ic128bae021684a57b2549146b666bae9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTItMS0xLTI3NzQz_b6b0caa1-8e61-4c95-9554-d8e1661a199c"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i174b4bb16b14432aaeeb74b47fc49556_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTQtMS0xLTI3NzQz_6dcede5a-f057-4588-9206-644832f44964"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtNi0xLTEtMjc3NDM_86590912-d088-4a89-b44c-8a7ce404965c"
      unitRef="shares">2247000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtOC0xLTEtMjc3NDM_afca3ae4-daa8-48ef-92fa-a7f5f459edcd"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTAtMS0xLTI3NzQz_acc08e48-28a1-4719-a791-adfe42b15595"
      unitRef="shares">2048000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTItMS0xLTI3NzQz_e64bb57d-0d63-4331-a57b-411f1e5aa5a3"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTQtMS0xLTI3NzQz_f0653ebc-5258-46c7-bd0c-b41ce413b32f"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzY4ODI_b2538625-e132-41df-b3ff-6e0696e87191"
      unitRef="usd">1100000</us-gaap:ProceedsFromWarrantExercises>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="id8512f475d73400cabc282795a6d7b65_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzE3MDQyNDMwMjg1ODQ4_5c41e71d-53c9-4a9e-9cb4-ba4980643690"
      unitRef="shares">1600000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzE3MDQyNDMwMjg1ODY2_32a13328-c767-440f-8b94-7d7a6f124ba6"
      unitRef="shares">500000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzc2ODI_a0c53eb4-adfe-4204-a6ca-b08e86aa9328"
      unitRef="usd">1100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzgwMDM_1d5c3655-8171-4437-8dda-543569741cf1"
      unitRef="usd">1100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id470afa5cc9848b2a4b4f535d4b6c1f0_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg4MTI_1cc293e3-8973-4028-abc7-de95552be397"
      unitRef="usdPerShare">1.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4ec6e4d46e284f0594c5222b5698833c_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQzOTgwNDY1NjY1ODA_ffa3ef42-1aa7-4fa3-a8c4-da265355ee9f"
      unitRef="usdPerShare">0.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg4ODc_72ddfcca-3acf-4e2a-8bfc-2b08fe51aac4"
      unitRef="usd">2000000</us-gaap:ProceedsFromWarrantExercises>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg5MTE_2d2b27ac-860a-4ff6-b756-555d199675da"
      unitRef="shares">3400000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1f9a990e22cc41d8af941ad8a743ae8d_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzkxNTI_1291e85c-1290-4c08-9f0f-80e65f007714"
      unitRef="usdPerShare">1.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icc016955920f4e64b8ed1852c953e88a_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzkxNzY_0f0aa094-14f6-4dd7-8759-3a82218dbc7e"
      unitRef="usdPerShare">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iae3ad21e639847039d2f1b31b55bc122_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQzOTgwNDY1NjY1ODg_31e1df23-6a93-4a34-b93a-f7b1748dd031"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sesn:OtherDividendAndAdjustments
      contextRef="i0db3ec5f4dbd471f8ba45bdc77ad6b70_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQyNTg_9a954fc7-9d2f-401c-94ff-40b2929f859f"
      unitRef="usd">100000</sesn:OtherDividendAndAdjustments>
    <sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued
      contextRef="i1dda2c9095f1418e975214cb9c010492_D20191001-20191031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwMjM1_b799e79d-f1b9-4df3-b4c4-87f31d62e20f"
      unitRef="number">0.501</sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTUy_ad7ff1da-ba2d-46c5-8ee6-4bf9607c3cf0"
      unitRef="usdPerShare">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTU4_2793cb63-ab65-4ca2-b28f-b778369ea774"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExMjQ3_9073db12-96ee-4d9e-a540-ac65ed7cb195"
      unitRef="usdPerShare">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExMjcx_6f8cc366-09b6-4939-8583-570c45bef617"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90ZXh0cmVnaW9uOjg5NjhlNzM5ZjM2MjQzMWViNjE0ODY2ODg0MDZhMGI3XzI2NTI_0de47367-445f-4cf0-b1cc-3fd8c4b9543b">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#x2019;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The two-class method was not applied for the twelve months ended December&#160;31, 2021, 2020 and 2019 as the Company&#x2019;s participating securities do not have any obligation to absorb net losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of December&#160;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90ZXh0cmVnaW9uOjg5NjhlNzM5ZjM2MjQzMWViNjE0ODY2ODg0MDZhMGI3XzI2NTM_17f75c07-f177-4cae-8a58-5d989d57f860">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of December&#160;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i150fe7eff7ea4fdb9a21acd3372500e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItMS0xLTEtMjc3NDM_39a0808f-c9d2-42f1-991b-cbc252ad0fb9"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5156f45bd4749bab08cc813bedda252_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItMy0xLTEtMjc3NDM_e76a5d14-38e6-44ad-8d7a-457737977b18"
      unitRef="shares">2247000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if90f693a8f7e416ba3582374b0255711_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItNS0xLTEtMjc3NDM_2909ea05-d786-4317-b624-39325a9fa0fe"
      unitRef="shares">22895000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMS0xLTEtMjc3NDM_08d38973-b036-4532-8535-f59d6eed6280"
      unitRef="shares">15703000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ifc1156bb975047729b334bf2e3fa2fc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMS0xLTEtMjc3NDM_2cb9d910-4172-4a92-9f7e-16207187cdaa"
      unitRef="shares">15703000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMy0xLTEtMjc3NDM_dafa9df4-9ca2-435c-91ec-c63628a4731b"
      unitRef="shares">10147000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ica1ef2678e204ea598c3a695c7bf3daa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtNS0xLTEtMjc3NDM_af73c356-a304-4f6e-8966-302801591b55"
      unitRef="shares">6236000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtMS0xLTEtMjc3NDM_ffa71af8-7574-4c20-a6f8-b6c8ffb594b1"
      unitRef="shares">15902000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtMy0xLTEtMjc3NDM_e4d017ca-379f-48ca-8788-261f3bb5852c"
      unitRef="shares">12394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtNS0xLTEtMjc3NDM_b16b51bc-d679-47ec-bdfd-2e0addd079a1"
      unitRef="shares">29131000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTU_b27d7d5c-6561-442c-b226-22dd2b03cc22">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:277.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#x201c;evergreen&#x201d; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#x2019;s stockholders in May 2021, the Company&#x2019;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 8.9&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 12.8&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#x201c;Retention Program&#x201d;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#x201c;RSU&#x201d;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. The Company recorded an expense of $0.5&#160;million for retention-related RSUs for the year ended December&#160;31, 2021. Additionally, the Company expensed $0.6&#160;million in relation to the cash bonus portion of the retention program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As none of the retention milestones were met in the year ended December&#160;31, 2021 and achievement was deemed not probable, the Company did not record expenses for retention-related PSUs. As of December&#160;31, 2021, the unrecognized compensation expense for the retention-related PSUs, granted on October 1, 2021, was $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A summary of the status of restricted stock units is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,041&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining contractual life of unvested RSUs and PSUs as of December 31, 2021 is 9.75 years. The Company did not grant restricted stock units during the years ended December 31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2009 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-of-Plan Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here were approximately 2.8 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense of $5.1&#160;million for the year ended 2021. The stock option related expenses were&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.6 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.8 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.2 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the years ended December&#160;31, 2021, 2020 and 2019, respectively.  The RSU related expense was&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.5&#160;million for the year ended December&#160;31, 2021. The Company did not record RSU related expenses for the years ended December 31, 2020 and 2019.  As of December&#160;31, 2021, there was $10.4 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.7 years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2021, 2020 and 2019 were $2.16&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.56 and $1.02, respectively. The total intrinsic value of stock options exercised for the years ended December&#160;31, 2021, 2020 and 2019 was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTE_357bbcb8-85d6-41a2-a41d-b4d589ef2c05">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:277.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItMS0xLTEtMjc3NDM_337bb4a4-5e78-4570-900d-22177a44ccb9"
      unitRef="usd">973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46b84bfa887d467f8571564e41e8618e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItMy0xLTEtMjc3NDM_40131021-58fb-46ff-a77f-93bb3dc55a75"
      unitRef="usd">350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd3279ce60c04cfdb6610631e4f95328_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItNS0xLTEtMjc3NDM_78d72139-f29c-44b9-91d3-1908cb1ff2de"
      unitRef="usd">188000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6966455303f44235a15aa41b9bdb897d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtMS0xLTEtMjc3NDM_233ec184-4205-404e-b0e0-c8602953579e"
      unitRef="usd">4170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8dfe926ee5f4392a3f17922b1910370_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtMy0xLTEtMjc3NDM_bda2f461-dd85-4b3b-9e50-b93abbbd4ed9"
      unitRef="usd">1407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i33db38ac6691417da69866ecf8c6be7e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtNS0xLTEtMjc3NDM_cf34d716-cfe8-4db9-b7fb-075db583b612"
      unitRef="usd">1049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtMS0xLTEtMjc3NDM_633b37c4-85dd-4e12-9513-3bb766bdce0a"
      unitRef="usd">5143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtMy0xLTEtMjc3NDM_7d1a2ff3-adaa-4eae-a67d-d3e15f55c371"
      unitRef="usd">1757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtNS0xLTEtMjc3NDM_3e7ce7b9-480e-40ae-aaa3-11e79164b199"
      unitRef="usd">1237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i3155b0a68be6497d8886c0858eccfe59_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5NTM_7f397d5d-fd56-4455-a781-aa5cf2216c07"
      unitRef="shares">7900000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i9b59ed3d58ff421abae5edfb38249ce6_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5Nzc_1faa14ff-51ff-4546-a461-cb0bc6c9f11f"
      unitRef="shares">12000000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie05ac20284034cf78dcee6454eac36b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5OTM_36c99eb0-2bee-44a3-a63a-08abd1b2e085"
      unitRef="shares">8900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTE2_dda0d53f-8e02-418c-9648-50b542563c11">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9542ee3724344137b968a7e2f78a7249_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjkxMDY_e3a34e56-839b-4dd2-a02f-2cffbe2d36bd"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6565370c486e4b11b00a6d3e11fa682f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjkwODk_ea415101-6e77-440a-bfbe-2274bac09b3d"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjg5NzM_a844a8a3-b635-44d9-95e9-f0c7ef043ab1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie05ac20284034cf78dcee6454eac36b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzMTYz_f608c282-7fb8-4e98-b36b-48376fbc2691"
      unitRef="shares">12800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="id3fee83c1a8e4b838f1b1364ca7244be_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk0ODY_5697cc46-5dcb-4e6a-95c7-7bcb2fe6d7b3"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1MzA3Njk_54200e50-1ab3-468c-943c-4a011f117b7d"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:ShareBasedPaymentArrangementExpenseOnCashBonus
      contextRef="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTE4_f8a0cdbb-4a94-4798-bfea-e6434cfcf962"
      unitRef="usd">600000</sesn:ShareBasedPaymentArrangementExpenseOnCashBonus>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary
      contextRef="i5019c429efc54a3d939b95facb6113a9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk1MTQ_84d6940c-d869-4b0f-9fd3-b45c6a765963"
      unitRef="number">0.50</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i5019c429efc54a3d939b95facb6113a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk0OTQ_d1812718-027e-4b3c-9601-09947a368e6b"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i7f275e89a3774f7cbca3fb8965e7a354_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzNDE0_0e54b0c3-fd3f-43ee-bbe8-b8adb21be1d4"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTA1_7f0bb4b7-f92b-4b90-bb0a-134cdf78c1a2">A summary of the status of restricted stock units is presented below: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,041&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i75020eb264af4e39a21665962a79801e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzEtMS0xLTEtNDk4ODc_0af45ba9-406e-4a90-85da-ed259cb407a0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzItMS0xLTEtNDEyNTE_ad38eb0f-e78b-4d24-ad20-91465f17c271"
      unitRef="shares">2482000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzMtMS0xLTEtNDEyNTE_92847b98-fede-4836-991b-512ca3b9f43e"
      unitRef="shares">559000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzQtMS0xLTEtNDEyNTE_56772896-3e55-466f-b924-dedd6bd06979"
      unitRef="shares">3041000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3950633399b7426dbfabb5690ebcde85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzQtMS0xLTEtNDEyNTE_d80264ab-c6f1-432d-8ba1-4fc5db1e7474"
      unitRef="shares">3041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1NTA3Njc_1c50baf7-8259-4358-97fc-383961d622dd">P9Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1NTA3Njc_3d5b5c3f-0d63-4510-a5d1-3a733e187fbb">P9Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i30373a67e51d44d48f81e5dc9200383a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTMx_41193f40-646d-48d3-82c4-a484608e1b8b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if99964945ffc46049f3cdcd6ac3fa481_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTMx_89bd10bc-200f-49ca-a17a-c27214aa05a4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzExNTY_4d6a45b1-b542-4bf2-892d-bb500b4edec8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzExNTk_6dd553a0-c5ee-402b-a919-c45d33571c02"
      unitRef="shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if520d25ca9304b37b3cf574ce10e6659_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzIxNjU_57055c67-cc86-4818-af1c-6d59c8b43fb6"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTI_19016efd-c1b8-4ac8-8179-78e19a38ed25">The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2021, 2020 and 2019:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtMS0xLTEtMjc3NDM_4fb695d8-f96d-432b-bdb4-8116f61acbdd"
      unitRef="shares">3942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtMy0xLTEtMjc3NDM_af5a338a-5672-46b1-b946-f9bc81ba9069"
      unitRef="usdPerShare">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i04ad27b86d2646489f5ab053b12babde_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtNS0xLTEtMjc3NDM_c1af431e-c713-46cb-b3f4-03de97517791">P9Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i707ab57c26dd479d83f5e95b7b236b54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtNy0xLTEtMjc3NDM_946d63df-3b2f-4a9b-8a09-1abb6ab3a5e7"
      unitRef="usd">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzItMS0xLTEtMjc3NDM_72c04cd1-c468-436c-934a-700911e575d6"
      unitRef="shares">3986000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzItMy0xLTEtMjc3NDM_d3b3cf70-d72c-413e-b1c2-b5ca851d10f0"
      unitRef="usdPerShare">1.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzMtMS0xLTEtMjc3NDM_584c1449-a173-4e86-965c-5eb271ff6357"
      unitRef="shares">90000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzMtMy0xLTEtMjc3NDM_7e0d9c39-c378-4032-af62-6152d71b3730"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzQtMS0xLTEtMjc3NDM_bb8d0f39-4f50-45f0-b2ca-e7535b38223f"
      unitRef="shares">1602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzQtMy0xLTEtMjc3NDM_afa21597-1064-43d5-a903-66e7a8ed164f"
      unitRef="usdPerShare">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtMS0xLTEtMjc3NDM_66cbf305-e0ef-427c-8021-e5ec776b7e3b"
      unitRef="shares">6236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtMy0xLTEtMjc3NDM_b9c521cd-7545-45da-91c0-62797951edf3"
      unitRef="usdPerShare">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtNS0xLTEtMjc3NDM_b48fde18-61db-4058-8b6f-9333c5a4800b">P8Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtNy0xLTEtMjc3NDM_4cc96530-aa66-4f10-b59a-daf0fda028db"
      unitRef="usd">358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzYtMS0xLTEtMjc3NDM_4b3841e4-d52f-4008-83a9-832fd0195c77"
      unitRef="shares">4044000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzYtMy0xLTEtMjc3NDM_16d92292-6fe3-4122-af15-7130fb390083"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzctMS0xLTEtMjc3NDM_f2a9282c-51e0-4d92-ad77-f5ea652a117c"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzctMy0xLTEtMjc3NDM_4e6c5364-1148-45b1-b441-6a965e9dd9bf"
      unitRef="usdPerShare">1.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzgtMS0xLTEtMjc3NDM_bc2d3678-803a-4dfb-ad69-561685710fa7"
      unitRef="shares">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzgtMy0xLTEtMjc3NDM_c31b0853-16a8-4b93-8ee0-14860c31b5d3"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktMS0xLTEtMjc3NDM_11066062-e3db-45ef-95bd-de78ce7a14ae"
      unitRef="shares">10147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktMy0xLTEtMjc3NDM_12e67679-3e50-4533-a5a8-53d867e6854d"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktNS0xLTEtMjc3NDM_2176f3a1-16e3-4663-8089-777ad18ae62d">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktNy0xLTEtMjc3NDM_2a51f7c8-8320-44ba-a7ef-2351ea17524e"
      unitRef="usd">3160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEwLTEtMS0xLTI3NzQz_5fbfe593-ba80-446d-898e-667aab23d766"
      unitRef="shares">8273000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEwLTMtMS0xLTI3NzQz_050d040f-73e9-4af7-9aa9-65dd15e4cc3d"
      unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzExLTEtMS0xLTI3NzQz_5981ec71-4c8f-43d5-9e55-50dea1c0e5f8"
      unitRef="shares">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzExLTMtMS0xLTI3NzQz_0d078480-c179-45c8-b0d7-cde184a61258"
      unitRef="usdPerShare">1.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEyLTEtMS0xLTI3NzQz_61343905-a4eb-48a5-ad99-cf11f75d7a0f"
      unitRef="shares">2683000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEyLTMtMS0xLTI3NzQz_22ea50e1-5302-4425-b3ab-e6fe21e5d1b4"
      unitRef="usdPerShare">3.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTEtMS0xLTI3NzQz_8ea95c32-8a3d-4175-810e-2295d18d848e"
      unitRef="shares">15703000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTMtMS0xLTI3NzQz_4a09f860-8337-45b6-9981-483726e727b6"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTUtMS0xLTI3NzQz_9ff0ac61-c10b-49e2-81d4-3d9062f49e70">P8Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTctMS0xLTI3NzQz_d7b14e7d-0431-4818-a98e-0fc70df2494d"
      unitRef="usd">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTEtMS0xLTI3NzQz_48d8c939-c9cc-4f20-9a62-36b8327d683b"
      unitRef="shares">7562000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTMtMS0xLTI3NzQz_2aff1d20-bdb3-45da-8e13-380f8baf8d12"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTUtMS0xLTI3NzQz_e89ec540-10a7-4681-bed9-7e598477d0a7">P7Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTctMS0xLTI3NzQz_621d72b9-fdb2-4448-9ab2-22349e84cb52"
      unitRef="usd">59000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzMTc3_54ef698f-abba-4e89-bb7d-fb71f8ea83ea"
      unitRef="usd">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NDU_02263348-6907-486d-b8de-b16e19ec44fc"
      unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NTI_8557f087-3ae3-4b3e-a899-55b265425390"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NjA_da286c26-cc58-4032-854d-74a7795db2c6"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NDc4MDIzNjY0OTQ_54200e50-1ab3-468c-943c-4a011f117b7d"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia6a7749193cc45fc901d310757b0a9ff_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzOTg3_3db97a04-1c97-4468-a8c9-f9a48116feef"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65d8a19fb4244ecfaa96a4eff824e050_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzOTg3_a79266fa-2bfe-480e-8dcc-3093a85e8f0e"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5Njk_c67aff2a-a40e-489d-ae65-a75a81234de9"
      unitRef="usd">10400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NzY_169da346-0358-46d5-b2f0-deab461a4e4a">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTA_969a9284-3480-41de-8c6a-403507a2648e"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTQ_beb476de-a8eb-4189-8f0b-44e1d2f94987"
      unitRef="usdPerShare">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTg_30313e36-e370-41d6-ad0c-a8b3a2fd9b14"
      unitRef="usdPerShare">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NDc_19a2bfb9-873d-4103-a765-22711de56d68">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItMS0xLTEtMjc3NDM_65efe2c0-9add-42c6-944a-6828b471a122"
      unitRef="usdPerShare">3.32</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItMy0xLTEtMjc3NDM_aac145aa-6d15-47f0-b1a8-9bd22a6e3d8f"
      unitRef="usdPerShare">0.87</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItNS0xLTEtMjc3NDM_686a18d6-f807-471c-9c89-1086046fddb9"
      unitRef="usdPerShare">1.02</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ifc1156bb975047729b334bf2e3fa2fc6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtMS0xLTEtMjc3NDM_2185f3ea-22f8-45c6-ae81-77a4951cfe8a"
      unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i8645ab0e887d4a8bbf9664668f155fb6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtMy0xLTEtMjc3NDM_61c50b18-69b6-492e-af9d-537d4c21c75c"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i558d72c250fc4f3bb70e9309cb978078_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtNS0xLTEtMjc3NDM_4400ccfa-7208-4d06-8cd7-6484d8473ec5"
      unitRef="usdPerShare">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtMS0xLTEtMjc3NDM_8ae8262e-af93-4e14-9f8e-b0f80eacdbb6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtMy0xLTEtMjc3NDM_c51e0daf-bcc2-42f4-ac46-40e824f0502f">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtNS0xLTEtMjc3NDM_0c9f6813-25a6-4e06-b3dc-6b4288c96255">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtMS0xLTEtMjc3NDM_ad46d9db-4f64-4db4-a568-7ae41b8394d6"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtMy0xLTEtMjc3NDM_c822a83e-fdad-4b87-a63e-ad694d82bab7"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtNS0xLTEtMjc3NDM_39191ac1-e412-4e5c-afdc-94d184d17a64"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtMS0xLTEtMjc3NDM_24708e79-e564-4aba-8461-8ed11561df42"
      unitRef="number">0.746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtMy0xLTEtMjc3NDM_62e4abfd-6f9e-419e-b0f3-491027340377"
      unitRef="number">0.715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtNS0xLTEtMjc3NDM_3415844d-410f-40d4-9b84-e0db664eeda2"
      unitRef="number">0.781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctMS0xLTEtMjc3NDM_48bb6acb-62b0-4bcb-b470-110abd404332"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctMy0xLTEtMjc3NDM_32887a4c-0702-4a30-afe9-b108b9c01861"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctNS0xLTEtMjc3NDM_98d729b7-d032-4a41-b423-79ba1ce5f540"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzI1MzU_1acd523e-d03f-4ae4-8b72-49ebc072b126">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&#160;31, 2021, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States - 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada - Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2021, 2020 and 2019, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3408800d9ca34cbc9107500cccfb1efe_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3MTI_8a2b1789-e134-492e-93d7-c1991ae1ce3b"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i19aa28ed63b64ecf8600a587af11639c_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3Mzc_f08fafb3-79e5-407a-aec4-e3b044fe6fa8"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i2265e9372ef14f33a95d480831dcfd36_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3NTQ_e9b22e89-c96d-4d10-b07f-4e4cee2c956f"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i256cad603adc478fbe2bb635d926f6d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNTgyNzI_065af96b-282d-4303-b6cf-3ac6cb798501"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzE3MTM_e5affa62-7f28-4b8b-b2a0-b737eba59473"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee
      contextRef="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzE5MTI_8dd89fb0-95ca-4c20-8dec-e499164ff2e8"
      unitRef="usd">4000</sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i0714416d3dbb41bf905d3f30d60053a9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIzMjM_935adc23-ae41-4405-878a-1d3b224b8b66"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDA_c1e9a30a-afbc-45ba-a0fc-60ac00ae8d67">INCOME TAXES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(107,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 73pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Benefit (Provision) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record current or deferred income tax or benefit for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#x2019;s effective income tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Income Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $71.8 million, $65.6 million and $57.7 million have been established as of December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $6.2 million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability of $4.0 million primarily relates to the potential future impairments or amortization associated with IPR&amp;amp;D intangible assets, which is not deductible for tax purposes and cannot be considered as a source of income to realize deferred tax assets. As a result, the Company recorded the deferred tax liability with an offset to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's NOL and R&amp;amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Beginning in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $0.8 million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#x2019;s R&amp;amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s R&amp;amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2020 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NTU_56a7f71b-5213-4c34-87e2-c41eea4cf7c4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(107,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ib2b01c3a7a584c8c83ef29c8a5d2f83b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtMS0xLTEtMjc3NDM_d0b88f1d-b196-40fe-b671-673259e43c64"
      unitRef="usd">-32757000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2cc2b6152b3a498aa18f90d825cf3988_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtMy0xLTEtMjc3NDM_5a88f9f5-4570-4f81-9b4f-766d56dd0bcc"
      unitRef="usd">-35529000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="iff556de6a08542a29c8cf9c6757a93ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtNS0xLTEtMjc3NDM_fab755ec-12ab-4abb-b378-eea07439def0"
      unitRef="usd">-27468000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtMS0xLTEtMjc3NDM_58ac6779-1629-4b0f-bbbf-f1bc84902577"
      unitRef="usd">24148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i95faf853daed44049bbacea1c98c9719_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtMy0xLTEtMjc3NDM_beb33a98-ba3f-4602-b167-6cbdb0f65479"
      unitRef="usd">14577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4fac383649084445a8d938fea7593c9f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtNS0xLTEtMjc3NDM_026e35c2-ef0c-456d-aa8a-121cc4502e5b"
      unitRef="usd">-80032000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtMS0xLTEtMjc3NDM_cef87955-0aef-4804-bdb6-9df1892e6f8d"
      unitRef="usd">-8609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtMy0xLTEtMjc3NDM_ccaf83a0-53e3-4af2-b20b-e6c0a127e290"
      unitRef="usd">-20952000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtNS0xLTEtMjc3NDM_360e8447-7a24-402a-ba82-2fa2e552165d"
      unitRef="usd">-107500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NTI_b7c8d363-1535-4b96-9941-83e3f03a010a">The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 73pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Benefit (Provision) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtMS0xLTEtMjc3NDM_8a891cfb-ca83-4865-912b-34b10cba0b7f"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtMy0xLTEtMjc3NDM_84fef57f-e223-4640-94f4-fc93e824732a"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtNS0xLTEtMjc3NDM_dc5e317b-7132-4830-9d43-3c130a7280d7"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtMS0xLTEtMjc3NDM_ddbb4f2a-2192-4625-b2e6-79c88acb4f5f"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtMy0xLTEtMjc3NDM_a15318a3-23bd-4f50-8dde-134ea677e873"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtNS0xLTEtMjc3NDM_97d3c3ec-bbc7-471b-a125-f045072a222c"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtMS0xLTEtMjc3NDM_fbd78772-6c1f-416b-971e-cb6f6140baa2"
      unitRef="usd">286000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtMy0xLTEtMjc3NDM_78a574d5-c94e-49f1-82bd-0d5127ecd8e2"
      unitRef="usd">1445000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtNS0xLTEtMjc3NDM_d67ab485-e165-4644-b2ca-261232240b68"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtMS0xLTEtMjc3NDM_80d62ff3-6801-401b-95e6-56a2180b9197"
      unitRef="usd">286000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtMy0xLTEtMjc3NDM_69758ab0-aa75-4ac2-b736-930a6d3432ca"
      unitRef="usd">1445000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtNS0xLTEtMjc3NDM_12ffa86a-70b9-46b8-bb2c-9e9bc071855c"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtMS0xLTEtMjc3NDM_e85d1a07-2b1a-40e7-960c-931099bece97"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtMy0xLTEtMjc3NDM_7d92c272-6860-401a-b32b-27ff42bf2b47"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtNS0xLTEtMjc3NDM_30a0fd62-b98c-4923-9c95-80aefc1e8c1c"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktMS0xLTEtMjc3NDM_8def22d1-3a63-43af-9b33-41961b439850"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktMy0xLTEtMjc3NDM_80199037-1932-431b-97d3-48ce2aa93b7a"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktNS0xLTEtMjc3NDM_09f5d096-5b26-4602-990f-9878adb9c4cf"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTEtMS0xLTI3NzQz_7800ab6a-5beb-4011-8f34-26c4d2133a57"
      unitRef="usd">-8559000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTMtMS0xLTI3NzQz_0e8b000e-cad0-40fa-b32e-d17ac845c983"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTUtMS0xLTI3NzQz_ad773e5c-de13-429b-9399-8172e5e03333"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTEtMS0xLTI3NzQz_2b3875ee-08c2-4164-83a7-a22438219db9"
      unitRef="usd">-8559000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTMtMS0xLTI3NzQz_36b52200-ad3e-43f9-a193-3400eea39022"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTUtMS0xLTI3NzQz_1ea73fe4-96f2-4b70-951e-f743f9a2401c"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTEtMS0xLTI3NzQz_e0747521-e657-4024-aaa4-d3f11b4f50b6"
      unitRef="usd">-8273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTMtMS0xLTI3NzQz_c91fa86c-ec1c-4a96-a62d-d6ef59591251"
      unitRef="usd">1445000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTUtMS0xLTI3NzQz_11e4feb4-0c7f-4439-a6df-33a17d11cee9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDU_d9672778-2601-45cd-bd19-4fc992eaf06d">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#x2019;s effective income tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Income Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItMS0xLTEtMjc3NDM_190197df-b2b5-4796-a587-5156eeb161ae"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItMy0xLTEtMjc3NDM_10a44062-16ba-4961-8d32-649503ad755d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItNS0xLTEtMjc3NDM_5b062622-f62e-4d40-bcd4-41e692564b32"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtMS0xLTEtMjc3NDM_64ea8c05-6c46-4a0c-9014-e3c2421e68e8"
      unitRef="number">-0.159</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtMy0xLTEtMjc3NDM_25aa62fb-84b4-4e5b-95b2-254df64c596a"
      unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtNS0xLTEtMjc3NDM_c8db928a-0a05-47a2-a028-a4804baf3cbe"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtMS0xLTEtMjc3NDM_412fe960-fb48-4672-93c9-e0b4c6c04c54"
      unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtMy0xLTEtMjc3NDM_789763d8-a001-46ba-bc4e-d3f9d094dc2a"
      unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtNS0xLTEtMjc3NDM_aceb3015-d23f-442d-8909-e34e97f77309"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtMS0xLTEtMjc3NDM_b040c9d6-6445-4847-9bea-58515b221b10"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtMy0xLTEtMjc3NDM_fd490530-2667-409c-a99c-4f6f468a920c"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtNS0xLTEtMjc3NDM_7e13a3fe-b8d4-45fa-bb63-8d8f1a9ae8db"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtMS0xLTEtMjc3NDM_23135495-964d-41b8-9769-92c774615620"
      unitRef="number">1.782</sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtMy0xLTEtMjc3NDM_edbc5082-c9ea-4f5e-a469-31f611309b06"
      unitRef="number">0.144</sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtNS0xLTEtMjc3NDM_1bc2f351-1e86-4d99-bcf1-1647a83b449d"
      unitRef="number">-0.180</sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctMS0xLTEtMjc3NDM_08aa8c70-65b6-4112-a167-46196ebc9c48"
      unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctMy0xLTEtMjc3NDM_3f56cc69-599a-47f9-9306-4b6c67b4f9ee"
      unitRef="number">-0.066</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctNS0xLTEtMjc3NDM_bcd8eef6-c4e0-48e6-a801-92437734fd73"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtMS0xLTEtMjc3NDM_3d9bd497-1917-465b-b6fd-dac07214d9b8"
      unitRef="number">-0.014</sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtMy0xLTEtMjc3NDM_739adad7-61ed-48bd-9fea-3d61807d6b7a"
      unitRef="number">0.002</sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtNS0xLTEtMjc3NDM_966ffbce-25db-47ff-9a20-c2e0538a53f0"
      unitRef="number">0</sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktMS0xLTEtMjc3NDM_098685b1-a2d8-4bf9-9044-6e93e3d50e89"
      unitRef="number">-0.138</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktMy0xLTEtMjc3NDM_a928c3c8-3c16-48d8-a249-5d81cf3c79db"
      unitRef="number">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktNS0xLTEtMjc3NDM_482f0ea3-fd94-473e-9f2c-96d767bc3f24"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTEtMS0xLTI3NzQz_044ca513-47c0-482c-a587-6676d1755255"
      unitRef="number">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTMtMS0xLTI3NzQz_9812ad41-03ae-4908-b4b9-fa95f5331818"
      unitRef="number">-0.069</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTUtMS0xLTI3NzQz_2aa965d7-250e-4da7-8892-319fc2cb01c3"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTEtMS0xLTI3NzQz_989248c7-8812-4080-9f72-2263528d9252"
      unitRef="number">-0.723</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTMtMS0xLTI3NzQz_5f202e7d-2276-49dd-8f72-c39963d566a1"
      unitRef="number">-0.377</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTUtMS0xLTI3NzQz_f71fb798-07df-4b5d-823f-443443cc2483"
      unitRef="number">-0.079</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTEtMS0xLTI3NzQz_53ee16e9-0377-4aa2-b0ee-18aef786c200"
      unitRef="number">0.961</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTMtMS0xLTI3NzQz_b10c5702-a11d-4bff-8d9c-d6df5218944d"
      unitRef="number">-0.069</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTUtMS0xLTI3NzQz_f0acc336-a0e3-47da-9a62-35f21a7641c4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1Mzk_02fd80eb-6420-4c13-af65-a657fac522cc">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtMS0xLTEtMjc3NDM_41874ceb-eae2-4218-a32e-95c60caec2ca"
      unitRef="usd">63381000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtMy0xLTEtMjc3NDM_a7d387fe-ded0-4613-9eaf-9508c6834ae9"
      unitRef="usd">57935000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtNS0xLTEtMzMwNDc_899a12a1-de4a-457a-8bbd-22b898f40cca"
      unitRef="usd">50727000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtMS0xLTEtMjc3NDM_b7b4a9c7-c67e-4116-a6d7-62dd967131d0"
      unitRef="usd">4316000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtMy0xLTEtMjc3NDM_3574bfd8-e83a-4127-9334-abf786633bc4"
      unitRef="usd">3787000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtNS0xLTEtMzMwNDc_1ea65883-ab00-4298-b2c9-d77229592c13"
      unitRef="usd">4385000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtMS0xLTEtMjc3NDM_c5505b89-d677-4611-a567-aa3d05d72077"
      unitRef="usd">4058000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtMy0xLTEtMjc3NDM_3b5dfabf-c900-470c-907c-e1c153f8369a"
      unitRef="usd">3811000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtNS0xLTEtMzMwNDc_9407d777-17a9-4884-b13b-b6662b34c554"
      unitRef="usd">2464000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <sesn:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtMS0xLTEtMjc3NDM_523ffd9a-9132-4ecf-9fd1-0ee590dbf0f4"
      unitRef="usd">53000</sesn:DeferredTaxAssetsCapitalizedStartUpCosts>
    <sesn:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtMy0xLTEtMjc3NDM_ccfaca49-8352-4244-abee-a856494f80d9"
      unitRef="usd">70000</sesn:DeferredTaxAssetsCapitalizedStartUpCosts>
    <sesn:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtNS0xLTEtMzMwNDc_e43507d6-7bba-4959-b906-438f698303a9"
      unitRef="usd">91000</sesn:DeferredTaxAssetsCapitalizedStartUpCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctMS0xLTEtMjc3NDM_477313b8-6e45-4303-ac3d-c591d64cd756"
      unitRef="usd">41000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctMy0xLTEtMjc3NDM_61ef5f1f-4b57-4b87-80ef-80b57b54767e"
      unitRef="usd">28000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctNS0xLTEtMzMwNDc_283ad6b9-8772-43f6-8e4e-a3c3bc3fe2e7"
      unitRef="usd">57000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtMS0xLTEtMjc3NDM_fc760acb-bc0a-4e2e-9ce9-0343ed2f0a05"
      unitRef="usd">71849000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtMy0xLTEtMjc3NDM_e59a37ce-2adc-4be5-9f1a-f286935dd616"
      unitRef="usd">65631000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtNS0xLTEtNTAyNzg_ffbc12e5-d8d3-4995-8a63-d9da7bd2e183"
      unitRef="usd">57724000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTEtMS0xLTI3NzQz_a9bac230-a183-490a-88c0-89452a0c7ec5"
      unitRef="usd">3969000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTMtMS0xLTI3NzQz_534be684-7626-4de0-814e-f598b3a87e02"
      unitRef="usd">12528000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTUtMS0xLTMzMDU4_4e60731a-9274-4b17-83f6-4f0711d99018"
      unitRef="usd">12528000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTEtMS0xLTI3NzQz_95d4d839-52c8-4be8-998a-141bae1b4144"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTMtMS0xLTI3NzQz_ae61da26-5608-419a-aecc-3524673e7391"
      unitRef="usd">12528000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTUtMS0xLTUwMjc4_b7ec587a-925d-4823-ae85-c8152750c983"
      unitRef="usd">12528000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTEtMS0xLTI3NzQz_4665cd25-79e6-4131-8c1c-55964adfa678"
      unitRef="usd">71849000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTMtMS0xLTI3NzQz_21e4ba14-f6d8-4ec5-b7f6-76ac61788979"
      unitRef="usd">65631000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTUtMS0xLTMzMDY3_02c21fe3-80e9-4065-9b5c-bd2680c86274"
      unitRef="usd">57724000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTEtMS0xLTI3NzQz_eebc79b5-61c8-4657-a985-6e3e9d14de50"
      unitRef="usd">3969000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTMtMS0xLTI3NzQz_c464b6f9-efe6-42fe-a56d-15d368c042e6"
      unitRef="usd">12528000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTUtMS0xLTUwMjc4_285c2812-1ee6-4b87-a44d-3846b74a0482"
      unitRef="usd">12528000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjQ1_ab6395b8-a28b-4d91-8256-7eb7d0fd0734"
      unitRef="usd">71800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjYz_3f12769c-e720-40dc-aace-b94e08354012"
      unitRef="usd">65600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjgy_5158db8a-53ee-4a3e-8ed9-1a5aec83554e"
      unitRef="usd">57700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzIxOTkwMjMyNjU4MDA_1e9d7313-0f76-4413-a2dc-f7695627d438"
      unitRef="usd">6200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzIxOTkwMjMyNjYwNTI_cea191ea-b59d-40f3-8a5d-9faa8a503a35"
      unitRef="usd">4000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDk_4d0c8547-28ca-4a15-b648-5be74c0f54ff">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's NOL and R&amp;amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Beginning in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i92b0f304a6e34b6abcd67c26db8d37c6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzItMS0xLTEtMjc3NDM_c31aadf1-0c5c-48fd-b2a5-adb50833094d"
      unitRef="usd">101100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6573654cd29340309dbe2c811248a720_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzMtMS0xLTEtMjc3NDM_19f9014d-f263-4b14-9a65-acbfcad7ab22"
      unitRef="usd">118900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibda208642281438089144b87cd645d8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzQtMS0xLTEtMjc3NDM_a7d1c543-85f2-4385-b0ae-5b59de8aa431"
      unitRef="usd">138400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ied6b0fe41f5b4f79ac97691814a89591_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzUtMS0xLTEtMjc3NDM_4b4fe745-bfab-4a63-8a9f-d277d1268af3"
      unitRef="usd">2500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia696bc1cbc724e098ee3bd580cfb8b6c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzYtMS0xLTEtMjc3NDM_840d4a5b-2ab7-492b-967b-3108c426e2f8"
      unitRef="usd">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id24bd2e4f3be4ae1b8b83df732484432_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzgtMS0xLTEtMjc3NDM_0ba1f4a2-0f92-4028-a68f-37a4c406b17e"
      unitRef="usd">31200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5bb901b4a5ff4839828a1c82f4bea528_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzktMS0xLTEtMjc3NDM_f4154d1d-5dd4-4304-9477-f47f323d2f29"
      unitRef="usd">5100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i878819bdb7ce45d78433cd5efbbd8d27_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzEwLTEtMS0xLTI3NzQz_75a83bcb-e450-40e8-9e1d-3e46323f406f"
      unitRef="usd">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <sesn:OperatingLossCarryforwardsDecrease
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzMxMDA_1ad8ccbf-ee8a-44de-be95-eedf2d2dc2b1"
      unitRef="usd">800000</sesn:OperatingLossCarryforwardsDecrease>
    <sesn:LicenseAgreementTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE4NTUx_b4367986-203d-448d-925a-3ee61b44e866">LICENSE AGREEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Zurich&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#x201c;Zurich License Agreement&#x201d;). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.5&#160;million and $0.3&#160;million related to achievement of a development milestone, (the submission of the Company&#x2019;s BLA with the FDA in December 2020), in the year ended December 31, 2021 and 2020, respectively, and a regulatory milestone, (the Company&#x2019;s receipt of the CRL from the FDA in August 2021), in the twelve months ended December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Micromet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#x201c;Micromet License Agreement&#x201d;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2021, the Company may be obligated to pay up to &#x20ac;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&#160;million at exchange rates in effect on December&#160;31, 2021). The Company is also required to pay up to a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#x20ac;50,000 (approximately $56,625 at exchange rates in effect as of December&#160;31, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#x20ac;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ecember 2020. The Company recorded an expense of &#x20ac;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#x2122; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with XOMA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#x201c;XOMA License Agreement&#x201d;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#x2019;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#x2019;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Roche License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into the license agreement with Roche (the &#x201c;Roche License Agreement&#x201d;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#x2019;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#x201c;Roche Licensed Product&#x201d;) and pursue ongoing patent prosecution, at its cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Buy-Out Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche License Agreement provides for two &#x201c;option periods&#x201d; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#x201c;Initiation&#x201d;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#x2019;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#x2019;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS Business Development Partnership Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qilu License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#x201c;Qilu License Agreement&#x201d;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to develop, manufacture and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Vicineum (the &#x201c;Qilu Licensed Product&#x201d;) for the treatment of NMIBC and other types of cancer (the &#x201c;Field&#x201d;) in China, Hong Kong, Macau and Taiwan ("Greater China&#x201d;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#x201d;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#x201c;Royalty Terms&#x201d;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#x2019;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MENA License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as long-term deferred revenue as of December 31, 2021. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of December&#160;31, 2021, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EIP License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2021, the Company entered into an exclusive license agreement with E&#x130;P Eczac&#x131;ba&#x15f;&#x131; &#x130;la&#xe7; Pazarlama A.&#x15e;., (&#x201c;EIP&#x201d;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#x201c;EIP License Agreement). Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company is in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The EIP License Agreement is subject to the provisions of ASC 606 and as of December&#160;31, 2021, none of these amounts have been received by the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No initial transaction price was estimated by management as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt; none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</sesn:LicenseAgreementTextBlock>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i996be0ab5ebb4bf2948b029b33aae0b8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NzA_46b31acb-b551-41cd-80c9-e4b589c121f3"
      unitRef="usd">500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NTM_45f33d60-a3f1-4a64-bb15-2e455f0a33dd"
      unitRef="number">0.04</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2ODg_390dca06-1e02-46f7-ac3a-532899a7f600"
      unitRef="number">0.10</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NDY_7f96f067-e986-469f-a207-09bbcba12dd7"
      unitRef="number">0.02</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc3MDY_1fca1d71-03f0-43d3-b25d-96df5de59886"
      unitRef="usd">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i810bedfc811b413cbc1b773410810321_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5MzA_159be6b0-12fc-4c9e-882a-c7eb53e2758c"
      unitRef="usd">300000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODI5ODk_91bada3f-85b0-4bb1-a883-3395c6570f91"
      unitRef="eur">2400000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5NzY_ef474ea3-46a2-441b-9387-f6bf8cae4e08"
      unitRef="usd">2700000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0Mjc_34644c48-842d-4727-b892-ab0ddb8c0cb5"
      unitRef="number">0.035</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
      contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0MTY_cbd306f9-7547-4f23-9930-d2f2b1557ee9"
      unitRef="number">0.015</sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent>
    <sesn:LicenseMaintenanceFees
      contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0MDE_553a1f9c-cfc5-4b5b-82a1-355703d884db"
      unitRef="eur">50000</sesn:LicenseMaintenanceFees>
    <sesn:LicenseMaintenanceFees
      contextRef="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5NjM_7b576a14-f2db-4230-a5d5-a031f245fe0b"
      unitRef="usd">56625</sesn:LicenseMaintenanceFees>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODM5OTU_c94339fd-ea86-4eef-ad34-e707bf3e0cb3"
      unitRef="eur">700000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQwMDA_9e9a313e-9350-4c9b-911a-d523c14b02ed"
      unitRef="usd">900000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQyMjI_40612604-2ac5-4d7b-9d43-fa6ffa2c521f"
      unitRef="eur">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQyNDE_5da66ef8-7f45-47bb-8b32-19762fdc83a2"
      unitRef="usd">600000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4NTM_3e694845-ac2f-4247-a3b1-ab579932aa05"
      unitRef="usd">250000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4NzM_8bfaec35-cdf7-4363-9107-96c156bc28af"
      unitRef="number">0.025</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4OTQ_f12511a0-b228-401f-9391-52c20ce22364"
      unitRef="number">0.0175</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i7e35e96c504045f9b37880d11d241235_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4ODM_049458ad-37f4-49a4-b5e8-7665b102b1ae"
      unitRef="number">0.50</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementUpfrontFee
      contextRef="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM2ODI_f8eee220-75c9-4a27-81ef-170af996ad4b"
      unitRef="usd">7500000</sesn:LicenseAgreementUpfrontFee>
    <sesn:LicenseAgreementAdditionalUpFrontFee
      contextRef="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4MjU_fabeb4df-7636-4d63-a722-adcb141a3065"
      unitRef="usd">262500000</sesn:LicenseAgreementAdditionalUpFrontFee>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i7c28bbf66e0b4945bbdff22096e98ec1_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3MTE_7a252c73-f3ff-44db-a1c2-8d7006b9c5d1"
      unitRef="usd">197500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i53830883489044f7a20fd0f2afe3ada7_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3NDE_ffc96ffa-a69c-4ff0-8d8c-4c468ef8612b"
      unitRef="usd">72500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i536ac10f94b7496ebcf21cf333f739f3_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTY2_0ca4358e-e936-4824-a0ec-e81d2cc1a78e"
      unitRef="usd">30000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i36fc4d06bbde4724b5f3f5d605df0dda_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3Njg_7a54c76d-77d0-48b3-bee2-21e200cc783d"
      unitRef="usd">50000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ibf1e9a4c5180446d85e2e5552350fe42_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4NTM_c3754d4f-581b-4efc-a62f-47471ace49c9"
      unitRef="usd">75000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i672850f3381947678ce8bad19d353cfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzM4NDgyOTA3NjQ2Mzk_1d9ebcd6-a6d7-418f-b633-c36529488477"
      unitRef="usd">65000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i34be4d2750144c28965180b21ad35c2c_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4ODA_3bc8218c-3ed1-48ef-9a1c-e5bda87f81fa"
      unitRef="usd">22500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i58f3a5e587554717a5b2e59570cb1b71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTc5_5a5e683b-7f7c-4fd2-8b96-ab5a9e55ed1c"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i58f3a5e587554717a5b2e59570cb1b71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTky_d32400c9-510e-481e-9707-846d09e54e0b"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:AccountsReceivablePaymentTerms
      contextRef="i592275577a9d4f158b7f51ca29978045_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjA3_d008f4a7-2870-47ea-84bc-43dab66ff329">P30D</sesn:AccountsReceivablePaymentTerms>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i695006bd273747aeb95e43b893e8b867_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjEz_c5caa3f9-de7f-45c5-9f78-553872bb3834"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjI2_2d6ef542-d325-488f-a8df-f4573102205b"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="iced271cdb5d7466d9c7c148965459481_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5MzQ_f7c7ca7e-d344-4cb2-944e-4ae2c7d9e5b5"
      unitRef="number">0.075</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i013a145bc60a457a851dd9b22eab7d0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5Mjk_74a8684e-bd01-40b9-8799-5e7fee26fe59"
      unitRef="number">0.15</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="id8f7872b3f9441f786d65989d956951c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMDEwMjA_90106d6a-c665-46a4-ad9e-c35113548237"
      unitRef="number">0.50</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementOptionPeriods
      contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjQ0_93bb2f11-7a09-42c2-b583-4513ca585c9c"
      unitRef="period">2</sesn:LicenseAgreementOptionPeriods>
    <sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod
      contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5NTg_3f71932f-22b9-4526-981f-5e332c251f30"
      unitRef="usd">135000000</sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjUx_b3c7ede6-6383-4c4d-b7f7-8daad62b1e27">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjYw_242c3d74-1e19-4cca-8266-b82a758863d7">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod
      contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwMzA_1a5643bf-06b9-4f67-a666-1964506b79e2"
      unitRef="usd">265000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct
      contextRef="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwMDM_b404ac80-37e0-409e-8eb7-fccf4ecd4c2a"
      unitRef="usd">220000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwNTY_b2b2ec78-fcb7-4c4b-9075-bd999cfa042f"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
      contextRef="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwODE_d340b8dc-2ba0-46cb-a41b-55e2bac12ae5"
      unitRef="usd">23000000</sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount>
    <sesn:BusinessCombinationRoyaltyPaymentPercent
      contextRef="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwOTg_59723fe1-4ba2-4974-a0bf-6448075ded86"
      unitRef="number">0.12</sesn:BusinessCombinationRoyaltyPaymentPercent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxMTc_262e8abf-7d74-4d9f-8e3a-5b4a2fde86c4"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3854b11b1f004bb585ab8a3ed3e68622_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxNDQ_e2d6b05c-2e04-4948-a9f3-e25d67a5e374"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i028e8f65759541db8dc7760918e71d52_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxNzE_0dfaecb2-6764-4ece-b2b7-c2871e090f2f"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i028e8f65759541db8dc7760918e71d52_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyMDA_77615bbd-a7e0-4abf-bd69-1f3a942be962"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i77d8a2af6cca4ab8b80ffdc3f2434161_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyMjk_daa2a2d4-348c-4c9d-8ab8-631268a96f18"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:BusinessCombinationMilestonePayments
      contextRef="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyODA_29fd2ff7-0b6c-4626-b08b-deacdbe2d1c1"
      unitRef="usd">3000000</sesn:BusinessCombinationMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyNTY_0b8eab48-f015-4f46-8b49-8262b2aadc4a"
      unitRef="usd">23000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQzMDU_10a7a7b6-125c-4ae9-be9b-e5e7a90abc2c"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i818c0861bdb74095a88cb8cfcda94efa_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjc5_d085c774-fa87-4821-ac81-c17aeaa4d9d7"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3fb1bcb7e3874976b1397e8d0fc3b469_D20201130-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQzODQ_3f68c78a-7438-4474-9b35-4ad312459c38"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1a168b0aa4c647e1997b38ac0934768d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0MDk_8b590708-a3cd-4c21-be67-4305183b45cc"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i1a168b0aa4c647e1997b38ac0934768d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0Mjc_9d02c0ad-b085-45fc-95ee-ee39324c1c47"
      unitRef="number">0.50</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5b79f0dfcd8c4696998a76eff4413ecf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzExNTQ0ODcyMTg1NDU2_58c700ad-b375-438e-9f02-93a674990f5e"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0ebdbf98df0844558086fd4461793449_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0NDU_cebbb13b-dabd-494d-b766-78cd7c9b20a0"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i34d384e7e18448558f3f9903191a5912_I20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0ODg_c4a654d6-5fda-4377-8a2f-29c943e194c0"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i149c70a89b234c42b784e047bac76480_D20210805-20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ1MTU_d9dfb2c3-07ea-4102-982a-4a7735b93d36"
      unitRef="usd">2000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i544162f98c2149b991bf17fc6d17e544_I20210805"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ1MzM_a99e27e9-904f-4d40-9413-d2e5a9cd07ed"
      unitRef="number">0.30</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzE0NTE_7fc057fb-ea4e-42b5-93c7-77cf6deb561d">RELATED-PARTY TRANSACTIONS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its facility in Winnipeg, Manitoba from an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019. For each of the years ended December&#160;31, 2021, 2020 and 2019, the Company paid $0.3 million of rent, which includes the related operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company pays fees under an intellectual property license agreement to Protoden Technologies Inc. ("Protoden"), a company owned by Clairmark, an affiliate of Mr. Dan. Pursuant to the agreement, the Company has an exclusive, perpetual, irrevocable and non-royalty bearing license, with the right to sublicense, to certain patents and technology to make, use and sell products that utilize such patents and technology. The annual fee is $0.1 million. Upon expiration of the term on December 31, 2024, the licenses granted to the Company will require no further payments to Protoden. For each of the years ended December&#160;31, 2021, 2020 and 2019, the Company paid $0.1 million under this license agreement.&lt;/span&gt;&lt;/div&gt;Due to his retirement in July 2019, Mr. Dan was not deemed a related party during the twelve-month period ended December 31, 2020 and 2021; as such, only payments made through the nine month period ended September 30, 2019 are considered payments to a related party.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i289b399c61c441cdbd3ee11d6f7a9ff8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_2d4482c9-cc3a-4f5f-b2d0-24a6b7fb81e2"
      unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ida0bc936be4b4983b3016c269a7787db_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_4969f2d5-e078-4922-a550-b6e6a0c2d61f"
      unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_f15229b3-cb11-4f07-82e7-0fbcd985751f"
      unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzc0NA_48098db3-4e0f-4e92-b434-ed07703f9957"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_2b9f8af3-3047-4374-bef5-2ea7eca26be3"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ic637e93aa17d4ad6a3c0e4e24f9685b5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_6230ad3d-60dd-42e6-bf4c-1dbb7201dbc7"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i41763d631ab94cc3954f93769f016e8a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_fb358299-49eb-4235-9233-9a3958acedd9"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xNzA0MjQzMDIzMTgwMw_6abdc339-b097-4a80-8157-1e37aa4e9629">RESTRUCTURING AND RELATED ACTIVITIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#x201c;Restructuring Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restructuring Plan included a reduction in the Company&#x2019;s workforce by 18 positions (or approximately 35% of the Company&#x2019;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and benefits costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December&#160;31, 2021. The Company expects that substantially all of the accrued restructuring costs as of December&#160;31, 2021 will be paid in cash by the end&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of September 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xMDk5NTExNjI4OTM3_547cb409-6bab-4767-a05e-0ddcdd2467be"
      unitRef="position">18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xMDk5NTExNjI4OTMy_3c663bda-18b4-404c-84bd-7315b29ea92c"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xNzA0MjQzMDIzMTgwNA_d3572ad2-a300-4d59-bc3e-edc42f35e014">The following is a summary of accrued restructuring costs related to the Restructuring Plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and benefits costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="id7ea168da84a45ce835565576cb8541c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV8yLTEtMS0xLTMxODAy_1a1efc48-e788-4410-9c6e-470af48bae7f"
      unitRef="usd">2792000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib3a50664b1a24d31b0f259776c76eef4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV8zLTEtMS0xLTMxODAy_ea1690b4-ab92-447a-a532-c1bbc7fcdb4c"
      unitRef="usd">2736000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i77fcf675f74847e4ab66d5e451e81521_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV80LTEtMS0xLTMxODAy_7782ab3f-9597-4336-b749-d9a7919117b1"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV81LTEtMS0xLTMxODAy_67d91dff-b38c-460a-84c7-fbcc6a64d01e"
      unitRef="usd">5528000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV82LTEtMS0xLTMxODAy_9a18663b-4742-416d-a1f5-27beb1f3f5ad"
      unitRef="usd">4031000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i8984440967a74e3abe0feaafbe79712a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV83LTEtMS0xLTMxODAy_2caf5d69-2d96-44bb-9867-a778112c30d6"
      unitRef="usd">1497000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzIxMjc_0b9f0752-f471-4c15-bc57-2d175dcb74be">SUBSEQUENT EVENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 7, 2022, the FDA granted the Company&#x2019;s request for a Type C Meeting (&#x201c;Type C Meeting&#x201d;) to discuss the study protocol for an additional Phase 3 clinical trial that the Company plans to conduct for potential resubmission of a BLA for Vicineum&#x2122; for the treatment of BCG-unresponsive NMIBC. The Type C Meeting has been scheduled for March 28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2022, the Company received written notice (the &#x201c;Notice&#x201d;) from Nasdaq indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice has no effect at this time on the listing of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;), which continues to trade on The Nasdaq Global Market under the symbol &#x201c;SESN&#x201d;. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company&#x2019;s Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is not in compliance by July 25, 2022, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for, or fail to regain, compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist the Company&#x2019;s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to actively monitor the closing bid price of the Company&#x2019;s common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously announced, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#x201c;Review&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Review took place over the course of five months, involved full cooperation from the Company&#x2019;s management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is now complete.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Review, the Board continues to fully support the Company&#x2019;s current management team and believes no changes or amendments relating to the Company&#x2019;s prior disclosures to the SEC or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <sesn:ReviewPeriod
      contextRef="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTI1_fc9f9379-7ad4-469f-92d0-49252a2fb463">P5M</sesn:ReviewPeriod>
    <sesn:NumberOfDocumentsReviewed
      contextRef="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTMx_f220db26-35c5-4df5-b9af-50c30648ca4d"
      unitRef="document">600000</sesn:NumberOfDocumentsReviewed>
    <sesn:NumberOfInterviews
      contextRef="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTQw_a13451ad-b933-49ed-8664-a08dbfc39f46"
      unitRef="interview">39</sesn:NumberOfInterviews>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP2[&W@+@W(>1C$/(0N1=)Q_U"JKS_H1L(A%$9"-@&BXX68),A7 &R]="[VH
M 4$ _U>5@ V3T'F;V8X5*=16#@G9%L8M0=5S8PX6QU]P631:MK;1PFU;$EXY
MX+9>+!N+)P3"3\0KQZN]X^$.>&#&E"'3Z;1XE-#?][J(7>I2)<1VU BVG_>J
MQ.JU2ZS@0 4/F@+Y%_*1UR]?',J! M(?]AW'PYA5B=5KV6 [[&+=PL7:_-
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M(MT^Y4OW%&1YRCE-#P&&<X \! W#E].'>_O#%]+?WFG4.XW:^;#-Z::N:24
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M.0*O1'F@6UY(OBF..%^YE#PM?JX9A5RA!/!\Q;G\N% OJ(_5I_\#4$L#!!0
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MHG0Z%TH1KYM4'4BV,L_VGDG5!,RT5'T=<9V@]A>,R6V@#VB_%.%?4$L#!!0
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MD=P"V]4(#MO5",RVJ_M,A-N/_E?U?I\)75IVC,D&2AJ2I&6<R;)6PKIU^W2
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MA4+>;NI-=/VEAC&3/<+./-8:LHU5RN5O@4LN:TT(H_V(2\,J.TGE7W?5'\Z
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M1CN"*J0 <"GDIOC.>1&4C.A5U)CC[D <^D.*FTI_;J:L6,RGXLY@CF*A_9U
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MP,1^ZB)3CO97 #,6C(+5\;=^(95 .[\>$52-W  \2C4IO"U-2QVRU,DES",
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M4S#1T0+\/K< Y?H+*6C_D\#1OP!02P,$%     @ =49<5+VX#0V[ @  N@4
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M(6>E*56YL.*!C'C*I"'QY\W,.@-N_/4"_G&/?^SQC_^/8+X(Q;5X82N9T-4
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M=H,]N@MW6#:,F-+%HNM-+<"U$<"B[$E/7+?8H!U;2UEM3:5A3'$%C9+*/><
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M[D)1GL,CDT?]%B8$%P@N.,JHX*LT)>]C\9#BRO'A$#-.@TQJ*R=7^Y +NS'
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ME/R#,*1,H$/SKL:(SL?#\7B\I;[G%\.+R?E>S=UAR,=6EV!F)/T81*9BPH^
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M(^WRQ,"(Y$ZO:YMQ4HP3$Q!<Y'<V' O[LV4RXHDO04ZTH =-Y@K!USE =&U
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M_7* 3>LY&0YCI-7)W8Z#"PV$7GJ\2$MGF]'3BPGM#AG%:U45.?L6I%T(H%4
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MR7$#;'PKQ(DW9;B?%\;3;1^&.3VOT+( [2^-\?6$#>P>;(._ 5!+ P04
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M^NMEW/-)9R"J+J'A\>GD95QCX(#Z$TKV)[9/K]Y\7QN 5!:U8J7H]NW-]&I
M'[#Q"_NA+\V5,L3%3=8%.&3(M\)E2YJ<)IX'7>XGQUWRMP8YE2E(DK1V.L ,
M,C;H3-$!;VHXOHU++;>YLR7="B_%/6DC05?4Z!%7VC,8MH"LLBJT,,!=Z[",
MN[X=#T8CK@.ZK$N::PGWL&#VNG8J4L(6@6C U]"PT#X* K5,2*/!F\+.P3P,
MOU.A3Z#%JW@2<B"ZV?5K<_8]F**3XY/1@3@\&!\F:I-]D5)C2>4YZBQ%8V!"
M0.%FD:QSJT&^-V!A9HF=J'39W0Z!5^G#C#]L:>S3>JGAJZU],:J0R%(]9R#5
M*$PI<ORFG".6&Q&SZ]EM SV@&^X1F77R@?*]/)R.1P?9X<'1X<'EX6Y8,!>"
M*N6TE6SN^'1$2 MEI' DQ<;W";ZIH7I!O]0%HNNDC2X+'R[$$VY_UN%PQY[#
M2;.LL)XU?SCXA!>Z9%.)OD,ECP105WW.%.(H11YL([\43C7U9:L8HRH6;[S*
M:FZT-*\A6:&4L.$D:Y?"'<$!6K['8D,4B,__/0/FFT>,=8Z40+NO1:'S3:,8
MU$"M>>2!+N03XJ5528$.8/1;+N"VUD_]+E1KG=H*?B0G*MQFUEH712P:P.\*
M!X\:[4FJH!RX%7%RX;*L.(O^-7_ZG( I0RJKS6YE6=NZD(A1^ 9EW%85LKTV
M.FQ8@*@J%4NW:F2Q/8_4$%O]ETJPQ9Z K(I4$%K_H3<9&3,SS5QP&S34H2G>
M_SDF=RJ# *EP<Y]TSLHZBZ,BJ'Z,.<WIK<%X3 @&%RMX2\R1K[9B[?W_R;!.
M_=A3$?R +D&$4RMM:P]CA3&V!KKL[S5K:H6+Y>$5X#.PXG?*7OS<M@VH%=A.
MR3Y#WU"8QB6KQ"P[$[OGBH??IK5B(U(%TS=S@L4:"5D\F"G09'V(ID,!M-V_
MN6ICN 48,AVABNC+;5;[IF=$AS5=V^;]Z :)09,6RB@7%>/.MJTVW3G LXAM
M!_^:UIVD\&:[@@QDBA>Y"IL=O"YE[R,%6\Y2-*8U>-W>\?R1);#&GMKY2$#.
M,LLXO"*PS,H6W-3S&B(SBXN/2Y$?>_<^5Y;"X.82K0E*@ 6Q=0? 2XLRB?YN
MZ(?1J#]"]90@EC?[9.'1C\F+?""2E=7.,19_Y/L6^P2A:C<*)4G$JF(\KAN8
M_A!T-R&5RG4*:.1J#$01YZDB;+,J$9$<E$)OIWFRL1M$0BP'^].PT>H+8Z-"
M<]0*M8H%DS*8NL CUU_LDM%2*%,TDX[=BXYDPP$>.U$6:M=T=&R<75]1$S,\
M\W9QMD&0C-I.H9]N9A\NFQ&T.SQ^7>@U>[^<0(E[WEJX-'D_6?#X"OH0.K'T
MM;G'5J#ZH%!4L7C^]X&ZJ\A@WX5EV+D (FH6\9KK8_J'=!=L5]N;]&6Z0#YL
M3]=P3$P+C7)9J!Q'1X,7)SURZ6J;7H*MXG5R;@,NI_$1W0#UD3?@>VXQV#<O
M+*#]_\+%/U!+ P04    " !U1EQ4NK&<</(C  #0>0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6SM7>MO&T>2_U<:NLVN!5"T)#\3)0%DVLYI8<>&
M92<X'.[#<*8I]GHXPYV'9.Y??_6KZN=PAG*RNX=;8+_8DCC375U=[Q>_OZN;
MS^U:ZTY]V915^\/1NNNVWSU\V.9KO<G:>;W5%7VRJIM-UM&OS<W#=MOHK."7
M-N7#\]/3IP\WF:F.?OR>__:^^?'[NN]*4^GWC6K[S29K=B]T6=_]<'1VY/[P
MP=RL._SAX8_?;[,;?:V[3]OW#?WVT*]2F(VN6E-7JM&K'XXNS[Y[<?8<+_ 3
MOQA]UT8_*QQE6=>?\<M5\</1*2#2I<X[+)'1?[=ZH<L2*Q$<?[6+'OD]\6+\
MLUO]-1^>#K/,6KVHRU]-T:U_.'I^I J]ROJR^U#?_:>V!WJ"]?*Z;/E?=2?/
M/GMTI/*^[>J-?9D@V)A*_L^^6$1$+SP_G7CAW+YPSG#+1@SERZS+?OR^J>]4
M@Z=I-?S 1^6W"3A3X5:NNX8^-?1>]^/UI[=O+S_\EWKW6EU?_?3SU>NKQ>7/
M']7E8O'NT\\?KW[^2;U_]^9J<?7J6CUX7Y<F-[H]_OYA1UMC@8>YW>:%;',^
ML<W9N7I;5]VZ5:^J0A?I @\)9@_XN0/\Q?G!%5_J?*X>G<W4^>GYV8'U'GE$
M/.+U'DVL=YGG=5]UIKI1[ISJOR^7;=<0X?S/@0T>^PT>\P:/)S;XU&I5K]2K
MMC-$3+H=0^)O6T%]7&M%O+C-FHQ)G#Y<F2JK<I.5JNWH&>*?KE4&U)_734$?
M:2*P;JU^NKQ\K[*J4!VMT?0EK8;?&GW3E[Q8B]7PX?6K!?WYK[UIZ!G\H1<P
MM <#+V8M\?667YPQFQ2* /I+7]P("#E]8 K=:.R1M765+4L]4W=KDZ]5MEH1
MDPHH>ELW'3V5;7 =# 6MK3O9IC39TI2F,W;;PK1Y6;=]PR#1)KA VG#R'=FE
M(+C=^48QYC$S DZC;W756P#T%Y*/+?U2] UH)[R$W[:Z,74QYXM:U)MM5NT8
M.70EM-8D!H&ZM2'>;TQ.<&&/QFBZNYGZ7-5WE>H:7146@%L/\&U&N_7T-@'1
MJ!71;=W@RNC0FZPB&8NSJ:4N#;U$']3T<W0;JB?6;/@$N6GR?D/XH#WI/N50
M+0DZ1H!<&C0"?T(',BU^I5T^X]3AUK,E*0)9,6N:'3Z\S<I>'[A5!C>C^ZSJ
M#L 5IMRI;$LT#N!73;VQYVOKOB'HYNJR[-9U?[,>/>1A/&.?" %W:UW1*H7F
M(^_X8Z'E?DM78BK1@JQ-;C-3\DN6I&@+'=["(G/U-@"D<6Z& 0\?O/F,&+FZ
MJ8$L02T],U-FI2I-YVU)=\Z :;Q<_(4T!*-ZKEX26NE*^:Y,^UF6[ND"FXZ4
M,^/65+=U>4O'(8'0!9+\XW\\/S][=M&J9=^2R&D=8=&S (*T]6<R#XBY"F,9
M')_?D#:59=I^^1?-VE61MN7C6MZ:/J=@F4BT)P)WM+7)=L31) P:N6CW>N&>
M$$[:U&VG6G-3F17Q!Y";;!/(S]#QK%Q99:8)M$?XR*H;P]?'9#A3-W5=W)FR
MY"4B0>($%U_[!;V9U[CH[ OM]H!^*_O"\;U<,5-'2=8."UNP!1D)NH'DH[?L
M?L<7.)+.&D@_R#$BUK+>"JE8D7(A:&9"("CH(JL4FG9^0"T]\6KIR4&E\I[$
M5FZV4 "$F 6M2MJOX/7'--3O7BR6@9[@<O\$86="=0'#S%FLPYP0CLAWQDQ^
MMZY+DA0D'6DIHDA"DR%64;^ 3#N3,3(-KUB0*B.R\ \9R#C_W M3JT_7E^JJ
M(@,#+\6?=)HN[,&K3\?JC=D8@AKBIP0]Z2:W IXLAJK-<BMA:(%E5K(@5>N,
M6&2IB6U(/)$QQ\<V580&>N?0I3[UE_KTX#V0P4KF:*46/=%=E>_41\!43M[J
M[U^-KW5%8@:_T-7E[IGTCD2B9(0\<!_=0HQ\940J?KI6!5UBUAQ"P3./@F<'
M@5YD[7JF\*]Z1<8+\2;H::8^D+ @M0K,\X< ; 'NJKI@12V(6TVG/I <'4/7
M_\W.$</\B5@%KQ"BUKIDTZH@(Z.E)PU^W+!X=>P!!:H(C3>Q<6,J$I)=S_O
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MYUZR/;]'R=;$*IW(5$@8-AO&Y-3O64<E?];^SV(JPXD$J<(N:CM8N%!]%0L
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M\2WY  SGJ& I-%ALQX6T7P@8[IIPQXOCS%*ZYJO0]="]M>\4+A[MZD<B%+E
M3K\E\[[FU&*(R\[2L.9$E7B40AJM5(X^Y[A0](QTA^[\$Y,I;%<%PM[./^RR
M;>>?:G/B,5>S\_3TJ8_B=;Y2<BR=]]S=LW]M).W&(?1M8[@T@:TG2:H)]0:E
M[T1?.H-@U9<KDM?2.Q=5Y@8S<D!84?.:GQ:4^OYMI[?DZ9\=JRL["B>4S<6)
M?W(-OGU\H<Z/2=S(D?QC\6W0Z3;<&+8?3^=!75$<*H8_<%FTF'QS1<%V9=XY
M?0J R("8@._1L7J[7_L?3<"7H,Z0K[GTN4'-HIN@P*9<XC7;'1X?8\)^G6)I
M;P-GZDP<V*X%(GURG BWB!HX6 ^[)R4"Q!+;%;0,"Y3Q'>9)8@[[? B\^C;M
M&F %K=Z[O,/E2 G(H& DM05CSAIC\\W8MX[$1#.Z0-1YNA^?].H;C7-)"XEP
MF7"6'23F1@ZX 4A[=Q4B1]R/96TINXCSP:Z<O>7AD'+BI(#071W^;TBTV?98
MGLJ*N5DSY^JY\.\X[B04:-K[84_O>1_[*OGZFJ@1.ZE4Z9JZ=%.9K2S5X9.9
MCZ".=/A#C-O5#]Z5C2B' ;_P@_PBSGNUJ?[7XNW[.?$M1@YRBIP;1$:'"NPB
MBHO9Q;L%7JSZ6PJSAJ,1--A"_*6AOI0K; 6\B!UD+!?/QF)KD_$_SO<"VH#&
M0^@O$\&"D V!UFCK6(9;F5B78SH/SHZM50XI3R<(U#"&)6NC^KR*Y*;2W?#>
M Q+Y%BZ.%4\-=/@J0'W*(6DFUYQ)@WN719+5)51F/LHTDH;P;!^?=PA:U*;F
M6F11*%\"-6[>1!+KMX<X: B'[_TX._SU&R3=<=;X^]S(M*I[6Z$S'F$ZO.2E
M-4-X$C?9^U=5W"#EVCM>7UZ_</G"J/?BVY.S\YE*@E2V ^/9X]/C[]2UA,UW
M3B9&@".HE+YXA(7MHD?'<Q7]JGS\O769JGB=Y(N+N*%B4R?]B+[RV-.69930
MT<$Q"@^[K0LDI!;^ZP]B>*3^1MI*8BH<- NP56IQ(%]+M_)-B1E"UGC(;PK0
MN3%<$,8I%$# @2,7$PL5VS$\2(SY!AT>OA\FH%KKV,TCE!A,&P0XI&?Z^%+?
MH.P4,*S@^'J".'MBA^2@4:_<A2(U&6>X,5WGVY$E:<AL&;J;4XQR13^.P5W&
MK&%=H]>M?'N.-!AR]['HFC3/ U_3D$-KJ_XET^/W2&U^9V^G;01ZO*W)]669
M[BL:#6!!A]",\WV_JJ_@H%@(7YIQ=OC;+EXCY_<+*_K(8AT5!@<7PM>D?L=5
MP#\<<22KN=5'/P*)Z2S%\.TE["@.OD&$#QY_J\W,UYOX:JNHA,<6GKI!CS)*
MQ7X'2I3O&<_33T]MC@2UBQ:'U&@[6<?MPAW1'"%Z*2JG$P*<JX45+1.EPJO1
M;X])PD]D3$7)6MOAJOC;,4Y*'G?CQ]J(Z<6=1*;ST3V;HW:#!NS"^]V.8X-R
M]A:S>>_]T3O "+S.S?#1D3D]-OC&7_#!1VBC7/HTG)+,:*TK22ZD3/LY4]^1
MBMBZ=N"_]G7'%A2[@"SWV<W,!T@V[OMPPQ<FR'KG]ZU'HMJ0_#V\VL5!0*97
ML:^G5K0L?2$SJ@M=GKCV8A_^YF]_:\-M0/@%M',=%CZ./0?!:8&%FN$;<S4F
M<1Y&7[*[T<T-?Y5P*S$C^;Y=_U?EOJ[X4KZD-SPNWW7\-FM(>: .<$6OGLZ?
M/3F20EWW2U=O^2M[EW77U1O^$66!NL$#3S JB[!K?\$&_DN<?_Q?4$L#!!0
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MW\+D?OKT^&P&IG#\Q&8QJI-!2Y-[ ](*<E>7&U?>'E>N!W<BU9&"ZS3$\#U
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M$(^5()8\Q]%Z SXOC*&#X@-T_PR+_P%02P,$%     @ =49<5)=@NHNT @
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M560J90N+4JYV"(>(H-,;#>#=FR$+V =8*9F@MK.!YY @ 06=$>6['O;@*W5
MP0A8'^ZEH?O_WX%8#3NLWZ<U[(P&(;SV\OZ1J@HD)G9V:.IL)4PML/:T'4_S
M6I5_W>O9=D>%9$)#C@F%=J\&?0]4/2]JP\C2:70K#2G>;5,:L:BL ]TG4IJ#
M81.T0WOV!U!+ P04    " !U1EQ4(0A4"W\#  !P"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6RE5FV/VD80_BLCJU5!RIW!''E!@,21BQJIEYS"
MI5%5]<-B#WB;?7%WUT?X]YU9&Q_M<312/V#V9>;99V:?\7BZL^ZK+Q$#?-/*
M^%E2AE!-TM3G)6KA+VV%AG8VUFD1:.JVJ:\<BB(Z:95F@\'+5 MIDODTKMVY
M^=3604F#=PY\K;5P^VM4=C=+ALEAX9/<EH$7TOFT$EM<8?A<W3F:I1U*(34:
M+ZT!AYM9LAA.KL=L'PU^E;CS1V/@2-;6?N7)^V*6#)@0*LP#(PCZ>\ E*L5
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M\2AV%,>CXWS'.6LYV0><*8,[K5QI8:X*+-X2Q"2P4\GV*F?L4\9KS$^@G_:
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MC*SL<LH91D<;\/E$2K.X( /M)Z3C?P!02P,$%     @ =49<5!-8N#'- @
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MR]&O-]][E/6M^?6C?" P/ "X'2JYH#KZ!;5?I"((XO!P.)VBB%?,#XAB$HO
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M\D:^.;';W$BV3 ^])DQ*%J67"X(5>1V@WL^8VMAG-_H<+3\W[?X/4$L#!!0
M   ( '5&7%0&H-XCJP0  )P4   9    >&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;+U86V_B.!3^*Q::E6:DEL0A)*&B2)1+8=6R76@[#ZM]<(,!:Y*8=1QH
MI?WQ:R=I0D)BF%D)'B!QSG=NW\DYQMT]93_"#<8<O/M>$-XV-IQO;S0M=#?8
M1V&3;G$@GJPH\Q$7MVRMA5N&T3(&^9YFZ+JE^8@$C5XW7GMBO2Z-N$<"_,1
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M0/Y@_V4^_WR ^QC*N$0QV<!2YD,7SJ?(G^1Y1_%]]L!;<P7/Q:RY@Z\8(C0
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M@X5 ,DT2(E[&$//#L($;KQ-+NHV4F7!&@QW9P@K4E]U"Z)%3LH0T 28I9TC
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MD6Y$01@#_7[#==F+@7%0MK:C?P%02P,$%     @ =49<5'&&!]Y9 P  - T
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MK5)-'6 \Z?.2B62+N)&9,*G:HG@X5[TQ<&V@WD\9D]N)=I!UVZW_4$L#!!0
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M6Q_7@Z@.A&JB>&'VU"U7N$.;88)G* @=@.]CSM7K1&_3S:D\_0=02P,$%
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MH?$':+_0VGT8OJ^Z5S'["U!+ P04    " !U1EQ4FUWS); $   1$@  &0
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M@# %>G_.N5I/3,^J/U'!'U!+ P04    " !U1EQ4M0K'=[4"  #(!P  &0
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M16(FWX$1N2:"RKZM(%[MU8[RV#YFL;EG8AO3Z!)Y^ *YCHM/J(]>K^X<J]N
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M#^T)'#KZPA<,$[$>E, Q4H:HYX7[?4]F-90Q*+,#^S4M8I7G8TT2.6=AR_S
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M;^HV&/XK%CK36JDCL7.#BB(5:$_93M>NM#N:IGU($P-1DYC9IG32?OR<"W$
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ME]@/,<T$Q/LY(7S[D!FHKNN'_P%02P,$%     @ =49<5.%NS#P6 P  ,@H
M !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULS5;);MLP$/V5@4X)T$:;
MEZBP#3BQVP;H8EA=#D4/C#2VB%"D2E)Q^O<E*5FU'=O(,1>)R[S'-XO$&6V$
M?% %HH:GDG$U]@JMJW>^K[("2Z*N1(7<[*R$+(DV4[GV5261Y Y4,C\*@H%?
M$LJ]R<BM+>1D)&K-*,>%!%67)9%_;Y")S=@+O>W"DJX+;1?\R:@B:TQ1?Z\6
MTLS\CB6G)7)%!0>)J[$W#=_-PL "G,4/BANU,P;KRKT0#W9REX^]P"I"AIFV
M%,2\'O$6&;-,1L>?EM3KSK3 W?&6_;USWCAS3Q3>"O:3YKH8>]<>Y+@B-=-+
ML?F(K4-]RY<)IMP3-JUMX$%6*RW*%FP4E)0W;_+4!F('$ Y. *(6$!T">B<
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M- O1^=D%.D,I08\)77-,8MXSA<Q1S61&93[#(A_G2#ZV@^XH$0E'8Q)#_)[
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M%?(RU<U$/I" J0#Y?4&IV'74!-63*_@/4$L#!!0    ( '5&7%2;L+&/*0<
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M\W;:V%W;V'7:^"V?HLH"\DJYV@K G/*(C4&6;E@F&7BAP+AC,]&M"($E)5R
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M><A7 /E]0ZDXO:@)JIO*Z;]02P,$%     @ =49<5.6J#(J4 P  9 P  !D
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M:[)/Y#T[?L)2T(WFBU@BS!..I:UK0;07DJ4E6'F0TJQXD\<R$&< K]< \$N
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M#C/LH$&:#?A](X0^3(R!MB<?_P]02P,$%     @ =49<5/;&^2;S @  Q @
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M<*D_,U"8 /U^SKG:3<P&]8?+\"]02P,$%     @ =49<5&TZ4PDZ P  [PL
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MJ?GF 6EO,-<G0NC7C1W#LZ^H_C]02P,$%     @ =49<5'Y2AOO)"@  >D<
M !D   !X;"]W;W)K<VAE971S+W-H965T-S4N>&ULQ5QI4^-($OTK%>S.1D\$
MC56Z-4L3P6&Z30,-!O:,_2#DLJUH'1X=T$SLCY_2Y9)0*57R>C5?0(;*5!Y5
M[V5E23Y^#:/O\9J0!/WPO2#^=+!.DLTODTGLK(EOQT?AA@3T/\LP\NV$?HQ6
MDW@3$7N1"_G>1)8D?>+;;G!P<IS_[2XZ.0[3Q',#<A>A./5].WH[(U[X^ND
M'U1_F+NK=9+]87)RO+%7Y($D3YN[B'Z:;+4L7)\$L1L&*"++3P>G^)='+$F9
M1#[D;RYYC6O7*//E.0R_9Q]FBT\'4F82\8B39#IL^NN%G!//RU110WXMM1YL
M;YH)UJ\K[9>Y]]2;9SLFYZ'W=W>1K#\=F =H099VZB7S\/4+*3W2,GU.Z,7Y
M3_1:CI4.D)/&2>B7PM0"WPV*W_:/,A(U 1EW",BE@"PJH)0"BJB 6@JHH@):
M*:")"NBE@"XJ8)0"AJB 60J8[P6,#@&K%+!$[X"E*G.2L,@VV<+9QE6ZL7"^
M<95P+)QQ7*4<"^<<5TG'PEG'5=JQ<-YQE7@LG'E<I1ZW<M\I4B4?"V=?KK(O
MY]F?% L^1XL+.[%/CJ/P%479>*HON\@A)Y>G(.$&&3P^)!']KTOEDI/KV?GT
M]F&*3C_/I].;Z>WC _J(;NTHLC/40A\N2&*[7OPS^LN?3$57_XK< #VNPS2V
M@T5\/$FH"9FBB5/>[JRXG=QQN]-T=80D[1#)DHR?'B[0AS__S-%R#FNY#5^.
MD"+E6J1N+1>PEJO4$]$R[=%B!U0+SK7(W5HN82T7Q-EJ >+R&=;R0#:51UCO
MUO)%($>%+9"665]T@Y8M&Q*YX8*CZVHOT?DJ;!&DY1K6<F-'(K;<#- R?9JC
M#^7ZXNFZ%8\.,(^_#=#29]&=\#R$++K?2];G [3T^?6PET@_"FO!%E?+A(+X
M%LGE+9++N5JE0^VW:&4'[F]V7G2>!@MT9L=NC+XMT5U$8A(DQ7_^?4WET"PA
M?OP?X*[*]JY*?E>UBS]<A];*!%$ZH-6R9R<D^_U"@I3P,EXH,W)E6>7^<B+K
MFJI*DG0\>:DGHCT08UG16P,?VP/9B(9'ZM8C5<RC540(W0@DAR@*WVPO>4.4
M%'E>7<(*Y2-)^HD'>KN)W0\6:X1!VX9! _4\1G80V\469A/1F/" 2>-E29):
M6;H3'?A0#-2A@0UW]*T[.NC.O>NEZ&YMTPV50]+$=6P/G8='A^@Z61RA_Z(B
MZVZP0J=5WF,@BL;VML:(B]+<WM4$G;T+$ZK:I2[ZKD=H%4F5;^PWCE,%XYGM
M5:E(0-"MK1W6'L'AJ]4RP^),D6NK-45DDS?GVNK@J80E5C-+H%]/FV44!DD5
M4V[I*;7O+DN\&5^.U*&133MKM3V&UW"8B,Z!BU*5^"3 C)BP#)HQ+^&SO/TA
MHG6@D\W]%6\:7/1HPWT(AQEW89B\SE*ZXDD<(R?TG]T@7XN'@FNF5%U/&QPN
MQC\81O"G@.Z\HMBE$0N7Z%\I!=\UY"Y#=*R-"$:802^&L?==_E'X[+FK,MCE
M5.!6A[!6M8,?Y\/EFGXQ;,<&O+S6;K2@7D74-[HG=_W41^%K0'.W=C>P:[!B
M+'7Z-ERPZ1RC$ QS2,,Y-QCB'*RXJZZ9#Y=KNL98"<.T-/VQR6@IWG)2$B+;
M6;N4F8KYN40+>NV%F_SC%@^XSK991N.B?)NU%  M9,9%<@\7<=""UC/GH>?9
MSV'9QCF-:#6W*JO9><' V>JGOM,%?TYUY@711<WK&[[732L9$\EX1.B1:WLB
MF"PXQ;SMAVG!W?:S1U"ZR7OTC>S'&^*X2Y=&!\Q]>6\@]TVK&2_),"_=N$X4
M^B1!IY^A*#!&D=4QH\\(1X;W$#L"?X]6Y4CC \APN:9?C-!DF$+V""#7Y:WJ
MP*!S .2F'(>5YFQKCKKE:./5T-]XVHS.B<L848;Y9^#&X[Y4UR@Z#8Z]\W)@
MPUY9[328L9P,DPJPV=]6JQ%9I$XQ:9TP6+C998R"D":6\.<O?$_<.7\'RS6]
M9@0HB^W+LN-3FC [< A:$L)/$8?@=%W6WB?(XDU/?GH41FX*3&[_^'9SBF;9
M*J.@=>WZ+EUL4-.*\9$R)A\IC(^4/Y"/E#8?R5HW'RFU'A_,1SOB>(]6N6L=
M#)=K^L5X48%W6KL7\#V*M<X"?@?!IG.,?)6>!M[.!7R/8GQD:'S?!LLU76/\
MJ_1M*)TU5)<JC+"4,?MS"N,=93#OI)N/15>)(C'OT$YI=^D,J-Q4&!TH@FVZ
M&B@M"IZC3-YK%Z<?I\N092K#?Q7&_^TFI$)$WN'AI=KNM94-M'=EQ)7PR'N1
MD4VG&/>H<%?NKD31A$0^CW(O>^05"2WL-Z@[K3(^4@?S4;@I>O[Y66U,MY*=
MI[:S4GDC]1W185RC"AXH,8N>T[<P32JB3(,%B=#2C>*D:2O70LXYDJ*!>:R=
M$PT^*"H,R;8#E"HKNTLCPZS*(C\H[+HQ=Q[/>NXGD'=&#BJ,Q8)1CDE6\0J$
MN7V^(^MPF!G8JS#8G_TO=NEMNWJ6,:,.%=[KY"1$E\=#^AR37]-L14]?6HS:
M5,[X035'Y"6548$*4\%=%#J$T&5/(=^O;>( ^)VJ[1T"'&.-X;\&XW\5X^G9
M[*.D8.A8D\&O-F;IKS&HU6"H%>,RC5/#\[E,XX OG\M$=#:=8FBMP6C=QV7W
M/?)<3"NJR5TDFUXP)-<$D5SHG/*JU#8@GK5#][Z.66/"TZN;HG2'_&10JNEC
M3GT&E1H,E3L\4M&CT>C8.U[M*'<_7*X9"X;L&ESY<S)<[#PA[0R_-6O$#.L,
MJ'48J'?(<(]&K'4]-K.KX/T.@LUP,([1X1*]G>0!58+.*$4?\Y$OG:&^WH/Z
M.U0).N?1+Q T=0;?.@S?5;1GUQ]UR#^&POJ8!^5Z[1DEN-3=917!&CL;45>[
M"M[O(-@,!Z,-7:S"OLSW>K-@X3IYX"'E#(?U,2MLG2&T/KS9LJ\.\!>]W8O!
M%M@E,AC$&V*U>/-DV:Z?+)<U4_ZZ4GZR+' *UK2&(:PQ9A5O,,@U_K@&_A>C
M7=(;8"?-8)!M]+7P]Y0]H=V8P;#;&/-HVF 0;PQN@.PMCY\-3CL$SB.C"$.@
M]3WP^0[N8QV'V=.P- "S&13/VG.N8S;2#0;CQN!&^A[7H]GUC%]7'AD-&# -
M[+(>([)*Z>8TC-Z$P-1DT&Y*(R;/9"!NPF7R_S5YY;WKR=/ Y)F,!,R^!UJ'
M)\\)?3_K_=I>%6BA'#* -Y4Q<\@ W!S<!=]C#MN=%@-L*YN, $RQ3LM#T4H6
MJBY-!M/FF)T6D\&P.;C3LK_G"\SVTSIPD]^LO;  P_C-]/845<9OW\ 8_EZ&
MR0#8'+-38C&LM00[)4*]QFN+\QX!5$E8#'PM&'S[7V(XM]KO!,#OA3 $M6 $
M%7F[Z-)J]ZW?^U[L944'WHH.O!<=^" PL!DB!NB6V$,WY>3H>6OBMM2&Y9HE
MTI'VWMR>44U;&0E8, E,G=]LQZ5<Y[Y[QRI&-W;TG22-!0RM(X;?UI@]&HLA
MNP47X ,?<3RS.$>0X!IB6&_UO'X@L(;.K#9FP_.30;8%0_:PG%,H?WR:?YW^
M$TI"[;VR,<$[^W*7ZL;9]?Y6Y5FE[MV"4]X%?U+[ H?L6VEH %=N$"./+*F4
M=)1M**/B>UZ*#TFXR;_3X3E,DM#/+]?$7I H&T#_OPSI-"T_9%\3L?VZG9/?
M 5!+ P04    " !U1EQ4Q)-GL_ "  !I"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970W-BYX;6RU5EU/XD 4_2N3Q@=-E-*"" 9(T&J61%P"N&:SV8>17NBL
MTYGNS"":[(_?.]-:P4##BR]T/NXYYYZY96Z[:ZF>=0)@R&O*A>YYB3'9I>_K
M>0(IU369@<"=A50I-3A52U]G"FCL0"GWPWJ]Y:>4":_?=6MCU>_*E>%,P%@1
MO4I3JMZN@,MUSPN\]X4)6R;&+OC];D:7, 7SD(T5SOR2)68I",VD( H6/6\0
M7$8=&^\"?C!8ZXTQL4Z>I'RVDV'<\^HV(> P-Y:!XN,%KH%S2X1I_"TXO5+2
M C?'[^RWSCMZ>:(:KB5_9+%)>E[;(S$LZ(J;B5Q_@\+/N>6;2Z[=+UGGL2U4
MG*^TD6D!QGG*1/ZDK\4Y; ""UAY 6 #"SX#F'D"C #0.!30+0-.=3&[%G4-$
M#>UWE5P39:.1S0[<83HTVF?"EGUJ%.XRQ)G^Y.9N,+N)SL:#R>PGF4T&]]/!
M]6SX_7Y*CB,PE'%]0L[(PS0BQT<GY(@P04:,<ZR9[OH&,[ \_KQ0N\K5PCUJ
M04A&4IA$DQL10[Q-X&/J9?[A>_Y7825C!/,::02G)*R'P8Z$K@^'UW? HX/A
M0:?"3:.L1L/Q-??PC>@?J9AY(].$*D@DCT&1?^26SAFWRWCXCTP(EL'RE(RH
M8$9R6J';+'6;3K>Q[RT 3@W$9$P5JLP4%9KF_\M?=QA*A@92_;M"Z+P4.J\T
M. %A"+SBI:7!NE&%<.:$S8?PKG<KISYWU/8Z>^G7:XVN_[)9[@-BHNJ8+5^M
MTE>KTM=822-C$%BLH3!XB^&UMJ*<X'H&:*WBZ"Y*B8NOK5&[%&I_78URZB#8
M.MS@4Y':.PKP*2:JCMDRUBF-=2J-#82P-5D $.R7Z,NV12:6Q(!*B5P0#MA!
M=KGJ')",OW$)IZ"6KIEI,I<K8?+[K%PM^^7 M8E/ZU?81_.V]T&3-^$154LF
M-.:Y0,IZ[0(S4GECRR=&9NZJ?Y(&&X<;)O@M ,H&X/Y"2O,^L0+EUT7_/U!+
M P04    " !U1EQ42,#[ BD"  ">!   &0   'AL+W=O<FMS:&5E=',O<VAE
M970W-RYX;6RE5$N/FS 0_BLCI$JMM V$)-OMBB"11]M(VR@BR?90]># 0*PU
MF-HF;/]];4-0*B5[Z05[[)GO88\)&BY>Y!%1P6O!2CEUCDI5CZXKDR,61 YX
MA:7>R;@HB-*AR%U9"22I+2J8ZWO>O5L06CIA8-<V(@QXK1@M<2- UD5!Q)\9
M,MY,G:%S7HAI?E1FP0V#BN2X1;6O-D)';H^2T@)+27D) K.I$PT?9V.3;Q.>
M*3;R8@[&R8'S%Q.LTJGC&4'(,%$&@>CAA'-DS !I&;\[3*>G-(67\S/Z%^M=
M>SD0B7/.?M!4':?.@P,I9J1F*N;--^S\3 Q>PIFT7VC:W,EG!Y):*EYTQ5I!
M0<MV)*_=.5P4^/Z- K\K\*WNELBJ7!!%PD#P!H3)UFAF8JW::BV.EN92MDKH
M7:KK5!@OM[MX/]_MX]7Z*T3K!<3+IVBW7$ TWZV>5[O5<@L?84V$(.;\X/T"
M%:%,?@A<I?D-BIMT7+.6R[_!%=7Y $;>'?B>/ZRXI.9>_H5QM?S>@]][\"WN
MZ)8'E$K4B:H%+7,@90HQ,J(PA<C<N:9!"3^C@\[23?#K#<91SSBRC.,;C.NZ
M.*  GL'9A@1D5-^/H;UV,BW>O<4S#^44#A\"]W1%P[C7,/X/#7=0H: \-4."
MI;JFZ6W\T63@>>^N'99[T6[FY7XG(J>:G6&FD;S!IXD#HGT-;:!X93OPP)7N
M9SL]ZA\("I.@]S/.U3DP3=W_DL*_4$L#!!0    ( '5&7%0KO?!K&0,  (P*
M   9    >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;+U676_:,!3]*U:TAU9:
MFS@)7Q4@ 6$;4MM5?'0/TQY,N)"HB<UL ^V_G^V$ "VD3*KZ0F+'YYQ[C\WU
M;6X8?Q(1@$3/:4)%RXJD7-[8M@@C2(FX9DN@ZLN<\91(->0+6RPYD)D!I8GM
M.D[53DE,K7;3S#WP=I.M9!)3>.!(K-*4\)<N)&S3LK"UG1C&BTCJ";O=7)(%
MC$!.E@]<C>R"91:G0$7,*.(P;UD=?!/@B@:8%8\Q;,3>.]*I3!E[TH/!K&4Y
M.B)(()2:@JC'&GJ0))I)Q?$W)[4*30W<?]^R?S/)JV2F1$"/);_BF8Q:5MU"
M,YB352*';/,#\H1,@"%+A/E%FVQMS;50N!*2I3E819#&-'N2Y]R(/0"NG@"X
M.<!]#?!/ +P<X)T+\'. ;YS)4C$^!$22=I.S#>)ZM6+3+\9,@U;IQU3O^TAR
M]356.-D>]D?CX:0WG@P']]]1YSY P_YM9]P/4*<W'CP.QH/^"%T$($F<B$MT
MA2:C %U\N41?4$S1.&(K0>A,-&VI@M&4=I@+=S-A]X0P=M$=HS(2J$]G,#LD
ML%4612KN-I6N6\H80'B-//P5N8Z+CP34.Q_N'($'9\-QHR0;K]@8S_!YIS8&
MA.2K4*YX3!>HQX1$RFBDIH&O ?V^5>O10$(J_I2H^86:;]3\L]3"B/ %'-O3
MC*5F6'1)6;<K%;?>M-?[/K]=Y!RN",I6',1?*>*OE,;?(R)"2_*B*I(\>A@S
M>'5/\<IW/'Q<M5JH5O_#M7QKCJE7WZACOU$[+EXKQ&NEXB-8 R<T!',NID!A
M'DN!0G521,F)J!?T]4\X?XU"K?$AYZ_QQDBWUG"/&XF=70UTRD^/*D1<W4!(
M E<UEI@;Z3TC\5Z)Q9]@)79W>NZ'F)G3'+KI54^XN2M<V"N5_RDCX*HG. CB
M/3-WA0K[GV'FKK#@\LIRMIF5=VN:O7=-IZ!X=+NC_[$K*K-KKI@M6JJ.:21>
MS7=UJV6N_QU-UJ?=J?!B*E "<T7I7-=45#QK?;*!9$O3#$R95*V%>8U4NPA<
M+U#?YXS)[4 +% UH^Q]02P,$%     @ =49<5(]J%;]1 @  B04  !D   !X
M;"]W;W)K<VAE971S+W-H965T-SDN>&ULC511;]HP$/XKISQMTD8@0-I5(5)I
MJ59IK1@9W<.T!Y-<B-783FT'6FD_?K83,MH"6AX<GWW?=]^==1=MA7Q4!:*&
M9U9R-?$*K:L+WU=I@8RHGJB0FYM<2$:T,>7:5Y5$DCD0*_V@WP]]1BCWXLB=
MS64<B5J7E.-<@JH9(_)EBJ783KR!MSM8T'6A[8$?1Q598X)Z6<VEL?R.):,,
MN:*"@\1\XET.+J:A]7<.#Q2W:F\/-I.5$(_6N,TF7M\*PA)3;1F(^6WP"LO2
M$AD93RVGUX6TP/W]COW&Y6YR61&%5Z+\23-=3+QS#S+,25WJA=A^Q3:?L>5+
M1:G<"MO&=W3F05HK+5@+-@H8Y<V?/+=UV ,,!T< 00L(G.XFD%-Y332)(RFV
M(*VW8;,;EZI#&W&4VT=)M#2WU.!TG"RGR>S[<G;_ V8/9DW@PS5J0DOU$3Y#
M4J\4/M7(-<PV9HU\;6):I)^V_-.&/SC"'\"=X+I0,.,99J_QOM':"0YV@J?!
M2<(;7/4@./\$03\(*-<H-^:E,I'6[)W 5P&&746&+L#P6$7>Y R_OAD/N-7(
MU.\3_*..?^3X1T?X%V@%0X62BNQ004_#Q\!<04\H&7=*QB>I[FNV0@DBAUWY
ME.DSJPXS^ .':]IH;(A#1VS[?A.'??M%_N: H+ 3%/ZGH.YAE1'2&8>4A.^4
M#+^\4>'OM0=#N79#0$$J:JZ;3NE.NSESV;37/_=F2-T1N:9<08FY@?9[9Z80
MLFG\QM"B<LVV$MJTKML69E:BM [F/A="[PP;H)N^\5]02P,$%     @ =49<
M5(75=P9+ P  [!0   T   !X;"]S='EL97,N>&ULW5A1;]HP$/XKD3M-K30U
M0-I 5D#:D"I-VJ9*Y6%OE2$.6'*<S#$=]'&_9[]JOV2^.(1 ?8SU88,%M;'O
M\WWW^>Y"W/8+O1+L?LZ8]I:ID,6 S+7.W_I^,9VSE!:76<ZD09),I52;J9KY
M1:X8C0MP2H7?:;5"/Z5<DF%?+M+;5!?>-%M(/2#=VN39VX=X0-KA%?$LW2B+
MV8 \G+_^NLCTS2O/WL_>G)VU+EL/%S>[R'D%71#?27Q] #%*BY&&!ZEM[=/;
M0LF[AY'OX\:H>]O439V_UQ4YG1NNB&.WY=[0S^\_D")LD$89_*J1AOTDDYM^
M"H@UF,@T9=XC%0,RHH)/% >OA*9<K*RY X9I)C+E:=/(1DH;+,63A=MV!CU>
M\:1<9JJ,;2/8WY-J^0ZPGH% +D0ML$.L8=C/J=9,R5LS*1>7QF>05XW'J]PH
MG"FZ:G>NR<:AO)D@DTS%3-5AVF1M&O8%2T".XK,YW'66^P!JG:5F$',ZRR0M
M-:P]JH&AG3(A[N$+X$NRQ;U,&C4M*RKKH1%4#2V-G0!_D\UR-VFO7L3KY?PQ
MT^\79CNRG$.GL#O%$KXLY\ND%H"QMW%VFN=B]4[PF4R9W?S! 8=]NO;SYIGB
M3R8:M,K4&)@BWB-3FD^;EF^*YF.VU.MV6B:XYLX):OZ[>9XQR1053=&F]X\Y
MRR]67+TQ_X7F\FME5[%39- ]?HW5">'818:G(/(DRMT[!9'1\8L,3D!C=?8\
M.I%^=1)J'+>V#ENUU8-#[8!\AN.SV 3U)@LN-)?5;,[CF,EG9RY#K^G$_"FW
MQ6_6QRRA"Z''-3@@F_$G%O-%&M6K[B 1U:K-^"-LKQW6)VH3B\N8+5D\JJ9J
M-BF'GAF8J-4%#KO(;7FY$<S'8FX$,"P.I@#SL5Y8G/]I/SUT/Q;#M/6<2 _U
MZ:$^ULN%C,H/%L?M$YG+O=,H"H(PQ#(Z&CD5C+"\A2'\N-DP;>"!Q8%(?Y9K
MO-IXA^SO ZRF^SH$VRG>B=A.\5P#XLX;>$21N]I8'/# JH#U#L1WQX&><OL$
M 505TX8]P3@211@"O>CNT3!$LA/"QUT?["D)@BAR(X"Y%00!AL#3B".8 M"
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MYE7;/Y9' 9:&8&FT6&X8)*'OS9R4S]BEXSN!RUERPWF: $ = =1/!LC.H@Q
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M2P$"% ,4    " !U1EQ4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '5&7%0\ZQK'[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M '5&7%297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ =49<5 Q?@RJ=!@  QAH  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M '5&7%3R&L3'( (  ' %   8              " @> .  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " !U1EQ4)9K2H&4&  ">&P  &
M            @($V$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ =49<5*T*Z ;B @  OPD  !@              ("!T1<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '5&7%2SDJMZYP4  &(7
M   8              " @>D:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " !U1EQ4</:,A^H&   S(P  &               @($&(0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ =49<5.AI!@R"
M @  -08  !@              ("!)B@  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( '5&7%3&U#1C^P<  ,4B   8              "
M@=XJ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !U1EQ4
M_>VCO><6  !L1P  &               @($/,P  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ =49<5%_XP=7M!0  A@T  !D
M     ("!+$H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '5&7%0ENP< UP(  !@&   9              "
M@:V!  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ =49<
M5(:""W-E"@  ,"   !D              ("!NX0  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " !U1EQ4O;@-#;L"  "Z!0  &0
M        @(%7CP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( '5&7%1T*N+DQPD  !L:   9              " @4F2  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ =49<5!6A:DS%!0  )PX
M !D              ("!1YP  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " !U1EQ4Z2&Z6L(0  #U-   &0              @(%#H@
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '5&7%3Y\":#
M/P8  / /   9              " @3RS  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ =49<5!I"1VKL#   +2<  !D
M ("!LKD  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !U
M1EQ4@=:$%Y %  !*#0  &0              @('5Q@  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( '5&7%3/,]ASX0P  (0B   9
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M970R."YX;6Q02P$"% ,4    " !U1EQ4NK&<</(C  #0>0  &0
M    @(&: @$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M '5&7%3=\<_:@00  !(.   9              " @<,F 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ =49<5/%/PRKJ @  )08  !D
M             ("!>RL! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " !U1EQ4EV"ZB[0"  ##!0  &0              @(&<+@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( '5&7%3Y<[)YR (
M , %   9              " @8<Q 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ =49<5"$(5 M_ P  < @  !D              ("!
MAC0! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !U1EQ4
M!H<=XUD$   ?"@  &0              @($\. $ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( '5&7%1,?9#(V (  -,%   9
M      " @<P\ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ =49<5#W1K*7#!0  =@X  !D              ("!VS\! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !U1EQ4W)ZA(,P&  !.$@
M&0              @('510$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( '5&7%036+@QS0(  .(%   9              " @=A, 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ =49<5&"A:58_
M!0  X1,  !D              ("!W$\! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " !U1EQ4^"HGQ $(   @+0  &0
M@(%250$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '5&
M7%2&KWDU; 0  $,5   9              " @8I= 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ =49<5 :@WB.K!   G!0  !D
M         ("!+6(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    " !U1EQ4;]KY/_$#   C#0  &0              @($/9P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( '5&7%33<;(S0 ,   L)
M   9              " @3=K 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL
M4$L! A0#%     @ =49<5#MTDZV[ P  Y@X  !D              ("!KFX!
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !U1EQ4<88'
MWED#   T#0  &0              @(&@<@$ >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;%!+ 0(4 Q0    ( '5&7%3(CLO<9P(  +0%   9
M  " @3!V 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M=49<5-_?CLF4 @  AP<  !D              ("!SG@! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " !U1EQ4]]Y2S#$#  !Y"P  &0
M            @(&9>P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( '5&7%3A4? .Q0(  *$'   9              " @0%_ 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ =49<5.]_&\\& @
M\0,  !D              ("!_8$! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " !U1EQ4)X+S-:4$  !:%0  &0              @($Z
MA $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( '5&7%1R
M12KEZP(  ($(   9              " @1:) 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ =49<5'<2)QM- @  (04  !D
M     ("!.(P! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '5&7%3P@=2"5 4  (<?   9              "
M@?&< 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ =49<
M5.&T..X#!0  NA<  !D              ("!?*(! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " !U1EQ4X6[,/!8#   R"@  &0
M        @(&VIP$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( '5&7%2M<UX? 0,  'X)   9              " @0.K 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ =49<5)NPL8\I!P  X"0
M !D              ("!.ZX! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " !U1EQ41]ZYC]@"  !R"   &0              @(&;M0$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( '5&7%34E&Z)
M)04  +44   9              " @:JX 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ =49<5.6J#(J4 P  9 P  !D
M ("!!KX! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " !U
M1EQ4UC=#"[T#  "?"P  &0              @('1P0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( '5&7%3VQODF\P(  ,0(   9
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M970W,RYX;6Q02P$"% ,4    " !U1EQ4'XH*!S4#  !1#0  &0
M    @(%$UP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M '5&7%1^4H;[R0H  'I'   9              " @;#: 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ =49<5,239[/P @  :0@  !D
M             ("!L.4! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " !U1EQ42,#[ BD"  ">!   &0              @('7Z $ >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( '5&7%0KO?!K&0,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( '5&7%1"@QS %08   0T   /
M      "  6[U 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !U1EQ4NTG2
MWV("  "T+@  &@              @ &P^P$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !U1EQ4W2=K"Q@"  "%+0  $P
M    @ %*_@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5P!7 -@7  "3
%  (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>260</ContextCount>
  <ElementCount>456</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114106 - Disclosure - RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLES</Role>
      <ShortName>RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2116107 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2120108 - Disclosure - INTANGIBLES AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL</Role>
      <ShortName>INTANGIBLES AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2127110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2129111 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2134112 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2142113 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2145114 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2152115 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2154116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2162117 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2164118 - Disclosure - RELATED-PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2166119 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2170120 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2317302 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - INTANGIBLES AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables</Role>
      <ShortName>INTANGIBLES AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LEASES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2335306 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2355309 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INCOMETAXES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2367310 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLESDetails</Role>
      <ShortName>RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RECEIVABLES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLES AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - LEASES - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESLeaseCostsDetails</Role>
      <ShortName>LEASES - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - LEASES - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447424 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2456430 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails</Role>
      <ShortName>INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2457431 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails</Role>
      <ShortName>INCOME TAXES - Components of Income Tax Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - INCOME TAXES - Schedule of Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - LICENSE AGREEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails</Role>
      <ShortName>LICENSE AGREEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2465437 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="sesn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2471440 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sesn-20211231.htm">sesn-20211231.htm</File>
    <File>exhibit1030-rsuandcashrete.htm</File>
    <File>exhibit1031-performancexba.htm</File>
    <File>exhibit108_formindemnifica.htm</File>
    <File>exhibit231eyconsentforfy20.htm</File>
    <File>exhibit41-fy2021form10xk.htm</File>
    <File>sesn-12312021x10kex211.htm</File>
    <File>sesn-12312021x10kex311.htm</File>
    <File>sesn-12312021x10kex312.htm</File>
    <File>sesn-12312021x10kex321.htm</File>
    <File>sesn-12312021x10kex322.htm</File>
    <File>sesn-20211231.xsd</File>
    <File>sesn-20211231_cal.xml</File>
    <File>sesn-20211231_def.xml</File>
    <File>sesn-20211231_lab.xml</File>
    <File>sesn-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sesn-20211231_g1.jpg</File>
    <File>sesn-20211231_g2.jpg</File>
    <File>sesn-20211231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="804">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sesn-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 30,
   "contextCount": 260,
   "dts": {
    "calculationLink": {
     "local": [
      "sesn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sesn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sesn-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sesn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sesn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sesn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 616,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 76,
   "keyStandard": 380,
   "memberCustom": 35,
   "memberStandard": 50,
   "nsprefix": "sesn",
   "nsuri": "http://www.sesenbio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sesenbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114106 - Disclosure - RECEIVABLES",
     "role": "http://www.sesenbio.com/role/RECEIVABLES",
     "shortName": "RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116107 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120108 - Disclosure - INTANGIBLES AND GOODWILL",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL",
     "shortName": "INTANGIBLES AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129111 - Disclosure - LEASES",
     "role": "http://www.sesenbio.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.sesenbio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134112 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142113 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145114 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152115 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154116 - Disclosure - INCOME TAXES",
     "role": "http://www.sesenbio.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162117 - Disclosure - LICENSE AGREEMENTS",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164118 - Disclosure - RELATED-PARTY TRANSACTIONS",
     "role": "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED-PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166119 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170120 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317302 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - INTANGIBLES AND GOODWILL (Tables)",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables",
     "shortName": "INTANGIBLES AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - LEASES (Tables)",
     "role": "http://www.sesenbio.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335306 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT (Tables)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355309 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367310 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "idbcc2cd80c644c9bba710067ba49b410_I20180430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "idbcc2cd80c644c9bba710067ba49b410_I20180430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i9280baa377514c5b8f3b86112af15bc1_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i02b5f8ea9c52413084c453c81936288b_I20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i02b5f8ea9c52413084c453c81936288b_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "ic253a6e3f3ea4d2085234df3e59a15d4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i461f7c863e8845a1bf3aecbdde6819d0_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - RECEIVABLES (Details)",
     "role": "http://www.sesenbio.com/role/RECEIVABLESDetails",
     "shortName": "RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Detail)",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
     "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i6fe412d00cd048258c144cd9ed556654_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
     "shortName": "INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i6fe412d00cd048258c144cd9ed556654_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i65d83f49999a40659f8cb5c98716447b_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLES AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i02b5f8ea9c52413084c453c81936288b_I20210930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i754f4ed1114d47c585642ec702c9d897_D20210101-20211231",
      "decimals": "-2",
      "lang": "en-US",
      "name": "sesn:OperatingLeaseMonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - LEASES - Lease Costs (Details)",
     "role": "http://www.sesenbio.com/role/LEASESLeaseCostsDetails",
     "shortName": "LEASES - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - LEASES - Future Minimum Lease Payments (Details)",
     "role": "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails",
     "shortName": "LEASES - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i072f60a137e94674991638220c6ed9ec_D20210601-20210731",
      "decimals": "-6",
      "lang": "en-US",
      "name": "sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sesn:NumberofVotesEntitledForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sesn:CommonStockSharesIssuedAndReservedForFuture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i0bf44be67ed84033b15e86e3de2e9088_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i0bf44be67ed84033b15e86e3de2e9088_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "ifd395e5e95f84b618c6884bc4356ae1a_I20190630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "ic253a6e3f3ea4d2085234df3e59a15d4_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447424 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i75020eb264af4e39a21665962a79801e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i3950633399b7426dbfabb5690ebcde85_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "ic253a6e3f3ea4d2085234df3e59a15d4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456430 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
     "shortName": "INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457431 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails",
     "shortName": "INCOME TAXES - Components of Income Tax Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails",
     "shortName": "INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i8984440967a74e3abe0feaafbe79712a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i6573654cd29340309dbe2c811248a720_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - INCOME TAXES - Schedule of Credit Carryforwards (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
     "shortName": "INCOME TAXES - Schedule of Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i6573654cd29340309dbe2c811248a720_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - LICENSE AGREEMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
     "shortName": "LICENSE AGREEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i028e8f65759541db8dc7760918e71d52_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
       "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465437 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)",
     "role": "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED-PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
       "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i3f510aea6f994552bf507f53bf801c46_D20220101-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:ReviewPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471440 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i3f510aea6f994552bf507f53bf801c46_D20220101-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:ReviewPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20211231.htm",
      "contextRef": "i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 90,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "TURKEY"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "United States:"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sesn_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2014 Employee Stock Purchase Plan [Member]",
        "label": "A2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]",
        "label": "2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]",
        "terseLabel": "2018 Warrant Amendment, Amendment to Securities Purchase Agreement"
       }
      }
     },
     "localname": "A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ATMFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Facility [Member]",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "localname": "ATMFacilityMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_AccountsReceivablePaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Payment Terms",
        "label": "Accounts Receivable, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "AccountsReceivablePaymentTerms",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedRestructuringChargesRelatedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges Related, Current",
        "label": "Accrued Restructuring Charges Related, Current",
        "terseLabel": "Restructuring charge related"
       }
      }
     },
     "localname": "AccruedRestructuringChargesRelatedCurrent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.sesenbio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "terseLabel": "Shares of common stock issued to the selling shareholders (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current",
        "terseLabel": "Change in fair value of contingent consideration - short term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Change in fair value of contingent consideration - long term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "label": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Milestone Payments",
        "label": "Business Combination, Milestone Payments",
        "terseLabel": "Business combination, milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Royalty Payment Percent",
        "label": "Business Combination, Royalty Payment Percent",
        "terseLabel": "Royalty payment, percentage"
       }
      }
     },
     "localname": "BusinessCombinationRoyaltyPaymentPercent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ClassOfWarrantOrRightIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued During The Period",
        "label": "Class Of Warrant Or Right, Issued During The Period",
        "terseLabel": "Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "label": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "negatedTerseLabel": "Warrants Cancelled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Minimum Percentage of Securities Issued",
        "label": "Class of Warrant or Right, Minimum Percentage of Securities Issued",
        "terseLabel": "Minimum percentage of securities issued"
       }
      }
     },
     "localname": "ClassofWarrantorRightMinimumPercentageofSecuritiesIssued",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone",
        "label": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on commercialization milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on development milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on regulatory milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue based on Specified Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CommonStockAndWarrantOrRightsPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock And Warrant Or Rights, Price Per Share",
        "label": "Common Stock And Warrant Or Rights, Price Per Share",
        "terseLabel": "Stock and warrants price per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockAndWarrantOrRightsPricePerShare",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_CommonStockSharesIssuedAndReservedForFuture": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Issued And Reserved For Future",
        "label": "Common Stock Shares Issued And Reserved For Future",
        "totalLabel": "Total shares of common stock issued and reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndReservedForFuture",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Policy Text Block]",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_DebtInstrumentIndexRateHighYield": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Index Rate, High-Yield",
        "label": "Debt Instrument, Index Rate, High-Yield",
        "terseLabel": "Index rate, high-yield"
       }
      }
     },
     "localname": "DebtInstrumentIndexRateHighYield",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_DeferredTaxAssetsCapitalizedStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized Start Up Costs",
        "label": "Deferred Tax Assets Capitalized Start Up Costs",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedStartUpCosts",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "terseLabel": "Discretionary match per participating employee, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_EBI031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBI-031 [Member]",
        "label": "EBI-031 [Member]",
        "terseLabel": "EBI-031"
       }
      }
     },
     "localname": "EBI031Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EczacibasiPharmaceuticalsMarketingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eczacibasi Pharmaceuticals Marketing Agreement",
        "label": "Eczacibasi Pharmaceuticals Marketing Agreement [Member]",
        "terseLabel": "Eczacibasi Pharmaceuticals Marketing Agreement"
       }
      }
     },
     "localname": "EczacibasiPharmaceuticalsMarketingAgreementMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Contingent Consideration, Percent",
        "label": "Effective Income Tax Rate Reconciliation Contingent Consideration, Percent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_FacilityinWinnipegManitolaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility in Winnipeg, Manitola [Member]",
        "label": "Facility in Winnipeg, Manitola [Member]",
        "terseLabel": "Facility in Winnipeg, Manitola"
       }
      }
     },
     "localname": "FacilityinWinnipegManitolaMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_FirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Indication [Member]",
        "label": "First Indication [Member]",
        "terseLabel": "First Indication"
       }
      }
     },
     "localname": "FirstIndicationMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IL6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IL-6 [Member]",
        "label": "IL-6 [Member]",
        "terseLabel": "IL-6"
       }
      }
     },
     "localname": "IL6Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite [Member]",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IssuanceOfWarrantForCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Warrant For Common Stock",
        "label": "Issuance of Warrant For Common Stock",
        "terseLabel": "Deemed Dividend on adjustment of exercise price on certain warrants"
       }
      }
     },
     "localname": "IssuanceOfWarrantForCommonStock",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option",
        "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option",
        "terseLabel": "Renewal option"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementAdditionalUpFrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Additional Up-Front Fee",
        "label": "License Agreement, Additional Up-Front Fee",
        "terseLabel": "License agreement, additional up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalUpFrontFee",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "label": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "terseLabel": "License agreement, amount payable upon achievement of specified milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under First Option Period",
        "label": "License Agreement, Buyout Amount Under First Option Period",
        "terseLabel": "License agreement, buyout amount under first option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderFirstOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period",
        "label": "License Agreement, Buyout Amount Under Second Option Period",
        "terseLabel": "License agreement, buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "label": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "terseLabel": "Buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achieved",
        "label": "License Agreement, Milestone Achieved",
        "terseLabel": "Milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchievementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achievement Expense",
        "label": "License Agreement, Milestone Achievement Expense",
        "terseLabel": "Expenses related to achievement of development milestone"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchievementExpense",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment",
        "label": "License Agreement, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayment",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestonePaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment Term",
        "label": "License Agreement, Milestone Payment Term",
        "terseLabel": "Milestone payment term"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentTerm",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementOptionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Option Periods",
        "label": "License Agreement, Option Periods",
        "terseLabel": "License agreement, option periods"
       }
      }
     },
     "localname": "LicenseAgreementOptionPeriods",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty On Net Product Sales",
        "label": "License Agreement, Percentage of Royalty On Net Product Sales",
        "terseLabel": "Royalty payment obligation, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSales",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "label": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "terseLabel": "Third party minimum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "label": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "terseLabel": "Third party maximum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "label": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "terseLabel": "License agreement, period to pay buyout option once exercised"
       }
      }
     },
     "localname": "LicenseAgreementPeriodToPayBuyoutOptionOnceExercised",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementProceedsFromMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Proceeds From Milestone Achieved",
        "label": "License Agreement, Proceeds From Milestone Achieved",
        "terseLabel": "Proceeds from milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementProceedsFromMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "label": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "terseLabel": "License agreement, royalty payment, reduction, conditions not met"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Rate",
        "label": "License Agreement, Royalty Rate",
        "terseLabel": "License agreement, royalty rate"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyRate",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Text Block]",
        "label": "License Agreement [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_LicenseAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Up-front Fee",
        "label": "License Agreement, Up-front Fee",
        "terseLabel": "License agreement, up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontFee",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Revenue [Member]",
        "label": "License Revenue [Member]",
        "terseLabel": "License and related revenue"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MENALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MENA License Agreement",
        "label": "MENA License Agreement [Member]",
        "terseLabel": "MENA License Agreement"
       }
      }
     },
     "localname": "MENALicenseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MassachusettsAndPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts And Pennsylvania",
        "label": "Massachusetts And Pennsylvania [Member]",
        "terseLabel": "Massachusetts And Pennsylvania"
       }
      }
     },
     "localname": "MassachusettsAndPennsylvaniaMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MicrometAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Micromet [Member]",
        "label": "Micromet AG [Member]",
        "terseLabel": "Micromet AG"
       }
      }
     },
     "localname": "MicrometAGMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NetOperatingLossCarryforwardAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryforward [Axis]",
        "label": "Net Operating Loss Carryforward [Axis]",
        "terseLabel": "Net Operating Loss Carryforward [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardAxis",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_NetOperatingLossCarryforwardDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Net Operating Loss Carryforward [Axis]",
        "label": "Net Operating Loss Carryforward [Domain]",
        "terseLabel": "Net Operating Loss Carryforward [Domain]"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardDomain",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NonCapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Capital Loss Carryforward [Member]",
        "label": "Non-Capital Loss Carryforward [Member]",
        "terseLabel": "Non-capital loss carryforwards"
       }
      }
     },
     "localname": "NonCapitalLossCarryforwardMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NumberOfDocumentsReviewed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Documents Reviewed",
        "label": "Number Of Documents Reviewed",
        "terseLabel": "Number of documents reviewed"
       }
      }
     },
     "localname": "NumberOfDocumentsReviewed",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberOfInterviews": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Interviews",
        "label": "Number Of Interviews",
        "terseLabel": "Number of interviews"
       }
      }
     },
     "localname": "NumberOfInterviews",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Lawsuits",
        "label": "Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "NumberOfLawsuits",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberOfPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Patients",
        "label": "Number Of Patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "NumberOfPatients",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberofVotesEntitledForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Entitled For Each Share",
        "label": "Number of Votes Entitled For Each Share",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberofVotesEntitledForEachShare",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_OperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent",
        "label": "Operating Lease, Monthly Rent",
        "verboseLabel": "Monthly rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRent",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeaseOtherMonthlyOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Other Monthly Operating Expenses",
        "label": "Operating Lease, Other Monthly Operating Expenses",
        "terseLabel": "Related operating expenses"
       }
      }
     },
     "localname": "OperatingLeaseOtherMonthlyOperatingExpenses",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeasesAreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Area Of Office Space",
        "label": "Operating Leases Area Of Office Space",
        "terseLabel": "Office space (in square feet)"
       }
      }
     },
     "localname": "OperatingLeasesAreaOfOfficeSpace",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "sesn_OperatingLossCarryforwardsDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Decrease",
        "label": "Operating Loss Carryforwards, Decrease",
        "terseLabel": "NOL carryforward reduced amount"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsDecrease",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Line Items]",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Table]",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OtherDividendAndAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Dividend And Adjustments",
        "label": "Other Dividend And Adjustments",
        "terseLabel": "Deemed dividend"
       }
      }
     },
     "localname": "OtherDividendAndAdjustments",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability of Achieving Clinical and Regulatory Milestones, Percentage",
        "label": "Probability of Achieving Clinical and Regulatory Milestones, Percentage",
        "terseLabel": "Probability of achieving clinical and regulatory milestones"
       }
      }
     },
     "localname": "ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ProceedsFromIssuanceofCommonStockandWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance of Common Stock and Warrants",
        "label": "Proceeds From Issuance of Common Stock and Warrants",
        "terseLabel": "Proceeds from issuance of common stock and common stock warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceofCommonStockandWarrants",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ProceedsFromValueAddedTaxRecovery": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Value Added Tax Recovery",
        "label": "Proceeds From Value Added Tax Recovery",
        "terseLabel": "Proceeds from value added tax recovery"
       }
      }
     },
     "localname": "ProceedsFromValueAddedTaxRecovery",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_QiluPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co., Ltd.",
        "label": "Qilu Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLtdMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention Program [Member]",
        "label": "Retention Program [Member]",
        "terseLabel": "Retention Program"
       }
      }
     },
     "localname": "RetentionProgramMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ReviewPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Review Period",
        "label": "Review Period",
        "terseLabel": "Review period"
       }
      }
     },
     "localname": "ReviewPeriod",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "label": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetRelatedToAdoptionOfAccountingStandard",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RoyaltyRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue, Percentage",
        "label": "Royalty Revenue, Percentage",
        "terseLabel": "Royalty revenue, percentage"
       }
      }
     },
     "localname": "RoyaltyRevenuePercentage",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_SaleOfStockAdditionalSharesAuthorizedForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Additional Shares Authorized For Sale",
        "label": "Sale Of Stock, Additional Shares Authorized For Sale",
        "terseLabel": "Additional shares to be issued"
       }
      }
     },
     "localname": "SaleOfStockAdditionalSharesAuthorizedForSale",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockCommissionFixedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fixed Rate",
        "label": "Sale Of Stock, Commission Fixed Rate",
        "terseLabel": "Commission fixed rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionFixedRate",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "label": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateSalesPriceInTransaction",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Weighted-Average Price Per Share",
        "label": "Sale of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_SecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Indication [Member]",
        "label": "Second Indication [Member]",
        "terseLabel": "Second Indication"
       }
      }
     },
     "localname": "SecondIndicationMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "terseLabel": "Percent of base salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "terseLabel": "Shares received per award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ShareBasedPaymentArrangementExpenseOnCashBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Expense, On Cash Bonus",
        "label": "Share-based Payment Arrangement, Expense, On Cash Bonus",
        "terseLabel": "Expense related to cash bonus"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementExpenseOnCashBonus",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "label": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "terseLabel": "One-time milestone payment upon first sale of product"
       }
      }
     },
     "localname": "SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "label": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "terseLabel": "Percentage of net sales of quarterly earn-out payments during earn-out periods"
       }
      }
     },
     "localname": "SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "label": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "terseLabel": "Period during which quarterly earn-outs are payable after date of net sales"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "label": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "terseLabel": "Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharesOfCommonStockReservedForIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "label": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "terseLabel": "Shares of common stock reserved for issuance for:"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForIssuanceAbstract",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_StockIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2009",
        "label": "Stock Incentive Plan 2009 [Member]",
        "terseLabel": "Stock Incentive Plan 2009"
       }
      }
     },
     "localname": "StockIncentivePlan2009Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "verboseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Exercise Of Warrants, Value",
        "label": "Stock Issued During Period, Exercise Of Warrants, Value",
        "terseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsValue",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, New Issues, Issuance Costs",
        "terseLabel": "Issuance of common stock, issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewIssuesIssuanceCosts",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Exercise Of Warrants",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "negatedTerseLabel": "Warrants Exercised (in shares)",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_SupplementalLeaseInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Lease Information [Abstract]",
        "label": "Supplemental Lease Information [Abstract]",
        "terseLabel": "Supplemental Information:"
       }
      }
     },
     "localname": "SupplementalLeaseInformationAbstract",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Zurich",
        "label": "University of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViciniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vicinium [Member]",
        "label": "Vicinium [Member]",
        "terseLabel": "Vicinium"
       }
      }
     },
     "localname": "ViciniumMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViventiaBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viventia Bio, Inc.",
        "label": "Viventia Bio, Inc. [Member]",
        "terseLabel": "Viventia Bio Inc."
       }
      }
     },
     "localname": "ViventiaBioInc.Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Or Right Outstanding [Roll Forward]",
        "label": "Warrant Or Right Outstanding [Roll Forward]",
        "terseLabel": "Warrant Or Right Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "WarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_WarrantsExpiringJune2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring June 2020 [Member]",
        "label": "Warrants, Expiring June 2020 [Member]",
        "terseLabel": "Warrants, Expiring June 2020"
       }
      }
     },
     "localname": "WarrantsExpiringJune2020Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring March 2023 [Member]",
        "label": "Warrants, Expiring March 2023 [Member]",
        "terseLabel": "Warrants, Expiring March 2023",
        "verboseLabel": "2018 Warrants"
       }
      }
     },
     "localname": "WarrantsExpiringMarch2023Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2022 [Member]",
        "label": "Warrants, Expiring November 2022 [Member]",
        "terseLabel": "Warrants, Expiring November 2022",
        "verboseLabel": "2017 Warrants"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2022Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedMay2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "label": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued May 2015"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedMay2015Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "label": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued November 2014"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedNovember2014Member",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Cost of Capital",
        "label": "Weighted Average Cost of Capital",
        "terseLabel": "Weighted-average cost of capital"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapital",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_XOMAIrelandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA Ireland Limited [Member]",
        "label": "XOMA Ireland Limited [Member]",
        "terseLabel": "XOMA Ireland Limited"
       }
      }
     },
     "localname": "XOMAIrelandLimitedMember",
     "nsuri": "http://www.sesenbio.com/20211231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r98",
      "r99",
      "r237",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r104",
      "r113",
      "r119",
      "r180",
      "r401",
      "r402",
      "r403",
      "r435",
      "r436",
      "r474",
      "r475",
      "r477",
      "r478",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r104",
      "r113",
      "r119",
      "r180",
      "r401",
      "r402",
      "r403",
      "r435",
      "r436",
      "r474",
      "r475",
      "r477",
      "r478",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r104",
      "r113",
      "r119",
      "r180",
      "r401",
      "r402",
      "r403",
      "r435",
      "r436",
      "r474",
      "r475",
      "r477",
      "r478",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Protoden"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe",
        "verboseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r236",
      "r247",
      "r362",
      "r365",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r597",
      "r600",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r236",
      "r247",
      "r362",
      "r365",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r597",
      "r600",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r283",
      "r285",
      "r555",
      "r596",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168",
      "r283",
      "r285",
      "r555",
      "r596",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r236",
      "r247",
      "r315",
      "r362",
      "r365",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r597",
      "r600",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r236",
      "r247",
      "r315",
      "r362",
      "r365",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r597",
      "r600",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r98",
      "r99",
      "r237",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r283",
      "r286",
      "r599",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r283",
      "r286",
      "r599",
      "r609",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r32",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r48"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43",
      "r202"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r33",
      "r405",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r401",
      "r402",
      "r403",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r368",
      "r371",
      "r408",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r261",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r235",
      "r261",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Increase in warrant value"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r371",
      "r397",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Total Share Based Compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "netLabel": "Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r83",
      "r199"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r157",
      "r160",
      "r166",
      "r179",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r464",
      "r467",
      "r496",
      "r538",
      "r540",
      "r576",
      "r587"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r55",
      "r93",
      "r179",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r464",
      "r467",
      "r496",
      "r538",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r93",
      "r179",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r464",
      "r467",
      "r496",
      "r538"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r372",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r360",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r360",
      "r363",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r82",
      "r462"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value included in loss",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r457",
      "r458",
      "r461"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration - short term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion",
        "verboseLabel": "Contingent consideration - long term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r40",
      "r85"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r86",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r85",
      "r87"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r503"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r269",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r269",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "netLabel": "Shares of common stock reserved for issuance (in shares)",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "verboseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at December\u00a031, 2021 and 2020; 199,463,645 and 140,449,647 shares issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r292",
      "r293",
      "r366",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r70",
      "r581",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive Loss After Taxes"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractTerminationMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Contract Termination [Member]",
        "terseLabel": "Contract termination costs"
       }
      }
     },
     "localname": "ContractTerminationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r271",
      "r272",
      "r284"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r271",
      "r272",
      "r284"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current Tax Provision"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r432",
      "r442"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r432"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r432",
      "r442",
      "r444"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current (provision)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r432",
      "r442"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r433",
      "r442"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r433",
      "r442"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r94",
      "r433",
      "r442",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total deferred benefit (provision)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r27",
      "r28",
      "r422",
      "r577",
      "r586"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r433",
      "r442"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r415",
      "r425"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net Deferred Tax Liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "negatedLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution retirement plan, maximum employee contribution deferred"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r83",
      "r200"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r359",
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r122",
      "r125",
      "r132",
      "r133",
      "r134",
      "r139",
      "r140",
      "r478",
      "r479",
      "r582",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r125",
      "r132",
      "r133",
      "r134",
      "r139",
      "r140",
      "r478",
      "r479",
      "r582",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r96",
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "United States federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Impact of foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock option cancellations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Foreign taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "negatedTerseLabel": "General business credits and other credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period unvested stock to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and benefits costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for sale under 2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r101",
      "r102",
      "r103",
      "r108",
      "r116",
      "r118",
      "r142",
      "r180",
      "r261",
      "r268",
      "r401",
      "r402",
      "r403",
      "r435",
      "r436",
      "r477",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r601",
      "r602",
      "r603",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r358",
      "r481",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r480",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r480",
      "r481",
      "r484",
      "r485",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r238",
      "r316",
      "r317",
      "r322",
      "r358",
      "r481",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r316",
      "r317",
      "r322",
      "r358",
      "r481",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r358",
      "r481",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r358",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r487",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]",
        "terseLabel": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r194",
      "r196",
      "r556",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r190",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r359",
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r183",
      "r185",
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLES AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r83",
      "r184",
      "r186",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r367",
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r83",
      "r197"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r83",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D intangible assets:"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r67",
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss Before Taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r95",
      "r445"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Pre-tax income (loss) U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r573",
      "r579",
      "r583",
      "r594"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total Loss Before Income Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r95",
      "r445"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Pre-tax income (loss) Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r204",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r418",
      "r420",
      "r427",
      "r440",
      "r447",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r117",
      "r118",
      "r156",
      "r416",
      "r441",
      "r448",
      "r595"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit (provision) from income taxes",
        "negatedTotalLabel": "Benefit (provision) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r412",
      "r413",
      "r420",
      "r421",
      "r426",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable (net)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "terseLabel": "Increase in other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Total Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r189",
      "r192"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentCreditMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project.",
        "label": "Investment Tax Credit Carryforward [Member]",
        "terseLabel": "Investment tax credit carryforwards"
       }
      }
     },
     "localname": "InvestmentCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r525",
      "r527"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments (2022)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r93",
      "r161",
      "r179",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r465",
      "r467",
      "r468",
      "r496",
      "r538",
      "r539"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r93",
      "r179",
      "r496",
      "r540",
      "r578",
      "r589"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r93",
      "r179",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r465",
      "r467",
      "r468",
      "r496",
      "r538",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r25",
      "r26",
      "r93",
      "r179",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r465",
      "r467",
      "r468",
      "r496",
      "r538",
      "r539"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "RECEIVABLES"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MajorityShareholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.",
        "label": "Majority Shareholder [Member]",
        "terseLabel": "Majority Shareholder"
       }
      }
     },
     "localname": "MajorityShareholderMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r145",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Negative cash flows from operating activities incurred",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r59",
      "r61",
      "r67",
      "r69",
      "r84",
      "r93",
      "r107",
      "r111",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r130",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r179",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r479",
      "r496",
      "r580",
      "r591"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net Loss After Taxes",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r122",
      "r123",
      "r131",
      "r134",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r131",
      "r134"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r105",
      "r106",
      "r109",
      "r110",
      "r119",
      "r120",
      "r121",
      "r177",
      "r178",
      "r181",
      "r182",
      "r287",
      "r288",
      "r289",
      "r290",
      "r404",
      "r437",
      "r438",
      "r439",
      "r476",
      "r500",
      "r501",
      "r502",
      "r529",
      "r557",
      "r558",
      "r559",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r157",
      "r159",
      "r162",
      "r165",
      "r167"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r519",
      "r527"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease (including related operating costs)",
        "verboseLabel": "Operating lease cost, including related operating cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Minimum Lease Payments:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESFutureMinimumLeasePaymentsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r515",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Right-of-use assets related to the adoption of ASC 842"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r524",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r523",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r48"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r48",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other restructuring costs"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r79",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r76",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-Based Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r372",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r123",
      "r135"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Deemed dividend on adjustment of exercise price of certain warrants"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December\u00a031, 2021 and 2020; no shares issued and outstanding at December\u00a031, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock under ATM Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r78",
      "r400"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from sale of common stock pursuant to ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercises of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r43",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r42",
      "r201"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r203",
      "r540",
      "r584",
      "r590"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r203",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Composition of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r340",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r532",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Rent expense in related party transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r340",
      "r532",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Annual fee for remaining term of lease"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r340",
      "r532",
      "r535",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r530",
      "r531",
      "r533",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED-PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Percentage of fair value in excess of carrying amount"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r411",
      "r554",
      "r626"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r24",
      "r85",
      "r87",
      "r610"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r87"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted Cash",
        "verboseLabel": "Short term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r24",
      "r87",
      "r610"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r209",
      "r212",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING AND RELATED ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, period percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r83",
      "r206",
      "r213",
      "r215"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charge"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r209",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Restructuring Reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r268",
      "r405",
      "r540",
      "r588",
      "r604",
      "r608"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r108",
      "r116",
      "r118",
      "r180",
      "r401",
      "r402",
      "r403",
      "r435",
      "r436",
      "r477",
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r154",
      "r155",
      "r158",
      "r163",
      "r164",
      "r168",
      "r169",
      "r171",
      "r282",
      "r283",
      "r555"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "License and related revenue",
        "verboseLabel": "Total Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r522",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of units issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Benefit (Provision)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r342",
      "r343",
      "r346",
      "r347",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Expected Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r371",
      "r396",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Carrying Amounts and Fair Values of Financial Instruments Measured"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r190",
      "r193",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of Pre-tax Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Composition of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of the Status of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r43",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r209",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r372",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r377",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r51",
      "r91",
      "r143",
      "r144",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r254",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r242",
      "r243",
      "r244",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r269",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding and Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Common stock purchase price, discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Unvested grant restricted stock units (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Unvested weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for sale (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r379",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares under Option (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r370",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the First Anniversary of Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting at End of Each Successive Three-Month Period Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r372",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of original number of shares subject to the option vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r391",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested stock options outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r520",
      "r527"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term property leases"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r53",
      "r65",
      "r66",
      "r67",
      "r101",
      "r102",
      "r103",
      "r108",
      "r116",
      "r118",
      "r142",
      "r180",
      "r261",
      "r268",
      "r401",
      "r402",
      "r403",
      "r435",
      "r436",
      "r477",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r601",
      "r602",
      "r603",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r142",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Shares available for grant under 2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r30",
      "r31",
      "r261",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Sales of common stock under 2014 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r261",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r261",
      "r268",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock awards and vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r30",
      "r31",
      "r261",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Sales of common stock under 2014 ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r261",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r261",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options and vesting of RSAs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r35",
      "r36",
      "r93",
      "r175",
      "r179",
      "r496",
      "r540"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity (Deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Credit Carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash operating activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.",
        "label": "Time Deposits, at or Above FDIC Insurance Limit",
        "terseLabel": "Insurance coverage limit"
       }
      }
     },
     "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance change"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding for diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 16
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r631": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r632": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r633": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r634": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r635": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r636": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001485003-22-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-22-000033-xbrl.zip
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MSO>U@&#_W7V=9OMHC_I9]W"__O93;97^:?=HS6$?4%)6J&_U;+C.0CWHGB!
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M)@6F8(ZG((D)WE.^T",/44K**-+QON*H.H#7(4229OS'0!SV=#,J89=!V*B
M5!QE' !08NJ\.?R'$DZ^90;/%Z:<;#!]I#'\,Z4:S2!,5G]4$:E"1H-($2T[
M=Y:XC28(Z0-N<5<KDS" JWT%(ZT"FW<U)A.)98C5!J$S;)+0V2= E&DX#22*
M:> IS0=3&]&>%L4?@5.E\,>< #AW=*E(WY9[Y-\ /H/F"&! Z3W+>:]0AK!M
MX*"N&,'R$0U \]PAG=Q_NFRQBS(8F-N7%1IH-CT@+DI3D&ZLZL%7.VLFX<@V
MBY:-,Z:5PD5JSM!NU[*QUK&0OFCM+2 RITE$=J)I#$UQI( @E(HXV5L>PL$>
MZHXU!YV&T: A.%I4J';O:*Q*^Z-,K)NA*=!&,+<)[&00_R(J!X8[J<?7^JQ6
M[\RX;,QNIH)K<( H<Q.'%$.KE"V[KM<L(31FM]WQ(SG(-/%B"6J_/F-2X#@;
MD5L%56B3F( :JPH+&5W%E 5B#6X26KX )H%4+H5U09Z3JT0O,VM41<<H?-?<
MW-:9*%@R"%=VOA9G=(6OZ)D-+#_?U"#GOU&5_AM2@RUY9TSV$BC=,PVI#FC.
ME/0?/46#N<,&<']C_ 4T)=) P.IB 1R7>:;6X5YTQA9<>,2:K!^O3W9\616N
M<3OFP%[A\V7;E"V;:0>^0!4#\&.B,.435KCS12['2A>B43L.][^JKM%M08K"
MMMLD;4.K](\5A,T,WA"K:4#0)N^I0<BA*D":>2 <.9(BS<-\@$'SU"(NL6H5
M EV5?2FN@LWX*M9S@P*RUFC/Y_ND\TTUO*IC1(5"1M:#04(R9%,5IGPMY7BZ
MB@U50PP/:441Y!&L$ 2D*Z,)O S[!)R9*6]F661Z=-A-XJ^_/$.H.(F,> !*
M)V@/*8?D$6@,D38G%*@\<>I42U.!C\XNM%(X#E4$2"3&GAQ3WP5RV7K>*/%P
M;,Q[0'564A:.;]A\BE+&0TQAXAHY[298#D!(-\*89,@3%R=!KQBH;/#62,(4
MY/J#9Y?=KNE28:U5PYNUHLB*8HYF!H$E%('^F->(2P\C)N@< H4EAG<EB7[K
MW"8)1&LD_68(<.#:C0Y+6X"=S*R_D&V3WQVEJ@^OT)@P.YP7O2K]/Y-PL6,7
M/$.%>R:5EQ[+2+C4 4*A>U#K=0ZHIC2UQ^?FQ9G6,0':,^FD)PHO>TJK8.1O
M#M%]D>$(H!KJ5\#399RXY.8W&BOJ(I[@.(@/=(/CQCI#2L^'WMT9&0<I%F8G
M0[QG"7,LW&'A,!  QX,CH50LCYO<*8,T@*T@61PX>ZW^Y;@3S#KA(> IB?'F
M2_&CU@0);8ZYQF!??RAO),*VA/N:E#-3#L>@L(V$YV%8+9)C-*0-?#M(9NX8
M2&^R")!/.*35AKE8'38D 94+**J#EA5RYI0W /T7'][&/B8Z8@3,R@AJ.UF:
M\HL$:D,]]?$9PS0D1C!0U8]MXMJ@9%/@!BF)\C^)M"Y$_"PBFD@X@9K[VK*V
M,W<H?"0J DTZ=(1&"G&L+(DOHGMD2)C]".*E8(%,<_Y,>+G2;,H"5_;U4.M8
M!6:;8UUI=*%"V6T![SEN#^_1P4F,.+-[]%R#2>DVE?4T((SXW=/E6Q*R;+8,
ML"'Y,(?M5-^BL7VYD&4Y5&]X;558)XW- P>N"<JK++H%G%1Z]"<]:U3P%5&C
M"E]1=>96+H;6BC*0D]9PR/=+HJC8 *!9#++)=%GL1QB5_)658,;/2#HJ6!3B
M!:,D],'JKH^6+BL,;2"(T]80Q(!_9F\Y6)+A9BO561N.M7$YB2O[$J2=(9!L
M(NUMN,V%"@XQ2_':TW]N^/"7)7VNK85)(YF0,1>1M"5QC!E_.CT=O4;H>K)B
ME+LSZ:R,:( 5A4$4>C)283F?CX9)&SL\5+I1^1U<O4Z3)*(\M"*Q$!?-JW1:
M? TM/J63Z,DK1:=E7&BZ,"MSART% XV-A<% 4!K]BKQ$\C3#1C$_$DQ*G0*F
M56P$5DZ;6;6_B@,B1$-OGAM59[%NV[WEUIRE'I1.L#;V!(OW)!]*3Z)KTBIH
M/$0;O<8IRATPGK5MT+$Z5<=8_]J1"&M[^:)_<J'M8QM:>RHLRL@*VJDPA*4A
MM41U9K(;M$5\[L$<,^$G""?T'69-(#K4XF7&I5>IBC[D>6@)5VU<TMTJMOH1
MS@ -C4V7P3V AA1J1YTI1Y[Y2EO\.RWU!$S#&,,H5%-+#Y'UX7P"=3/O0TLJ
MZU8H&UV[USN:C768IQSM;#=>>PI:YT=-G5S#!?G?=/TP(OE$>-6]/*R%]&4$
M?!F;M$-TXAM@+'%NY%SZ>^=FQ:EWWE=^D P]Z0#[2;](R/C09J;G^+/Y,U?4
MM3R3YH>F7[.V)?TH#A.GHL%,,Z.$]P[H[@DPI\M-D@,#%9;C2FS;J^;7/E[:
M1!AVSSV4!=FY-R#HNF/I L.NNF "UAJ-LIQ7E,Q9M*[635)=A9!&SO.HOP(B
M67(61FW3<II"K5NI4+,4+BYP1#DRHCDW''&AD@V*.45S81@8C\L5C#9=:BGI
MR.1 "]^F_I13B(#?(6^*/6W_ILE2*5<CGKR\)#,^3S^;8I*""F&#/"LMYI%E
M!:)+@0=;R[K"109\R!XRW,H7NU1(!>TAD]I#0.@CA?F<"TZ9KG:>R=0H%UZ8
M<K<-!8QGK3'VW\K($9['?:&2UC2F>[;UU[#UDWBB0JGS3)"NA6_J39%X,5%@
ML^6F( .0G#]IU6T!C,:Q[D%4#-/KW'#[*F$RU5XJL/AT<07QM'+>7/7N\Z&#
M7)4*3^&&&B-8B XH#VF)8\JB<][-W,M!J&)3\=G)ZD!'E(F2^CQ1VZ0N 7;#
MI)B;;>;8<L62RT H>%W3U2&;S+<:+ ^5Y0*E.RQN<"31"L5+0YEF7B]Q\S;0
M;*LLR5LPX*T%=@6#2S_!QH0-J Y_G&W90=T!D97<0=8)-^).KKZY(K*UNAF*
MC"A3"MX1MH$0HC_F+8&"XJ3@L@6'R[7"2\22ZIOH" -]*XEUOJ;^#A)ECTUU
ML080\E1&IG?>\BS:<P9#3&20^9L*JADM#JLADZ!,0[H8L[J$F*\]GU7C6D"0
M32OU6FG)VG3__;.-VK*&_!ZF$7)05Q4NY+K0AH+2CFS!P9 ^#C4-C&%!V J(
MO\B0RRCEJ0\H#Y65?DN\V3L[/2[Z+^T&!MB6( D7\ HV,-'RCS*77)T.I6VQ
MYVR1# \.6Y(MLBG>TFCO3E.82:ZQU6"2UB:3G5!CX:_J?F6I.>=SI;S"QW1O
MPO"-R7+D#IBC0G][$%B1*TPN8>)[*)4#K#N*S<V\LS@/W#9(P<:5(*U,D:F(
MPF6Q9"T8&B >UXP69^4>&/4(L7-%443F2C'P"7(\I9'7K'8(+@3<?HC!%V,5
MFW(/JE8E)V;J^2M(8(QMB#'(2D<E?B2\A\+2SD1)706"RYF!J/)C'@(8T8;T
MJ(R;^FR(3Z:%C1XV7Z91C,TN==',PL"EM>HQ\#FJGJ#D'*S42.,@.)C>3-Y4
MU)UU6IG:NRV:1)D/M3!&QP<E.?S.YQNGP&I?!)E784*1:U2= NS7ZYJ2[I$*
M'4U15<TMI54J/3Y/DQWN8^/8?P.*'J&A+70. 0]#UR9TYGSX:'[![UI[I;&R
M;+3'?NAT$]"]H1#6<)'G:IJIW6C_5043Z]@[U+)7P]L\EJ;>^6Z.,60VO*X7
M*MH E6UWRZPM37I!/]<3(-LDJ.<^8<@NKZZNWP\N;Z^N6[VI5;SDY8O>\?[%
M]_]WDVSKT1]>;?2G%M=L<OTWM)O[7^-;A+W]37Z,<)V3?41OO(T>4O5GV\II
M(S_8!M=([UBU]C\3,*5'B\=NN?C:)NIUM(X!:S&Y.$/=G)/<B<M):5DO$TPK
M0V.JF%9!I3U@B25>FO.0<S'H[$>34DO/IVIHP"6J)J%*QA/*&$D/(\+#R)P?
MZWX7[XDGT]P2CFV^4R>CJ6,Q'LTRK"L:SD3L$$W5/ATUUM4N=;LM9[SHZEU,
M7@Y#[H^S[%]S,AU]GED+J;I$E ?KLPC%J)U^5:<<6G?J2"HMG$>ZK&4TPNIZ
M_>I8^.2L ON?^J@Z0KC+SY@LJ<J2?9 ,<II,*3\2$#)<Y!-?"IT/JO8D?>JG
M!#J^&OMPTF[%%U6RH%-5P&T;.SRY2#*K5X)[C'1S83@PS"NRS6KR?0UL!W(*
M)"L'4R--/P5#U!V6]G_,F6?4!P)+?V@[.[EFP@4T ;N12T/;!7#C18(Q3YLS
MI.EH->!L8XG5]K"6/I>]7]9<# (E[5=<LH_54V/RB10C=JV]5& GOD.,I3PO
MC#=C1D"N[V^N<2P8[9)R=_6M*24N8*J&AQU6\#XA*GJ)6*#FAEZQRP=&6'6?
M.]T3EGAY+H#+ >"A+Q9TGCI4K(@UU/K&EK/0RBX$[-B5:A557D(C>52:=$A)
M'R;G34L1Y23DX.R8/-QI*K< 7L#VI4.T 9M!-[9NM0UHO2C4[->4)5C10WX-
MS=3*+<>R#;01:9VUD3;_U:%BFV&=4K#4$<Z*ET(5T#?)T:Y"G"4.1;X6K<XE
ME&RYY(O)>.32F79,<Y8T \%F*%M7*F8 8(M(V_EHN5+'HE QJ9R:GT=QH=<4
M!Q*G?<\$Q55  \-!LE*:8EE*;S]7EG*?M<6Y_NQ,2$I?:@]O[^RP;UZ]PRWU
M]H='NSTX=\J;2+PQQ7+T T11\-X#7S@K:%5-P>0GY\=^HRS8^L#X^C!\K!'1
MEG&^?TAU,[ZSYOG45GD8'^ML>\;#MN-AGN=E3DS6X)/_NY\8-C>N.:4GG=?*
MXVF(MWJM#XCL#96[@/\F\=1[_5]02P,$%     @ =49<5 L[TL#K%@  4[0
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M$<>WYJX-HO&_A!6:[\(D)V8E.3&85PABY8<S3 46LT5P*7V:/)+2;,?GP6K
M<@OE%'Q%6)'= $AGUG;N)G&=X#E=QDD,%Q(V T)-+[-U;E)=\#*>T7BU9Q0T
M@?;WGW>J6A+(<D$&1"G;'LXX70'B@Z9)YU!SHE)_:A?65 ?"MQD;<O !@!&
MX;%8 :0,: ?T.2+@?G(80+<H5[!@AFAG6(&EYG-0JP&R>XO])V:'N[@SY'8(
ME!%];<MDNXW&K/\V7>JED23788]8Y,%T'D#'8)$I)B=LV+;611>68,?K[[?U
M&N.W_;?>EF?_;-M**[$P'E19HO\EN.]B893,J=(F /22% ]:N0/7H_J!L&:N
MM *B("6UQ PF"5L!%X'=%7 K'L^HM9K))%C81S/Y6NB;DC'6M<:Q@,@/U,<H
MYPW1+I)UWGPK!9F<JO5C,+K!XVV!NDZZB6^_F FXTF\9EWZ!$P+:"W3"USP.
M_?<Q'H6*9VBCU7(<7 <=H8K]?S1>P@WTX] ^R# 42>D^4# ]6P86A,IP <SQ
M @Q=2A@TF1M0A=1ZU2R#>%)H O#>>^&%@NC?[Q!VJ-\ JSJ$C<F>'MJQU_/9
MBS>A;%>#?(BWD$!Z6SC@ OF5,1YL6,QBX$31AH^! CAM'!L3*CG/*>M>E$RX
MQY>&'?#9(?\&PWB1'T3D!"O8>XN8\#B6A.QH>JIC869;&9-2< .,.U&1'R+G
M[W<'KYC-EPDNP>Q4N^PH- EV,&AW3WX\[*![W#[J_?AA^X/VZ8]!,_S4P+_J
MY&VUTOQQJ-0-:57.<M>'1%_H#YCL#R3+CX(WUIEN-Q5^CM&R0VW2R9)<Y$WY
M6M_NZ:7X9\,Z7,)'./WU=/ZA,SMNGVP4.Y:JZ;A%!X-VKVSNT!?4OE&W4$;^
M>VFLZCU^W?GE655M#<"&'T?'I^??>_;M6=]4@YSGGJ.6$/#="8PHT?_^231/
M[UGSE':[_ZQYGE[S/-E1II]--[V7+B@A^?,X0_UM5=).6*=N,MC;1FG5YVA;
MG4FZ@5K;ZDQ;I4+!&DRN*'. @+E=P:7J4G73I4?*;ZX-]=)L?9*_ESJ)&<HY
M9G4Q-VLI<-\$)7DG$5SM@2[".%VXOG(<"MGQ,@)YP%*",+*7,2S(U!FRF7M?
M3"-09\I?LHD0-D(7J>K \0R?K?Q '_##X=ZI&-1U)7UAP2U!\ZKAM(8Z).U;
M&JBHMWG#8TR9"F=39;)7/YG<-!RJELZ3SB]&"L*9],/E0;A0;+_?>\5$/'"V
M;J8_LK.5.!0< L9A[2T:!]*6W$>P:ES22=L3@+#.N72_:Y0U99 _QVMU/'V1
M_;FSTQ+U%<)^_83P$;]_M64LXD@M'LS NCET/ZA85S%'+;#6.>,N.TVE55LS
M[GF^PN'&D3T5X<L7@V-8 Y@W'IC#S<"J,W8EK+A&K?M;]$C8_BN"J9FJ=66!
M\7'YJ0U*J=\8E-)[Y4^$#"-=@?[LZL*TKFE0_>)2!$$"IKC70.FF8)IVM/O[
M_%5MMK_7/D8Z#+]9PM-2B&B8A0P$0VF5B 27;@(>Z.^/T9W2=@YT@\'7%J$"
ME@"G-T!?.$9:I1CZ DX>'6C\'VQ%@$SDHQK1?[0TG!H^PO]5!,/R*! MAOHI
M@[I(;7YD^#/ME0#N/+%N$%DSF)9AUD3)332#XS+G<P&6/!2.-N\\ C[A%%$Z
MR\*T6\F4*K 7^?,#5< /,9D@01],I^7\Y&* 1I:>>KK4'@+(,XE\W"4-M TJ
M0>=13E)C&N<@'PGRBD8E*),, GWP)S^B/LD#L[J>E#8Z9I(@M[\\=8N6A;BE
M%6]VW,,DJ#BY@$R#HP;%TQ<%SM$TD2XLD]LZYH(!; T\GFC(37RO7A!1.9U9
M$S3%N$Z:HD.$N)ZT8'^D2B!-QMUM%9DC<12T$TV;2QOQJ",-_&!@>F77&YY,
MB,Y)^3XCE)>H)]@^")<M)CH(1PS@*YJB6\!<:20?XJX,UFZ%]B@@!S.K>@R<
M!ZZ/ WH$1:O2YZ*#-]F4P7> !UN)3J.EK-=F)35I8\RC2O*=;.'*M:=-RPFG
M%A2!:DP[$TM,HA 5D>X;P<TX+A&&@?\]GUMA3,"T:]*?G/<XPD9-I(^T):O$
MMYG-MRF@8W@^THM\"*5$4#Y*TDK0]"8U0YP8)R*R6AROFPON$EE S<J)%,F!
MK4=DB">JLBA-#5!I@\:XON9L%AV& /:A=_* 76F*=ULKQ'[)EW$5_"8<!U5?
M(*>@OL*8OF!>Z#QQB\V6'KJC%LFXGW%-$24*$@@"V$)=J;S,84V'+_(7[R.X
M5+M;H/EBN30/2Z#K/ 9>MXRS)#'O@;CIT!Q_&96<#UP$G0']=R2-%L.W+*'.
M0K%4"U=CP,SH.#AZ6:+"'U,:N!M/#/0\H='5/%&;0<95,Y?Y6FL\2.4D%" C
M&9]S,(Y4A;)J@+)XW1QEH5UQ/#_+[M$0SI1C/^N*'Z,K3-SC9XA,YP<UD8NE
MD6(\%,MKE7.2/7ZR(OI1:9P9N:%TZ$^ZUK42UV/5\&6O)N^^5)PA:,0QNZ/&
M".9M00/F6ZX\R^7W]3<-2L=/*LF,1^DLY2US+4,FD>_*8+;ZC$G13C5!((X;
M(Q C_HU]Y!!(^KOM#<*:L*VU2]6N[023].)!L<%..Z?G["8]^76"V5LV=/2?
M.][\HJ7/-!**$[HS<OH#LK9DCC&MJC, 8/+'(9>N,:/<?I#6VCP >.)X)HZN
M#!!.467DN6FE0]:^XF5L>B9Q,D,Y&$]@+AG]\V1@O WC J53"T$(T0OM!ZXF
MZ93 PZRNS*2V8N<=$SQ\2K=5S127@FEF"#QT&E57@9$<*NM)%*E,W )3<NV@
M.G&_;Z:?F=:K-%M>W(:5:1>8GR/Y6#HR7*9>%O<Q()/48L>-N9*6M[N2]Q/V
MBC[=2#8N*%+]?,^ZO:.3/GQV_- N'O.H0\V]-CI:YUPA M=;W4J<:F!E*C(#
MG^J$@301\AH)*>LA"#Q$K#.U_!04:CS>->8+7.ZP.\PF1B@]MLAV5-(PI <N
MG<HH(YY/$XQB[:H2ZZSB%Z SQHF[[K7Q"*M1CAY=WHQBSO8*RS76 6Z*@&LF
MOIJ;XF-@,C]?(5K(ILHB49E<Q]*KP"*ET](VJL4<A7!)DSN+CY!G1TWR7.,E
MI=DTU!$9>2:<ZN971A8+4G<1QB45K*_$JRO8631"^A6I\13F,$D?82NN<KUH
M[$@++$GR$B/&QZ8<F[&F8>&@>ZE&%9NVN.>^CNW=(/0CJZ+%6CUQEO<6Q%(1
M:)2+7?(W@Y""XTQ,X\?Z U0O3$F,W7,'%7BZ[W6 K1JYP#*11@G 7(-)6DE#
M)TN!'$P-:J"B/F\KH44IR^%K%IZ6=K&G75JV-')LFT)OJ5*5TUYR$IO*S!"D
M,4KA/D(Y%B)6-CQ6"]FGF;*J!U)8,-]Z'G$MLPP-P)8R;HA=X"G5D%1$$[P&
MZ<_BE$S)=JZB7#N-7)8_J_;RY>FTNT:A3F :@:S+1I;UM$XY2IURH?V7M%:L
M,<# R9P6J97+E@FP%4T#\OPGC<F>?)2!)1R'NT)%C>FM^IP\V2!Y$H4SY6.T
MJJ6R GBQ8_?Q&L7YJPYLEJ!.+)-O15<M^9S'>KS*&9OKM!]$WQIT09JKC%]8
M 3O)U&(R #R>T T]V"P<!?].%'$F79RYV?-5J&.IH)7B#3&Q8) 0(&GH+E(C
M);-@<I7C9:Y'RI2)D$MCYSMV9;KEEH=*,AOI"O,+G$B,_?"C,;C*5-,IF<@F
MR&RC8KL;Q>Y,3'0)@TN(N^U:H)"WB_9:Z"$@LU)JSF0U)]S*P&LK2H7H%%BT
M;,P4ZFZ?R.$@/QC 60E%# RR"&(MR$/B+&)J$1PG]!?!#8S?14?8A3FX<S @
MR.I<!G$_U^)3='H.AIA)+X4HY7PLFAQB-".O+"8:(EJ-;>4;/Z\YD*A]JTXR
M]XB=-+FO0>=TI_&FD3#*U&/>'KDRT^ZNV [=%X3HH=;FVH&'B&CNQ4& .>RY
M3/DG=JV3W$IVX6MS?OAE]_3D*)_[,]6$$6+;(W\)M]!I4+)B! FR-=)(QTW[
MM8Z<Z\($F;:,R QQB$4NW(H0:W7O1BI0Q( N;H&3+_0K-S%[+&*D5>0ZJ @]
M!)6&\9?9I%B6+DU0/':=%,]CQKZJSI26/+6@UD$C;5;4U._CVI>O*+OKXQ&&
MO,K2Y=M]&5]!X7Q2/DRQPO"!Q\T;6EPQ5:'DB7>JDSY)UB2G$3&'*Z:@NRP5
MN8%P'JN>6C-%-5:?IO.@G,@-N0]D1,_<(=@Z';@07^/C+'K89!FPCGSUL=!V
M/*UEEN:JQ\#K]N7#*XTA011[DA[&P?1BL@ZX/F732.#COJB39#[B$GS <))J
M\;_SQ<XEL#K"(X_6CZ@*AT8;Q":,W^,BL(A@:8D"Q:]\FY!]B2,@C9%W^"*I
MV-^'\<&#*W ^B0W-V1,?^-"W#>XPD_]$CQ=^U]X$C96"IK9]A^\NJ'M-F?WQ
M,JO5M%*[UEF!"B76,M_0BR TO>/+$H28:V<40QH9(06+/EGE>PK*JBU!;F#V
MH.%OCOZ>=\T^@R;J!IJH'U]EWOK*+BXOA[>CBYO+8>T%8IT=>OFB>]0Y?_J?
MNS1Y6[^/NM9OH-VPC\.S?FN>?EN_HX^]YO.ING:7L10;3[49"]P \[!N[O^*
M@E!.EMLN.7_;+@X5:0\3YA(#5,:Z30,E]XK0J_3]&0B>PE Z#TB@\T<0AT=.
M@A;(Y)/T,3\W/36<!B$>E^B8^BJ:S@A?D6Q&@)N19JTV?5WJ=^Y,?<^9[/-7
MJZPL=9O!K2G2NN(E)P'K8:*B3UN-AT1QRY)(+/^6%KT[^B@JXJ]]G[O3%-T<
M[TQ+[V?Z]J(5^<7'#Y$1B]$+>:K>SD+S3KJME";. WWV9C*1EHR;94R%2ZE*
MY@KJQV$)81>OB:%#V84GR1W0_G(>S0D%&%%WP@R8) ,PJJXI2Y?:#4"$IZ8N
M[+1=\>;3M,I3E7?=3[HGK)\)KC'0_6)@PQ"18P[B8TQO.1%=Y?$E-F?4Q5E%
M;:X"8454H2:A;K&D74PF.$<:X0;KY;Q*\_5Y-O$%'CN(>2%+;OR0:*P+TVG/
M")CF"G(V\1S8_GBE?!9SGR99X'E*FC=#W@+S2-N$Z)<S*29LJ'.4#X)]0HXE
MA!36<+'*7MT_QF9"$D)5?S4G, #"'QSL"X+?$Z/JEIW4D(QV8ZQ+FI0HC5O#
MD"[/5$PY$-QWQ9+V4Y=?%:F&E9G1O/!7)9!@]-2KJ,H1QY9')1 ] E+$:#%M
M190547J[%8-3YXG=LK#G+9"-9(/K(H;NG@1LO<P=3J\X=I%1<#JKI95:J8Z6
M64 3F=;:F&FS;S+-=QO29?I"PQ1C7G)'E?X2X'(5XQ0T%&7:M#L7$4RQD(E+
M=61A3ULZU9:6_ ULUR32L>2.'5A,'Y/B82/#0GFD-;7!"L)<GQ(.(D[K?A!4
M50,/# =)CPKE#UAT.YD#%O=:C6.?G^$W:T96^D+G][NG_4%\ZQTNJ=L9OS[H
MPKX34"%RIE3)TQ>01,%]JSFY[%75A9/KABQ=?5AE<QIN&T0T99RGKX7O)ONU
MZN>VB:GG'6_ZCF>U2YKP8S7>^;_[CF';OA6[]%W[M79[GC.[/R"S>SA6]A+^
MFX5SY^W_ U!+ P04    " !U1EQ4_N\-Q;!&   .TP$ '@   &5X:&EB:70Q
M,#A?9F]R;6EN9&5M;FEF:6-A+FAT;>U]67,;1Y;N^_T5=>48#QE1@KAI=SN"
M%NEN==NR0U*/XSY-)% )H*Q"%;H64IA??\^66U4")+4T 0TF)MPB4,C*Y>39
MSW=^^+\7O[UZ__]^OTSF[:)(?O_G3[^\?I4\>/CHT1^GKQX]NGA_D?SM_:^_
M)&>CH^/D?:W*)F_SJE3%HT>7;QXD#^9MNWSQZ-'U]?7H^G14U;-'[]\^PJ'.
M'A55U>A1UF8/?OP!/X'_:I7]^']^^+\/'R87U:1;Z+)-)K56K<Z2KLG+6?)'
MIIL/R<.'\M2K:KFJ\]F\34Z.3DZ2/ZKZ0WZE^/LV;PO]HQGGAT?\]P^/Z"4_
MC*ML]>,/67Z5Y-E?'N39^/3X]/3LZ=%T_/QL?#113YX^>7SV_(F>/'Z>C2='
M_WT,DWP$C_-OFG95Z+\\6.3EP[G&][]X>K)L7U[G63M_<7QT]!\/@N=:_;%]
MJ(I\5KZ@V<*WTPK6)E]/JJ*J7WQW1/_W$K]Y.%6+O%B]^,_W^4(WR1M]G;RM
M%JK\S[2!'7[8Z#J?\H--_C_ZQ3&^G/Z\EMG .$5>:C,[GM+EQWD^SMOD^&CT
M[(='^+Q9TW!EJI[!XL95VU:+%\?/8'QO$1/84%W?RRIX&IF>5+5"0GO1E9FN
M\:D'/[Y^<W'YZYO7/[]^=?[^]6]ODO._OKV\_/7RS?MPL>N7>6*6F<.@9?OB
M],GRZY_56?2LWL_S)GD-TUB4^32?T%J3\UFM-=V*@^^_>W9R<O32?D)_'[\\
M3.!G"Y7I1#5)-4V^_^[Y\4O\[^G+%.Z(]V<R7B6JS)*Q;J^U+I-WNH'__I17
M*;QV,DH3E5SH0EVK6B>PV4O9[^2@G>M$WOZJ6BQ5N3+O3FE _QW^P[*85FOS
M_"BA5;I5-=U2UXV&.TXCU7I9J G]P7-519$L:WV55YWWL\:N =\F<Z+GW2MA
M"5=P$,!!\)FF&_^I)RUL5 MTC/O4!A,9);>EF.VY& ]^?'OYZO7[\U_>[2"U
M__&WR[>7Y^_29 X?%BLXK<52MT@22!!5V21S=:7AG.$+G2PJH,E:%]VD5?!(
M6R7P6OAZV8V+?%*L8.PB\XFVP=N0Y36<>54W*1PX7"D8.*GJ)"^3"FBB3B9J
MJ28@O&!575GHID%2 3J"=RWKZBK/0 A=Y^T\@=OUKPYD$G[<PI!X*]IY776S
M.8S6=" $)QJ'M@_FO7NL9@H>;.'SJL[R$A^I\^8#W=A)H?(%T[^:R.3E<9C/
M N:3DR2LNI8)5^<UK1]6A%MA?GC%2X&WC?5<%5-YV-^6[[][_/SE+E,+KN>G
M2M49+N["G*]9J>$$/A.BIRVOG"-9 )W5(,CA=-NY:E,BB!ID"FUFV]:PF<*-
M6CB&!$ZT@).$QV$C8)<S^+M)@Q=>Y\"GD+4LED2="_@=_1:/'O\[J_ $QZK)
MX9<*Z !X6%,5.M$?E[IL=)H4N1KG1=ZN/(J"D83B[*V@<Q>FYC,^&K ;-WF6
M [W SD_K:I$ R=,TS.#PQ2@Y+]HYD2Z.,>WJ,F_F1%]3&&'B4S3NUAC9K$HF
M70-$H6I^&Z@]N@&^K#*8(-(>/*P6L,SDG\A\L^1="R3>/(0%Z_Z]A)_S]1NC
M@H>WCECH$JA<][9UK(M<7^E&SFF67\%<)EU=(Y^ R7S0H"U6<"ANZ!:^RV"8
MWDH6"D=+U)7*"S4N:&MSO(ZR"6T'E[XJ@1'!X2!+@OG!^A9Y)S>3^ "Q(?UQ
M4L#,X86PE2U+%P4\J@6"3V,\)_76;(X17NS=X&"#JOC.$%L::SRHO$05&7D"
MS%<D&Q)S)=0$V\1[ 3-Z"/O3= O\&9[_C-D1L%+X!Y(1"'\^.)Y?BY0 ,V8Y
MR1L/>ZHRT?'AA==5![Q6N#.<QYCX8"N[YQB7/<7X@I!B=3%%C0 >!3IE9JF1
M#$$=\?2/_N56C=MT<ZX@PY%;$]'CLG$S^$!\Y67#6RR'J(&#PQDV Q8NT["2
M!'<X6\.!1KXB@G,$CE'A1&']:)308?5?L.SJIA/QAF/]59>Z5@6,Z?;B%W5M
M7D57C-B@4=I\MG?QUU>_^%K7#7M,Y (/X<^0BF #&CA.$8-"!O.A7*,'Z#(
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M&!4<<,^I<Z%ZC@;*4/"\"A[)!3K!AK4K,FT'CG6OHH$Z;4US[L"E,B0@@W_
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M$Q-XG!#()CDF'-%M>O/-&[.3_'X+PS;O(K!69P1KE4]OB(;J!=4+L]5I+>'
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M3& I[K.,NQ'7=7K:C))X.^PN#@>M 4"3424[?MT,)0GV*):M </G" '[:?'
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MM$Z:9=71&+SQ:8('U&!_Z"L8&S4S=A+9 \H0E*OA!';^B"?$*>&U1DFIJ1W
M%4:%=EG./=TE.?<.,Q<DSGB_XNUU/WD(^=Z&(@;'5PA'WP G2_U%7C!E]8%H
M;'Q8"G*O0=(U%6Z")QOA%M PL"<I4RA&89%H]W'$G8@CGNSCB/LXXB<2CV46
MG'MATST6TLIF(T_R%!#C$*&T1U._I"AL6/L*K9$;P\%029"7VHP6/[?R]EQ/
M<&6D1$-0\6_\E0\6Z\' <J(AP].B:@6:!CO2C/O1ZA6\:8&.=[L2)D[8I@X]
MX:)#F=!'/*>:HL7 4Q $HS!K$!XBK2M(NS7A <JB"5*.Q,%A$F#6YT*Z_D0'
MD\-U2ZU 99(CV5REYQ%3^@U1$\.T@"K884"E$@V8=CVZTW"A\RG7I F%[72Y
MQ;-=T@XO7;WE3B9U;F?5@C'.7!L39$HY^@#)5O+\P#G#TI$F1ZA&0_-:[-]N
MP1<DB-X ;ZZDD0..Q/R9FHM03)9"7-TDQ$T,'#LV,=$!L_=,S&$?VHV1-@0>
MTUR;)]ZI?I(_OIV8U.W>OY-TN8W)Q@-I8<$Z2926;5[K-4&AGL>F'W*@0)[@
M DO#*2D,X<9EF)RB,PS@8*X*5638]_"5()9D"@@I'1FQF4Q5,>7C+ZB_0/I%
MYK6YM>,0WE5Q?P,;G9," 0GLF$+ANU3U\*WNE04YQ2HL25+LD:+38AE),+8E
MAUBSG%PO<_(122REEZ@4PJ::"O1=EK+/=TG*_EIEH0OV#XQNUO?KCGE3>42=
M)@M_CDA)IE1JDV/&.GS+ KVBDI)&=P/OKC2>'MY4JOJA$*]S7TYOUI?[Y@"Z
M:HVWU5P/U1^7O) ;ARWM.&P!T<^#(<6;2U9?>'0[>'=.CG;I[KSA.H<@Z'+/
M?LQ>D+B1D@S&,<"ZC&D/J,'=!E*)QIK1C^LK X7"]MIB04TY)M;^ ZZ_K'2I
M,&P!X@_+@0C[(Y^T)A(4=+5A6C>YFEY(J(HTC!2!R($TZ>32.'#_.X3.3"E0
M#]O$=!89U.\WT5UR@J^V#>E"E)$P%XDGGK<NX62(MK(.H,,KMMOEBWR\>Q>Y
M^=I3IA%?P!4"S>HNM?KW<9#G3/"X+:F!SJ$8&XR<^4$T##YWI5S%-8A'5CAZ
M["9(7HLUD,^ZPI2O8C=J=0A/%;FM[)LK26F48CC)(/9D^HHKXJM%TBAND$E5
M:75LX@,D2S;^4 %'3^ "^ 6_UO76HI+36=ZP=8Q/,,,$J[?%LD"PKS%_SL*V
M<B:.#=-B<_9>YH//.7*J3.;WIN32<W. @;N65'/D;B4E,B%V5RX9 E]W1RAY
M IMY24;85$T:4//1OPKF1B.0EK89J*U41+O).!M,!W#3K-[_I6L^85*?*3JV
MBZ;V]KF 7D_[R%621 8/4[X8B7#*>!.RQ1B[:E%88E FEO-120&K=-&0@50S
M3.(Q&;>NJ</>B_(%(=>GO8U-*"JPX>H$XU ,S7Q2V[#:O2D2P%^2G_(*2[PG
M(PSBG9P]3GZFM/%W+1 ?4-Z[#H@+.VX<[6/C.Q$;/]W'QG<_-OYRB]G&*[48
MUWDV \'VZWER=')\=H)K/$=?+:-W8Z)-\FJ>ZRDP$]- ]C=V[]]!$-W3^MBM
MZIQ'GK2UMB;I3M.N1L?KNJZWGRMZM\'$/-DE$_-5Y:H,[CF5>WT6!&<'K $&
MRZ=^&9?K2.?7;PY1%7,T"1U"RK"#:C0?+JBEIJSB(M>=GS:]"IM&^+FMM,U6
MR90:J'@)E0/*FC(\EBF+HEJHH#I*?YQ0)J[Z2$TF_ HIOI2($SVLE_(*2O 5
MK@9K#2 LE\>$[K%>(2I7I,=+T//2)E>8Y Q%'23%PIZJW-B(MJ4S[:X4PW@)
MQ6&?Y3A.@8WEUGJ*Q8-2]Z<3HUXYG"U;QQIR(&L>8R[^G"JOPFH7]P"=DSP2
M(BC8.OV#YM#?<3(KN<8<OYGE%-P5B.6JOR";06-^+L5[WFJFRGNCT;(/*.1F
M*H=O@#.2*#M2V>&GK3U".+20FS=@I[G]Z2YQ^W/'.W^1["X0 (V$:/_>U7F#
MGO+[EP7#= XJV9'$^$*<>L#MI(VAB959S]V,7%!TK9EZ77Z5!S^?14!-4JD.
MNK:%"HB+2!X&@V48J^S$BX9>I"+G:AL:H,8^D*-$4 5B98=Q+/[;U,M$>]:$
M8!^]^CR3Z^+5C'(B =8%DRU)Q1O4.,:5\GFHDIQI:/BL FJAP$@G?K1X1Y<U
M85!!%B<L:\'"LE"1KQ#PGX_-R[-D9M/P88#8TD#6Y+K#[@ RQ#]+PD:G$Z/S
MD^:;IB35/NP&G*#$1%QE8JL3=QV:;KS(O<IB@Y[XIW=-#(F$4Q^T8/^2>VA*
M@$$/JBBZ%29V"AP#.E4E&=&5ZWBQ*LHHXAP,F@ZYV-91NT\Q3%^N2/H]MKA/
M7I'O@&0ZIJ?,)&\I.AX^Y69I6Q/PCTCUFN!U,2DB?.F]2<;4$ZYZC>ZP%+%Z
M^V*ABZB27AHP$-(*4IRI<J#%3$W,D:*0WAC<&)CNB\'_C^\=-82F"+A$X_[4
M%J"-&0VIC/ ;D).=Q>9<OZ -E^7 O"IU27/<H[M*EMAW251"A!E)/;7.WO/U
M;S7W-?IVYQKW'D/]<('Z'J-[YLAE8(FYG'*WV&FQ?[9+8O\U;AMPP0*/BZK=
M@(:_>ECQ3B)>HNE^.@QJGQATQY8O$V_>DN1M*UI9IA#C0%^^8;M!^ [S\Y&D
M\QG5T((A9DP*'J.M9FQO#9)C<!9&_R!^X76,^0V%%SY@VM28.2;2G#N(<1E.
M1(&N7D5%;A$&2KAPC>O#C:FH&:/I@C5K #D(&5?;'+J@C\TNWZJ=PMW_-6\F
MNBA4J:ONGB_3/QN;3;E0S:3#1Y!Z2B#)6#2;BRATTC4V=@9&I,:D2.^'UZ@P
MHIX!3+Q&-!Y.4IES []U#9^ QG5M@KR6YT^D;<FZ?$VN0C&7CNY0%$Z]K7QP
M#5'J1: *6,0GPDA]I?#'[4Z0*MVW*\WCO:WPRDR".0**(<$8;'%K,N"52<9P
M%3[<ZSV@LOXOP/\VA\SVH;MM"MV=[4-WGQBZ0U+*L[\\R+/QZ?'IZ=G3H^GX
M^=GX:**>/'WR^.SY$SUY_#P;3X[^^^S!%H;[[HE3O_>\359;[8M!ZSJB;"H0
M>83DPMAR#@)<C:NK.Z$>WHH];<U.O;M\=_DF^>GU;VGR^LVK3UCGOWO"/ZTH
M#'L3SM1V7?!UL_U2__5I[3X.Y0W87/MCV:)5/R#VPYD)^X/Y'#2ZW6+GK]]<
M7/[ZYO7[R\MMG^M]'O^>C>[4<6T[*3_X\9PSJ8*$V?^=9W1?HF[[YK4_C6V:
MUS:<QG8YJ;8T07BCOO7C#URZ9+<!4\@>(OB\6C;ZA?G'2VQZ7*C5B[PD.J ?
MO0S?]1CF?87U6!-5B(..2(2_=DL:'?&R6IA.FYDWR]<C^NI1FPV_.ST=/3]9
M__71Z'CM=QN'/1X]/WK^Y8<]&CU[NOZG_K"/:"?J'@T?G]+1M9C#4S1+5?[E
MP?,'O5*1%T?),3VU:9SCP3BGF\?Y.H_2[!X1X=R+5_=&GG;R#+TWD[G.NH*B
M0[\B5#+FHU_DTZFN-65>ME5R^7&>C_,V.3X:G=S&32V=.FYE]ZS]V;][(Z@N
M&VY_=8UY$#:+DM/(N.L/M53EE$IN!R'^P0#%UF8F.S^A342Q2:=A9)NZ-@3
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M+]YD.Q?5NCR&PSM'OO^DSM]AZ,8]73NZ+F<D.@54L%PR8)!G#[PF2,>1I\@
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M;Y!F2[3Q905H._RKE/3[F"_^ U!+ P04    " !U1EQ4&RYT@B4#   B#P
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M%EH'L=T<7),1#',$U2(23!;#L->X;'T_N$1RR6#F$43SF:X"*,$<BM5".<^
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M4,((:=H.I&&7:9KSF#U"IK1E*J6)2EBC7OD7BY1&&V"1-"&:C(%K!CBP@MU
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MG&!I(J*D3D5XYA1LLP\8)TBELM9>"B&K!NN)V0?D/(^(.#3'1N><@_9!+,3
M/%$.1R(C9M%S$T#GP=@Q%PCC?HZCT683C?H@0, \>F6T8XA39H(QD7&M@O"6
M&FNCJ$&.Q1S$!L\HI\&HU&S&6P*@DT%Q@2W'H/0RZGE@-8A97X:33X(RTPLG
M-P38+<#/VB 9"V A4>F\H\A2*Z@.\YO*_Q.(?<S;@P\'IN@8%P;]5"7I3>]]
MWS\P$YY6ZCYEG&K!,)98,12E @TU1*6I0_J\_?63I.1:4AD-AC)J&9@OD;E(
M=,1$B$!2/JJPJ 9-BN:ES.?#%&8B%$4;&37&,DTHD)S&SJ:$80_&()E_NWT.
MP3,]0QV(AT<I9>!$,.NP 9, &YYB$9#T)"P8]3Q./=6'.>,UFH'2(!CCA@DD
M=? N,&219(:Y4<69Q2&D1X?4]&C*1VQ"\E6:X)G&V,;HD+<B>.RE,S6(E9^W
M&K8/8XRG:G4 (ZDH9=)XJP,R-L6B^VBPJD%$^AR#:8JN9!R0XDYB2ST+J08:
M0B'0Z )1QIL:Y+[="4S;O=C_;HHP>7'7>:$GXC!8M48I(R-+WD;O0421B+")
MW&*[8/3TV(":'D7%U!O!><]\U,Q$9KC5T:9"4\A0PFN0##B/9;@?A*:D"#QJ
M$9CUD@F.+2$\(JH)4<(A4H/8\CD'U12IBA.+J.3:1I1"_RT/6+I(C'3,(#O'
M?HAE[?/9U#Y_$([A ,,($2G_!.Q%JA4/5$IM Y%6!3/'4GB)AC-'P^EQ0^D%
M 1SC&H'6KH@V+')%7(PQ>"1D'8(#YA1':M3<<EYX(@.ER2HA"$6IM*@VAO@H
M:8A>PY4Z:%%+9%P8SBAB8)AXA)Q'P!FKODC,>1T\YZ(>E30>'QGGA9/HB /&
M*$HN-.,!^ >E3%&73OF5875(U:P;\*9(>=PK&IF&_PQ#@NNHG.5.*XD%8_)Z
MFZHY#5F_0XK$E$+6#:/1!">P")@)210-E&'%"' MS\PCUB:_CTDQD[9&OU 4
M_;PY5=M\+P<_ZD\UNCB>8^(659*SR(+'&#//I..*"T:"DX@X[966-0C,GM!.
M?+,Z3>C.MD]9^5>\B0>#?O$R7;@S#B@<4O@IM4(K%K0STC 1;>J/'D,(<]P4
M8R:@GY8B<0[-?B@ZMU-UNC().,^G<L;?F"DO>XQ@";NP=F?4")2'8+S%Z6@
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M1@\+<.R8D]5!_Z!7P)Y?U9W7X&K9S]V;X9O6Q%H57%+!F?,I\@Y1I+T-Q"E
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MO"Z)>TG<\T\#E^A[X5($QY1<$6ER(0"%EU?(=B<UB!MV&@"->G@V-U2P&QN
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M6MG@Q9&A-#531-RM/LZ_9/'5FNJKAUE(U;'A?;!A/6@09<R-"I&MJ?VFSD>
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MP1*!]X+.;89_V+WBGF[&%N:IT9AG7I_@*N6SWJ4AO_JW/20'YU7E67, FAG
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M!: ';$+U(]C:)4^40-^M4A+&!@M)ABS'%\P@\+PY>[B9[ZA;S4+O&Q [9A+
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MB.[(0"^BG#N(/&2-\!:C!W7>K' 3BS0-<AG"A](@X9KD)O-<'\BG5\IH[HI
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MS7D7";:T/?DF17((STG2/%)OK7%J:*2:"SBK<5]F''\B:[RN[HH'24!S:#K
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M]8Q1Z"ZU(P+F,_Y>.EC7-^0_3@X.O:%2@9\DI02@%'3B/K9V'WD-?!W&M%2
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MG1SZ$]$@0#J/X>D-NHANEY7IF/@A;N?1.4*Z3Q_WCY]V3-RE93HF?HC;>30
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M Y(L??S7FT?7W#_'0!W7!)+]B0^CT+S!@?="<G8,U\/>(WPEH <V4PL?J(E
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MR"S?>X0?$(G-RRPO?2DA-9+ FY!Y W+DF[A/ZV&A\D2?ZVZR=.''Q:(_)%<
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MEYK^@H2APA!R?7'DR D3P3:)S_&,3!BU5/,%:QL,@[>,_=UNGW,9=5M$J$U
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MK'7]E2FGHXBCC!IB6AK5GDCIRU7ITIKUYJ%/X#3;V[<F49P=C5*6=UP@PY+
MG@H<-8V6 /-U+H640U&H8,W?)$K_)[&TCRQZ\3RNURV=V=6I-8$^?VLAM%!Y
M+%",)4ZZ5B+[-E CAI]YZB'?/"H42>7M6+G3R2B-)*!*H5([0*W<$BEC&"5
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ML0I\?ZA[9 +>/S!PX]'"A*4"?V(CC"%R#$EM5N!'139B702E,3ZKN?EFZU0
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M.O'^J/T)C]K[5\]OA2R[EM'UAQ^>CUIBH(W(8"+ ;I\5D],BDQP,^+A")1(
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MX&+JKJ0^,J5#5YT&@"XW \(_K/=:FORXBP++<2^.%&XA57.#3"&G2?;41/9
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M#WXH:=9"2#9/Y69&[X)-$ZVL[I0XIU74@YC9Y#*H"^\>$*CUT[X:&J$/,G*
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M1,?(0DP#?USCK'9?I357R<:[SF>A:#E&@X(T2@)]+#O4MT_9@:(FX49AF,7
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M'EMLJYK2Y6)/0'O32,PF7T8J.>/TNV(!M?^.G[5NLP;*Z-6S60$_W+UB)_N
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M/B'W07@P7U>.)&^4OF!L\/,4E"Q0808"\"XW>F@2H$.)UE&=[]47=MK\@),
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MYS2"3#1D0#V>]J1P5OV K?WJZ!BQDYAR3%+#;N(T12:W\<YM2#6RUJ/AJ(-
M\ZS&Y6)F$'KI#,R 7NDP8)?P>8&&H^&._5#,:*$^E4R]<8%.>^6L%Z&*0]5P
MVX81AX1?XKX/.^%<D3-*X)Q-!YDX8(:Z328#B)8>CS!\W]29!QHZ8G"V@YPD
M14'T:83M;K.U^>N+Z4>QDIYG?10P6K=TJM<UK 4LM:&*H<?Q$KDKTI 2:4G@
MOOG;78UI*-U@.?,GHQA*WC9L!I/PL/ J7Z'%V;J51JADP)<MD- V=@[M-D)/
MVIW7JD+PU@>FK)ZX-6QN9_!NT+';06P9*YEXM:\N7<7^O R:S:L1$6?Y,GZ1
M(=U23Z=A-?<*Z>\8++P!L]T+G2&8RH?5?)X+VET=[>SH+,>*T"M1#HDJQ0_S
MXR,M4^R6?@^&;<3YP;=8]9]%RK\P.:'']48"4.QA2WU]#8>KT.HIJ96RIDE!
M</MYNP'@!:V$@$AFD5@<!X*2TT;3=.$Y&VPC;1@6;*J!]QTW"0]"WQ7EB8>"
M]NZVV%I92T&KEJF4J2H+I?KN2/$\VI EC<F1%S_) C@M(S=S:=&T&:)-EKGO
MY'/ZUJYB%/@MLIV7,EZ(VN#J?W8[MYD 8NCT_Y.<U4@5RV;*"OHVM4^NN$1Q
MUI$TBC'E;#*CO8+2IJE$B"C-6,):SDG;MS4G"&ZKXKH<7"B0.3@L"U0M\H+Z
MF.(66BTJ_YNO>Z1K/;V2(F"3.956OG36N48.85)J\%^+ DSBQ:IDV3-/^)06
M#3C&2-3$L..HQNDE]0R^A?>H8P2Y-HZC;@7%@#'4*7K@KD!+R7LR>QGG\ 8J
M:-0 \]F.^+!0-J$].&P>"JFT96@X0UM\EI^FB4(,A1;!\I/ZBKBT296%L\RR
MPTHY<];)+FVL,>\2NED=9J']=RJ2QINOS5\2W?#M/;KAB^:!WTET]#D:.3^/
MC9SOHBS_Z(K5);*U87+*0:J5J#!I*N5V78)>DUD@&FCKMD A.\1!*)&7>"[?
MWS:;%H$=<7]W=T33<P;!<&)9.@!>_>A(4WKM)Y\([68@5:>YD&IF1238TCR^
M1FQ0B1-WB*KGS-C#GPA!<5=<;I4I'*^0Y/30:.ZD-?!Z$ FPZ10QTH>3\PI:
M8RQE12J;,ZH5!"DXSF-LJF;FX%4E25J8Q7).IRMM-UQ?2!5HFN/DNDM2G_EG
MTDMDQRW3/N]H4LV,J>RGM4SU5H2.\)=T5^UP#90^BJM-1EI%%(,.LP<?, /8
MQ=$E2JR,J]8D/J[9**GQ!))=UE"(E='?+K8TT9J?I)V)/![\VVW(.?>ZF02X
M< \\'@^T#9]Y@SMS\ 6L;DPC#*58L,EF=2#=9K56OA3XQGULL%WQ<X58\;Q(
M^"W$=-0%<U..U>C(8C3%>?W)D64%=]16&D>T3[*YH;5NS%MI:_ X&J-RYE9*
MH1BAU=['-()SLGU=3US')/YO= M)4 C!E5-::>O7"TIM! \VC#TX?=;XT#:<
M)8_LMG0+-1+VI3PDV=LA21L8BO@3R9E('C;PU;LLUA"RZKN!WV4@? UIRI6V
M?Y^4^6E5@WE-=*)K0(D2AVVD<8 I5\#B^*RIC1Y_4O#!R U39YSP3K]!/44-
MQP!T.I][HN@610W"U^">?H\7;)T,#/+*H8V,5J [+-0%.,(!';X?K42W\Z7"
M<>@O]9P^(4H5OI&IQ%4%"(SR*A>N7-.HL*,F^%X:AHP?*A"GJK7;.U=RP->G
M;[#<T>4OV8\JSJ//PU,V*)%E(4KU.3CV T;RSR5K##!OHETLBR5[NOUQ,"(3
MIX5;[1+6QE83.G'(1OJ(5KA=&G>W\ ^XHWN:8$/,)0CA@6]LQ$ AO>4JAV+:
M:R 9JL7=>2]S-\^UDN0RL(039XIJL@$"#_%N ](@F86R%U_/= @:I2F":SR%
M>I=.U%'-^T;DR\NU*!?,A<B<=0C>,.N1]@6)T!"M_&[#<;?YL^(+6]U?!*[>
M%'OG\KCA3O;<FE$A#%I4V]S&2)3RR%!BIH(CZY6H9_'LJZ)<&F'UC2!RHYA/
MU_T>.D4)P2CKQC&;!CY\D@7S[K(3)99*:"+7C]*%6"<K*X<;<6:+*]S<]*[.
MG60HZ\:W=EZJ6^K,I- MK.CNC\-F*._(%4%B)6RQVQ6:D&\\1W5C9S+E?IE>
M\_N)3<-E5>MA^V4G>WO)8EHFYS=:49X2VJ'DB*?YP7JF;;UT".MCKR')8F3?
M3A/W-W'M:LSN-'%YY1)!(I=M0N/2$R)ZGE@NJ?E>?@Y4+V*LN89MTW)*\\>?
M@T09D/!CNIN(E%D/(C"J@2RV6':L56%85IA:LD!UIY>P6JKP@9$[$2!J[#=B
MBQP/P(PQI*3J-,O,*D_M-RDJ*"HC%>FOR]UD;_(F^)#&97:@UM%;=V#0_3:9
M[K:'\N>-JC7U ?P 7.*G.F=B$:0E4,XJ),#H,<@-=IJE>C"!$B"4OW:+W:.E
M8$C$]FY&*_[)%,ZK>9"=B6WXX>CHAQ_9#5=7?K(QD!&*\1TA-53@;5V5FY:Z
M?%X@:%(PHS^)Z_F&^!EF+IGLO_L:CENZ"+\BD!6C.QUKX&5.]_QCDX\_I2;Z
M5'GL0XAT\*3EP97B\OB.<QC]$ZYAB;):(CB1T,OUI5I5)/(#KHCC!/QJ+4 S
M7SS[&4IU>/!I"ZXA+@_6GD9\U@G-Q<IKO1:Q;R0-YH3>-4HH-806CKX+W(/*
M&8X>Q<(V(850^=G#ABKBH!#."_KG>[+,L7SOY6$HF@B:3!5H1 $:," =E!$I
M8./;\1EI:L<8$6D[')A@)WN!<-=P(/"R=4Z4N&AE)+)+/C0*Z!#H0J5QI#QH
MXMS92-9&&W,6NH7@TXFQ(U=9/7H.'HC#&@T?SKF=&#O'.&\+M>0[2M]>%EZ0
M<T'B;95YET,D]0@&9VRHLDL"DYPU,SR_>!-KO>CD@%K=9N+QA0<X28 FV=H&
M4*BZ3JQ)HP0R78? !"[O.4[][L8$K<O"7"96AN-Z<M2*&2=O00=FL==@_*G)
M75PZ45E+UPX1K<]R$5. /-"01?@ABLOQ%/6&:#79MTQ[)'I;W(54:"$7=1E(
MF0=6*'6N![:.:U]30>807P;J<LT0/'.-U_8F*'%YSXH9\T)@Q=CJ95\+R:(B
M>$EHJ"I)"%MA!YK8"9BH&\[%DUEZ'RN1V\<60Q?12%J@2^TR>,:]B&)=XEB?
MAJHH@T==J$B\@%B9E04\K5X+-S]3@?BS]#%_ACL&^B#0IJN84F[3(6>2>%6=
M1B>M3@F3WK)*=(^6G Z9R1PT- PSB?"%ZNIK+<Z0^+C'*3B)>[![CU/X'9?7
M<GH.))5-&;2?@+/4>QL%D\NQ"PN8U7<*32ZI0PQ._=<T8P9WLU(<*6YCJ"!I
MA6^T3"Y9<%,U149C+N>Y*Y?V79;2I*M)ET1C;A0M7"\T75^F#;S\F.6R8L+M
MN5'?M4FLI3!T0$B%=*37G321#L?C8E9(C*BSV7U6UUE]T3H9*'-/$2(WM4TZ
M"-[<-Y'V0=T8W1 RY6#T1R4I,<#8SK03\=+(MT!W26.0P<S-F8,II&:'(%'H
MO))3S,W$[??6&#;@1]99S' M $ 8.RI.30SMH"99J0%JC65^*F%=K!>!)UVP
MB@D4<BJ+-"WA@M3>9(L<GTD9"]N7DQ4RNW2L"NTB0>\5+<7&3'].:6Q4WM>;
M@W"48%EF#B^<(,F7]6 &BM/2C$A4/D4-M])): OK7WXG[TT?5-6QOQ+;P1/.
M)IP2C-MHS2Y:TGQ!MHXMPK*Q):KIK:KG'*.+=_D9U,++,^6=X/4N9\91Q0-.
M/N!LVM@Z) 0M=WJ3Z 1$),2<M&,9@HG=6 CDUI%:+^^( W2].$BL+QT \)O-
M-IQ"SF=:+>8^*1E?O>_. ?&N#!CX/;VP5*!Z)=H516LNU.J$[!&U60Z9Z1J/
ML3;B(G/EL@0:3\1PAW<9@]K;3_X8NJM?LJO#H60F1Y;AA,+KKRW8E#0Z][%K
M?-[HJB%ES:&L"I@@N13M66]X^^+=3 ?$(MHC5T1[_(<6T79Z&KB2VEY#@S^@
MP):+:S-O8[BISUDZ.>E"7\(7\.R0LX;%FG,S4YG <.(R<(3*L'51_X7H@13[
M2XE_H $(DO?,8!URLDH-RPE[MA@1.0]@^V2]C?^+/:&T- A/.NS8B!$71<7E
M(-&N=#7I,KTV.P5%.:MLP'L>R[;>23T8DBU)1L7%1*5C\$;YTZ99EL% ^K.C
M5]NK2H\;!/B/;U\_.^(G;XC07_U,3@/=UA6_82+']7I]CSCZ_)9.Z\:I&>$O
M1T!*JYH3$C&6LHV+;(]\#Y9"9,$H:0 7*B[/B\SU8V;[6GL#:%0>)(>3\,N4
MO>(LKK<2Y\56B,.EU(;#8X=QEJ\'\\";F=A#V\,ZM,@K.LWL7(-F%F!:24,/
M5#AJP.TX>*JP1C?+BBN5Q,"2#/^:;#B4Y?J.4A''?&&Y@P*/E810?T8<@13)
MK NDG,\H'DSZWLABN67EMK_S4%J7:1](MD7S2;UPQ8E&9)W6CG&\H"E/ZP9V
M*&/SX3M&JTQ*%9T^G-07%5#F7&K(T8K:L+^EI61TWNFRR8M9\ 4J[E[\_K9*
MFBM]G"..)LKF,XD6MN>_\OGB>_UG.?$-2(_><@-2/F=2$":Y+"WEDRXK17P2
M]B$\9Z%I:%M3YJQ,*2&TN%(8G^.^>@8!*4>+P$"V5/PS6#G8"$;Q]0%U=AK)
M'6U(W=+$@&A*WJ,\P$8;W)3G?%'S==UH$7._]0=7FVA'NJ3K1QQ/[V*T2NDF
M0F6E[Y/&/(;@$N8+2;L6%;B'\R5?5+OC*@72WI!%4IM_-\WTM'BC EJ-9-;^
M[MXN&!>*EO,WV;N3?"YN'YMYL?@;^^&]P4O$4@F8UCB?6(GZL2+XCR.=. [L
M(5K^3'ACCO"80S3#1:IC+IZS&LO:V/?([L4+V@,Y)N\!LT;;/&6Y ZDUK>;,
MF 3EPCTX/ ++M4O*S4RM23+K@@Z-FPW9H8*ME2'05IZYHY_/5!7*(2[9JE5Z
M=K<\B%]Q>U]UU\]R<B+&'+-CIV)"1Z'1<@T:'YN)\@7#8^/0NAMWEC2NE\N'
M=XI]B0L89;^/>6M3'OM.AZ!^J:\/@<9$GAE_-Q/F%PT[0I(49>@"TOP[__7_
M]I[L?M__[UV\(9OF<LBFBZ[5?[>R6J$U@!006W_:2W:;8QZLFPU&_=TU5^D
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MY*1=2@52!.'(:V)B;Q1PE'^$.[YP!V4>.7_S3AK,)#C,&R'3A&9R96F-T/)
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M+: N2B2H@ (F;%"%N*:#*0CGT?< 0:^HQZ_6T6H,:WLB[4R%\@[9\WAA''W
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M IGRG9%^ND(8W\TMYP.K+)]TLO+2=*AJBPQ[X8K;54X5%$IN^9]+ ^=\RV5
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M"N7TX#T9*'3ST9]JO%VI4=P?BN4LW:8)+'SN]\ZJVF23JTXF+. 0 #6>=[9
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M=CNQA':JRG"L!SSVVA&+J'7QA7-STEGD<_+;RS??-$J*B7Z >Z19,K8C:WJ
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M:,5C"8 !/9>N!F6KJ+UT7X"L)=X 5>*-#TS1':TNE. FH)ICQI +NYH[]7^
MAE7H7@FY4RF*)",4[L&H52MU_#3[UX@D557;,9\$.0)! /DW1>R8W&-&]B]E
M1MSWEW)LL-IQAYSP8FB+7%@# 1+#T\V@8+9P8:4V9JFBXN77*.^)DJM<8]H*
MLM5-8X\:"JD_<V7-4H,C9=AE=$N("_X%L]"W;%R^U&D!,6[< ;>:>%BYA"5H
MMN6^A:5<4PY#\*/+0G"W79&(3<E3]79>-!]^@R-3& <K\X)\V8^.J2KC'$0+
M1;:C9Z#"Z8YT+CV@733D=R^V)3!0.*EPQ%*?6#&7!@Y@74"MN6<@O,D) Z;H
M:H'GC)N"?T? XV<O_HB QX,QX;.BGFW73'G2/9VQ 61_@/23T%26V9JR($SK
M9Y=O<DE[_MT("3-WN_N]>NU'8,Y@ <8/B@\]5_!_E_0O-ZV@=.S# %+G$E,3
M5/58&\(=+G2H<<_]8T-F=K'!C[:?<>,Q_RD:Q+=_OXSI77OB* 7LLMAPA^ZV
M/=$P)U=3UBAO@J7RU%!TX+SJL3^,=>J]YH]^S=-Q8VT*V0F'>"?1,LLW&-Q_
M.F6=#$W<ZCOLX=,^U%5S6YZ3>T-)ZZL-JX-!PH9(-VG%%C9@,.8K<?"B,YNC
M+LJ3ZFJ1)E'.!'-C9_'1,6_8&$ER,BQ*#Q,)NM;%'#/419<:^BVV0A)BE!I>
MC'U_'V\6/_]>AG1E!*6-7-?4ML9;64)SY#C3#!-F4-[VS\GK_GF2XB[5!Z:\
MHP7,23PF,.-2*#*]+^PW1  !*K=KY\&>Y#:[F^7B]25FB^FL%8(_T&]*;3$)
MZA@<T78C87B5 >D(NGO8 MVP/>@VXH/9L7;*Y:/*+#I[FL OYYK,HWXX$UE&
ML@!E8=I)>FU#:33>28WKG9"ZS(YE]T-8%>J+&+M8I %Z'DG.CE-V*%/&8BP]
M 1BT!<T=RG4A\TN9 N1&T>3:A?#5U56=KS/_NI3KZ'Y,/YGZW8XND]Y)0/["
MAO@BT>+%4C7$>]K5GD-(Q+HV.;Y 2TVRI1QS]0EC%HG #:LI'-??H:P_F S&
MY?3]49;FNT-X-1%E"TF%#HID(6(D@E"E!PW];EA56&ZWQ7>RR)O(X]99YE*4
MR*PR$B7LD&2440CU)#,8AEH?>*1BYM?M;,MDL($^239@QBEI?\R23QW8:[3P
M0?[_S&^2)B0^<CJCKQUX]_6LI5V!0$+;*\&[7 CY^7&#',(&X6J"8958!<ZK
MS"S-@91%UJ')4PJSN3>=,[H,\!7A7TR\:SGVJV&](PY0AY\VX7\8YE=4ICV)
M0+G1M-.'A%=BBD!17DF2YII>YMIV:$%D1B._I:LU;4?B)FE;B#I8ZJ+CLG[@
M9=U?0DH#'R=RF;CV9DWQLMP&^01BO^'F8QN^IXLP;Y*EIR2HY(K>#'(WQH7>
M6) :-V<.WX/.#N"]8M',Q##56*IP[/ Z+LI#L+58*<9S(->#>'*+*3=3Q^*>
MU-I@<6[Q2(28<) ]3KT?%LVT"(O>8MKS6$1> -]"GL LY^.Z.H1UI=2W8,(4
M?3<1N@[9-,,F'FP02K5SY]:;98Y<:U5WBM)WJ48,<VB&PA05]5LRJ-OC:GGH
MAM:BZ1:=!A>038:FOP%FFO6*N2V(353&L"_"3*72JR)41Z6$A:MK,']2NW>'
M]S"3M<<GH*BAFL5G0#"JH9$B.ZHA_<5!Z4N]E4JXFFJ-,HR'7+P@7KI:)D,7
M)>.,ZT:^X]C QM3.TT(8T#-E*A.5=!9;XF#)=(_$SI(D8YF16T* N!."/VT#
M5#'@H8^[ZA!L<$@TD'Q?#>T5@:/#8BKS ?;+BE($6TYH^2^WNJTTA1 D!,W&
MLVKJA:*M0-N2"[O'=0&S&Q:ABDCZQ?:SJS:DV,$FGNJ!*[;2XT]4C=^>P6I5
M(!:)9=]C#^?A+4H_<P3P=(+0W;?Z%MT /\8JR82;14:6R,Z_U%"/K6X/OP3N
M5&L/@:[!TD7HB6@3S((LLES!KBJ:6>"0XQ6R"/_MX#WKG&BR+)R3L2.F57)0
MX63D>&]9\5B1[G\0<,E=JMX6/934O_7<4?_F+A[[N,KXFOJB7(@2_:N51%!&
M_HRH "MI_DBA-*#!(W JTU:!Z"JQ9$S@\KY35MZF#4G,(W*:C610='DV$Z;&
MBFT8R/@DZ*8 5J4.!8;E!_$V+4G!Y=L#A+TUUW0Z.8]*U4?(JH6LGATAJ[_C
M\+(JNE5F5@N0Q&1#&:1A?-K<-;.ZF#H1*R^:R7E9DDLATLO^*]]3@?[LQ<E_
M<P>3Q5G85EC)'RATS&\6V7ZW&D5K!I^HX4_EMW]3H[8H0+[)&432?R+D+J)9
MJ5F@M#V2WY90Q3N',[=)]+-T0L".%7I+:(&0"%-A<E%H\WFBY'Q#:L_<$-)-
MIQ#M(KXQ/II (U#\3DHY)$<#H?5\1D/+%Z<JDSECPQP"!,4M)#Z07/4Z58?!
M")D(8/&Y3\B+HFV&*LQ  /?SS%7/&].*=&:NES#G]AT.>02<\S,?9>@^;_*5
MDS WI)N#,<@X.#6-[LAQ^#WB#0*O.1RQ+;6HW.HN&B.3LP@*56=$B$/[?+A8
MCSY[ 7'^NCL(W-/?(;H5TL&O_,&FY8G4:=I"=.OZSO$0D4&HSZ.+<&@%=9RT
M&X?&Q"B>!0Q[#T<IKAGC[5(83B.!OCRKBIUB;&ABHZCZ[8!F.\G#H/).&# J
MOU)/IMJON.9^)4#/&=03N(6'KK+Q9QLE,0[5)-V_;0'B?LCTV$X"AIUPI0:O
M[TX"@H0D,Q5UW $^8=4P"C*]GBR1I(0^R^N:2J2M%#XU'4P^P'S+6Z+F-M@@
MUC7W$0J]QN@2V".#) J\=Q(L.M#IO:V_0"=S3DVP+6E JNI+@+;;]H*+]V^Y
M#; JP5K.+0F43(XJL+WI3Z9=S3JZN>-24ABL)L3=+VX6ZH#W65"&^(-;Q*'Z
MVD"M3?BQ@[I5M ^G?D@I,[YTU&J0Z4$<<O4BQ^R(XX/M@#=ZW*QYO\=CIG+L
M$RF6S695/4?S<] U39,-;36K5J);=45VVBY5XH2, IZJ?">CP 22JR(7B@VZ
M-F9P7KE&(E!&MFR;2-4=+MZM5&#*X%>/F@#J$FA:UA'&2T:(_,#X#+S^#S^^
M4[%2[]T7:__MG]QJ09-Q/FLURR,MH#^Y\)IX+9ZRF >R= 7>L5>^;MN'3K__
MX>*='GXLP6U7?QA2;U?R4BLS+:ON.4UB0I+-^<!\*9(X1<B9^"&AR *I+O]<
MA;1[]*DBL8$"[,=1ZGO69Z1']TC-WE]5GOC7LLM!!)9T%^4<^8^<:D4YR!D$
M)N&A*\HCT7CY1ZJI*4D4!UB,?N-FD=T>KR0*Q0!M$9?2)B<6XVNR-%<Y:X?2
M7/-W"^TFNX%W:'1V,+GJ5R0<%'&C8!(QR.&5:#RUI68>M$$[^U$2DU2/!G '
M^P4*;;(*1<WTSN/.Y!P,Y95*A0#'K<_5>0K1<..31_=,@O8,V@%/DX+@;3EY
M.VLKJ)"S%OQ9U(+?;%6Q,9_\E-=HL/C1M>0_/J/OB'@7?37]6/2[GJN:/%D@
M(*>=F6B[X'05_./UY8=S67A)SRE1+ $)3HU7.9Y3I,AU>7?9T$6[3)8JZYK?
M1N \K#7-!">$(F.7<JY,Z\FRIGT2%N?P2Z)^OJ#'$?6PJXJ;>F^(T\*/H)M+
M;G/A3SOMMF_4?Q.+,WQMSK3F#6\5.Q!F3)GAIC]?JL!J=<F';Z,ZY2.[G>06
MMG)(Q1-!!>3T6];0UV!'9X5N<5,70_?F+?9A[,'^W(!N&>QIBN6C4JA;;ZK:
M+Q[R-;8-0*U 44->_BM:\&=^V8NZ:%'Z8V\KG7YT_GUT;@/XL]3J,;Q=]HE+
M$HN??%-48?;#.2.)DF0&?D)CK7<+G+%CO);,7.<B'DNI I4XI]N7/H"C/@DZ
MF/U**F7"4OUZ3K;L72\!_IW/9&A_<MIW*4NXJGDC,/<*WT"\2>E^["Q^>5N(
ME&VG_F4:89&0UPS#"+8:;YCII"+<K%_GNW^*Z OMLVT#VO5(14.7Y/W\5/UY
M44 0IV-7;7G>MANDTX(- X70E;<\Y= QMA/(_=!'VF_*.<&^)E[W9+,;F!R'
MU(/KB5/WCF<_H(R45I^9 44:7>-_(S/'#V^Z=_A>>)(ZG@-''-9 ],]MZ=RY
M>^21(&V0M.(#HA]9^O^AL/9)KK*WUMVFQ8:<F1_::@=4%\.$*$V$PX]F@H>L
MDTW:!L';?G[3#R/=(C.B'AK/^8,,*1OP24A3Y1XNKP1RBFQ9>57A&)#9RUA0
MUP:KR8S'@-6[IA(]_=K4A&T:',]42*V1U@[4%QD7PT?&;*=&7,(%%X2<10.+
M1:+F1LDZ<(4!B+84#B\)"A!=-ED:]YDCE6HC@3:+N2Q%3_K.(:^XV-"5FE/=
M'GN#&R$,($#B]E^5HDGGXDX"TXF(%T>^3+M&ABRPKD5/:Y_2UD!P=9-6)%2"
MFVBEM/E%4LX:PNXE @@%#AF[)VDYOG$,O;P17@MD'PR+@<VE#J88L@ =JR5S
MG<]DR$QW;F-Y"_RN 'DO:1._W;8P!G+<I]]C '/#>DCBG=KL1J\-F+>02;D8
M,![J$+J@"E.+86R#0NXTI@T1HF;2N_0^(1"(J3@_!]<%*ZJ1HU8WNF\;.;[(
MPUE5MX#ZDAYT@[[JK%%.=9B!:9*K8/:F<"RQ,_VM6 TZ96IF\KAF36F)R(Q@
MC@Z^-^:K"<BQ6E"S8L9U\23'"5B:BP4GQ#0Y2>^=<*/H2'E'EPVC2-WURF[)
MY1+;(LG. =["H;DYPBTLW.+E$6[Q.PYOM ,2'S&D(4M5 >0L%MY&"HK W,C*
M[<CHP>,B\CRSW"61S$<BJGBAKY+=-&8+DZ[&LN+X SM#D5DP$60=?4A)M!GD
MK2^)-Q3-Q%HU[CS\1!,.;*,B9-_\-%SX;C2K.A)9@B0HV=B*]R?'^Z&>L?<L
MV7%&-9P$ _/(<V@=&5M;54:3/X0+<O^2EW? YIJIYD1T=0_?U^3(;AG?T\FE
MGXS94D!_C+6U.6/<_$;.93@K7<92"7C$"[ 2(1H-H?6>>:=P.78T5WHX)U2:
M24]6T8_2NBR: %N0>NV6RB]A&S(!:<>G03W.9O=Y\Y;6">[>7WIC )@TO4)U
MQ$SZT?T9?KD^'\"^4K7AWH7XPX*HAM5D!9)^BB6]_\!D!29+V>0+UX;8*Y*7
M@9VPV##$;:3$< .&K+;A1[#=1B/U/R,90*JS25_2REW3"_E!\T,J;@I2AP@5
M\=^Q*HN,VNUN2CPZ9#@"="OCI9/V "7]4_+.0\B=OA_+C)(YT:9M:PR0W\IL
M>46Z&FEJ9D#QKQC4&VCAUQ]#,*8?&X\;I"X\4_Z!V]U&B./\8[$.-EX5;=3T
MK<HO\Z+D8 [O'C#&H0XZ>-SUB^&Z2L?P!9;+T5*X"8FZF)UKJ<Q6$$">^^5:
M@80C1)VKG5T6P-X<J@&^/Z2$O.] !3%86%8Z'*>+6UF(0Z5%HP?N&=$@J$?!
M-@EJ&IRA^Y58U+2JJF9(@.9+_W;.9 4HZC_4R=H/22PGEV[3.HP@ES!84F6S
M<JWD[Q..?Z5;#N6O"-?27 D7*3[4RM*N?[]X?_[M>;2!?[MX#?OA3<_/$J0'
M-I!&V\_72OHM]186QC*/TX?C^<]4"VCR4U&6Q<9=A<)Z?"O#UP@CM>#YG(&(
MDLYRSB0$1S52_B>HEY@T0J =;8=9P?73+>F>;Z\H/W_V2BNZ-TZ;&JB6>_'^
MQUC#X2HJRG\!0:-_7^;S6%*04[?0-D+4,UC6)Q1INCS!!1.)-D)&O.9VH7Q-
M(AR<NFS)L:(\9X[LZ,6;"RX:-W3R4'I1,.HY7J#DM'\P J9T(B$"=K:D9T\G
MY_PN=-4/=/2<3]XX+MTO'?RU6/U.*M]^=2_^?_;>A#F.(TD3_2MIW.$NN99
MXR!(JF4S9A H=G-&%+DDU;W[GCU[EE69!:28E5G* V#UKU\_(SSR*  42:"D
M6K.=%E%5>41X^/GYYSD5T<(QU$8\L KL:/+K"I5;VLM&DE1*^E<P"O F[F(R
M3II)D ;>2:*U/4ZU1UV;AQ3NP;-(L4QO*BV=N"X+P6S(@>C?!H&IF?9"U_S
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M19W]*99 ;B6?Y56(Y.B-4*,B*T22GE',\YI1^,HN#%D+=R9&W$8W2-?49/R
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M=,['@-<O&VLU)3TQG%E@:3.DOVRS65 <R+6TZGF9=HWTBX6QGX E*Z$J5@I
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M' B405NT[TV$U&80IR'$%SEBLU[2,&"XF>54R)IS;62'R+R;?7>A@G@(G&]
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MWI-8!XH0.5K>F*B8!A-@(0S^F_C71HZ=FR3JZI:6;>-&^_\HW\_VXPT4=3I
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M4,H]/4&WK\.1($E=1-[7X1X\FUR9+)F0F^D.$L=GCH.!5T* 8&B2 D9IQ^;
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M8<]&-O;,9J#?%G#GK<P&,C#:,X%+H[_DTL&DY^#PTQS"VLV3$X;T( >_PA7
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M9HJU)- <+6W@1=_P"!BEC3&;-?2< G7VAD,0PO2?<)V7P9"^"T=F8+&<+U&
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M18:.0H0LO0*^8=179EI$LX7/",Z9_AOH94+O&L'O'!P?*!'"YVX29Y$9",L
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M^C06"X\]O)?)"O>SV+W.<@NZ6W3R1RV1+J^TT)LZW)P1$,[L](=;XIBOZY&
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MZHUBIY83H5"'*Y'B%9DKB$!6!'Y.1#4!DD'5!H?<,8H!"/ KZ "X\F$PA6_
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M4+TB4VH95?P0M:,/K[BF( 6^(<UD*-S$1H*_6$-2'HYB_/"F@3<(0K 8!;F
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MC]KC+Q204\S@6X3#ZH8S!\(JW>1W4YX.A83@BW28!%-%BU7SZ9%N:%Q=WZ$
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M9$AEL&Y%X3()?#\4CR1</@AP4]#F^B+GRYWI(79'NM=AEIYN.H"EB:+CK(,
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M@NDS];1HVSR*U6@LTZQ-M!MAO"W"PL<Y$O>*)([?FGB9[*6QD;O!0QP&4ST
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M_23'(R>@?-@-##2&O+Z__*I>?U;77?IXI-_*Q]N)T5@J&#U\5?L#_3ER\TH
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M/CU+?+*8$<T]"<1KZC"4#!/JXK^8TH@Y6N 3S/A4/7PZG\$GJJG%R#. $12
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MAUUR?+HY'E>/.;OS'(_;;[\BL'OUOI_L/G<.JRP#CK]-#*;F]B<6_;2O7I/
MB>$ B]0O4WD5_3)$@8E^F%",21QLA&-61W0^KC(6BB> J?MYA)6Y3?Z;>$\&
MUPRN2[PXG\%U2>!Z=AE<D=:$0>(!]BC:NH0[(!TW0%LHO8J4#!RN;3!55VR^
MO6<&UR7%XJIL?9<G7[4_2Y_@ZE&_#PXUK*XVNFJ'ST7A+-::SVIF<6JF,1?T
M=$@S%; "'-&H9I!TR8;'@&!%N.0P2!'6-C"%=4'GF[2LCIZI7LPU@]^S!+_%
M6ML9_!8*?F>S!:8:(\$1<!!Q0+D.(-K5\0_.I822*NAUROC@NKPBZ_,BP:]J
M_:^F' <2M^1ZI^F6W:SG\-3=L>ZQRF?EL%R-JN]:VK3:K6%K-,9E?]BSWX]Z
M[7A4@Z*:0_Q52]>$AV>U/[9]:-G6\,_<7.OF/%$UZ'TU:HUZ+M;:%W2_7[.T
M!4IFU7O?K<1DA,G8Z!-]EF:5/2,__^H-/PM3MS+E3&/V>5]R3V[-NLR2Z)'I
M:TVD&$M#9D2PJ<2) ^6=!M*SP#5EQCH>_?ZZ9,^PW"GCT;/$HT4/\LYX] @U
MWB,\$@9)Z$T:/8,4H$(H( FQP$8O'#'MHF[Q:7H%@@^^HE'1XJX5,/+ZIS[?
M%7M,LR@=^)27G)%HX4ADYRPCSPRAWED0$OY03B6(&"2 MD0RQ$P0)EI&LH[9
M@^=4Y,MBE17B!=H268@?08AGS G&H'+:4^!TH(!:G>9@"0ZP9]XSG(9A%>:$
M$@]V;RIZ8:SJYL2V#SX*@JOU_0_?/9V+&>4K*0LV)[;B0]/K/K>&1UNG@[AU
MWQ_#TEF>KKF<4NDQ'LF(1Q8R 9#T"%"O)5"4(Q"I*B@4&ADC%G:%M7H!ERS,
M"S8K[B[,V<)83'WNI,^-IM[@Z!Q@*Q2@FM'H(=  #"74&*FCJY!Z[M;9P[OA
MY8#%_=*-\3?BFE/&,<K@H.5\7Q?RF2,72S8U7I\.XC(&@ZU>Q[2ZQ:%?$&-K
MFA;9 %D*7'V?-T P4\J+R,Z*IX9ZP0')* :.<RV)#H'A2O;0R'&-:AH@BQ+Q
M;)8\4,YG\RC>I10N!)9# B@7#!CM%!"266(%%5:[%+U4LDK1RY<4^"@[Y=CY
M6J@< 7F,MCE716(SYMP><X[G6_T;S#RD5H+@* ?4.@*4XA(0'6FF$.:$J=09
MO$J.4 YL5-.NR#*Z(!F=L0N\LIAZC !1+*2VO!Y(B 7 VD*GI#.$1'U(96Z=
M\Y2M<Q9E%2RDU<,JP]&B3(:<MUTF3,VW_#=82622YP(]!)0I"+3V#A@BG ]2
MR%!T#T=UQN6"_)=5Z>N2!?\Q[9 L^$L6_!G[1&LNC#,I;N$9H%YJ(*W   OD
M-+:&!X^CX,LZ?'AWOT?N.?*PNY(+O'=VJPT_]>6XNR_R!=R<:TZU5,RWYYY9
M0/"Z/&4Q/KS6"Q.OX*373S_/<<+JI2]S5[1EF GS/;HY\UQ;0@!"(IH)EN+H
M'R +D*8$N<"Y\V)M@^$ZK%3918XV5M/*SY)>'4F?#5@*9Y7R&AA.'*!8!:"<
MH&F<L$040^>]7=M0JBX??@^CHC'+JALNDQ+NH?XU,4O/<G75DLV3\;'O=FVO
MXP_TKZE81=-G6%H@+,WWRZ,4Q^./B&18,(!"38 1C  >V4-0%LE)>7&QA"\J
M3+&B(<AG+<J+LC^R*#^F*,]:&$0R*FP49411]"6L!\K'/Z32EB&$*$<H=7^K
M,[RH7$.NE7K8);$<$JGBY;'L$BT!L,ZG@Q_?T-[!]Z]&&H^9A8!S) $U.M5V
M&@9HU$%"0LNIT]6[<I)C']6T/;)(/X5(GUT6:2\=\TX[P((J[H4JH)-P$XB)
MY% XST/U1/HE!3G*<NWNU0FX'.MXY)+M/&UYP6[1I[D(!XS8XP,*P OO :6$
M &4(!"1HPIP5DG*:;XH]?Q%>5D5WGH=Z?U&=B6!@H0@3R ".7!15:SA0.M5X
M(Z\Q],0XPE.UY',-7ZQ&4?<B;8>[%$D]2U1:0F%W]G66X>M\NCPN]/C35^\$
M%M9CX"AWJ;&>!A&E.'#2I9]XP8E;VV"B3A^>.[FKG*Q0<./EROX2:KNS["])
M]L\NR[ZC4:A]]"=LJO&F1D.@C481"HA/H0Y<M)] B-8A1*LB_"^@\+@*$R2O
MFRGY+E^2JYPME5%T<?[>_- &0:6UG"M@0\" TN" X5I$/)4.(1[=/8C6-KBJ
M0S(_J[&BEV3R[;C5MJ"RQ"]4XF<B/ A;;J6RP$)* 66< @6= 8P(SA$BR9**
M=A/!=<@>G"%ZJ??B*OV,%V!DWF;N7[[JMJA!CZ[U8_SLT2- ^OU7!(X?TNJZ
MZ!"_ JI8Y!,PQ/O^N.YKD%BC7OO733KNO>_O'^F^7XAUN]M\,ZOL)JLI^/2]
M[N_U]X=ZZ-T_NGWJ+]X^4G4PJ[I;J+KOP\;6)57WP[W]A[I__]W^@ML_S''O
MY][;YE%CVWW_<OSZ>WPO/#QNG.W%M7TYCGLZWH'-=(Z=#^Q+6Z+F=GSVP2?:
MB'MI;'\B7Y%3!A$6@,8AVL<0:Q MG&@X0VZ(ML(IQVZVG*[AJOM94)FKG@57
M<<LXD='A\M!%:TPY"122 BA"L2;(I>CVV@9<ORJ&-?>#VHGNUWXD8M=.?#2&
M$KG_JEW+DL7G@\?!N(+U!INGPZ->/Z*VNYV-GUGTJ5GTD'W%7*'(F!A(R%(7
MG8AY6B(/G/5&<<X0H_X&X+N2RY:$>9G+5I;+".%,V:A>6=2F@!JE@4$" 1?A
MB!MO3" 1"%FZA7WE3>QY,"P9KZ8GW%#3PUIMVUO?,;Y?.K($U6L)SXIAX8GE
M*@67NX/!Z2P37U&6EOGWJ?G7PJ]08L5TX(!8EBKIT_1;&!4Y@2HR X%$PSNC
MY%*9:^]T.!A&MH_>6N:P5> P:B/-$=. ZZ"2J>BC R(B8#H:^8YJ9YVLE![.
M'+9B'*:9<YSP *QS)#5($,!0%YU=H3EFRBO#;:4X+"O(U6$NZR%U2"A@B,*
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M?YVDC.<@)])S(GVAY1D#K_OVJ,BDNZA-V[V3='W@N;2=78F80TF"S:[;OB#
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M=-V#1!<=Y53ZJLEY3NZL!)F>PD7/<W&7#[:SCKF2V"$2%+ P55SB:"$J&SQ
M4O,0XI^:)#.1/-A.S!*<@3:3J1J>>0;:Y0/MK#_.)%6"(02BUT+3>$P!=) >
M"$.IBL0DM"AMKQ30/G8;^CP<\^%"GH=C/IW4'PX;6Y>D_H=[^P]U__Z[_06W
M?YCC'FN\W65[!^WC)MYAAYU=V'C[YOMA)SYG>P?N??[PJX'?M.+^21-)U-S^
M3IH'GVCCH$'W#NS/KSAX3@35@,C498Y&,TUZ)H"1S"#H/&8T-9->SG3,9QC[
MOC*R1) S7@FGK</4>RN=PTY@BU%JI<[(@LM \G3,Y<CAC/8ED!'$D0,AJD=
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M .IAQ7"(( )_V?KP]M,[/#J4@[[7GF,2A[+#0?U@+!:?G($64]U=Y';^WQ-
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MHMHQ9T<4<RK*HDBM#QFN,@"KO@\,MF*AVN-_M2) C9ZN'0X!/L-?WOP:@@'
M>6GE:3WRNUG.!PTY[6GU$FQ/()WILW"9;@5HK9WW^J9ZYO1F\=&;"E@K Q'+
M79__!M&&VP==$(C5NQ\V=&<W0C&H>,>H13OT!&LOG17BSCAVA.#DT_$Y>K0^
M3$;*F<A=U <<FCB4KL^D]I=UG/"?^K] A2O_A>R%(.'>UA=7105('U &#Y3+
M<3T:@"Z.S]H%6:H%Z-S5*[9^]>LL<$'GPS["C3?-RR6@?:J]9MHK+9U2US@V
M?6<J'#>^6BL?0.0=''I@^M>5EJ $@"CB(.!; =\UB$FEZN"<3;"\OD!E=/0%
M-@UHZ/1J,+G&>NT'4.E+U0OKA<_L<,4M3?7 R\D(P\=CY'S@574^JP5[-0]O
M'(VB'CI*Q,!XA\S4N'32;DK]#IS[_6H;P\FX%@!PA,A80-M#]67FFFIE;]FM
MS&QJ&<-5&W*6"B#HH-23:IT!\Z5+"83_7/:,67IW&*57^U$<O15S;I0(S/@P
MTTR'<4Q#([B686J42!*CA<J$B^RG(?>1??C+K#^%L!EWRAL4.P";L"39&SBR
MV6U*YA,P9@MK1L"6. -F?+WO>!3LAWVW>#ASEQP TF@/-CN^=D=:_O*#&;F]
MPP6[']]N=$SZRAPY!Y\/OAUV3].<4ZTR2D $9(3&-B5Y(C5)#4WRB#'#=;:U
M0[<7B]H"0.H^$HZG%Z2_TC%S@3]T;% Z3I81?J=DRJ;U.@4=-*E0R?SF=$-@
MR974.G">N3EJ95;2*$ZM45S33,><ASQ52:I"&Z99E#BGWP*1+I0S563:8"4@
M+C1?Q)DYLO\>HEI9DV9)=-,>IB1^=33UY[>C[JD,M1*IBDF:B8A01A61-@'"
MRGF81C:C5+&MG8AO+TYU^S\5C'T=>G?*\ K$1_FS&KL]L8&6JGN>.KSV65);
MKTP;P@\5$R Q3Z#;#1'6<PYS8=&CAD8,?/*]*4#/#\ 8>BL&*-(TW"7880MO
MQX:U_>#<Z?#CTG.#<M0YNS"K:5.UOQ_I2)7ITFD([55B=EZB5&TYO$B]!%/M
M!M:O*R><*ZR27TTKS8_W\$UPG"NF%,3G:(E5IEWIL(!7PGD  PX'QIN4&/[R
M'AQ0_L=! <SH7&N!@2?@PPVZA#[#[5:K1..VJ'Q+_A0*YRD%R0%BMC015A]&
M[;;[+?BE!QH6F*.&.$2KEU;M!U?^O^^24I<"!.=)G@F>4*,HSP3-DDC$&1<V
MT>IN@M=MH=I!O8&C@4%B.JC66O8?^@0G^*X'-NXQG.#0?O!>F5:<+H>^+_3@
M[)3&QE#&+-&QYH2*5!.9I G!*?&*:ITFH0'HB[?9:GD*A.+,[)KN+=Z!(^.9
MR%Q3<ZRN%/W_[I:F>G!)O#/!B]^!3-=,IRQ)9$ZUB'1,*2:?"P$T$>:A9G$:
MAK*ET\V@T^][WP[^/ U%"/=%,Y(;&:.(ED3D84YL;,+<L)1&/-S:R6Y2^WY
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MH4R$?G,-!HW>']1]2;MUB\&6H98SE(H.STY%G.5@_1O"%+6$<N$F^V3$6(P
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M#Z@;?2CKVC_TT<H8:)3$SI>\61Z0I]"##M]^.34"E/,HI20%"4-HHBS);6)
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M?&Z"5DM#W.%@C:$=7XF2#ES9(4XF&OT(Y%/*I6*YBFC&J,XIS[(D-E)F5J8
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ME:^[&VV%<:Z4S4(5A:"8QEPP;*NG69+JF&<R<;2U$*9-9FCKKW(+7;^#7=C
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MMB>1)5YGL%UIB<<CZ (%PX0--O"[6*3UBM]]Q>UQ""E.,%BEB<P(QZQ@4/0
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M+8/O#QK&#R^][S8"TG1^C:RN'63B&S3TL#&$BWW7X?F#U_:TT??Q^*%[TKB
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M/\^7O=G*K.P;[_<3"SSBNF0[%2JWP +HM^T#1*]FPU3_]&!X+7"P!H=],+<
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MA$]R, P,!Q,A\R3/F<LU381.*:"-6FQ 5@<)?AE=S3,O@LH\-R[GF4A,FHI
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M4Z=;Y2T(?O\9RR(H/$9<M*@*6WEJ7E<7U-4%/ZRZ( N>)ZFCU#H*=IN0-N&
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MG:"<,*RXXX(Y11('MU(5 ??U>8=:P:]6\)WS/?B]N;]#4WO(!/B"!_4.3J
MJHXXY0H9YPV@/HL%IEPH*U<H^*P^K_"$%K,)4T&:V6J2%)F8#E2<I?:>(&%)
M;AKAFPMA',N;!$^7^W%S7[879:+U6_X2..4K11-$!<9Z+]))YX7S_6A0*<'W
M=^BE'*HY"GOQ#4S#/VGX;SO@M8"N[\77U6-MG:;*D+'$(OJ\158T]P\.G;
M(VR!I*<B]43WR!;4H,(7N'#,&D/BBU=<+ CL?ZVM5U&'4>LP:AU&O<\P:N/I
MQ21[95_]']=6?TF ;02@)H&VOQ;HA.O06=J6+IK;7_#NR5NV!Z_OGFR='_*"
M:1S![2TTBX@#L$+:P+[$@H,=B16JD'%I[&P"FZ<]BZL"R3/279FL?DILIDJ$
M_C!&T,1<,K90WY"K0:?,P:0X=44:M4S.GB7HDE]9BO?GU*TL6>TON?TXD?\5
MS&E*2(_*$J:K$<J]*I?!)L=MNIYW5'$+8W3=TW!E88 %K5Z5\%Y5BI*W3W<,
M\YE,<^5G3FQE3@!/,K937YH+D%7U&#-^::\;DZOV,A5II*OGI;@=$C6<11-<
M08I >"&I8H%QHCAUH._<U$CT!R+1DX^'5%&)3<&0MN W<8T+I+!5*!@,2\-D
M])(M1Z))D&^W]!8L0="<R:+0/+?^#N"):!5IC*HP='D,K%[ZAUCZRW>'6C-M
MB-)(A'1$D@6++%4."2(#L9)X&<2+5V+9TI<%/.V+7QJP1-T1*DQ&*B.Q$&,"
M=E70?>+ISCK+R?K.>;GECC&"+.-M9"9X-&NH\YXS*NW.MC5=/T&H=/E)Q5C"
M<\L+^Z9M\Y05G3L*,9T[70=L>(OC#>O<3WYY,?_UQ?F_3Q]MJ=!P@L C-[&"
MJ^UTE.1K*YSW)P#ZNKC@[3'L_2>):PQ[A_3OQ\OFY9=#$HWPQOIDQCSBV$ED
M/2'(*J? SQ 6FUM V*4)WR4,,"M2P"MC-<_TR)%:?>3H-JPYQ8LG<5!IW6)S
MR_/[^L&9-;9</AS8_]M<I$+FQ'OE7&\8_%^ML0.SCMP^!R.F*_%YO_VE^<?N
MZ>?MK7. 3RG'R/8^->'[?[9W_VC2@\NWI'FZ0SXO,%VUVWN?X)KT\Y?F]A8&
M(R9V+YTXN(2QGG[$,)(3&-_%P?X_7P"B\=W+CX?<,4F)\XBZZ!"748% <XJP
MQ!'[4"CG[?QI-J5]88*FI+"*6\_!>P].%3CUJ)+2L'EZC:W7K]]_W-EN[/S[
M[YW=#SL?[D#J<^TM7_TPOI9%:5HSFI;'$*0OAU9R(Y1BJ/!6(^ZM00:K A',
M.&-"1HKYO&"LG<VZXASWK>AA3"DCDW,X=V2'N1EGTPKZEYK&I:9Q69=V,S6-
M2TWC4M.XU#0N-S8-[T,_Y&1NVARG0F.K&MP\U3Y<MVRR_^2Z:7UW*]P[EK*.
MNVD!^NK\6F'VD5"!3[@]$:F=$J0]L?9:=T/Y97NMLU;S],WQYY-_OGP^.8"Q
M <+_E"+VNX#Z_VQ]WO8GN_M-LK?_EN]^F&NO=?KVXN#3F]/=3^]/=T\^\N;V
M.QCSEFC2C^+@],\ON[1)FI<IV7-$_GWY=J%1HN>"8NP,DDH)<#?!\;1,461D
MU$41"UP0_>(5V5!\5?G<]VK&_78<O*ZQ8&V6?E*S=,?#$K596@^S--?UCXFH
MG"(&,>$2(0@GR$0G4'2&P*Y3R"AL,DM,+E*^/ZY9^M%=NQ]#+?\V%[UNNXUR
MNF(JJG(G$I";$B\]:>OTO:!I%/7<.3UK=R]">%_._%3,LS9+]VZ6%LG3L(O6
MNN 0%@5#7&&#M X,:3!)5A?6XM16FF[ .J\13=$]]6:NM?F^L$:MS8^CS7,@
M(T2.HV<>$5,0Q!D'MT=3AZC"2E%M([4X^S[ZMB#C"9".K37    ^Z W=H"R_
M*(_?-RJT43.-_:#(S&0%7I?]#RHS5=NF>[=-B\1C$A:J ).$;"P$XH$'9!,W
MHN$A4,VPMK)(MHGK[T8:->_8^JKT/4<U;J72:TFZ_$2T>0YI4$6-XI@CIAA%
MW,5$8D 8HI3I@F$N"^OOC73Y"5.0/4HPH]>-(9\'3,<W0QW%>/@H1F60IF?^
M3:B=G@<P18O,6#8:AHDRB%#N %@0@I0S 6$L0N&-#H7)P$+?.N%3AS">D"K?
M5PCC.E6NM?5VVKI C.X#+BA&0AF"N"@,TM88Q&F@ A?,"$E?O"H47R-=?0X!
MBKUT4JB.1#PT4,C3O%C?75N7NUB7@P4LX#SVDGB'A"XTXMH;9"V!/Q6-RBHL
M'9,O7NDU<DCJ ,.:XH!:4^]74^=P@+4.MOV"H:A4 !P0)3(L:D0I:"HW!==2
MOWA%%P]K/Y_8P2KZ<J(>F;Z\THK&SGR51,UA7C/?/BSS[3T';.H$]4-:?;?(
M8AZL $"FD/<X(NZ41FDC /MON1!&BL+9%Z_4!EW2I:.FOJU)S-?$8-6F_!Y,
M^3T'[&I3_L"F? [ $^8*0B('*QX8XL:I%,AC2#K-B090'UDB/MS0DM6F_-Y9
MS,==DF::'"SMFG33)B1ZW(1DW8F"E_?](/C!&W^\[IZ>MDKJ\JV.?YVG^BAT
MW)KV^_@R:EX$1F+W=/=RA^V>'ER 8F.X']W;_OSE\Z?=8WBGO7OZD>^!L6A>
MS#<O B-!8=3[CGX^><L.+M_#_0[X[NG[]@'=H0?T(X5[<[CFY;\OW\(U=@YU
MJ@"PWJ26>X#L..5(1XV1,1H+%:3B6,SW^XB%X%[S0CE*>!1"2X<YTQS0?:$T
ME?-M'5[O-9MO]YL[N_L?&EN[VXW7>[O[;W?_V-E]_?9.S3^NO__L>(VEW#+#
MA(B:,U6 ,('[$0KA"B-A(UNGQA.WI,?Y*QREEL2];M7<O?\D&W2_28T\4[>\
MS&V:R6&GNZ2=FM2C-;<K[0_M2=6UN9T?_6SRZ!NIQW3KM"*43.#BJ.JSUVOU
M*_K:=%FP_:V.Z:7N:\->/S<#'#%/)C:(,-.+M+IQOV'.$XEO;D>=;].8Z>N<
M7]IHM$;] BM>ULPKVCKN=GW9P?NB 5:GG[X:OIUE^U.V574.!I6Y+,H6?,/!
M<2*X+-DRCH:M_-[LI"1ZBI[OEQ=TT\9M1'L>X2D[)05J8L*N&HEWVA>YA2!
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MEDI85?A"2'%=#^QZZW@"]F .^WH3C?:1(^T,V ,F'-(D..0*!KL&N#:,I!P
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M&,68U=180>XO+U&K^EJK^MU"?;5K_0.T=BXOP6PA?,$T8'#O$#<A(N.91XK
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M;0<_WYU_/GG?:O[Q^73OCS];\/O)WO;GT^;)@8#-AN]MOSVT5#!54($"810
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M,^K6X,;[@8E>)]KN1>>R_\VSV#MIAZV:;>80^#!"%('@^U[Q[/ FMTK[.;J
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M7 /B,0^D%X0AYIR2T@4?L7WU6FP1/JM)T<LIW]C,O8$*X"N 7V #=>4%RQ7
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MW5^D-^4:?1HLT=OK%3K,3?YFEO_F3)<-!<Q5),CO'^8$>7],O,#.)H4T%0;
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M ?5](C]YP)4*JK3Q&7Z/KNB7XXIND[",:8N$5!1QF=,3#)>@]\YKXJS!TN3
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MHDXXOGK=:L_85I[X0Z^(H7;"+%/;K=UDS8=#2H8F'(SVFVZ.L\XS^'"J3F'
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M#/?I(%I\N /K^0Z6<[PDX 42B!\@Q:1^N$L!@_G!X9MC(TT>#,X1RRVN. G
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M!IB%CD$R)_.0)"TQM@*<M$2(9,;WR87HDPLL;AM1LS3KWR^\DH/T!GRL?,A
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M^K+<^.>L, .Q-;>+UVU 2\AE-\FX[?\UHW_.GV+X.7>440J8E&:,4LYRZL"
M2G+J!?=2*I6KPN;9/$<XFAOFO30R4=R+(N<ZL7GBE6%9;IE;NNCJO+-962UF
M'Z,YUJ7KO)430=-&=JM)+*A,((N^/B_];_4OSURO/._KR]]Z@W"XX4O/9M>)
M"YM3EV&=\>WI"6TE\92J\'9UY^KMK?#6G D0WQ/Y%E77OYULI=>^=]-ETW0K
M2_,ONNS-[PFV7FQ&Z9TN>TN^XU:7,!4+GUWBMD5>62F;;M=;CPY:-(%9NKEH
MXWW%MK2\[7O8PBN^96C7W26^<)<G_N5V+KG#SOVJFY/F7\)\CZ&(<W?1P/WM
M.[+00Q/4C[[E ]7]QLABON*T$S73=3\/#O_L6#T:78*K=J%';J'?\*L+BI9M
MR ^M)_JOKWK$50DQW;,M8U*ZN1@R>#J<\R3/I);<,VU\4GBM"^-E+E.JC_>7
M%0Z0A=CQ0A"F"A8/3OX<EN7S-FW-!H\'DS/BAF-27;R)(+-'&JFI LCT_8MN
M<G#D/AX<_=Z#]Y.##^[LW=$.?7^V!^_M)>\^O(9KO>YU%P+([S^^NWJ5'M!7
M:??%O\X./KRB!_3]:7?W/7P?WCN"M;_H7AR\V+_X]U5W ::%ITIRZPWQVE/"
M::J(9M237-@LL=I;:O7&=L8VF5JL*WCTH--K.?63RBE+!=.99P7SFCN:*$$9
M=_"7R'4J' ]R:B%)OY93JR.GYO%EI&-*%AXVU"4XY8*1W.L"Y%2B;*88US[?
MV!9R,V>+H!-K.;664ZLII[C+$9ZU4"[SW*<\5\Q0F;C49EFF=+"G%E/Q:SFU
M,G*J0<:Y@M=V[;'*0<%0G<*&<DVXD)HH8["YQ&"6@"<6[2F1;$JZV$_RZ.'^
M?P;G]O7_Z+/S9[O53+&;_=Q?M5__.SJ&^X.7HZ'U9?G:EUZ/[.G.P.WZ3[X_
M/#\+(P_7TNRAI-FK!>_02,-U;B6QF?0X92PC.D.,<>I <<F4I2[9V.:;+/WJ
MB41K,([59>YOYDVMF?M[,O?\L#$AN2F<(EXQ,%52*DG.&"?:8#M)QIC!TD&V
M*=576RIKYEY=YOYF+LB:N;\C<\_[(:G7F5"* 3<G">$T5\10FQ,G):6YR*E-
M6=#<ZJO#):N'K?,SN"$[UHXFP&K3*<>_&.[.*C@?\$O]VM[G<S\H/<JRT2>/
M1</U"553$M?2[*&DV=L%/\0*D0BC0'QE,LPX3HD6F21:,Y<()VDB)4JS1"Q.
M$WCTP=\UGW]S/V3-YS^(S^==$B-< ?X'L3E:+3*Q)$^D)3ZUJ6"%8EFNT251
MZ4^8C%[S^3=W2=9\_F/X?-X[R7DBP1.1))4Z)UPI3DS*</9HEE'#..A[OK%-
M-WGV$\Y$_AF\D^?ZO#>&55YYW'H]&I/).>Q).5ZG2+Z9EQ(F,BZ(M-9)O,&#
M>'O^'(]A+:+N):+>+;@<8%H6A<LUR5-&"?>V('GA4I)XL#839XJD !$E%O$^
MUZ'1GX9CO];?6'/L-^78.>?!VD);S7.BF,!25HZI#.^)5B+C.2]4XO*-;9FL
M.?;GY=BO]1S6'/LM.7;>#?"<"1Q-3J0QFO!<Y,3D248X4T4&1Y<P#1R;?[6O
MO\Y0? L?X%<<=[P*28DJ/K&6/?>0/7:Q\45*EC*C""@* 1(G841;!B0J\M1E
MW#HILHUMOHXS_L0L^NVZ1-8L^B4L.F?09ZDO1)$&Y&X)/Y0D*O$%_("_C> R
MDZ 9Z3KE]Q.SZ+=KD%BSZ!>PZ+P%3Q73+C/@<TL)/C<K,J+@G(AFEN$88$^]
MQ+:L%6+1GQ1E_TLL^)M_OA@-RZ4P:0^ T/\((5A7UR$(![5.6#Z<G#M9\!8*
M*[-$6T.,333A'COD;<#BY\P[6B0Z$1O;,MU4?!$Z^JN03K\)D.D/1FC^%;G_
MF_D::^Y_>.Z?<T3PC)BTGE#M+#@B7I"\2#4IJ,IR)IS+TFQC.Q.;&7NH6.6:
M^W\J[O]F;LR:^Q^<^VL?Y^!HY_+@ZN2X*(Q-*?"\4XX1GN>"*)TQXG*GI7'4
MISA%3,A-2;^Z6NE[<?^O,,1X!O^NA>I\)Q"\ZS;@P0 FOS@D].LN<EU_U_S<
M?UG!%/QBY7;7#VWZ+OYV:T[ 7!UQJT1@>;MC53&P5M0/I:CW+A9&Y.D<:)VR
MA&A0R:"IP557RB9$Y5Q0G5CIK<#V@3Q[@/E.C]0(_\F9_ANXV6NF7RVFGY_?
MS< ASQ0G,J,9X<X#OZ?<DT+DRC"MI$_HQG9*-\623.&:ZW\*KO\&[O6:ZU>+
MZ^NFX.Y5=_<M/^8^2R1+-<FIY(2;5!*%V4=>)#)-79XGJ5HMKK_%>ZEGK< Z
M_<V"XC%_\B'+)W^UY&LKA/$U59<_6Q3V1[J$S>3+EK98"_X'%/R+8]!S,.*=
M8CD1U"K,Q2B2YTJ3E*=&^]3PE/.O]_'NRRN/J%[L5^;_A_8.U_S_[?E_SMW3
M/DN=!D]/9 GP?YIKHKVUA G*,\F\9'GZ (;?6@#\E +@H1W%M0#X]@*@]OS>
M7L":^;'!**Z2Z/D)1[BB# 2 $L2J5% I$IMC.O;1"(!U.>H=?_ZE^]604XU#
M@_7 ^G4AZFJX04TU2G-&._41K87A PK#JP5OB&>9L(X*(G.?@37$4J)L:HD0
M><:U*W0FU;5UJ?<.@ZV,-;0N2EM)=V@M![Z;')CSBFCJN=$I)T7F%*+5"&)D
MD1&9:9NE.*%<YM=6J*[EP"\N![Y9=>I:#GQK.=!.B[UCQPFU-"T\PT;9G/ D
M$R0WPA+C:*82JS(J^;6UJJLG!QXR723$RCA'RV=1?XUS=,N\7C_N--6PP)R=
M.EIQ^87N<#REWQALK1M.3-\WI_YU8O0'CJE;?B;W'E/W@!NT*OIE^<ZL3B7F
M6J4\H$I)%EQ,[XV5H$1(EF+"+1.2Z%S!GY[YW*7<>9$\=,+M =AGQ2=VK@7I
M6I"NA,.^%J3?3)#.^>B69]QD14Y@\S/":>%QB(4C<' L4S;AU&</GKA82]*U
M)%U+TN]=,;R6I \K2>=2P%0)2U5*2>I1DB(PF.;<$:9X9B37"5</4?*_,I(T
MA$'^.=9PT^WP/$C*O4$,K<$KKO=I^W_A1_TH9WITTAO4*\Z >:I7PA+IK(#[
M,"G'O>)RCF>OC?E\A_@E16;>'P2TH;*$S>N,3WUGY+'FOHI;=(9%>/'Y\ P6
M??F/I3A%FQU8A3[Q6)./W%_VX)A*3!_#Q?K^DX:7SX<E<.PG'\:L#?R)#G_X
M3_#1@?6=W@ N//:CL]X UW%QZA$VK-,;=WIEYVPX\IU^[Z/O7\)B8.\&PS'^
M@B1PYN'2HR"%AJ-PRVK%2];9N>C!^_AE4S^F=UN=H^E#Q^L42[_<PV<_]P.'
M3PD?*SW0DNYW"J#WX0@VH3>P_8FKM_'$#\)D^'C!<E(4/=O#K\(ED<#PXV'U
MHQXL?#P,7_*?SWO3+^$K!X=_ABV[R[3L[QS^#N03MZ\BC\ZI+NL'A\V#M9<=
MH"L\7]Q ^.4<GVTS/%&+9HSO]V WRWBHMQWZK?1XS3GO $G"G^6D/][L?%JL
M<BAQS__KVX=;Q#<+YV>/5-&]__=I8L_^&NB_\\GAAY,KN%L/5!1[1T$Y?7@%
MRJA_>G#430]?O$O>[[X&1?8VA6M<@M)BW=U7EP>[7?@,_/OA57JL3<9R8131
M5!D"]D=*%!49D=Y(EQ0ND8QCJGYK465U@$'Z@4#O0P9?Z"RNR>#;D<&[JV-6
MI%1FN25>TH3PQ%FBM?7$Y-PGB@D.)X*9VJW%B>HU&00Q=1]*^$)C=TT)WXX2
M3BZ/12J4,TH3P;PG7#-/E'<Y2;70W@(I".XQ5[>UB)[94,*I!FO%>#_H^!+M
MPUYY"BI'!Y6QZZT_,WX4<T LW>R@V \_DT!">.B;J'G.O46SIW^Y=8/*5E9D
MWG]#E=WYD?8"6@OW82DJ\E1H39U,+&>I4=2#SC6%SJ7+'77'N[C9"?R/W$W9
M+K+2/+<]!VOCQ.\/=L[ ++_C^.Q?C]'V/Q\>?83WN\!D;WEW=^<X];E#K'>2
M%!*\10Z_P;E9 G_E(J/2<:9 XF[1Z]D,3$2PU\K@#Z"9M\1*ZUP U^GQ>-0S
MD^"IU;8S6LH%FM+P^Z77HPZ:ZNX:[FP8\ X^W:T^W/?DG8$?+^]6O/S1UNNR
M$OT#O^:?._#/NXN#H_UCZS48!UX3(W('%DO!B-+"D;S0&GY)F&9B8YMO+0Y6
M:O@'G$F@7Z \=+S!!RMKYC@?CL'1ZJ&[.AE/P+/J@?_4&Z'W50;'^0R=Z,H!
M!B]J:'O!A;OHC4\[#0@2L.489&,/N:YV_2].>_84'3;TMX#A)K D?#^P(M#G
M^60$OK^/\]6M'E1N61TFB%I4@R<_&0%S PU7?C$LO'+=EKEX<]Y<RR6$URS&
MB=QB%&#**N&Q-#K9!5P-[W4R'#IT&^<$0]SH@\D9<*Q] ,TTRSIO)F=P7)>'
MQ>%YB!4,3OX<EN7SMF]_!/?[O3^T'W\Y!GF5'NQ^/.8NL4IP2:BR&HRW5!"3
M<44$B"ENDT+PHM@ H\SJ<]C8\6B"546/1YP70]1K(684=%D9* (N4LZ%.>;C
M0/C[,,3(ED6$:OWY%L0_$/^;<9 %^)WG>J"=OM%R[3R!;U<2I7SZVSTT92OZ
M.5<$9D'0^!%L=/685? S!G1AP_OZO/2_U;\\JR$->H.P;>%+SV;OAS>8"^:&
M^\6WGUWTW/@4\Q5;2<00K:K;JCM7;V^%M^8"U/$]D6]1=?W;R59Z[7LW739-
MM[(T_Z++WOR>8.O%9I3>Z;*WE#O> W7Q!IS.2/(KE;B+'LT=8#E_VAW8FP;8
M?_<@34*VH3?XE;?DZ'0TG)R<SFS!'1GD,:#3SJC .T'2/A"HZWVP6Q_#+1^R
M1OQQ]\_^X5W(_*%--FMV$9 EX'+TD.:^9N;.JE7(+-^E>U?(K&2-RU=CSN?4
M@*^><,P!<9-I8UTF+<V<48Y)F]TUD'*]$_CHPR15)8MX1_?YP8?W_<._7Y]U
M7^PGW2.+81#1/?KK]/W?>PSNA]=(#Q<J6?H?WGTXH0=G;\7[%^]@/:\^'USM
M"?CNYX.__^B_.[+P;.A)ON7_OMI?&"MC6:JU*U*26&$)5X4CAFI!M#,B48PE
M.7<;V^"J;_W,<RB_#G?^AYHNRYGT8#CPG;NH]/66M;?L/J;>O7 Q?E*U_C4H
MEC^;)E_VB#^-)L^$9)G@UM&<\02T@C.>6@6ZFRLM:;+6Y-]9DW<7-'F:%WF2
M<D<*FC'$H^4DUQEH<FL*JYW4AF)):JJV'FH^W"KVV=]?/J^X6J+ ;5^DR'_E
M'5-?I\A_6O\\Q'J^0HVO'?+'K<:-TS11&:=4I9RI1.4IQ^8%\,NY<,JMU?AW
M5N.O%M2XEBZU@C.B1('SK)4@)M&>"*Q]\$IKSA!=E*FMKQ[UMG;('X$:_X5W
MC"=K?_Q&?_PNK2]KU_PG=\V]RTQ2>)X6PO!"YMKF,LM34/!:Y2)/[ZK3C_3G
MYX&.VOJ\KO1=*_5[*/6W"TJ=P\EXR4&5%]H0CK-;E<X+XJ@$=4\SI0L&$F]+
MK#WSQZ2@J%Q[YM]7I?_DGOF#*/2UD_ZX%;K.\LS8U!HK*?=)KKQGQ@F5V,(H
MD]FU0O_>"OW=@D)7/'%<"T.H-I+PG!J29](0EB;*<IIY6JB-[61))^W:1U]A
M]?2%"OT7WK%OXZ.OM"*/C0)W*IC\'J;?3WN-M7$X'^\!/4)LG/W:Z>-TQK6!
M^"L:B(YRXZCG!3.>X\1!911SA624*\X971N(W]M /%DP$!.CTX)K2I(BIX0G
M5!&=J8(PJ;GE2692";*&I4MZOM<6X@K;.TRL+<15L!"COLI^"K5>!OBS7M&S
MV+8=QKF'CE3_^1QNBYWH\"$WG>[^OV;TSZ_"ZO=QC/PZ8?1+)HR$,7F2&JY%
M47#%<D653JVB!3=>"ZK6YL/W-A\^+I@/!4\%=ZDCPCE..$LXR;F4I."R8)0Y
M6M!\8UM\?5/&.F'T7:T'NBI1@\>R8^N$T2W& QH*YZ/AI][ (HA-;_#)E^.S
M"DYUG4CZE>,$2BJ5YL89:3T73BK.F'7"%\8XY:A<*_KOK>CW+A:&VTBA%3/6
M$#@B1./TBN0>%#_S/ --7_ D*S:VUW&"1Z:WOE#3_\([MDS3-XCS 6'IGS.8
M8\MPZ%L83-75.=V2"(@44=:'0-X(_];[Y*<X2/\]BXM5H2@ETZ]H4P[[D_'U
M7UD&Y_2=-S'@9OU!:#X+2M7^>3J:HF&<>&)&7G\DNH#E_J;[%_JRW/CG+(I5
M;T#F=O&Z#6C!6]T()+8=0A?+ECAWE)4RH;EAWDLC$\6]*'*N$YN#B#0LRRUS
MMP&:W7OFP/<ZJ+<#,-X"#AG.0@1M/1R==7;L&*''TEQEG2?XW@:\\H^GFW="
MNN_H$6*DF0_>CB-"X*<>K#58A\.RC,"$#I\ZXLI?AKOO([$.L)+8?_*#B>^\
M\:-//>LC#CV"J/EXX1YL@AY%0[-$]#/$4;,@/W0/-P]KE\+X@N& O'T3(07U
M1;EUMZ6?Z<N.\0';L/4$&E&F@1SZG3[<?5R1141OP]6&S:J78"=GD\C7'1M
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MH)%IHP[&10?#+WP).7/Z!1![%R@8XB-4) >Z>^YCD=#BELP]92^839?P9*,
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M:6SS]IO.+C)UIO#2TRS)/'>9P\E]$CQV(!9E1*96:;A#N.)OZ&+V[!V89']
M*CKN-(1<WE%CKLRC+5>A"\\5!ZR\!P%I3U?T$6\=S=%V<C6XSO$1]>PC5EH.
MC+"R&L$4'[KS9"/^LO&T<OA/P"@;STSUP$!K'XSC3[ZY>LA*XE"=^MKA!=1P
MH.RJ#VWBGV?ZH]^<.@C@X)8Q-EUZL/ F(?!>Z^5S/0Z6PG0XD .;TE9&RKQZ
M&YWXX #IDQ#VG0ZUA5/8.W^^T^W84]CJD:Z,Y&CM],[.)H,A\/*'R4FC[,_
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M]VH/".P=/4ZLYDPH3WR.ZEY13G3B+?$J==3:5$L%+AA;#)O.TA8*NQZVD<_
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M#;UFZ+LP-$Z&H'GA:%%(DI@,&#JC&3&),K!7VCH#EG1JTXWMV\J/%NK88G@
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M<N$]\9[EC'*;6G[S;)9Y*R6TC 6-$!TY],Q:,JFI ^U-E<223I8@\8.0P];
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M%D0VM;H0+LL)=7E&0.D:DBLLJI-2P8E9EKAL8SO=Y+E\/&;E/T-!R+(VDKM
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M 841KP#(I<_/?5"0OKH7/L_",G2]_M.("5:"ESGP_4=)=3.SI4)?6@1K0)
M;)B$3>V-*ZU^9\Z?D;\8-0#*W$0H_=","5_58[_9X$1T>D D0>P$\.E/0&"A
M-VAX'L,.7R''6E)ZB=R] 9)O9<YG!T<$^$^]X:3$R,A@,)S X[O-I?O^^U"/
M@I;8K>!R9\?9A;<;ZZ'J2 SSDM%\\.<8O E@)$#O<7[1IQX\16441BB^X62,
MAP8O3D N]Z?GH,$\Q!A.I(IZE,*9#FWV&.P9(1;PT$[*RG0(%%79F\-B,]")
MTV/=.?$###FA[0<&3JUTVA9LV>Y^O(_1&>^"'QYB%P=(GU(7?GPY<[W97GO<
M@J:__ML,KJ!WBPXM'?'Q?9OT SV,A\./Z#+8N(O504Y&93CYFR(VK!!IHKW.
MBCSG0E!3B$06@IE"):GE68C8T#IB@_^I^3%5L(#8#SV3+H"GLK^!^KD 4ZOT
M@U\N>K,']X'W=[OP'<N[1_OI<6%S1-7*B=2.$Y[E!<D1W9CG5%!-"\,SMK%=
M(&L$:)]R/@P# GOP:=A'EZ28]+&;>5B'@J<P%_,2J#669NSUV68 ;PA4@\,]
MAB/L; ;BO3;E5 _NG@?S^Q+"60K1$.BH;K;?K>Y61L+R[FXYJ!^.S_##Z:O[
M^;B ;7:&9H0)*PAWA2 FUP41B65)QI75W&UL9TFR"8)I$:2A/N@RBN1K"2(H
M(SR<[T,1^_7MRO5I-Z?]ZN)8IXR+5#LX8\80/,X1E66<Z$0Y4UB6%SS;V&;Y
MXD$W!QB4MIV,1F%FU2!$=L[0-@";;GCI*UP>- HG?<P%E;^PMMT?1__O(IJ\
MX(#\PINQ4T:,)R"+*0@'4E0T#:/1.Q.]07UU"39H<.Z6>R@5'<[IJZJGMX]C
M<T(,RH*V.L')]J,X9#>F16/" 5W=X=*K@Q\"7W -O%HSZNK-WO-.9:U&@*CI
M=6KS,SY4';G]:__-T4X5MOU2\*C-^I8+"%08=+G0HQBM_H4I[!HG&*%@IF9/
M<(<;=P>/#[&]1_X\XH+?.?K>/H$O1\.\=T[F+L[M+=_[1?-OXOK\V_\__:3\
ME$H@E5&2FV,' %!+ P04    " !U1EQ4/+I8UTX9  #U# $ $0   '-E<VXM
M,C R,3$R,S$N>'-D[5U;DZ.XDGZ?7\'61NR9B5AW&9NZ]4[W"<K&W=[U[=BN
M[NE].4&!L-G!X$%079Y?ORD);&Q "-O5Q1PJ9F+&!<I,25\JE9FZ\.O?GU>.
M](1\;'ONAPOY7?-"0J[AF;:[^'#Q,.\U;B_^_O&GGW[]MT;CM_OI0.IZ1KA"
M;B!U?*0'R)2^V\%2^FHB_+MD^=Y*^NKYO]M/>J/QD1)UO/7&MQ?+0&HU6ZW#
MM_[[F^L;V;IMM1KFS9W54.0;HW'7;C\V;EK7NFXVK]JWS=9_+MY?(^4&_FDV
M;LQ'*'9KZ(V[:_.J85W= 8U^+5]9C.DS?H^-)5KI$C3,Q>^?\8>+91"LWU]>
M?O_^_=WW]CO/7URVFDWY\K?A8$:+7D1E'=O]?:_T\Z/OQ.7;E^3UHXY17!PC
M[.X5AP?(?;2]=X:W I*6++?:<ER:\+(YW&T7![IK;+F;@=\(-FN$LVG@]25Y
M3>0T&TVYT=J39 9;LJ28JTOV\D+2@\"W'\, ]3Q_U466'CI $KI_A+IC6S8R
M00\<1)#>*Y!X'>C^ @4C?87P6C>00$]\_$F2"$#V:NWY@>2F2"T=/]*J8C^@
M9*1AI L9I //T .JIZ0\CMN6HKI$3H#)7XT=CW?/V+RX%*]!B!L+75\?48LD
M):M)]*1\;1(:*]_=W5T^$Q7,KD>F3M'R#?*S(;?*B<U33G'9\%<CICM''7;#
MKUP=8KH3ZY YX/(THHB2_HT%JY$]@ 4[(28@K;\J(Q CX]W">[HTO- -_ U5
MYX(AD$42_T&5_QCY)K(IHS\40>D[ O*SP7X>(QD':[],L[?EZ:^,!NNNZP64
M WD2/5NO;=?RV -X1+3U?:RR4V3%-CTU-V78!?J_][IO^)Y38$0NU[ZW1GY@
M(YR<URB#I8^L#Q=D=FO$ION?CO[X#FH2%TD)V!]WY/4ED"!GL&M)3$M4']@#
M!@YB?5/EAJ]]5+;A0 *S'P/Z+]]^0W?*MA](C-#YUVB^B:RRS0<2V[6/:#VA
MGL-[R38_7'0\<,HO)/+L8=K/=ZZH2%8XYA;SVU7D8Q/\7?A7:NS\]X9$J7Z]
M/"Q[P"7$R!R['^GO0\V.B*,B',(#E1"FV^_+3++H8=QYG"Y50],.^F!L_16M
MB6COINCX'0V:T-KO:,I 2G"H4:=WQJ/9>-#OJG.M>Z\.U%%'FWW6M/E,6+=S
M&7!@D*F^MZ'O9]!Q*%;X!"LIXB4Q9F^(S&<3W8=6+5%@0SU/AF>?&Q\K&#**
M.%;2SWN\?ZDI=K,Y_'>HC>:S<6\\T:;JO ]OU5&W,QY.IMIG;33K?]$&X]E1
M0ZT$=SZV;8@[>-CN!$GCGK03)8$L:4^81*2]@=WK?%9'G[19?S2;CSO_\WD\
MZ&K3F?:/A_[\6U?K]3O]^:F "TC@@ZXTF]?BH$?BI/Y(2@K\CW^_;<DW_R4Q
MP=+/D>BW\2X"T,G&_!1Q?.6X:C9O7DPYWB:'-'KJ['-O,/YZ\CRP8\0'^+K9
MO"T!,'"5*-L:8=759IUI?T)FNG'O_@&&EB8^3V<3<S!IR4U99N&?C0W'PZ&/
MR!\[/@2(F%/=8>BB0+<=?!(:,0\>*$H3_A4%!2P<8UDGBW:OSOI@=\ %G(&U
MH'ZA*"I9I/P1TI99W)X$@W(A,"3YU B V<-PJ$Z_C7NS_J=1'V98%?J@TQD_
MC.;]T:<)6/1.7Q.V6X+<^# I,HWK]V"*&!.@$JRE'6\I9OZ&W4%O3SS'-FPD
M;.U*<N5AV6I>M=+V3QQ+</4B,76RB6( C'3?AXH^H9*3V9'<^=/<M9*VK"5@
M;DA;>;6<!:=:1]M#80J>QL.HPUQH460+N/"-[HU,$W1["#*&>XCML:P10CVU
M/_VB#AZ@X>KL84K;KXZZO?Y('77ZZH $SM.'4G"58<G'[E:F";@][ AWB;*7
M$OQIRFTK04J(>,,RJ^/G^J,C/G.69\S#M=V\:Z<GS[*X2C\S474RIR5PF(6K
ME>YO/$O%& 58=\V!K3_:CDW6CX=()[UNZD%/M_TONA,BSYTB(_1]VUW<Z]C&
M)2??5Z@9=^(&HY_VM4NK&,SUK+*29TFLNA+45TI46(IK+.F!1.HLT4I+GBMM
MJRW1>M?2 2BA%\?Z?:>(X.N0K*1=AR-TJ-XNX#&6H;/4W07"MKLS E;'<P,8
M2] 1\ O;)O)IPWZ G3JB-GR]@KCB9+=FWS9%591L=\\&P8MM/:6]BKZIXDG@
MK]:ZN\%S+]"=JNFE>-7X2MI6Z#KHCU%26NF_88E6^TUI#T/H_A?U?B">K$R2
M< ,L&?RD%,@)ZGIV<\FAFT')'UE7"EU$SNOT6FKY9$JVS\R_@2DAR^(38CY$
M <BDY>O]M9R&(&9#S=F64<TQ*)<GX'#@)@3DFW8ZS9J-1QW#_JQNG;#-X!L(
M1[4_0GM--BO [RERR-%&U3#"54A_=A$TWK 3,_\I:)XBEF\5;Q6Z\T)$!>!%
M5 T:C6\K0O^*JB(EZB(E*Q.;U[HKT+'AMA O/M1W2O-.&.IZ1\]]$@9\ZA._
M #KFTWC<_=H?#$2QRJ'FSHVMIIP>B E&%*"85>V1*#<_<GEP9\B6W$[G,_-0
MJ>,<F=VU)++T,)7A67TR52ULZ!F6RBUI^$Z0P#6'+9*M%H:V(24DDN!Y)S/.
M4+_9R;BWCIWC!+GQ86TK<FJ1BP-KO><YM=.9/FA=[;>)-IJ)9SH.R?@S&XRS
ME-\1<9!B%O7M\W)3638Q?PZ[:J?74P[[OXYSUT%?4@/O0G.P9T$4XX?(U)[7
MR 402MJQ\HSY)NU:D5-A>@K :(:B<NBZ*9,DQ:)J:=\ZX^&P/Z=)<7H0C>XZ
MTD9EMJ#R6/#MWHV<=C 2W*+C:@E^;\"07E!-DTK1G<3YYY(C\%CV_'%XJ\BI
M8( +*!FG6W')X]RU'(P#32WA8T2E^4/L3DX[>XRP=OU:SH_8H^&Z#Q  IY?-
M&7D=G0;6\F,CG!QJKMEIRXJ<\M\B .H>O[!N&" =HXZ'2^<6\LCY>)"UQ%P\
M*#.)<JLQ(KTP@'X9 MM5N*)=,M$W9*W@.(2*V?$1:RMR:KU]BQAC+D7<(P!C
M_K7$\.1; HZZ!* ED]1-^MA'@M??XL/;$;LW3/HEEXJ+V/!=@:MV>M\*#Y\Z
M.@BY/4S62X--SW9UU[#=1=EC5B79\@WBM2*G-F)P@6Q(3(ZT%?1F&?=NL_"1
MA7P?F;/ ,WX_%[;97/G0WBAR:AVQ -JM&(G*>4,VB4''6ZT\]ZRP9K#D8WJK
MR*D,>@&F3,8;H.G>WVWDW<'0QSA$)MU1@Y'_A$S+\\DS<A/QN5 _5BY?->Z4
M5BK)6* :R;W!22UAE8EV\[#J2% ?*:[0FQHEX?Q* N_R 8TP/R[L2E-II<_!
M\V&/!;S!F-7M1Q]_+\V8#ZRLM$J%0$E@ZYT+TM3IJ#_Z-"-W_DV@ISZK4TT4
MQ4Q:;JP*XR^]&!"SD7XFC'Z1@)5$>=4<AG(Q*H<#-SQ5VNWT]O)<2.H8FV;U
M;$E[QV/!MVR*TA(?,+6T8+3E]^I,HU>F:J-9J?NK<JCY5NQ*3J\M4$8-RDE*
MLJH]$B53;3P>?$-VW4[O!<Y#I8YV++MK9TO=1_<Z\"0[89"+:2VC_2]EW;KC
M)?"MX(W2$AYPY!61V* BI:3,>%O/FYW<]M;1'KP8-SZLMTHKM2;(@;7>GGK.
MX(KS(^06V)!<4!*=7/:L!_<)X0"1+$G@VT9P9)KUS&+Y&G&GM-)K)9R!ODO*
ML(K0/$Q\=AN>QI61=K6I<W8O&TO2'^,UD5$Z+R/,D O[55-II5=6.+!3!",)
M;TANN^8K(E^ 1*;ZA'Q]@?KN.J1W%JD8AZLS EQ"#A]W66F)NVP-*9;;B 1+
M3#(=] G9M=0(;3@9C+]IVKTVTGK]^62@CH1W#6;2<D.@JY:<WLX3LY$B/A)E
M5',,RF8*."SX8ZFMM%++7=F(U')\]$=@3+2Y^IOX9MHD"7\T*')ZJQ2CEBAY
M/?NY['G30T)NN']UU4X?D$KV>1U#_$0?)L_/3'P8[\]]%_H:#3Q<_C!I*:Y\
M,W6MM#,.D"9@.SR2 V(:($=B@J2?B:A?ZF["DCBPCIGKSQ/?>[+Q$5Y>><9\
MC&^4=L9I4@[&$;8@2MK)JCO&4V1XKF$[["H0SR+)*Q+ ;F$Y+DEW@@0^ZK=*
M.[4(>X#ZOD""?"PRJ0)USM+E#,5NM-<,NB?K)MKSC'=!(7PMN%/:&7<_<,9^
M+)5"GW-O;<TUX?BK ?)9<%&\;BKM5,+] ,5Z9V,373LSEL@,'7*A):BQ'72@
M8S:6YW_7??.$D2G$EH^BK+130?H!BK$4NJ^-RI'V!-42W$&_0XZ'JY^F6KF/
M/Z0)N7'C=4M.[RB/>$@[)G7N^://#!8RX@^=MM).'WY*(5-[,SC5!N13@Q-U
M.O\VGZJCF=JA*P#B]Y'FT//'C2*GM^M'K!J4EY1D]H9'^6MB^6SX8^=*:6?<
M&9N'3DW'#;EWNC,'*$:?U%$WZA[2)5_Z\Q(7;10SXH^D:SE]2&*/)[V?(>(J
M[=B^8;7KBW)Y3E%VW.SG]4T[?4V*"&YUS(H6]OBQ3D9YQGS#>:NT,Z8U 5#?
MW) "(,X-K!B>=TK[*.-:2PQG#_?D+ BXU=J7,C%7BHX[X=TTY8RC7UL6$N-1
MXVXO_2'+;'+NP+B1%:48A'_U4?#KY3-^KZ_7MFMYY G[VW4]5G?Z")X@AWW<
MG8 %_>_^,W$24G7-Z!S3V)^2O3%XXML&FB"?;H&]D/1''/BZ$7RXL'0'PP-7
M7Z$/%V58N+;C$)?APT7@A_#W\Z/OV._7R+<]DS3FPX7MX@#H+R0<@C@["$GU
M/_E>N/YPP4K; 5I=2 $M;09^@_S"A >5T8>WA-/%96Z;Q_Y"=^T_:<= C>DW
MRL9D!7(+-75KD@UFM67M%28O;JP9LN^[Y+;6#-XOH:1OA(^T97&[&2NR"]%=
M"+3X/L2VBS &J!YMEXK<^[[,'"##+'/.+AGHNP&"!@5X>SR6'D&%QF@N5'-#
MNSIZ">BJ!E#Y"/$5Y0?7X@S=OZ]L4:<SH<6='EW_2#>+AD80$JPZ0+Q .+JJ
MOQ-"6XFNYW18"0XE!A9[]:@[Y$3QAPN#)FI+=0$,=S"F_D:@$P8P_%V,U 7@
M0MX,;8@7 J"/KO>9(W^5VWXQXA?".282:.1OXZ':]P$1LL2U E;F$*T>D9]G
M0?++G[TM.P-I>BO=%FE-]A$+E9CU!2UZO]D5B9!027X?AB#@%8PM\F8&^N5O
M<J$]KY 7G5:(.(%NT^[[S;;,!WZ_3!7 [MD^#OJN:1M4$+_Z.86KT(Z=J42Z
M;RQA7NZB)^1X]/,HT1X <7,KP*.J!O>+;8 #&:[X2!Z6J@*$XS7U ]P%O?\-
MJS[2Q];8LF 2F*UU(]^O*"9\P>:!C=)?TJAN/W&8V)-.G@UU_W<4T#?G-[)"
M0E^P4TLX\_'5"S ^;>(?_7?HHE:SU>3K?Q%5%<8#[8%)")9(3_A $UJ'+O4%
MORYM8_F/4/?!378VFNZ[8W)VPB?^$:F]:L&++OB)GC5" 4R6)+',TY7S2WM]
MYRQQRP]K!VL3BQVT9YC?;8S&5JP1^1U4EL]KQQ\$@;%%JWUPQD8LKA>FKX8A
MF)'M@*:H*Y-7N@H#/YE0V=Y=WM'7=J [3-T2=U6QNU/C"Z*$DC2E>59(DTD[
M;$RV]/;L9_#5P-R(*' FV<OJK6#8 "K(4GZ(K[#I<E505<VRD$%6BK:[?$G7
M[N_,S?D8<Q3(Y:)W#M:50/@PBW$?;KPP4%=>Z 8/@*I/PRIV )7-*<()$1%6
M9?K@AT8J_<%U@<KO"E1!USN.CO%V@H\2W*.05'!L44>25@ S[V"^1 5@'LWO
MM<TQK>C8>L#L8V]1*G+NJ:9'-6],OK%#5!*J/2,?286((K<7CF-V@E*;Z/'E
M=+JG$]L4;&SWJ^VZ]AHMACK8;,_1"S(KA725&0%>K+$>T]CHUO;(YH)WZ%G@
M7('.DLWVS%_F#X&C&%;"LG?)C$R":S?P[4?*?P):IJW6CK>!6,C&8$&IJ^5O
MAGI@+$G^/E%XJ#^3EJJN&^H.L^+0ZH@\WZ]Y:;%5'5R'L]].0\;6U-OH3K 9
MNQ!Z3GS/# T6@4;*)#RCEN)9"27,;P'SE\B:&"C %)'ZDY#9A:F$H1XW$<;5
M^#MGF)Y31"7Z3)T/8XO+M\L9!:M@B%.'JZ)(SOZ37)"C^\'#FG[_A&="!!D<
MG^?^H;9@NS2H@KE#3RB1LB^_O)C%XZ]B% \;(3ZJ,R@K"OX7B K!(=3O;0^"
MPW=%2QV9A:LPC&%2>63G$C?$S26]3J9J!^87 V9F<B?Y@FPB\F >C\'!.^.;
MB^S)?*NPGIJ3;QVA[_0ACM-3?$-7DDM51WG&UIF!!T$A\E=QSIZFN(+]@4RG
MX#+[<4HPK6Q>H>.1BGEL!W-BL6L*-LT-T2-9[/+<V1H9MF4C<]LPOADYE6L5
M[,W4,Y8%S=PK4H4Z'\Y2#VO+AUBFQXF/>"25U=HI"L@T!:&<[RU\O6#]/J]T
M%1#;YFL1'H!](10X/ZN=5?:E$ERBVR7W-Q2,@R7RAZ! 2V>S?1-_TUEP4T(!
MCZI..T-MI*;<1*YB\BBJH)P4B*[]9)O(-<$34LW_"S&=X#A0\FBJ"MTA"+M5
MOX=UKZP%S2:NK"W='WO1L)OR%ILX%'\9@%DBC^W%>%A[;B**]:RT8R(.?FG&
MU56,PJW[A3-6*1:O/9%%4 [!-H*_0'H8!FZ^H<LK_E<9 BRVFWN@JVQEE*V$
MCJ$F\0:=4DE. 685V-^4MW%KNWH2[\;RK,/=6]MO^-+0.'Y(*W_$3K&3!58B
M-\PR!BXI#9$>65B9?_?F2X]>3-[S0F@/*MI<5(9%%;RB0]V/5CZXNVNX-%5(
M(&4?-\K:+Y((YS&[[[WOQLL7.23QA6*;D><:!?O*?WQ%JFJPU5935N*%1CI*
M8CM"!DG!4HP0;15&4T&JB.ZV'KN)LP6[<TVD.?W^29DH<?95Z"O>MF/;I5N.
MXV-]-K3A@:4DR?2K.\1#US%$)>1 H&5Y?@ E(N>4[52'\:*&P=+S(X?MN.W/
M+U*/UW<<$KD7[GG7=+GJ'&P5&POQRD?6F#C'6!/A7X7!)M(:,C?%BAUIZQG[
M2H1[%7I*,_[4#?L1@CNPF?Y*-Q"( (3Q;CR+Y<..8%2%]F>;P[&+YO8*'1[#
M)3D!NO&4./WD*F^Z5::DJ2W)N[(IAO2!JMU(B!*^8#!TO+SWW+!@/BK!IJH>
M'WBET=82<M5Z\C90_K@IIJO",$GE#'S/0,C$/=];';\1HX!+9:&.MBYW/2.D
M$0P8?AOQ]I5Q*%[(/2*)K07R14*5$(Q$WP6E6['0+&I";GB26[XB2<##0#VR
M*]M->Q!5LB0_'GDP%\4)G;+QOS#;2B1[DD,MW@KB68G#4OKV1IM\6UV.256'
M+SL%-D[6.SX2UO/\N%U%PZ LE]<>'(DS8KM%+M:(.&*C-2?E1 Z:"3"IK *$
MZS5[!I,N608K8?W$:%\;;+$()6-SW#D"'P[;*K@R\5P\T+_CT.98NW3!<R=[
MRT[5 X0Q0D3M2#B52*$>7 P1UWR*7/1==]AZ3O[\=AK75W=@<G8^ID^J%]PA
M49)-90.SHLNDCKZ%JL)M/KSF8N0]49/3:K9:Y2[(R**L@MEZ<,'F^ICN=/Y?
MT$]CR6]7?ODJM(;%/P7G1O<+O7X>N?!0,KMK(7DJF61U(,*/W<&Q-=')?D9V
M9>38CSB:19FD'R"YLD.;+(?=1J-4A5<FVZH3_0B\W9')5*JM>)WM1,95&$H<
M Z:PZ6RH;Z"I5T?;P6PV56B[R-4),!Q6.OEN5M>&TCX"E<WW^8YG6(DH?S?:
M(S@A%DL$J+G-+J2KK'78OU2 W--$CLZ3,YH0J_18(K5 Y0MH7SN6.[B2B)S?
M&5M1RC@74#Y1%3:M'#&EG7-ZK+!*=]%CT'?)3;CD.;D.AQJASX#H-QLY^=U0
M3/@R >PZ%+JWZL?L#BJZ^_('UZ*J.;"A;?@PP07JIX)C#JER59CW\ZY#\AS;
MV,S1<W#O\*8[4?(7;&H02Q'Q@-F],!C<$&0_D0HEKH7.]V6*R%X_H$JX&,D;
MSNFYW6TJG=W1)G+?6S&/E[%_PO<)9=B>_<6DHJ4H<0:5<$</8XHAN6T8 HIV
MN5 D158%$Q1G0^G5_21/49Q(3A9]]:SI,??!G/5RF8KH:,:0.LQ[YK=;C+BR
MGN8A;,4S)X>B(I-E5,-H28IO:+++5L*ZH&"W^G*P+ZA+F>3N)Q*@K$(+,R\%
M3"Z_''FO8 Z+U[Y*,+%R'M]*MH!!M(#XC%I#>M-PGWT91C>XZW7'L*IJ&!*?
MI6$C4.#&EWR"5XUMDSMCV'WRIDDOG2*IPR?$^3Z( &55P3N<#)+Y%7%?X8#J
MU1VCXD3X[HFLG)I4S^)5!?.<.X?@+@*G1.?<-B9"6M6/BJ0/-+::S;NRAR"3
M-%4 4VS?SLL<&N'SK4+OL/#,L[YX <(:^=Z:0Y,&FFXL^1\.$*!\=7/V#]L)
M]T]D=+Q!4+ IO8"H$JAQ_%SUV<Z]UJ"8[CR'ODP;ZHNC/-B12S]QXF "TKAQ
M:+K@:V]5._J+//$W&DC.DGWL\' )[SQ?_LF3\\HIPB&$-& ]0HR" *LN5,QU
M\<9YTEV[X&9M$<HJ#-QH<B#N[8)] #8Q*P1+SYQX],HOW1'/PYS$\_73,_0;
MMMA8HI7^\:?_!U!+ P04    " !U1EQ4UI;"(!8?  #\,0$ %0   '-E<VXM
M,C R,3$R,S%?8V%L+GAM;-U]67-;.9+N>_\*7\_KS3+VI:*[)V19[E:,RO:U
M[*Z>)P96F],4Z>&AO/2OOPF2VBF)"T =5U2%+%$4SP?DA]R02/SY/[^?C9Y]
M3=-N.!G_Y3G]A3Q_EL9A$H?C3W]Y_O'#:S#/__.O?_K3G_\/P#]?OC]Y]FH2
MSL_2>/;L<)K<+,5GWX:SS\]^CZG[U[,\G9P]^WTR_=?PJP/XZ_R/#B=??DR'
MGS[/GC'"V.W?3G_52M-L&(.H;09!=0#+N0?-E'.12&X(^[^??E5):/R/@(X>
MWV:" ZNBA"PM_HU35.;%AXZ&XW_]6KYXUZ5G.+AQ-__Q+\\_SV9??GWQXMNW
M;[]\]]/1+Y/IIQ>,$/[BXMW/EV__?N?]W_C\W=1:^V+^V\NW=L-5;\2/I2_^
M^=O):?B<SAP,Q]W,C4-Y0#?\M9N_>#();C:?\T=Q/;OW'>4GN'@;E)> ,N#T
ME^]=?/[7/SU[MIB.Z624WJ?\K/S[\?WQC4=VJ4MC/YS\$B9G+\H;7AR^?7/Z
M]N3XU<&'HU<O#TX.WAP>G?[]Z.C#*<*??]SLQY?TE^?=\.S+*%V\]GF:,KZ6
MNC'"8)2R!8C_N/_#7ESA"VX4SD?SZ3C!GY<?6<#4@9J^S](XIL647#QT- DW
MWC0J IE,+_YRY'P:S5\=G'?PR;DO@Y.A\\/1<#9,W8 ;S8Q+"I+F!H12!GPF
M&9P(405OD)/^YMR4@70XDKD$L^O\7(S+SWY1)NU%&LVZBU?FTPB$+J7Y'RM
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M3Z!K=A=7$Q;-8;S]4N:L._J>IF&(,S%P1AF5I8=(90+!=.F+:PE$[QVA5JK
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MG,4!VG*V'7&P8/9^SN]I&['MB1W;BZ&M>;I^"=M ."(9%PEBXAFM9LC@6&F
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MJ:Q*KJ@C3I3-VR,6QV("6^<:[P4<:515WKS+NY;D*Z3A/9QJ3S 1(\5W(*;
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M,JZ(UA%?FET!#1Q,XDH[U8H>&X6]0]Q[N>JN8/W.)MN &C<J0X@1WSG_!:V
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M:P6J5@#^@Y!XVRJOT</7C\_V!JG\57RSK_C*E=25R;X?C:X1[;0, B01,GA
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M*.UU8R(RJ4 ""XHP:E.PUFD=ZB3^K0!VBPQ^0;Q9/ZAN*:5W'5&UF9")VTK
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MLI3MR&A&1EIN=YPE D(0@E$.KDZ?OQ? L&X*GVR.8,OH:L.E"AA0@"0E"1P
M#>;23 F8)U'@_[.UG-'*IM]K+%6PA#J7*%6PC"XVTW_XY&#_X/#O>V_>'YRN
M<9_ZR%,ZN.Y\#MO<;20WE"<7!7>,R\#0[)8)M+/6,QM9]KU'GK=FK];81"&.
MCX83:&RLH1^4 H+0;XX)[MR &(R(D@KB?-1$.I\(@HPD(Q=D%CEF6L=I;8MP
M[:ZU-^/</?H()K/CN)P4CTIY$HQ!$])80SQ'GX@E<&A**J52G17H*51;:"%:
M@RT/VM!VI8C:R?>WB6S3?#=(/2:2]I(!"0*!24UQ<50ZE:Y_*0?O3;+^N86H
MW5 [IOL*\NWZUN@A+3_ZZP+S$XQ*IS3J5 #FB!>!$?0J$:3A:*A%*JAE8&$^
M!&R!ZI\>9Q?UWJ%DN[X*F:?DQ]$PHODS?H=B>DA/13VW8#P!7@YV0T#,5#BB
MG4#9I)#=BA4XGAQV%RE13^X5[@".)V<PNIO^^/YV)2RUN#*1D  7+&<3L1E-
M\6A<%C0%$%)6L1L68]HQNG2LA JYY8>#.$*/#=["]._#P3S6GF!!,6$=P;]X
M6>(4<29EDJGD/'/K4ZP3 O,\MAVE2\=*>4@;M6[%B]OU;GH(GM!+_.2_E2O;
MKS"Z[N',05&DLD8L: B+7$J1TG)$9 -ZD$D:VFJO>7:H'6- !?D^U+Y>=]$X
MC6>0KLZA%-.X)XQ&$BB1=_V!'\2FZ]9,*M.[#G2"%$4WB' 9$*P,%B6B)!'<
M9,]T2"K4*=.W(N!-W8EN9%'9A-)>RN7FZ548-WTL)@=?BZD^2Z+VPCO!928T
M:]QL><C$QFAP[Q4LFN""J+25+0"TK>O+C7!AGG\=Z*3"T?XCL&8=D5H JWH3
MN1#:=FX=.U'@\Z180_H;I8=FE%D-BEA;]N#$2^V]DF=&G=9*HR$?ZYRZ;I@6
MSUP5;I85RPB]/AMN;IV\X8*:;(B(N;0*S9:$D")Q-F<EE#! Z]0N>13.YBWB
MCM3U- E6D'7'6;7[9:.$T:4?3:Z/_,64YE08IU+TZ'AI(-(*00+7@J2@ B!4
M;F2K^*A6R;6/(?@13(A.I-]US0JXO!K%,W_O'' >XLU+T 9D]Q4MVL+;?+V+
M]34YW)0:NBZ,T1ILP*7,,AJ(IPI*Q4F.*US3VB$(PV/F.K4J>O0:N/)$48TM
M4649Z7=]DW<RQ(5U5L7 11VT<R0(YHFDP(C7TA&N:<#_49/27,;M@F.T>P_=
M<$V&.C(?=B"PKB_@_]8_O_IXYD<7/L+5I!26W1^^GZ19F\MD%%BC".A2OBV#
M) [0)I9<QA!#L-*J5JI\<IB=4VYW0MU,?8Z/)\<?#TX^_6/OZ.W!WSX??BRE
M%SZ.AFA73:[](!W\]U7_LLC)EYK#Y[X4=X_QZN*J^?(M7(X@]N]56U@E5JQK
M"!T$FE65RGS-C"0]-:P$J#$IHO<N4I6R8B)2D:+J=0UF/8]R-O+'<S^8[-T;
M_N[0UR*ON8Z4Y)P=.E$FE.6M^-34J 0BR%"GW?7SV-;UIQ>.\.MH.![WI$[H
MX.5$1%/%AR><>:#H\3&MBO^7N:C3!>QI7)OWL#MFR;RKW:$:*I1M6/CZX6+8
MB'V0]BZ&HTG_?YJ?+YQ,+WBII<^H</0UB^N)=D)*A@AK 4(JG:^J18EV,H.=
M(]Y65%OA7' AL".8]'B&'$0)!*0)L:4L28@9_17GC&;4@V%UZN8\A6KGJ-29
M"BHTR[D[*UN(\B89$$U6IGPDP?F2#&@$L5&FTL(U<9.$";S.AM<6X:9NQ"N3
MI8I"7LKE]\(IO;F^O9UQ6@405! FDT)'.96.)I&14G$.0# K*B5,M "W_1/M
M+DG1=IE:43F;W,SN7>RT@5CU;KP%R.W<DG>NX+8$6E,[VR)2!F\\4T0%72+9
MHB.."4XBKN+E^EARL6'G=LOWZ2^"/TLHI0)O;B'-[GQ+<2E/$WJ='O=WB/A5
M=H9X:YES5"FMZR1JSP%Y03;SJLH:=B?I"I[^NZL12O1J!,T%\K?RU7C6?H)+
MW&.5)SJ4DWV'6SH"*MTO@PF.<["A4D/XA9AVCPX=R;_"DE *%%]-8#1/6*62
M52X",4V9;E\J-5JK2':07*E5)6R==G<+ .T>)[J0? V7>I@GO_L1O"WI_\/[
MP'2V,0AJ2 P4)QN4)=:CPT^= Z]QJIZU*G>_O ^]"-+ND:(;Z5?(=GM?TF7.
MAN?I\.)R-/PZ+4-Q PWW,)$"[F::6T>DC(%XS24!HU7T4AGC8Q5B/ %J]ZC1
ME086YKIU>E][6.KE_WI82E;L';W]]?CX[6^'[]^7-6\X;AX^S(?E*O!+'QW_
M::VO-<IXK#%:![>P7<UU[L*5VFRXRY:JP"6-V0?)$M4I)"8M*.BM,>Z:YF01
M$[SO?X4T/\#=,6*R(27*,I$ZXQ\Q<>*D1J]*2.^,83JG.@YH&W3K9W=^_^!9
MTBD+SGK S5O$H''F01(+@1$7C#/.FK)45YGT D!;J%?4-3<>YG"N+_H*+M;=
M(><3$I@><^);K(RPE"@K5.DK5T*M(WY+D\T00J:ICMO='N/&BI;69DLEM6S[
M2J)$B9U._*1YVJ\P_#+REV=-S_6F?)PR5#$?"/,2!69U)H%:2VC@X+(R,=E6
M&32M@EP7PMC^=4.W*A]V+?J.@Z!/IY2Z#VD6)=@"5.>!\@OA;#XPOB-U#6O)
M>F-$T-Y8ZE6II%2NU9QRQ.>8B$L@F:81LFN54/42"?!$M/LF];^,B#O4>Y,I
M-+KN?3[M,1 VL.Q0%R5X-Z(S:!D8(J1PT@2NE'AJ]1]#_-.7X==?;IXXU?/-
M-XV:&P7?C;?9T.B.!#]<2VH=Y[\=7)6C@QM7/K"H8TR>!,<DD8J)8L%:PC/5
MH?00T+F[O+?[([]F/:XEQ8Y7WX^C8;J*D^/1*8R^]N--Z]IHP93ZJ9$EQ&.<
M(B53EV3(BKLDN)FOV[*&5A]#L,/&V-H"[SB!\09/2=:\032^H78;4)W;80OA
M;-X.6U]3#]7>D9CK+ */@)/ E0@^$9IX2;(KS9Z<BZ7PC+=1 V/M:LJ^1-T_
M88)M2/7+2+?K!,._]R-*\;;'<4(D%I(@(K"2CYTI+F<J$^<8H\DY<+Q=5=CO
MG[O9;;HC20^[$5.-R(C%N]*;ZP_^G\/1_KD?CQNZJA@D#>4("A1:)H(G$A3E
MZ#$8K5WV5M@ZA[M+@-S1?;ZVNBK<F#X!]0[HO53.-G#K]F=9#O"6.K34(D![
MHG6FO1K]-):$+8()RK%(K"YU[[A'9TL:?"N!IX@.5+"L4O372R#;<\U:7BC7
MEE%:!8X=#IHZFN/Q"8P!GWR&QL'#>)6@$DTZ<&)R*!&/N*][&ATQ4CMOJ4M&
MU:G=U K>B[H775_)#ZY(N];09GJZ/![0<.1'HZ;?:><!(@^>7"T8Y.DYS&?:
M,QZR0R.Z9-I;K7U&,UCA?]K:G#U?$/CQ8(P-!'E8%84O)<B$LLA-;N,T8%Y$
M*1EW.D9H54[G909Y7%SZ_JB\,<</ FD.OL7SJ]0??/EU.$R_]\_/>Y9FT-Q1
MPIE4Q9&1)"3NB6(6O5E-J:>5JGDO _-%+7RK\>C!:E=-317\S5L<%*)6T7J2
M12IQWXD1#\R0E+S(5"4O59T ZQUFPDK"K6 AG<!ER:T??/F,$_Z(3G2I>O*E
M^,9W+=:0F;A!'^=]7+6O2R/3I@EVCYL8L]:R,%.7[M:!^)PH"=%IB)F:#'5B
M:5?'O(-$VI "*X3OSUZ!NT7Q?:DT@EX(YU$H8IQ$:. IL<HDPI37("E-P=39
MIQ_'LX.4Z4#P%0ZAECB6,R+$P',@+)M22@R0LUH:_-;Q##Z5UJ-_1"5V0Y9*
M:GD)48DG.(?I[4YRW##M(Z$..&["$CW8<KNCO.%9*1JT:Y4OU*[4YFS85W
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M'S<2ZNGH)4"DA.F(@F$4>0X\$I'!&*V$L\JT6CS6@K$;A-FP.BH<'#]&]1N
MA?&]Q#5P0-?(I)(IA4@)6FJ&2 _ED#N&7*DKVS/ =H,_-;30X7'R(QOG!UP
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M-,%:+4/MQWS-[*@IW@JI*X^2^. ;C&)_/-TY;W]YRUS6T^ S;I::&!LRD=Y
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MW+S,D4B 0(+ =3]$JE.0P:!1^F/&7W7NLBTO\)<2?_7H=*8EMH0(/GD@0JA
M9,@&C06>"6X#.2094Z!UCM070GJ!<5E+J;P-DY86_:9\O%FEO!;0ZA8F7 QN
M2_4)NU%C&W*LH8,-T\1+:S(5B91(9]QO$R->94X\E3Z#XD'FO!OT>*YVX<;9
ML8SHNW;[9XY$8RFB=?-?5P- 1='9Y0UH32$EXK,PI)2\(D%IC4:9S[840/"N
M78K T^.\D!/!5?3QR'%@%\*L= I\"^T#/OH,L8E9[V9.*65)$\M9:6S%-0D,
M2N-?X9+)C"'G5U+TW$ [JNEUQ%G[E3X:?FU (3Q^ X]')J0J+8A2^2-R1RP#
M2ZS4B:)KY:-G*VG[X5@[JO UA=KU6=T3\.3T-.F#O^:4J5F?;QF]HV@ )U].
MFD6PQ/GDB)'9!Q,L@%_JOJ?MP+O/AK7%W?4IW?-8[W["Y"QP+"3.LV.$&[1W
MI/&!6)6!H+2$R]%DM?X"L7#T'X8D:PK^A43+')6_)_VO50I]+!QD$_$S3\]L
M+I &U9.5I3IF126-V;)2#<@:+3WWW,GG VD>#%<UHB99R3V8T#0?+-7-)'%!
M.!*,8%JF)))YC1$U'T?#")#&[_ EOQEB=FV"'IQFWG+GB6I:$E%A2?"1DM+J
MRC%@R?@Z5]U/H7HAR]UJS)CW<SL3?^>E.9:\6 -;[/?(T(+/ELARQ19T%L1;
MZDJ@?N:FG87T8F\S*[*ANL0K'([MI7]>C2=-U.RGX5W#^(^^GPX'-Y4?;K#>
M5)I)R3I=2.P\H\4RX.7NE1+'.(,0K..^3GF?I:'N!*DVHZA-55QX-F;0F]*@
M$^W.E*2=7H"&A.YD:1,-"J+G$C:W/[^Z(,]U&%9?85T[><>3,QB][7_M)S1)
M]_"_NW>D!Q #4^B[)*U+T^E2$$N'0!07.O$875;M?+DG!MD)]7<JR0YC)N[B
M/(:S^0ZG\_V 8KZXNL"--2) _P6&]WK_WBQ^2$E7VBN1,N72XQ4W6,<$ 6\X
MNK942[E$M-X*"':'&QO1P4/BJ(HA)RH9W!LC)[$YM#39$!\4)Y8*J<JQ1]8;
M;*;[DD)..M] EA?XRP\Y\<GD*,M)5:222.0QL>4K ]XQFHT6?H,12R\TY&0I
ME;<..5E&])N.)6@![8^0DQ74N$Q0P0HZV#!-J),JV*;<-2ZS$M\%@M^B3<4=
MMU2#='*#:6PO,N2D%CN6$7WM^^GYNW.KF? EPE/'LEQZ5JY0C2#,9YL$BUF
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M,VCC$TNV]]2#UXR@&$SZJ7]^54+8[DS*@V_Q_ KQE8B@0KFK29.0?)P/_&B
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M[22@R1!%)I8R3KSVR0DE992-<]".WT7I^!KOW'EI%W4UB-%?P70V&<9R&;U
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M]PX.>M5.[7R@=?#+U@K^&M[EJ_$W?S/[]F[TMO0%&Z?;./O@$?2 !]R 0ZG
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M;!.:8SB&E5GQ,!YPH- ;N(7O_;?YY9B7X\D]> /-I->BY(=DARNTL(A+,$I
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MN,;%7'/.,>XG[^<9Q,7HQ2QPY8&4K!2 A(0$/$5\ 1=S5^"2+F 3 )"7!U@
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M468WJ >JAH>/QB)O. S6<*4(^)_*S5N(=*X4O#NAXHBHMGXMZ8^DX-*&0I.
MTGIW>1ARC!Z3#RZOPRT=+N"<JV@OKU5O"^</NW?D*E*[;:<1+<X+PT_,G)H9
M-U<H5TNC^.+2U[F0,8U!WG-7V9Q&#,:?^0&G2VEB?1=KGIE(2NDC'56V;U\H
MM5"^L(LP+"$ASER6*4>+U<IFB"AE$Z*F&D<0FNODZ=!8+E"EFT.,L6&VJ7)#
MN986-3B-F8IP@%$9'G].B(C5.QY,%P 6YT'23&%!Y%GREV5Q35/G"Z QW;8J
M)O14,4==UAB:73W1<?MK.*.[_SN6MPOCZ<7PX/D<G%OL['R*')@,Z@N*Q4W.
MF>0H-^Q=<H<QKE1:[BE*0E)*R[^<H75T+W^\%OP^<H[VJODU%OD;I;E)ELS.
M=YR1;]M.N)SFN#>2QHGUFR<Q;N]Y6Y6R>LA;!9'?U(ZF&9L4/)6Z2PY;\;"8
MQTH=))([S4^_ &@-VT,/DV_I;<(^H@2I6%$V5=7[]\_QOFHIUXK"85E7Q15:
M_WB<!%;I-!]<CHA*9W5:>1^JL":%CQ>GAP]=? <&[0_5[Z$7/"[C)Q._#9.*
M35&$6.7J?'KOFJ^O0?<0$+^#*=2(R$BHKG_CWH;4FNS@];J!+SO6^D+!!W[C
M=B'/":>KL,YOP*N6IF6,AZD8 U7*)*[Q$Z2BH7K>S2M\(URZNMN0HSE>+[)A
M"KW;P5[\P8_<ZIQ@Y<JJNT? OK%<4$)^GPCZ*5=<![SV#-$48+UX+SI3=(1S
MP!X[D7 Z8=>ROI !@HQ7C,#P,\]IY/'RBS.D3H8)V%TL(Q-'IP:3]J%RL.67
M)18D)0/[8"*TDRQZQG@IX",'%DJ(;^!UWQR%C%)5ZYV!D<5]?-7$[H)YZ&G@
M-,7Y4,_!2/C)Q@S4NJ\:<HJSWU.K.)>\/@-7%@X]F!FO:SZ8F?8,M8D]3&T1
ML!NA];/H<L*3VE6I=:^56I*+710",UHF9WPXH,(NI W@$ZP!<;RD[N9=2?X<
M0<ON:NF;.-JC0GVB<O; ZQ-QY) LJ.78R[MCPW"@!$2FZ1(_+^Z+'F_#JQKG
MF=N7JDVX),0UNXQZ 3A"]G.$I1$9/D<!ZSE(3CY0W)!+%EF'[_(O>D["DO-<
M:2)S9LS< O7 #D=D7#XD!ZQ/"7T;D86O5=2Q#D=W/BK1FKR;]:!_BNEU<HW)
MJD-0:"-)\,/*Z<&IZ*0J_M$$$1K?%'A5JR8,^L+1\]KT')OC%R<BG8U=[0 -
MZ:DV%!18S]W )MC,*;W>Q''+UD;!A@U7E:NN=.P%\,[JS.+5 )](+:URX 6@
M$-->^3PBM(2?&U/TBO0]"^?=>8' @O6,DNHAT3:FX-1P\9XKDVE/@UZTS9<<
MOUX9?IQ>FE>MZ%X7LO"EN/>K^*T+H*UR]@(XWK$Y0V:!OH NOH3'G%<GGZ$+
M+UN=,\*+^H=9W3W5C!Z]O:]7?-_V[5/<J+WL&'$^&-I4Z7YM\SF\%!W/ONZA
MX>?K*NZ<5"PA7/VO;4O/@LRJ-42FMXX*2NL??7$N7)NF'^9]8^48C-,4GCFP
M+R?_WMYN4>:=<YD[OMO!@JA)RG#)<-^&Q]4,7I_'%EF29&_0!9[2V$VLZ KE
MNKQZ,A(]YF114(+SA!ES9\C9-T3\$4^O4P[> K7K[,"<Y]U8WA$-=@FIYRT=
MM_'M(KW7XI9#U)2Y@M.JIASKRBP4Q23;NJOG:4_I0=O1YO4VY^/G0^/UJQX%
M#-#7U6ZGHRO)+37C5>7PQ/DC!B-//9://N)=! SG\'SE6C9JEM?@S"<KUN5G
M)/5$\W&:"%+72?^/L/JWZ>[?H'=$M'D!K-,AS,\AO'U\2.!3OW-CZ@(8O7L!
M[&D[+9B"-D.'* ;ABO=3 EGG0PR#X)599:';Q6IU<F8<<9Q,A-KHM\:2N-J4
M"3SV5UF7]. :$-H]#C.]PU6;<Q$]J5/'"R""$W'$FJ@_?RVM1S.2Y_,Z2L!D
MN+;=WL*P%%&$8^PN@'M++Q E^_T%L% "_=19@0@OAWN(ZOD8"AN?S\SO=KT
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MJPH8RCU5P5X]%D]'#<L+?#/+?Q+:T4D7%/'$EIO <#S]A/,%Z*M"T07P<:(
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M:4V0&^Z3?O$;7Q^Y,$AM;P74D%:-@XEDV;CKTK9]>AA MS+MQ2V?1N"+K5X
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M;">[)#I!UR^ #U9E,J(%(ETG:;N).6L_S)U;7X8,-G^U:LXJ[5CJN6S^NPM
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M=!2DFSW^[19">O]JAYRR*I^#89%XH84*'Q4\JD)!8UNW*]*H3TK^H\H_L7%
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MC(LS)5+JA!8]N"JJQHR(/-[]2%SB06&A(E>04?0]:2#AJK?Y5J-;(7=K.MQ
M3LYB;P!XP5@F6<P_8L48'V74R@+!BR].LG4I4$HIF)!A<XB;5#CGW88Y&Y6;
M%5S'S2"/#7\P>[PN:P<?@N+SEZ: A;V\.?T7'8Q>6G+.)9&4.3["B/69?LJ(
MNS'J9<T3&E?EFC=7J:(5D!JE,BR)_^Z9L9 JQ28F*DW3DRBJ<773^'$X1'O
MDC?FPP#']6&Z\-=3S4YD45_X.HLE;5_4F77PSS[B05;@#]]UG*8,,<QRB5-O
MEP.7\AP82$FI8D9(T4P;5!S[Y0>F^DQ3JI-2FD60A^D;!M_+/@/>+TW/BT;L
M?G2KG?'GR'W72SJ]!W9H\+0=:&I4K[KQ0"YQC,FMQ'MQO$,+I4Z$E@)NS7IB
MA3IA]FCU$5BM8\,@Z\IGFL?OAS2PWR/=LI4YJ1L:49(?BM0W[-3Z.#X3ZRX>
M;\V[MK8\3"K7P.(WQAN?=TC"N%#1XARA@)3_JN$:BMDX^QZK8>9HO _YQ#3E
M'>^RIV^:RXCQT66!"!Z=%\2)LGPFI*)0F6V.8O1P?>HZW[/H;<D,:5>"6,P3
M[3[MM%"!MD7J3,HE XIR0RKL2/GMI+I"\RS(7!]:WN !Y"KXH&7\%A-AV[2C
M3":\03G-]<U,.:[TW;77*NY@M-#K,0V:+_N99#V8E\?;SU+8>;L.9K[:/YQM
MY.@_U\,)CS)0^[ X%'!*D/V^4*SY2WXJ[P;V6?3\V'J376A1P&=NGG/X+:O_
MQ=Y;1\69=/O"C02") 2"!G=W=R)X<'</[L%IFD" X!8@.,'=W=W=:=R#NTM_
M9,Z=F>1]9W+DGG7ON[Y[_JBU>C^RY5>[=E7MJJYGD0;-C[CXJ?E$=MIW'_#
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M)YYK!C9#E-FW[+?B2T":3:W)HO7QY1&V&^XE/T-'M\]6OJQAZ$&&55DY^1#
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M#H4H!-.KS74M=]= >'5Q"0$THYBON7<)_\))"6=''F #A=X"SAM%^]%5QB"
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M3^$EX=S'KP8O'N))\I]HB]V!Y=3M%U9';#KF X&T&.^AB\&;:6^TKJ'F ;-
MX>RJK&2?D7F6JH;BV4/GP]/-G;8\'UD,^WS#6YX%G)T?JH97QBEF[9 ((E&
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MV")6>R)QE*#H\Z.N=9GR,JLSPEG^XR^;NHW2"F##[RZR;!W.(CM^","LVO6
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M5C8KATH7BF>M:7TDR',+V37Y(M0MKB8'N*Z*=#W@-*P=^NXR%5255SH&40^
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MT:_P1O)*P76X&K^I5(#]9TEV*G<23<=@BI.FRD/\DY/#F"O<A?^DA<C8SCV
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M[%EU+/.4LB@TO:ATR@H+V55S2/O].8[EAL*X[!DC7KS2T+97![=B1<$[;->
M%Z])4KY0U+;2;?E#Q@-@>(PXF4W/Y\ZVS#@O;EMW-PMOQ7*G'2LGWR6]'P7W
M69;VFRM(NQVV8&)%OV7P3",59DN45'UB3,NW_#3!S2)/]>I%EX66=?3AFEC$
M42*+[?%HSER]&6XG,IH ^K&9AGSCN"M&WC9\M@AN;0O;%)S0$^0S1S825K5O
M_LV#_%V]U'1MK==F"> \YB8$LNJJQD2.U$H3\==ZU8I1K*&G7AR$<9X<-F>T
M,LDK!Q9Z92H+:@M]E1_M'=Q?3?A]OF7,VH&%J%+91-=",>N 1%AAQRK@7 ?C
M;XD('JI%?YFQ/4?43R4B%Y7.8H?J^YP>+KPL*3\H,)2S1>U;&I!#BEB4E0+4
M3 V@)O1Q.@B\!ZQJQ]QU@.4VY1[GTYG#7W9Y)]T#:OADM:6%T/;QD_[X'J9R
M:2D&D+FT;Q4$*MPB 54?6P)P>_@$#N2,QZ,V*Y12H^DYYY?L>_#VLKS#!'8%
MKD.-OZG/O!I9W;@X!Q<<-X*%?(8'9H2OWV=NOK[2PX4R+_ 2%A9M@;.T$:U%
M2AUU$GPY*QCFNCKC@(J!&(\JRHW\+G94)5 R&K]$*<H'OS^,NRY1N TB&H
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M _Q>([X) ?C^@^-Q[:<TGTIZ!F3_VDS]>B?KR5_%Y_-^[+)SC'/X<1*]#T^
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M]:YA7!@UDU0"AI0Y2*>0\AY;8IR0*-*C\6<.\_\?.ITD7,9_OOW*OH2TH3R
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M.+K@J IJ;\03[#W*4RIHL.]8,;3&(':(A"+HO6M'/\'R/#0V'/R:'U+/,49
M)9W$MW^<XJ7GZQ%6;S<PZ\./*=<VW'2<61;-C:PFD;9NOMZR2=^%!Y#<,<Q%
MOV0G]X+:9WN3KQ8O;/O8,@(C955IET4XFQ=.9B;'"-E<+#&6;!/"Y NKC5,0
M].B5NMG%[VK)KJ_?I<E8.LM'FDRR)]MUU01"'S_O$QWPH0#B,>/.]_PER$57
M.%]W:%3BV<./9CH":P>(A0+;EY<[(7&9\'PQQKX<'@8)5GIVEU>M-X651V$I
MEH>P!@&0H( ;5T:3,%5NP"PYT3UVIB M X*(Q3NY^[.HY+UO;&R''T' >=85
M<V0X$[I%J1[5C(^TF,C@)YRX(I#;92%WAQ=?W-NY,A(0SF*V"NE&-GG$=POQ
MPER--)3M8/CKXP\*U[XDRW%[I)Y6P;TM+S1&\W<L)!,%(>A9A-MNT=GA>\L"
MKU^+3IH#!?;49=7$:SB-OK,6$5J+IQ%BVQOJX*:%O6Q3;> \ZE)=%&1#^93C
MTN<!$#]8%I#YX6TCGLG>TD?6#(W0Z4W:L@3L+_P,TFKW0>YT@3&HKX!U*-68
MH Z1&$S.\]Z8ZY;83F<#N4=>>I<'R\QL)BHB-(O;$F7B<[1JE,2E;0D,70_*
M6O#VD04)-,KP-LBM9!O/(^HU[YXA(ZFDA-3UFN^L#=%G!4JC$UPDN:2K4;U'
ME4R:"ZE+,^;#YAC\1>X,DT5A*;2<Y"U\EWJ$<5V+RYL1HFS$_\:1%W ZSOYM
M%O<:<L+96=+.=9/CZ^W%O:RHXOL\?4&=1"X'[SMQ\L5HK&NI(_;>%C7!#)"!
M/=:^]R8MBM/]&A8F-*WB%(M508XQ-W/14ZE9[+U] I:Y]_X+5X'S8T76O\XG
MGWCAK%-CN5'."4>14LX+#_-0DY<_U^^_T><?E1%\*&J@6$6T3L$5S^YOI)],
M;]:I<IV&C8[EFW=IMA!!MO::3-$(G*4%T;13I?5O[:4?M&1:?Y47B-=/1$I_
M!TM%DD$@.SUY@UC7!KPN'FU&WZ8@/F?>'KUYAEV">E67"PF#[N8$D_/ABXE
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MU^"F:66)5/('QH7^EO5M'*CD\/91TZ+YHG^ KR'2X,DUR0:O?4]_FO61%[[
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MM@ [$"CIY0D2R\BUPQ0W2\:)EO.]22C22LNH9JTYL^K4WW=]<S1M $)L#WR
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M'GHE))^@@Q0*C-^@6\*&:HO(YC,'\6X>\@^(S2TWT._^E4QYCNYB*SS*C [
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M_Q:* 5^4H!]WL$<O&6TA;=9O:^MPV/FJBA]\VS$RPH^$O-D46S>N.>V"B^K
MX)O](JXR=BMZE31FS:A">$ 8KTGLOA#[P+CDT(6P^P2R:XVFG*/N-Q<*<=Q(
M8=%EK3R>FF31CBMCBU_TU Y&U%(G=$I?OC[5,_*:,]IP^FUN2^K<8[6>\.&
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M$/$V(E\"#>GM'"CZAK94)G7U\$%9I/8D;S5!K#H/,RGOMOML-P1]V$_LY!\
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M6M]>1GA1K P/"T[X@X3>>&_IJCAQ^^)S%2>D_=_OD?]/\/K?ZO\#4$L#!!0
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M><_\@V@W+WU<ET^KKC*YY+/D8=(0#"M9A)R]YI.$:[8-;M:@CZN")6X$=R:
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M9I*.A>(\!"B^B.7:=.P$E-&;S.(;2ZE7+< 36;3GB$0F0''6=F4")7 S5C!
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M41MHS>GK/]1X(^-]*SCGU<JM.@W$[<:V-V"KOBS]XT TU8H6!#ERKM62S$Y
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MF@O8BLE./FQD72J+ WSK>V0OW7CPV)%'&AIW#6V7=$9,Z;]_;FSKOJ;GH._
MHJ'O$JLKD/(E./.*Y:&8;06XW:C;=U7XEF6DJ:+;@^<5B\]>\KS^LV-8Z(_P
MH)[ T?@=)>P8PHSB-&/O1_YGS4>X'VSB#B\&?7Y)"A*WBZ5ITYM:/0A*L6AA
M76$PJP<E3&Z,T;Z(OT5S(V!$W"GD/N&5,TE)6;;D]T:I?<H8'KW[4DEP!(/;
MFVPQU[@J0PK_D'\$=3HHK<N#@#L,!D#?@FB+81&MUZ4S:>7FC\5XA@&],-6)
MBLO]*KO'7:[C\O)]W[O<@0_D8+9P> _4#$H+Y"/MI^)G=GHJZ;[F.9U[V&GD
M\4RU\<:DG1L=KKO#DQ+%^T[Y'+V]7?DGQQ5! +27%HO91NVYQ5<?IW:/^4SQ
M:5D/K_LY)NK+ZHOK/3J5'#R=WYQZP<64Q74?@?'0#XBI6HH=61@;C30F3M9A
MA7X+2*84.);TECPQ?W$T5B+#,2E8BH31IK]#NS?0,;J:-([A5E,6$X!VT+4,
MR?5M>V!7WW']6^4O;OZUXE429WI^LW'M*\50Y]+2]63L??6B-%B*U4+\5>@#
M=5CLVA,NVJ$Y/#;:+R14W8*U6R<] BJDHCX)Q.S5V0X9:4Q(W0J+I+"WA4#^
M5*CY$&YM<Y+6%9"U,0[DMN<0!@_^4%A(4EGZ6=<RHGAS<?7"]03I6['263],
M^[_"!['N3. X\FX[.!1:ZH$6U&8G03NF0M\HE,$=ND5:2M9CUXJ_;IG(O."X
M8/Q44\3GQVV[. \(R28YQI@B.$9S]89$W",K1I(%:6R!1)/5TXR>VD93&XA]
M]J&>",^JU/<??B;IO9D+:,:@6=7"O7SK)1T!!G<*J:R+H4'"QA76DH_D*9)R
MYURFES>7&ZT][1YV>201'_@,]R3O/D!=U[1]].?[QF6@5F50VLV_/%"G:H?\
MIS/;1FFJ;D3>@5 NR]P<WWZ9[*:$K$?V!^5]G_O>0M<L]D#BCN_T7'KCKQ2;
MSZ^KAM1I'4D<!M,,S+QTJ2:M/]0<31$'J]]=^6UJ!P@F",'3R;#5P#ET,A-@
ML?IN)?8@6:)L&$H(#"0X=I;!//?:ZMNV*8VO^X]FO#(IS;#5\C.ZUG3PLRF0
MX&T5[X#\H$D=V/OU9'WU10D2,LS@\7 0Z#'7_8*4"JVXY;YW\\*T6<O8]H1,
M^;,",<+M#B__$XJ:XUK4<TA1\!)>(+E=N9Z$I4D[['0CN!TOERT?Q\148_S%
M!L2"HU](M*JK7[(^QBY]949O)@UVAC&$KA\KH=J@^EMT,#$CAK"C2!UPO"@(
M[IAFE/5U9-U%J]A][;96#K><<N[[I)&F>\0V1^+@:N7<.M=O:,.]3,W2K$<L
MIKYEIH7CAU(>GJ,,ZQ1]NE;,!*K%TF]#K]Z(]^K93H/MGH/]%F_TMOR=Q<B0
MV9/$$;#@Z<$/V(-!Z ][SGGY;Q3RPVD>T&2_;WO%G_LK/J^MK?AF)M0E4FLW
MDN2_M8NBON0)@UID]CZ7T]]6UXC?4:=^7_B=/?+%;Z.XMEA?YDQ93&^'ALO%
M+TAS8OY4/"4+%*2J(-7!^3D!T2"(_1#RLFXL?PU^0 %P7 V_X3XGU!>Z<#&X
MZ+/==-V)?HG*8<9IQMBL"MA%=0X:(22':8<0!"*?0+I"'(V_(R]73E\.#:QP
M^?$ZQ:N*D'W3T&3(-.6C[+D"V[2%F6TOY+ Y(V)32VL7MC"#/3Q).TO=1U,@
M]768NQ+B03]/!N^XOWR5PT:7=5,(1IE(=-5.$L_]="7:)^-$Z?X#Y:@_3Z=
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M@\+!E7ML;1K3.B%K#&=!>R(E8"GM9J7:'IE 2=?\7/4 *M<@<<!3P,* 32?
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M7=-Y&O_&C.R3+6K)-5<)Y0%?G8-D;FWBX_-F'?N>=P<JTOCU&%R*0"SHG'W
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MC*M\C3B*0B=(G.01?);C,)(];.<<? ^H/6IE&:_*4::V>G>DJ\ST!2[J"%%
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M0/?]4\LBG"LVDMLS9HI'^Z$)%YH8Z#N"I6T63H5.K5O4:3$A" \F)$.J^-X
M0WN&!DOX4)#TS0]#&H#QPA8^^,^ 73*"^+VSU]^=N+]Y@\NQB@D)3P42$I@0
M(;8.-C9)ANR(O2&-"W<91HAQ.#>B'4156K),I91_7$I) .+F^-,9JR9O!/88
MAG'.OM@/%Y=;1_E";>B__Z8BPH1T?D3B*,KVZ 6>F_!;5Z@7HTX47OY_BLK6
M]XKU2NWUHQ4T_=ZH'%TFU!H_AJ;<'*YS)&&FEZ?XM3T<O3T.82.(E>F/:N*,
MS:5N?6(]-II5R2IF.2^%(-GVC(\*CE.YEJ!G96&C^!Y9!O">>TR'T;UCAAO#
MG:*!)H@@!$^)XVY/W*YOCRT"^RECX:_GH)N. 3T,]G(L0_T\M!!:QA:.!1^J
MWFYC\8;CQR^1](C'KAX'/UDD6SX=NLGW1,E(6%9LI$U3=MF9K-XH!.68)7F%
M^<*Y?RS@.#WJ8!\;PH@<XEQ&"L.KPC83<X&!F#-AEK(\A(V(_0T/O0 %H162
MT!P]PC?>0<7#A;RUO@ 'Y.=72 48X/;$K?GWC([ATBU)I\M15YF0X110UF$(
M&C+]\%P:][KA*$.)GA*LAKH!',I>J-Q->N?A7-R9YX:WC-EJP2I4NT>^]=<=
M<-Z7FQSB?O9B;%JFK,"O*9)I?(2$&@"CB@#J+>C#I\OJU5M334LOJ&:'S\5-
ML'Z^UEIZ"-#0NCKYNN,R;09&LIT:GZYAM 3T0&884C4C""HQ%4:HQ%4V5Z"G
MP[<RKBJ#5,@#^90)05E$F<KRZ-CWC)G^0QLSIH1AY-" I@[ZA?)"$ ,UW+3?
M\S([T W'@ X&NR]HY>MLR\D@-:?E<2]/)06#$:8%Q)%7_.[9>F>07=6,,"&B
MF0PHFHIB0OIBEV" S# .F( $=X;WS)@@4A$D.!8XY;?B334*'IX4)GFU*8XA
MK@-(0I"-5@6.+%;CF7_0ZO7*K'_XX@L#]2\?<6<9"AIMP4D%J^[!P8.07_]5
MJR>/K9F8/F!O@Z"BJ<[H)D^8,V(TL%4S/)2($5'[/".O0<O75IU>NC>HJI("
M>3YAR2[Z;O9T3%:\#>#<@2$A8'A'2A/0/8T&)65I3Y,1 _H+=UC>4Z$.5N!/
M^%155QZJZX&7_-B<]UKCQIQ:@&4Y8Q24F.?M'3LPY5//82Z*(0BAXCHVLHEM
M#?7A\.[W-_L_Y'2?N%9[,TGQL-9-7CV"\YX&"V!F!CUN2S&FUS0(T0( .NEI
M\(E%W(&''B8&+RU(9Q"RU\IK$.F/49\F;QQ;D#BQ?>N^<FHJC+<Z:_G#JF?P
M]^"O->JQ=1I474"F@VCP 5D [/885D:WJE>T'O'$-G-K]!(.96\?AD L,RQ9
MJ"JH!Y_HV0U[ /6.7=/D#[F+#4K]'N712)--=E\/L2_B%N:=> )/0NK:DC'*
M](W^A#VHSZZ?^4]71BPNU+2V(^<@#K+,"A /O);*(#62\&9 OXR8D@(9ET<B
MT$LKN,U+2=_PZ(YWZ(AU%19IT!T@OW3+=]^ <%)E0E[>'$$OWP,9=^]Q[->S
M@T'(+67& 203(I-?#/I9MR\3\E[_AGQ4) 6T@-6K_S4&X-^SDD]^Z0#($>QE
MKY%HE.%M2YLG%2^Z(:_Y3W0WZFCLJ8H?G:&DD2/:O2(K4RWJ_1Q5WVGZV.6%
M]-V^-=V\Q=8[Q(0 )Q&TQ")61O,2&&[3ZT#\?V5"I'$@R_D$YJ6%H8(H"_?T
MW'&C _H[\5<WLW@U>S'W@TZZ'=2UH6-A;G!AE#B DXC_,&G5=N<AL'JYVZ7D
M\Z/3W++T/H=XJ@C*;D17!:5</Z2ZLS)75SF856X0SL.[;'Y1B8W:W@!^54@X
MNK/%$,R\_NA-#;DQ'.$==%U?%4X]9 J^S4Q!9<V;L[I/F[8^XLNP'CD_+L=6
M&!$?W1@]S"[F5V .=V!"7LC/T^^#_7%!=1^4PY8Q!>-]9]"=YRI?<R&!GI[&
MX2@>="AHZJYU(?&>Q[<O[.=^>2.2+'"_;C,A0>C-LXB/PS#R3VYJ-.WC+SD=
M]D@9[J*]?)/)4=VO4"^I<,9PNAJ (/>8]SX,[-;54?LNZA<K4V)M)13OP]M*
M'2D+_C+%N^45/;5O>:O[@=6]09FJ="&7.SPG;[[(VS'\A'V)]H3N:-JC&?4K
ML$TC;-;O/:%@ZQZ::'HP*%87YHIL["I9QUW^@ZLO_@VK*8QN\IGH0R[.*$F\
M_;S8:ZY,%%>:L*5KMCU:1_?S.RYUHQ @B^% 2FCUX0@IZ>>J '0!PL4O9+U9
MYQZERTOFUY0Q,LRV(B:$_;B2\4$_@1]LY[")VL= N/#37Z!,";$*5(9()G%O
M09 C?_--("*G6>D+^_TBP9]+?=7BW!KYN?>Z J&?=Q_8%IK1TXX9>:_O7%9S
M'!<S_[@Q->8W[1E!,J$$DN#/4(J%/_PC6M)%^XH>3FC=J*JUK<:N$&-.71Y0
M_"IY9O:3V+SJ@KG[BXRHDY#_7#4-<=&$;5H2EHL)&1E'+T3*O2EC0N+/@9)L
M%ID#@&\BC6S!;5&F=H_;S'G 9K[#6G9$((E@CT/^E.U9_GS]Y]$H/[GMTC^D
M@;K>8.,DL/&I7MBR F[WY-(W-.$=;MUV2Y'*BF/$VFRN_7,QI>@8J20 XY'[
M WK9YA(U=-'$^M5?O(T3?'1X/*.1!%[TP+(4W70.-AOEAJ&(O&5"]#L<E/_9
M2VR"GEV!O_^87L^$'+7MV9V6982X_;PQ@IOE ,UK)P5^D.D]LYW;2$8.=!OD
M,'H"NT6.8*B^QH14X;IPISS0@RV,7?#.=W#FA>B9+NBVT(Y%DKJ,5)F9_ITN
M&(B2?QK3V+>P?P;TF$:VBK[_.<A_^/MRQ)IE!^@GE2N&12AI^D>&H/\5VO4:
MX,8T-_\"OGXN,\]V8;CFV8;=.!WS)?8*Z1O_'6-VEOWW=3V'*/N:DZ%ACSLB
M<<X3BFU,2!G\6;"TL>]'F<\$N@(38EP:<E) /B><U'K7E<6^+:7S8M4M-FV1
M[PC^(,1L5ZY4,<9Y%RJ&HPD4M$,A3(@SR#EU=0=0ZOF>(K'+(N'Y!4S(;3<)
MV8%;=2X>.66?3/SN5:4*;%RN"N%+:CDTZM SDTOCKR5:AJ&DR:772,XM6"X[
M:QJTIO038W!D:_&XJ<WC?OS%?"].Z90[5YNBC2!.8I^^ZVA10.82XN^/H(0#
M$43$X4GDI$+O3W+%$VT-[/BBASL.+QB)^\HA]5G[DX!"ZPY7R-6X(][7'7[O
MNZ)(Y []/<TNZUOL_]&EX92)E\_'7]*$N'71YT?#^5,/'^?)_W:@35A8W5/T
MT3N+ON#M^I]>S4S(T[,E;Y'.E3EKY$>;AN_<<"0S' ]*M4_;U[NH9?I$<1E"
M8L+_CH:V/E&E_V&1SK'/X80,4_&"'MWY>U:-3W_,*WS1?(C^Y+7R]2-C#"'H
M6W19?%B7HX%D$$:4E[N2((F,UEC-:8B:4<J;.,[GGLW>(4;@/3_<\'O3&^ 1
M7"PW<@5E/2/'S:=6'51LG*\O_BI>;NJ"Q[[9BQKR^'.M(<,RO,<+/Z>-BU\X
M7@E*^E$8^,*?ZV?7_0.MR#+8>5?!77[GWW,[<K:!T07/7SXXGG)KY$'(6O+M
M$&/M01.KKG$FI)$)47:IDIO:'8(>IX'P"HGRKVW&L[5[V$S-/!MN.$>"QY?+
M<[2D[]<5^9S8<2U*='2ZO"S1QVLN7M5V/T+G\NI$^P_+>GT05R;EU?3W'T@M
M+KN<FGN ?EA$)1\V<MK#0S5$P#[EZ@D.Z^R6(YS-IK/YWA(]J?7<#O0PFB(1
M,[9!]&L)C+W1:K: $U -,K0:=.9MHQ1HK-WC,SHJH_/Q8]=!3XNCOC*?R^"
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M$@SO.^_01\#6.<ER+N<\3A>Y5^AN(0M._M@EI5AXLLK>54CH\<;;,JC1EV\
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M9BV_YG@S@6Y7 CXHZXR:C\SQ.+6Y9\*J6D/C\MZ&O),K7T\Y!YA^F,(/81%
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MU0,(H@K#&^FFGHQ>BF0O>C-8Y+R[C\#T.5=K2DXQW+]C)4UXZ,CL.X+@DD*
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M2XJ0F]4E>.L1<K,?DS_,0U5<1DBL82>X?(8.:4J>6\%)AL5_XE@FN[TQS5J
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M._?UJG"T/[W%AZ[7L-?=<O^ X:XLZ(@S5P.S&  V\E%K[U XZ:R_Z5#>0GO
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MD9#@:!*,'0C&%30CGK<"C#WTM9"\V36/\%KI79O''QR):OK[$MW]XT9^-#%
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M?&REU#FH"U'>TR]6O3PG#*1Z4EQW]W?ER:31.OQ?KCQ<++D8[Y2^BMF?9?^
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M<%=6)5W[H-5E3PEI8_ZM>O,UX<(/?;PQ24 -,YGN%6WJPHDI0SVV>3,A7?&
M^''>0Y!Z4D'!G7O%2*.E2&[UU/<\@]#UM+I?]H5L&) >$D1I^.DOV17B&TUJ
M__K)]LP(U2_A6KIS8U180W#)UZ3=B3BU@\)?Q&RUL$)UXE#O;+?'E%FUG@GX
M[MVC+@T +B)<8!7AATH>\*XY"R2%1S@<B.F[V7Y$(5A3.$QG+W(%_TMV-* (
M=RI]_'[NE Y47?&TL1KL25E0\R7:>F0((A/Z9O,^3 U]EE.&5@ZB#JCU.&#V
M,KX,,/S.R^%RI8Y=[K.<"/))$^/W..QL6MC6DX^W 0-]#(K(@U#PG8.I#C5.
MJ!&?IG#RP/[!CB-+<JYK5%^9(U?ASZMJM_5+)>S9_=E1,\W/V0=Y],6O6OCQ
MEF&E7V_9S>_T#@P_,!C7.K;59/++PFJ]7XFOF^DHEB([C :K+)&7H]2FERL.
MCXB_UK!5.W&U95=#(+7"IP]GSGX-EM%?AM,=0R>:?!@':EU-VG,JM4S5S;[%
MOG;UD<NKG SOVHR(O&507F6.NJ>[\(F<DJ*Y8]PQ.6;4_OJRQFM6Y.\ISK:W
M#(&*GVOCY3*W'[LZ2\OL5&DKJM<ZRE>J4FFEK)S=!9=%&Z OEGL_7&FT69Z#
MUMFLG9M<TU 9)=^9\<AZOC^WXH-R/OX1G)R[5VID T?$43/?A<J7B>]$%7:X
M*1".97S*,=7U/:@M_/&*X_ERJF?'JWT_QMRS*Z@Z=Y/)4*(0LP F"D3P#P-E
MK<PLJ'M]-<J?;8YA?(XH1!%5GGSQT/0RDI4=4&CF0<KDO*E?F@CRV&<_==KP
MQ![*^IIH4&D'&;_;!Z:4<Z:M,6WVN;6$Y%V6L[F'VMV5#+5\_''KV2R.&UP.
M.,G=7OSBJ@MFB'"K:J(IA)8K<P[ NA=<]7-3'4I[K!H3(D7Z+G(_XG#B)=&/
MYZ:%UR!]TPL]35Z50 $/POSZEG$)(]="GQTO23U4RW&]:#F.U,]\\XAX^KI?
M,AG3EWGT74K1+JV[ ?S5SR?"_<O"N'4REBP3Z&M8R%/NTN"[<D5Y*B:="I7U
MVZM0-;8:H+\N7B3AZP#6IRW5UD]J+=J6FOC2[0<P#C9@K5E&26]%Q(?G[1AB
M(_VHXI* B=->_4S2&@XYMB_MNZ'WU\_6SO=M#R8$+A1L2&]DL27M.MS$A[#>
M.FE9)+$-G9W>/(A80/YP]Z/)QK"U(EVI6JRI2W*&Q(,]WR'=WS)>)[%)G\\6
M>V(?;O1$P_T&XQ$27%5?-[$AT^OYRWDJ(R=KF4?.S*1G=;Z7EU>9.BTZGSE#
MDAX&_&CB\6@?ZFR4^4A8+OS\1),6HZO\BKG:,]7L[Y7 Q'G8DN>"8A!""*W$
M6(7+LFW<2U$Z5C5T;C&=.',%&T<0^SJ"+U?QFS8=RUR_T/(N]D9*B^N$U(VG
M80>FWPA=!@-\%8"EZ<3":W6Z<^ 2*"$W^I?L-R,_%4\ZC879^(V/ZZO>_?5M
MKW*BB 1F?=?KUWE!]N=&FK(LL-UM%Y977O,@=^\,!7BH^*?\W.@UB^)>'4G.
MO$'2F55(;<!_7,%.6PYVP_?4-B,<Z96$B AJ>DKDSZP$M:=N&FZ+7X<[ \^(
M"+#D#Y^0X3@;*6>3V6;D#UHM<K;N#&5SX.$=47P<OI846V7A5=HW(=>(F-70
M<KN2%4=6>OO]2Y9OPA-*U:D;GR,(E;BO$H^L84QV!.&7S&;AS[I*)UR&G6(O
M[<=&I=]9H(<RZ][%_"V:5U<\ZR>3^8C4YL/?[I@]IRZA[B$07*39^*JM5VV*
M]B.FBU#3D_#MEND=6OI.;\R!1J"D!(5O#W)9WJ4]HW=:JT)B<Y5RCJ2]>;;F
M:'1YN. G37$FBI.&UJ%&/0NU9F^)$,-1UL50Y($;C6&S1>JO#,KD7>HM'+/Z
MM@V_4?LV+V;I9WS)FHW_A7U6;/1C9&'&!8/]@GF3''<D8.;Q>XAP-D$=+1&V
MIDF3:9\-<1QFV]*0"JX^<XH23GYRM\O<*Y< "^?*VK432O[$S_'N00*?VM$O
M/]RXY+C<8U+F8_GA*/K>?_O1JB+QQO@K!Q6]_\]NS+28_'D)^@NV#0J#W48
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MI8C^<PH4GGA>U_,H7K7?GZP5:+ ?')Q"/V4#$JC)6-8^,-"-FMIB3=A55(M
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M9B %6GL*R+R^<&?/G8Z3K4(-)OKWRK[=W^WQW(]K5\YJ43*+'P]C]3HX.XT
M#Q'J<2-Z4[CP0]B]0;B&(Q[TBFUGSUV+2:-M7MJC1Q-S3ZP/JP>Y")^YLIZI
MMGG#-A&RG<_Z_6;8V]L<TY?S_!9WZ?$_Y6S :F9-M;,@"1(UI1JCJ-6C39]
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M PUJ_FZ.X1HHM#RF<!V<".HWR7\WQ9[KFB^W!A;G>#P@5,.GP,/^=^>\6"#
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M/_!P$.;X*EAYBKY9L/@]<]7_ 5PG=QMM6*RQ'J!N24ZAWZVUOYZS:4%2+VN
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MA_OC]VW9@!1J\C,;*&G]:AZ+/4DUCZOUKY,=K),9;GY4F+L:MRAHHFJYI_G
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MHX<!3UEM;]S(E\W1AY)SYQ_@?Q@N,QJR'JL'TVQ(KGCP<.M*)\,6LHBJSQ0
M7[CX4NS;!(];VPS<'SK^MC%IKX?E^5K_D<N^=GVQ<;G<U;US]RV3GXOGCFX:
M?-I0#1SL0/Z%N\%)Y(H291DE#!G1WA33E'X[!GOL"8C;?OW;UTW>N9E3;W_
M;''78#;K.[G<IA$WJC>U!2FA!3'7<L&2<[:71#O<YW^4O_1S2CG.D4@;#BT8
MU,ZHUOC68Z;L&ISPZPZJ%'BSJKWNLWH4CI=OS)?PJO6)15'#03+%F^!!<9_=
M-3YB:]?QB)G6FG%#_^!WJ;KIQ)^>;;C)*G)YP!S,*':$#1JH02)@M*_38*I=
MR&*F(G5VP3K(\>X1VYWW>"<3OKP/[.U_]*.RODJ%D&6&^1@W]N+&NFKWV,.H
M7Y^^$7_@1TJFF?1HJ@]=G32(<B?NP:CUUSH<?^E-Z?T=&V]2&Z#_K*'3ZQ[M
MF8)PQ_<ZXY]!E+H\L!?6]28HQ=!E=563&E&R06T834H\XC0;B$C;6"V_KY3Q
MX,;4DQ;RX8S5O49\3L'\=2:.W_^DL8&O@<<<]/M9&XO*+_?*_^XL>[\RKHE&
M85N1U*N$,$)%?TNN%Y78:BVOV*?U?,.[0-#*WJ%5Q.NMI7A,07?*Y,G':A$@
M#;[V"/,%S 3@"EIH$B&)N=JS"IGXW//2<"ZM2%L74C=D?/?5NM@FXLC \X1W
MBE>EFJ-3_0J5*WYW$KNW>O,14ZU-#@*4P;#23K$@-^O>S7$NNS#O@@ !Z8B!
M+5\=8R-9$>BI0J$W5Z+1" !7!=2+G7]0:Z,UK/;+K]C .\]@1E&=.!R#UK@V
M-H =)].M_#N9FO9=/.,!U I(-)UE7D)?80.?"7"A_R[D#N-=G20L?0771L>.
M$^A75G"_.[U.(_V[_V^>E[(2/9-;X",%-K1^G9#KTXZW6Y<1TC I3UI?GW,N
MUPMRMOJY\HCS\1TW;8D?K;O'AV6D3V0_X,:&!#6RA(^!>K<88D$UTY%/<L'D
MZUW^*/&*\-^QNBEZMK6&(24_;&(/7;*X.]:<PQ%ZR4LQ--@<5!R$)$E_%]6K
MH"A':D+^9*'S%*$)+V3;_.'&@EU$_$&'X>_Q)0VKLMZGVV>.J7(:ZC]6NU!?
M/NCUS6_K:@W!;Z?>A[X^_=Z/8E5G#,6OP*SWB9+;5GW+Z>738I:6OYQP7ZVT
M"OCI5_H23XMV6[Q25*]<')L.MS)B+'#T_T\N^?].W;!<F$7EGR\A5L;[GMWV
M:GX8N%I!+6E%R^!<\'N";*;R8CK#, &%BW-DH\&F]7/,5(-9 ]>%>M_U2*3*
M*<_U7RA0 0^)>U_H(ZX6U!1O<!"7AGB&_NA""UQT^\.L#FD?NB>-R)(=AW64
M8P/9?6@(N42&8*2Y'PB)![+PEC@J+A]'2P.8S[_C2HSLF6F0)QN(TL'5&^,6
M-J78 ,]V!1N0SO[/0X2B7(Z15[K.'9GWPFJS@<9TTF0VZ7=P+!L(9]JS@;AN
M-B#L#7LI@0UT+VFP$)L^+,W3R,*)XZ#&E$^TXW[J1"%%B.OB@#:*9^)XUEL'
MA].*J::5+B,N$81*AHFT+"4_2(J.H]HTRCA8(1&@S9D>IX%-OC+/S8H20_N:
MJN*YG].RWX:D3]'0R6CJW!JHLL:4?PLS7#9@#=-Z+=Q_5FC&1K,,W^\32_Y,
M:B3A)Z2C#&D5CVMA(#@PXE(5V6O1^S9%)=<Q266T\<%T6<"$##7S]>0:PG;Q
MI&%\9FKN(HWWL-?A?==O5<0)<I^W ( '$G^?'_E/-AI#NC4L?MCIQN])(*J?
M!';L('P.X[7(WBVG D\Q.A[W/Z1M%\_*.]@;QHG9T@KKQ);._]YA4BS>:=@C
M,G$0N?PM [&Z:D^ PD\C/UO4'+TYBD4WHIZ8..HQ=F#V@5%4&;HE%1_!4@MJ
MPIRFT?'>M#MU>Z5$QW >NHG#]I@WN@T2LF$]7V)"^57>_EM]_Q<V@+?%C?G,
MHD5P]96X]2AD!&FS%V8*O1V;CVK^'_8/&&A8\)G9//.>#W/'(&T\%R[T8AZ9
M;V@SH^^HN,5<"+GTQ+SK,>HDU \G\' [%J?AW7PVP!?8'#Y(6%7;EXE;'LT%
ML(AN="V))H#[BMZ6J3N$FVS_S@82W=G 4WL6)QOH&J?!Z+;3&@W%VNU!AE^U
M6=. SI*I4JS(M5@D> P>>,8.18%Q+Y3T6P=S'69S+U+9P/XNGLG^8)T57S:@
MG$YU8[5VB+$!4R?B,%Q&/B%-:C"%R)(HJHL+&_A61J2264)%X#YJ-@7_!++)
M _,I$2/X)]HA9JX],O%G.[*2[!]:7[7A'!+-?<[)P2/N.,H_OY"3LKQO_M1]
M]'[6*(IZ&3&,;C+8.VB@"UT'0[(<'$'7[C(SI\V<E-T!2F%^D4L[;LGU/GZS
M-_'Z3)S-8*+F,6CHIV^S+TH6Y?9W'Z?;0+JL&V/K?#PK=V3)>H0X;#T[E3#G
M&8C8]5Q5WFDG\/SNAY%CPFIZGK[*75 ++;45%4OFJ@VA#II3QS)%P4!:.+V.
ME+9NO@M,&^WHU1=Z.WRFYG)/(06E<+D8N6D<_\M/=WJ1 "K.K[;2N.CQ-.-F
M-A!)%G.C=CZ%;*DV3:IO.RA$8</91>S>A L1[Z=XVI.*+K@X<LCQ7-Q&TO.8
M<0;2V!$R(IO:VK3&YS&ATN,URS#\]++TRM#WN(?/S*1M]V-\JW;O(="=F8EU
MLJP6LE V%=^(YE^L$^]*<:U*4K/H4.KKV,I-,U*:?;;EYO1HZ6W/969!;68:
ML\G,P1T;A*L?):_CV0"7FT(@?D7\"(_*I2NAC;(SHHBI@5IG^B:\3J]BNTC"
MN,D,@\.TE#R&"^8\K37*GRC<_'XBR-RR/,13K>;F1SNN@V.:-]6X6R9.KWAN
M1M';F4]8TBPR4KB4#?!#5EVN-.&HW"7+.P,#M"4I23.Y'S<C'E&KC[9,UY^@
M%^51<%_Q M M<%\^1I\FF3'($AOX79+C:/MGW:C'7ISWZH6<DQF(6E[=>=VB
MRT99EH&!:) ?G:9^[&*I*\.>AN+]^U%@YB&?& (5SG!#K=>I:U&_D5R0'N%Z
M6=3U7A'7Y$N]<Y;ED@3I%V_4/Y=&*25,MVF/8@<))?/Q=:H8.Y#K$<4\C@T4
MFX=M,GF:) <SA7RX#=^?PWTL J/+FGS;JH^]X1X#%#.-3S#O@8$P&]L$SU'7
MZ%>B)E^3PE<#-)X,+'0;9GE*B2[=:XECT"-?O_HJE+1S[?GO9G@1E 1"(JUT
M3V92G6)>+"1 )9[IJ37V-BG]DF9"E&\\=9[3[984!/"O/3'<D['\A[@^:[IQ
MX!BV_4@Y>0X;@FW[#$HUL@&J+W[U$%;W>+C44_7#^Y,;K@3AV^U1Q5,Z#XV<
MBZ]GW0@<01SXC)K,. *=JH'7>SS*_0)+7.B8.7_;Y#)1F:'A,VQ'+35X&.73
M5O+C&W?0?(+:;S+]*^Q<&\P.9NUF(>H*^(&Z<9%V/#_WR06-N,\CX[OK.Y^O
MGV_OE,<]B9;O1WTE@P>4ZY'#>=.SK4TD#O# 8 /K8'6W,Y5Q*GZ,-G+X^:VS
M+>6CT O4_MG'.Q5O)]_H^QWGM&UDR@9@((E2UYR][[EZ@@3M;)U#0S+-M"WX
MVCMQ+LB1M,[FB</4M<BB58S+QQNGRK-Q<K5S**4^B?@AS:2K<>HF<)DVQP:&
M2ZQHW*V0C"7#PB'(C'@^=4(G\9=0L<'-XH?[-W0XNN[N)3BC2^5588LT6#\<
MCX-,>'6CKH+GID)(N[7FEDQ3; TZM>:3-4=_K=M=VJ@LNN\PN#(*>Q(&)7.&
M(EQXZH37BDT%K< 4E]&VMADB4%-%G*Y-N16M\W %M#HQ<N2-OX35\YR,3"@1
MS^+R65>_)G4R:333ZH\6&_@!+0\&D(?4!UF\L]2T0<JUBBB?6C6EE)?/[(+\
M4VC*]# NWVME^Q=T7KT>WNN_&C.'FLS)GV)*L024&?QM/FQ E/SW,Z_SW:_1
M OOMPYZRNGIPNQVR8I/.$*M9>W#U@B@79 1R=VJK':*^4]@.?,QG31G]\3"O
M]'/BY6M9%8%'C<[,>%F&.PRN9L$6_0#5X!3'7=ZC !(GAR!#@\<R*U*^CF/7
MQ^TB&>V?ORXPS-_YVE5I>/"_5E"#"CT?K;3@:Z0NVTT<]_FYF+>EAN3!=J5:
MCN'J^TA<LV$#I@]KN?R<W#M_O;IXT:CGA$*>PDBE!JAP;2W4WP=41:S>(\GE
M43-0$HJT PQGRGU^U\80YV\,X^\5,ARC(Z3+</)Z[(?9'TM_1L4UEU''6R'E
M3,YNXZA2L]-+@?:'#T5@K\<USCWT?D"H;;?7G]?&,^ \7J^"<B./IJ,K!@R4
M,5K=F#.%]ON-JM^6IJ3^B/$3>??DQ;!QMJ@: 2%_0:4LY ")JNK(!AY$)J4E
M8XMQ*OG7H2QFLC#^/N,&KOZ<,GBY"_^X8TKFQVM]B=[1*^MM/W8W +O;MD)"
M;. ,NF,(Y)A\A&,)A=+*RT*FD,(3GGM24@L=;BR)76]5^O&Y:=89=R3^ZQM
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M8CAY-:#H\E:1:\(0L308Z7+D," T"8/\=R>F>+.=1S8^SW3**-O,[#WCT\V
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M:MFPLEVL!UA)X%/D"V!(F\B&&98 2+M(1D [:XGU57&3"_1CPPY+05KTZCS
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MOD7TEPP/\8L)B]>\C(9,T:VQ2S\(CWRKB3V.#B6L41QWG08U@3CUZP55Y^,
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MH\K%EWB'79==VRY\,EWX66$IFW1?ZLJ#]>-!4NX$\!3T"$ /0YKRLU7R.NH
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M7>6Y#L6NJ[&]:=7?-N]#<&KPGWGPW'\HR/&7!:X^)(2#&UIXB$R',E]!5(I
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MKM'Q$,#'-L3"/_8\"+QIU^9*+Y PTR[SEE17> W3'IK;3M3PE'"7:N?+PKV
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M+O\]?G$&0W*L#TEKJ5_L$_J85C<?;]<]^X_@( #1X6 !^3I4S^ 0#_8\;U$
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MW>=>?B3[N;H)\8%QWZ5KIWU@;PE]5$!+H7$]^SG#?&Q/I5_VL.WO]0GRG:K
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MQ.Q"[J^ $CX870#/57O[9@^<KL/))KAM8[#\%@B3/T)W3 /AL(E=2#>>$>J
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M/C(G'#F&]T)V-%_%G@E^U%KW8#RWO 388(X/#$PAW>U/<7^ZV:7(X/$SAMQ
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M<:Z9>6S06TN%W-JR<7%Q1R99Y,G[E*\[29LJ?(Z=[*:A8\^?7H48^^#74X+
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M%+61O%!_E4S7O/'"JYD:9W\;I5]0O';KM?P]W0) A0R_!2S-.G\/$%I[FWS
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M[M>&)O(@)H?\ W=+P_;PN-8L\\0.AIDF\A]PG+"9 BBHM*;0.)9Q.T9NK*_
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MGV6&G2J&KVH.":KO0K#7R1.5J#8;OW)(BEUO64EJH#*7?:XT38=N"=;M/9*
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MT& 6$5+X5OAK53_':?OS7^\82RX>B8X*A;5289]JGI:"*+=>U,MJEHW.,PW
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M%;?I-\B$)FY 7GLKKE):]CW%WY*<F^-Y5ZV]T$M+W%NF%NJ9J'YEU(_7^MR
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M3<+W*:)F3=>LTTE[K'SZ]Y_LIRT4QL< MVT<_@0?>O=)5ZYYFU)(M?,FE^*
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M\>= B,\S)6#WAIBG7_M5J_0VIW8VMO1$?_"MA5JU3!\1N<3V;)H-!'T<ZCB
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MI6=P+\H&54&Q0"HVB>Y:Z/FD]./#CT4_7=!Q@4TM5Q].1N/5/A=F-<8LJ]8
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MM7'YUA@?7[T_'(WQ/@M1Z_=W<AT\@T7<&>LYJ'LLL,AFML%E&/5HW*LZQ,%
MJ]#+/VH2XP(+7:\QN>[7<'R_Z;H9OT7O.,OYWGOURLELS<3$T%JF+_:7_MG
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M#;,I9QCIS:=H_/ !N 35'5?J'*<%Y.T:ZC[1N9,Q>WG-S>*7[X9\E48/X#L
MP.;"<B<0%*5Q-.X-NE(]H56(BG 9@1E\A"8X>PK0;"(LR@G'KGX^V@_\%E"7
M:@*^:F,*I7EO_1$6T[<Z%VC(S^3JI"FO8"M9COM^M4JWRI*;J[FHR,"Y^]J,
M5[;FD$ 8!E:"EKE#CIR^@21=WP/\#-W_V3:*^=58D7H+Y>;FJ=-(2G$.,QLS
ML;SC)P%)N=X@\>)81/&'NRJS)]]5AY7O["9D4'S)(*5 +%6FMQ<EPNR;+/[+
MDZDYQ&S!&0&M0M6YH8AKPZ9%Z9=?36K3FV [=Z)P.VP)I&;ZNY8\7#!=@-UU
M&(%+QF _9Z<TNQ9:^&D)3+:CEAS\UR[1KC=&3^K%G<:W\7X9]*)M)BB;O[YR
M=M(!_<6EUL][K18S<)..8;P X9XC)%HYF&U8$6,V:M6<4FSS+3Q* /K4E:?]
M^?L,A:/00(L%,6D7-H6\G*U.R;N-UA.#S,/1A9Y D@60>I\EE.+=J/@"[[S$
MT?% J#3[?8.O]Q(>7HJ4'3FGQZY\,U 1?>%DN;)EOMV+[=>HQ0>3]-Z*U))@
ML+;[IO'B?@&3MX8VI'4L7J2%!H8FS.%\LKX0AM\,3P2)1!\7CNNKOW.#/S/X
M\RFF8 )ED'IRFW[,"NVY!Z J*84C/%#1N\P\'%&S;3>SAM@R6U_EEE,0<\JF
M+M,@U\S34L"Z'!YA8Z?V(*O%CE;+I? [+)<V^ +Q"/E3Q8U1S-*O[#H$FQ8Q
MV&)$NS^9QWJ8HS3H".JA0JV&2%CB%A%R>FY$>Z%\'Q6;R1#ZL5@SQ@NZQ9P*
M](_JV9[C$EWB/FD/KPZYY*1%64?<(!4KG5MHI;Y+R-]-1SQL??+B;FTR<<L"
M](6.I^ZWH7 DU^Z#%X,,6MLF;Q%>P<^1IC/.&\H&OYFL26**Q!SL\N(YZ6E\
MUY+#_;E?VGCS[!Z >?@6[=HJ@@N#6WA+NXUUI1\+M:],[Z;KEW]L:3RC(KW5
MYZ9G)\LII0$N&[51J9T?FT+(R;^S<9;_@G"'3)AT(BHYU_!X9(PQ?\(&C;.C
MUAMRI$Y!:]LZW<U#)FSQKO6G-B+X& L7!O< GY]4DA,I!J2-;N"1B;XP G^$
M^%?O@8.W-[*^?!:KG4.^Z)407.*%O[8''EW*8BH,JU735J&HTY!W#]54YUV'
M!B0.E"491' =M#'XZ@4)W-AJ1+RQVQ;.1A)28_< WJD1Z8AV/S3N^:[T:QQ8
MZ.'N$>31M<"9NU(7=W7KZ\(+9'\E1>W4<1R"OVN-8.3L >X?A@LSN]R$J0:$
M\1&Z!:2(ZA?(:X6/SQIGP%K2[S@O<$^<&]0>A@\@/R.?[0'NJ<>JXOECF%*I
M':UBS@TH]Q%\8^[#NUD.JO)*N>O7112(QVWR 2BS:,/Z3$2CQJ5T6'_AZS6/
MX[=Z',>5,2!U!"X33#KO&LKD*J?Y0TL)<M"YBYAFP1+/X-QKV46F]PWUH\OL
MKJ0>SS([(>'U\6"*-4<+^";+WC]&NS-"G9M'U8V%<C:T+>/5?$^(=R]A%9)<
M7X;+ *&YM-H$=:7^;TSA^]O3(T0]M>)>!#L(%XNMPJ[%S_4U^Y&0;62J8^_X
MKL]82DY):T'0XUJ(UM7P!,WGYQ6D<PBM;%135K0\P1P# IH#"/R"4'G*:Q(V
M.F@/(-"GT)CRMO@FN-/OB6O_:V*3TH)>-QQO8U:W$)KY;;B2S$\7!%%X&6]
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M@0#N#WT?OX8-NT6\L$M(]4#8DKY OA:_2^#XWYT@\O^G@=B;^#\ 4$L#!!0
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M*D'!6M+J-?MX^3?PM9;9<..LWVR8T=9@& ],7^?!:TU;O6!R2E]V$HQ*8[W
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M46_B=1F-4$)P $./,X@2FD(L4@XYYDR&@4!(&)4M'%WRJ9'FY]7C(RE>] :
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MDT8&$A(B$4Q]PGBH.)B&B?&YW%FB3(V &^% _F1NM3N8$(-#O=%@'IA>:SU
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M1.@CPC2!U),8"LHX%3)(>&S4@>+D2%.CEXV@H)*TZ2U="VM;7_HHO(:1)2Y
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MZBR$3650'* D%&K]XE&HV\BKGPB+&11QD*2)AX,XMFO*8"_#U-:O[3:$.TJ
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M[@_#T#Y%)=@@H;F'=7:;V;T[Q+@IV@?5V\NU/ORMOFF"![N<;AY&M3++6.
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M_%%\(=\/>/P)DA3%,H4D%'HG12B;PO,%))QY 2->3&.K\YZ.L:9&!;6H514
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MK*R3([MM=<"CU@<\B0(\D6*9L>RI#L@4C?07ZAN5=A;%,0:>^VXJG=B,#LS
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M)2F6AD<<Y]0:?#W:@'%-XCY;+/2^.B7SZHBB=U.=?62],/6PT.M0J/N*^(1
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M!R]IBT*^;!7.H0EE <,<\MA+((J(,H9U:&S$A8<\C(A OG%*Y]C23XUE:TV
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MZ#QVSQ'E(\K4^.%^+>&&_@+S.E'2;WHO7/X-W- E%=0GD937\-@1RSB@#\Q
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M'(>=3FWY;"1LSX[*ZGQV557#7>RDOC12XPCX=L=%H2$=>&$[$9/1@OS% M$
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MUM=FQ_N8FMVZE1(T8CK<%YU T>(6[7)L!I[T![#XW*>=P,?A4NURG$:Z6?/
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M_,&9\ A=NF]./S9!ZI_T<D07M5/6)_V[<I:Q)&51H:!(<@61X@32+&&0YKG
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M9W7OP58S[\3J(4;8;ND;>=P&7L0ZH_#-A,>;R0?^>!;FQ&@W8*?&:Z#8FV
M!PZ\N5RND:-N@@%Y&'(3KFD/M]V;!2W+.]5$B3=!XE]??C"YOE.WOY[G36S/
MQQ=3^^?QN[DCG*_$C-,8F[0XD*6T@$BS-F01B2!'6"J*>9[0W*':Y"6R6''
M^+4GM]D8;NJ3?6V\&B>$RO&@M/0\N&B(^DEX<,3'8=U* W"W34\"[IK<%Z!6
MP_Q31Q%0:P*T*J#6982!</#E'6% 1G+E'6Y@W+QY+T2TUYG7M^WQ?'DOU'[/
ME??2MD)6@>^<#GQXW3W2'!Y4.Y]FOU.%L>D%M!;FWZ416N^-?LHU?9+5/W[4
M*\+6H6\6Y3$F&8\ARE@&48XR2)C,8):R-&9Y+C*575Y!?C#YI[:1:06&M)88
M/!F18645*^,16[OGK523:+2^#2_KQYHE\U*_O;$_(;O=SX0_C!&/^[JZ=\_\
MS-7.T6/!^OROP> *U"B8756-PQ5HD0 -%/4CP( !=C[8 =-@O<\XADV>-;(.
MXZ;<>I\!.DC4]4YB>&P*]69S_2+%@]3[RQ>^J=9SO1-=ZYWH@UR8#=1-4\(C
M3T6:*1S!C"J]#90Y@QAQ DDL"A-.0V1FM5JZ=3NU16Y/8E,L3(L,UK7(#OL+
M>]@MMG:#@#G\$9J1&>SCV4@-&K&OP,V96BB7(.NP5QL$X9%V9X&0=MN*.0/6
MN_FR;VV\[9:SAGL;+/>W/9TFJN209A5:55&7=:Y 56CBIH)"BLW&QYSH81Q'
M,,Y2$IDD.[%P2G]VM)>I,7>3/W4KI6<NQN.(6CH 7(K3P*3L#I'[E7H?!&&O
MNX_V-.Y5=)^R!]?$O0_[GJBLUIM'N?[QQ536K'WWHU0#EA=0TDS/?2XPQ$P4
M4$B5H$R2C%*G&K"'74QMXE<25A7OP'.3H!(LC+".OO='P+3=_E\"T> [="T<
MK-"IQ*O=:T+NF4\I'WA;>]#-R#O/4VH>;@Y//GEI+OSFYK TR:#++RNZ-/>*
MVXQ^#Y++^4\3J%Q'X.=24&UH$9@BO?8CA5*HUWX"49H5F=[L$4F=HG@\Y9@<
M770RL+>*7%5IU_5_*F6J._Y=LLV=/GY9$WS'SY)\AA^5H1EJP &Y(!.^%YP#
MY<%WD^6=LN![ 78Z![Y?<WX4^P^ZGIMF/B\U ^D]6QVC^66^E)\W\D<Y4TD2
M(Z8R&$6Q,HG-8DA5DL)8&U4%445*X]R%2L_T-S7*;,4%K;R@B0?^TX@,*ID=
M2?$<XG;D%Q#'@4GN,@B=:<P2F*!T=:[/D>O=6P%P6-[>[C6/D_CJ1J"\ZQ9
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MP4:#R@FLT0'0_KULZ'&S/3L88S0&/U!HE !&BVUYBV9@.N4/]<#<;@>F56>
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M4R<E^&.I&ZFC*.K44?=R/5^)62PQ4I)F4*(,0\0HA@1+9-(W95S%4D;**CN
MKP!3HY5&!4!;':X J[1H4K" %Z,'*.NXGM5SG<.U4L7!(O 9*0O3:6#\A[Z
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MKO-%C+:RVQPH7#D>=OS6"\H]\ULH@$.5@3H/UA#%GD[T/H:23N=!L2S<U-&
M1[3XSAY/=]'$K#\L/YMDQ^6CR=WT*)?5[F^2XCP34._((#+'QVDN ,T3!IA"
M&$(>%Y#;IU"Q[W=L-%;)7,VN-I-5D^/J62[KLY[JU$<L9C.Z++>_M3P <AV5
M;CKK$>L!CX4B+?8FD\;#,JHEUV9:A;L6OCXVZ@=@AXCP?H >*!0\).!N\>#N
ML'4&@CLT-UP$N+N.>Z'?'J^[+09"3B=OFP^MSFQ\/Q=OC3^84"GDD#" I%(
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M@/8KYM@(>'MT5 >/1&N]X5E&M0Z5B\SJQV)=:CU<8Z-Z&F8[:_CU!Z_GI2%
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M,=@IY.C;\=4KC>EP)VG!AO-^OGZJ6EV$#,/J ?]^DNT'D.]UTO2' _9L@O^
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M^XHM"KN\9+$S3KS-*F4V2P=.O)^ER1 \G7^_6\RKDZDUG9G;V612Q'%!!,*
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M%&1D-Q9V::2_B>:5_.87Z_E4&W/3VLG;Y'^K\EL['Y>[C(OEV7A/:/=]$-X
M_:4&^M,&Z%KXUIU> [TC?\ #;P_4PIYNNP@P[%&V!S1'Y]8^;;A1'3>>"\N7
MR;<O$ZR(@*FB0!09-P26 $8H YJ[$ID5>1K;7?IMFQP;+7W3[*-G0U47UC(^
M? <?B!&)!8R!+$SA*R0HP"+7.WB*$$]RD<LBL?.E]$-H&,?)/8PL2UOM@-3-
MMGZ*]\RAWSZ]_WK_-OKR]?;K_9?KN?%8QXZ$(,W#->$U_ZBXKF*YG:8&X:YC
MT5M&.O$7S_/MQ=/38EY1VB-=/BRK[TQ4*><?Y;)BMTD1%XSS# (1$SW1L"1
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ME%+53!&+V8PNR^UO+<NG.(U)-ROVA73?)$AW4D_=1!O,V[HIE=R&%NNZ*3W
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MAQVFZ-[)[O[F9?M(D_S]UIPP;/R-]8YI_51G\S;F"%_I?91</B43F B,&6(
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M%, P*S1?,<%P@7,66UUUGFQ];"S5RA?=_N8P'8\PLR"G:Y#HF9QV0+B\A;%
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MNK<I6U?^A_I;;(XFEQ_IBO\P&;]V_R[U9SY?311,N5)4#Y@HM%6=*0QP$N<
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M<@&Z^-K60S*@BL9_5:M';4RM+L)"A7U;\-NITV_<V_>I]F\+]*,] ZP9U)R
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M_3G,+G\N;_CY>(9P0%)7?[J\_IS^]4^+\>7G2;KYV:=YROBSM)CB(QFE;/W
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M2VT=1M^:2; .]U-CT%RZOK:=)Q[?+:U%6D?(OH)M%!UL%+BDGEL+*@2!3(0
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M[Z_FX1.*^_W$31<C8@+/QAI<C3HCFU*!\V5ZEM3$)!9"EG5J,G8D>-@&! U
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M67Z/&EK=H(FDC.]Q$;C$\$]07O;(F$'EG)B)/*/;U2EP?OC)PX;"O>ILUI<
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MJEK&\U!J; "R[\N%I?GR^OVD!$/351WNY]5A[8.EJ"+U&%,YD.4VFT!.P&/
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MGET6/M:3##YOQAN<3LLU$70F2Y!T$X9;@QLW1<'E<@54<$?!<2=*^1)Q69F
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MQGIQTQ'0IF!S%*!S+%VLT,TR1EO0*#2JO(Q"5L;C"]0U LH^X/#]1-Q^NFD
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M6+5<ZE*NRCPG'.N]6#Z"  @"?SOY[<WIQUVJ"&[_^2"G^X_2,]"I.R$()RM
MW1QX.BN\MKH ,Y+5<=89'(H$PE0K9JP,F[4<VGHQ/T#,WI,X9F&Z>#M;XN+3
M/&2DL/_=\@O.;[WIYLCW$\GT-_KCOY\YA9Q0Y\'G5//%KF9X;28)J"CI6TSK
M-F5_.Y$[;NRY+X+N3=MHKK%>*Z5NK?4]"ID>>,K0EJAE&=!#<.):2(48068A
M0+DBP>F4 <F!THD79QM-RVM@D#ZF+Y@OSK'>@EYU++W$^@KUA/57M.'2CC[]
M?//JR^R^MZA9T1J$(O]1J>C <ZU "EL"-S%3 -=$!CL2W)]1V@9%=XW2(;36
M@>O_\8+\R_^^( &??J</UVV@@PQ>"D7VO!@+2L1"WEVR$+/DR48?96J3B7V$
MH''!=1 PW 7@ )KI$V#K(WK#&7<&-3A7:'5F43OXU&:/S!NCC:<OVIPE/TK2
MR" ;0N'/@V@'Z?<'HW4U1K!",ELLR%3J@(WB(,:<P+M2M-32(FO3\NA!<KJ#
MSRZJ?AI .\A]Y-ZZ+ZJYQCG)</GC;?AZN:28M%[G%* P@^082$FQ@ZE#K'1$
M8DU8M5$1ZD8M=A^B8-P3D4-N9X/H8.RN[/CM8IZ^A%L=#.^RM%YJD<#O.(L0
MF,;:M$C0FEC-4H_2BE2$R1L-A=BL9_NF9(W7UGM_S<]:JV'L0ZX/,UJ-5ZVO
M?3+1> ]1\@"*(8=@E =A6*3_F,WY3L'0(^=/MQXZ8D_W-OJ:#2"\L97^;Y/S
MB_=?POQK2'BQK W17LS>+/.:DY*M1F<UH*DS> HJ\$ANGQ(JQ12C4TYO!(,G
M7S-BM_?VP!A.P!TXOS_MTK70K6[4-YOSF^LJMA2M3(I)\"&9.G NTP8M$I2L
ME"JRI,+:',IM2N&XY]1CA/%-=-<1)F]8>8O+JR*3DK5(6@>(UDI0UED(@NPQ
MSTBR)$GJW":T?XJJ<<.S-CAX!&Q[*V7L_?%NP_#K#J&7C40QGW&935 <:;<G
M1I1A"$Z;7$=8YQ)#L-F%C?;(9U\U;JS6%#<-9#TV<NXO@??A1V7K$\Y)2HYY
M"C+(@P@R<E Y$%-6%,#$)',<'=X]Z7X$-D^_9]Q]KCUF!I3RV("Y"__W\UE"
MS(M7)-;[2T&S(!S: "AJU4N,Q&,]A#9>DBQS+'['H1!/OG;< J;#FZ#A=-"!
MIW2WF.'VEBP=<Z4V\,I(AM6[#*XP \GZ(EF.*)5JXB<]3M.XW<D/XB4-I) .
MH/5ZFN9(8?1+O/SW]?0N;V>21\VE\T#_U.1_+?6VN4!A2H@B7,B-#G*?IVTC
MJ)FCAMK "AI[K[QMER_OWN6,^5/XJY:E?L?YCS.2%,7*M&R,J&=-5A8(WK%Z
M[=_%)$56EFVT/S[[JHW08X\2/0UDW6L%W/L/[]Z??OCTGR=O7Y[^VY^OW]>N
M5;O4P#WXG$&JX)ZG<* Z.%+X-YPO?[P_#],E0>KTOR\FWZHW=-.7R* IO ZT
M-KY.QM0%').*PGBC4Y")Z]+&EC]+VKX;V:,O>*CR,S+&,TH&SI.=5+D.=<W,
M0S(*+1;FY-U3DM9BZ*Y$=U@LW=W5FFGKF*S4ITL?9B!;]>F61]3"8CU$[<'L
M5BY8/#,<0A8(JK  7C$&F<?(DF.%LS8]O\:S6S?XYSI$KW,MDPFT2W-?R[=D
MK UDE',B:A;]89D_&ANU#6XVME&[:>:8+-,5Z^$6UZ'.VSH/=:1B2A=?+U:?
MOD0B(TUN-?H<RISM0T(S&SB87 YF.*T1$E?@3-G7G@@!'&9)BSTK^L30DC#'
M:3AOCF(?7ZB7/8ZB4[10$T0?:H\C*VF1JDS+561AL[11M#&?FU+8NQ'=!D./
M7X(84$L=Y,T>Y>:W']=EU][H2&ZK!*[J%L%RG3^8."2LK=\D=[)1+<4&Q/5R
M&V)(5&RZ?^^HHIY1=ZM6VQ<,-G -.IJ:TTD>/)<"DF"V7@)00K:Y^+8!<9U:
MNET!L;'#N)MV.@#<-0M79?NUTTM@&6(,%A0F^JQX"\$Y[CW3VI@V36WO$-(I
MD'95]&PXJ7< FE<7\^ED>3''547<7_6SQ9J3+!39;QW Q%IAZR,",5#GL$<;
MO1#H&H6RC],T;G%.:R@-I(L.4%5G35S0X^XN#JVSTSXAV!B(C5 ;OCFGH7C,
MOO80D:Y-A/,(0>,6[K3&TQ!:Z !,'V=E^0\2Z,O:F7EVFQ%37(J264B1D7"B
M=N!"4<"\QV!(-(&W:63R*$GCENZT!M0PFN@ 4F_JZ?R7V7E^_?7;?/;]L@/8
MFA7:IV6.M&,;X2B"5BE",$(!VGI4HK2UH<VLZ2>(&K=,IS6LAM)&!\!Z5%1O
MKDL$7$$E3&)02B&.LHWU"E.]ZLVLSBBCB@>.^=[TT2E]W$3#;@KJ&7*_SV>+
MQ9DRV1=7,LCL:+,7F;B)S$'D1M?[W$7( Q](K>CJ-"C<$06;@FQ[E70 L$>/
M2KZ=XTIATWSR=39?3OYG]?U'F3^+01D5"H%%V%(O5GF(.5N0SB'&[*P.S>ZK
M#<)!I^'G,* =1<W;P]M?PGN*GRNE;2WH6UR>B8(ERGK]A:T*6LBIC:E(R-Y;
MPUE RP]<?D14=1JW-K:>VZIC=]M91V0>]A3_;9C/5YUB]^@,N-%SFYVW/\W!
MP0[12V2*8S:@/:\!@Z1]-9D M*WR'&021;:YC-K\$/VV5;YCC,]X"#DQ@9!8
M9J"T0:@W]2!K7KPN1NO2IN;J":(Z=?%V0LI=&S64+@8<&C:PD7I=IPS__KJV
M Z55_ON[=R___?6;-[N8I4>>-(@AVH3*@4S/[[-9_L?D_)S4_;I6$GV>4"QZ
M.8WHIA#VI@Y#"ILB^?BZK(;*6@WT%0?'1"0_WUK;:$C[5F3N:Y(V>ME-"1YZ
M#"6C!R,H>E>E)/ \*,#BZ!_E,N-M4FO;T3FNX6J'L[M&K*'V>BV@?-A>[%[<
M_>3S&EJXA@7>V^$OFA*CE0$">MKL:D+#LYS ^"02:F9B:-.3\:!V[B8U>?==
M]/HK2E8ZN5DN7G@>G4_ G:V2"1X<N0"0(T-5T"GZOW$IX\;$'I/%VP9QCU<X
MMM'C<9F]>CX\6TSJPV?W!+)''+K'VQJ:S.VY'<6@%BN3SA&!FYH<QE)J'Q8)
MS@:378Q&V3:W_D8RJ*\FT\D2WTR^X[W77I[V\,RTE8Z!=E*#<EB[SR;ZDF57
M,,;"<ILRMLUI/";SN0V^'C>?@VIMY'ZO'TE5JS/GWW'V>1Z^?:G] R]GV6O+
M- \1R+\EY]H9DA5S#E@4Z(NV*;N-<DD;]7=]E(Q>RK^'U?EL: 6,C2+\?)>%
MJX;<P3H6=.VG50^IO?802LK@,RIN6*JWWH9#T6-DC-<8=B#USH:6]8B 6763
MF/\X^_/C&4?I(B^>E%B;DZ84P7&T()7TRD:A]9/YZ@6F__5Y]OU_KY]X"9#U
M%RM\K)!Q\[X183",TF9[27!D(W%Z4;/2Z]*FR)-)*0>(GBM0FDOPT3H0A6*8
M.F_/;):SW\@NW'[S>*V A\7 7A(=,/.^&Q;>SV?Y(BW?S3_B_/LD75YID<FA
MS4I!XIDXL%Y#'?D!!8L6/DMA[S;4V0,3#U'02PE8,V=C;[&/;$+6]->$Q9J#
MQ7H)*11:QI"!K>[/KZ8^^]KR(Z3@DD'.-VO#NPUV[I,QW@:SOV;OPV1/,8_=
MP>MODT3KZ.+K]2T2+5>W@67DM;-U8;1F= 'O.6?9>_1BLRZZ/S]W=)7OJZ79
M,"+KH%;O";/YVX\_PG_-YB_.PV*Q6AHZ1<4BQ?\*-6VY4F2(F@ERP:TQO@0G
M79MVE%L0V4L'^2;;46NE]8W'&\9N38"0T4;M>0)G:O\\$<@-5)8$BB(G<NVB
MXXWN'&Y'Z+@YF6: V1R8>VNO W"^GJZZ+BX6'TA]1,D7VD;N7VV*.K-LH@!;
M8KW02SM 8,F#5<8'QWRVNLT)YT;D=0O$_0%RK[GJT-KJ ()/"/#-=3%M=C%G
MQFD)F[J.4Q;@E2&I216\M=R4W.;&T";4C7OC<?P=>C<U=0"]NXQ<-<7FT;N
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M#AR+7&'=*!1X+PRPG%Q13@7#VX160YL*>MJ+V6)YITBA>,6-39'PZ6L_/R;
M&2T L\M%F)2%;7.-X!&"NC(.V^C^P>'K>PJ\@SS@0S;N*B7UXX]03VF6/^ZP
M:+TAGZ@R9HVK=Q0E1*L=!*^SS2DY?M?!;+CO/$/LN.>P@^*MK:+ZWJ&&Z'WS
MR),&W+4.TMOF#J:0A<R"\%!/1D$A%O H&'B;94S:V9PW:J Q^OY5X;UZYDM<
MI/GD6U7"Y9U5:;14V3MRKQRQ&%%!B)&!=:@DHN6WAB(WL#</$M75/K8-!AZV
M*_L+?NPQ(H\.R^"A%IV453/C3!$ >>@A)58K"APZ2P9YLT'DQSR,9C E;S1]
M9AN)CPV;1P<KE*RES+: U#'5)BRTBSHG0>:HM0B>OC'@#*-CFCZSE7HWFCZS
MC:P[F#[SXN1,.!Z-YQEJ0T'RY$P@3RX6R%QB*$@_Y$^U*=EN^LR+DQZGSVRE
MM-E>$AR[4/"/L%B$].5B@<M5\OD]3J>+'^??PW02UAU7=-)6V6 @<5OGL!@+
MM"=[8)B*,N2#4NBW4=+]^7?U.(9F%S"T$.V82%E^FY_]<7(6BY&1PB[ A(;,
M(Z=PSXL(A4LEM?;<L[R!::B/N[0+];,;H[!^S3CUH0U L(/4QE;R^Y,SCD4*
M(25DKT+-_6+M*J(AT 98>+#6Q;V5_'XS)0]>HME(R5M*K8=>A"MW)\3 B[(.
M$F/D'P<>ZT:5:*/R/.D@XI".X'8=*AOFK8:/%W:3: \P6.]#TD>;>&V8570!
M)2TA/]>[A42N+T8%&?6P0.BB+^'V*GND)>4V\AN[)^%/S119<N1I^%HJ+NIM
M]XS@7?!@1,PY&C3.;W3.>JPM*;=2W*,M*;>1XMCJ_ZF98A$JN5H/9Q.C7<O2
MWA>--""$TTPI65@<+H'484O*G=6_LQ2[.1>[NP.^N6[#(W622=$&:(VJ/7H=
MH3GJ"#QC;<PDI6G4N.@9PL:]-S:TW]!"&V,G$^[4DYS,,;PK[TJ9)/SX+20\
M$Y8G6[('71)YV$;5@C--\:Y3.B?ZZ-EFTP:?>U./.>D==3IK)>!N3-'/7'W"
M^==WI19!K@Z #%GBY(N$$NK>JJ,&IWT"S;RF5:<ILFIU"/@<;3T&,ON!K)%>
MQK9+-Z*J30;G\^H!K*IM[ZRGJP+9#SC%?X3S=RN)GID4%&)BP$TB07)&:PI%
M EG06K+\WFF[D=':BXP>=[\!+-KA5-.IN5LS5%?7618&!48)-JLZG1$3Q*0M
M!:58NV"F6%*K@KTG"1OW/O6A#=VN&AG;ROW,Q1]DJ+^<__A0;UV2$\HHT!&
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M@-4='M972%(PC(N$(&00H&I!M4-F@"NKF TA:-8RZW&'G)%A-)RZ9T/+O@,
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M%"H&D%U_YJ/V)5@SPKC+V<1$AE1Z4-8[<-84" R=YP$9VLU \-1;QKT#TLY
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M@1@S*AFM$[Y-/>4C!(WL;/:&P2'4U@'Z?J\-@W%5*GUQV;^Z6.4XIQ@OL^1
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M*@;)9BF8RZSK]A:/Z>FWO.2H=M[.[!\BB!8,&@DO9"R>:/?"5!N 05#HP-J
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M(V=HX-E'TIL5<0>S?0#8>332YW_=S\;S/$Y5+.N(,),BV5K]M?@0,YW 43M
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MV3^PIN4V5Y>]R2X(#2CJZD))Y..Y"$4%%NE;TG'>"#@[O[J?>0-'PE.W@AA
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MWYC:[,JSG 'P*?RH[/K\K49<OH[Q^^)GTW+U#=.XC#'_O" Q0NYUD+: CK&
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MS>LR%HM:.'B+0A/RY7CBI::FDB+>I=KZ40=@V@19G"S%='7IYT7"AG/3K%5
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M2P$"% ,4    " !U1EQ47LM8ZW08   8O0  '@              @ $
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M=@  97AH:6)I=#(S,65Y8V]N<V5N=&9O<F9Y,C N:'1M4$L! A0#%     @
M=49<5%XN'_=N$   >E,  !P              ( !WGL  &5X:&EB:70T,2UF
M>3(P,C%F;W)M,3!X:RYH=&U02P$"% ,4    " !U1EQ4&RYT@B4#   B#P
M&@              @ &&C   <V5S;BTQ,C,Q,C R,7@Q,&ME>#(Q,2YH=&U0
M2P$"% ,4    " !U1EQ4(U/./I@(   _+P  &@              @ 'CCP
M<V5S;BTQ,C,Q,C R,7@Q,&ME>#,Q,2YH=&U02P$"% ,4    " !U1EQ4!^)V
MH% (  "(+0  &@              @ &SF   <V5S;BTQ,C,Q,C R,7@Q,&ME
M>#,Q,BYH=&U02P$"% ,4    " !U1EQ4@##=20T%  !C&   &@
M    @ $[H0  <V5S;BTQ,C,Q,C R,7@Q,&ME>#,R,2YH=&U02P$"% ,4
M" !U1EQ4T90>8^H$  !*&   &@              @ & I@  <V5S;BTQ,C,Q
M,C R,7@Q,&ME>#,R,BYH=&U02P$"% ,4    " !U1EQ44VEVG>V:! #>Q"4
M$0              @ &BJP  <V5S;BTR,#(Q,3(S,2YH=&U02P$"% ,4
M" !U1EQ4/+I8UTX9  #U# $ $0              @ &^1@4 <V5S;BTR,#(Q
M,3(S,2YX<V102P$"% ,4    " !U1EQ4UI;"(!8?  #\,0$ %0
M    @ $[8 4 <V5S;BTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ =49<
M5*)I6R]F?@  &U(% !4              ( !A'\% '-E<VXM,C R,3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( '5&7%201FX/(K ! !LR @ 4
M  "  1W^!0!S97-N+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( '5&7%1=
M$N_?@?H  ,-( 0 4              "  7&N!P!S97-N+3(P,C$Q,C,Q7V<R
M+FIP9U!+ 0(4 Q0    ( '5&7%0>TTB8$T<! /&B 0 4              "
M 22I" !S97-N+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( '5&7%14%P;=
ME24! +<R#  5              "  6GP"0!S97-N+3(P,C$Q,C,Q7VQA8BYX
M;6Q02P$"% ,4    " !U1EQ4K*T@FT.]  !%?P@ %0              @ $Q
M%@L <V5S;BTR,#(Q,3(S,5]P<F4N>&UL4$L%!@     3 !, ,@4  *?3"P
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
